PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	GJERTSEN, MK; BAKKA, A; BREIVIK, J; SAETERDAL, I; SOLHEIM, BG; SOREIDE, O; THORSBY, E; GAUDERNACK, G				GJERTSEN, MK; BAKKA, A; BREIVIK, J; SAETERDAL, I; SOLHEIM, BG; SOREIDE, O; THORSBY, E; GAUDERNACK, G			VACCINATION WITH MUTANT RAS PEPTIDES AND INDUCTION OF T-CELL RESPONSIVENESS IN PANCREATIC-CARCINOMA PATIENTS CARRYING THE CORRESPONDING RAS MUTATION	LANCET			English	Note							REJECTION	Mutations in codon 12 of K-RAS are frequently found in pancreatic adenocarcinomas. T-cell responses specific for individual RAS mutations can be elicited in vitro by stimulation of peripheral blood mononuclear cells with synthetic peptides. Mutant ras peptides are therefore a candidate vaccine for specific immunotherapy in pancreatic carcinoma patients. When vaccinated with a synthetic ras peptide representing the K-RAS mutation in their tumours, a transient ras-specific T-cell response was induced in two of five patients treated. The vaccination protocol involved multiple in fusions of large amounts of peptide-pulsed antigen-presenting-cells obtained by leucapheresis. These results indicate that specific T-cell responses against mutations uniquely harboured in tumour cells can be induced in cancer patients by vaccination.	NATL HOSP,INST TRANSPLANTAT IMMUNOL,OSLO,NORWAY; NATL HOSP,DEPT SURG B,OSLO,NORWAY; RED CROSS & NATL HOSP BLOOD CTR,OSLO,NORWAY	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway			Klemp, Marianne/AAQ-5652-2021	Klemp, Marianne/0000-0002-9530-8344				BECKER JC, 1993, INT IMMUNOL, V5, P1501, DOI 10.1093/intimm/5.12.1501; FOSSUM B, 1994, INT J CANCER, V56, P40, DOI 10.1002/ijc.2910560108; FOSSUM B, 1995, CANCER IMMUNOL IMMUN, V40, P165; GEDDEDAHL T, 1992, INT IMMUNOL, V4, P1331, DOI 10.1093/intimm/4.11.1331; GEDDEDAHL T, 1993, EUR J IMMUNOL, V23, P754, DOI 10.1002/eji.1830230328; JUNG S, 1991, J EXP MED, V73, P273; KAHN SM, 1991, ONCOGENE, V6, P1079; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; VAESSEN LMB, 1992, CLIN EXP IMMUNOL, V88, P213	10	164	173	1	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1399	1400		10.1016/S0140-6736(95)92408-6	http://dx.doi.org/10.1016/S0140-6736(95)92408-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475823	Bronze			2023-01-03	WOS:A1995TG20700011
J	ASOLA, MR				ASOLA, MR			A DIVER UNCONSCIOUS AFTER GASTROENTERITIS	LANCET			English	Note							PERITONEAL-DIALYSIS; AMINO	At the end of 1994, a 23-year-old man went on a diving holiday to Sri Lanka, where he got gastroenteritis. Upon arrival home he became disoriented, dysarthric, and ataxic. When he was admitted to Turku University Central Hospital, on Dec 18, severe metabolic acidosis was found. Examination of cerebrospinal fluid, electroencephalography, and computed tomogram of the brain were normal. Because of the history, decompression sickness was suspected, and the patient was transferred for hyperbaric oxygen treatment. On arrival he was deeply unconscious and his breathing had to be assisted with respirator. Chest radiograph revealed right-side lobar pneumonia. In faecal culture samples, no pathogens mere found and a test for Clostridium difficile toxin was negative.			ASOLA, MR (corresponding author), UNIV TURKU,CENT HOSP,DEPT INTERNAL MED NEPHROL,SF-20520 TURKU,FINLAND.							GORTNER L, 1989, ACTA PAEDIATR SCAND, V78, P706, DOI 10.1111/j.1651-2227.1989.tb11130.x; GOYON JB, 1994, PAEDIATR RES, V35, P357; PEINEMANN F, 1994, J INHERIT METAB DIS, V17, P3, DOI 10.1007/BF00735389; SALLAN SE, 1969, LANCET, V2, P1423; WENDEL U, 1980, EUR J PEDIATR, V134, P57, DOI 10.1007/BF00442404	5	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1338	1338		10.1016/S0140-6736(95)92347-0	http://dx.doi.org/10.1016/S0140-6736(95)92347-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475775				2023-01-03	WOS:A1995TE91600013
J	ALLABY, MAK				ALLABY, MAK			CONTRACEPTIVE SERVICES FOR TEENAGERS - DO WE NEED FAMILY-PLANNING CLINICS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether the effectiveness of contraceptive services for teenagers is related to the balance of service provision between general practitioners and specialist family planning services. Design-Cross sectional study with routinely collected data from family planning clinics and family health services authorities and published data on births and abortions. Setting-Eight health districts in the former Oxford region. Subjects-Girls aged under 16 and women aged 16-19 who attended a contraceptive service during 1991-2 or who gave birth or had an abortion during 1990-2. Main outcome measures-Attenders at family planning clinics as a percentage of all users of contraceptive services. The conception rate:uptake of contraceptive services ratio was used as a measure of effectiveness. Results-In comparisons between districts the percentage of all users of contraceptive services who attended a clinic varied fi om 38% (95% confidence interval 28% to 48%) to 79% (72% to 86%) among 13-15 year olds and from 14% (12% to 15%) to 44% (42% to 46%) among women aged 16-19 years. The conception rate:uptake of contraceptive services ratio varied twofold in the older age group and more than threefold in the younger age group. It was lowest in districts where clinic attenders comprised a large percentage of all users of contraceptive services. Conclusion-Contraceptive services for teenagers may be more effective in districts where clinics play a large part in delivering the service, particularly for girls aged under 16.			ALLABY, MAK (corresponding author), NORTHAMPTONSHIRE HLTH AUTHOR,DEPT PUBL HLTH MED,NORTHAMPTON NN1 5DN,ENGLAND.							ALLEN I, 1991, FAMILY PLANNING PREG; IBBOTSON S, 1992, BRIT MED J, V305, P835, DOI 10.1136/bmj.305.6857.835-b; JARMAN B, 1984, BRIT MED J, V289, P1587, DOI 10.1136/bmj.289.6458.1587; ROXBY M, 1992, HLTH NEEDS ASSESSMEN; SHEPHERD M, 1988, CONSUMER PREFERENCES; 1992, GUIDELINES REVIEWING; 1992, ABORTION STATISTICS; 1992, HLTH NATION STRATEGY; 1992, FM1 OFF POP CENS SUR; 1990, FM1 OFF POP CENS SUR; 1990, ABORTION STATISTICS; 1994, 37 FAC PUBL HLTH MED; 1991, ABORTION STATISTICS; 1991, FM1 OFF POP CENS SUR	14	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1641	1643		10.1136/bmj.310.6995.1641	http://dx.doi.org/10.1136/bmj.310.6995.1641			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF698	7795452	Green Published			2023-01-03	WOS:A1995RF69800024
J	MCGEE, MP; TEUSCHLER, H				MCGEE, MP; TEUSCHLER, H			PROTEIN HYDRATION DURING GENERATION OF COAGULATION-FACTOR XA IN AQUEOUS-PHASE AND ON PHOSPHOLIPID-MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR; WATER; VESICLES; FUSION; FORCES	The energetic contribution of protein solvation-desolvation reactions to generation of coagulation activated factor X (FXa) by the extrinsic pathway protease complex was determined using the technique of osmotic stress. The initial rate of FXa generation by limited proteolysis of human FX was measured in reaction mixtures with human tissue factor (TF) and factor VIIa (FVIIa) assembled either in aqueous phase or on phospholipid membranes. Osmotic stress was induced on the surface of reacting proteins with either polyethylene glycol, or dextran of 6000 and 500,000 molecular weight, respectively. These inert polymers are sterically excluded from the the solvation shells of proteins and thus increase the water activity in the excluded spaces. The volume of water transferred either to or from the excluded spaces during formation of reaction intermediates was calculated from the ratio of change in free energy of activation with change in osmotic pressure, Delta G*/Delta II. For aqueous phase-assembled reactions, Delta G* values decreased with Delta II at ratios of -2.36 +/- 0.38 and -2.26 +/- 0.26 kcal/ mol/atm for polyethylene glycol and dextran, respectively. These values correspond to 5488 +/- 883 and 5255 +/- 604 mol of water transferred from the reacting protein surfaces per mol of FXa generated. At a physiologic osmotic pressure of 7 atm the work of transfer corresponded to 16 kcal/mol, approximately 70% of Delta G*. The observed osmotic effects were independent of the viscosity, temperature, and ionic strength of solutions. For reactions assembled on phospholipid membranes, Delta G* increased with hn at a ratio of 0.35 +/- 0.05 kcal/mol/atm, corresponding to 814 +/- 116 mol of water tansferred from bulk solution to protein surfaces, At physiologic osmotic pressure the work of transfer is 2.45 kcal/mol, approximately 12% of Delta G*. Results indicate that for factor Xa generation in aqueous phase the work of desolvation is a significant component of the free energy of activation. Results also suggest that phospholipid membranes catalyze the reaction by reducing the desolvation component of the free energy of activation.			MCGEE, MP (corresponding author), BOWMAN GRAY SCH MED, DEPT MED, RHEUMATOL SECT, MED CTR BLVD, WINSTON SALEM, NC 27157 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042812] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42812] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CARSON SD, 1980, SCIENCE, V208, P307, DOI 10.1126/science.7367861; COLOMBO MF, 1992, SCIENCE, V256, P655, DOI 10.1126/science.1585178; DOUZOU P, 1994, P NATL ACAD SCI USA, V91, P1657, DOI 10.1073/pnas.91.5.1657; GAWRISCH K, 1992, BIOCHEMISTRY-US, V31, P2856, DOI 10.1021/bi00126a003; Glasstone S., 1941, THEORY RATE PROCESSE, P10; HANN K, 1994, ANN NY ACAD SCI, V714, P265; JEANNERET VP, 1954, HELV MED ACTA, V21, P1991; KNOLL D, 1983, J BIOL CHEM, V258, P5710; MACDONALD RI, 1985, BIOCHEMISTRY-US, V24, P4058, DOI 10.1021/bi00336a039; MASSENBURG D, 1993, BIOCHEMISTRY-US, V32, P9172, DOI 10.1021/bi00086a024; MCGEE MP, 1992, J BIOL CHEM, V267, P24333; NEMERSON Y, 1988, BLOOD, V71, P1; PARSEGIAN VA, 1986, METHOD ENZYMOL, V127, P400; PROUTY MS, 1985, J MOL BIOL, V184, P517, DOI 10.1016/0022-2836(85)90298-0; RAND RP, 1993, BIOCHEMISTRY-US, V32, P5925, DOI 10.1021/bi00074a001; RAND RP, 1989, BIOCHIM BIOPHYS ACTA, V988, P351, DOI 10.1016/0304-4157(89)90010-5; RAND RP, 1992, SCIENCE, V256, P618, DOI 10.1126/science.256.5057.618; RAPAPORT SI, 1991, ANN NY ACAD SCI, V614, P51, DOI 10.1111/j.1749-6632.1991.tb43691.x; RAU DC, 1990, SCIENCE, V249, P1278, DOI 10.1126/science.2144663; ROBINSON CR, 1994, BIOCHEMISTRY-US, V33, P3787, DOI 10.1021/bi00179a001; ROBINSON CR, 1993, J MOL BIOL, V234, P302, DOI 10.1006/jmbi.1993.1586; SLACK JR, 1973, BIOCHIM BIOPHYS ACTA, V323, P547, DOI 10.1016/0005-2736(73)90163-6; SMITH RL, 1973, J BIOL CHEM, V248, P2418; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; WEBSTER HL, 1982, CLIN PERINATOL, V9, P505; ZIMMERBERG J, 1990, BIOPHYS J, V57, P1049, DOI 10.1016/S0006-3495(90)82623-0; [No title captured]	27	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 23	1995	270	25					15170	15174		10.1074/jbc.270.25.15170	http://dx.doi.org/10.1074/jbc.270.25.15170			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RE666	7541037	hybrid			2023-01-03	WOS:A1995RE66600050
J	WEINER, JP; PARENTE, ST; GARNICK, DW; FOWLES, J; LAWTHERS, AG; PALMER, RH				WEINER, JP; PARENTE, ST; GARNICK, DW; FOWLES, J; LAWTHERS, AG; PALMER, RH			VARIATION IN OFFICE-BASED QUALITY - A CLAIMS-BASED PROFILE OF CARE PROVIDED TO MEDICARE PATIENTS WITH DIABETES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AMBULATORY CARE; FAMILY PHYSICIANS; SPECIALTIES; POPULATION; INTERNISTS; ASSURANCE; OUTCOMES; SYSTEMS; MIX	Objectives.-To demonstrate that claims data ''profiling'' can be used as an ongoing method to support ambulatory care quality improvement; to measure the quality of office-based care provided to elderly patients with diabetes in three states; and to identify factors associated with better attainment of quality standards. Study Design.-A cross-sectional study based on a 100% sample of the Medicare claims (Part B and Part A) submitted between July 1, 1990, and June 30, 1991. Setting.-All primary care practices (both solo and group) actively seeing Medicare patients with diabetes in Alabama, Iowa, and Maryland (n=2980). Patients.-All elderly (greater than or equal to 65 years) Medicare patients seen by the study physicians and assigned a diagnosis of diabetes (n=97 388) by any office-based physician during the year. Main Outcome Measures.-The proportion of patients with diabetes receiving the following procedures (from any provider) at least once during the study period: hemoglobin A(1C) measurement, ophthalmologic examination, total cholesterol measurement, and blood glucose measurement. We considered the first three services to be optimally recommended and blood glucose measurement to be of limited use. Results.-Based on analyses of services provided in the ambulatory setting, we found that 84% of diabetics did not appear to receive the recommended hemoglobin A(1C) measurement, 54% did not see an ophthalmologist, and 45% received no cholesterol screening. Practice patterns varied considerably across the three states (up to 2.38-fold), even after adjusting for patient case mix and physician characteristics. Patients of general practitioners were less likely to meet recommended quality criteria than patients of internists or family practitioners. Patients receiving care from rural practitioners were less likely to receive services, either recommended or not, than those in urban locations. Conclusions.-Elderly patients with diabetes do not appear to be receiving optimal care. This study underscores the value of practice guideline development and dissemination in the ambulatory arena. This study provides substantial evidence that existing administrative claims data can be used to support ambulatory quality improvement activities.	BRANDEIS UNIV,HELLER GRAD SCH,INST HLTH POLICY,WALTHAM,MA 02254; PK NICOLLET MED FDN,MINNEAPOLIS,MN; HARVARD UNIV,SCH PUBL HLTH,CTR QUAL CARE RES & EDUC,BOSTON,MA 02115	Brandeis University; Harvard University; Harvard T.H. Chan School of Public Health	WEINER, JP (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,JOHNS HOPKINS HLTH SERV RES & DEV CTR,BALTIMORE,MD 21205, USA.		Garnick, Deborah w/I-9009-2012					ALLERHEILIGEN DA, 1990, DIABETES MELLITUS RE; BRANCH WT, 1987, OFFICE PRACTICE MED; CHASSIN MR, 1986, NEW ENGL J MED, V314, P285, DOI 10.1056/NEJM198601303140505; CHERKIN DC, 1987, MED CARE, V25, P455, DOI 10.1097/00005650-198706000-00001; Corrigan J M, 1993, Jt Comm J Qual Improv, V19, P566; DIEHR P, 1990, HEALTH SERV RES, V24, P741; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; Garnick D W, 1994, J Ambul Care Manage, V17, P44; Garnick D W, 1994, Int J Qual Health Care, V6, P163; GARNICK DW, 1994, JOINT COMM J QUAL IM, V20, P679, DOI 10.1016/S1070-3241(16)30117-1; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; GREENFIELD S, 1992, JAMA-J AM MED ASSOC, V267, P1624, DOI 10.1001/jama.267.12.1624; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; JENCKS SF, 1992, JAMA-J AM MED ASSOC, V268, P900, DOI 10.1001/jama.268.7.900; KRAVITZ RL, 1992, JAMA-J AM MED ASSOC, V267, P1617, DOI 10.1001/jama.267.12.1617; LASKER RD, 1992, INQUIRY-J HEALTH CAR, V29, P287; LATHERS A, 1995, J AMB CARE MANAGE, V18, P56; Lawthers A G, 1993, Jt Comm J Qual Improv, V19, P552; Leatherman S, 1991, QRB Qual Rev Bull, V17, P349; LINN LS, 1984, INQUIRY-J HEALTH CAR, V21, P266; Lohr K.N., 1990, MEDICARE STRATEGY QU, V1; MCPHERSON K, 1982, NEW ENGL J MED, V307, P1310, DOI 10.1056/NEJM198211183072104; PALMER RH, 1988, INQUIRY-J HEALTH CAR, V25, P119; PALMER RH, 1994, FINAL REPORT EXTERNA; PALSEY B, 1987, AM J PUBLIC HEALTH, V77, P659; Romano P S, 1993, Med Care Rev, V50, P451, DOI 10.1177/002570879305000404; STARFIELD B, 1994, JAMA-J AM MED ASSOC, V272, P1903, DOI 10.1001/jama.272.24.1903; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; STARFIELD B, 1993, PRACTICE VARIATION O; TOBIN T, 1959, ECONOMETRICA, V26, P24; Weiner J P, 1990, QRB Qual Rev Bull, V16, P424; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WELCH HG, 1994, NEW ENGL J MED, V330, P607, DOI 10.1056/NEJM199403033300906; 1994, HLTH 1993; 1993, DEV EVALUATING METHO; 1988, DIABETES CARE, V11, P745; 1994, REPORT C 1994; 1989, DIABETES CARE, V12, P365	38	291	292	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 17	1995	273	19					1503	1508		10.1001/jama.273.19.1503	http://dx.doi.org/10.1001/jama.273.19.1503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX418	7739076				2023-01-03	WOS:A1995QX41800032
J	MUSTONEN, P; KINNUNEN, PKJ				MUSTONEN, P; KINNUNEN, PKJ			ON THE REVERSAL BY DEOXYRIBONUCLEIC-ACID OF THE BINDING OF ADRIMYCIN TO CARDIOLIPIN-CONTAINING LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE LIPID-PEROXIDATION; RESONANCE ENERGY-TRANSFER; MULTIDRUG-RESISTANCE; ESCHERICHIA-COLI; DNAA PROTEIN; TUMOR-CELLS; RAT-LIVER; PHOSPHATIDYLCHOLINE BILAYERS; MITOCHONDRIAL-MEMBRANES; ADRIAMYCIN RESISTANCE	The binding of the cytotoxin adriamycin (doxorubicin) to phospholipids, DNA, and RNA was investigated using (i) fluorescence quenching by this drug of liposomes containing pyrene-labeled phospholipids and (ii) monomolecular cardiolipin films on an air/water interface. In accordance with previous studies, our fluorescence experiments revealed that the acidic phospholipids, phosphatidylglycerol, phosphatidylmethanol, and phosphatidic acid all have high and comparable affinities to adriamycin mainly due to electrostatic interactions whereas binding to phosphatidylcholine was much weaker. Highest affinity, however, was possessed by cardiolipin. Addition of 4 mM CaCl2 reduced the binding of adriamycin to the above lipids. Moreover, in the presence of calcium the affinity of the drug to the different lipids was similar. Ca2+ concentrations > 100 muM began to reverse the binding of adriamycin to cardiolipin-containing liposomes whereas lower concentrations had only an insignificant effect. The association of adriamycin with DNA, RNA, and cardiolipin was then compared by observing the reversal of the cytotoxin-cardiolipin association by nucleic acids. The affinity of adriamycin was found to decrease in the sequence DNA > cardiolipin > RNA with relative affinities of 7.8, 2.3, and 1, respectively. Penetration of the drug into cardiolipin monolayers spread on an air/water interface resulted in an increase in surface pressure pi whereas only a very weak increase was observed using dimyristoylphosphatidylcholine films. Removal of adriamycin from lipid monolayers was achieved by adding DNA into the aqueous subphase. Similar to the fluorescence quenching studies increase in pi after the inclusion of adriamycin into the aqueous subphase was significantly reduced in the presence of Ca2+ concentrations > 100 muM, whereas lower concentrations had only an insignificant effect. Residual drug-phospholipid interactions in the lipid monolayer observed in the presence of Ca2+ were also reversed by DNA.	UNIV HELSINKI, DEPT MED CHEM, SILTAVUORENPENGER 10A, SF-00170 HELSINKI 17, FINLAND	University of Helsinki								BARABAS K, 1992, J BIOL CHEM, V267, P9437; BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; BERMAN HM, 1981, ANNU REV BIOPHYS BIO, V10, P87, DOI 10.1146/annurev.bb.10.060181.000511; BURKE TG, 1985, BIOCHEMISTRY-US, V24, P1768, DOI 10.1021/bi00328a030; CANAVES JM, 1991, BIOCHEM J, V279, P413, DOI 10.1042/bj2790413; CHAIRES JB, 1982, BIOCHEMISTRY-US, V21, P3927, DOI 10.1021/bi00260a004; CONSTANTINIDES PP, 1990, BIOPHYS CHEM, V35, P259, DOI 10.1016/0301-4622(90)80013-W; CONSTANTINIDES PP, 1986, J BIOL CHEM, V261, P196; DEKRUIJFF B, 1982, BIOCHIM BIOPHYS ACTA, V693, P1, DOI 10.1016/0005-2736(82)90464-3; DIETEL M, 1990, CANCER RES, V50, P6100; DOROSHOW JH, 1991, NEW ENGL J MED, V324, P843, DOI 10.1056/NEJM199103213241210; DRAKE JM, 1991, SCIENCE, V251, P1574, DOI 10.1126/science.2011737; DUPOUCEZANNE L, 1989, EUR J BIOCHEM, V181, P695, DOI 10.1111/j.1432-1033.1989.tb14779.x; EILERS M, 1989, J BIOL CHEM, V264, P2945; ESCRIBA PV, 1990, BIOCHEMISTRY-US, V29, P7275, DOI 10.1021/bi00483a017; FAN D, 1990, CANCER RES, V50, P3619; FERRERMONTIEL AV, 1988, BIOCHIM BIOPHYS ACTA, V937, P379, DOI 10.1016/0005-2736(88)90260-X; FIALLO MML, 1986, BIOCHIM BIOPHYS ACTA, V854, P143; FOJO AT, 1987, P NATL ACAD SCI USA, V84, P265, DOI 10.1073/pnas.84.1.265; FREDERICK CA, 1990, BIOCHEMISTRY-US, V29, P2538, DOI 10.1021/bi00462a016; FREZARD F, 1991, BIOCHEMISTRY-US, V30, P5038, DOI 10.1021/bi00234a028; FULLFORD AJC, 1980, BIOCHIM BIOPHYS ACTA, V598, P237; Gianni L, 1983, REV BIOCHEM TOXICOL, V5, P1; GOORMAGHTIGH E, 1987, BIOCHEMISTRY-US, V26, P1789, DOI 10.1021/bi00380a043; GOORMAGHTIGH E, 1982, BIOCHEM BIOPH RES CO, V104, P314, DOI 10.1016/0006-291X(82)91976-3; GOORMAGHTIGH E, 1980, BIOCHIM BIOPHYS ACTA, V597, P1, DOI 10.1016/0005-2736(80)90145-5; GRIFFIN EA, 1986, BIOCHEMISTRY-US, V25, P7875, DOI 10.1021/bi00372a013; HENRY N, 1985, BIOCHEMISTRY-US, V24, P7085, DOI 10.1021/bi00346a010; HIRAI H, 1991, BIOCHIM BIOPHYS ACTA, V1088, P191, DOI 10.1016/0167-4781(91)90054-P; HOUSEAL TW, 1989, BIOPHYS J, V56, P507, DOI 10.1016/S0006-3495(89)82697-9; HUART P, 1984, BIOCHIM BIOPHYS ACTA, V799, P199, DOI 10.1016/0304-4165(84)90296-4; HUBNER W, 1991, BIOCHIM BIOPHYS ACTA, V1066, P166, DOI 10.1016/0005-2736(91)90183-9; KAIHOVAARA P, 1991, BIOCHEMISTRY-US, V30, P8380, DOI 10.1021/bi00098a015; KARTNER N, 1983, SCIENCE, V221, P1285, DOI 10.1126/science.6137059; KINNUNEN PKJ, 1993, FLUORESCENCE SPECTRO, P159; KONTTILA R, 1988, BIOCHEMISTRY-US, V27, P7443, DOI 10.1021/bi00419a040; LEMMETYINEN H, 1989, J PHYS CHEM-US, V93, P7170, DOI 10.1021/j100357a029; MACDONALD PM, 1987, BIOCHEMISTRY-US, V26, P6292, DOI 10.1021/bi00393a050; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V857, P123, DOI 10.1016/0005-2736(86)90105-7; MIMNAUGH EG, 1985, BIOCHEM PHARMACOL, V34, P847, DOI 10.1016/0006-2952(85)90766-X; MIMNAUGH EG, 1985, CANCER RES, V45, P3296; MIMNAUGH EG, 1981, TOXICOL APPL PHARM, V61, P313, DOI 10.1016/0041-008X(81)90352-5; MIZUSHIMA T, 1992, BIOCHEM J, V285, P503, DOI 10.1042/bj2850503; MONTAUDON D, 1986, CANCER RES, V46, P5602; MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006; MUSTONEN P, 1991, J BIOL CHEM, V266, P6302; NEIDLE S, 1977, CANCER TREAT REP, V61, P928; NICOLAY K, 1987, BIOCHIM BIOPHYS ACTA, V892, P320, DOI 10.1016/0005-2728(87)90236-2; NICOLAY K, 1984, BIOCHIM BIOPHYS ACTA, V778, P359, DOI 10.1016/0005-2736(84)90380-8; NICOLAY K, 1985, BIOCHIM BIOPHYS ACTA, V819, P55, DOI 10.1016/0005-2736(85)90195-6; POHLE W, 1990, BIOPHYS CHEM, V35, P213, DOI 10.1016/0301-4622(90)80010-5; POSADA J, 1989, CANCER RES, V49, P6634; RIORDAN JR, 1985, PHARMACOL THERAPEUT, V28, P51, DOI 10.1016/0163-7258(85)90082-8; ROGAN AM, 1984, SCIENCE, V224, P994, DOI 10.1126/science.6372095; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7131; SEKIMIZU K, 1988, J BIOL CHEM, V263, P7136; SIEGFRIED JA, 1983, J BIOL CHEM, V258, P339; SIEGFRIED JM, 1983, CANCER BIOCHEM BIOPH, V6, P137; SINHA BK, 1984, CANCER RES, V44, P2892; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; THUREN T, 1990, CHEM PHYS LIPIDS, V53, P129, DOI 10.1016/0009-3084(90)90039-T; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; TSURUO T, 1983, CANCER RES, V43, P2905; YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305; YUNG BYM, 1988, P NATL ACAD SCI USA, V85, P7202, DOI 10.1073/pnas.85.19.7202; YUSA K, 1989, CANCER RES, V49, P5002; ZWELLING LA, 1982, CANCER RES, V42, P2687; [No title captured]	69	33	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1993	268	2					1074	1080						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KG077	7678246				2023-01-03	WOS:A1993KG07700049
J	KESTEN, S; REBUCK, AS				KESTEN, S; REBUCK, AS			NASAL CONTINUOUS POSITIVE AIRWAY PRESSURE IN PNEUMOCYSTIS-CARINII PNEUMONIA	LANCET			English	Article									TORONTO WESTERN HOSP, DIV RESP MED,SUITE 4-009,EDITH CAVELL WING, 399 BATHURST ST, TORONTO M5T 2S8, ONTARIO, CANADA	University of Toronto; University Toronto Affiliates; University Health Network Toronto								ISSA FG, 1986, CHEST, V90, P165, DOI 10.1378/chest.90.2.165; KERBY GR, 1987, AM REV RESPIR DIS, V135, P738; LOMBARD RM, 1985, MED CLIN N AM, V69, P1317, DOI 10.1016/S0025-7125(16)30989-0; MACFADDEN DK, 1987, LANCET, V1, P1477, DOI 10.1016/S0140-6736(87)92219-7; MAXFIELD RA, 1986, CRIT CARE MED, V14, P443, DOI 10.1097/00003246-198605000-00001; MURRAY JF, 1984, NEW ENGL J MED, V310, P1682, DOI 10.1056/NEJM198406213102529; SANDERS MH, 1986, CHEST, V90, P330, DOI 10.1378/chest.90.3.330; SHAPIRO BA, 1983, CHEST, V3, P558; SULLIVAN CE, 1981, LANCET, V1, P862	9	14	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 17	1988	2	8625					1414	1415						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R4150	2904534				2023-01-03	WOS:A1988R415000014
J	KELLERMANN, AL; ACKERMAN, TF				KELLERMANN, AL; ACKERMAN, TF			INTERHOSPITAL PATIENT TRANSFER - THE CASE FOR INFORMED CONSENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KELLERMANN, AL (corresponding author), UNIV TENNESSEE,MEMPHIS,TN 38103, USA.							[Anonymous], 1986, HIST THEORY INFORM C; ANSELL DA, 1987, JAMA-J AM MED ASSOC, V257, P1500, DOI 10.1001/jama.257.11.1500; Beauchamp TLC, 2019, PRINCIPLES BIOMEDICA; CURRAN WJ, 1986, N ENGL J MED, V312, P374; Feinberg J., 1984, HARM OTHERS; FRIEDMAN E, 1982, HOSPITALS, V56, P51; FRIEDMAN E, 1987, JAMA-J AM MED ASSOC, V257, P1850, DOI 10.1001/jama.257.14.1850; FRIEDMAN E, 1982, HOSPITALS, V56, P84; FRIEDMAN E, 1982, HOSPITALS, V56, P82; FRIEDMAN E, 1982, HOSPITALS, V56, P75; FRIEDMAN E, 1987, JAMA-J AM MED ASSOC, V257, P1856; FRIEDMAN E, 1982, HOSPITALS, V56, P80; FRIEDMAN E, 1982, HOSPITALS, V56, P77; FUCHS VR, 1987, NEW ENGL J MED, V316, P1154, DOI 10.1056/NEJM198704303161812; GAGE LS, 1987, JAMA-J AM MED ASSOC, V257, P1942, DOI 10.1001/jama.257.14.1942; GILLESPIE R, 1987, CAL ACEP LIFELIN OCT, P1; HICKS TC, 1982, ANN EMERG MED, V11, P296, DOI 10.1016/S0196-0644(82)80126-1; HIMMELSTEIN DU, 1984, AM J PUBLIC HEALTH, V74, P494, DOI 10.2105/AJPH.74.5.494; KELLERMANN AL, IN PRESS AM J PUBLIC; LASKY PC, 1981, HOSPITAL LAW MANUAL, V2; MACDONALD MG, 1986, HLTH CARE LAW PRACTI; NUTTER DO, 1987, NEW ENGL J MED, V316, P1156, DOI 10.1056/NEJM198704303161813; Oday L A, 1987, Healthspan, V4, P23; PROSSER WL, 1987, HDB LAW TORTS, P103; REED WG, 1986, NEW ENGL J MED, V315, P1428, DOI 10.1056/NEJM198611273152231; RELMAN AS, 1985, NEW ENGL J MED, V312, P372, DOI 10.1056/NEJM198502073120610; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; WAXMAN J, 1987, HLTH ADVOCATE, V153, P8; 1986, ANN EMERG MED, V14, P1221; 1987, JCAH PERSPECT, V7, P3; 1987, ANN EMERG MED, V16, P1302; 1980, B AM COLL SURG, V65, P13; 1987, ACEP NEWS, V6, P5; 1987, GAOHRD8731 GEN ACC O	34	9	9	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 8	1988	319	10					643	647		10.1056/NEJM198809083191010	http://dx.doi.org/10.1056/NEJM198809083191010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P9226	3045547				2023-01-03	WOS:A1988P922600010
J	AVERBUCH, SD; STEAKLEY, CS; YOUNG, RC; GELMANN, EP; GOLDSTEIN, DS; STULL, R; KEISER, HR				AVERBUCH, SD; STEAKLEY, CS; YOUNG, RC; GELMANN, EP; GOLDSTEIN, DS; STULL, R; KEISER, HR			MALIGNANT PHEOCHROMOCYTOMA - EFFECTIVE TREATMENT WITH A COMBINATION OF CYCLOPHOSPHAMIDE, VINCRISTINE, AND DACARBAZINE	ANNALS OF INTERNAL MEDICINE			English	Article									UNIFORMED SERV UNIV HLTH SCI, NCI, BETHESDA, MD 20814 USA; NHLBI, BETHESDA, MD 20205 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)								BERGMAN SM, 1978, J UROLOGY, V120, P109, DOI 10.1016/S0022-5347(17)57063-9; BOLANDE RP, 1974, HUM PATHOL, V5, P409, DOI 10.1016/S0046-8177(74)80021-3; BRAVO EL, 1984, NEW ENGL J MED, V311, P1298, DOI 10.1056/NEJM198411153112007; BRENNAN MF, 1985, CANCER PRINCIPLES PR, P1179; BUKOWSKI RM, 1984, J SURG ONCOL, V27, P89, DOI 10.1002/jso.2930270207; DEASIS DN, 1978, CANCER, V42, P2005, DOI 10.1002/1097-0142(197810)42:4<2005::AID-CNCR2820420448>3.0.CO;2-4; DRASIN H, 1978, WESTERN J MED, V128, P106; FELDMAN JM, 1983, ARCH INTERN MED, V143, P1799, DOI 10.1001/archinte.143.9.1799; FINKLESTEIN JZ, 1979, MED PEDIATR ONCOL, V6, P179, DOI 10.1002/mpo.2950060211; GOLDSTEIN DS, 1986, ANN INTERN MED, V105, P887, DOI 10.7326/0003-4819-105-6-887; GOLDSTEIN DS, 1984, CLIN CHEM, V30, P815; HAMILTON BPM, 1977, ARCH INTERN MED, V137, P762, DOI 10.1001/archinte.137.6.762; HELMAN LJ, 1987, P NATL ACAD SCI USA, V84, P2336, DOI 10.1073/pnas.84.8.2336; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KATO K, 1987, CANCER RES, V47, P5800; KEISER HR, 1985, HYPERTENSION, V7, pI18, DOI 10.1161/01.HYP.7.3_Pt_2.I18; LEVINSON PD, 1983, METABOLISM, V32, P998, DOI 10.1016/0026-0495(83)90142-7; LEWI HJE, 1985, BRIT J UROL, V57, P394, DOI 10.1111/j.1464-410X.1985.tb06295.x; Manger W M, 1985, Curr Probl Cancer, V9, P1; PRITCHARD J, 1987, NEW ENGL J MED, V317, P1026; Remine W H, 1975, Bull Soc Int Chir, V34, P97; SCOTT HW, 1982, SURG GYNECOL OBSTET, V154, P801; SISSON JC, 1984, J NUCL MED, V25, P197; TAUB MA, 1982, CANCER, V50, P1739; VANHEERDEN JA, 1982, SURGERY, V91, P367; Voorhess M L, 1968, J Pediatr Surg, V3, P147, DOI 10.1016/0022-3468(68)91001-4	26	287	293	1	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1988	109	4					267	273		10.7326/0003-4819-109-4-267	http://dx.doi.org/10.7326/0003-4819-109-4-267			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P8124	3395037				2023-01-03	WOS:A1988P812400003
J	BRAHAMS, D				BRAHAMS, D			RESTRICTED DISCHARGE OF MENTAL-PATIENTS	LANCET			English	Editorial Material																			0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUL 23	1988	2	8604					231	231						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P3561	2899716				2023-01-03	WOS:A1988P356100066
J	BOON, A				BOON, A			MEDICAL NEGLIGENCE - A SUITABLE CASE FOR TREATMENT	LANCET			English	Editorial Material											BOON, A (corresponding author), S BANK POLYTECH,DEPT LAW & GOVT,LONDON,ENGLAND.							[Anonymous], 1978, CMND7054; BRAHAMS D, 1988, LANCET, V1, P43; BRAHAMS D, 1986, LANCET, V2, P1346; BRAHAMS D, 1985, LANCET, V1, P589; 1986, CIVIL JUSTICE RE FEB; 1973, WLR1, V1	6	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAR 26	1988	1	8587					718	719						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M6259	2895258				2023-01-03	WOS:A1988M625900055
J	BELLET, PS; KALINYAK, KA; SHUKLA, R; GELFAND, MJ; RUCKNAGEL, DL				BELLET, PS; KALINYAK, KA; SHUKLA, R; GELFAND, MJ; RUCKNAGEL, DL			INCENTIVE SPIROMETRY TO PREVENT ACUTE PULMONARY COMPLICATIONS IN SICKLE-CELL DISEASES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE CHEST SYNDROME; LUNG-DISEASE; ANEMIA; INFARCTION; CHILDREN; ADULTS	Background. This study was designed to determine the incidence of thoracic bone infarction in patients with sickle cell diseases who were hospitalized with acute chest or back pain above the diaphragm and to test the hypothesis that incentive spirometry can decrease the incidence of atelectasis and pulmonary infiltrates. Methods. We conducted a prospective, randomized trial in 29 patients between 8 and 21 years of age with sickle cell diseases who had 38 episodes of acute chest or back pain above the diaphragm and were hospitalized. Each episode of pain was considered to be an independent event. At each hospitalization, patients with normal or unchanged chest radiographs on admission were randomly assigned to treatment with spirometry or to a control nonspirometry group. Each patient in the spirometry group took 10 maximal inspirations using an incentive spirometer every two hours between 8 a.m. and 10 p.m. and while awake during the night until the chest pain subsided. A second radiograph was obtained three or more days after admission, or sooner if clinically necessary, to determine the incidence of pulmonary complications. Bone scanning was performed no sooner than two days after hospital admission to determine the incidence of thoracic bone infarction. Results. The incidence of thoracic bone infarction was 39.5 percent (15 of 38 hospitalizations). Pulmonary complications (atelectasis or infiltrates) developed during only 1 of 19 hospitalizations of patients assigned to the spirometry group, as compared with 8 of 19 hospitalizations of patients in the nonspirometry group (P = 0.019). Among patients with thoracic bone infarction, no pulmonary complications developed in those assigned to the spirometry group during a total of seven hospitalizations, whereas they developed during five of eight hospitalizations in the nonspirometry group (P = 0.025). Conclusions. Thoracic bone infarction is common in patients with sickle cell diseases who are hospitalized with acute chest pain, Incentive spirometry can prevent the pulmonary complications (atelectasis and infiltrates) associated with the acute chest syndrome in patients with sickle cell diseases who are hospitalized with chest or back pain above the diaphragm.	CHILDRENS HOSP,MED CTR,DIV GEN PEDIAT,CINCINNATI,OH 45229; CHILDRENS HOSP,MED CTR,DIV HEMATOL ONCOL,CINCINNATI,OH 45229; CHILDRENS HOSP,MED CTR,CINCINNATI COMPREHENS SICKLE CELL CTR,CINCINNATI,OH 45229; CHILDRENS HOSP,MED CTR,DEPT RADIOL,CINCINNATI,OH 45229; UNIV CINCINNATI,COLL MED,DEPT ENVIRONM HLTH,DIV BIOSTATE & EPIDEMIOL,CINCINNATI,OH 45267	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL015996] Funding Source: NIH RePORTER; NHLBI NIH HHS [5 P60 HL 15996] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLAS SK, 1991, J NUCL MED, V32, P1617; BARRETTCONNOR E, 1971, AM REV RESPIR DIS, V104, P159; BENDIXEN HH, 1964, ANESTHESIOLOGY, V25, P297, DOI 10.1097/00000542-196405000-00006; BENDIXEN HH, 1964, J APPL PHYSIOL, V19, P195, DOI 10.1152/jappl.1964.19.2.195; BUCKLEY MMT, 1990, DRUGS, V39, P86, DOI 10.2165/00003495-199039010-00008; CHARACHE S, 1967, ANN INTERN MED, V67, P1195, DOI 10.7326/0003-4819-67-6-1195; CHARACHE S, 1979, ARCH INTERN MED, V139, P67, DOI 10.1001/archinte.139.1.67; CHARACHE S, 1991, DHHS NIH912117 PUBL, P20; CRAVEN JL, 1974, BRIT J SURG, V61, P793, DOI 10.1002/bjs.1800611012; DAVIES SC, 1984, LANCET, V1, P36; DOHI S, 1978, CHEST, V73, P592, DOI 10.1378/chest.73.5.592; FABRY ME, 1989, P NATL ACAD SCI USA, V86, P3808, DOI 10.1073/pnas.86.10.3808; GELFAND MJ, 1993, J NUCL MED, V34, P614; HARCKE HT, 1981, J NUCL MED, V22, P322; HEBBEL RP, 1980, NEW ENGL J MED, V302, P992, DOI 10.1056/NEJM198005013021803; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; KRASTINS IRB, 1982, CRIT CARE MED, V10, P525, DOI 10.1097/00003246-198208000-00009; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MILLER ST, 1991, J PEDIATR-US, V118, P30, DOI 10.1016/S0022-3476(05)81839-6; MORRIS CL, 1993, BLOOD, V81, P3138; Olin BR, 1995, DRUG FACTS COMPARISO, P242; Palmer J, 1983, BLOOD, V62, p59a; PLATT OS, 1994, NEW ENGL J MED, V330, P1639, DOI 10.1056/NEJM199406093302303; PLATT OS, 1993, HEMATOLOGY INFANCY C, V1, P732; PONCZ M, 1985, J PEDIATR-US, V107, P861, DOI 10.1016/S0022-3476(85)80176-1; POWARS D, 1988, MEDICINE, V67, P66, DOI 10.1097/00005792-198801000-00005; RUCKNAGEL DL, 1991, LANCET, V337, P831, DOI 10.1016/0140-6736(91)92525-7; RUPPEL G, 1994, MANUAL PULMONARY FUN; Sain A, 1978, Clin Nucl Med, V3, P85, DOI 10.1097/00003072-197803000-00003; SPRINKLE RH, 1986, AM J PEDIAT HEMATOL, V8, P105; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; VICHINSKY E, 1994, BLOOD, V83, P3107; WEIL JV, 1993, AM REV RESPIR DIS, V148, P249, DOI 10.1164/ajrccm/148.1.249	33	171	173	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					699	703		10.1056/NEJM199509143331104	http://dx.doi.org/10.1056/NEJM199509143331104			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637747				2023-01-03	WOS:A1995RV22700004
J	GEDDES, JR; JUSZCZAK, E				GEDDES, JR; JUSZCZAK, E			PERIOD TRENDS IN RATE OF SUICIDE IN FIRST 28 DAYS AFTER-DISCHARGE FROM PSYCHIATRIC-HOSPITAL IN SCOTLAND, 1968-92	BRITISH MEDICAL JOURNAL			English	Article							AFTER-DISCHARGE; INPATIENT CARE; PREVENTION; RISK	Objective-To examine period trends in the rate of suicide in the first 28 days after discharge from psychiatric hospital. Design-Cohort study of patients discharged from psychiatric hospital. Setting-Scotland. Subjects-Ah patients aged 15-84 who were discharged from Scottish psychiatric hospitals during 1968 to 1992. Outcome measure-The rate of suicide (classified as codes E950-9 and E980-9 according to the International Classification of Diseases, Ninth Revision) within 28 days of discharge per 100 000 person years at risk for five year periods during 1968 to 1992. Crude, within cohort rates and externally standardised rates were calculated. Results-Overall, 196 male patients committed suicide in 20 520 person years at risk, and 171 female patients committed suicide in 24 114 person years at risk. A significant Linear trend was seen in period effect on externally standardised mortality ratios in both sexes: a decrease in male patients (P=0.008) and an increase in female patients (P=0.0001). The adjusted standardised mortality ratio in 1988-92 compared with 1968-72 was 0.62 (95% confidence interval 0.39 to 0.98) in male patients and 2.73 (1.64 to 4.56) in female patients. Conclusion-The increase in the rate of suicide in the 28 days after discharge in female psychiatric patients makes this an increasingly important period to target. The rise has occurred against the background of a reduction of 60% in the number of psychiatric beds for adults.	ROYAL EDINBURGH & ASSOCIATED HOSP,EDINBURGH EH10 5HF,MIDLOTHIAN,SCOTLAND; NATL HLTH SERV SCOTLAND,DIV INFORMAT & STAT,EDINBURGH EH5 3SQ,MIDLOTHIAN,SCOTLAND	Royal Infirmary of Edinburgh; NHS National Services Scotland				Geddes, John/0000-0002-5281-5960				ALLEBECK P, 1987, ACTA PSYCHIAT SCAND, V76, P414, DOI 10.1111/j.1600-0447.1987.tb05626.x; APPLEBY L, 1992, BRIT J PSYCHIAT, V161, P749, DOI 10.1192/bjp.161.6.749; BAKER RJ, 1978, GLIM SYSTEM; Breslow N. E., 1987, STATISTICAL METHODS, VII; Charlton J., 1992, Population Trends, P10; Clayton DHM, 1993, STATISTICAL METHODS; COLEMAN M, 1986, INT J EPIDEMIOL, V15, P1347; DIEKSTRA RFW, 1993, ACTA PSYCHIATR SCA S, V371, P9; ENGBERG M, 1994, ACTA PSYCHIAT SCAND, V89, P35, DOI 10.1111/j.1600-0447.1994.tb01482.x; FLOOD RA, 1968, BRIT J PSYCHIAT, V114, P443, DOI 10.1192/bjp.114.509.443; FULLEN I, 1993, BRIT MED J, V306, P710; GEDDES JR, 1994, BRIT J PSYCHIAT, V164, P564, DOI 10.1192/S0007125000051989; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; GUNNELL D, 1994, BMJ-BRIT MED J, V308, P1227, DOI 10.1136/bmj.308.6938.1227; ISOMETSA E, 1993, LANCET, V342, P1055, DOI 10.1016/0140-6736(93)92913-E; Kendrick Stephen, 1993, Health Bulletin (Edinburgh), V51, P72; KING E, 1994, BRIT J PSYCHIAT, V165, P658, DOI 10.1192/bjp.165.5.658; KING EA, 1993, LANCET, V342, P744; KREITMAN N, 1994, HLTH B EDINB, V52, P300; MCGONIGAL G, 1992, Health Bulletin (Edinburgh), V50, P309; MORGAN HG, 1992, BRIT J PSYCHIAT, V160, P149, DOI 10.1192/bjp.160.2.149; VASSILAS CA, 1993, BRIT MED J, V307, P300, DOI 10.1136/bmj.307.6899.300; 1978, MENTAL DISORDERS GLO; 1986, MAKING REALITY COMMU; 1992, HLTH NATION STRATEGY; 1991, EGRET EPIDEMIOLOGICA	26	50	51	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					357	360		10.1136/bmj.311.7001.357	http://dx.doi.org/10.1136/bmj.311.7001.357			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640540	Green Published			2023-01-03	WOS:A1995RN46900014
J	SIMOONS, ML				SIMOONS, ML			ANOTHER CORONARY REPERFUSION REGIMEN	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; PLASMINOGEN-ACTIVATOR; IMMEDIATE ANGIOPLASTY; THROMBOLYTIC THERAPY; TRIAL				SIMOONS, ML (corresponding author), UNIV ROTTERDAM HOSP, THORAXCTR, ROTTERDAM, NETHERLANDS.							[Anonymous], 1990, LANCET, V336, P65; BODE C, 1993, CIRCULATION, V88, P292; BOER MJ, 1994, J AM COLL CARDIOL, V23, P1004; CHESEBRO JH, 1987, CIRCULATION, V76, P142, DOI 10.1161/01.CIR.76.1.142; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HUNT D, 1992, LANCET, V339, P753; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SIMOONS ML, 1993, CIRCULATION, V88, P2556, DOI 10.1161/01.CIR.88.6.2556; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; VERSTRAETE M, 1985, LANCET, V2, P965	12	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 5	1995	346	8971					324	325		10.1016/S0140-6736(95)92219-9	http://dx.doi.org/10.1016/S0140-6736(95)92219-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623525	Green Submitted			2023-01-03	WOS:A1995RM71300002
J	YOKOKAWA, K; MANKUS, R; SAKLAYEN, MG; KOHNO, M; YASUNARI, K; MINAMI, M; KANO, H; HORIO, T; TAKEDA, T; MANDEL, AK				YOKOKAWA, K; MANKUS, R; SAKLAYEN, MG; KOHNO, M; YASUNARI, K; MINAMI, M; KANO, H; HORIO, T; TAKEDA, T; MANDEL, AK			INCREASED NITRIC-OXIDE PRODUCTION IN PATIENTS WITH HYPOTENSION DURING HEMODIALYSIS	ANNALS OF INTERNAL MEDICINE			English	Note							ENDOTHELIN; UREMIA	Objective: To determine the involvement of nitric oxide production in hemodialysis-induced hypotension. Design: Examination of nitric oxide synthesis, cyclic guanosine 3'5'-monophosphate (cGMP) levels, and endothelin-1 levels in plasma before and after hemodialysis. Setting: Veterans Affairs medical center. Patients: 13 patients with end-stage renal failure who were receiving hemodialysis: Six patients had hypotensive episodes during dialysis and 7 did not. Intervention: Patients received heparin at a bolus dose of 2000 U at the initiation of dialysis followed by 1000 U/h during 4-hour hemodialysis sessions. Results: Nitric oxide production markedly increased during hemodialysis-induced hypotensive episodes; this increase was not seen in patients who did not have a hypotensive episode. In both groups, the plasma cGMP and endothelin-1 levels decreased after hemodialysis. According to multiple regression analysis, standard coefficients of nitric oxide production, plasma cGMP levels, and endothelin-1 levels with mean blood pressure after hemodialysis were -0.743, -0.07, and 0.31, respectively. Conclusion: Nitric oxide production increased in patients who had a hypotensive episode during hemodialysis but did not increase in those who did not have a hypotensive episode.	WRIGHT STATE UNIV, DAYTON, OH 45435 USA	University System of Ohio; Wright State University Dayton	YOKOKAWA, K (corresponding author), OSAKA CITY UNIV, SCH MED, DEPT INTERNAL MED 1, ABENO KU, 1-5-7 ASAHI MACHI, OSAKA 545, JAPAN.							ABBOTT EC, 1966, CAN MED ASSOC J, V94, P1155; BEASLEY D, 1992, KIDNEY INT, V42, pS96; BOULANGER C, 1990, J CLIN INVEST, V85, P587, DOI 10.1172/JCI114477; CLOZEL M, 1993, NATURE, V365, P759, DOI 10.1038/365759a0; CONVERSE RL, 1992, J CLIN INVEST, V90, P1657, DOI 10.1172/JCI116037; KOHNO M, 1990, AM J MED, V88, P614, DOI 10.1016/0002-9343(90)90527-K; KOYAMA H, 1989, LANCET, V1, P991; LETTGEN B, 1992, PEDIATR NEPHROL, V6, P60, DOI 10.1007/BF00856837; NORIS M, 1993, KIDNEY INT, V44, P445, DOI 10.1038/ki.1993.264; REA RF, 1993, J CARDIOVASC ELECTR, V4, P587, DOI 10.1111/j.1540-8167.1993.tb01246.x; YOKOKAWA K, 1991, ANN INTERN MED, V114, P213, DOI 10.7326/0003-4819-114-3-213; YOKOKAWA K, 1993, J CLIN INVEST, V92, P2080, DOI 10.1172/JCI116805	12	108	109	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 1	1995	123	1					35	37		10.7326/0003-4819-123-1-199507010-00005	http://dx.doi.org/10.7326/0003-4819-123-1-199507010-00005			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE665	7762912				2023-01-03	WOS:A1995RE66500006
J	NAISH, J; STURDY, P; TOON, P				NAISH, J; STURDY, P; TOON, P			APPROPRIATE PRESCRIBING IN ASTHMA AND ITS RELATED COST IN EAST LONDON	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; MANAGEMENT	Objectives-To determine the patterns of preventive to reactive prescribing for asthma among general practices in the City and East London Family Health Services Authority area and their relation to prescribing cost. Design-Descriptive study of asthma prescribing during April 1992 to March 1993. Prescribing data were linked with general practice and population data on one database. Setting-City and East London Family Health Services Authority area, including all general practices in contract with the authority, which covers the inner city London Boroughs of Hackney, Tower Hamlets, and Newham and the Corporation of the City of London. Subjects-All 163 general practices as at 1 June 1993. Main outcome measures-Ratios of prescribed inhaled corticosteroids plus cromoglycates (prophylactic treatment) to bronchodilators; distribution of the cost of asthma prescribing; distribution of overall generic prescribing; proportion of asthma generic prescribing; distribution of cost of overall drugs prescribed per prescribing unit. Results-Practices approved for band 3 health promotion or asthma surveillance and those with a general practitioner trainer had on average higher ratios of prophylactic to bronchodilator treatment and significantly higher asthma drug costs than other practices. Those practices with high levels of overall generic prescribing had significantly higher prophylactic to bronchodilator ratios than those with lower levels of generic prescribing. Practices with higher levels of asthma drug generic prescribing also had significantly higher prophylactic prescribing. However, the proportion of generically prescribed asthma drugs was lower than overall generic prescribing. There was no correlation between the ratio of prophylactic to bronchodilator asthma prescribing and the proportion of overall drugs expenditure, but high spending practices spent significantly more on asthma drugs. Conclusions-Pressure to reduce the cost of asthma prescribing may lead to a lowering of the ratio of prophylactic to bronchodilator treatments. However, reducing prophylactic prescribing would run contrary to the British Thoracic Society guidelines and might worsen the quality of asthma care.	UNIV LONDON QUEEN MARY & WESTFIELD COLL,LONDON E1 4NS,ENGLAND	University of London; Queen Mary University London	NAISH, J (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,DEPT GEN PRACTICE & PRIMARY CARE,LONDON E1 4NS,ENGLAND.							BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; GELLERT AR, 1990, BRIT J GEN PRACT, V40, P197; HARRIS CM, 1990, ANAL PRESCRIBING GEN; HAY IFC, 1987, LANCET, V2, P609; HORN CR, 1989, RESP MED, V83, P67, DOI 10.1016/S0954-6111(89)80062-9; Jones K, 1992, Qual Health Care, V1, P110, DOI 10.1136/qshc.1.2.110; MCGAVOCK H, 1988, BRIT MED J, V296, P90; NEVILLE RG, 1993, BRIT MED J, V306, P559, DOI 10.1136/bmj.306.6877.559; PANTON R, 1993, BRIT MED J, V306, P310, DOI 10.1136/bmj.306.6873.310; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; TURNERWARWICK M, 1989, J ROY COLL GEN PRACT, V39, P239; 1994, PRESCRIPTION IMPROVE; 1993, BRIT MED J, V306, P776; 1992, BRIT NATIONAL FORMUL, V23; 1994, HLTH E END ANN PUBLI; 1993, HLTH SERVICE INDICAT	17	45	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 14	1995	310	6972					97	100		10.1136/bmj.310.6972.97	http://dx.doi.org/10.1136/bmj.310.6972.97			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833736	Green Published			2023-01-03	WOS:A1995QC22300023
J	PEARN, J				PEARN, J			THE EARLIEST DAYS OF FIRST-AID	BRITISH MEDICAL JOURNAL			English	Article								First aid, as a profession in its own right, has a history of only 120 years. It evolved from the teachings of the Royal Humane Society and military surgeons, who saw the wisdom of training in splinting and bandaging for battlefield wounds. In 1878 two Aberdeenshire military officers, Surgeon-Major Peter Shepherd of the Royal Herbert Military Hospital, Woolwich, London, and Colonel Francis Duncan established the concept of teaching first aid skills to civilians. This radical new enterprise, conducted under the auspices of the newly formed St John Ambulance Association, was a natural evolution from the body's philanthropic and ambuance transport work. Shepherd conducted the first class in the hall of the Presbyterian school in Woolwich using a comprehensive first aid curriculum that he had developed. Within months of that first class, local Woolwich civilians used their skills when the pleasure boat Princess Alice sank in the Thames at Woolwich, killing 600 people. Within a decade, the new discipline of first aid spread rapidly throughout the world, and by the end of the 19th century, hundreds of thousands of St John first aid certificates had been awarded in four continents. Shepherd's pioneering classes changed the world's concept of the need for the provision of skilled prehospital care.			PEARN, J (corresponding author), ROYAL CHILDRENS HOSP,DEPT CHILD HLTH,BRISBANE,QLD 4029,AUSTRALIA.			Pearn, John/0000-0002-8815-2994				CANTLIE N, 1939, J CANTLIE ROMANCE ME, P19; CLIFFORD Joan, 1971, SERVICE MANKIND FURL; FLETCHER NC, 1929, J AMBULANCE ASS ITS, P12; FURNEAUX R, 1963, ZULU WAR ISANDHLWANA, P89; LEAVENSWHITE W, 1878, SOUTHPORT VISIT 0713; PEARN JH, 1993, MED HERBS WOUNDWORTS, P1; VINCENT WT, 1890, RECORDS WOOLWICH DIS, V1, P434; 1885, CITY PRESS      0218, P1; 1878, BERROWS WORCEST 0504; 1879, KENTISH INDEPEN 0215, P1; 1878, KENTISH INDEPEN 0119, P1; 1885, MED PRESS CIRCU 0311, P1; 1878, WOOLWICH GAZETT 1130; 1878, KENTISH INDEPEN 0302; 1878, DAILY TELEGRAPH 0314, P2; 1878, STANDARD        0122, P1; 1878, DAILY CHRONICLE 0625; 1878, KENTISH MERCURY 1130; 1878, DERBYSKIRE TIME 0720; 1879, STANDARD        0212	20	22	22	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1718	1720		10.1136/bmj.309.6970.1718	http://dx.doi.org/10.1136/bmj.309.6970.1718			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7820000	Green Published			2023-01-03	WOS:A1994PY71700030
J	ROY, CW; ARTHURS, Y; HUNTER, J; PARKER, S; MCLAREN, A				ROY, CW; ARTHURS, Y; HUNTER, J; PARKER, S; MCLAREN, A			WORK OF A REHABILITATION-MEDICINE SERVICE	BRITISH MEDICAL JOURNAL			English	Article									LOTHIAN HLTH BOARD,EDINBURGH,SCOTLAND		ROY, CW (corresponding author), ASTLEY AINSLIE HOSP,REHABIL MED UNIT,EDINBURGH EH9 2HL,SCOTLAND.							BRUDNY J, 1985, ORTHOTICS PROSTHET, V39, P14; CAY EL, 1973, J PSYCHOSOM RES, V17, P231, DOI 10.1016/0022-3999(73)90028-7; DONABEDIAN A, 1978, SCIENCE, V200, P856, DOI 10.1126/science.417400; GARDINER BM, 1980, PSYCHOL MED, V10, P159, DOI 10.1017/S0033291700039702; GARRAWAY M, 1985, STROKE, V16, P178, DOI 10.1161/01.STR.16.2.178; JARMAN CMB, 1982, POSTGRAD MED J, V58, P606, DOI 10.1136/pgmj.58.684.606; MAGUIRE PA, 1986, BRIT MED J, V292, P1251, DOI 10.1136/bmj.292.6530.1251; MCLACHLAN G, 1976, QUESTION QUALITY, P3; SMITH ME, 1979, BR J OCCUP THER, V42, P139; WRIGHT V, 1982, J ROY COLL PHYS LOND, V16, P178; 1986, J R COLL PHYSICIANS, V20, P160; 1972, MED REHABILITATION P	12	5	5	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 3	1988	297	6648					601	604		10.1136/bmj.297.6648.601	http://dx.doi.org/10.1136/bmj.297.6648.601			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	Q0168	2971420	Green Published, Bronze			2023-01-03	WOS:A1988Q016800032
J	MULLAN, K				MULLAN, K			WRITING A WRONG	BRITISH MEDICAL JOURNAL			English	Article											MULLAN, K (corresponding author), UNIV ULSTER,DEPT PUBL ADM & LEGAL STUDIES,JORDANSTOWN,NORTH IRELAND.							FINCH J, 1982, NEW LAW J       0225, P176; 1988, TIMES           0314, P19; 1983, LAW SOC GAZETTE, V80, P3003	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1988	297	6646					470	471		10.1136/bmj.297.6646.470	http://dx.doi.org/10.1136/bmj.297.6646.470			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	P6653	3139151	Bronze, Green Published			2023-01-03	WOS:A1988P665300030
J	RYLANCE, GW; WOODS, CG; CULLEN, RE; RYLANCE, ME				RYLANCE, GW; WOODS, CG; CULLEN, RE; RYLANCE, ME			USE OF DRUGS BY CHILDREN	BMJ-BRITISH MEDICAL JOURNAL			English	Article											RYLANCE, GW (corresponding author), CHILDRENS HOSP, LADYWOOD MIDDLEWAY, BIRMINGHAM B16 8ET, W MIDLANDS, ENGLAND.		woods, christopher g/A-1361-2010					ARANDA JV, 1976, J PEDIATR-US, V89, P315, DOI 10.1016/S0022-3476(76)80478-7; CATFORD JC, 1980, BRIT MED J, V280, P1435, DOI 10.1136/bmj.280.6229.1435; CLEARLY J, 1976, J R COLL GEN PRAC S1, V26, pS34; CLEARY J, 1976, J R COLL GEN PRAC S1, V26, pS52; GORDIS L, 1969, J PEDIATR-US, V75, P957, DOI 10.1016/S0022-3476(69)80332-X; HAGGERTY RJ, 1972, PEDIATR CLIN N AM, V19, P101; JEFFERYS M, 1960, Br J Prev Soc Med, V14, P64; MACUKANOVIC P, 1976, HLTH CARE INT STUDY, P223; MORELAND TA, 1978, EUR J CLIN PHARMACOL, V14, P39, DOI 10.1007/BF00560256; RYLANCE GW, 1979, J CLIN PHARMACY, V4, P95, DOI 10.1111/j.1365-2710.1979.tb00144.x; WHYTE J, 1977, ACTA PAEDIATR SCAND, V66, P767, DOI 10.1111/j.1651-2227.1977.tb07987.x; 1972, PEDIATR CLIN N AM, V19, P117; 1986, BR MED J, V292, P1590; 1980, GENERAL HOUSEHOL GHS	14	41	46	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 13	1988	297	6646					445	447		10.1136/bmj.297.6646.445	http://dx.doi.org/10.1136/bmj.297.6646.445			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P6653	3139137	Green Published, Bronze			2023-01-03	WOS:A1988P665300016
J	EPSTEIN, AM; STERN, RS; TOGNETTI, J; BEGG, CB; HARTLEY, RM; CUMELLA, E; AYANIAN, JZ				EPSTEIN, AM; STERN, RS; TOGNETTI, J; BEGG, CB; HARTLEY, RM; CUMELLA, E; AYANIAN, JZ			THE ASSOCIATION OF PATIENTS SOCIOECONOMIC CHARACTERISTICS WITH THE LENGTH OF HOSPITAL STAY AND HOSPITAL CHARGES WITHIN DIAGNOSIS-RELATED GROUPS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									BRIGHAM & WOMENS HOSP,DEPT MED,DIV GEN MED,BOSTON,MA 02115; BETH ISRAEL HOSP,CHARLES A DANA RES INST,DEPT DERMATOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; HARVARD COMMUNITY HLTH PLAN & HARVARD UNIV,INST HLTH RES,BOSTON,MA; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT BIOSTAT,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School			Cumella, Edward/V-5552-2018	Cumella, Edward/0000-0002-8500-8428				ARMITAGE P, 1971, STATISTICAL METHODS, P350; DAVIS K, 1975, J HUM RESOUR, V10, P361, DOI 10.2307/145196; EPSTEIN AM, 1985, AM J MED, V78, P101, DOI 10.1016/0002-9343(85)90469-3; HORN SD, 1985, NEW ENGL J MED, V313, P20, DOI 10.1056/NEJM198507043130105; JENCKS SF, 1987, JAMA-J AM MED ASSOC, V257, P198, DOI 10.1001/jama.257.2.198; KLEINBAUM DG, 1978, APPLIED REGRESSION A, P209; RUSHING WA, 1978, AM SOCIOL REV, V43, P521, DOI 10.2307/2094776; STERN RS, 1985, NEW ENGL J MED, V312, P621, DOI 10.1056/NEJM198503073121005; 1983, FED REG, V48, P39876; 1980, GENERAL SOCIAL SURVE, P271; 1982, FED REG, V47, P43285; 1978, MULTIDIMENSIONAL FUN; 1984, FED REG, V49, P276; 1985, TECHNICAL APPENDIXES	14	96	96	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1988	318	24					1579	1585		10.1056/NEJM198806163182405	http://dx.doi.org/10.1056/NEJM198806163182405			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7765	3131674				2023-01-03	WOS:A1988N776500005
J	CUMMINS, RO				CUMMINS, RO			INTERHOSPITAL TRANSFER OF ACUTELY ILL CARDIAC PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											CUMMINS, RO (corresponding author), UNIV WASHINGTON,SEATTLE,WA 98195, USA.							BRAMAN SS, 1987, ANN INTERN MED, V107, P469, DOI 10.7326/0003-4819-107-4-469; CALES RH, 1984, ANN EMERG MED, V13, P1, DOI 10.1016/S0196-0644(84)80375-3; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; CURRAN WJ, 1985, NEW ENGL J MED, V312, P374, DOI 10.1056/NEJM198502073120612; EISENBERG MS, 1984, SUDDEN CARDIAC DEATH; FUNG AY, 1986, AM J CARDIOL, V58, P686, DOI 10.1016/0002-9149(86)90338-3; HICKS TC, 1982, ANN EMERG MED, V11, P296, DOI 10.1016/S0196-0644(82)80126-1; HIMMELSTEIN DU, 1984, AM J PUBLIC HEALTH, V74, P494, DOI 10.2105/AJPH.74.5.494; JONASSON O, 1987, JAMA-J AM MED ASSOC, V257, P1519; KOREN G, 1985, NEW ENGL J MED, V313, P1384, DOI 10.1056/NEJM198511283132204; MILLER PF, 1987, ARCH INTERN MED, V147, P1565, DOI 10.1001/archinte.147.9.1565; OLSON CM, 1986, AM J EMERG MED, V5, P33; RUBENSTEIN DG, 1988, JAMA-J AM MED ASSOC, V259, P1695, DOI 10.1001/jama.259.11.1695; SCHIFF RL, 1986, NEW ENGL J MED, V314, P552, DOI 10.1056/NEJM198602273140905; THOMAS F, 1986, CRIT CARE MED, V14, P227, DOI 10.1097/00003246-198603000-00012; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; TOPOL EJ, 1986, CATHETER CARDIO DIAG, V12, P151; URDANETA LF, 1987, ARCH SURG-CHICAGO, V122, P992; WALSH DG, 1987, ANN EMERG MED, V16, P243, DOI 10.1016/S0196-0644(87)80166-X; WEST JG, 1979, ARCH SURG-CHICAGO, V114, P455; 1985, ANN EMERG MED, V14, P1221; 1976, MANUAL HOSPITALS, P36	22	4	4	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1988	259	11					1707	1708						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M3903	3343776				2023-01-03	WOS:A1988M390300036
J	FUKAURA, A; TAZAWA, H; NAKAJIMA, H; ADACHI, M				FUKAURA, A; TAZAWA, H; NAKAJIMA, H; ADACHI, M			DO-NOT-RESUSCITATE ORDERS AT A TEACHING HOSPITAL IN JAPAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							CARDIOPULMONARY RESUSCITATION; POLICY; CHOICE; STILL				FUKAURA, A (corresponding author), SHOWA UNIV,SCH MED,TOKYO 142,JAPAN.							[Anonymous], 1990, CRIT CARE MED, V18, P1435; Arai T, 1994, Masui, V43, P600; ARAI T, 1994, ICU CCU, V18, P657; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BERLOWITZ DR, 1991, J AM GERIATR SOC, V39, P472, DOI 10.1111/j.1532-5415.1991.tb02492.x; BROWN BW, 1977, STATISTICS BIOMEDICA; Fukaura Asato, 1994, Journal of Japan Society for Cancer Therapy, V29, P1696; GLEESON K, 1990, ARCH INTERN MED, V150, P1057, DOI 10.1001/archinte.150.5.1057; JONSSON PV, 1988, ARCH INTERN MED, V148, P2373, DOI 10.1001/archinte.148.11.2373; MILES SH, 1982, ANN INTERN MED, V96, P660, DOI 10.7326/0003-4819-96-5-660; Murakami K, 1986, Gan To Kagaku Ryoho, V13, P2693; Murakami K, 1989, Gan To Kagaku Ryoho, V16, P740; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; Sato Ikuyo, 1994, Journal of Japan Society for Cancer Therapy, V29, P1677; SCHWARTZ DA, 1986, J AM GERIATR SOC, V34, P807, DOI 10.1111/j.1532-5415.1986.tb03986.x; SHAPIRO GR, 1991, PROG P AM SOC CLIN O, V10, P325; STANLEY DP, 1989, MED J AUSTRALIA, V151, P257, DOI 10.5694/j.1326-5377.1989.tb101190.x; STANLEY DP, 1989, MED J AUSTRALIA, V151, P260; STERN SG, 1992, CRIT CARE MED, V20, P1263, DOI 10.1097/00003246-199209000-00013; STEVENS CA, 1994, J MED ETHICS, V20, P41, DOI 10.1136/jme.20.1.41; STOLMAN CJ, 1989, ARCH INTERN MED, V149, P1851, DOI 10.1001/archinte.149.8.1851; TAZAWA H, 1990, Journal of Japan Society for Cancer Therapy, V25, P1448; TAZAWA H, 1986, Journal of Japan Society for Cancer Therapy, V21, P2454; Teshima H, 1987, Nihon Kyobu Shikkan Gakkai Zasshi, V25, P305; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; UHLMANN RF, 1984, CRIT CARE MED, V12, P879, DOI 10.1097/00003246-198410000-00009; VANDELDEN JJM, 1993, J MED ETHICS, V19, P200, DOI 10.1136/jme.19.4.200; WITTE KL, 1984, HEART LUNG, V13, P159; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; 1989, J MED ETHICS, V15, P129; 1995, ASSAHI SHIMBUN  0328, P3; 1991, PUBLIC OPINION POLL, V23, P46; 1992, NIHON ISIKAI ZASSI, V107, P1209; 1974, JAMA-J AM MED ASSOC, V227, P864	34	27	28	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 21	1995	333	12					805	808		10.1056/NEJM199509213331218	http://dx.doi.org/10.1056/NEJM199509213331218			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU809	7643902				2023-01-03	WOS:A1995RU80900028
J	HU, LQ; COLMAN, RF				HU, LQ; COLMAN, RF			MONOBROMOBIMANE AS AN AFFINITY LABEL OF THE XENOBIOTIC BINDING-SITE OF RAT GLUTATHIONE-S-TRANSFERASE-3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; SEQUENCE ANALYSIS; ISOENZYME 3-3; CDNA CLONE; RESOLUTION; SUBSTRATE; COMPLEX; LIVER; TYR(115)	Monobromobimane (mBBr), besides being a substrate in the presence of glutathione, inactivates rat liver glutathione S-transferase 3-3 at pH 7.5 and 25 degrees C as assayed using 1-chloro-2,4-dinitrobenzene (CDNB). The rate of inactivation is enhanced about 5-fold by S-methylglutathione. Substrate analogs bromosulfophthalein and 2,4-dinitrophenol decrease the rate of inactivation at least 20-fold. Upon incubation for 60 min with 0.25 mM mBBr and S-methylglutathione, the enzyme loses 91% of its activity toward CDNB and incorporates 2.14 mol of reagent/mol of subunit, whereas incubation under the same conditions but with added protectant 2,4-dinitrophenol yields an enzyme that is catalytically active and contains only 0.89 mol of reagent/mol of subunit. mBBr-modified enzyme is fluorescent, and fluorescence energy transfer occurs between intrinsic tryptophan and covalently bound bimane in modified enzyme. Both Tyr(115) and Cys(114) are modified, but Tyr(115) is the initial reaction target and its modification correlates with loss of activity toward CDNB. The fact that the activity toward mBBr is retained by the enzyme after modification suggests that rat isozyme 3-3 has two binding sites for mBBr.	UNIV DELAWARE,DEPT CHEM & BIOCHEM,NEWARK,DE 19716	University of Delaware			Hu, Longqin/AAR-7076-2021	Hu, Longqin/0000-0002-1799-5652	NCI NIH HHS [F32 CA66276] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA066276] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMSTRONG RN, 1987, CRC CR REV BIOCH MOL, V22, P39, DOI 10.3109/10409238709082547; ARMSTRONG RN, 1991, CHEM RES TOXICOL, V4, P131, DOI 10.1021/tx00020a001; BARYCKI JJ, 1993, BIOCHEMISTRY-US, V32, P13002, DOI 10.1021/bi00211a008; BHARGAVA MM, 1978, J BIOL CHEM, V253, P4112; BODANSZKY M, 1984, PRACTICE PEPTIDE SYN, P62; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COBB D, 1983, BIOCHEMISTRY-US, V22, P805, DOI 10.1021/bi00273a015; COLES B, 1990, CRIT REV BIOCHEM MOL, V25, P47, DOI 10.3109/10409239009090605; COLMAN RF, 1984, BIOCHEMISTRY-US, V23, P3281, DOI 10.1021/bi00309a025; COOKE RJ, 1994, BIOCHEM J, V302, P383, DOI 10.1042/bj3020383; COWAN SW, 1989, J MOL BIOL, V208, P369, DOI 10.1016/0022-2836(89)90398-7; DING GJF, 1986, J BIOL CHEM, V261, P7952; DING GJF, 1985, J BIOL CHEM, V260, P3268; FAIRCLOUGH RH, 1979, METHOD ENZYMOL, V48, P347; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HU L, 1994, PROTEIN SCI, V3, P127; HUANG YC, 1984, J BIOL CHEM, V259, P2481; HULBERT PB, 1983, J PHARM PHARMACOL, V35, P384, DOI 10.1111/j.2042-7158.1983.tb02962.x; JI X, 1993, BIOCHEMISTRY-US, V32, P12949, DOI 10.1021/bi00211a001; JI XH, 1994, BIOCHEMISTRY-US, V33, P1043, DOI 10.1021/bi00171a002; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KATUSZ RM, 1992, ARCH BIOCHEM BIOPHYS, V298, P667, DOI 10.1016/0003-9861(92)90464-8; KOSOWER NS, 1987, METHOD ENZYMOL, V143, P76; LAI HCJ, 1988, J BIOL CHEM, V263, P11389; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; Penefsky H S, 1979, Methods Enzymol, V56, P527; PICKETT CB, 1989, ANNU REV BIOCHEM, V58, P743, DOI 10.1146/annurev.bi.58.070189.003523; PLOEMEN JHT, 1994, J BIOL CHEM, V269, P26980; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; REINEMER P, 1991, EMBO J, V10, P1997, DOI 10.1002/j.1460-2075.1991.tb07729.x; ROWE J, 1994, FASEB J, V8, pA1467; RUSHMORE TH, 1993, J BIOL CHEM, V268, P11475; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; SMYTH GE, 1991, J BIOL CHEM, V266, P14918; TSUCHIDA S, 1992, CRIT REV BIOCHEM MOL, V27, P337, DOI 10.3109/10409239209082566; VANDERJAGT DL, 1985, J BIOL CHEM, V260, P1603; WANG RW, 1993, PROTEIN SCI, V2, P2085, DOI 10.1002/pro.5560021209; WUNSCH E, 1958, CHEM BER-RECL, V91, P542, DOI 10.1002/cber.19580910312; ZALL DM, 1956, ANAL CHEM, V28, P1665, DOI 10.1021/ac60119a009	42	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1995	270	37					21875	21883		10.1074/jbc.270.37.21875	http://dx.doi.org/10.1074/jbc.270.37.21875			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU757	7665611	hybrid			2023-01-03	WOS:A1995RU75700071
J	TARPY, SP; CELLI, BR				TARPY, SP; CELLI, BR			LONG-TERM OXYGEN-THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; VENTILATORY MUSCLE RECRUITMENT; CHEST WALL MECHANICS; AIR-FLOW OBSTRUCTION; CHRONIC LUNG-DISEASE; HYPOXEMIC PATIENTS; EXERCISE CAPACITY; MEDICAL PROGRESS; MILD HYPOXEMIA; SLEEP		ST ELIZABETH HOSP, DEPT PULM & CRIT CARE, BOSTON, MA 02135 USA; BOSTON UNIV, SCH MED, CTR PULM, BOSTON, MA 02118 USA; TUFTS UNIV, SCH MED, BOSTON, MA 02111 USA	Boston University; Tufts University								ADAMO J P, 1990, Respiratory Care, V35, P153; [Anonymous], 1980, Ann Intern Med, V93, P391; ASTIN TW, 1967, AM REV RESPIR DIS, V95, P567; Barach AL, 1922, J AMER MED ASSOC, V79, P693, DOI 10.1001/jama.1922.02640090001001; BARKER AF, 1994, CHEST, V105, P248, DOI 10.1378/chest.105.1.248; BENDITT J, 1993, AM REV RESPIR DIS, V147, P1207, DOI 10.1164/ajrccm/147.5.1207; BLOCK AJ, 1974, CHEST, V65, P279, DOI 10.1378/chest.65.3.279; BRADLEY BL, 1978, AM REV RESPIR DIS, V118, P239; BYE PTP, 1985, AM REV RESPIR DIS, V132, P236; CALVERLEY PMA, 1982, AM REV RESPIR DIS, V126, P206; CHRISTOPHER KL, 1987, ANN INTERN MED, V107, P802, DOI 10.7326/0003-4819-107-6-802; COUSER JI, 1989, AM REV RESPIR DIS, V139, P627, DOI 10.1164/ajrccm/139.3.627; CRINER GJ, 1987, J APPL PHYSIOL, V63, P195, DOI 10.1152/jappl.1987.63.1.195; DEAN NC, 1992, AM REV RESPIR DIS, V146, P941, DOI 10.1164/ajrccm/146.4.941; DODD DS, 1984, AM REV RESPIR DIS, V129, P33; DONAHOE M, 1989, AM REV RESPIR DIS, V140, P385, DOI 10.1164/ajrccm/140.2.385; DOUGLAS NJ, 1990, AM REV RESPIR DIS, V141, P1055, DOI 10.1164/ajrccm/141.4_Pt_1.1055; FERGUSON GT, 1993, NEW ENGL J MED, V328, P1017; FLEETHAM J, 1982, AM REV RESPIR DIS, V126, P429; FLENLEY DC, 1981, LANCET, V1, P681; FLETCHER EC, 1989, CHEST, V95, P757, DOI 10.1378/chest.95.4.757; GONG H, 1992, CHEST, V101, P1104, DOI 10.1378/chest.101.4.1104; GRANT I, 1982, ARCH INTERN MED, V142, P1470, DOI 10.1001/archinte.142.8.1470; GRANT I, 1987, ARCH GEN PSYCHIAT, V44, P999; HEATON RK, 1983, ARCH INTERN MED, V143, P1941, DOI 10.1001/archinte.143.10.1941; HEIMLICH HJ, 1989, CHEST, V95, P1008, DOI 10.1378/chest.95.5.1008; JOHNSON JT, 1991, ANN OTO RHINOL LARYN, V100, P108, DOI 10.1177/000348949110000205; KOO KW, 1975, AM J MED, V58, P663, DOI 10.1016/0002-9343(75)90502-1; KROP HD, 1973, CHEST, V64, P317, DOI 10.1378/chest.64.3.317; Levi-Valensi P, 1983, MED THORACA S4, V5, P502; LEVIVALENSI P, 1992, EUR RESPIR J, V5, P645; LEVIVALENSI P, 1992, EUR RESPIR J, V5, P301; LOCK SH, 1992, THORAX, V47, P98, DOI 10.1136/thx.47.2.98; Luft U., 1965, HDB PHYSL, P1099; MACNEE W, 1988, AM REV RESPIR DIS, V137, P1289, DOI 10.1164/ajrccm/137.6.1289; MARTINEZ FJ, 1990, AM REV RESPIR DIS, V142, P276, DOI 10.1164/ajrccm/142.2.276; MORRISON DA, 1992, CHEST, V102, P542, DOI 10.1378/chest.102.2.542; ODONOHUE WJ, 1995, CHEST, V107, P301, DOI 10.1378/chest.107.2.301; ODONOHUE WJ, 1990, AM REV RESPIR DIS, V142, P721; PRIGATANO GP, 1983, J CONSULT CLIN PSYCH, V51, P108, DOI 10.1037/0022-006X.51.1.108; ROBIN ED, 1958, J CLIN INVEST, V37, P981, DOI 10.1172/JCI103694; SLIWINSKI P, 1992, AM REV RESPIR DIS, V146, P665; STANEK KA, 1979, J APPL PHYSIOL, V46, P1115, DOI 10.1152/jappl.1979.46.6.1115; TABACHNIK E, 1981, J APPL PHYSIOL, V51, P557, DOI 10.1152/jappl.1981.51.3.557; TARPY S, 1992, AM REV RESPIR DIS, V146, pA646; TIEP BL, 1990, CLIN CHEST MED, V11, P505; TIEP BL, 1987, CHEST, V92, P263, DOI 10.1378/chest.92.2.263; TIMMS RM, 1985, ANN INTERN MED, V102, P29, DOI 10.7326/0003-4819-102-1-29; WEINBERGER SE, 1993, NEW ENGL J MED, V328, P1389, DOI 10.1056/NEJM199305133281906; WEINBERGER SE, 1993, NEW ENGL J MED, V328, P1462, DOI 10.1056/NEJM199305203282007; WEITZENBLUM E, 1985, AM REV RESPIR DIS, V131, P493, DOI 10.1164/arrd.1985.131.4.493; WRIGHT JL, 1992, LUNG, V170, P109	52	130	131	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 14	1995	333	11					710	714		10.1056/NEJM199509143331107	http://dx.doi.org/10.1056/NEJM199509143331107			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV227	7637750				2023-01-03	WOS:A1995RV22700007
J	SHAW, GM; LAMMER, EJ; WASSERMAN, CR; OMALLEY, CD; TOLAROVA, MM				SHAW, GM; LAMMER, EJ; WASSERMAN, CR; OMALLEY, CD; TOLAROVA, MM			RISKS OF OROFACIAL CLEFTS IN CHILDREN BORN TO WOMEN USING MULTIVITAMINS CONTAINING FOLIC-ACID PERICONCEPTIONALLY	LANCET			English	Article							NEURAL-TUBE DEFECTS; VITAMIN SUPPLEMENTATION; PREVENT RECURRENCE; WESTERN-AUSTRALIA; DIETARY-FOLATE; ORAL CLEFTS; PREGNANCY; LIP; SMOKING; PALATE	Women are advised to take folic acid before they conceive as a precaution against neural-tube defects. However, the use of folic acid in preventing orofacial clefts is unknown. We investigated whether a woman's periconceptional use of multivitamins containing folic acid was associated with a reduced risk of orofacial clefts. We derived data from a population-based case-control study of fetuses and liveborn infants with orofacial anomalies among a 1987-89 cohort of births in California. We interviewed 731 (84.7%) of eligible mothers with orofacial cleft case infants and 734 (78.2%) mothers with non-malformed control infants. We found a reduced risk of orofacial clefts if the mother had used multivitamins containing folic acid during the period from one month before through two months after conception. The odds ratios ranged from 0.50-0.73 depending on cleft phenotype. Controlling for the potential influence of other variables did not substantially alter the results. Maternal daily consumption of cereal containing folic acid was also associated with a reduced risk of orofacial clefts. Women who used multivitamins containing folic acid periconceptionally had a 25-50% reduction in risk for offspring with orofacial clefts compared to women who did not use such vitamins. However, this association may not be attributable to folic acid specifically, but may be a consequence of other multivitamin supplement components, or behaviours, that are highly correlated with the use of multivitamins containing folic acid.	CHILDRENS HOSP,DEPT MED GENET,OAKLAND,CA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	SHAW, GM (corresponding author), MARCH DIMES BIRTH DEFECTS FDN,CALIF BIRTH DEFECTS MONITORING PROGRAM,EMERYVILLE,CA, USA.			Shaw, Gary/0000-0001-7438-4914				BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; BOWER C, 1992, AM J MED GENET, V44, P647, DOI 10.1002/ajmg.1320440524; Briggs R M, 1976, Clin Plast Surg, V3, P647; CONWAY H, 1958, Plast Reconstr Surg Transplant Bull, V22, P450, DOI 10.1097/00006534-195811000-00003; Croen L A, 1991, Paediatr Perinat Epidemiol, V5, P423, DOI 10.1111/j.1365-3016.1991.tb00728.x; CZEIZEL AE, 1993, BRIT MED J, V306, P1645, DOI 10.1136/bmj.306.6893.1645; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DANSKY LV, 1987, ANN NEUROL, V21, P176, DOI 10.1002/ana.410210210; DOUGLAS B, 1958, Plast Reconstr Surg Transplant Bull, V22, P94, DOI 10.1097/00006534-195808000-00002; HILL L, 1988, J EPIDEMIOL COMMUN H, V42, P1, DOI 10.1136/jech.42.1.1; JORDAN RL, 1977, TERATOLOGY, V15, P73, DOI 10.1002/tera.1420150110; KHOURY MJ, 1989, AM J DIS CHILD, V143, P333, DOI 10.1001/archpedi.1989.02150150091023; LAURENCE KM, 1981, BRIT MED J, V282, P1509, DOI 10.1136/bmj.282.6275.1509; MILUNSKY A, 1989, JAMA-J AM MED ASSOC, V262, P2847, DOI 10.1001/jama.262.20.2847; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; NELSON MM, 1960, CIBA F S CONGENITAL, P134; PEER LA, 1964, PLAST RECONSTR SURG, V34, P358; PEER LA, 1958, PLAST RECONSTR SURG, V22, P422; SAXEN I, 1975, INT J EPIDEMIOL, V4, P37, DOI 10.1093/ije/4.1.37; SHAW GM, 1995, EPIDEMIOLOGY, V6, P219, DOI 10.1097/00001648-199505000-00005; SMITHELLS RW, 1983, LANCET, V1, P1027; TOLAROVA M, 1982, LANCET, V2, P217; TOLAROVA M, 1987, SCAND J PLAST RECONS, V21, P19, DOI 10.3109/02844318709083574; WAITZMAN NJ, 1994, INQUIRY-J HEALTH CAR, V31, P188; WEGNER C, 1992, NEUROLOGY, V42, P17; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; WITTER FR, 1982, AM J OBSTET GYNECOL, V144, P857, DOI 10.1016/0002-9378(82)90369-6; 1991, STATISTICS EPIIDEMIO; 1991, LANCET, V338, P131; 1989, HLTH HABITS HIST QUE	30	373	387	0	14	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					393	396		10.1016/S0140-6736(95)92778-6	http://dx.doi.org/10.1016/S0140-6736(95)92778-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623568				2023-01-03	WOS:A1995RN65600007
J	DENISON, MS; WHITLOCK, JP				DENISON, MS; WHITLOCK, JP			XENOBIOTIC-INDUCIBLE TRANSCRIPTION OF CYTOCHROME-P450 GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							ACYL-COA OXIDASE; PEROXISOME PROLIFERATORS; PHENOBARBITAL INDUCTION; AROMATIC-HYDROCARBONS; RAT HEPATOCYTES; AH-RECEPTOR; ENZYMES; BINDING; SUPERFAMILY; MECHANISMS		STANFORD UNIV, SCH MED, DEPT MOLEC PHARMACOL, STANFORD, CA 94305 USA	Stanford University	DENISON, MS (corresponding author), UNIV CALIF DAVIS, DEPT ENVIRONM TOXICOL, DAVIS, CA 95616 USA.							ANDERSEN JF, 1994, BIOCHEMISTRY-US, V33, P2171, DOI 10.1021/bi00174a025; BARS RG, 1989, BIOCHEM J, V262, P151, DOI 10.1042/bj2620151; BELL DR, 1991, BIOCHEM J, V280, P249, DOI 10.1042/bj2800249; BURGER HJ, 1992, P NATL ACAD SCI USA, V89, P2145, DOI 10.1073/pnas.89.6.2145; CHAN WK, 1994, J BIOL CHEM, V269, P26464; CONNEY AH, 1982, CANCER RES, V42, P4875; ELFERINK CJ, 1994, RECEPTOR, V4, P157; ENGLISH N, 1994, J BIOL CHEM, V269, P26836; FOURNIER T, 1994, J BIOL CHEM, V269, P27175; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; GEARING KL, 1994, J NUTR, V124, pS1284, DOI 10.1093/jn/124.suppl_8.1284S; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GONZALEZ FJ, 1990, TRENDS GENET, V6, P182, DOI 10.1016/0168-9525(90)90174-5; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pa.35.040195.001515; HE JS, 1991, J BIOL CHEM, V266, P7864; HENRY EC, 1994, MOL PHARMACOL, V46, P1022; JAIN S, 1994, J BIOL CHEM, V269, P31518; KAIKAUS RM, 1993, J BIOL CHEM, V268, P9593; KELLER H, 1993, TRENDS ENDOCRIN MET, V4, P291, DOI 10.1016/1043-2760(93)90048-J; KOCAREK TA, 1994, BIOCHEM PHARMACOL, V48, P1815, DOI 10.1016/0006-2952(94)90468-5; LI H, 1994, J BIOL CHEM, V269, P28098; LIANG QW, 1995, J BIOL CHEM, V270, P4438, DOI 10.1074/jbc.270.9.4438; LOCK EA, 1989, ANNU REV PHARMACOL, V29, P145; MASON GGF, 1994, J BIOL CHEM, V269, P4438; MOTOJIMA K, 1993, CELL STRUCT FUNCT, V18, P267, DOI 10.1247/csf.18.267; NEBERT DW, 1991, MOL ENDOCRINOL, V5, P1203, DOI 10.1210/mend-5-9-1203; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; OKEY AB, 1994, TRENDS PHARMACOL SCI, V15, P226, DOI 10.1016/0165-6147(94)90316-6; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PALMER CNA, 1994, J BIOL CHEM, V269, P18083; POLAND A, 1982, ANNU REV PHARMACOL, V22, P517, DOI 10.1146/annurev.pa.22.040182.002505; PORTER TD, 1991, J BIOL CHEM, V266, P13469; QUATTROCHI LC, 1994, J BIOL CHEM, V269, P6949; RAM PA, 1994, BIOCHEM J, V301, P753, DOI 10.1042/bj3010753; RAMSDEN R, 1993, J BIOL CHEM, V268, P21722; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SAVAS U, 1994, J BIOL CHEM, V269, P14905; SAVAS U, 1994, MOL PHARMACOL, V45, P1153; SCHUETZ EG, 1993, HEPATOLOGY, V18, P1254; SELYE H, 1971, J PHARM SCI, V60, P1, DOI 10.1002/jps.2600600102; SHAW PM, 1993, MOL PHARMACOL, V44, P775; SHEPHARD EA, 1994, DNA CELL BIOL, V13, P793, DOI 10.1089/dna.1994.13.793; SUTTER TR, 1994, J BIOL CHEM, V269, P13092; SWANSON HI, 1993, PHARMACOGENETICS, V3, P213, DOI 10.1097/00008571-199310000-00001; SWANSON HI, 1993, BIOCHEMISTRY-US, V32, P12841, DOI 10.1021/bi00210a037; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; WAXMAN DJ, 1992, BIOCHEM J, V281, P577, DOI 10.1042/bj2810577; WHITLOCK JP, 1993, CHEM RES TOXICOL, V6, P754, DOI 10.1021/tx00036a003	50	312	327	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 4	1995	270	31					18175	18178		10.1074/jbc.270.31.18175	http://dx.doi.org/10.1074/jbc.270.31.18175			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM642	7629130	hybrid			2023-01-03	WOS:A1995RM64200001
J	VIRGO, KS; VERNAVA, AM; LONGO, WE; MCKIRGAN, LW; JOHNSON, FE				VIRGO, KS; VERNAVA, AM; LONGO, WE; MCKIRGAN, LW; JOHNSON, FE			COST OF PATIENT FOLLOW-UP AFTER POTENTIALLY CURATIVE COLORECTAL-CANCER TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTOPERATIVE SURVEILLANCE; CARCINOMA; COLON; RESECTION; SURGERY; RECTUM; RECURRENCE; MUTATIONS	Objective.- To estimate the cost of follow-up among colorectal cancer patients treated with curative intent based on the broad spectrum of surveillance strategies suggested in the literature. Design.- Economic analysis of the costs associated with 11 separate surveillance strategies. Charge data were obtained from the Part B Medicare Annual Data file and the Hospital Outpatient Bill file. Setting.- Ambulatory care. Main Outcome Measures.- Medicare-allowed charges and an actual-charge proxy for 5 years of follow-up after treatment for colorectal cancer patients on a nationwide basis. Results.- Medicare-allowed charges varied widely for the 5 years of posttreatment follow-up from a low of $561 to a high of $16 492. When Medicare-allowed charges were converted to a proxy for actual charges using a conversion ratio of 1.62, the range was $910 to $26 717, a 28-fold difference in charges. Conclusions.- Charges vary extensively across follow-up strategies, with no indication that higher-cost strategies increase survival or quality of life.	DEPT VET AFFAIRS MED CTR, SURG SERV, ST LOUIS, MO USA		VIRGO, KS (corresponding author), ST LOUIS UNIV, HLTH SCI CTR, DEPT SURG, 3635 VISTA AVE, POB 15250, ST LOUIS, MO 63110 USA.		Virgo, Katherine S/AAG-3188-2021	Virgo, Katherine S/0000-0002-2069-0585				Adloff M, 1989, Chirurgie, V115, P228; ANDERSON C, 1994, SCIENCE, V263, P1080, DOI 10.1126/science.8108722; BEART RW, 1983, MAYO CLIN PROC, V58, P361; BERNSTAM VA, 1992, HDB GENE LEVEL DIAGN; BRUINVELS DJ, 1994, ANN SURG, V219, P174, DOI 10.1097/00000658-199402000-00009; BUHLER H, 1984, CANCER, V54, P791, DOI 10.1002/1097-0142(19840901)54:5<791::AID-CNCR2820540502>3.0.CO;2-R; BUIE WD, 1993, GASTROINTEST ENDOSC, V3, P691; CALI RL, 1993, DIS COLON RECTUM, V36, P388, DOI 10.1007/BF02053945; DELTURCO MR, 1994, JAMA-J AM MED ASSOC, V271, P1593, DOI 10.1001/jama.1994.03510440053032; DEVENEY KE, 1984, AM J SURG, V148, P717, DOI 10.1016/0002-9610(84)90423-9; FISCHER DS, 1983, FOLLOW UP CANCER HDB, P4; FISCHER DS, 1992, FOLLOW UP CANCER HDB, P34; FLEISCHER DE, 1989, JAMA-J AM MED ASSOC, V261, P580, DOI 10.1001/jama.261.4.580; GALANDIUK S, 1992, SURG GYNECOL OBSTET, V174, P27; JUHL G, 1990, WORLD J SURG, V14, P255, DOI 10.1007/BF01664886; KELLY CJ, 1992, CANCER-AM CANCER SOC, V70, P1397, DOI 10.1002/1097-0142(19920901)70:3+<1397::AID-CNCR2820701531>3.0.CO;2-A; KRONTIRIS TG, 1993, NEW ENGL J MED, V329, P517, DOI 10.1056/NEJM199308193290801; Makela J, 1992, Surg Oncol, V1, P157, DOI 10.1016/0960-7404(92)90029-K; MOERTEL CG, 1993, JAMA-J AM MED ASSOC, V270, P943, DOI 10.1001/jama.270.8.943; NAVA HR, 1982, CANCER, V49, P1043, DOI 10.1002/1097-0142(19820301)49:5<1043::AID-CNCR2820490533>3.0.CO;2-Y; OVASKA J, 1990, AM J SURG, V159, P593, DOI 10.1016/S0002-9610(06)80074-7; OVASKA J, 1990, GASTROENTEROLOGY, V99, P1849; OVASKA JT, 1989, SCAND J GASTROENTERO, V24, P416, DOI 10.3109/00365528909093068; ROBERTS PJ, 1988, SCAND J GASTROENTERO, V23, P50, DOI 10.3109/00365528809096956; ROCKLIN MS, 1990, AM SURGEON, V56, P22; SAFI F, 1993, CANCER DETECT PREV, V17, P417; SANDLER RS, 1984, CANCER, V53, P193, DOI 10.1002/1097-0142(19840101)53:1<193::AID-CNCR2820530134>3.0.CO;2-V; SIDRANSKY D, 1992, SCIENCE, V256, P102, DOI 10.1126/science.1566048; STEELE G, 1991, WORLD J SURG, V15, P583, DOI 10.1007/BF01789202; STEELE G, 1986, COLORECTAL CANCER; SUGARBAKER PH, 1987, SURGERY, V102, P79; TORNQVIST A, 1982, BRIT J SURG, V69, P725, DOI 10.1002/bjs.1800691213; VERNAVA AM, 1994, DIS COLON RECTUM, V37, P573, DOI 10.1007/BF02050993; VIRGO KS, IN PRESS ANN SURG ON; 1992, DIS COLON RECTUM, V35, P389; 1994, JAMA-J AM MED ASSOC, V271, P1587; 1960, CONSUMER PRICE INDEX	37	121	123	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1837	1841		10.1001/jama.273.23.1837	http://dx.doi.org/10.1001/jama.273.23.1837			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776499				2023-01-03	WOS:A1995RD11600025
J	LIMOUSIN, P; POLLAK, P; BENAZZOUZ, A; HOFFMANN, D; LEBAS, JF; BROUSSOLLE, E; PERRET, JE; BENABID, AL				LIMOUSIN, P; POLLAK, P; BENAZZOUZ, A; HOFFMANN, D; LEBAS, JF; BROUSSOLLE, E; PERRET, JE; BENABID, AL			EFFECT ON PARKINSONIAN SIGNS AND SYMPTOMS OF BILATERAL SUBTHALAMIC NUCLEUS STIMULATION	LANCET			English	Article							INTERMEDIATE THALAMIC NUCLEUS; MOVEMENT-DISORDERS; DISEASE; PRIMATE; TREMOR; DYSKINESIAS; REVERSAL; LESIONS	In monkeys rendered parkinsonian, lesions and electrical stimulation of the subthalamic nucleus reduce all major motor disturbances, The effect of electrical stimulation of the subthalamic nucleus was assessed in three patients with disabling akinetic-rigid Parkinson's disease and severe motor fluctuations. Quadripolar electrodes connected to a pulse generator were implanted in the subthalamic nuclei on both sides, Patients were evaluated with the unified Parkinson's disease rating scale and timed motor tests. 3 months after surgery, activities of daily living scores had improved by 58-88% and motor scores by 42-84%. This improvement was maintained for up to 8 months in the first patient operated upon. One patient was confused for 2 weeks after surgery, and another developed neuropsychological impairment related to a thalamic infarction which improved over 3 months, In one patient, stimulation could induce ballism that was stopped by reduction of stimulation. This is the first demonstration in human beings of the part played by the subthalamic nuclei in the pathophysiology of Parkinson's disease.	UNIV GRENOBLE 1,DEPT CLIN & BIOL NEUROSCI,F-38041 GRENOBLE,FRANCE; HOP NEUROL,LYON,FRANCE	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CHU Lyon			Broussolle, Emmanuel/H-1592-2017; Benazzouz, Abdelhamid/E-5050-2016	Broussolle, Emmanuel/0000-0002-0410-9519; 				ALEXANDER GE, 1990, TRENDS NEUROSCI, V13, P266, DOI 10.1016/0166-2236(90)90107-L; AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; AZIZ TZ, 1991, MOVEMENT DISORD, V6, P288, DOI 10.1002/mds.870060404; BENABID AL, 1991, LANCET, V337, P403, DOI 10.1016/0140-6736(91)91175-T; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; BLOND S, 1992, J NEUROSURG, V77, P62, DOI 10.3171/jns.1992.77.1.0062; CAPARROSLEFEBVRE D, 1993, J NEUROL NEUROSUR PS, V56, P268, DOI 10.1136/jnnp.56.3.268; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DELONG MR, 1985, J NEUROPHYSIOL, V53, P530, DOI 10.1152/jn.1985.53.2.530; FAHN S, 1992, NEW ENGL J MED, V327, P1589, DOI 10.1056/NEJM199211263272209; Fahn S, 1987, RECENT DEV PARKINSON, V2, P153; HAMADA I, 1992, J NEUROPHYSIOL, V68, P1850, DOI 10.1152/jn.1992.68.5.1850; HITCHCOCK ER, 1988, LANCET, V1, P1274; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LINDVALL O, 1992, ANN NEUROL, V31, P155, DOI 10.1002/ana.410310206; Miller WC, 1987, BASAL GANGLIA 2, VII, P415, DOI 10.1007/978-1- 4684-5347-8_29; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NGUYEN JP, 1993, ARCH NEUROL-CHICAGO, V50, P498, DOI 10.1001/archneur.1993.00540050050014; PILLON B, 1986, NEUROLOGY, V36, P1179, DOI 10.1212/WNL.36.9.1179; POLLAK P, 1993, ADV NEUROL, V60, P408; Schaltenbrand G, 1977, ATLAS STEREOTAXY HUM; SHANNON KM, 1990, CLIN NEUROPHARMACOL, V13, P413, DOI 10.1097/00002826-199010000-00003; Talairach J., 1957, ATLAS ANATOMIE STERE; 1992, MOV DISORD, V7, P2	25	1059	1102	3	66	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					91	95		10.1016/S0140-6736(95)90062-4	http://dx.doi.org/10.1016/S0140-6736(95)90062-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815888				2023-01-03	WOS:A1995QB80400009
J	WALT, RP				WALT, RP			PREVENTING ADMISSIONS FOR GASTROINTESTINAL-BLEEDING	LANCET			English	Editorial Material											WALT, RP (corresponding author), BIRMINGHAM HEARTLANDS HOSP,DEPT MED,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND.							JENSEN DM, 1994, NEW ENGL J MED, V330, P382, DOI 10.1056/NEJM199402103300602; KOCKALL TA, 1994, GUT S5, V35, pS47; LABENZ J, 1994, DIGESTION, V55, P19, DOI 10.1159/000201117; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; MARCH L, 1994, BRIT MED J, V309, P1041, DOI 10.1136/bmj.309.6961.1041; PENSTON JG, 1992, ALIMENT PHARM THERAP, V6, P629; POWELL KU, 1994, Q J MED, V87, P283; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0	8	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					77	78		10.1016/S0140-6736(95)90057-8	http://dx.doi.org/10.1016/S0140-6736(95)90057-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815883				2023-01-03	WOS:A1995QB80400004
J	WOOD, PD; STEFANICK, ML; DREON, DM; FREYHEWITT, B; GARAY, SC; WILLIAMS, PT; SUPERKO, HR; FORTMANN, SP; ALBERS, JJ; VRANIZAN, KM; ELLSWORTH, NM; TERRY, RB; HASKELL, WL				WOOD, PD; STEFANICK, ML; DREON, DM; FREYHEWITT, B; GARAY, SC; WILLIAMS, PT; SUPERKO, HR; FORTMANN, SP; ALBERS, JJ; VRANIZAN, KM; ELLSWORTH, NM; TERRY, RB; HASKELL, WL			CHANGES IN PLASMA-LIPIDS AND LIPOPROTEINS IN OVERWEIGHT MEN DURING WEIGHT-LOSS THROUGH DIETING AS COMPARED WITH EXERCISE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV WASHINGTON,SCH MED,DEPT MED,SEATTLE,WA 98195; UNIV WASHINGTON,SCH MED,DEPT PATHOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	WOOD, PD (corresponding author), STANFORD UNIV,SCH MED,STANFORD CTR RES DIS PREVENT,730 WELCH RD,PALO ALTO,CA 94304, USA.			Superko, H. Robert/0000-0002-3542-0393	NHLBI NIH HHS [HL-07034, HL-30086, HL-24462] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086, T32HL007034, R01HL024462] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; BALLANTYNE FC, 1982, METABOLISM, V31, P433, DOI 10.1016/0026-0495(82)90230-X; Brownell K. D., 1980, OBESITY, P300; GLUECK CJ, 1980, CIRCULATION, V62, P62; GOFMAN JW, 1966, CIRCULATION, V34, P679, DOI 10.1161/01.CIR.34.4.679; HUBERT HB, 1983, CIRCULATION, V67, P968, DOI 10.1161/01.CIR.67.5.968; MANNINEN V, 1988, JAMA-J AM MED ASSOC, V260, P641, DOI 10.1001/jama.260.5.641; MARTIN JE, 1982, J CONSULT CLIN PSYCH, V50, P1004, DOI 10.1037/0022-006X.50.6.1004; MILLER NE, 1981, BRIT MED J, V282, P1741, DOI 10.1136/bmj.282.6278.1741; SAMPSON EJ, 1975, CLIN CHEM, V21, P1983; SAVIN WM, 1980, CIRCULATION, V62, P55, DOI 10.1161/01.CIR.62.1.55; SCHWARTZ RS, 1987, METABOLISM, V36, P165, DOI 10.1016/0026-0495(87)90012-6; Siri W., 1961, TECHNIQUES MEASURING, P223; SOPKO G, 1985, METABOLISM, V34, P227, DOI 10.1016/0026-0495(85)90005-8; SORBRIS R, 1981, EUR J CLIN INVEST, V11, P491, DOI 10.1111/j.1365-2362.1981.tb02019.x; STEFANICK ML, 1987, CARDIOVASCULAR DISEA, P61; WARNICK GR, 1982, CLIN CHEM, V28, P1574; WARNICK GR, 1982, CLIN CHEM, V28, P1379; WILLIAMS PT, 1986, METABOLISM, V35, P45, DOI 10.1016/0026-0495(86)90094-6; WOOD PD, 1985, FED PROC, V44, P358; WOOD PD, 1983, METABOLISM, V32, P31, DOI 10.1016/0026-0495(83)90152-X; 1987, DHHS NIH882926 PUBL; [No title captured]; 1984, REFERENCE FOOD TABLE	24	578	587	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	1988	319	18					1173	1179		10.1056/NEJM198811033191801	http://dx.doi.org/10.1056/NEJM198811033191801			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q6975	3173455				2023-01-03	WOS:A1988Q697500001
J	KELLEY, MA				KELLEY, MA			CRITICAL CARE MEDICINE - A NEW SPECIALTY	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											KELLEY, MA (corresponding author), UNIV PENN,DEPT MED,PHILADELPHIA,PA 19104, USA.							BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BERENSON RA, 1984, OTAHCS28 PUBL; BIRNBAUM ML, 1986, CRIT CARE MED, V14, P1068, DOI 10.1097/00003246-198612000-00017; BUTLER PW, 1985, CHEST, V87, P229, DOI 10.1378/chest.87.2.229; DANIS M, 1987, CRIT CARE MED, V15, P138, DOI 10.1097/00003246-198702000-00012; ENGELHARDT HT, 1986, JAMA-J AM MED ASSOC, V255, P1159, DOI 10.1001/jama.255.9.1159; GREENBAUM DM, 1984, CRIT CARE MED, V12, P1073, DOI 10.1097/00003246-198412000-00016; GRENVIK A, 1981, CRIT CARE MED, V9, P117, DOI 10.1097/00003246-198102000-00012; HORN SD, 1985, NEW ENGL J MED, V313, P20, DOI 10.1056/NEJM198507043130105; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KYFF J, 1987, CRIT CARE MED, V15, P41, DOI 10.1097/00003246-198701000-00009; LUCE JM, 1988, CHEST, V93, P163, DOI 10.1378/chest.93.1.163; SCHWARTZ WB, 1987, JAMA-J AM MED ASSOC, V257, P220, DOI 10.1001/jama.257.2.220; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; STRAUSS MJ, 1986, JAMA-J AM MED ASSOC, V255, P1143, DOI 10.1001/jama.255.9.1143	15	31	32	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1988	318	24					1613	1617		10.1056/NEJM198806163182410	http://dx.doi.org/10.1056/NEJM198806163182410			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7765	3374531				2023-01-03	WOS:A1988N776500010
J	KRISHNASWAMY, S; MANN, KG				KRISHNASWAMY, S; MANN, KG			THE BINDING OF FACTOR-VA TO PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV VERMONT, DEPT BIOCHEM, HLTH SCI COMPLEX, BURLINGTON, VT 05405 USA	University of Vermont					NHLBI NIH HHS [HL-38337, HL-35058, HL-34575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034575, R29HL038337, R01HL034575, P50HL035058] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BABUL J, 1969, ANAL BIOCHEM, V28, P216, DOI 10.1016/0003-2697(69)90172-9; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; Bevington P.R., 1969, DATA REDUCTION ERROR; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; DAVIE EW, 1975, ANNU REV BIOCHEM, V44, P729, DOI 10.1146/annurev.bi.44.070175.004055; DURBIN J, 1950, BIOMETRIKA, V37, P409, DOI 10.2307/2332391; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; ESMON CT, 1979, J BIOL CHEM, V254, P964; FRANCIS RT, 1986, J BIOL CHEM, V261, P9787; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V21, P2285; GUINTO ER, 1982, J BIOL CHEM, V257, P38; HIBBARD LS, 1980, J BIOL CHEM, V255, P638; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; ISAACS BS, 1986, BIOCHEMISTRY-US, V25, P4958, DOI 10.1021/bi00365a036; JACKSON CM, 1968, BIOCHEMISTRY-US, V7, P4492, DOI 10.1021/bi00852a046; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P9684; KRISHNASWAMY S, 1987, THROMB HAEMOSTASIS, V58, P297; KRISHNASWAMY S, 1987, THROMB HAEMOSTASIS, V58, P133; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; Lackowicz JR, 1983, PRINCIPLES FLUORESCE, P111; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPE PD, 1984, J BIOL CHEM, V259, P9959; LECOMPTE MF, 1987, J BIOL CHEM, V262, P1935; Lundblad R L, 1976, Methods Enzymol, V45, P156; MANN KG, 1981, BIOCHEMISTRY-US, V20, P28, DOI 10.1021/bi00504a005; MANN KG, 1980, CLIN LABORATORY SCI, V3, P15; MAYER LD, 1977, BIOCHEMISTRY-US, V22, P6226; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1979, J BIOL CHEM, V254, P1326; NESHEIM ME, 1984, J BIOL CHEM, V259, P3187; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; ODEGAARD B, 1987, J BIOL CHEM, V262, P11233; OMAR MN, 1987, J BIOL CHEM, V262, P9750; PRIGENTDACHARY J, 1986, EUR J BIOCHEM, V155, P133, DOI 10.1111/j.1432-1033.1986.tb09468.x; PUSEY ML, 1982, BIOCHEMISTRY-US, V21, P5262, DOI 10.1021/bi00264a022; PUSEY ML, 1984, BIOCHEMISTRY-US, V23, P6202, DOI 10.1021/bi00320a048; SATOR V, 1978, ARCH BIOCHEM BIOPHYS, V190, P57, DOI 10.1016/0003-9861(78)90253-9; SHEPARD GB, 1977, BIOCHEMISTRY-US, V24, P5234; SUTTIE JW, 1977, PHYSIOL REV, V57, P1, DOI 10.1152/physrev.1977.57.1.1; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TRACY PB, 1979, J BIOL CHEM, V254, P354; TUCKER MM, 1983, BIOCHEMISTRY-US, V22, P4540, DOI 10.1021/bi00288a029; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; WEBER G, 1966, J BIOL CHEM, V241, P2558; WEBER G, 1952, BIOCHEM J, V51, P145, DOI 10.1042/bj0510145; WELTMAN JK, 1973, J BIOL CHEM, V248, P3173	53	135	136	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1988	263	12					5714	5723						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	N0898	3162734				2023-01-03	WOS:A1988N089800036
J	LANCASHIRE, MJR; LEGG, PK; LOWE, M; DAVIDSON, SM; ELLIS, BW				LANCASHIRE, MJR; LEGG, PK; LOWE, M; DAVIDSON, SM; ELLIS, BW			SURGICAL ASPECTS OF INTERNATIONAL DRUG SMUGGLING	BRITISH MEDICAL JOURNAL			English	Article									ASHFORD HOSP,DEPT SURG,ASHFORD TW15 3AA,MIDDX,ENGLAND; ASHFORD HOSP,DEPT RADIOL,ASHFORD TW15 3AA,MIDDX,ENGLAND									CARUANA DS, 1984, ANN INTERN MED, V100, P73, DOI 10.7326/0003-4819-100-1-73; DOBBIE P, 1986, MAIL SUNDAY     1026; FREED TA, 1976, AM J ROENTGENOL, V127, P1033, DOI 10.2214/ajr.127.6.1033; MCCARRON MM, 1983, JAMA-J AM MED ASSOC, V250, P1417; Mebane C, 1975, J Fla Med Assoc, V62, P19; SINNER WN, 1981, GASTROINTEST RADIOL, V6, P319, DOI 10.1007/BF01890277; SUAREZ CA, 1977, JAMA-J AM MED ASSOC, V238, P1391, DOI 10.1001/jama.238.13.1391; WETLI CV, 1981, J FORENSIC SCI, V26, P492	8	60	60	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1988	296	6628					1035	1037		10.1136/bmj.296.6628.1035	http://dx.doi.org/10.1136/bmj.296.6628.1035			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M9668	3130126	Green Published, Bronze			2023-01-03	WOS:A1988M966800009
J	GABIZON, R; MCKINLEY, MP; GROTH, DF; KENAGA, L; PRUSINER, SB				GABIZON, R; MCKINLEY, MP; GROTH, DF; KENAGA, L; PRUSINER, SB			PROPERTIES OF SCRAPIE PRION PROTEIN LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									UNIV CALIF SAN FRANCISCO,DEPT NEUROL,HSE-781,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS022786, P50NS014069, P01NS014069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG002132] Funding Source: NIH RePORTER; NIA NIH HHS [AG02132] Funding Source: Medline; NINDS NIH HHS [NS14069, NS22786] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALPER T, 1967, NATURE, V214, P764, DOI 10.1038/214764a0; BARRY RA, 1985, J IMMUNOL, V135, P603; BARRY RA, 1986, J INFECT DIS, V153, P848, DOI 10.1093/infdis/153.5.848; BARZILAI A, 1984, P NATL ACAD SCI-BIOL, V81, P6521, DOI 10.1073/pnas.81.20.6521; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BAZAN JF, 1987, NATURE, V325, P581, DOI 10.1038/325581a0; BELLINGERKAWAHARA C, 1987, VIROLOGY, V160, P271, DOI 10.1016/0042-6822(87)90072-9; BELLINGERKAWAHARA C, 1987, J VIROL, V61, P159, DOI 10.1128/JVI.61.1.159-166.1987; BENDHEIM PE, 1984, NATURE, V310, P418, DOI 10.1038/310418a0; BOGONEZ E, 1985, P NATL ACAD SCI USA, V82, P4891, DOI 10.1073/pnas.82.15.4891; BOLTON DC, 1982, SCIENCE, V218, P1309, DOI 10.1126/science.6815801; BOLTON DC, 1984, BIOCHEMISTRY-US, V23, P5898, DOI 10.1021/bi00320a002; BRAIMAN MS, 1987, J BIOL CHEM, V262, P9271; CARLSON GA, 1986, CELL, V46, P503, DOI 10.1016/0092-8674(86)90875-5; DEARMOND SJ, 1985, CELL, V41, P221, DOI 10.1016/0092-8674(85)90076-5; DEARMOND SJ, 1987, NEUROLOGY, V37, P1277; DIENER TO, 1987, CELL, V49, P719, DOI 10.1016/0092-8674(87)90607-6; DIENER TO, 1982, P NATL ACAD SCI-BIOL, V79, P5220, DOI 10.1073/pnas.79.17.5220; DIRINGER H, 1983, NATURE, V306, P476, DOI 10.1038/306476a0; DIRINGER H, 1983, EUR J BIOCHEM, V134, P555, DOI 10.1111/j.1432-1033.1983.tb07602.x; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; GABIZON R, 1987, P NATL ACAD SCI USA, V84, P4017, DOI 10.1073/pnas.84.12.4017; GAJDUSEK DC, 1977, SCIENCE, V197, P943, DOI 10.1126/science.142303; HAY B, 1987, BIOCHEMISTRY-US, V26, P8110, DOI 10.1021/bi00399a014; HAY B, 1987, MOL CELL BIOL, V7, P914, DOI 10.1128/MCB.7.2.914; HILMERT H, 1984, BIOSCIENCE REP, V4, P165, DOI 10.1007/BF01120313; HOPE J, 1986, EMBO J, V5, P2591, DOI 10.1002/j.1460-2075.1986.tb04539.x; HUNTER GD, 1971, J COMP PATHOL, V81, P23, DOI 10.1016/0021-9975(71)90051-X; HUNTER GD, 1967, J THEOR BIOL, V20, P355; HUNTER GD, 1971, J INFECT DIS, V125, P427; HUNTER GD, 1979, SLOW TRANSMISSIBLE D, V2, P365; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARON R, 1979, BIOCHEMISTRY-US, V18, P4781, DOI 10.1021/bi00589a003; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MCKINLEY MP, 1986, J INFECT DIS, V154, P110, DOI 10.1093/infdis/154.1.110; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Millson G. C., 1979, Slow transmissible diseases of the nervous system. Volume 2., P409; MORIYAMA Y, 1987, J BIOL CHEM, V262, P9175; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PRUSINER SB, 1987, NEW ENGL J MED, V317, P1571, DOI 10.1056/NEJM198712173172505; PRUSINER SB, 1980, P NATL ACAD SCI-BIOL, V77, P2984, DOI 10.1073/pnas.77.5.2984; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1982, BIOCHEMISTRY-US, V21, P6942, DOI 10.1021/bi00269a050; PRUSINER SB, 1984, CELL, V38, P127, DOI 10.1016/0092-8674(84)90533-6; PRUSINER SB, 1983, CELL, V35, P349, DOI 10.1016/0092-8674(83)90168-X; PRUSINER SB, 1981, P NATL ACAD SCI-BIOL, V78, P6675, DOI 10.1073/pnas.78.11.6675; PRUSINER SB, 1980, BIOCHEMISTRY-US, V19, P4883, DOI 10.1021/bi00562a028; PRUSINER SB, 1978, BIOCHEMISTRY-US, V17, P4987, DOI 10.1021/bi00616a020; PRUSINER SB, 1987, LAB INVEST, V56, P349; PRUSINER SB, 1984, METHODS VIROLOGY, V8, P283; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; WESTAWAY D, 1987, CELL, V51, P651, DOI 10.1016/0092-8674(87)90134-6	52	68	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1988	263	10					4950	4955						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M7886	3350818				2023-01-03	WOS:A1988M788600071
J	RIBI, HO; LUDWIG, DS; MERCER, KL; SCHOOLNIK, GK; KORNBERG, RD				RIBI, HO; LUDWIG, DS; MERCER, KL; SCHOOLNIK, GK; KORNBERG, RD			3-DIMENSIONAL STRUCTURE OF CHOLERA-TOXIN PENETRATING A LIPID-MEMBRANE	SCIENCE			English	Article									STANFORD UNIV,MED CTR,SCH MED,DEPT MED,DIV GEOG MED,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,DEPT MED MICROBIOL,STANFORD,CA 94305; STANFORD UNIV,MED CTR,SCH MED,HOWARD HUGHES MED INST,STANFORD,CA 94305	Stanford University; Stanford University; Howard Hughes Medical Institute; Stanford University	RIBI, HO (corresponding author), STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305, USA.			Ludwig, David/0000-0003-3307-8544	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021144] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21144] Funding Source: Medline; NIGMS NIH HHS [GM07276-12, GM07365] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGARD DA, 1983, J MOL BIOL, V167, P849, DOI 10.1016/S0022-2836(83)80114-4; AMOS LA, 1983, PROG BIOPHYS MOL BIO, V39, P183, DOI 10.1016/0079-6107(83)90017-2; DUBOCHET J, 1982, J MICROSC-OXFORD, V128, P219, DOI 10.1111/j.1365-2818.1982.tb04625.x; DWYER JD, 1982, BIOCHEMISTRY-US, V21, P3227, DOI 10.1021/bi00256a030; EIDELS L, 1983, MICROBIOL REV, V47, P596, DOI 10.1128/MMBR.47.4.596-620.1983; FINKELSTEIN RA, 1974, J IMMUNOL, V113, P145; FISHMAN PH, 1980, J MEMBRANE BIOL, V54, P51, DOI 10.1007/BF01875376; FISHMAN PH, 1978, BIOCHEMISTRY-US, V17, P711, DOI 10.1021/bi00597a024; Gaines GL, 1966, INSOLUBLE MONOLAYERS; Gill D., 1978, BACTERIAL TOXINS CEL, P291; Gill D M, 1977, Adv Cyclic Nucleotide Res, V8, P85; GILL DM, 1976, BIOCHEMISTRY-US, V15, P1242, DOI 10.1021/bi00651a011; HOLMGREN J, 1981, NATURE, V292, P413, DOI 10.1038/292413a0; Kornberg R.D., 1987, PROTEIN STRUCTURE FO, V2, P175; KUROSKY A, 1977, J BIOL CHEM, V252, P7257; LAI CY, 1980, CRC CR REV BIOCH MOL, V9, P171, DOI 10.3109/10409238009105434; LAI CY, 1977, J BIOL CHEM, V252, P7249; LUDWIG DS, 1986, P NATL ACAD SCI USA, V83, P8585, DOI 10.1073/pnas.83.22.8585; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P3855; MIDDLEBROOK JL, 1984, MICROBIOL REV, V48, P199, DOI 10.1128/MMBR.48.3.199-221.1984; MOSS J, 1977, J BIOL CHEM, V252, P797; REED RA, 1987, BIOCHEMISTRY-US, V26, P824, DOI 10.1021/bi00377a025; RIBI HO, 1987, BIOCHEMISTRY-US, V26, P7974, DOI 10.1021/bi00398a064; RIBI HO, 1987, THESIS STANFORD U; SATTLER J, 1975, EUR J BIOCHEM, V57, P309, DOI 10.1111/j.1432-1033.1975.tb02302.x; SIGLER PB, 1977, SCIENCE, V197, P1277, DOI 10.1126/science.197.4310.1277-a; TAYLOR KA, 1976, J ULTRA MOL STRUCT R, V55, P448, DOI 10.1016/S0022-5320(76)80099-8; TAYOT JL, 1981, EUR J BIOCHEM, V113, P249, DOI 10.1111/j.1432-1033.1981.tb05060.x; THOMPSON TE, 1985, BIOCHIM BIOPHYS ACTA, V817, P229, DOI 10.1016/0005-2736(85)90024-0; TOMASI M, 1981, J BIOL CHEM, V256, P1177; TOMASI M, 1978, FEBS LETT, V94, P253, DOI 10.1016/0014-5793(78)80949-1; TOSTESON MT, 1978, NATURE, V275, P142, DOI 10.1038/275142a0; UNWIN PNT, 1984, NATURE, V307, P609, DOI 10.1038/307609a0; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0; VANHEYNINGEN S, 1982, MOL ACTION TOXINS VI, P169; WISNIESKI BJ, 1981, NATURE, V289, P319, DOI 10.1038/289319a0	36	158	160	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	MAR 11	1988	239	4845					1272	1276		10.1126/science.3344432	http://dx.doi.org/10.1126/science.3344432			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	M4254	3344432				2023-01-03	WOS:A1988M425400021
J	HAINSWORTH, JD; GROSH, WW; BURNETT, LS; JONES, HW; WOLFF, SN; GRECO, FA				HAINSWORTH, JD; GROSH, WW; BURNETT, LS; JONES, HW; WOLFF, SN; GRECO, FA			ADVANCED OVARIAN-CANCER - LONG-TERM RESULTS OF TREATMENT WITH INTENSIVE CISPLATIN-BASED CHEMOTHERAPY OF BRIEF DURATION	ANNALS OF INTERNAL MEDICINE			English	Article									VANDERBILT UNIV, MED CTR, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, NASHVILLE, TN 37232 USA	Vanderbilt University	HAINSWORTH, JD (corresponding author), VANDERBILT UNIV, MED CTR, DEPT MED, DIV ONCOL, A2127, NASHVILLE, TN 37232 USA.							BELINSON JL, 1984, CANCER, V54, P1983, DOI 10.1002/1097-0142(19841101)54:9<1983::AID-CNCR2820540933>3.0.CO;2-2; COLEMAN M, 1985, CANCER, V55, P2342, DOI 10.1002/1097-0142(19850515)55:10<2342::AID-CNCR2820551008>3.0.CO;2-2; DECKER DG, 1982, OBSTET GYNECOL, V60, P481; DOUGHERTY J, 1985, P AN M AM SOC CLIN, V4, P122; GERSHENSON DM, 1985, CANCER, V55, P1129, DOI 10.1002/1097-0142(19850301)55:5<1129::AID-CNCR2820550531>3.0.CO;2-O; GRECO FA, 1981, OBSTET GYNECOL, V58, P199; LOUIE KG, 1986, J CLIN ONCOL, V4, P1579, DOI 10.1200/JCO.1986.4.11.1579; OMURA G, 1986, CANCER, V57, P1725, DOI 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J; RAZIS DV, 1982, ONCOLOGY, V39, P205, DOI 10.1159/000225638; SCHWARTZ PE, 1980, AM J OBSTET GYNECOL, V138, P1124, DOI 10.1016/S0002-9378(16)32778-8; STEINER M, 1985, CANCER, V55, P2748, DOI 10.1002/1097-0142(19850615)55:12<2748::AID-CNCR2820551203>3.0.CO;2-F; SUTTON G P, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P120; VOGL SE, 1983, CANCER, V51, P2024, DOI 10.1002/1097-0142(19830601)51:11<2024::AID-CNCR2820511111>3.0.CO;2-I; WILLIAMS CJ, 1982, CANCER, V49, P1778, DOI 10.1002/1097-0142(19820501)49:9<1778::AID-CNCR2820490908>3.0.CO;2-Z	14	144	144	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB	1988	108	2					165	170		10.7326/0003-4819-108-2-165	http://dx.doi.org/10.7326/0003-4819-108-2-165			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L9765	3124679				2023-01-03	WOS:A1988L976500001
J	OBRIEN, J; LONG, H				OBRIEN, J; LONG, H			URINARY-INCONTINENCE - LONG-TERM EFFECTIVENESS OF NURSING INTERVENTION IN PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article											OBRIEN, J (corresponding author), SOMERSET HLTH COMMISS,DEPT PUBL HLTH MED,TAUNTON TA1 7PQ,SOMERSET,ENGLAND.							HAHN I, 1993, BRIT J UROL, V72, P421, DOI 10.1111/j.1464-410X.1993.tb16170.x; LARGOJANSSEN TLM, 1992, FAM PRACT, V9, P284; MOURITSEN L, 1991, BRIT J UROL, V68, P32, DOI 10.1111/j.1464-410X.1991.tb15252.x; OBRIEN J, 1991, BRIT MED J, V303, P1308, DOI 10.1136/bmj.303.6813.1308; 1991, AGENDA ACTION CONTIN	5	20	20	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1208	1208		10.1136/bmj.311.7014.1208	http://dx.doi.org/10.1136/bmj.311.7014.1208			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488903	Green Published			2023-01-03	WOS:A1995TD76800027
J	KHAW, BA; TORCHILIN, VP; VURAL, I; NARULA, J				KHAW, BA; TORCHILIN, VP; VURAL, I; NARULA, J			PLUG AND SEAL - PREVENTION OF HYPOXIC CARDIOCYTE DEATH BY SEALING MEMBRANE LESIONS WITH ANTIMYOSIN-LIPOSOMES	NATURE MEDICINE			English	Article							MYOSIN-SPECIFIC ANTIBODY; MYOCARDIAL-INFARCTION; REPERFUSION; SIZE; LOCALIZATION	The hallmark of cell death is the development of cell membrane lesions. Such lesions in the myocardium are usually associated with acute myocardial infarction. Minimizing myocardial necrosis by thrombolytic reperfusion therapy constitutes the only major treatment to date. We envisioned a method to seal these membrane lesions using immunoliposomes as a novel adjunctive approach. An antigen to intracellular cytoskeletal myosin in hypoxic embryonic cardiocytes is used as an anchoring site, and a specific antibody on immunoliposomes as the anchor to plug and to seal the membrane lesions. H9C2 cells were used because they are cardiocytes and are propagated in tissue culture and their viability may be assessed by various methods. Viability assessed by [H-3]thymidine uptake in hypoxic cardiocyte cultures (n = 6 each) treated with antimyosin-immunoliposomes (3.26 +/- 0.483 x 10(6) c.p.m.) was similar to that of normoxic cells (3.68 +/- 0.328 x 10(6) c.p.m.), but was greater than those of untreated hypoxic cells (0.115 +/- 0.155 x 10(6) c.p.m.) or hypoxic cells treated with plain liposomes (1.140 +/- 0.577 x 10(6) c.p.m.). These results were reconfirmed by trypan blue exclusion and by fluorescent, confocal and transmission electron microscopy. They indicated that cell death in hypoxic cardiocytes can be prevented by targeted cell membrane sealing. This concept of cell salvage should be applicable in the prevention of cell death in different biological systems.	MASSACHUSETTS GEN HOSP,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital	KHAW, BA (corresponding author), NORTHWESTERN UNIV,CTR DRUG TARGETING & ANAL,205 MUGAR BLDG,BOSTON,MA 02115, USA.			Vural, Imran/0000-0002-1627-3834				ALLEN TM, 1994, ADV DRUG DELIVER REV, V13, P285, DOI 10.1016/0169-409X(94)90016-7; BLEIFELD W, 1977, CIRCULATION, V55, P303, DOI 10.1161/01.CIR.55.2.303; BRAUNWALD E, 1985, J CLIN INVEST, V76, P1713, DOI 10.1172/JCI112160; GELTMAN EM, 1979, CIRCULATION, V60, P805, DOI 10.1161/01.CIR.60.4.805; JENNINGS RB, 1985, CIRC RES, V56, P262, DOI 10.1161/01.RES.56.2.262; JENNINGS RB, 1983, CIRCULATION, V68, P25; JENNINGS RB, 1960, ARCH PATHOL, V70, P68; KATZUNG BJ, 1975, PFLEUGERS ARCH EUR J, V260, P193; KHAW BA, 1976, J CLIN INVEST, V58, P439, DOI 10.1172/JCI108488; KHAW BA, 1979, CIRCULATION, V60, P1527, DOI 10.1161/01.CIR.60.7.1527; KHAW BA, 1986, CIRCULATION, V74, P501, DOI 10.1161/01.CIR.74.3.501; NARULA J, 1995, CIRCULATION, V92, P474, DOI 10.1161/01.CIR.92.3.474; PASTERNAK RC, 1994, HARRISONS PRINCIPLES, P1066; REIMER KA, 1983, AM J CARDIOL, V52, pA72; ROBERTS R, 1994, HURSTS HEART ARTERIE, P1107; ROBERTS R, 1979, ISOZYMES CURRENT TOP, P115; ROGERS WJ, 1977, CIRCULATION, V56, P199, DOI 10.1161/01.CIR.56.2.199; SIMOONS ML, 1986, J AM COLL CARDIOL, V7, P717, DOI 10.1016/S0735-1097(86)80329-1; TANDAN R, 1987, J NEUROL SCI, V79, P189, DOI 10.1016/0022-510X(87)90272-3; TORCHILIN VP, 1992, FASEB J, V6, P2716, DOI 10.1096/fasebj.6.9.1612296; TORCHILIN VP, 1988, LIPOSOMES DRUG CARRI, P63	21	68	70	0	7	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1195	1198		10.1038/nm1195-1195	http://dx.doi.org/10.1038/nm1195-1195			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584994				2023-01-03	WOS:A1995TC53700046
J	WALSH, JME; GRADY, D				WALSH, JME; GRADY, D			TREATMENT OF HYPERLIPIDEMIA IN WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY HEART-DISEASE; FOLLOW-UP; PROSPECTIVE POPULATION; SECONDARY PREVENTION; CHOLESTEROL LEVELS; BLOOD CHOLESTEROL; SERUM-CHOLESTEROL; NICOTINIC-ACID; RISK-FACTORS; MORTALITY	Objective.-To assess the evidence that lipid lowering prevents coronary heart disease (CHD) events in women. Data Sources.-English-language literature assessing the effects of cholesterol lowering with dietary and/or drug interventions as primary or secondary prevention on CHD events in women. Main Outcome Measures.-Coronary heart disease and total mortality were the primary outcomes assessed. Angiographic regression of coronary atherosclerosis was a secondary outcome. Study Selection, Data Extraction, and Data Synthesis.-All nine of the identified studies that met the criteria were included. Relative risks for CHD and total mortality were calculated from available data. Summary relative risks were calculated using meta-analytic techniques. Conclusions.-There is no evidence from primary prevention trials that cholesterol lowering affects total mortality in healthy women, although the available data are limited. Limited evidence suggests that treatment of hypercholesterolemia in women with coronary disease may decrease CHD mortality. Future research should address the role of dietary and other nondrug treatment of hypercholesterolemia in women at high risk for CHD.	VET AFFAIRS MED CTR, GEN INTERNAL MED SECT, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, SAN FRANCISCO, CA 94143 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	WALSH, JME (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT MED, BOX 1610, SAN FRANCISCO, CA 94115 USA.							ACHESON J, 1972, ATHEROSCLEROSIS, V15, P177, DOI 10.1016/0021-9150(72)90067-6; [Anonymous], 1965, LANCET, V2, P501; [Anonymous], 1968, LANCET, V2, P693; [Anonymous], 1975, JAMA-J AM MED ASSOC, V231, P360; ARONOW WS, 1989, J AM GERIATR SOC, V37, P501, DOI 10.1111/j.1532-5415.1989.tb05679.x; BARRETTCONNOR E, 1983, AM J EPIDEMIOL, V118, P489, DOI 10.1093/oxfordjournals.aje.a113654; BENGTSSON C, 1993, BMJ-BRIT MED J, V307, P1385, DOI 10.1136/bmj.307.6916.1385; BROWN MA, 1989, ENERG BUILDINGS, V13, P51, DOI 10.1016/0378-7788(89)90017-0; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BUCHWALD H, 1992, ANN SURG, V216, P389, DOI 10.1097/00000658-199210000-00001; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; CARLSON LA, 1988, ACTA MED SCAND, V223, P405; CARLSON LA, 1977, ATHEROSCLEROSIS, V28, P81, DOI 10.1016/0021-9150(77)90201-5; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; CORTI MC, 1995, JAMA-J AM MED ASSOC, V274, P539, DOI 10.1001/jama.274.7.539; CRIQUI MH, 1993, NEW ENGL J MED, V328, P1220, DOI 10.1056/NEJM199304293281702; DAYTON S, 1969, CIRCULATION       S2, V40, P1; DORR AE, 1978, J CHRON DIS, V31, P5, DOI 10.1016/0021-9681(78)90076-0; FRANTZ ID, 1989, ARTERIOSCLEROSIS, V9, P129, DOI 10.1161/01.ATV.9.1.129; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; JACOBS D, 1992, CIRCULATION, V86, P1046, DOI 10.1161/01.CIR.86.3.1046; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; Kannel W B, 1992, Ann Epidemiol, V2, P5; KANNEL WB, 1979, AM J CARDIOL, V44, P53, DOI 10.1016/0002-9149(79)90250-9; KANNEL WB, 1979, JAMA-J AM MED ASSOC, V241, P2035, DOI 10.1001/jama.241.19.2035; KANNEL WB, 1974, DHEW NIH74599 PUBL; LAROSA JC, 1990, CIRCULATION, V81, P1721, DOI 10.1161/01.CIR.81.5.1721; LEREN P, 1966, ACTA MED SCAND  S466, V181, P1; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1991, ARCH INTERN MED, V151, P1141, DOI 10.1001/archinte.151.6.1141; MIETTINEN M, 1972, LANCET, V2, P835; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; PAN WH, 1986, AM J EPIDEMIOL, V123, P504, DOI 10.1093/oxfordjournals.aje.a114266; PEDERSEN TR, 1994, LANCET, V344, P1383; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSE GA, 1965, BMJ-BRIT MED J, V1, P1531, DOI 10.1136/bmj.1.5449.1531; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SIMONS LA, 1986, AM J CARDIOL, V57, pG5, DOI 10.1016/0002-9149(86)90659-4; STAMPFER MJ, 1987, CORONARY HEART DISEA, P112; THOM TJ, 1987, CORONARY HEART DISEA, P270; Trial of clofibrate in the treatment of ischaemic heart disease, 1971, BRIT MED J, V4, P767, DOI DOI 10.1136/BMJ.4.5790.767; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; Woodhill J M, 1978, Adv Exp Med Biol, V109, P317; 1991, VITAL STATISTICS U A, V2; 1980, 801527 US DEP HLTH H; 1971, BRIT MED J, V4, P775	54	61	61	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1152	1158		10.1001/jama.274.14.1152	http://dx.doi.org/10.1001/jama.274.14.1152			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563487				2023-01-03	WOS:A1995RY05600031
J	GARDNER, AW; POEHLMAN, ET				GARDNER, AW; POEHLMAN, ET			EXERCISE REHABILITATION PROGRAMS FOR THE TREATMENT OF CLAUDICATION PAIN - A METAANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PERIPHERAL ARTERIAL INSUFFICIENCY; INTERMITTENT CLAUDICATION; WALKING TOLERANCE; OCCLUSIVE DISEASE; VASCULAR-DISEASE; BLOOD-FLOW; DISTANCE; MUSCLE; ENZYME; RANGE	Objective.-To identify the components of exercise rehabilitation programs that were most effective in improving claudication pain symptoms in patients with peripheral arterial disease. Data Sources.-English-language articles were identified by a computer Search using Index Medicus and MEDLINE, followed by an extensive bibliography review. Study Selection.-Studies were included if they provided the mean or individual walking distances or times to the onset of claudication pain and to maximal pain during a treadmill test before and after rehabilitation. Data Extraction.-Walking distances and times and characteristics of the exercise programs were independently abstracted by two observers. Data Synthesis.-Thirty-three English-language studies were identified, of which 21 met the inclusion criteria, Overall, following a program of exercise rehabilitation, the distance (mean+/-SD) to onset of claudication pain increased 179% from 125.9+/-57.3 m to 351.2+/-188.7 m (P<.001), and the distance to maximal claudication pain increased 122% from 325.8+/-148.1 m to 723.3+/-591.5 m (P<.001). The greatest improvement in pain distances occurred with the following exercise program: duration greater than 30 minutes per session, frequency of at least three sessions per week, walking used as the mode of exercise, use of near-maximal pain during training as claudication pain end point, and program length of greater than 6 months, However, the claudication pain end point, program length, and mode of exercise were the only independent predictors (P<.001) for improvement in distances. Conclusions.-The optimal exercise program for improving claudication pain distances in patients with peripheral arterial disease uses intermittent walking to near-maximal pain during a program of at least 6 months. Such a program should be part of the standard medical care for patients with intermittent claudication.	UNIV MARYLAND,CLAUDE PEPPER OLDER AMER INDEPENDENCE CTR,DEPT MED,DIV GERONTOL,BALTIMORE,MD	University System of Maryland; University of Maryland Baltimore	GARDNER, AW (corresponding author), VET AFFAIRS MED CTR,CTR GERIATR RES EDUC & CLIN 18,GERIATR SERV,10 N GREENE ST,BALTIMORE,MD 21201, USA.				NATIONAL INSTITUTE ON AGING [K01AG000657, K07AG000608, R01AG007857] Funding Source: NIH RePORTER; NIA NIH HHS [K07-AG-00608, K01-AG-00657, R01-AG-07857] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALPERT JS, 1969, CIRCULATION, V39, P353, DOI 10.1161/01.CIR.39.3.353; ANDRIESSEN MPHM, 1989, VASA-J VASCULAR DIS, V18, P63; ANDRIESSEN MPHM, 1989, VASA-J VASCULAR DIS, V18, P56; BLUMCHEN G, 1970, CARDIOLOGY, V55, P114, DOI 10.1159/000169274; CARTER SA, 1989, J VASC SURG, V10, P642; CLIFFORD PC, 1980, BRIT MED J, V281, P1508; DAHLLOF AG, 1974, EUR J CLIN INVEST, V4, P9, DOI 10.1111/j.1365-2362.1974.tb00365.x; DAHLLOF AG, 1976, SCAND J REHABIL MED, V8, P19; EKROTH R, 1978, SURGERY, V84, P640; ERICSSON B, 1970, ANGIOLOGY, V21, P188, DOI 10.1177/000331977002100306; ERNST E, 1987, VASA-J VASCULAR DIS, V16, P227; ERNST EEW, 1987, CIRCULATION, V76, P1110, DOI 10.1161/01.CIR.76.5.1110; FEINBERG RL, 1992, J VASC SURG, V16, P244, DOI 10.1016/0741-5214(92)90114-N; FITZGERALD DE, 1971, ANGIOLOGY, V22, P99, DOI 10.1177/000331977102200208; FOLLMANN D, 1992, J CLIN EPIDEMIOL, V45, P769, DOI 10.1016/0895-4356(92)90054-Q; GARDNER AW, 1993, ANGIOLOGY, V44, P353, DOI 10.1177/000331979304400503; GARDNER AW, 1991, MED SCI SPORT EXER, V23, P402; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HALL JA, 1982, J CARDIAC REHABIL, V2, P569; Hedges L, 1985, STATISTICAL METHODS; HIATT WR, 1990, CIRCULATION, V81, P602, DOI 10.1161/01.CIR.81.2.602; Hiatt WR, 1988, J CARDIOPULM REHABIL, V12, P525, DOI DOI 10.1097/00008483-198812200-00005; HOLM J, 1973, SCAND J CLIN LAB INV, V31, P201; JONASON T, 1987, CLIN PHYSIOL, V7, P63, DOI 10.1111/j.1475-097X.1987.tb00635.x; JONASON T, 1979, ACTA MED SCAND, V206, P253; JONASON T, 1987, SCAND J REHABIL MED, V19, P47; JONASON T, 1981, SCAND J REHABIL MED, V13, P137; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; LARSEN OA, 1966, LANCET, V2, P1093, DOI 10.1016/S0140-6736(66)92191-X; LEPANTALO M, 1984, SCAND J REHABIL MED, V16, P159; LINDGARDE F, 1989, CIRCULATION, V80, P1549, DOI 10.1161/01.CIR.80.6.1549; LUNDGREN F, 1989, ANN SURG, V209, P346, DOI 10.1097/00000658-198903000-00016; LUNDGREN F, 1989, CLIN SCI, V77, P485, DOI 10.1042/cs0770485; MANNARINO E, 1991, ANGIOLOGY, V42, P513, DOI 10.1177/000331979104200701; MANNARINO E, 1989, ANGIOLOGY, V40, P5, DOI 10.1177/000331978904000102; Pedhazur EJ, 1982, MULTIPLE REGRESSION, V2, P101; ROSETZSKY A, 1985, ANN CHIR GYNAECOL FE, V74, P261; ROSFORS S, 1989, SCAND J REHABIL MED, V21, P7; RUELL PA, 1984, EUR J APPL PHYSIOL O, V52, P420, DOI 10.1007/BF00943373; SCHERSTEN T, 1982, PRACT CARDIOL, V8, P45; SKINNER JS, 1967, CIRCULATION, V36, P23, DOI 10.1161/01.CIR.36.1.23; SORLIE D, 1978, SCAND J CLIN LAB INV, V38, P217, DOI 10.3109/00365517809108414; TRAN ZV, 1989, J CARDIOPULM REHABIL, V9, P250; TUNIS SR, 1991, NEW ENGL J MED, V325, P556, DOI 10.1056/NEJM199108223250806; VOGT MT, 1992, J CLIN EPIDEMIOL, V45, P529, DOI 10.1016/0895-4356(92)90102-S; WILLIAMS LR, 1991, J VASC SURG, V14, P320, DOI 10.1016/0741-5214(91)90083-7; ZETTERQUIST S, 1970, SCAND J CLIN LAB INV, V25, P101, DOI 10.3109/00365517009046196; 1991, GUIDELINES EXERCISE, V16, P99; 1992, J NIH RES, V4, P95; 1986, SPSS X USERS GUIDE, P620	50	560	581	1	32	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 27	1995	274	12					975	980		10.1001/jama.274.12.975	http://dx.doi.org/10.1001/jama.274.12.975			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RV734	7674529				2023-01-03	WOS:A1995RV73400033
J	GARATTINI, S				GARATTINI, S			CULTURAL SHIFT IN ITALY DRUG POLICY	LANCET			English	Editorial Material											GARATTINI, S (corresponding author), IST RIC FARMACOL MARIO NEGRI,MILAN,ITALY.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297				GARATTINI L, 1994, PHARMACOECONOMICS, V6, P417, DOI 10.2165/00019053-199406050-00003; GARATTINI S, 1993, LANCET, V342, P1191, DOI 10.1016/0140-6736(93)92181-R	2	17	17	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					5	6		10.1016/S0140-6736(95)92647-X	http://dx.doi.org/10.1016/S0140-6736(95)92647-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF985	7603156				2023-01-03	WOS:A1995RF98500005
J	LYNCH, JW; RAJENDRA, S; BARRY, PH; SCHOFIELD, PR				LYNCH, JW; RAJENDRA, S; BARRY, PH; SCHOFIELD, PR			MUTATIONS AFFECTING THE GLYCINE RECEPTOR AGONIST TRANSDUCTION MECHANISM CONVERT THE COMPETITIVE ANTAGONIST, PICROTOXIN, INTO AN ALLOSTERIC POTENTIATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; FUNCTIONAL EXPRESSION; AMINOBUTYRIC-ACID; MULTIPLE MECHANISMS; CHLORIDE CURRENT; GABA RESPONSES; BETA-SUBUNIT; NEURONS; CHANNELS; RAT	Contrary to its effects on the gamma-aminobutyric acid type A receptor, picrotoxin antagonism of the alpha 1 subunit of the human glycine receptor is shown to be competitive, not use-dependent, and nonselective between the picrotoxin components, picrotin, and picrotoxinin. Competitive antagonism and non-use dependence are consistent with picrotoxin binding to a site in the extracellular domain. The mutations Arg --> Leu or Arg --> Gln at residue 271 of the glycine receptor alpha 1 subunit, which are both associated with human startle disease, have previously been demonstrated to disrupt the transduction process between agonist binding and channel activation, We show here that these mutations also transform picrotoxin from an allosterically acting competitive antagonist to an allosteric potentiator at low (0.01-3 mu M) concentrations and to a noncompetitive antagonist at higher (greater than or equal to 3 mu M) concentrations. This demonstrates that arginine 271 is involved in the transduction process between picrotoxin binding and its mechanism of action, Thus, the allosteric transduction pathways of both agonists and antagonists converge at a common residue prior to the activation gate of the channel, suggesting that this residue may act as an integration point for information from various extracellular ligand binding sites.	UNIV NEW S WALES, SCH PHYSIOL & PHARMACOL, SYDNEY, NSW 2052, AUSTRALIA	University of New South Wales Sydney	LYNCH, JW (corresponding author), ST VINCENTS HOSP, GARVAN INST MED RES, 384 VICTORIA ST, DARLINGHURST, NSW 2010, AUSTRALIA.		Lynch, Joseph/C-8636-2009; Schofield, Peter/C-9669-2011	Schofield, Peter/0000-0003-2967-9662				AKAIKE N, 1985, EXPERIENTIA, V41, P70; AKAIKE N, 1986, J PHYSIOL-LONDON, V379, P171, DOI 10.1113/jphysiol.1986.sp016246; AKAIKE N, 1987, CELL MOL NEUROBIOL, V7, P97, DOI 10.1007/BF00734993; AKAIKE N, 1989, J NEUROPHYSIOL, V62, P1400, DOI 10.1152/jn.1989.62.6.1400; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; BETZ H, 1988, NEUROCHEM INT, V13, P137, DOI 10.1016/0197-0186(88)90048-4; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CONSTANTI A, 1976, BRIT J PHARMACOL, V57, P347, DOI 10.1111/j.1476-5381.1976.tb07673.x; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; Curtis D.R., 1974, NEUROPOISONS THEIR P, P207; DEVILLERSTHIERY A, 1992, NEUROREPORT, V3, P1001, DOI 10.1097/00001756-199211000-00014; DEVILLERSTHIERY A, 1993, J MEMBRANE BIOL, V136, P97, DOI 10.1007/BF02505755; GALLAGHER JP, 1978, J PHYSIOL-LONDON, V275, P263, DOI 10.1113/jphysiol.1978.sp012189; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; GRENNINGLOH G, 1987, NATURE, V328, P215, DOI 10.1038/328215a0; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HERZ JM, 1989, J BIOL CHEM, V264, P12439; HILLE B, 1992, IONIC CHANNELS EXCIT, P390; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLLAND KD, 1990, J NEUROSCI, V10, P1719; INOUE M, 1988, NEUROSCI RES, V5, P380, DOI 10.1016/0168-0102(88)90024-7; LANGOSCH D, 1994, EMBO J, V13, P4223, DOI 10.1002/j.1460-2075.1994.tb06742.x; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; NODA M, 1982, NATURE, V299, P793, DOI 10.1038/299793a0; PORTER NM, 1992, MOL PHARMACOL, V42, P872; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; RAJENDRA S, 1995, TRENDS NEUROSCI, V18, P80; RAJENDRA S, 1994, J BIOL CHEM, V269, P18739; RAJENDRA S, 1995, NEURON, V14, P169, DOI 10.1016/0896-6273(95)90251-1; SCHMIEDEN V, 1989, EMBO J, V8, P695, DOI 10.1002/j.1460-2075.1989.tb03428.x; SCHMIEDEN V, 1992, EMBO J, V11, P2025, DOI 10.1002/j.1460-2075.1992.tb05259.x; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SHIANG R, 1993, NAT GENET, V5, P351, DOI 10.1038/ng1293-351; SIMMONDS MA, 1982, EUR J PHARMACOL, V80, P347; SMART TG, 1986, PROC R SOC SER B-BIO, V227, P191, DOI 10.1098/rspb.1986.0019; TAKEUCHI A, 1969, J PHYSIOL-LONDON, V205, P377, DOI 10.1113/jphysiol.1969.sp008972; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; VALENZUELA CF, 1994, BIOPHYS J, V66, P674, DOI 10.1016/S0006-3495(94)80841-0; VANDENBERG RJ, 1992, NEURON, V9, P491, DOI 10.1016/0896-6273(92)90186-H; YAKUSHIJI T, 1987, NEUROSCIENCE, V22, P1123, DOI 10.1016/0306-4522(87)92987-3; YOON KW, 1993, J PHYSIOL-LONDON, V464, P423, DOI 10.1113/jphysiol.1993.sp019643; ZHANG HG, 1994, J PHYSIOL-LONDON, V479, P65, DOI 10.1113/jphysiol.1994.sp020278	45	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 9	1995	270	23					13799	13806		10.1074/jbc.270.23.13799	http://dx.doi.org/10.1074/jbc.270.23.13799			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RC448	7775436	hybrid			2023-01-03	WOS:A1995RC44800035
J	CHAN, R; HEMERYCK, L; OREGAN, M; CLANCY, L; FEELY, J				CHAN, R; HEMERYCK, L; OREGAN, M; CLANCY, L; FEELY, J			ORAL VERSUS INTRAVENOUS ANTIBIOTICS FOR COMMUNITY-ACQUIRED LOWER RESPIRATORY-TRACT INFECTION IN A GENERAL-HOSPITAL - OPEN, RANDOMIZED CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							CHEST INFECTIONS; MISUSE	Objective-To see whether there is a difference in outcome between patients treated with oral and intravenous antibiotics for lower respiratory tract infection. Design-Open controlled trial in patients admitted consecutively and randomised to treatment with either oral co-amoxiclav, intravenous followed by oral co-amoxiclav, or intravenous followed by oral cephalosporins. Setting-Large general hospital in Dublin. Patients-541 patients admitted for lower respiratory tract infection during one year. Patients represented 87% of admissions with the diagnosis and excluded those who were immunocompromised and patients with severe Life threatening infection. Main outcome measures-Cure, partial cure, extended antibiotic treatment, change of antibiotic, death, and cost and duration of hospital stay. Results-There were no significant differences between the groups in clinical outcome or mortality (6%). However, patients randomised to oral co-amoxiclav had a significantly shorter hospital stay than the two groups given intravenous antibiotic (median 6 v 7 and 9 days respectively). In addition, oral antibiotics were cheaper, easier to administer, and if used routinely in the 800 or so patients admitted annually would lead to savings of around pound 176 000 a year. Conclusions-Oral antibiotics in community acquired lower respiratory tract infection are at least as efficacious as intravenous therapy. Their use reduces labour and equipment costs and may lead to earlier discharge from hospital.	ST JAMES HOSP,TRINITY CTR HLTH SCI,DEPT PHARMACOL & THERAPEUT,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY CTR HLTH SCI,MED EVALUAT UNIT,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY CTR HLTH SCI,DEPT STAT,DUBLIN 8,IRELAND; ST JAMES HOSP,TRINITY CTR HLTH SCI,DEPT RESP MED,DUBLIN 8,IRELAND	Trinity College Dublin; Trinity College Dublin; Trinity College Dublin; Trinity College Dublin			Clancy, Luke/O-6597-2019; clancy, luke/ABA-1826-2020	Clancy, Luke/0000-0003-2407-2263; 				BAIN PG, 1990, BRIT MED J, V300, P1463; CASTLE M, 1977, JAMA-J AM MED ASSOC, V237, P2819, DOI 10.1001/jama.237.26.2819; DAVEY P, 1990, PHARM J, V244, P793; DAVIES AJ, 1992, J ANTIMICROB CHEMOTH, V29, P1, DOI 10.1093/jac/29.1.1; DENTON M, 1991, BRIT MED J, V302, P327, DOI 10.1136/bmj.302.6772.327-a; DUNAGAN WC, 1989, AM J MED, V87, P253; FEELY J, 1990, BRIT MED J, V300, P38; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; MAKI DG, 1978, AM J MED SCI, V275, P271, DOI 10.1097/00000441-197805000-00005; MCCONNELL J, 1993, LANCET, V341, P1208, DOI 10.1016/0140-6736(93)91025-H; ODONOVAN C, 1987, BRIT J CLIN PRACT, V41, P1044; REEVES JH, 1989, CHEST, V96, P1292, DOI 10.1378/chest.96.6.1292; ROBERTS AW, 1972, AM J HOSP PHARM, V29, P828, DOI 10.1093/ajhp/29.10.828; SCHECKLER WE, 1970, J AMER MED ASSOC, V213, P264, DOI 10.1001/jama.213.2.264; ZALIN AM, 1989, BRIT MED J, V229, P1279; 1986, DRUG THERA B, V24, P101; 1992, MONTHLY INDEX ME SEP	17	84	88	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 27	1995	310	6991					1360	1362		10.1136/bmj.310.6991.1360	http://dx.doi.org/10.1136/bmj.310.6991.1360			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB005	7787537	Green Published			2023-01-03	WOS:A1995RB00500020
J	WEIL, J; COLINJONES, D; LANGMAN, M; LAWSON, D; LOGAN, R; MURPHY, M; RAWLINS, M; VESSEY, M; WAINWRIGHT, P				WEIL, J; COLINJONES, D; LANGMAN, M; LAWSON, D; LOGAN, R; MURPHY, M; RAWLINS, M; VESSEY, M; WAINWRIGHT, P			PROPHYLACTIC ASPIRIN AND RISK OF PEPTIC-ULCER BLEEDING	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ANTI-INFLAMMATORY DRUGS; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION; CONTROLLED TRIAL; MORTALITY; ACID	Objective-To determine the risks of hospitalisation for bleeding peptic ulcer with the current prophylactic aspirin regimens of 300 mg daily or less. Design-A case-control study with hospital and community controls. Setting-Hospitals in Glasgow, Newcastle, Nottingham, Oxford, and Portsmouth. Subjects-1121 patients with gastric or duodenal ulcer bleeding matched with hospital and community controls. Results-144 (12.8%) cases had been regular users of aspirin (taken at least five days a week for at least the previous month) compared with 101 (9.0%) hospital and 77 (7.8%) community controls. Odds ratios were raised for all doses of aspirin taken, whether compared with hospital or community controls (compared with combined controls: 75 mg, 2.3 (95% confidence interval 1.2 to 4.3); 150 mg, 3.2 (1.7 to 6.5); 300 mg, 3.9 (2.5 to 6.3)). Results were not explained by confounding influences of age, sex, prior ulcer history or dyspepsia, or concurrent nonaspirin non-steroidal anti-inflammatory drug use. Risks seemed particularly high in patients who took non-aspirin non-steroidal anti-inflammatory drugs concurrently. Conclusion-No conventionally used prophylactic aspirin regimen seems free of the risk of peptic ulcer complications.	UNIV BIRMINGHAM, QUEEN ELIZABETH HOSP, BIRMINGHAM B15 2TH, W MIDLANDS, ENGLAND; W MIDLANDS REG HLTH AUTHOR, PUBL HLTH MED, BIRMINGHAM, W MIDLANDS, ENGLAND; QUEEN ALEXANDRA HOSP, PORTSMOUTH PO6 3LY, HANTS, ENGLAND; ROYAL INFIRM, GLASGOW G4 0SF, LANARK, SCOTLAND; UNIV NOTTINGHAM, NOTTINGHAM NG7 2UH, ENGLAND; UNIV OXFORD, HLTH CARE EPIDEMIOL UNIT, OXFORD OX2 6HE, ENGLAND; UNIV NEWCASTLE UPON TYNE, NEWCASTLE UPON TYNE NE2 4HH, TYNE & WEAR, ENGLAND; UNIV OXFORD, RADCLIFFE INFIRM, OXFORD OX2 6HE, ENGLAND; UNIV BIRMINGHAM, INST CANC STUDIES, BIRMINGHAM B15 2TJ, W MIDLANDS, ENGLAND	University of Birmingham; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital; Royal Infirmary of Edinburgh; University of Nottingham; University of Oxford; Newcastle University - UK; Radcliffe Infirmary; University of Oxford; University of Birmingham								ALVAREZ AS, 1958, LANCET, V2, P179; [Anonymous], 1988, Br Med J (Clin Res Ed), V296, P316; [Anonymous], 1991, Lancet, V338, P1345; [Anonymous], 1980, CIRCULATION, V62, P449; BJARNASON I, 1988, GASTROENTEROLOGY, V94, P1070, DOI 10.1016/0016-5085(88)90568-9; BJARNASON I, 1987, GASTROENTEROLOGY, V93, P480, DOI 10.1016/0016-5085(87)90909-7; BOUSSER MG, 1983, STROKE, V14, P5, DOI 10.1161/01.STR.14.1.5; BREDDIN K, 1980, HAEMOSTASIS, V9, P325; CAIRNS JA, 1985, NEW ENGL J MED, V313, P1369, DOI 10.1056/NEJM198511283132201; Canadian Cooperative Study Group, 1978, N Engl J Med, V299, P53; COGGON D, 1982, GUT, V23, P340, DOI 10.1136/gut.23.4.340; ELWOOD PC, 1974, BRIT MED J, V1, P436, DOI 10.1136/bmj.1.5905.436; ELWOOD PC, 1979, LANCET, V2, P1313; FAULKNER G, 1988, BRIT MED J, V297, P1311, DOI 10.1136/bmj.297.6659.1311; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HENNEKENS CH, 1989, NEW ENGL J MED, V321, P129, DOI 10.1056/nejm198907203210301; LANGMAN MJS, 1985, BRIT MED J, V290, P347, DOI 10.1136/bmj.290.6465.347; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LAPORTE JR, 1991, LANCET, V337, P85, DOI 10.1016/0140-6736(91)90744-A; LEVY M, 1988, ARCH INTERN MED, V148, P281, DOI 10.1001/archinte.148.2.281; MEADE TW, 1992, THROMB HAEMOSTASIS, V68, P1; PETERSEN P, 1989, LANCET, V1, P175; PRITCHARD PJ, 1989, BRIT MED J, V298, P493; RODERICK PJ, 1993, BRIT J CLIN PHARMACO, V35, P219, DOI 10.1111/j.1365-2125.1993.tb05689.x; SHORROCK C J, 1992, Gastroenterology, V102, pA165; SOMERVILLE K, 1986, LANCET, V1, P462; SORENSEN PS, 1983, STROKE, V14, P15, DOI 10.1161/01.STR.14.1.15; The Aspirin Myocardial Infarction Study: final results, 1980, CIRCULATION S5, V62, pV79; VANGIJN J, 1991, NEW ENGL J MED, V325, P1261, DOI 10.1056/NEJM199110313251801; WALLENTIN L, 1990, LANCET, V336, P827; 1976, J CHRON DIS, V29, P625	31	459	480	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 1	1995	310	6983					827	830		10.1136/bmj.310.6983.827	http://dx.doi.org/10.1136/bmj.310.6983.827			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ857	7711618	Green Published			2023-01-03	WOS:A1995QQ85700016
J	ALMROTH, S; LATHAM, MC				ALMROTH, S; LATHAM, MC			RATIONAL HOME MANAGEMENT OF DIARRHEA	LANCET			English	Editorial Material							CHILDHOOD DIARRHEA; HEALTH-EDUCATION; MOTHERS; DISEASE		CORNELL UNIV, DIV NUTR SCI, ITHACA, NY 14853 USA	Cornell University								[Anonymous], 1978, LANCET, V2, P300; BARROS FC, 1991, B WORLD HEALTH ORGAN, V69, P59; Benakappa D G, 1990, Indian J Pediatr, V57, P21, DOI 10.1007/BF02722124; BENTLEY ME, 1988, SOC SCI MED, V27, P75, DOI 10.1016/0277-9536(88)90165-7; BENTLEY ME, 1988, SOC SCI MED, V27, P107, DOI 10.1016/0277-9536(88)90168-2; CHUNG AW, 1948, J PEDIATR-US, V33, P1, DOI 10.1016/S0022-3476(48)80147-2; CHUNG AW, 1948, J PEDIATR-US, V33, P14, DOI 10.1016/S0022-3476(48)80148-4; FIELD M, 1977, NEW ENGL J MED, V297, P1121, DOI 10.1056/NEJM197711172972011; GREEN EC, 1985, SOC SCI MED, V20, P277, DOI 10.1016/0277-9536(85)90242-4; GREENOUGH WB, 1987, CEREAL BASED ORAL RE, P52; HOYLE B, 1980, AM J CLIN NUTR, V33, P2365, DOI 10.1093/ajcn/33.11.2365; HUFFMAN SL, 1991, J DIARRHOEAL DIS RES, V9, P295; KHINMAUNGU, 1985, BMJ-BRIT MED J, V290, P587; Mahalanabis D, 1983, J Diarrhoeal Dis Res, V1, P76; MARTINEZ H, 1991, J DIARRHOEAL DIS RES, V9, P235; MULL JD, 1984, J FAM PRACTICE, V18, P485; OYOO A, 1991, HEALTH POLICY PLANN, V6, P380, DOI 10.1093/heapol/6.4.380; RASHEED P, 1993, SOC SCI MED, V36, P373, DOI 10.1016/0277-9536(93)90022-V; SCHULTZ SG, 1977, AM J PHYSIOL, V233, pE249, DOI 10.1152/ajpendo.1977.233.4.E249; Tulloch J, 1987, World Health Stat Q, V40, P110; WILSON R, 1989, CEREAL BASED ORAL RE, P13; 1993, SELECTION FLUIDS FOO; 1983, LANCET, V2, P259; 1990, WHO1988 1989 PROGR C; 1987, DECISION PROCESS EST; 1978, WHO CHRON, V32, P369; 1993, WHO1992 PROGR CONTR	27	16	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 18	1995	345	8951					709	711		10.1016/S0140-6736(95)90873-0	http://dx.doi.org/10.1016/S0140-6736(95)90873-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM732	7885128				2023-01-03	WOS:A1995QM73200014
J	HOGE, CW; SHLIM, DR; GHIMIRE, M; RABOLD, JG; PANDEY, P; WALCH, A; RAJAH, R; GAUDIO, P; ECHEVERRIA, P				HOGE, CW; SHLIM, DR; GHIMIRE, M; RABOLD, JG; PANDEY, P; WALCH, A; RAJAH, R; GAUDIO, P; ECHEVERRIA, P			PLACEBO-CONTROLLED TRIAL OF COTRIMOXAZOLE FOR CYCLOSPORA INFECTIONS AMONG TRAVELERS AND FOREIGN RESIDENTS IN NEPAL	LANCET			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; ISOSPORA-BELLI INFECTION; CYANOBACTERIUM-LIKE BODIES; DIARRHEA; TRAVELERS; ORGANISM; PATHOGEN	Cyclospora is a coccidian (previously referred to as cyanobacterium-like bodies) that has been implicated in cases of prolonged diarrhoea. The average duration of symptoms is more than three weeks, and no specific treatment has been shown to shorten the illness. A case report suggested that co-trimoxazole may be effective. Expatriate persons with gastrointestinal complaints and cyclospora detected on examination of faeces were recruited from two clinics in Kathmandu, Nepal, between May and August, 1994. Participants were assigned in a randomised, double-blinded manner to receive either co-trimoxazole (160 mg trimethoprim, 800 mg sulphamethoxazole) or placebo tablets twice daily for 7 days. Of 40 patients included in the study, 21 received co-trimoxazole and 19 placebo. There were no significant differences between these two groups in age, sex, time in Nepal, duration or severity of illness, or presence of other enteric pathogens. After 3 days, 71% of patients receiving co-trimoxazole still had cyclospora detected, compared with 100% of patients receiving placebo (p=0.016). After 7 days, cyclospora was detected in 1 (6%) of 16 patients treated with co-trimoxazole who submitted stool specimens compared with 15 (88%) of 17 patients receiving placebo (p<0.0001). Eradication of the organism was correlated with clinical improvement. There was no evidence of relapse of infection among treated patients followed for an additional 7 days. Treatment with co-trimoxazole for 7 days was effective in curing cyclospora infection among an expatriate population in Nepal.	CIWEC CLIN,KATMANDU,NEPAL; US EMBASSY & PEACE CORPS MED UNIT,KATMANDU,NEPAL		HOGE, CW (corresponding author), ARMED FORCES RES INST MED SCI,USA MED COMPONENT,DEPT BACTERIOL IMMUNOL & MOLEC GENET,BANGKOK 10400,THAILAND.							BENDALL RP, 1993, LANCET, V341, P590, DOI 10.1016/0140-6736(93)90352-H; CONNOR BA, 1993, ANN INTERN MED, V119, P377, DOI 10.7326/0003-4819-119-5-199309010-00005; Dean A.G., 1994, EPI INFO VERSION 6 W; DEHOVITZ JA, 1986, NEW ENGL J MED, V315, P87, DOI 10.1056/NEJM198607103150203; HOGE CW, 1993, LANCET, V341, P1175, DOI 10.1016/0140-6736(93)91002-4; LONG EG, 1990, J CLIN MICROBIOL, V28, P1101, DOI 10.1128/JCM.28.6.1101-1104.1990; LONG EG, 1991, J INFECT DIS, V164, P199, DOI 10.1093/infdis/164.1.199; MADICO G, 1993, LANCET, V342, P122, DOI 10.1016/0140-6736(93)91330-O; ORTEGA YR, 1993, NEW ENGL J MED, V328, P1308, DOI 10.1056/NEJM199305063281804; PAPE JW, 1989, NEW ENGL J MED, V320, P1044, DOI 10.1056/NEJM198904203201604; POLLOK RCG, 1992, LANCET, V340, P556, DOI 10.1016/0140-6736(92)91759-2; SHEAR M, 1994, GASTROENTEROLOGY, V106, pA772; SHLIM DR, 1991, AM J TROP MED HYG, V45, P383, DOI 10.4269/ajtmh.1991.45.383; SOAVE R, 1986, CLIN RES, V34, pA533; TAYLOR DN, 1988, JAMA-J AM MED ASSOC, V260, P1245, DOI 10.1001/jama.260.9.1245; WESTERMAN EL, 1979, ANN INTERN MED, V91, P413; WURTZ RM, 1993, CLIN INFECT DIS, V16, P136, DOI 10.1093/clinids/16.1.136; 1993, MED LETT, V35, P111	18	131	138	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 18	1995	345	8951					691	693		10.1016/S0140-6736(95)90868-4	http://dx.doi.org/10.1016/S0140-6736(95)90868-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM732	7885125				2023-01-03	WOS:A1995QM73200009
J	MANNICHE, C; BENTZEN, L; HESSELSOE, G; CHRISTENSEN, I; LUNDBERG, E				MANNICHE, C; BENTZEN, L; HESSELSOE, G; CHRISTENSEN, I; LUNDBERG, E			CLINICAL-TRIAL OF INTENSIVE MUSCLE TRAINING FOR CHRONIC LOW-BACK PAIN	LANCET			English	Article									UNIV COPENHAGEN,HERLEV HOSP,DEPT PHYSIOTHERAPY,DK-2730 HERLEV,DENMARK	University of Copenhagen; Herlev & Gentofte Hospital	MANNICHE, C (corresponding author), UNIV COPENHAGEN,HERLEV HOSP,DEPT RHEUMATOL,DK-2730 HERLEV,DENMARK.			manniche, claus/0000-0001-5938-1483				ANDERSO AD, 1986, J SOC OCCUP MED, V36, P90; BIERINGSORENSEN F, 1982, DAN MED BULL, V29, P289; BIERINGSORENSEN F, 1984, SPINE, V9, P106, DOI 10.1097/00007632-198403000-00002; BLOCH R, 1987, SPINE, V12, P430, DOI 10.1097/00007632-198706000-00002; CADY LD, 1979, J OCCUP ENVIRON MED, V21, P269; CHAFFIN DB, 1974, J OCCUP ENVIRON MED, V16, P248; DAVIES JE, 1979, REHUM REHABIL, V128, P243; DeLorme TL, 1951, PROGR RESISTANCE EXE; Hansen JW, 1964, ACTA ORTHOP SCAND S, V71, P1; HOLM S, 1983, SPINE, V8, P866, DOI 10.1097/00007632-198311000-00009; HUTTON W C, 1977, Spine, V2, P202, DOI 10.1097/00007632-197709000-00006; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; JORGENSEN K, 1986, EUR J APPL PHYSIOL O, V55, P639, DOI 10.1007/BF00423210; KENDALL PH, 1968, PHYSIOTHERAPY, V53, P154; KOSTELJANETZ M, 1988, SPINE, V13, P393, DOI 10.1097/00007632-198804000-00003; LEHMANN TR, 1983, SPINE, V8, P308, DOI 10.1097/00007632-198304000-00013; Lidstrom A, 1970, Scand J Rehabil Med, V2, P37; MACRAE IF, 1969, ANN RHEUM DIS, V28, P584, DOI 10.1136/ard.28.6.584; MANNICHE C, IN PRESS UGESKR LAEG; Martin P R, 1986, Int Rehabil Med, V8, P34; MCKENZIE RA, 1979, NEW ZEAL MED J, V89, P22; MCNEIL T, 1980, SPINE, V6, P529; MILLION R, 1982, SPINE, V7, P204, DOI 10.1097/00007632-198205000-00004; MOFFETT JAK, 1986, SPINE, V11, P120, DOI 10.1097/00007632-198603000-00003; NACHEMSON A, 1979, SCAND J REHABIL MED, V11, P143; NACHEMSON AL, 1987, SPINE, V12, P427, DOI 10.1097/00007632-198706000-00001; NICOLAISEN T, 1985, SCAND J REHABIL MED, V17, P121; PLUM P, 1985, LANCET, V1, P453; ROLAND M, 1983, SPINE, V8, P145, DOI 10.1097/00007632-198303000-00005; SPARUP KH, 1960, LATE PROGNOSIS LUMBA; WADDELL G, 1987, CLIN ORTHOP RELAT R, V221, P110; WILLIAMS PC, 1965, LUMBOSACRAL SPINE; WULFF H, 1988, MEDSTAT; ZYLBERGOLD RS, 1981, ARCH PHYS MED REHAB, V62, P176; [No title captured]	35	171	174	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	DEC 24	1988	2	8626-7					1473	1477						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R5531	2904582				2023-01-03	WOS:A1988R553100015
J	RIGTER, H; BORSTEILERS, E; LEENEN, HJJ				RIGTER, H; BORSTEILERS, E; LEENEN, HJJ			EUTHANASIA ACROSS THE NORTH-SEA	BMJ-BRITISH MEDICAL JOURNAL			English	Article									UNIV AMSTERDAM, SOCIAL MED & HLTH LAW, AMSTERDAM, NETHERLANDS	University of Amsterdam	RIGTER, H (corresponding author), HLTH COUNCIL NETHERLANDS, POB 90517, 2509 LM THE HAGUE, NETHERLANDS.							DAVIES J, 1988, BRIT MED J, V297, P131, DOI 10.1136/bmj.297.6641.131; Fletcher J, 1987, Law Med Health Care, V15, P223; Gevers J K M, 1987, Bioethics, V1, P156, DOI 10.1111/j.1467-8519.1987.tb00024.x; GREAVES D, 1988, IME B, V38, P17; HIGGS R, 1988, BRIT MED J, V296, P1348, DOI 10.1136/bmj.296.6633.1348; KUHSE H, 1988, MED J AUSTRALIA, V148, P623, DOI 10.5694/j.1326-5377.1988.tb116334.x; KUHSE H, 1987, MED J AUSTRALIA, V147, P394, DOI 10.5694/j.1326-5377.1987.tb133560.x; LEENEN HJJ, 1987, HEALTH POLICY, V8, P197, DOI 10.1016/0168-8510(87)90062-5; Meyboom-de Jong B, 1983, Ned Tijdschr Geneeskd, V127, P946; OLIEMANS AP, 1986, MED CONTACT, V41, P691; PENCE GE, 1988, AM J MED, V84, P139, DOI 10.1016/0002-9343(88)90022-8; WIGHT JP, 1988, BRIT MED J, V297, P67, DOI 10.1136/bmj.297.6640.67-e; 1988, EUTHANASIA; 1986, VISION EUTHANASIA; 1987, ZORGVULDIGHEIDSEISEN; 1988, HEMLOCK Q, V32, P4; 1987, BIOETHICS, V1, P163; 1988, IME B, V39, P5	19	25	25	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 17	1988	297	6663					1593	1595		10.1136/bmj.297.6663.1593	http://dx.doi.org/10.1136/bmj.297.6663.1593			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R4933	3147088	Green Published			2023-01-03	WOS:A1988R493300027
J	RAMSAY, G				RAMSAY, G			INTRAVENOUS VOLUME REPLACEMENT - INDICATIONS AND CHOICES	BRITISH MEDICAL JOURNAL			English	Editorial Material											RAMSAY, G (corresponding author), WESTERN INFIRM,GLASGOW G11 6NT,SCOTLAND.							FALK JL, 1984, ACUTE CARE, V10, P59; FEEST TG, 1976, BRIT MED J, V2, P1300, DOI 10.1136/bmj.2.6047.1300; FORRESTER JS, 1976, NEW ENGL J MED, V295, P1356, DOI 10.1056/NEJM197612092952406; GILMOUR DG, 1980, BRIT J SURG, V67, P82, DOI 10.1002/bjs.1800670204; ISBISTER JP, 1980, ANAESTH INTENS CARE, V8, P145, DOI 10.1177/0310057X8000800208; MOSS GS, 1981, SURGERY, V89, P434; RAMSAY G, 1987, CIRC SHOCK, V22, P261; RING J, 1977, LANCET, V1, P466; SHIRES GT, 1960, SURG FORUM, V11, P115; SHOEMAKER WC, 1981, CRIT CARE MED, V9, P367, DOI 10.1097/00003246-198105000-00007; SMITH JAR, 1982, BRIT J SURG, V69, P702, DOI 10.1002/bjs.1800691205; STURM JA, 1985, INTENS CARE MED, V11, P227; TWIGLEY AJ, 1985, ANAESTHESIA, V40, P860, DOI 10.1111/j.1365-2044.1985.tb11047.x; YATES DW, 1984, ARCH EMERG MED S, V1, P1	14	12	12	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 21	1988	296	6634					1422	1423		10.1136/bmj.296.6634.1422	http://dx.doi.org/10.1136/bmj.296.6634.1422			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N5101	3132273	Green Published			2023-01-03	WOS:A1988N510100004
J	BRAHAMS, D				BRAHAMS, D			THE EUTHANASIA DEBATE	LANCET			English	Editorial Material																		BOOTHROYD J, 1988, LAW MAGAZINE    0318; BRAHAMS D, 1981, LANCET, V2, P1101; 1988, JAMA, V159, P272	3	1	1	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 2	1988	1	8588					779	780						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M7875	2895313				2023-01-03	WOS:A1988M787500061
J	DULIK, DM; FENSELAU, C				DULIK, DM; FENSELAU, C			USE OF IMMOBILIZED ENZYMES IN DRUG-METABOLISM STUDIES	FASEB JOURNAL			English	Review									JOHNS HOPKINS UNIV, SCH MED, DEPT PHARMACOL & MOLEC SCI, BALTIMORE, MD 21205 USA	Johns Hopkins University					NIGMS NIH HHS [GM-21248] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021248, R01GM021248] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLIS CD, 1986, ANAL BIOCHEM, V159, P58, DOI 10.1016/0003-2697(86)90307-6; BAESS D, 1975, ACTA BIOL MED GER, V34, P1745; BOWERS LD, 1986, ANAL CHEM, V58, pA513, DOI 10.1021/ac00295a001; BRUNNER G, 1979, ARTIF ORGANS, V3, P27, DOI 10.1111/j.1525-1594.1979.tb03801.x; BRUNNER G, 1983, ENZYME, V30, P181, DOI 10.1159/000469572; BRUNNER G, 1980, BIOCH BIOPHYSICS REG, P573; CALLEGARO L, 1981, ARTIFICIAL LIVER SUP, P202; DELUCA M, 1984, CURR TOP CELL REGUL, V24, P189; DULIK DM, 1987, DRUG METAB DISPOS, V15, P195; DULIK DM, 1986, BIOCHEM PHARMACOL, V35, P3405, DOI 10.1016/0006-2952(86)90444-2; DULIK DM, 1987, DRUG METAB DISPOS, V15, P473; ELMOUELHI M, 1987, DRUG METAB DISPOS, V15, P767; Eremin A.A., 1979, VESTN AN SSSR+, P86; FEIL VJ, IN PRESS J LABELLED; FENG PCC, 1983, DRUG METAB DISPOS, V11, P103; FENSELAU C, 1976, J MED CHEM, V19, P679, DOI 10.1021/jm00227a020; FENSELAU C, 1982, DRUG METAB DISPOS, V10, P636; FENSELAU C, 1977, SCIENCE, V198, P625, DOI 10.1126/science.335509; Grynspan E, 1985, Trans Am Soc Artif Intern Organs, V31, P464; HESSE S, 1978, CHEM-BIOL INTERACT, V20, P355, DOI 10.1016/0009-2797(78)90113-8; ISHIKAWA H, 1987, BIOTECHNOL BIOENG, V29, P924, DOI 10.1002/bit.260290803; JAKOBY WB, 1974, METHOD ENZYMOL, V34, P1; LEGOFFIC F, 1977, BIOCHIMIE, V59, P927; LEHMAN JP, 1981, DRUG METAB DISPOS, V9, P15; LEHMAN JP, 1983, DRUG METAB DISPOS, V11, P221; LISEK CA, 1986, DISS ABSTR INT B, V47, P613; LOSGEN H, 1978, BIOMATER ARTIF CELL, V6, P151; MAUGH TH, 1984, SCIENCE, V223, P474, DOI 10.1126/science.223.4635.474; MONKS TJ, 1987, DRUG METAB DISPOS, V15, P437; MORGENSTERN R, 1980, EUR J BIOCHEM, V104, P167, DOI 10.1111/j.1432-1033.1980.tb04412.x; MULDER GJ, 1979, TRENDS BIOCHEM SCI, V4, P86, DOI 10.1016/0968-0004(79)90189-0; PALLANTE S, 1978, DRUG METAB DISPOS, V6, P389; PALLANTE SL, 1986, DRUG METAB DISPOS, V14, P313; PARIKH I, 1985, CHEM ENG NEWS, V63, P17, DOI 10.1021/cen-v063n034.p017; PARIKH I, 1976, J MED CHEM, V19, P296, DOI 10.1021/jm00224a018; SCHUBERT F, 1985, PHARMAZIE, V40, P235; VANBREEMEN RB, 1985, DRUG METAB DISPOS, V13, P318; WINGARD LB, 1983, BIOCHEM PHARMACOL, V32, P2647, DOI 10.1016/0006-2952(83)90070-9; WOOLF TW, 1986, PHARM RES, V3, P1335; YAWETZ A, 1984, BIOCHIM BIOPHYS ACTA, V798, P204, DOI 10.1016/0304-4165(84)90305-2	40	20	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	1988	2	7					2235	2240		10.1096/fasebj.2.7.3127263	http://dx.doi.org/10.1096/fasebj.2.7.3127263			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	M8947	3127263				2023-01-03	WOS:A1988M894700002
J	LANTOS, JD; MILES, SH; SILVERSTEIN, MD; STOCKING, CB				LANTOS, JD; MILES, SH; SILVERSTEIN, MD; STOCKING, CB			SURVIVAL AFTER CARDIOPULMONARY RESUSCITATION IN BABIES OF VERY LOW BIRTH-WEIGHT - IS CPR FUTILE THERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV CHICAGO,PRITZKER SCH MED,CTR CLIN MED ETH,CHICAGO,IL 60637; UNIV CHICAGO,PRITZKER SCH MED,GEN INTERNAL MED SECT,CHICAGO,IL 60637; UNIV CHICAGO,PRITZKER SCH MED,DEPT PEDIAT,CHICAGO,IL 60637	University of Chicago; University of Chicago; University of Chicago			Silverstein, Marc D/D-8592-2011					Avery GB, 1981, NEONATOLOGY PATHOPHY; CAPRON AM, 1986, BIOLAW LEGAL ETHICAL, V1, P217; DEVRIES LS, 1985, LANCET, V2, P137; FROHOCK FM, 1986, SPECIAL CARE MED DEC; GILLIS J, 1986, CRIT CARE MED, V14, P469, DOI 10.1097/00003246-198605000-00007; GOLDENBERG RL, 1985, AM J OBSTET GYNECOL, V151, P608, DOI 10.1016/0002-9378(85)90148-6; GROSS RH, 1983, PEDIATRICS, V72, P450; HACK M, 1986, NEW ENGL J MED, V314, P660, DOI 10.1056/NEJM198603063141036; HANLEY JA, 1983, JAMA-J AM MED ASSOC, V249, P1743, DOI 10.1001/jama.249.13.1743; HART SM, 1983, ARCH DIS CHILD, V58, P612, DOI 10.1136/adc.58.8.612; KOOPS BL, 1982, J PEDIATR-US, V101, P969; KWONG MS, 1985, PEDIATRICS, V76, P585; LAZZARA A, 1980, PEDIATRICS, V65, P30; LEE KS, 1980, AM J PUBLIC HEALTH, V70, P15, DOI 10.2105/AJPH.70.1.15; LEVINE RJ, 1986, ETHICS REGULATION CL, P13; LEWIS JK, 1983, ANN EMERG MED, V12, P297, DOI 10.1016/S0196-0644(83)80512-5; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MCCORMICK RA, 1978, HASTINGS CENT REP, V8, P30, DOI 10.2307/3560325; MILLIGAN JE, 1984, AM J OBSTET GYNECOL, V148, P499, DOI 10.1016/0002-9378(84)90734-8; PLEASURE JR, 1984, AM J DIS CHILD, V138, P783, DOI 10.1001/archpedi.1984.02140460073024; RAJU TNK, 1986, CLIN PERINATOL, V13, P233, DOI 10.1016/S0095-5108(18)30818-2; SAIGAL S, 1984, J PEDIATR-US, V105, P969, DOI 10.1016/S0022-3476(84)80093-1; SINCLAIR JC, 1981, NEW ENGL J MED, V305, P489, DOI 10.1056/NEJM198108273050904; STARFIELD B, 1985, EFFECTIVENESS MED CA, P9; STRONG C, 1983, HASTINGS CENT REP, V13, P14, DOI 10.2307/3561546; TORPHY DE, 1984, AM J DIS CHILD, V138, P1099, DOI 10.1001/archpedi.1984.02140500005003; VONSEGGERN K, 1986, CRIT CARE MED, V14, P275; WILLETT LD, 1986, CRIT CARE MED, V14, P773, DOI 10.1097/00003246-198609000-00003; 1985, SAS STAT GUIDE PERSO	29	107	107	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 14	1988	318	2					91	95		10.1056/NEJM198801143180206	http://dx.doi.org/10.1056/NEJM198801143180206			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L6001	3336398				2023-01-03	WOS:A1988L600100006
J	MOSIOR, M; NEWTON, AC				MOSIOR, M; NEWTON, AC			MECHANISM OF INTERACTION OF PROTEIN-KINASE-C WITH PHORBOL ESTERS - REVERSIBILITY AND NATURE OF MEMBRANE ASSOCIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID-VESICLES; PLASMA-MEMBRANE; MODEL MEMBRANES; HUMAN-PLATELETS; LIPID VESICLES; ACTIVATION; CALCIUM; PHOSPHATIDYLSERINE; DIACYLGLYCEROLS; FLUORESCENCE	A variety of approaches have been employed to demonstrate that the interaction of protein kinase C beta II with phorbol ester-containing membranes is reversible, is not accompanied by significant insertion of the protein into the hydrophobic core of the membrane, and is qualitatively similar to the interaction with diacylglycerol (DG), First, we show that under conditions when protein kinase C is bound with equal affinity to membranes containing either DG or phorbol myristate acetate (PMA), increasing ionic strength causes a similar reduction in membrane binding, The similar sensitivity to ionic strength indicates that the forces mediating the binding of protein kinase C to PMA are not significantly different from those mediating the binding to DG. At sufficiently high concentrations of PMA and relatively low concentrations of phosphatidylserine, the binding of protein kinase C to membranes became markedly less sensitive to ionic strength, suggesting that under these conditions direct non-electrostatic interactions with PMA dominate over electrostatic interactions with the lipid headgroups, Importantly, regardless of the strength of the interaction with PMA, protein kinase C exchanges between vesicle surfaces: protein kinase C bound first to phorbol ester-containing multilamellar vesicles exchanged to large unilamellar vesicles upon addition of an excess surface area of the latter, Lastly, the enzyme's intrinsic tryptophan fluorescence was not quenched by bromines located at various positions in the hydrophobic core of the membrane. In contrast, the enzyme's tryptophan fluorescence was significantly quenched by probes positioned at the membrane surface, In summary, our results are consistent with protein kinase C binding reversibly to PMA- or DG-containing membranes primarily via interactions at the membrane interface.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043154, R01GM043154] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 43154] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHENDEL CL, 1985, BIOCHIM BIOPHYS ACTA, V822, P219, DOI 10.1016/0304-4157(85)90009-7; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P9317, DOI 10.1021/bi00450a011; BAZZI MD, 1987, BIOCHEMISTRY-US, V26, P115, DOI 10.1021/bi00375a017; BAZZI MD, 1990, BIOCHEMISTRY-US, V29, P7624, DOI 10.1021/bi00485a012; BAZZI MD, 1989, BIOCHEMISTRY-US, V28, P3577, DOI 10.1021/bi00434a064; BELL RM, 1991, J BIOL CHEM, V266, P4661; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BLUME A, 1983, BIOCHEMISTRY-US, V22, P5436, DOI 10.1021/bi00292a027; BORNER C, 1992, J BIOL CHEM, V267, P12892; BRUMFELD V, 1990, ARCH BIOCHEM BIOPHYS, V277, P318, DOI 10.1016/0003-9861(90)90586-N; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548; CRABOS M, 1991, BIOCHEM BIOPH RES CO, V178, P878, DOI 10.1016/0006-291X(91)90973-B; DAEMEN FJM, 1973, BIOCHIM BIOPHYS ACTA, V300, P255, DOI 10.1016/0304-4157(73)90006-3; EAST JM, 1982, BIOCHEMISTRY-US, V21, P4144, DOI 10.1021/bi00260a035; EPAND RM, 1992, EUR J BIOCHEM, V208, P327, DOI 10.1111/j.1432-1033.1992.tb17190.x; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FLORINCHRISTENSEN J, 1992, J BIOL CHEM, V267, P14783; FLORINE KI, 1987, BIOCHEMISTRY-US, V26, P2978, DOI 10.1021/bi00385a004; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; KAZANIETZ MG, 1992, J BIOL CHEM, V267, P20878; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LADOKHIN AS, 1991, BIOCHEMISTRY-US, V30, P10200, DOI 10.1021/bi00106a018; Lakowicz J.R, 2006, PRINCIPLES FLUORESCE, Vthird; LETO TL, 1980, BIOCHEMISTRY-US, V19, P1911, DOI 10.1021/bi00550a028; MARKELLO T, 1985, BIOCHEMISTRY-US, V24, P2895, DOI 10.1021/bi00333a012; MOSIOR M, 1993, BIOCHEMISTRY-US, V32, P65, DOI 10.1021/bi00052a010; MOSIOR M, 1994, BIOPHYS J, V66, pA30; MOSIOR M, 1994, J BIOL CHEM, V269, P13798; NELSESTUEN GL, 1991, J BIOENERG BIOMEMBR, V23, P43; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; ONO Y, 1986, FEBS LETT, V206, P347, DOI 10.1016/0014-5793(86)81010-9; ORR JW, 1994, J BIOL CHEM, V269, P8383; ORR JW, 1992, J BIOL CHEM, V267, P15263; ORR JW, 1992, BIOCHEMISTRY-US, V31, P4667, DOI 10.1021/bi00134a019; QUEST AFG, 1994, PROTEIN KINASE C, P64; RASMUSSEN H, 1992, PROTEIN KINASE C CUR, P216; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SNOEK GT, 1986, BIOCHIM BIOPHYS ACTA, V860, P336, DOI 10.1016/0005-2736(86)90530-4; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TANFORD C, 1980, HYDROPHOBIC EFFECT; ULBRANDT ND, 1992, J BIOL CHEM, V267, P15184; ZHANG GG, 1995, CELL, V81, P917, DOI 10.1016/0092-8674(95)90011-X; ZIDOVETZKI R, 1992, BIOCHIM BIOPHYS ACTA, V1134, P261, DOI 10.1016/0167-4889(92)90185-E	49	99	100	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25526	25533		10.1074/jbc.270.43.25526	http://dx.doi.org/10.1074/jbc.270.43.25526			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592722	hybrid			2023-01-03	WOS:A1995TB46600039
J	LLOYD, DCEF; HARRIS, CM; ROBERTS, DJ				LLOYD, DCEF; HARRIS, CM; ROBERTS, DJ			SPECIFIC THERAPEUTIC GROUP AGE-SEX RELATED PRESCRIBING UNITS (STAR-PUS) - WEIGHTINGS FOR ANALYZING GENERAL PRACTICES PRESCRIBING IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To derive cost comparators for prescribing by English general practitioners in eight specific therapeutic groups, based on age-sex related weightings, and to confirm, from a new dataset, earlier age-sex weightings for overall prescribing (ASTRO-PUs). Design-Calculations based on one year's prescribing data from selected practices using AAH Meditel software, held on MediPlus by Intercontinental Medical Statistics (IMS, UK and Ireland), and research practices using VAMP software, held on the General Practice Research Database. Setting-112 English practices with 739 672 patients and 510 British practices with 3 126 570 patients. Main outcome measures-Cost based weightings for 18 age-sex groups and for temporary residents for eight leading specific therapeutic groups and for prescribing overall. Results-The two datasets were similar in age distribution and in the way that prescription numbers were distributed by age-sex band in each therapeutic group. The cost based weightings for specific therapeutic groups showed great variation in the use of these groups for patients in different age-sex groups. When these weightings were applied to the prescribing of practices in two family health services authorities they differed in their power to predict prescribing costs: for cardiovascular and gastrointestinal drugs predictive power was particularly high; for drugs for infections it was particularly low, since these are widely used at all ages and for both sexes. Cost based weightings for overall prescribing derived from the IMS data were similar to those of the ASTRO-PU system even though they were derived by different methods from different datasets. Conclusions-The weightings (STAR-PUs) offer a sound basis for cost comparisons at the therapeutic group level. Cost-based weightings for overall prescribing derived from the UMS data were reassuringly similar to those of the existing ASTRO-PU system.	UNIV LEEDS,RES SCH MED,PRESCRIBING RES UNIT,LEEDS LS2 9NZ,W YORKSHIRE,ENGLAND	University of Leeds								BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; SLEATOR DJD, 1993, BRIT J GEN PRACT, V43, P102	5	53	57	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 14	1995	311	7011					991	994						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA079	7580642				2023-01-03	WOS:A1995TA07900027
J	MEADE, TW; DYER, S; BROWNE, W; FRANK, AO				MEADE, TW; DYER, S; BROWNE, W; FRANK, AO			RANDOMIZED COMPARISON OF CHIROPRACTIC AND HOSPITAL OUTPATIENT MANAGEMENT FOR LOW-BACK-PAIN - RESULTS FROM EXTENDED FOLLOW-UP	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare the effectiveness over three years of chiropractic and hospital outpatient management for low back pain. Design-Randomised allocation of patients to chiropractic or hospital outpatient management. Setting-Chiropractic clinics and hospital outpatient departments within reasonable travelling distance of each other in 11 centres. Subjects-741 men and women aged 18-64 years with low back pain in whom manipulation was not contraindicated. Outcome measures-Change in total Oswestry questionnaire score and in score for pain and patient satisfaction with allocated treatment. Results-According to total Oswestry scores improvement in all patients at three years was about 29% more in those treated by chiropractors than in those treated by the hospitals. The beneficial effect of chiropractic on pain was particularly clear. Those treated by chiropractors had more further treatments for back pain after the completion of trial treatment. Among both those initially referred from chiropractors and from hospitals more rated chiropractic helpful at three years than hospital management. Conclusions-At three years the results confirm the findings of an earlier report that when chiropractic or hospital therapists treat patients with low back pain as they would in day to day practice those treated by chiropractic derive more benefit and long term satisfaction than those treated by hospitals.	NORTHWICK PK HOSP & CLIN RES CTR,HARROW HA1 3UJ,MIDDX,ENGLAND	Imperial College London	MEADE, TW (corresponding author), UNIV LONDON ST BARTHOLOMEWS HOSP & MED COLL,WOLFSON INST PREVENT MED,MRC,LONDON EC1M 6BQ,ENGLAND.							Fairbank J C, 1980, Physiotherapy, V66, P271; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; SIMON R, 1975, BIOMETRICS, V31, P103	3	145	148	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					349	351		10.1136/bmj.311.7001.349	http://dx.doi.org/10.1136/bmj.311.7001.349			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640538	Green Published			2023-01-03	WOS:A1995RN46900011
J	VIDAL, M; HOEKSTRA, D				VIDAL, M; HOEKSTRA, D			IN-VITRO FUSION OF RETICULOCYTE ENDOCYTIC VESICLES WITH LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOSOME-ENDOSOME FUSION; MEMBRANE-FUSION; TRANSFERRIN RECEPTOR; VESICULAR TRANSPORT; SENDAI VIRUS; PROTEIN; REQUIRES; INVITRO; INHIBITORS; EXOCYTOSIS	Since reticulocytes have a high demand for iron, which is required for heme biosynthesis, these cells are highly specialized in the endocytosis of the iron carrier transferrin (Tf). From the resulting endocytic vesicles (EVs), iron is released and the vesicles rapidly return to the cell membrane where they fuse, causing the release of the apotransferrin. Due to a lack of other intracellular compartments, the endocytic vesicles can be readily isolated. In this study, we have investigated the fusogenic properties of EVs, using liposomes as target membranes. Membrane fusion was monitored by a lipid mixing assay based on the relief of fluorescence self-quenching, using octadecylrhodamine B-chloride (R18). Application of this procedure was verified and solidified by analysis of the fusion event by an independent lipid mixing assay, after in situ labeling of EVs, and by determination of the mixing of aqueous contents. We demonstrate that the endocytic vesicles are particularly prone to fuse with target membranes that contain dioleoylphosphatidylethanolamine (DOPE). Relative to DOPE, bilayers composed of phosphatidylserine or phosphatidylcholine show a reduced fusion activity with EV. The specific and strong inhibition of fusion by cyclosporin A and a peptide known to interfere with the propensity of DOPE to adopt the hexagonal HII phase suggests that the mechanism of fusion involves the ability of this lipid to readily adopt non-bilayer phases. ATP, GTP, and/or cytosol are not necessary to obtain fusion. However, trypsin treatment of the endocytic vesicles inhibits fusion, indicating the involvement of (a) protein(s) in the fusion event.	UNIV GRONINGEN,PHYSIOL CHEM LAB,9712 KZ GRONINGEN,NETHERLANDS	University of Groningen	VIDAL, M (corresponding author), UNIV MONTPELLIER 2,CNRS,URA 1856,PL E BATAILLON,CC 107,F-34095 MONTPELLIER,FRANCE.							ADAM M, 1986, J CELL PHYSIOL, V127, P8, DOI 10.1002/jcp.1041270103; ARTS EGJM, 1993, EUR J BIOCHEM, V217, P1001, DOI 10.1111/j.1432-1033.1993.tb18331.x; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BECK KA, 1992, J CELL BIOL, V119, P787, DOI 10.1083/jcb.119.4.787; BECKERS CJM, 1989, NATURE, V339, P397, DOI 10.1038/339397a0; BETTEBOBILLO P, 1995, EUR J BIOCHEM, V228, P199, DOI 10.1111/j.1432-1033.1995.0199o.x; COLOMBO MI, 1991, J BIOL CHEM, V266, P23438; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; DIAZ R, 1989, NATURE, V339, P398, DOI 10.1038/339398a0; EPAND RM, 1993, BIOCHIM BIOPHYS ACTA, V1152, P128, DOI 10.1016/0005-2736(93)90239-V; EPAND RM, 1987, J BIOL CHEM, V262, P1526; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GRASSO JA, 1990, BIOCHEM J, V266, P261, DOI 10.1042/bj2660261; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; HOEKSTRA D, 1982, BIOCHEMISTRY-US, V21, P6097, DOI 10.1021/bi00267a011; HULTSCH T, 1991, P NATL ACAD SCI USA, V88, P6229, DOI 10.1073/pnas.88.14.6229; KAGIWADA S, 1993, J BIOL CHEM, V268, P1430; KELSEY DR, 1990, J BIOL CHEM, V265, P12178; KLAPPE K, 1986, BIOCHEMISTRY-US, V25, P8252, DOI 10.1021/bi00373a019; KOK JW, 1990, EUR J CELL BIOL, V53, P173; KREMER JMH, 1977, BIOCHEMISTRY-US, V16, P3932, DOI 10.1021/bi00636a033; LENHARD JM, 1994, ARCH BIOCHEM BIOPHYS, V312, P474, DOI 10.1006/abbi.1994.1334; MARTIN I, 1992, ADV MEMBRANE FLUIDIT, V6, P365; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; MULLOCK BM, 1994, J CELL BIOL, V126, P1173, DOI 10.1083/jcb.126.5.1173; PITT A, 1991, EUR J CELL BIOL, V55, P328; PLEY U, 1993, CRIT REV BIOCHEM MOL, V28, P431, DOI 10.3109/10409239309078441; RAPOPORT SM, 1991, BLOOD CELL BIOCH ERY, P151; RUTLEDGE EA, 1991, J BIOL CHEM, V266, P21125; SCHEULE RK, 1986, BIOCHEMISTRY-US, V25, P4223, DOI 10.1021/bi00363a009; SIEGEL DP, 1986, BIOPHYS J, V49, P1171, DOI 10.1016/S0006-3495(86)83745-6; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STECK TL, 1973, J SUPRAMOL STRUCT, V1, P221; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; STROUS GJ, 1988, J BIOL CHEM, V263, P18197; Sztul Elizabeth S., 1992, Trends in Cell Biology, V2, P381, DOI 10.1016/0962-8924(92)90051-N; TAKIZAWA PA, 1993, CELL, V75, P593, DOI 10.1016/0092-8674(93)90477-8; TOURNOIS H, 1987, BIOCHEMISTRY-US, V26, P6613, DOI 10.1021/bi00395a008; VIDAL MJ, 1993, EUR J CELL BIOL, V60, P261; VOGEL SS, 1992, J BIOL CHEM, V267, P25640; WASCHULEWSKI IH, 1993, BRIT J PHARMACOL, V108, P892, DOI 10.1111/j.1476-5381.1993.tb13483.x; YEAGLE PL, 1992, BIOCHEMISTRY-US, V31, P3177, DOI 10.1021/bi00127a019; ZAAL KJM, 1994, EUR J CELL BIOL, V63, P10	44	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 28	1995	270	30					17823	17829		10.1074/jbc.270.30.17823	http://dx.doi.org/10.1074/jbc.270.30.17823			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RM266	7629083	hybrid			2023-01-03	WOS:A1995RM26600031
J	SCHULMAN, S; RHEDIN, AS; LINDMARKER, P; CARLSSON, A; LARFARS, G; NICOL, P; LOOGNA, E; SVENSSON, E; LJUNGBERG, B; WALTER, H; VIERING, S; NORDLANDER, S; LEIJD, B; JONSSON, KA; HJORTH, M; LINDER, O; BOBERG, J; GUSTAFSSON, C; GRONDAHL, A; TORNEBOHM, E; JOHANSSON, M; LOCKNER, D; JOHNSSON, H; KOBOSKO, J; MALMROS, B; ARCINI, N; SAAW, J; STIG, R; WILHELMSSON, S; OHLSSON, A; MALMQVIST, K; ALKHALILI, F; PETRESCU, A; BROHULT, J; HULTING, J; EKLUND, SG; DAHLIN, L; MARJANOVICS, B; MALM, C; LINDGREN, A; FAGRELL, B; KALLNER, M; GRANQVIST, S; WIMAN, B; EGBERG, N; WADMAN, B; SNYDER, M				SCHULMAN, S; RHEDIN, AS; LINDMARKER, P; CARLSSON, A; LARFARS, G; NICOL, P; LOOGNA, E; SVENSSON, E; LJUNGBERG, B; WALTER, H; VIERING, S; NORDLANDER, S; LEIJD, B; JONSSON, KA; HJORTH, M; LINDER, O; BOBERG, J; GUSTAFSSON, C; GRONDAHL, A; TORNEBOHM, E; JOHANSSON, M; LOCKNER, D; JOHNSSON, H; KOBOSKO, J; MALMROS, B; ARCINI, N; SAAW, J; STIG, R; WILHELMSSON, S; OHLSSON, A; MALMQVIST, K; ALKHALILI, F; PETRESCU, A; BROHULT, J; HULTING, J; EKLUND, SG; DAHLIN, L; MARJANOVICS, B; MALM, C; LINDGREN, A; FAGRELL, B; KALLNER, M; GRANQVIST, S; WIMAN, B; EGBERG, N; WADMAN, B; SNYDER, M			A COMPARISON OF 6 WEEKS WITH 6 MONTHS OF ORAL ANTICOAGULANT-THERAPY AFTER A FIRST EPISODE OF VENOUS THROMBOEMBOLISM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; LONG-TERM TREATMENT; PULMONARY-EMBOLISM; WARFARIN SODIUM; DURATION; POPULATION; HEPARIN	Background. The optimal duration of oral anticoaguiant therapy after a first episode of venous thromboembolism is still a matter of debate. Methods. We performed a multicenter trial comparing six weeks of oral anticoagulant treatment with six months of such therapy in patients who had a first episode of venous thromboembolism. Anticoagulant therapy consisted of warfarin or dicumarol. Of the 902 patients enrolled, 5 were later excluded because they had congenital protein C deficiency; 443 were randomly assigned to receive six weeks of oral anticoagulant therapy with a targeted international normalized ratio (INR) of 2.0 to 2.85, and 454 were randomly assigned to receive six months of such therapy. The initial diagnoses were confirmed by means of venography in cases of deep-vein thromboses (n=790) and with perfusion-ventilation scanning or angiography in cases of pulmonary embolism (n=107); recurrences were confirmed in the same way. Results. After two years of follow-up, there had been 123 recurrences of venous thromboembolism that met the diagnostic criteria, 80 in the six-week group (18.1 percent; 95 percent confidence interval, 14.5 to 21.6) and 43 in the six-month group (9.5 percent; 95 percent confidence interval, 6.8 to 12.2). The odds ratio for recurrence in the six-week group was 2.1 (95 percent confidence interval, 1.4 to 3.1). There was no difference in mortality or the rate of major hemorrhage between the six-week and six-month groups. Conclusions. Six months of prophylactic oral anticoagulation after a first episode of venous thromboembolism led to a tower recurrence rate than did treatment tasting for six weeks. The difference between the two groups occurred between 6 weeks and 6 months after the start of treatment, and the rates of recurrence remained nearly parallel for 11/2 years thereafter.	KAROLINSKA HOSP,DEPT INTERNAL MED,S-10401 STOCKHOLM,SWEDEN; HUDDINGE HOSP,DEPT INTERNAL MED,S-14186 HUDDINGE,SWEDEN; DANDERYD HOSP,DEPT INTERNAL MED,S-18288 DANDERYD,SWEDEN; SODER SJUKHUSET,DEPT INTERNAL MED,S-10064 STOCKHOLM,SWEDEN; KOPING HOSP,DEPT INTERNAL MED,KOPING,SWEDEN; NACKA HOSP,DEPT INTERNAL MED,STOCKHOLM,SWEDEN; SODERTALJE HOSP,DEPT INTERNAL MED,SODERTALJE,SWEDEN; NYKOPING HOSP,DEPT INTERNAL MED,NYKOPING,SWEDEN; SABBATSBERGS HOSP,DEPT INTERNAL MED,S-11382 STOCKHOLM,SWEDEN; NORRTALJE HOSP,DEPT INTERNAL MED,NORRTALJE,SWEDEN; CENT HOSP VASTERAS,DEPT INTERNAL MED,VASTERAS,SWEDEN; ST GORANS UNIV HOSP,DEPT INTERNAL MED,STOCKHOLM,SWEDEN; LINKOPING REG HOSP,DEPT INTERNAL MED,LINKOPING,SWEDEN; LIDKOPING HOSP,DEPT INTERNAL MED,LINKOPING,SWEDEN; OREBRO REG HOSP,DEPT INTERNAL MED,OREBRO,SWEDEN; UPPSALA ACAD HOSP,DEPT INTERNAL MED,UPPSALA,SWEDEN	Karolinska Institutet; Karolinska University Hospital; Danderyds Hospital; Sodersjukhuset Hospital; Vasteras Central Hospital; Saint Goran's Hospital; Uppsala University; Uppsala University Hospital			Zanatta, Nilo/P-7137-2017; Schulman, Sam/I-7559-2019; Miranda, Fausto/N-9780-2018	Zanatta, Nilo/0000-0002-0959-9043; Schulman, Sam/0000-0002-8512-9043; Miranda, Fausto/0000-0003-2954-8638				ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; COON WW, 1969, ANN SURG, V170, P559, DOI 10.1097/00000658-196910000-00007; FENNERTY A, 1988, BMJ-BRIT MED J, V297, P1285, DOI 10.1136/bmj.297.6659.1285; HOLMGREN KAJ, 1985, ACTA MED SCAND, V218, P279; HULL R, 1979, NEW ENGL J MED, V301, P855, DOI 10.1056/NEJM197910183011602; HULL R, 1982, NEW ENGL J MED, V306, P189, DOI 10.1056/NEJM198201283060401; LAGERSTEDT CI, 1985, LANCET, V2, P515; LEVINE MN, 1992, CHEST, V102, pS352, DOI 10.1378/chest.102.4.352S; NORDSTROM M, 1992, J INTERN MED, V232, P155, DOI 10.1111/j.1365-2796.1992.tb00565.x; OSULLIVAN EF, 1972, MED J AUSTRALIA, V2, P1104, DOI 10.5694/j.1326-5377.1972.tb103752.x; PETITTI DB, 1986, AM J MED, V81, P255, DOI 10.1016/0002-9343(86)90260-3; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; Research Committee of the British Thoracic Society, 1992, LANCET, V340, P873; ROEBUCK DJ, 1992, LANCET, V340, P1296, DOI 10.1016/0140-6736(92)93002-5; SARASIN FP, 1994, THROMB HAEMOSTASIS, V71, P286; SCHULMAN S, 1985, ACTA MED SCAND, V217, P547; SCHULMAN S, 1994, J INTERN MED, V236, P143, DOI 10.1111/j.1365-2796.1994.tb01276.x; SCHULMAN S, 1988, ACTA MED SCAND, V224, P425	18	773	791	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 22	1995	332	25					1661	1665		10.1056/NEJM199506223322501	http://dx.doi.org/10.1056/NEJM199506223322501			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD996	7760866				2023-01-03	WOS:A1995RD99600001
J	BRANDSTATER, ME				BRANDSTATER, ME			PHYSICAL MEDICINE AND REHABILITATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											BRANDSTATER, ME (corresponding author), LOMA LINDA UNIV,LOMA LINDA,CA 92350, USA.							AGRE JC, 1991, ARCH PHYS MED REHAB, V72, P923, DOI 10.1016/0003-9993(91)90013-9; BACH JR, 1994, ARCH PHYS MED REHAB, V75, P626, DOI 10.1016/0003-9993(94)90183-X; BACH JR, 1992, ARCH PHYS MED REHAB, V73, P934; BORGSTEIN J, 1993, J HEAD TRAUMA REHAB, V8, P103; BOYESON MG, 1994, J HEAD TRAUMA REHAB, V9, P78, DOI 10.1097/00001199-199409000-00007; COPE DN, 1994, J HEAD TRAUMA REHAB, V9, P1, DOI 10.1097/00001199-199409000-00003; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; Hamilton B. B., 1987, REHABILITATION OUTCO, P137; JOHNSTON MV, 1994, ARCH PHYS MED REHAB, V75, pSC2; KRAFT GH, 1992, ARCH PHYS MED REHAB, V73, P220; Saal J A, 1990, Orthop Rev, V19, P691; SAAL JS, 1990, SPINE, V15, P674, DOI 10.1097/00007632-199007000-00011; WHITENECK GG, 1992, ARCH PHYS MED REHAB, V73, P519; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; [No title captured]; B HLTH INSURANCE ASS, V287	16	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1710	1712		10.1001/jama.273.21.1710	http://dx.doi.org/10.1001/jama.273.21.1710			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752431				2023-01-03	WOS:A1995RB09700039
J	LABIANCA, R; MARSONI, S; PANCERA, G; TORRI, V; ZANIBONI, A; ERLICHMAN, C; PATER, J; SHEPHERD, L; ZEE, B; SEITZ, JF; MILAN, C; PIGNON, JP; AITINI, E; APOLONE, G; AUZZANI, A; BANDUCCI, S; BARNI, S; BERETTA, GD; BIFFI, O; BUCCI, F; CARDI, G; CIFATTE, D; COLUCCI, G; COMANDONE, A; COMELLA, G; CONFALONIERI, C; CONFU, A; COSTANZO, M; CRESPI, C; DAMIANI, E; DEGIORGI, D; DONGIOVANNI, V; FABRIS, G; FABRIZIO, G; FACENDOLA, G; FANTONI, PA; FERRAGNI, A; FIORI, B; FLORIANELLO, F; FRONTINI, L; GALLI, E; GARATTINI, P; GHERARDI, G; GIOVANELLI, A; GUILIANI, F; GOSSO, P; JANNIELLO, GP; KILDANI, B; LEO, S; LIBERATI, A; MAFFIONE, G; MAIELLO, E; MAIORINO, L; MANENTE, P; MARTIGNONI, GC; MARZOLA, M; MASTRODONATO, M; MERIGGI, F; MOLINARI, B; MOLINARI, GF; MONFERRONI, N; NASCIMBEN, O; NATALE, C; NEGRETTI, S; PALAZZO, S; PANVINI, D; PARISI, V; PEDICINI, T; PERADOTTO, F; PESSA, S; PIATTO, E; PIZZI, G; PROSPERI, A; PRUSCIANO, F; RABBI, C; RAINA, A; RUGGIERO, A; SAVA, C; SCANZI, F; CARRARO, PS; SMERIERI, F; STIVALA, B; TAIANA, A; TARDIO, B; TESTORE, F; TINAZZI, A; TURCATO, G; ZONATO, S; AYOUB, J; BELANGER, K; BIRON, G; BODURTHA, AJ; BOOS, G; BURNELL, M; CANO, P; CHARPENTIER, D; CHOW, WSW; CHRITCHLEY, J; CRIPPS, C; DANG, SP; DAVIS, ML; DAVIDSON, M; DINGLE, B; DRYER, D; FERLAND, E; FIELDS, A; FINE, S; JOLIVET, J; KAISER, L; KERR, I; KOCHA, WI; KOTWALL, C; KRIEGER, H; LEPINEMARTIN, M; LITTLE, C; LOFTERS, WS; MAHEU, M; MOORE, M; PRESSNAIL, B; RAGAZ, J; RAUNER, H; REZNICK, R; ROSS, T; ROTSTEIN, L; RUDINSKAS, L; SCHACTER, B; SHAH, A; SKILLINGS, J; STERN, H; TWEEDDALE, M; VANDENBERG, T; WALDE, D; WATT, HJ; WONG, KWA; YOSHIDA, S; BALDIT, C; BARONI, JL; BAZIN, JP; BEDENNE, L; BLANCHI, A; BOGNEL, JC; BOSSET, JF; BOUCHE, O; BRANDONE, JM; BRICOT, R; BURTIN, P; CADOR, L; CHARBIT, M; CHARLIER, A; COUROUBLE, Y; COUZIGOU, P; CUILLERET, J; DELPERO, JR; DUCREUX, M; DUMAS, F; ECHINARD, E; ETIENNE, PL; FRIGUET, JL; GIGNOUX, M; GIOVANNINI, M; HERR, JP; LAFON, J; LETREUT, P; LATRIVE, JP; LAUVAUX, C; LOUVET, C; MACKIEWICZ, R; MAUREL, C; MESSERSCHMITT, C; MORAND, L; MOREAU, J; MORIN, T; NORDLINGER, B; NOTERDAEME, PM; OLLIER, JC; PICAUD, R; PEINKOWSKI, P; PLACHOT, JP; PORTET, R; DUBATY, HR; ROUGIER, P; ROZENTAL, G; SASTRE, B; VOTTELAMBERT, A; WATRIN, B; ZEITOUN, P				LABIANCA, R; MARSONI, S; PANCERA, G; TORRI, V; ZANIBONI, A; ERLICHMAN, C; PATER, J; SHEPHERD, L; ZEE, B; SEITZ, JF; MILAN, C; PIGNON, JP; AITINI, E; APOLONE, G; AUZZANI, A; BANDUCCI, S; BARNI, S; BERETTA, GD; BIFFI, O; BUCCI, F; CARDI, G; CIFATTE, D; COLUCCI, G; COMANDONE, A; COMELLA, G; CONFALONIERI, C; CONFU, A; COSTANZO, M; CRESPI, C; DAMIANI, E; DEGIORGI, D; DONGIOVANNI, V; FABRIS, G; FABRIZIO, G; FACENDOLA, G; FANTONI, PA; FERRAGNI, A; FIORI, B; FLORIANELLO, F; FRONTINI, L; GALLI, E; GARATTINI, P; GHERARDI, G; GIOVANELLI, A; GUILIANI, F; GOSSO, P; JANNIELLO, GP; KILDANI, B; LEO, S; LIBERATI, A; MAFFIONE, G; MAIELLO, E; MAIORINO, L; MANENTE, P; MARTIGNONI, GC; MARZOLA, M; MASTRODONATO, M; MERIGGI, F; MOLINARI, B; MOLINARI, GF; MONFERRONI, N; NASCIMBEN, O; NATALE, C; NEGRETTI, S; PALAZZO, S; PANVINI, D; PARISI, V; PEDICINI, T; PERADOTTO, F; PESSA, S; PIATTO, E; PIZZI, G; PROSPERI, A; PRUSCIANO, F; RABBI, C; RAINA, A; RUGGIERO, A; SAVA, C; SCANZI, F; CARRARO, PS; SMERIERI, F; STIVALA, B; TAIANA, A; TARDIO, B; TESTORE, F; TINAZZI, A; TURCATO, G; ZONATO, S; AYOUB, J; BELANGER, K; BIRON, G; BODURTHA, AJ; BOOS, G; BURNELL, M; CANO, P; CHARPENTIER, D; CHOW, WSW; CHRITCHLEY, J; CRIPPS, C; DANG, SP; DAVIS, ML; DAVIDSON, M; DINGLE, B; DRYER, D; FERLAND, E; FIELDS, A; FINE, S; JOLIVET, J; KAISER, L; KERR, I; KOCHA, WI; KOTWALL, C; KRIEGER, H; LEPINEMARTIN, M; LITTLE, C; LOFTERS, WS; MAHEU, M; MOORE, M; PRESSNAIL, B; RAGAZ, J; RAUNER, H; REZNICK, R; ROSS, T; ROTSTEIN, L; RUDINSKAS, L; SCHACTER, B; SHAH, A; SKILLINGS, J; STERN, H; TWEEDDALE, M; VANDENBERG, T; WALDE, D; WATT, HJ; WONG, KWA; YOSHIDA, S; BALDIT, C; BARONI, JL; BAZIN, JP; BEDENNE, L; BLANCHI, A; BOGNEL, JC; BOSSET, JF; BOUCHE, O; BRANDONE, JM; BRICOT, R; BURTIN, P; CADOR, L; CHARBIT, M; CHARLIER, A; COUROUBLE, Y; COUZIGOU, P; CUILLERET, J; DELPERO, JR; DUCREUX, M; DUMAS, F; ECHINARD, E; ETIENNE, PL; FRIGUET, JL; GIGNOUX, M; GIOVANNINI, M; HERR, JP; LAFON, J; LETREUT, P; LATRIVE, JP; LAUVAUX, C; LOUVET, C; MACKIEWICZ, R; MAUREL, C; MESSERSCHMITT, C; MORAND, L; MOREAU, J; MORIN, T; NORDLINGER, B; NOTERDAEME, PM; OLLIER, JC; PICAUD, R; PEINKOWSKI, P; PLACHOT, JP; PORTET, R; DUBATY, HR; ROUGIER, P; ROZENTAL, G; SASTRE, B; VOTTELAMBERT, A; WATRIN, B; ZEITOUN, P			EFFICACY OF ADJUVANT FLUOROURACIL AND FOLINIC ACID IN COLON-CANCER	LANCET			English	Article							THERAPY; COMBINATION; LEVAMISOLE; CARCINOMA	The role of fluorouracil and folinic acid and adjuvant therapy for colon cancer is not clear. We undertook independently three randomised trials to find out the efficacy of fluorouracil and high-dose folinic acid after surgery for Dukes' B and C stage colon cancer. The three studies by the Gruppo Interdisciplinare Valutazione Interventi Oncologia (GIVIO), the National Cancer Institute Canada Clinical Trials Group (NCIC-CTG), and the Fondation Francaise de Cancerologie Digestive (FFCD) were pooled for combined analysis. Each trial was multicentre and used the same treatment regimen (fluorouracil 370-400 mg/m(2) plus folinic acid 200 mg/m(2) daily for 5 days, every 28 days for 6 cycles). A pooled analysis of the results was done on the basis of a previously agreed protocol when there were sufficient events to detect at least a 10% reduction in mortality with 80% power. 1526 patients with resected B (56%) and C (44%) carcinoma of the colon were enrolled and 1493 were confirmed as eligible. 736 were assigned to the treatment group and 757 to the control group. Fluorouracii/folinic acid significantly reduced mortality by 22% (95% Cl 3-38; p=0.029) and events by 35% (22-46; p<0.0001), increasing 3-year event-free survival from 62% to 71% and overall survival from 78% to 83%. Compliance with treatment was good; more than 80% of patients completed the planned treatment. Side-effects were clinically acceptable with only 1 treatment-related death. The commonest side-effects were gastrointestinal, but severe toxic effects (WHO grade 4) occurred in fewer than 3% of cases. We conclude that fluorouracil plus high-dose folinic acid is a well-tolerated and effective 6-month adjuvant regimen for colon cancer.	IST MARIO NEGRI,CANC CLIN EPIDEMIOL LAB,I-20157 MILAN,ITALY; NATL CANC INST CANADA,CTG,TORONTO,ON,CANADA	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Queens University - Canada; Canadian Cancer Trials Group			Ducreux, Michel/AAG-9415-2019; Ducreux, Michel/L-7012-2019; Zee, Benny Chung Ying/G-5606-2017	Ducreux, Michel/0000-0001-8649-7449; Zee, Benny Chung Ying/0000-0002-7238-845X; Kaiser, Laurent/0000-0002-0857-2252				BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571; FRANCINI G, 1994, GASTROENTEROLOGY, V106, P899, DOI 10.1016/0016-5085(94)90748-X; GRAY R, 1991, BRIT J CANCER, V63, P841, DOI 10.1038/bjc.1991.187; GREM JL, 1987, CANCER TREAT REP, V71, P1249; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI, P170; LACHIN JM, 1986, BIOMETRICS, V42, P507, DOI 10.2307/2531201; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; MILLER JP, 1991, CONTROLLED CLIN TRIA, V12, P630; MOERTEL C, 1992, P ASCO, V11, P457; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; OCONNELL M, 1993, P AN M AM SOC CLIN, V12, P552; PATER JL, 1994, STAT MED, V13, P1337, DOI 10.1002/sim.4780131307; SILVERBERG E, 1989, CA-CANCER J CLIN, V39, P3; WOLMARK N, 1988, JNCI-J NATL CANCER I, V80, P30, DOI 10.1093/jnci/80.1.30; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; ZANIBONI A, 1993, P AM SOC CLIN ONCOL, V12, P555; ZEE B, 1993, CONTROL CLIN TRIALS, V15, P439; 1990, FDA DRUG B, V20, P4; 1992, J CLIN ONCOL, V10, P896; 1989, CLIN ONCOL ALERT, V8, P84; 1990, APR NAT I HLTH CONS	21	779	791	0	32	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 15	1995	345	8955					939	944						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QT919	7715291				2023-01-03	WOS:A1995QT91900006
J	THOMPSON, GR; MAHER, VMG; MATTHEWS, S; KITANO, Y; NEUWIRTH, C; SHORTT, MB; DAVIES, G; REES, A; MIR, A; PRESCOTT, RJ; DEFEYTER, P; HENDERSON, A				THOMPSON, GR; MAHER, VMG; MATTHEWS, S; KITANO, Y; NEUWIRTH, C; SHORTT, MB; DAVIES, G; REES, A; MIR, A; PRESCOTT, RJ; DEFEYTER, P; HENDERSON, A			FAMILIAL HYPERCHOLESTEROLEMIA REGRESSION STUDY - A RANDOMIZED TRIAL OF LOW-DENSITY-LIPOPROTEIN APHERESIS	LANCET			English	Article							CORONARY HEART-DISEASE; PLASMA-EXCHANGE; DEFECTIVE APOLIPOPROTEIN-B-100; ATHEROSCLEROSIS-REGRESSION; ARTERY DISEASE; LDL-APHERESIS; THERAPY; CHOLESTEROL; CHOLESTYRAMINE; LOVASTATIN	Low-density-lipoprotein (LDL) apheresis has the theoretical advantage over anion-exchange resins and hydroxymethylglutaryl coenzyme A inhibitors of decreasing lipoprotein(a) as well as LDL. To confirm this advantage, patients with heterozygous familial hypercholesterolaemia and coronary artery disease were randomised to receive LDL apheresis fortnightly (with disposable dextran sulphate/cellulose columns) plus simvastatin 40 mg daily, or colestipol 20 g plus simvastatin 40 mg daily. Quantitative coronary angiography was repeated after a mean of 2.1 years in 20 patients undergoing apheresis and in 19 on combination drug therapy. Changes in serum lipoproteins were similar in both groups apart from greater lowering by apheresis of LDL cholesterol (3.2 vs 3.4 mmol/L in drug group, p=0.03) and lipoprotein(a) (geometric means 14 vs 21 mg/dL, p=0.03). There were no significant differences in primary angiographic endpoints per patient but lesion-based and segment-based secondary endpoints were biased in favour of the drug group (change in minimum lumen diameter of lesions 0.07 vs -0.004 mm, p=0.046; change in mean lumen diameter of segments 0.02 vs -0.06 mm, p=0.01). None of the angiographic changes correlated with lipoprotein(a) concentrations. Per patient changes in % diameter stenosis and minimum lumen diameter in the two groups were as or more favourable than those observed in five published trials that assessed lipid-lowering drug therapy by quantitative coronary angiography. Although LDL apheresis combined with simvastatin was more effective than colestipol plus simvastatin in reducing LDL cholesterol and lipoprotein(a), it was less beneficial in influencing coronary atherosclerosis and should be reserved for patients unresponsive to drugs. Decreasing lipoprotein(a) seems to be unnecessary if LDL cholesterol is reduced to 3.4 mmol/L or less.	HAMMERSMITH HOSP, DEPT CARDIOL, LONDON W12 0NN, ENGLAND; LLANDOUGH HOSP, NHS TRUST, PENARTH, S GLAM, WALES; UNIV WALES HOSP, CARDIFF, S GLAM, WALES; UNIV EDINBURGH, SCH MED, DEPT PUBL HLTH SCI, EDINBURGH, MIDLOTHIAN, SCOTLAND; UNIV HOSP DIJKZIGT, CATHETERIZAT LAB, ROTTERDAM, NETHERLANDS	Imperial College London; Cardiff University; University of Edinburgh; Erasmus University Rotterdam; Erasmus MC	THOMPSON, GR (corresponding author), MRC, LIPOPROT TEAM, LONDON, ENGLAND.			Maher, Vincent/0000-0002-3592-4508				[Anonymous], 1991, BMJ, V303, P893; ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BRENSIKE JF, 1984, CIRCULATION, V69, P313, DOI 10.1161/01.CIR.69.2.313; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gordon Bruce R., 1994, Current Opinion in Lipidology, V5, P69, DOI 10.1097/00041433-199402000-00011; JAUHIAINEN M, 1991, ATHEROSCLEROSIS, V89, P59, DOI 10.1016/0021-9150(91)90007-P; JURGENS G, 1989, LANCET, V1, P911; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KOIZUMI J, 1993, ATHEROSCLEROSIS, V100, P65, DOI 10.1016/0021-9150(93)90068-6; MAHER VMG, 1992, ATHEROSCLEROSIS, V95, P231, DOI 10.1016/0021-9150(92)90026-D; MAHER VMG, 1991, ATHEROSCLEROSIS, V91, P73, DOI 10.1016/0021-9150(91)90188-9; MAHER VMG, 1994, JACC; MARBURGER C, 1994, AM J CARDIOL, V73, P742, DOI 10.1016/0002-9149(94)90874-5; MYANT NB, 1993, ATHEROSCLEROSIS, V104, P1, DOI 10.1016/0021-9150(93)90171-P; OLIVER MF, 1994, LANCET, V344, P633; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; ROSENGREN A, 1990, BRIT MED J, V301, P1248, DOI 10.1136/bmj.301.6763.1248; SCHAEFER EJ, 1994, JAMA-J AM MED ASSOC, V271, P999, DOI 10.1001/jama.271.13.999; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; STOFFEL W, 1981, LANCET, V2, P1005; TATAMI R, 1992, ATHEROSCLEROSIS, V95, P1, DOI 10.1016/0021-9150(92)90170-L; THOMPSON GR, 1985, BMJ-BRIT MED J, V291, P1671, DOI 10.1136/bmj.291.6510.1671; THOMPSON GR, 1975, LANCET, V1, P1208; THOMPSON GR, 1980, BRIT HEART J, V43, P680, DOI 10.1136/hrt.43.6.680; THOMPSON GR, 1989, ARTERIOSCLEROSIS, V9, pI152; TYBJAERGHANSEN A, 1990, ATHEROSCLEROSIS, V80, P235, DOI 10.1016/0021-9150(90)90031-D; UREN NG, 1994, NEW ENGL J MED, V330, P1782, DOI 10.1056/NEJM199406233302503; WARNICK GR, 1978, J LIPID RES, V19, P65; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WIKLUND O, 1990, LANCET, V335, P1360, DOI 10.1016/0140-6736(90)91242-3	34	220	225	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	1995	345	8953					811	816		10.1016/S0140-6736(95)92961-4	http://dx.doi.org/10.1016/S0140-6736(95)92961-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898227				2023-01-03	WOS:A1995QQ19500006
J	WALKER, P				WALKER, P			CONTROVERSIES IN MANAGEMENT - SHOULD OBSTETRICIANS SEE WOMEN WITH NORMAL PREGNANCIES - OBSTETRICIANS SHOULD BE INCLUDED IN INTEGRATED TEAM CARE .15.	BRITISH MEDICAL JOURNAL			English	Article											WALKER, P (corresponding author), ROYAL FREE HOSP,POND ST,LONDON NW3 2QG,ENGLAND.							STEER PJ, 1992, BRIT J OBSTET GYNAEC, V99, P415; STREET P, 1991, BRIT MED J, V302, P698, DOI 10.1136/bmj.302.6778.698; 1993, CHANGING CHILDBIRTH; 1992, CHANGING CHILDBIRTH	4	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					36	37		10.1136/bmj.310.6971.36	http://dx.doi.org/10.1136/bmj.310.6971.36			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827554	Green Published			2023-01-03	WOS:A1995QB06000031
J	CLEELAND, CS; GONIN, R; HATFIELD, AK; EDMONSON, JH; BLUM, RH; STEWART, JA; PANDYA, KJ				CLEELAND, CS; GONIN, R; HATFIELD, AK; EDMONSON, JH; BLUM, RH; STEWART, JA; PANDYA, KJ			PAIN AND ITS TREATMENT IN OUTPATIENTS WITH METASTATIC CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CARE; PREVALENCE; BREAST; BLACK	Background and Methods. Pain is often inadequately treated in patients with cancer. A total of 1308 outpatients with metastatic cancer from 54 treatment locations affiliated with the Eastern Cooperative Oncology Group rated the severity of their pain during the preceding week, as well as the degree of pain-related functional impairment and the degree of relief provided by analgesic drugs. Their physicians attributed the pain to various factors, described its treatment, and estimated the impact of pain on the patients' ability to function. We assessed the adequacy of prescribed analgesic drugs using guidelines developed by the World Health Organization, studied the factors that influenced whether analgesia was adequate, and determined the effects of inadequate analgesia on the patients' perception of pain relief and functional status. Results. Sixty-seven percent of the patients (871 of 1308) reported that they had had pain or had taken analgesic drugs daily during the week preceding the study, and 36 percent (475 of 1308) had pain severe enough to impair their ability to function. Forty-two percent of those with pain (250 of the 597 patients for whom we had complete information) were not given adequate analgesic therapy. Patients seen at centers that treated predominantly minorities were three times more likely than those treated elsewhere to have inadequate pain management. A discrepancy between patient and physician in judging the severity of the patient's pain was predictive of inadequate pain management (odds ratio, 2.3). Other factors that predicted inadequate pain management included pain that physicians did not attribute to cancer (odds ratio, 1.9), better performance status (odds ratio, 1.8), age of 70 years or older (odds ratio, 2.4), and female sex (odds ratio, 1.5). Patients with less adequate analgesia reported less pain relief and greater pain-related impairment of function. Conclusions. Despite published guidelines for pain management, many patients with cancer have considerable pain and receive inadequate analgesia.	UNIV WISCONSIN, CTR COMPREHENS CANC, MADISON, WI USA; DANA FARBER CANC INST, BOSTON, MA USA; CARLE CANC CTR, URBANA, IL USA; MAYO CLIN & MAYO FDN, ROCHESTER, MN USA; NYU MED CTR, NEW YORK, NY USA; UNIV ROCHESTER, CTR CANC, ROCHESTER, NY USA	University of Wisconsin System; University of Wisconsin Madison; Harvard University; Dana-Farber Cancer Institute; Mayo Clinic; New York University; University of Rochester	CLEELAND, CS (corresponding author), UNIV WISCONSIN, DEPT NEUROL, PAIN RES GRP, 1900 UNIV AVE, MADISON, WI 53705 USA.				NATIONAL CANCER INSTITUTE [R18CA026582, U10CA021115, R01CA026582] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26582, CA 21115, R01 CA026582] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLES TA, 1983, PAIN, V17, P277, DOI 10.1016/0304-3959(83)90100-8; [Anonymous], 1991, EFFECT CANC QUALITY; BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BONICA JJ, 1985, ADV PAIN RES THER, V9, P589; CLEELAND C, 1991, CANCER, V67, P823, DOI 10.1002/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S; CLEELAND CS, 1986, CANCER, V58, P796, DOI 10.1002/1097-0142(19860801)58:3<796::AID-CNCR2820580331>3.0.CO;2-#; CLEELAND CS, 1984, CANCER, V53, P2264; Cleeland CS, 1989, ADV PAIN RES THER, P391, DOI DOI 10.1093/BRAIN/113.5.1589; CLEELAND CS, 1992, PAIN ASSESSMENT, P360; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; DONOVAN M, 1987, PAIN, V30, P69, DOI 10.1016/0304-3959(87)90084-4; Ferrell B, 1991, Hosp J, V7, P9; FISHMAN B, 1987, CANCER-AM CANCER SOC, V60, P1151, DOI 10.1002/1097-0142(19870901)60:5<1151::AID-CNCR2820600538>3.0.CO;2-G; Foley K., 1979, ADV PAIN RES THER, V2, P59; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; FREEMAN HP, 1989, CANCER, V63, P2562, DOI 10.1002/1097-0142(19890615)63:12<2562::AID-CNCR2820631234>3.0.CO;2-0; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GREENWALD HP, 1987, CANCER, V60, P2563, DOI 10.1002/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; HATFIELD AK, 1991, MAY ANN AM SOC CLIN; HOSMER DW, 1989, APPL LOGISTIC REGRES, P25; JAGOX A, 1994, NEW ENGL J MED, V330, P651, DOI 10.1056/NEJM199403033300926; MCGIVNEY WT, 1984, JAMA-J AM MED ASSOC, V251, P1182; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MORRISON DF, 1990, MULTIVARIATE STATIST, P164; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PETEET J, 1986, CANCER, V57, P1259, DOI 10.1002/1097-0142(19860315)57:6<1259::AID-CNCR2820570633>3.0.CO;2-L; PORTENOY RK, 1989, CANCER, V63, P2298, DOI 10.1002/1097-0142(19890601)63:11<2298::AID-CNCR2820631140>3.0.CO;2-A; TODD KH, 1993, JAMA-J AM MED ASSOC, V269, P1537, DOI 10.1001/jama.269.12.1537; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; Zar J.H., 2010, BIOSTAT ANAL; 1986, CANCER PAIN RELIEF; 1989, PRINCIPLES ANALGESIC	33	1439	1482	0	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					592	596		10.1056/NEJM199403033300902	http://dx.doi.org/10.1056/NEJM199403033300902			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	7508092				2023-01-03	WOS:A1994MY57300002
J	LEWIN, E; ALBERT, AL				LEWIN, E; ALBERT, AL			WALK WITH ME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1988	259	23					3462	3465		10.1001/jama.259.23.3462	http://dx.doi.org/10.1001/jama.259.23.3462			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7295	2967383				2023-01-03	WOS:A1988N729500033
J	SALERNO, DM				SALERNO, DM			POSTRESUSCITATION HYPOKALEMIA IN A PATIENT WITH A NORMAL PREARREST SERUM POTASSIUM LEVEL	ANNALS OF INTERNAL MEDICINE			English	Note											SALERNO, DM (corresponding author), UNIV MINNESOTA, HENNEPIN CTY MED CTR, 701 PK AVE, MINNEAPOLIS, MN 55415 USA.							ADROGUE HJ, 1981, AM J MED, V71, P456, DOI 10.1016/0002-9343(81)90182-0; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; HOLLAND OB, 1981, AM J MED, V70, P762, DOI 10.1016/0002-9343(81)90530-1; NORDREHAUG JE, 1985, CIRCULATION, V71, P645, DOI 10.1161/01.CIR.71.4.645; SALERNO DM, 1987, J AM COLL CARDIOL, V10, P178, DOI 10.1016/S0735-1097(87)80177-8; SALERNO DM, 1987, AM J CARDIOL, V59, P84, DOI 10.1016/S0002-9149(87)80075-9; SALERNO DM, 1986, CIRCULATION, V74, P146; SALERNO DM, 1987, IN PRESS AM HEART J; STRUTHERS AD, 1983, BRIT HEART J, V49, P90; THOMPSON RG, 1982, JAMA-J AM MED ASSOC, V248, P2860, DOI 10.1001/jama.248.21.2860	10	11	11	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN	1988	108	6					836	837		10.7326/0003-4819-108-6-836	http://dx.doi.org/10.7326/0003-4819-108-6-836			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7293	3369773				2023-01-03	WOS:A1988N729300010
J	[Anonymous]				[Anonymous]			AUTOMATIC DEFIBRILLATORS	LANCET			English	Editorial Material																		ARONSON AL, 1986, MED INSTRUM, V20, P27; BRIGGS RS, 1976, BRIT MED J, V2, P1161, DOI 10.1136/bmj.2.6045.1161; CALDWELL G, 1985, BRIT MED J, V291, P627, DOI 10.1136/bmj.291.6496.627; COBB LA, 1975, CIRCULATION, V52, P223; COBB LA, 1982, ANN NY ACAD SCI, V383, P330; CUMMINS RO, 1987, JAMA-J AM MED ASSOC, V257, P1605, DOI 10.1001/jama.257.12.1605; CUMMINS RO, 1984, LANCET, V2, P318; DALZELL GWN, 1988, LANCET, V1, P695; DIACK AW, 1979, MED INSTRUM, V13, P78; EISENBERG MS, 1980, NEW ENGL J MED, V302, P1379, DOI 10.1056/NEJM198006193022502; EISENBERG MS, 1979, JAMA-J AM MED ASSOC, V241, P1905, DOI 10.1001/jama.241.18.1905; EISENBERG MS, 1980, LANCET, V1, P812; GEDDES JS, 1986, BRIT HEART J, V56, P491; GRAY AJ, 1987, BRIT MED J, V294, P1133, DOI 10.1136/bmj.294.6580.1133; HALLSTROM A, 1984, MED CARE, V22, P1083, DOI 10.1097/00005650-198412000-00003; HEBER M, 1983, INT J CARDIOL, V3, P456, DOI 10.1016/0167-5273(83)90118-3; JACK CM, 1986, EUR HEART J, V7, P404, DOI 10.1093/oxfordjournals.eurheartj.a062081; JAGGARAO NSV, 1982, LANCET, V2, P73; KERBER RE, 1983, J AM COLL CARDIOL, V2, P966, DOI 10.1016/S0735-1097(83)80247-2; MACINTOSH AF, 1978, BR MED J, V1, P115; MIROWSKI M, 1981, AM HEART J, V102, P265, DOI 10.1016/S0002-8703(81)80017-8; PANTRIDGE JF, 1974, PROGR CARDIOLOGY, V3, P173; REID PR, 1983, AM J CARDIOL, V51, P1608, DOI 10.1016/0002-9149(83)90195-9; ROSENTHAL E, 1984, INT J CARDIOL, V5, P441, DOI 10.1016/0167-5273(84)90079-2; ROZKOVEC A, 1983, CLIN CARDIOL, V6, P527, DOI 10.1002/clc.4960061103; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; VINCENT R, 1984, BRIT MED J, V288, P617, DOI 10.1136/bmj.288.6417.617; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1986, ANN EMERG MED, V15, P1181; 1987, J R COLL PHYSICIANS, V21, P175	30	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 28	1988	1	8596					1199	1201						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N5536	2897010				2023-01-03	WOS:A1988N553600006
J	ALLAIN, TJ; STEVENS, PE; BRIDGES, LR; PHILLIPS, ME				ALLAIN, TJ; STEVENS, PE; BRIDGES, LR; PHILLIPS, ME			DIALYSIS MYELOPATHY - QUADRIPARESIS DUE TO EXTRADURAL AMYLOID OF BETA-2 MICROGLOBULIN ORIGIN	BRITISH MEDICAL JOURNAL			English	Note									CHARING CROSS HOSP,DEPT HISTOPATHOL,LONDON W6 8RF,ENGLAND	Imperial College London	ALLAIN, TJ (corresponding author), CHARING CROSS HOSP,DEPT MED,LONDON W6 8RF,ENGLAND.							Ackrill P, 1986, LIF SUPP SYST ABST S, V4, P1; CARY NRB, 1986, BRIT MED J, V293, P1392, DOI 10.1136/bmj.293.6559.1392; MCANENA OJ, 1982, J NEUROL NEUROSUR PS, V45, P1067, DOI 10.1136/jnnp.45.11.1067; PRASAD BK, 1981, BRIT MED J, V283, P1087, DOI 10.1136/bmj.283.6299.1087; VINCENT C, 1978, NEPHRON, V21, P260, DOI 10.1159/000181402	5	37	37	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 12	1988	296	6624					752	753		10.1136/bmj.296.6624.752	http://dx.doi.org/10.1136/bmj.296.6624.752			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M5634	3126960	Bronze, Green Published			2023-01-03	WOS:A1988M563400014
J	THOMPSON, PD				THOMPSON, PD			THE BENEFITS AND RISKS OF EXERCISE TRAINING IN PATIENTS WITH CHRONIC CORONARY-ARTERY DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MIRIAM HOSP,DIV NUTR & METAB,PROVIDENCE,RI 02906; BROWN UNIV,RHODE ISL HOSP,PROGRAM MED,PROVIDENCE,RI 02903	Lifespan Health Rhode Island; Miriam Hospital; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	THOMPSON, PD (corresponding author), MIRIAM HOSP,DIV CARDIOL,164 SUMMIT AVE,PROVIDENCE,RI 02906, USA.							ADAMS WC, 1974, AM J CARDIOL, V33, P765, DOI 10.1016/0002-9149(74)90219-7; ADES PA, 1984, AM J CARDIOL, V54, P1337, DOI 10.1016/S0002-9149(84)80093-4; AMSTERDAM EA, 1974, AM J CARDIOL, V33, P737, DOI 10.1016/0002-9149(74)90214-8; BOVE AA, 1985, CIRCULATION, V71, P620, DOI 10.1161/01.CIR.71.3.620; BYGDEMAN S, 1974, EUR J CLIN INVEST, V4, P201, DOI 10.1111/j.1365-2362.1974.tb02335.x; CHOONG CYP, 1985, CIRCULATION, V71, P787, DOI 10.1161/01.CIR.71.4.787; CLAUSEN JP, 1976, CIRCULATION, V53, P436, DOI 10.1161/01.CIR.53.3.436; CLAUSEN JP, 1977, EXERCISE HEART DISEA, P39; CONN EH, 1982, AM J CARDIOL, V49, P296, DOI 10.1016/0002-9149(82)90504-5; CONNER JF, 1976, MED SCI SPORT EXER, V8, P145, DOI 10.1249/00005768-197600830-00002; DETRY JMR, 1971, CIRCULATION, V44, P109, DOI 10.1161/01.CIR.44.1.109; DISHMAN RK, 1985, MED CLIN N AM, V69, P123, DOI 10.1016/S0025-7125(16)31061-6; EHSANI AA, 1982, AM J CARDIOL, V50, P246, DOI 10.1016/0002-9149(82)90173-4; Ferguson R J, 1974, Am J Cardiol, V34, P764, DOI 10.1016/0002-9149(74)90693-6; FRANKLIN BA, 1978, ARCH PHYS MED REHAB, V59, P276; FRICK MH, 1983, CIRCULATION, V67, P491, DOI 10.1161/01.CIR.67.3.491; FROELICHER V, 1984, JAMA-J AM MED ASSOC, V252, P1291, DOI 10.1001/jama.252.10.1291; GOBEL FL, 1978, CIRCULATION, V57, P549, DOI 10.1161/01.CIR.57.3.549; HAGBERG JM, 1983, CIRCULATION, V67, P1194, DOI 10.1161/01.CIR.67.6.1194; HARTUNG GH, 1981, ARCH PHYS MED REHAB, V62, P147; Heberden W., 1941, CARDIAC CLASSICS, P224; KENNEDY CC, 1976, MAYO CLIN PROC, V51, P231; KLOCKE FJ, 1976, PROG CARDIOVASC DIS, V19, P117, DOI 10.1016/0033-0620(76)90020-7; Lamm G, 1982, Adv Cardiol, V31, P107; LAZARUS B, 1981, AM J CARDIOL, V47, P1075, DOI 10.1016/0002-9149(81)90215-0; LEWIS S, 1980, EUR J APPL PHYSIOL O, V44, P25, DOI 10.1007/BF00421760; MAY GS, 1982, PROG CARDIOVASC DIS, V24, P331, DOI 10.1016/0033-0620(82)90010-X; MILLER NH, 1984, CIRCULATION, V70, P645, DOI 10.1161/01.CIR.70.4.645; MITCHELL JH, 1971, NEW ENGL J MED, V284, P1018, DOI 10.1056/NEJM197105062841809; NOLEWAJKA AJ, 1979, CIRCULATION, V60, P114, DOI 10.1161/01.CIR.60.1.114; OLDRIDGE NB, 1978, ARCH PHYS MED REHAB, V59, P268; PATERSON DH, 1979, J APPL PHYSIOL, V47, P482, DOI 10.1152/jappl.1979.47.3.482; POLLOCK ML, 1978, HLTH FITNESS PHYSICA; PRATT CM, 1981, CIRCULATION, V64, P1125, DOI 10.1161/01.CIR.64.6.1125; REDWOOD DR, 1972, NEW ENGL J MED, V286, P959, DOI 10.1056/NEJM197205042861801; ROMAN O, 1983, CARDIOLOGY, V70, P223, DOI 10.1159/000173598; Rowell LB, 1986, HUMAN CIRCULATION RE, P213; SABLE DL, 1982, CIRCULATION, V65, P679, DOI 10.1161/01.CIR.65.4.679; SIM DN, 1974, J CLIN INVEST, V54, P763, DOI 10.1172/JCI107814; THOMPSON PD, 1981, AM J CARDIOL, V48, P844, DOI 10.1016/0002-9149(81)90348-9; THOMPSON PD, 1985, J CARDIOPULMONARY RE, V5, P321; THOMPSON PD, 1986, SPORTS MED MATURE AT, P309; VANCAMP SP, 1986, JAMA-J AM MED ASSOC, V256, P1160, DOI 10.1001/jama.256.9.1160; VATNER SF, 1976, PROG CARDIOVASC DIS, V19, P91, DOI 10.1016/0033-0620(76)90018-9; WILSON JR, 1983, CIRCULATION, V68, P425, DOI 10.1161/01.CIR.68.2.425; YASUE H, 1979, CIRCULATION, V59, P938, DOI 10.1161/01.CIR.59.5.938; 1982, JAMA, V247, P1707; 1986, GUIDELINES EXERCISE	48	30	31	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 11	1988	259	10					1537	1540		10.1001/jama.259.10.1537	http://dx.doi.org/10.1001/jama.259.10.1537			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M3523	3276936				2023-01-03	WOS:A1988M352300032
J	HELLER, RF; STEELE, PL; FISHER, JD; ALEXANDER, HM; DOBSON, AJ				HELLER, RF; STEELE, PL; FISHER, JD; ALEXANDER, HM; DOBSON, AJ			SUCCESS OF CARDIOPULMONARY-RESUSCITATION AFTER HEART-ATTACK IN-HOSPITAL AND OUTSIDE HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article							CARDIAC-ARREST; SURVIVAL	Objectives-To determine factors associated with cardiopulmonary resuscitation being attempted after cardiac arrest from myocardial infarction, in or outside hospital, and estimate short term and long term survival rates. Design-Descriptive cross sectional and cohort study. Setting-Community based register of all suspected heart attacks and sudden cardiac deaths in Lower Hunter region of New South Wales, Australia. Subject-4924 men and women aged 25-69. Main outcome measures-Rates of attempted cardiopulmonary resuscitation and survival after successful resuscitation. Results-Cardiopulmonary resuscitation was attempted in 41% of cases of cardiac arrest after myocardial infarction outside hospital and 63% of cases in hospital, Survival rates at 28 days were 12% and 39% respectively, Among the survivors, although 41% had another myocardial infarction (or coronary death), 81% of both groups were still alive two years later. Younger and better educated people were more likely to receive cardiopulmonary resuscitation in either setting, and being married predicted cardiopulmonary resuscitation being attempted outside hospital. Younger age predicted better survival rates after attempted resuscitation in hospital. Conclusions-The reasons for better education to predict cardiopulmonary resuscitation being attempted need explanation. The higher survival rate after cardiopulmonary resuscitation in hospital compared with outside hospital and the good long term prognosis for survivors in both settings suggest that attempts to improve success of cardiopulmonary resuscitation outside hospital may be worth while.	UNIV NEWCASTLE,FAC MED & HLTH SCI,CTR CLIN EPIDEMIOL & BIOSTAT,NEWCASTLE,NSW 2308,AUSTRALIA	University of Newcastle			Dobson, Annette J/B-5273-2008	Heller, Richard/0000-0003-3161-5967				BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; BEURET P, 1993, RESUSCITATION, V25, P171, DOI 10.1016/0300-9572(93)90093-6; DOBSON AJ, 1988, ACTA MED SCAND S, V728, P84; EBELL MH, 1992, J FAM PRACTICE, V34, P551; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; HALLSTROM A, 1993, AM J PUBLIC HEALTH, V83, P245, DOI 10.2105/AJPH.83.2.245; JOSLYN SA, 1993, AM J EMERG MED, V11, P200, DOI 10.1016/0735-6757(93)90124-T; KELLERMANN AL, 1993, JAMA-J AM MED ASSOC, V270, P1433, DOI 10.1001/jama.270.12.1433; SOLOMON NA, 1993, ARCH INTERN MED, V153, P1218, DOI 10.1001/archinte.153.10.1218; TRESCH DD, 1993, AM J MED, V95, P123, DOI 10.1016/0002-9343(93)90252-K; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583	12	18	18	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1332	1336		10.1136/bmj.311.7016.1332	http://dx.doi.org/10.1136/bmj.311.7016.1332			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496282	Green Published			2023-01-03	WOS:A1995TF90100019
J	WURTMAN, RJ; BETTIKER, RL				WURTMAN, RJ; BETTIKER, RL			THE SLOWING OF TREATMENT DISCOVERY, 1965-1995	NATURE MEDICINE			English	Editorial Material									MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT)	WURTMAN, RJ (corresponding author), MIT,CLIN RES CTR,CAMBRIDGE,MA 02139, USA.							Jobe P C, 1994, Physiologist, V37, P79; Kelly WN, 1994, CAREERS CLIN RES OBS; WILLIAMS GH, 1994, ANAL REV PATIENT ORI	3	42	42	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	NOV	1995	1	11					1122	1125		10.1038/nm1195-1122	http://dx.doi.org/10.1038/nm1195-1122			4	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	TC537	7584975				2023-01-03	WOS:A1995TC53700027
J	ALEXANDER, M; GRUMBACH, K; SELBY, J; BROWN, AF; WASHINGTON, E				ALEXANDER, M; GRUMBACH, K; SELBY, J; BROWN, AF; WASHINGTON, E			HOSPITALIZATION FOR CONGESTIVE-HEART-FAILURE - EXPLAINING RACIAL-DIFFERENCES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; MORTALITY CROSSOVER; PREVALENCE; POPULATION; SYSTEM; RATES; CARE	Objective.-To determine whether the higher rate of hospitalization among African Americans for congestive heart failure (CHF) could be explained by racial differences in the prevalence of clinical risk factors for CHF. Design.-Retrospective cohort study. Setting.-A large health maintenance organization (HMO). Patients.-A sample of 64 877 enrollees (27% African American and 73% white) of the Northern California Kaiser Permanente Medical Care Program who took at least one multiphasic health checkup (MHC) at or after the age of 40 years and were free of CHF at that time. Main Outcome Measures.-First hospitalization with a principal diagnosis of CHF. Results.-Among cohort members younger than 60 years at baseline MHC, the age-adjusted risk ratio (RR) (African American/white) for CHF hospitalization was 2.14 for men and 2.73 for women, while for persons 60 years of age and older at MHC, the age-adjusted RR was 1.48 for both sexes. Cox proportional hazards models were used to adjust for risk factors and length of follow-up. In persons aged 60 years and older, the race difference was explained by greater prevalence of hypertension and diabetes in African Americans (RR=1.12; 95% confidence interval [CI], 0.94 to 1.34 after adjustment for hypertension and diabetes). In those younger than 60 years, findings differed by sex. For men, African-American race was no longer a significant predictor of CHF after adjusting for hypertension, diabetes, left ventricular hypertrophy on electrocardiogram, and body mass index (adjusted RR=1.16; 95% CI, 0.86 to 1.56). However, among younger women, African Americans continued at increased risk despite adjustment for these variables as well as smoking, plasma cholesterol, renal function, alcohol use, and myocardial infarction (adjusted RR=1.49; 95% CI, 1.00 to 2.21). Conclusions.-In this HMO population, the race differences in first hospitalization for CHF are largely explained by known clinical and behavioral risk factors, although in younger women these risk factors do not completely explain the excess risk among African Americans. These findings highlight the role of hypertension and diabetes in the development of CHF, particularly among African Americans.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; KAISER PERMANENTE MED CARE PROGRAM NO CALIF REG,DIV RES,OAKLAND,CA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kaiser Permanente	ALEXANDER, M (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,MED EFFECTIVENESS RES CTR DIVERSE POPULAT,BOX 0856,SAN FRANCISCO,CA 94143, USA.		Grumbach, Kevin/L-9222-2016	Brown, Arleen/0000-0001-9948-8955	AHRQ HHS [HS07373] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ARELLANO MG, 1984, AM J PUBLIC HEALTH, V74, P1324, DOI 10.2105/AJPH.74.12.1324; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; BINDMAN AB, 1992, JAMA-J AM MED ASSOC, V268, P2426, DOI 10.1001/jama.268.17.2426; COLLEN MF, 1973, INT C SERIES, P332; GARFIELD SR, 1970, NEW ENGL J MED, V283, P1087, DOI 10.1056/NEJM197011122832006; GARFIELD SR, 1970, SCI AM, V222, P15, DOI 10.1038/scientificamerican0470-15; GARRISON GE, 1966, AM J EPIDEMIOL, V83, P338, DOI 10.1093/oxfordjournals.aje.a120589; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; GILLUM RF, 1987, AM HEART J, V113, P1043, DOI 10.1016/0002-8703(87)90077-9; GILLUM RF, 1991, CARDIOVASCULAR DIS B, P3; GRAVES EJ, 1994, ADV DATA VITAL HLTH, V249; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; KAPLAN GA, 1987, AM J PUBLIC HEALTH, V77, P307, DOI 10.2105/AJPH.77.3.307; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; NAM CB, 1978, SOC BIOL, V25, P306, DOI 10.1080/19485565.1978.9988352; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; RODEHEFFER RJ, 1993, MAYO CLIN PROC, V68, P1143, DOI 10.1016/S0025-6196(12)60063-9; SCHOCKEN DD, 1992, J AM COLL CARDIOL, V20, P301, DOI 10.1016/0735-1097(92)90094-4; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; WING S, 1985, J GERONTOL, V40, P78, DOI 10.1093/geronj/40.1.78; YUSEF S, 1989, HYPERTENSION S1, V13, P74; 1994, MMWR-MORBID MORTAL W, V43, P77	27	98	98	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1037	1042		10.1001/jama.274.13.1037	http://dx.doi.org/10.1001/jama.274.13.1037			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RX108	7563454				2023-01-03	WOS:A1995RX10800026
J	SAUNDERS, P; HERXHEIMER, A				SAUNDERS, P; HERXHEIMER, A			WHO MODEL LIST OF ESSENTIAL DRUGS - A BEACON THROUGH 2 DECADES	LANCET			English	Editorial Material									UNITED KINGDOM COCHRANE CTR,OXFORD,ENGLAND	Cochrane Centre	SAUNDERS, P (corresponding author), ESSENTIAL DRUGS PROJECT,LONDON,ENGLAND.		Saunders, Philippa TK/C-7489-2013	Saunders, Philippa TK/0000-0001-9051-9380				[Anonymous], 1977, WHO TECH REP SER, V615; 1990, LANCET, V335, P1003; 1995, WHO TECH REP SER, V850; WHODAP901, P13	4	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 26	1995	346	8974					519	519		10.1016/S0140-6736(95)91375-0	http://dx.doi.org/10.1016/S0140-6736(95)91375-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ986	7658773				2023-01-03	WOS:A1995RQ98600003
J	KEELEY, D				KEELEY, D			SCREENING FOR MELANOMA RISK IS MISGUIDED	BRITISH MEDICAL JOURNAL			English	Editorial Material																		COCHRANE AL, 1971, BRIT MED BULL, V27, P3, DOI 10.1093/oxfordjournals.bmb.a070810; JOHNSON N, 1994, BRIT J GEN PRACT, V44, P523; MARTEAU TM, 1989, BRIT MED J, V299, P527, DOI 10.1136/bmj.299.6698.527; NEWTON JN, 1995, BRIT MED J, V310, P502, DOI 10.1136/bmj.310.6978.502; ROBERTS DL, 1990, CLIN EXP DERMATOL, V15, P40	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					916	916		10.1136/bmj.310.6984.916	http://dx.doi.org/10.1136/bmj.310.6984.916			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719185	Green Published			2023-01-03	WOS:A1995QR97200028
J	LONGSTRETH, GF; FEITELBERG, SP				LONGSTRETH, GF; FEITELBERG, SP			OUTPATIENT CARE OF SELECTED PATIENTS WITH ACUTE NONVARICEAL UPPER GASTROINTESTINAL HEMORRHAGE	LANCET			English	Article								Patients with upper gastrointestinal haemorrhage (UGIH) are usually cared for in hospital. To evaluate the efficacy and safety of outpatient care of selected patients with acute non-variceal UGIH who had endoscopy, we retrospectively analysed 4.5 years' experience of patients treated without hospital admission. We developed practice guidelines for outpatient care, and prospectively studied patients treated during the first 6 months of their use. 78 (8.4%) of 933 patients in the retrospective series and 34 (24.1%) of 141 in the prospective series received outpatient care. The guidelines comprised early notification of a gastroenterologist, urgent endoscopy, clinical, laboratory, and endoscopic criteria for outpatient care, and details of care. In the prospective study patients treated as outpatients were younger than those admitted (52.8 [SE 3.6] vs 63.0 [1.5] years) and had a slightly longer time from onset of bleeding to endoscopy (2.4 [0.2] vs 2.1 [0.2] days). Outpatients were less likely to have alcoholism, other major concomitant disease, syncope or presyncope, or supine tachycardia. Outpatients had higher haemoglobin concentrations than inpatients (125 [4] vs 106 [3] g/L). Most patients in both groups had peptic ulcers. There were no complications in the retrospective series; 1 of the 34 prospective outpatients was admitted with rebleeding. All outpatients survived. The estimated hospital cost saved per outpatient was about $990. A substantial proportion of carefully selected patients with acute non-variceal UGIH can be effectively cared for without admission to hospital.			LONGSTRETH, GF (corresponding author), KAISER PERMANENTE MED CTR,DEPT MED,SAN DIEGO,CA 92120, USA.							CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2533, DOI 10.1001/jama.258.18.2533; CUTLER JA, 1981, DIG DIS SCI S, V26, P90; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; FREEMAN ML, 1993, GASTROINTEST ENDOSC, V39, P359, DOI 10.1016/S0016-5107(93)70106-6; GILBERT DA, 1990, DIG DIS SCI S, V36, P8; GOSTOUT CJ, 1992, SEMIN GASTROINTEST D, V33, P53; GUPTA PK, 1993, MED CLIN N AM, V77, P973, DOI 10.1016/S0025-7125(16)30206-1; HARLAND R, 1992, J ROY SOC MED, V85, P26; JOHNSTON JH, 1990, GASTROINTEST ENDOS S, V36, P16; KURATA JH, 1988, J CLIN GASTROENTEROL, V10, P259, DOI 10.1097/00004836-198806000-00007; LAINE L, 1992, GASTROENTEROLOGY, V102, P314, DOI 10.1016/0016-5085(92)91816-M; LAINE L, 1989, ANN INTERN MED, V110, P510, DOI 10.7326/0003-4819-110-7-510; LICHTENSTEIN DR, 1992, GASTROINTESTINAL EME, P92; LONGSTRETH GF, 1994, J CLIN GASTROENTEROL, V19, P189, DOI 10.1097/00004836-199410000-00003; LONGSTRETH GF, 1986, J CLIN GASTROENTEROL, V8, P23, DOI 10.1097/00004836-198602000-00006; LONGSTRETH GF, IN PRESS AM J GASTRO; TERBLANCHE J, 1992, ANNU REV MED, V43, P69, DOI 10.1146/annurev.med.43.1.69; WENNBERG JE, 1989, NEW ENGL J MED, V321, P1168, DOI 10.1056/NEJM198910263211706; 1989, JAMA-J AM MED ASSOC, V262, P1369	19	109	111	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					108	111		10.1016/S0140-6736(95)90068-3	http://dx.doi.org/10.1016/S0140-6736(95)90068-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7815854				2023-01-03	WOS:A1995QB80400015
J	LORENZ, W; DUDA, D; DICK, W; SITTER, H; DOENICKE, A; BLACK, A; WEBER, D; MENKE, H; STINNER, B; JUNGINGER, T; ROTHMUND, M; OHMANN, C; HEALY, MJR; BLACK, J; BROUWER, A; BRUER, HJ; DIETZ, W; ENNIS, M; GAJEK, H; HEINTZBAMBERG, D; HENNES, HJ; KAPP, B; KUNNEKE, M; MARSTALLER, M; MCPEEK, B; MOSS, J; OTTO, S; REHBOCK, C; REHN, D; REIMUND, KP; ROHER, HD; RUGELES, MS; SATTLER, J; SCHERHAG, A; TESCHNER, M; ZACZYK, R				LORENZ, W; DUDA, D; DICK, W; SITTER, H; DOENICKE, A; BLACK, A; WEBER, D; MENKE, H; STINNER, B; JUNGINGER, T; ROTHMUND, M; OHMANN, C; HEALY, MJR; BLACK, J; BROUWER, A; BRUER, HJ; DIETZ, W; ENNIS, M; GAJEK, H; HEINTZBAMBERG, D; HENNES, HJ; KAPP, B; KUNNEKE, M; MARSTALLER, M; MCPEEK, B; MOSS, J; OTTO, S; REHBOCK, C; REHN, D; REIMUND, KP; ROHER, HD; RUGELES, MS; SATTLER, J; SCHERHAG, A; TESCHNER, M; ZACZYK, R			INCIDENCE AND CLINICAL IMPORTANCE OF PERIOPERATIVE HISTAMINE-RELEASE - RANDOMIZED STUDY OF VOLUME LOADING AND ANTIHISTAMINES AFTER INDUCTION OF ANESTHESIA	LANCET			English	Article							ANAPHYLACTOID REACTIONS; ANESTHESIA; SURGERY; SEVERITY	Although histamine release is recognised as a common event during anaesthesia and surgery, few clinicians judge the resultant cardiorespiratory disturbances serious enough to warrant prophylaxis with antihistamines. We have assessed the incidence and importance of histamine release in a randomised 2 x 2 factorial study. 240 patients representing a routine throughput of major general surgery were studied during a standardised induction of anaesthesia and preoperative loading of the circulation with either Ringer solution or Haemaccel-35, with or without antihistamine prophylaxis with dimetindene (H-1) plus cimetidine (H-2). Cardiorespiratory disturbances were graded as detectable, clinically relevant, or life-threatening from observers' records of the anaesthesia and the actions taken by the anaesthetists. Disturbances that were accompanied by significant rises in plasma histamine were further designated histamine-related, and those that were not were designated histamine-unrelated. Anaesthetists, observers, and designators were blinded to whether or not the patients had received antihistamines and to which solution was used for circulatory volume loading. Clinically relevant or life-threatening histamine-related disturbances occurred in 8% of the patients who after induction of anaesthesia received Ringer without antihistamines, in 26% of those who received Haemaccel without antihistamines, and in 2% or less of those who received antihistamines (p less-than-or-equal-to .0001). There were 4 life-threatening histamine-related disturbances, all in patients who received Haemaccel without antihistamines (p<0.01). Histamine-unrelated disturbances occurred in 16% overall, with no obvious effect of Haemaccel or antihistamines.The histamine-related disturbances under anaesthesia were remarkable for their severity (even with small rises in histamine concentrations), for the prevalence of bradycardia, and for the absence of skin signs. Their likelihood and severity were increased in patients with tumours. The results of the trial make a case for routine prophylaxis with antihistamines as part of anaesthetic management.	UNIV MARBURG,DEPT GEN SURG,W-3550 MARBURG,GERMANY; UNIV MAINZ,ANAESTHESIOL CLIN,W-6500 MAINZ,GERMANY; UNIV MAINZ,GEN SURG CLIN,W-6500 MAINZ,GERMANY; UNIV MUNICH,INST ANAESTHESIOL,W-8000 MUNICH 2,GERMANY; UNIV DUSSELDORF,DEPT SURG,THEORET SURG UNIT,W-4000 DUSSELDORF 1,GERMANY; BRISTOL ROYAL INFIRM & GEN HOSP,DEPT ANAESTHESIA,BRISTOL BS2 8HW,AVON,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT MED STAT,LONDON WC1E 7HT,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL,LONDON WC1E 7HT,ENGLAND	Philipps University Marburg; Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz; University of Munich; Heinrich Heine University Dusseldorf; Bristol Royal Infirmary; University of London; London School of Hygiene & Tropical Medicine; University of London; London School of Hygiene & Tropical Medicine	LORENZ, W (corresponding author), PHILIPPS UNIV MARBURG,INST THEORET CHIRURG,ZENTRUM OPERAT MED 1,D-35033 MARBURG,GERMANY.		Ohmann, Christian/AAV-8608-2020; Ennis, Madeleine/GZG-4070-2022					ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; ASSEM ESK, 1992, MONOGR ALLERGY, V30, P1; Chalmers T. C., 1989, THEOR SURG, V4, P98; CLARKE RSJ, 1988, THEOR SURG, V3, P142; Dale HH, 1929, LANCET, V1, P1285; DICK W, 1992, ANAESTHESIST, V41, P239; DUDE D, 1992, AGENTS ACTIONS, V36, pC149; FISHER MM, 1984, CLIN ANAESTHESIOL, V2, P677; GENOVESE A, 1988, J PHARMACOL EXP THER, V247, P844; HOBSLEY M, 1983, THEORY SURG, V3, P55; LAXER RM, 1990, J RHEUMATOL, V17, P1; LEVI R, 1991, HDB EXPT PHARM, P347; LEVY JH, 1992, ANAPHYLACTIC REACTIO, P1; LORENZ W, 1976, BRIT J ANAESTH, V48, P151, DOI 10.1093/bja/48.2.151; LORENZ W, 1991, AGENT ACTION SUPPL, V33, P197; LORENZ W, 1985, NEW ENGL REG ALLERGY, V6, P174; LORENZ W, 1982, KLIN WOCHENSCHR, V60, P896, DOI 10.1007/BF01716946; LORENZ W, 1988, THEOR SURG, V3, P55; LORENZ W, 1983, ADVERSE RESPONSE INT, P83; LORENZ W, 1981, DEV BIOL STAND, V48, P207; LORENZ W, 1991, HDB EXP PHARM, V97, P9009; LORENZ W, 1905, N ENGL J REG ALLERGY, V6, P37; LORENZ W, 1992, AGENTS ACTIONS, V36, pC231; LORENZ W, 1991, HDB EXPT PHARM, V97, P385; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P843, DOI 10.1016/0735-1097(91)90863-5; Neugebauer E. A., 1993, HDB MEDIATORS SEPTIC, P1; OOSTING E, 1990, CLIN EXP ALLERGY, V20, P349; SITTER H, 1992, AGENTS ACTIONS, V36, pC219; STELLATO C, 1992, ANESTHESIOLOGY, V77, P932, DOI 10.1097/00000542-199211000-00016; WATKINS J, 1988, GUIDE IMMEDIATE ANAE, P1; WILLIAMS JG, 1983, BRIT MED J, V286, P775, DOI 10.1136/bmj.286.6367.775	31	115	116	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 16	1994	343	8903					933	940		10.1016/S0140-6736(94)90063-9	http://dx.doi.org/10.1016/S0140-6736(94)90063-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NF700	7512679	Green Submitted			2023-01-03	WOS:A1994NF70000007
J	KAMINSKI, MS; ZASADNY, KR; FRANCIS, IR; MILIK, AW; ROSS, CW; MOON, SD; CRAWFORD, SM; BURGESS, JM; PETRY, NA; BUTCHKO, GM; GLENN, SD; WAHL, RL				KAMINSKI, MS; ZASADNY, KR; FRANCIS, IR; MILIK, AW; ROSS, CW; MOON, SD; CRAWFORD, SM; BURGESS, JM; PETRY, NA; BUTCHKO, GM; GLENN, SD; WAHL, RL			RADIOIMMUNOTHERAPY OF B-CELL LYMPHOMA WITH [I-131] ANTI-B1 (ANTI-CD20) ANTIBODY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIOLABELED MONOCLONAL-ANTIBODIES; NON-HODGKINS-LYMPHOMA; EXTERNAL BEAM IRRADIATION; CARCINOMA XENOGRAFTS; ANTIGEN; DOSIMETRY; TRIAL; SEROTHERAPY; MALIGNANCIES; COMBINATION	Background. Many patients with non-Hodgkin's lymphomas are not cured by current therapies, and new approaches to treatment are needed. As part of an ongoing phase 1 study, we examined the effect of radioimmunotherapy with I-131-labeled B-cell-specific anti-CD20 monoclonal antibody in 10 patients with CD20-positive B-cell lymphomas in whom primary chemotherapy had failed. Methods and Results. Anti-B1 (anti-CD20) mouse monoclonal antibody trace-labeled with I-131 (15 mg containing 5 mCi) was given intravenously at approximately one-week intervals: first, without pretreatment with unlabeled anti-B1 antibody, to all 10 patients; then, with pretreatment with 135 mg of unlabeled antibody, to 8 patients; and then, with pretreatment with 685 mg, to 2 patients. Serial quantitative gamma-camera images and measures of whole-body radioactivity were obtained after each tracer dose. All known disease sites larger than 2 cm could be imaged. The effect of a pretreatment dose of unlabeled anti-B1 antibody on targeting of the tumor with the radiolabeled antibody was variable. The pretreatment dose of unlabeled antibody that produced the highest ratio of the tumor dose to the whole-body dose in tracer studies was then used to deliver higher doses of radioactivity for radioimmunotherapy in nine patients. Three patients received doses designed to deliver 25 cGy to the whole body (two patients treated twice, six to eight weeks apart), four patients received 35 cGy (one patient treated twice), and two patients received 45 cGy (one patient treated twice); each dose contained 34 to 66 mCi of activity. Six of the nine treated patients had tumor responses, including patients with bulky or chemotherapy-resistant disease: four patients had complete remissions, and two had partial responses. Three patients had objective responses to tracer infusions before they received radioimmunotherapeutic doses. Of the four patients with complete remissions, one remained in remission for eight months and the other three continue to have no disease progression (for 11, 9, and 8 months). There was mild or no myelosuppression. Conclusions. Radioimmunotherapy with [I-131]anti-B1 antibody is a promising new treatment for lymphoma.	COULTER CORP, HIALEAH, FL USA; UNIV MICHIGAN, DEPT INTERNAL MED, DIV NUCL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT INTERNAL MED, DIV HEMATOL ONCOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT PATHOL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, DEPT RADIOL, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NCI NIH HHS [R01-CA-56794, P01-CA-42768] Funding Source: Medline; NCRR NIH HHS [MO1-RR-00042] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042768, R01CA056794] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000042] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		[Anonymous], 1975, REPORT TASK GROUP RE; ARMITAGE JO, 1989, BLOOD, V73, P1749; BAST RC, 1983, CANCER RES, V43, P1389; BROWN SL, 1989, BLOOD, V73, P651; BUCHSBAUM DJ, 1992, CANCER RES, V52, P6476; BUCHSBAUM DJ, 1990, INT J RADIAT ONCOL, V18, P1033, DOI 10.1016/0360-3016(90)90438-P; DENARDO GL, 1990, CANCER RES, V50, pS1014; DENARDO SJ, 1988, INT J CANCER, P96; DENARDO SJ, 1988, ANTIBODY IMMUNOCONJ, V1, P17; DEVITA VT, 1989, CANCER PRINCIPLES PR, V2, P1741; DILLMAN LT, NMMIRD10 SOC NUCL ME; DYER MJS, 1989, BLOOD, V73, P1431; ELLET WH, NMMIRD8 SOC NUCL MED; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDENBERG DM, 1991, J CLIN ONCOL, V9, P548, DOI 10.1200/JCO.1991.9.4.548; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; GROSSBARD ML, 1992, BLOOD, V79, P576; GROSSBARD ML, 1993, J CLIN ONCOL, V11, P726, DOI 10.1200/JCO.1993.11.4.726; HALE G, 1988, LANCET, V2, P1394; KAMINSKI MS, 1992, J CLIN ONCOL, V10, P1696, DOI 10.1200/JCO.1992.10.11.1696; KNOX SJ, 1990, CANCER RES, V50, P4935; LINDMO T, 1984, J IMMUNOL METHODS, V72, P77, DOI 10.1016/0022-1759(84)90435-6; MACKLIS RM, 1992, RADIAT RES, V130, P220, DOI 10.2307/3578279; MACKLIS RM, 1992, ANTIBODIES IMMUNOCON, V5, P339; MASON DY, 1990, AM J PATHOL, V136, P1215; MEEKER TC, 1985, BLOOD, V65, P1349, DOI 10.1182/blood.V65.6.1349.bloodjournal6561349; NADLER LM, 1980, CANCER RES, V40, P3147; PRESS OW, 1987, BLOOD, V69, P584; PRESS OW, 1989, J CLIN ONCOL, V7, P1027, DOI 10.1200/JCO.1989.7.8.1027; PRESS OW, 1989, CANCER RES, V49, P4906; SCHEINBERG DA, 1990, J CLIN ONCOL, V8, P792, DOI 10.1200/JCO.1990.8.5.792; SNYDER WS, NMMIRD11 SOC NUCL ME; STASHENKO P, 1980, J IMMUNOL, V125, P1678; STEVENSON GT, 1988, INT J CANCER, P9; VITETTA ES, 1991, CANCER RES, V51, P4052; WAHL RL, 1990, J NUCL MED, V31, P84; WATSON E, 1984, MIRDOSE; WESSELS BW, 1989, INT J RADIAT ONCOL, V17, P1257, DOI 10.1016/0360-3016(89)90534-8	39	557	635	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					459	465		10.1056/NEJM199308123290703	http://dx.doi.org/10.1056/NEJM199308123290703			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	7687326				2023-01-03	WOS:A1993LR44300003
J	HAYASHIDA, M; ALTERMAN, AI; MCLELLAN, AT; OBRIEN, CP; PURTILL, JJ; VOLPICELLI, JR; RAPHAELSON, AH; HALL, CP				HAYASHIDA, M; ALTERMAN, AI; MCLELLAN, AT; OBRIEN, CP; PURTILL, JJ; VOLPICELLI, JR; RAPHAELSON, AH; HALL, CP			COMPARATIVE EFFECTIVENESS AND COSTS OF INPATIENT AND OUTPATIENT DETOXIFICATION OF PATIENTS WITH MILD-TO-MODERATE ALCOHOL WITHDRAWAL SYNDROME	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV PENN,DEPT PSYCHIAT,PHILADELPHIA,PA 19104; TEMPLE UNIV,SCH BUSINESS & MANAGEMENT,PHILADELPHIA,PA 19122	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	HAYASHIDA, M (corresponding author), VET ADM MED CTR,BLDG 3,UNIV & WOODLAND AVES,PHILADELPHIA,PA 19104, USA.				NATIONAL INSTITUTE ON DRUG ABUSE [P50DA005186, P60DA005186] Funding Source: NIH RePORTER; NIDA NIH HHS [DA 05186] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ALTERMAN AI, 1988, J STUD ALCOHOL, V49, P160, DOI 10.15288/jsa.1988.49.160; ANNIS HM, 1979, J STUD ALCOHOL, V40, P196, DOI 10.15288/jsa.1979.40.196; ARMOR DJ, 1976, ALCOHOLISM TREATMENT, P21; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; DENHARTOG GL, 1982, DECADE DETOX DEV NON; DIESENHAUS H, 1982, ALCOHOL HLTH MONOGRA, V3, P219; FELDMAN DJ, 1975, AM J PSYCHIAT, V132, P407; FULLER RK, 1988, ALCOHOL CLIN EXP RES, V12, P201, DOI 10.1111/j.1530-0277.1988.tb00180.x; GORDIS E, 1981, CONTROVERSIES CLIN C, P37; GROSS MM, 1973, ALCOHOL INTOXICATION, V35, P365; KOLODNER G, 1977, CURR ALCOHOL, V1, P311; LIPMAN RS, 1979, J AFFECT DISORDERS, V1, P9, DOI 10.1016/0165-0327(79)90021-1; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MCLELLAN AT, 1985, DHHS ADM851419 PUBL; Naranjo C A, 1986, Recent Dev Alcohol, V4, P265; NARANJO CA, 1983, CLIN PHARMACOL THER, V34, P214, DOI 10.1038/clpt.1983.155; O'Briant R. G., 1973, RECOVERY ALCOHOLISM; RICHMAN A, 1984, DRUG ALCOHOL DEPEN, V13, P65, DOI 10.1016/0376-8716(84)90033-4; ROSEN HS, 1988, PUBLIC FINANC, P247; SAUSSER GJ, 1982, J FAM PRACTICE, V14, P863; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SPARADEO FR, 1982, J STUD ALCOHOL, V43, P1124, DOI 10.15288/jsa.1982.43.1124; STINNETT JL, 1982, INT J ADDICT, V17, P1031, DOI 10.3109/10826088209057773; STOCKWELL T, 1983, BRIT J ADDICT, V78, P145, DOI 10.1111/j.1360-0443.1983.tb05502.x; TENNANT FS, 1979, J FAM PRACTICE, V8, P621; WHITFIELD CL, 1978, JAMA-J AM MED ASSOC, V239, P1409, DOI 10.1001/jama.239.14.1409	26	176	179	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1989	320	6					358	365		10.1056/NEJM198902093200605	http://dx.doi.org/10.1056/NEJM198902093200605			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	T1285	2913493				2023-01-03	WOS:A1989T128500005
J	MCKNIGHT, JA; BALNAVE, K; OKEEFFE, DB				MCKNIGHT, JA; BALNAVE, K; OKEEFFE, DB			DO IT YOURSELF CARDIOVERSION	BRITISH MEDICAL JOURNAL			English	Note									CRAIGAVON AREA HOSP,CRAIGAVON BT63 5QQ,ARMAGH,NORTH IRELAND; BELFAST CITY HOSP,BELFAST BT9 7AB,NORTH IRELAND	Belfast City Hospital	MCKNIGHT, JA (corresponding author), ROYAL VICTORIA HOSP,SIR GEORGE E CLARK METAB UNIT,BELFAST BT12 6BA,NORTH IRELAND.							METHA D, 1988, LANCET, V1, P1181	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1988	297	6664					1641	1641		10.1136/bmj.297.6664.1641	http://dx.doi.org/10.1136/bmj.297.6664.1641			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R6153	3147778	Bronze, Green Published			2023-01-03	WOS:A1988R615300019
J	PAGNIEZ, DC; MACNAMARA, E; FORTIN, F; DELVALLEZ, L; FRUCHART, A; DEQUIEDT, P; TACQUET, A				PAGNIEZ, DC; MACNAMARA, E; FORTIN, F; DELVALLEZ, L; FRUCHART, A; DEQUIEDT, P; TACQUET, A			WITHDRAWAL OF CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS TO TREAT MILD PERITONITIS	BRITISH MEDICAL JOURNAL			English	Article									HOP ALBERT CALMETTE,BACTERIOL LAB,LILLE,FRANCE	Universite de Lille - ISITE; CHU Lille	PAGNIEZ, DC (corresponding author), HOP ALBERT CALMETTE,NEPHROL CLIN,F-50937 LILLE,FRANCE.							BUGGY BP, 1984, AM J MED, V76, P1035, DOI 10.1016/0002-9343(84)90854-4; DUWE AK, 1981, INFECT IMMUN, V33, P130, DOI 10.1128/IAI.33.1.130-135.1981; GALLIMORE B, 1986, NEPHRON, V43, P283, DOI 10.1159/000183855; Guiberteau R, 1987, Contrib Nephrol, V57, P92; 1987, LANCET, V1, P845	5	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 5	1988	297	6657					1174	1175		10.1136/bmj.297.6657.1174	http://dx.doi.org/10.1136/bmj.297.6657.1174			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q8250	3144336	Bronze, Green Published			2023-01-03	WOS:A1988Q825000025
J	GLASS, AT				GLASS, AT			PHOTODYNAMIC THERAPY FOR BLADDER-CANCER - ETHICS OF A COLLABORATIVE TRIAL IN CHINA	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter											GLASS, AT (corresponding author), WALTER REED ARMY MED CTR,WASHINGTON,DC 20307, USA.							PROUT GR, 1987, NEW ENGL J MED, V317, P1251, DOI 10.1056/NEJM198711123172003	1	5	5	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1988	319	16					1096	1097						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q5315	3050521				2023-01-03	WOS:A1988Q531500027
J	KICKLER, TS; SPIVAK, JL				KICKLER, TS; SPIVAK, JL			EFFECT OF REPEATED WHOLE-BLOOD DONATIONS ON SERUM IMMUNOREACTIVE ERYTHROPOIETIN LEVELS IN AUTOLOGOUS DONORS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									JOHNS HOPKINS UNIV, SCH MED, DEPT PATHOL, DIV LAB MED, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV HEMATOL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University								BENDER BS, 1987, BLOOD, V70, P392, DOI 10.1182/blood.V70.2.392.392; COLEMAN DH, 1953, ARCH INTERN MED, V92, P341, DOI 10.1001/archinte.1953.00240210045006; EGRIE JC, 1987, J IMMUNOL METHODS, V99, P235, DOI 10.1016/0022-1759(87)90133-5; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; HAUGEN RK, 1987, JAMA-J AM MED ASSOC, V257, P1211, DOI 10.1001/jama.257.9.1211; HOLLAND PV, 1987, STANDARDS BLOOD BANK, P39; PIOMELLI S, 1973, J LAB CLIN MED, V81, P932; REGE AB, 1982, J LAB CLIN MED, V100, P829; THOMSON JD, 1987, AM J BONE JOINT SURG, V69, P320; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; WASMAN J, 1987, JAMA-J AM MED ASSOC, V258, P3135, DOI 10.1001/jama.258.21.3135; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6	12	174	176	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 1	1988	260	1					65	67		10.1001/jama.260.1.65	http://dx.doi.org/10.1001/jama.260.1.65			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N8728	3379725				2023-01-03	WOS:A1988N872800030
J	NOLPH, KD; LINDBLAD, AS; NOVAK, JW				NOLPH, KD; LINDBLAD, AS; NOVAK, JW			CURRENT CONCEPTS - CONTINUOUS AMBULATORY PERITONEAL-DIALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NIH, CONTINUOUS AMBULATORY PERITONEAL DIALYSIS REGISTRY, BETHESDA, MD 20205 USA; NIH, CONTINUOUS AMBULATORY PERITONEAL DIALYSIS REGISTRY, BETHESDA, MD 20205 USA; HARRY S TRUMAN MEM VET HOSP, COLUMBIA, MO 65201 USA; DALTON RES CTR, COLUMBIA, MO USA; EMMES CORP, POTOMAC, MD USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA; US Department of Veterans Affairs; Veterans Health Administration (VHA); Harry S. Truman Memorial Veterans' Hospital; Emmes Corporation	NOLPH, KD (corresponding author), UNIV MISSOURI, HLTH SCI CTR, DEPT MED, DIV NEPHROL, MA436, COLUMBIA, MO 65212 USA.				NIADDK NIH HHS [N01-AM-3-2244, N01-AM-3-2245] Funding Source: Medline	NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALDUCCI A, 1981, BMJ-BRIT MED J, V283, P1021, DOI 10.1136/bmj.283.6298.1021; BLAGG CR, 1983, ASAIO J, V6, P170; BLUMENKRANTZ MJ, 1982, KIDNEY INT, V21, P849, DOI 10.1038/ki.1982.109; BLUMENKRANTZ MJ, 1981, KIDNEY INT, V19, P593, DOI 10.1038/ki.1981.57; BRECKENRIDGE WC, 1982, ATHEROSCLEROSIS, V45, P249, DOI 10.1016/0021-9150(82)90226-X; BROYER M, 1985, P EUR DIAL TRANS, V21, P2; BROYER M, 1985, CAPD CHILDREN, P30; BURTON PR, 1987, LANCET, V1, P1115; CANTALUPPI A, 1986, ADV CONTINUOUS AMBUL, P182; CANTALUPPI A, 1985, ADV CONTINUOUS AMBUL, P154; CAPELLI JP, 1985, DIALYSIS TRANSPLANT, V14, P38; CASSIDY MJD, 1985, Q J MED, V54, P29; DELMEZ JA, 1982, KIDNEY INT, V21, P862, DOI 10.1038/ki.1982.110; DEPAEPE MBJ, 1983, KIDNEY INT, V23, P744, DOI 10.1038/ki.1983.88; FALLER B, 1984, PERITON DIALYSIS B, V4, P10; FALLER B, 1985, ADV CONTINUOUS AMBUL, P96; Flynn C T, 1979, Proc Eur Dial Transplant Assoc, V16, P184; FLYNN CT, 1979, T AM SOC ART INT ORG, V25, P114; GAHL GM, 1981, ANN INTERN MED, V94, P643, DOI 10.7326/0003-4819-94-5-643; GIACCHINO F, 1984, ARTIF ORGANS, V8, P156, DOI 10.1111/j.1525-1594.1984.tb04265.x; HAMILTON RW, 1983, PERITON DIALYSIS B, V3, pS8; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HUTCHINSON TA, 1982, ANN INTERN MED, V96, P417, DOI 10.7326/0003-4819-96-4-417; JUNOR BJR, 1985, PERITON DIALYSIS B, V5, P202; KEANE WF, 1987, PERITON DIALYSIS B, V7, P55; KHANNA R, 1985, ADV CONTINUOUS AMBUL, P79; KHANNA R, 1983, AM SOC ARTIF INTERN, V6, P197; Lempert K D, 1986, ASAIO Trans, V32, P557, DOI 10.1097/00002480-198609000-00037; LINDHOLM B, 1982, T AM SOC ART INT ORG, V28, P263; LINDNER A, 1974, NEW ENGL J MED, V290, P697, DOI 10.1056/NEJM197403282901301; MAIORCA R, 1986, ADV CONTINUOUS AMBUL, P176; MARIORCA R, 1983, LANCET, V2, P642; MCGONIGLE RJS, 1984, KIDNEY INT, V25, P430, DOI 10.1038/ki.1984.35; MEHTA BR, 1983, T AM SOC ART INT ORG, V29, P50; MION CM, 1983, ASAIO J, V6, P205; NIELSEN VK, 1974, ACTA MED SCAND, V195, P155; Nolph K D, 1987, ASAIO Trans, V33, P57, DOI 10.1097/00002480-198704000-00003; NOLPH KD, 1978, NEPHRON, V21, P117, DOI 10.1159/000181381; NOLPH KD, 1984, PERITON DIALYSIS B, V4, P232; NOLPH KD, 1986, PERITON DIALYSIS INT, V6, P28; NOLPH KD, 1981, AM J NEPHROL, V1, P1, DOI 10.1159/000166480; NOLPH KD, 1986, KIDNEY, P1847; Nolph KD, 1985, PERITON DIALYSIS B, V5, P19; NOLPH KD, 1983, ASAIO J, V6, P220; OREOPOULOS DG, 1987, PERITON DIALYSIS B, V7, P130; POPOVICH RP, 1976, ABSTR AM SOC ART INT, V5, P64; Potter DE, 1986, KIDNEY INT, V30, pS11; PROWANT B, 1983, AM J KIDNEY DIS, V3, P27, DOI 10.1016/S0272-6386(83)80006-7; RAMOS JM, 1983, NEPHRON, V35, P20, DOI 10.1159/000183039; RONCAR DAK, 1981, PERITONEAL DIALYSIS, V1, P136; ROTTEMBOURG J, 1983, P EUR DIAL TRANS, V20, P236; RUBIN J, 1981, NEPHRON, V28, P218, DOI 10.1159/000182203; Rubin J, 1985, ASAIO J, V8, P22; SALTISSI D, 1984, CLIN NEPHROL, V22, P21; SHAPIRO FL, 1983, AM SOC ARTIF INT ORG, V6, P176; SIMMONS RG, 1984, AM J KIDNEY DIS, V4, P253, DOI 10.1016/S0272-6386(84)80101-8; SLINGENEYER A, 1983, T AM SOC ART INT ORG, V29, P633; SLINGENEYER A, 1982, P EUR DIAL TRANS, V19, P388; STASON WB, 1985, OTAHCS3S OFF TECHN A; STEINBERG SM, 1985, ASAIO J, V8, P238; STEINER RW, 1984, ARCH INTERN MED, V144, P728, DOI 10.1001/archinte.144.4.728; TEITELBAUM SL, 1982, KIDNEY INT, V21, P180; TURGAN C, 1981, INT J ARTIF ORGANS, V4, P158, DOI 10.1177/039139888100400404; TWARDOWSKI ZJ, 1985, PERITON DIALYSIS INT, V5, P219; VERGER C, 1983, KIDNEY INT, V23, P823, DOI 10.1038/ki.1983.101; WELLER JM, 1982, KIDNEY INT, V21, P78, DOI 10.1038/ki.1982.11; WILLIAMS GW, 1983, KIDNEY INT, V24, P691, DOI 10.1038/ki.1983.212; WILLIAMS P, 1981, PERITON DIALYSIS B, V1, P82; WING AJ, 1983, AM SOC ARTIF INTERN, V6, P214; ZAPPACOSTA AR, 1982, AM J MED, V72, P53, DOI 10.1016/0002-9343(82)90577-0; 1987, REPORT NATIONAL CAPD; 1987, END STAGE RENAL DISE; 1986, HCFA03230 DEP HLTH H; 1986, HCFA03221 HLTH CAR F	74	75	77	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 16	1988	318	24					1595	1600		10.1056/NEJM198806163182407	http://dx.doi.org/10.1056/NEJM198806163182407			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7765	3287159				2023-01-03	WOS:A1988N776500007
J	LEIJTEN, FSS; HARNICKDEWEERD, JE; POORTVLIET, DCJ; DEWEERD, AW				LEIJTEN, FSS; HARNICKDEWEERD, JE; POORTVLIET, DCJ; DEWEERD, AW			THE ROLE OF POLYNEUROPATHY IN MOTOR CONVALESCENCE AFTER PROLONGED MECHANICAL VENTILATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CRITICAL ILLNESS POLYNEUROPATHY; MULTIPLE-ORGAN FAILURE; ILL PATIENTS; SEPSIS; DEFINITIONS; NEUROPATHY; SEVERITY	Objective.-To test the hypothesis that prolonged motor recovery after longterm ventilation may be due to polyneuropathy and can be foreseen at an early stage by electromyography (EMG). Design.-Cohort study with an entry period of 18 months. Polyneuropathy was identified by EMG studies in the intensive care unit (ICU). During a 1-year followup, amount of time was recorded to reach a rehabilitation end point. Setting.-The general ICU of a community hospital. Patients.-Fifty patients younger than 75 years who were receiving mechanical ventilation for more than 7 days. Main Outcome Measures.-A rehabilitation end point was defined as return of normal muscle strength and ability to walk 50 m independently. Results.-In 29 of 50 patients, an EMG diagnosis of polyneuropathy was made in the ICU. Patients with polyneuropathy had a higher mortality in the ICU (14 vs 4; P=.03), probably related to multiple organ failure (22 vs 11; P=.08) oraminoglycoside treatment of suspected gram-negative sepsis (17 vs 4; P=.05). Rehabilitation was more prolonged in 12 patients with polyneuropathy than in 12 without polyneuropathy (P=.001). Of nine patients with delays beyond 4 weeks, eight had polyneuropathy, five of whom had persistent motor handicap after 1 year. In particular, axonal polyneuropathy with conduction slowing on EMG indicated a poor prognosis. Conclusions.-Polyneuropathy in the critically ill is related to multiple organ failure and gram-negative sepsis, is associated with higher mortality, and causes important rehabilitation problems. EMG recordings in the ICU can identify patients at risk.	WESTEINDE ZIEKENHUIS,DEPT NEUROL,THE HAGUE,NETHERLANDS; WESTEINDE ZIEKENHUIS,DEPT CLIN NEUROPHYSIOL,THE HAGUE,NETHERLANDS; WESTEINDE ZIEKENHUIS,DEPT ANESTHESIOL & INTENS CARE,THE HAGUE,NETHERLANDS									[Anonymous], 1976, AIDS INVESTIGATION P; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; BARAT M, 1987, REV NEUROL, V143, P823; BOLTON CF, 1986, J NEUROL NEUROSUR PS, V49, P563, DOI 10.1136/jnnp.49.5.563; BOLTON CF, 1984, J NEUROL NEUROSUR PS, V47, P1223, DOI 10.1136/jnnp.47.11.1223; Bolton CF, 1983, NEUROLOGY CLEVELA S2, V33, P186; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; COAKLEY JH, 1993, INTENS CARE MED, V19, P323, DOI 10.1007/BF01694705; CORONEL B, 1990, CRIT CARE MED, V18, P486, DOI 10.1097/00003246-199005000-00004; DECOUL AAW, 1983, CLIN NEUROL NEUROSUR, V85, P197; DECOUL AAWO, 1985, CLIN NEUROL NEUROSUR, V87, P17, DOI 10.1016/0303-8467(85)90060-5; DECOUL AAWO, 1991, CLIN NEUROL NEUROSUR, V93, P27, DOI 10.1016/0303-8467(91)90005-A; DODSON BA, 1995, CRIT CARE MED, V23, P815, DOI 10.1097/00003246-199505000-00007; GORIS RJA, 1985, ARCH SURG-CHICAGO, V120, P1109; GORSON KC, 1993, CRIT CARE MED, V21, P267, DOI 10.1097/00003246-199302000-00020; KELLY BJ, 1993, CHEST, V104, P1818, DOI 10.1378/chest.104.6.1818; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LEIJTEN FSS, 1994, CLIN NEUROL NEUROSUR, V96, P10, DOI 10.1016/0303-8467(94)90023-X; LEMAIRE F, 1993, INTENS CARE MED, V19, pS69, DOI 10.1007/BF01708804; MESSA JBL, 1990, INTENS CARE MED, V16, P159, DOI 10.1007/BF01724794; NIJHOLT JLA, 1987, HDB CLIN NEUROLOGY, V7, P575; REPINE JE, 1992, LANCET, V339, P466, DOI 10.1016/0140-6736(92)91067-I; RIVNER MH, 1983, NEUROLOGY S2, V33, P164; Roelofs RI, 1983, NEUROLOGY S, V33, P240; SEISER A, 1992, WIEN KLIN WOCHENSCHR, V104, P294; SPITZER AR, 1992, MUSCLE NERVE, V15, P682, DOI 10.1002/mus.880150609; SPRUNG CL, 1991, CRIT CARE MED, V19, P849; WILLIAMS AC, 1986, BRIT MED J, V293, P790, DOI 10.1136/bmj.293.6550.790-a; WITT NJ, 1991, CHEST, V99, P176, DOI 10.1378/chest.99.1.176; ZOCHODNE DW, 1987, BRAIN, V110, P819, DOI 10.1093/brain/110.4.819	30	201	204	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 18	1995	274	15					1221	1225		10.1001/jama.274.15.1221	http://dx.doi.org/10.1001/jama.274.15.1221			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ120	7563512				2023-01-03	WOS:A1995RZ12000031
J	CHRYSTIE, IL; WOLFE, CDA; KENNEDY, J; ZANDER, L; TILZEY, A; BANATVALA, JE				CHRYSTIE, IL; WOLFE, CDA; KENNEDY, J; ZANDER, L; TILZEY, A; BANATVALA, JE			VOLUNTARY, NAMED TESTING FOR HIV IN A COMMUNITY-BASED ANTENATAL CLINIC - A PILOT-STUDY	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TRANSMISSION; WOMEN; RISK	Despite the increasing advantages of identifying HIV infection in pregnant women, only some 12% of HIV positive women attending antenatal clinics in London have been identified by named testing. As virtually all antenatal care will be community based within the next two to three years, we assessed the problems of introducing named HIV testing during pregnancy into the primary care setting. Planning the service took a considerable time and required the production of educational material for both staff and pregnant women and some reorganisation of procedures. Over a one year period an uptake of 44% was noted. Several problems were encountered including an average of 21 minutes needed to give information on AIDS and HIV, an adverse effect on the midwife-mother relationship, and anxiety (affecting both women and midwives). Possible solutions to this difficult problem are discussed.	UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT VIROL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,ST THOMAS HOSP,DEPT PUBL HLTH MED,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,DIRECTORATE OBSTET & GYNAECOL,LONDON SE1 7EH,ENGLAND; UNITED MED & DENT SCH,DEPT GEN PRACTICE,LONDON SE1 7EH,ENGLAND	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of London; King's College London; University of London; King's College London				Wolfe, Charles/0000-0001-8264-0981				ADES AE, 1992, AIDS, V6, P1031, DOI 10.1097/00002030-199209000-00018; BANATVALA JE, 1994, LANCET, V343, P1113, DOI 10.1016/S0140-6736(94)90230-5; BANATVALA JE, 1991, LANCET, V337, P1218, DOI 10.1016/0140-6736(91)92885-6; BARBACCI M, 1991, LANCET, V337, P709, DOI 10.1016/0140-6736(91)90286-X; BOYER PJ, 1994, JAMA-J AM MED ASSOC, V271, P1925, DOI 10.1001/jama.271.24.1925; Chrystie I, 1992, Health Trends, V24, P13; CHRYSTIE IL, 1995, AIDS CARE, V7, P135, DOI 10.1080/09540129550126650; CHRYSTIE IL, 1992, LANCET, V339, P364, DOI 10.1016/0140-6736(92)91682-X; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; COZEN W, 1993, J ACQ IMMUN DEF SYND, V6, P95; DELAMOTHE T, 1995, BRIT MED J, V310, P213, DOI 10.1136/bmj.310.6974.213; DESMOND N, 1994, BRIT MED J, V309, P877, DOI 10.1136/bmj.309.6958.877a; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; Flesch R, 1948, J APPL PSYCHOL, V32, P221, DOI 10.1037/h0057532; Holland F J, 1994, J Med Screen, V1, P176; HOWARD LC, 1989, BRIT J OBSTET GYNAEC, V96, P135, DOI 10.1111/j.1471-0528.1989.tb01651.x; MEADOWS J, 1994, INT J STD AIDS, V5, P400, DOI 10.1177/095646249400500604; MEADOWS J, 1992, LANCET, V339, P622; NICOLL A, 1994, BRIT MED J, V309, P376, DOI 10.1136/bmj.309.6951.376a; 1993, CHANGING CHILDBIRTH; 1994, GUIDELINES OFFERING; 1995, UNLINKED ANONYMOUS H; 1994, LANCET, V343, P1464; 1992, GUIDELINES OFFERING	24	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					928	931						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580555	Green Published			2023-01-03	WOS:A1995RZ23700026
J	LUND, BO; LUND, J				LUND, BO; LUND, J			NOVEL INVOLVEMENT OF A MITOCHONDRIAL STEROID HYDROXYLASE (P450C11) IN XENOBIOTIC METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ADRENOCORTICAL TOXICITY; MICE; 3-METHYLSULFONYL-DDE; PROTEIN; CORTEX; CELLS; DDT	Adrenocortical mitochondrial cytochrome P450 isozymes of the Cyp11 family normally synthesize steroids with a very strict substrate specificity. However, for the first time, P450c11 was additionally shown to metabolize and bioactivate the adrenotoxic environmental pollutant 3-methylsulfonyl-2,2-bis(4-chlorophenyl)-1,1-dichloroethene (MeSO(2)-DDE). This conclusion is based on a striking correlation between inductions of MeSO(2)DDE and deoxycorticosterone metabolism by forskolin in the adrenocortical cell lines Y1 and Kin-8, inhibition of P450c11-dependent activities in. Y1 cells by MeSO(2)-DDE, and metabolism of MeSO(2)-DDE by non-steroidogenic COS cells after transfection with a cDNA encoding P450c11. The interaction between xenobiotics and glucocorticoid synthesis should focus more attention to xenobiotic-induced hormonal disturbances.	KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED NUTR,NOVUM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet	LUND, BO (corresponding author), SWEDISH UNIV AGR SCI,UPPSALA BIOMED CTR,DEPT PHARMACOL TOXICOL,BOX 573,S-75123 UPPSALA,SWEDEN.							BAKER MT, 1984, BIOCHEM PHARMACOL, V33, P255, DOI 10.1016/0006-2952(84)90483-0; DOMALIK LJ, 1991, MOL ENDOCRINOL, V5, P1853, DOI 10.1210/mend-5-12-1853; HARAGUCHI K, 1989, CHEMOSPHERE, V19, P487, DOI 10.1016/0045-6535(89)90356-1; HORNSBY PJ, 1989, FREE RADICAL BIO MED, V6, P103, DOI 10.1016/0891-5849(89)90163-9; JENSEN S, 1976, Ambio, V5, P257; JONSSON CJ, 1994, ENVIRON TOXICOL CHEM, V13, P1303, DOI [10.1897/1552-8618(1994)13[1303:TAIBOT]2.0.CO;2, 10.1002/etc.5620130812]; JONSSON CJ, 1994, PHARMACOL TOXICOL, V74, P58; JONSSON CJ, 1992, REPROD TOXICOL, V6, P233, DOI 10.1016/0890-6238(92)90178-V; JONSSON CJ, 1991, FUND APPL TOXICOL, V16, P365, DOI 10.1016/0272-0590(91)90121-J; JONSSON CJ, 1994, TOXICOL LETT, V71, P169, DOI 10.1016/0378-4274(94)90177-5; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND BO, 1988, CHEM-BIOL INTERACT, V65, P25, DOI 10.1016/0009-2797(88)90028-2; LUND BO, 1994, ENVIRON TOXICOL CHEM, V13, P911, DOI 10.1897/1552-8618(1994)13[911:IVABAA]2.0.CO;2; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; SZABO S, 1989, TOXICOL PATHOL, V17, P317, DOI 10.1177/019262338901700208; TALALAY P, 1953, J BIOL CHEM, V205, P823; WONG M, 1989, J BIOL CHEM, V264, P12867; ZUBER MX, 1988, P NATL ACAD SCI USA, V85, P699, DOI 10.1073/pnas.85.3.699	18	41	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 8	1995	270	36					20895	20897		10.1074/jbc.270.36.20895	http://dx.doi.org/10.1074/jbc.270.36.20895			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RU054	7673111	hybrid			2023-01-03	WOS:A1995RU05400007
J	PLATERZYBERK, C; BONNEFOY, JY				PLATERZYBERK, C; BONNEFOY, JY			MARKED AMELIORATION OF ESTABLISHED COLLAGEN-INDUCED ARTHRITIS BY TREATMENT WITH ANTIBODIES TO CD23 IN-VIVO	NATURE MEDICINE			English	Article							NECROSIS-FACTOR-ALPHA; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; SOLUBLE CD23; TNF-ALPHA; IGE; RECEPTOR; MICE; ANTIGEN; LOCALIZATION	CD23 is a low-affinity receptor for immunoglobulin E (IgE) expressed by a variety of haematopoietic cells. Proteolytic cleavage of the transnnembrane receptor generates soluble forms, which can be detected in biological fluids. CD23 regulates many functional aspects of immune cells, both in its cell-associated and soluble forms. In view of the increased levels of CD23 in rheumatoid arthritis, we have studied the effect of neutralizing CD23 in type II collagen-induced arthritis in mice, a model for human rheumatoid arthritis. Successful disease modulation is achieved by treatment of arthritic DBA/1 mice with either polyclonal or monoclonal antibodies to mouse CD23. Treated mice show a dose-related amelioration of arthritis with significantly reduced clinical scores and number of affected paws. This improvement in clinical severity is confirmed by histological examination of the arthritic paws. A marked decrease in cellular infiltration of the synovial sublining layer and limited destruction of cartilage and bone is evident in animals treated with therapeutic doses of anti-CD23 antibody. These findings demonstrate the involvement of CD23 in a mouse model of human rheumatoid arthritis.			PLATERZYBERK, C (corresponding author), GLAXO INST MOLEC BIOL SA, DEPT IMMUNOL, CHEMIN AULX 14, CH-1228 GENEVA, SWITZERLAND.							ARMANT M, 1994, J EXP MED, V180, P1005, DOI 10.1084/jem.180.3.1005; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; BANSAL A, 1992, CLIN EXP IMMUNOL, V89, P452; BANSAL AS, 1993, IMMUNOLOGY, V79, P285; BANSAL AS, 1994, CLIN EXP RHEUMATOL, V12, P281; BONNEFOY JY, 1993, CURR OPIN IMMUNOL, V5, P944, DOI 10.1016/0952-7915(93)90110-E; BRENNAN FM, 1992, BRIT J RHEUMATOL, V31, P293; BRENNAN FM, 1989, LANCET, V2, P244; CHOMARAT P, 1993, ARTHRITIS RHEUM-US, V36, P234, DOI 10.1002/art.1780360215; CHU CQ, 1991, ARTHRITIS RHEUM, V34, P1125, DOI 10.1002/art.1780340908; CONRAD DH, 1990, ANNU REV IMMUNOL, V8, P623, DOI 10.1146/annurev.immunol.8.1.623; DELESPESSE G, 1991, ADV IMMUNOL, V49, P149; ELLIOTT MJ, 1993, ARTHRITIS RHEUM, V36, P1681, DOI 10.1002/art.23362; FELDMANN M, 1991, IMMUNOL REV, V119, P105, DOI 10.1111/j.1600-065X.1991.tb00580.x; FIELD M, 1991, RHEUMATOL INT, V11, P45, DOI 10.1007/BF00291144; FLORESROMO L, 1993, SCIENCE, V261, P1038, DOI 10.1126/science.8351517; HELLEN EA, 1991, J CLIN PATHOL, V44, P293, DOI 10.1136/jcp.44.4.293; HERBELIN A, 1994, EUR J IMMUNOL, V24, P1869, DOI 10.1002/eji.1830240823; LECOANETHENCHOZ S, IN PRESS IMMUNITY; MARCELLETTI JF, 1991, J IMMUNOL, V147, P4185; PIGUET PF, 1992, IMMUNOLOGY, V77, P510; PLATERZYBERK C, 1994, CLIN EXP IMMUNOL, V98, P442; RAO M, 1987, J IMMUNOL, V138, P1845; REZONZEW R, 1994, CLIN IMMUNOL IMMUNOP, V71, P156, DOI 10.1006/clin.1994.1066; STUART JM, 1984, ANNU REV IMMUNOL, V2, P199, DOI 10.1146/annurev.iy.02.040184.001215; TRENTHAM DE, 1982, ARTHRITIS RHEUM, V25, P911, DOI 10.1002/art.1780250801; VANDENBERG WB, 1994, CLIN EXP IMMUNOL, V95, P237; WENDLING D, 1993, J RHEUMATOL, V20, P259; WILLIAMS RO, 1992, P NATL ACAD SCI USA, V89, P9784, DOI 10.1073/pnas.89.20.9784; WOOLEY PH, 1993, ARTHRITIS RHEUM, V36, P1305, DOI 10.1002/art.1780360915; WOOLEY PH, 1993, J IMMUNOL, V151, P6602; WOOLEY PH, 1985, J IMMUNOL, V134, P2366	32	53	58	0	0	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	1078-8956	1546-170X		NAT MED	Nat. Med.	AUG	1995	1	8					781	785		10.1038/nm0895-781	http://dx.doi.org/10.1038/nm0895-781			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RM635	7585180				2023-01-03	WOS:A1995RM63500034
J	SOUMERAI, SB; LIPTON, HL				SOUMERAI, SB; LIPTON, HL			COMPUTER-BASED DRUG-UTILIZATION REVIEW - RISK, BENEFIT, OR BOONDOGGLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STATE; MEDICAID; THERAPY; COST; EXPERIENCE; DIGOXIN; CARE		UNIV CALIF SAN FRANCISCO,SCH PHARM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	SOUMERAI, SB (corresponding author), HARVARD UNIV,SCH MED,BOSTON,MA 02115, USA.				AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS007357] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009611] Funding Source: NIH RePORTER; AHRQ HHS [HSO7357] Funding Source: Medline; NIA NIH HHS [5R01 AG09611] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BLOOM BS, 1985, MED CARE, V23, P872, DOI 10.1097/00005650-198507000-00004; Cook T.D., 1979, QUASIEXPERIMENTATION; CYPRESS BK, 1983, DRUG UTILIZATION GEN, P87; GROVES RE, 1985, AM J HOSP PHARM, V42, P316, DOI 10.1093/ajhp/42.2.316; GRUMBACH K, 1990, HEALTH AFFAIR, V9, P120, DOI 10.1377/hlthaff.9.4.120; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; JAY ED, 1991, MEDICAL THERAPEUTIC; KASSIRER JP, 1994, NEW ENGL J MED, V331, P669, DOI 10.1056/NEJM199409083311009; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1824, DOI 10.1056/NEJM199406233302512; LEE PR, 1989, LANCET, V1, P263; LeGrady D, 1992, Nebr Med J, V77, P3; LEZOTTE DC, 1993, AUG INT SOC STAT VEN; LIPTON HL, 1991, CLIN PHARMACOL THER, V50, P616, DOI 10.1038/clpt.1991.194; LIPTON HL, 1993, MED CARE, V31, P1069, DOI 10.1097/00005650-199312000-00001; LIPTON HL, IN PRESS INT J TECHN; LIPTON HL, 1994, NOV AM PUBL HLTH ASS; MARCUS FI, 1985, J AM COLL CARDIOL, V5, pA82, DOI 10.1016/S0735-1097(85)80466-6; MARONDE RF, 1989, MED CARE, V27, P1159, DOI 10.1097/00005650-198912000-00007; Moore W J, 1994, Med Care Rev, V51, P3, DOI 10.1177/107755879405100102; MUIRHEAD G, 1994, DRUG TOPICS     0905, P76; MUIRHEAD G, 1994, DRUG TOPICS     0905, P80; Muirhead G, 1994, DRUG TOPICS     0905, P67; MUIRHEAD G, 1994, DRUG TOPICS     0905, P73; MULLINEX SC, 1989, 1989 IOW DEP HUM SER; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RODIN SM, 1988, CLIN PHARMACOL THER, V43, P668, DOI 10.1038/clpt.1988.93; RODIN SM, 1988, CLIN PHARMACOKINET, V15, P227, DOI 10.2165/00003088-198815040-00003; RUCKER TD, 1983, SOC MED CONFLICTING, P25; SHADER RI, 1993, NEW ENGL J MED, V328, P1398; SMALLEY WE, 1995, NEW ENGL J MED, V332, P1612, DOI 10.1056/NEJM199506153322406; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; SOUMERAI SB, 1990, HEALTH AFFAIR, V9, P36, DOI 10.1377/hlthaff.9.3.36; SOUMERAI SB, 1989, MILBANK Q, V67, P268, DOI 10.2307/3350142; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P549, DOI 10.1001/jama.263.4.549; Soumerai SB, 1994, PHARMACOEPIDEM DR S, P395; STASON WB, 1977, NEW ENGL J MED, V296, P732, DOI 10.1056/NEJM197703312961307; WALSER BL, 1994, PHARM COST CONTAINME; Wickizer T M, 1990, Med Care Rev, V47, P327, DOI 10.1177/107755879004700303; 1994, GAOAIMD94130 GEN ACC; 1994, ANN INTERN MED, V120, P423; 1992, GREEN SHEET 1992, V41, P3; 1993, AHCPR930550 PUBL; 1990, ANSWERS, V1, P4; 1993, HCFA03341 PUBL; 1992, FED REGISTER, V57, P49397	48	70	70	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1641	1645		10.1056/NEJM199506153322411	http://dx.doi.org/10.1056/NEJM199506153322411			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753146	Green Published, Green Submitted			2023-01-03	WOS:A1995RC19200011
J	MCNICHOLL, BP; LEE, J				MCNICHOLL, BP; LEE, J			PATIENTS WITH MAJOR TRAUMA WHO DO NOT USE EMERGENCY AMBULANCES	BRITISH MEDICAL JOURNAL			English	Article							FIELD TRIAGE				MCNICHOLL, BP (corresponding author), ROYAL VICTORIA HOSP,DEPT ACCID & EMERGENCY,BELFAST BT12 6BA,ANTRIM,NORTH IRELAND.							KNUDSON P, 1988, J TRAUMA, V28, P602, DOI 10.1097/00005373-198805000-00006; MACKENZIE EJ, 1990, J TRAUMA, V30, P681, DOI 10.1097/00005373-199006000-00005; WEST JG, 1986, J TRAUMA, V26, P655	3	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1442	1442		10.1136/bmj.310.6992.1442	http://dx.doi.org/10.1136/bmj.310.6992.1442			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613278	Green Published			2023-01-03	WOS:A1995RC10500019
J	OBERTI, F; RUGET, O; CALES, P; CARONPOITREAU, C; TRINCHET, JC; ABOURACHED, A; AJAVON, Y; BEAUGRAND, M; DUMAS, F; COUZIGOU, P; DROUILLARD, J; BALABAUD, C; GRELET, P; GUEBEL, A; MELANGE, M; PRINGOT, J; VANBEERS, B; HADENGUE, A; VILGRAIN, V; ERLINGER, S; DUVOUX, C; MATHIEU, D; DHUMEAUX, D; ZARSKI, JP; DALSOGLIO, S; MION, F; VALETTE, PJ; PALIARD, P; CLAUDELBONVOISIN, S; EMERY, JC; DESCOS, L; DAGENAIS, M; DUFRESNE, MP; LAPOINTE, R; HUET, PM; BAS, V; REGENT, D; BAZIN, C; BIGARD, MA; HUMEAU, B; BURY, A; LERHUN, M; LERAT, F; GIBAUD, H; RYMER, R; LEBODIC, L; MASLIAH, C; POULIQUEN, B; PERRIN, D; CHASTANG, C; CHAZOUILLERES, O; LORIA, A; POUPON, R; PAUWELS, A; MOSTEFAKARA, N; LEVY, VG; BALLADUR, P; DEUTSCH, JP; TUBIANA, JM; POL, S; BERTHELOT, P; VALLA, D; BOUSQUET, JC; OPOLON, P; BOUVRY, M; LABADIE, H; MARTIN, T; BRONOWICKI, JP; VETTER, D; WENGER, JJ; BUSCAIL, L; FREXINOS, J; JOFFRE, F				OBERTI, F; RUGET, O; CALES, P; CARONPOITREAU, C; TRINCHET, JC; ABOURACHED, A; AJAVON, Y; BEAUGRAND, M; DUMAS, F; COUZIGOU, P; DROUILLARD, J; BALABAUD, C; GRELET, P; GUEBEL, A; MELANGE, M; PRINGOT, J; VANBEERS, B; HADENGUE, A; VILGRAIN, V; ERLINGER, S; DUVOUX, C; MATHIEU, D; DHUMEAUX, D; ZARSKI, JP; DALSOGLIO, S; MION, F; VALETTE, PJ; PALIARD, P; CLAUDELBONVOISIN, S; EMERY, JC; DESCOS, L; DAGENAIS, M; DUFRESNE, MP; LAPOINTE, R; HUET, PM; BAS, V; REGENT, D; BAZIN, C; BIGARD, MA; HUMEAU, B; BURY, A; LERHUN, M; LERAT, F; GIBAUD, H; RYMER, R; LEBODIC, L; MASLIAH, C; POULIQUEN, B; PERRIN, D; CHASTANG, C; CHAZOUILLERES, O; LORIA, A; POUPON, R; PAUWELS, A; MOSTEFAKARA, N; LEVY, VG; BALLADUR, P; DEUTSCH, JP; TUBIANA, JM; POL, S; BERTHELOT, P; VALLA, D; BOUSQUET, JC; OPOLON, P; BOUVRY, M; LABADIE, H; MARTIN, T; BRONOWICKI, JP; VETTER, D; WENGER, JJ; BUSCAIL, L; FREXINOS, J; JOFFRE, F			COMPARISON OF LIPIODOL CHEMOEMBOLIZATION AND CONSERVATIVE TREATMENT FOR UNRESECTABLE HEPATOCELLULAR-CARCINOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							TRANSCATHETER ARTERIAL EMBOLIZATION; PROGNOSTIC FACTORS; ETHIODIZED OIL; MULTIVARIATE-ANALYSIS; NATURAL-HISTORY; GELATIN SPONGE; CISPLATIN; THERAPY; LIVER; EXPERIENCE	Background. Chemoembolization with Lipiodol (iodized oil) is widely used to treat patients with unresectable hepatocellular carcinoma, Severe side effects have been reported, and improved survival has not been clearly demonstrated. Methods. Patients with unresectable hepatocellular carcinoma who did not have severe liver disease and who met additional entry criteria were randomly assigned to receive either Lipiodol chemoembolization (70 mg of cisplatin, 10 ml of Lipiodol, and gelatin-sponge [Gelfoam] particles delivered through the hepatic artery) or conservative management involving treatment of complications and pain, Courses of treatment were to be given every two months for a maximum of four courses, The main end point was survival. Results. The study was stopped in December 1992, after a sequential analysis showed the lack of the expected benefit from chemoembolization. As of October 1, 1994, 39 of the 50 patients assigned to chemoembolization and 40 of the 46 patients assigned to conservative management had died. Twenty-six patients assigned to chemoembolization received all four courses of treatment. There was no significant difference in survival between the two groups, although there was a trend favoring the chemoembolization group (estimated relative risk of death in the control group, 1.4, 95 percent confidence interval, 0.9 to 2.2; P = 0.13). The comparison of survival between the two groups was not substantially changed by adjustments for differences in base-line and prognostic characteristics (adjusted relative risk, 1.3; 95 percent confidence interval, 0.8 to 2.1; P = 0.31). At one year, the estimated survival rates were 62 percent in the chemoembolization group (95 percent confidence interval, 48.6 to 75.4 percent) and 43.5 percent in the conservative-management group (95 percent confidence interval, 29.2 to 57.8 percent). In the chemoembolization group, tumor growth, as assessed by tumor size and serum alpha-fetoprotein concentration, was reduced and the incidence of portal obstruction was lower than in the conservative-management group. Liver failure occurred after 47 courses of treatment in 30 patients assigned to chemoembolization. Conclusions. In a group of patients with unresectable hepatocellular carcinoma but without severe liver disease, Lipiodol chemoembolization reduced tumor growth, often caused acute liver failure, and did not significantly improve survival.	CHU ANGERS,ANGERS,FRANCE; HOP HAUT LEVEQUE,PESSAC,FRANCE; HOP ST ANDRE,BORDEAUX,FRANCE; HOP ST LUC,BRUSSELS,BELGIUM; CLIN UNIV MT GODINNE,BRUSSELS,BELGIUM; HOP BEAUJON,CLICHY,FRANCE; HOP HENRI MONDOR,F-94010 CRETEIL,FRANCE; HOP ALBERT MICHALLON,GRENOBLE,FRANCE; HOP EDOUARD HERRIOT,LYON,FRANCE; CTR HOSP LYON SUD,F-69310 PIERRE BENITE,FRANCE; HOP ST LUC,MONTREAL,PQ H2X 1P1,CANADA; CHU VANDOEUVRE LES NANCY,VANDOEUVRE NANCY,FRANCE; HOP GUILLAUME & RENEE LAENNEC,NANTES,FRANCE; HOP HOTEL DIEU,NANTES,FRANCE; HOP ST LOUIS,PARIS,FRANCE; HOP ST ANTOINE,F-75571 PARIS,FRANCE; HOP NECKER ENFANTS MALAD,PARIS,FRANCE; HOP LA PITIE SALPETRIERE,PARIS,FRANCE; CTR HOSP PONTOISE,PONTOISE,FRANCE; CTR HOSP DELAFONTAINE,ST DENIS,FRANCE; CHU STRASBOURG,F-67000 STRASBOURG,FRANCE; CTR HOSP GEN ST NAZAIRE,ST NAZAIRE,FRANCE; CLIN ORANGERIE,STRASBOURG,FRANCE; CHU TOULOUSE,TOULOUSE,FRANCE	Universite d'Angers; Centre Hospitalier Universitaire d'Angers; CHU Bordeaux; CHU Bordeaux; Universite Catholique Louvain; Universite Catholique Louvain Hospital; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; CHU Grenoble Alpes; CHU Lyon; CHU Lyon; Universite de Montreal; Nantes Universite; CHU de Nantes; Nantes Universite; CHU de Nantes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre Hospitalier Rene Dubos, Pontoise; CHU Strasbourg; UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; CHU de Toulouse	OBERTI, F (corresponding author), HOP JEAN VERDIER,SERV HEPATOGASTROENTEROL,AVE 14 JUILLET,F-93143 BONDY,FRANCE.		Duvoux, Christophe/CAF-3432-2022; Van Beers, Bernard/N-2816-2016	Van Beers, Bernard/0000-0001-6429-1140				AKASHI Y, 1991, HEPATOLOGY, V14, P262, DOI 10.1016/0270-9139(91)91413-U; [Anonymous], 1992, DESIGN ANAL SEQUENTI; AOYAMA K, 1992, CANCER CHEMOTH PHARM, V31, pS55, DOI 10.1007/BF00687106; ATTALI P, 1987, CANCER, V59, P2108, DOI 10.1002/1097-0142(19870615)59:12<2108::AID-CNCR2820591225>3.0.CO;2-3; BISMUTH H, 1992, AM J SURG, V163, P387, DOI 10.1016/0002-9610(92)90039-T; BRUIX J, 1994, HEPATOLOGY, V20, P643, DOI 10.1002/hep.1840200315; CALVET X, 1990, J HEPATOL, V10, P311, DOI 10.1016/0168-8278(90)90138-H; CALVET X, 1990, HEPATOLOGY, V12, P753, DOI 10.1002/hep.1840120422; COLOMBO M, 1993, SEMIN LIVER DIS, V13, P374; COX DR, 1972, J R STAT SOC B, V34, P187; DUSHEIKO GM, 1992, LANCET, V340, P285, DOI 10.1016/0140-6736(92)92367-O; ENSMINGER WD, 1984, CANCER TREAT REP, V68, P101; IMAOKA S, 1989, CANCER CHEMOTH PHARM, V23, pS126, DOI 10.1007/BF00647258; KAN ZX, 1993, RADIOLOGY, V186, P861, DOI 10.1148/radiology.186.3.8381552; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KASUGAI H, 1989, GASTROENTEROLOGY, V97, P965, DOI 10.1016/0016-5085(89)91505-9; KHAN KN, 1991, CANCER RES, V51, P5667; Liver Cancer Study Group of Japan, 1990, Ann Surg, V211, P277; MATSUI O, 1991, RADIOLOGY, V178, P493, DOI 10.1148/radiology.178.2.1846240; MATSUI O, 1994, CANCER CHEMOTH PHARM, V33, pS84, DOI 10.1007/BF00686674; MIYOSHI S, 1988, J HEPATOL, V6, P332, DOI 10.1016/S0168-8278(88)80050-3; NAKAMURA H, 1983, RADIOLOGY, V147, P401, DOI 10.1148/radiology.147.2.6300959; NAKAMURA H, 1989, RADIOLOGY, V170, P783, DOI 10.1148/radiology.170.3.2536946; NAKAMURA H, 1994, CANCER CHEMOTH PHARM, V33, pS89, DOI 10.1007/BF00686675; NAKAO N, 1992, CANCER CHEMOTH PHARM, V31, pS72, DOI 10.1007/BF00687110; OHNISHI K, 1987, HEPATOLOGY, V7, P1285, DOI 10.1002/hep.1840070618; OKUDA K, 1985, CANCER, V56, P918, DOI 10.1002/1097-0142(19850815)56:4<918::AID-CNCR2820560437>3.0.CO;2-E; PELLETIER G, 1990, J HEPATOL, V11, P181, DOI 10.1016/0168-8278(90)90110-D; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RAOUL JL, 1988, RADIOLOGY, V168, P541, DOI 10.1148/radiology.168.2.2839866; SASAKI Y, 1987, CANCER, V60, P1194, DOI 10.1002/1097-0142(19870915)60:6<1194::AID-CNCR2820600607>3.0.CO;2-T; STUART K, 1993, CANCER, V72, P3202, DOI 10.1002/1097-0142(19931201)72:11<3202::AID-CNCR2820721112>3.0.CO;2-4; VENOOK AP, 1990, J CLIN ONCOL, V8, P1108, DOI 10.1200/JCO.1990.8.6.1108; VETTER D, 1991, HEPATOLOGY, V13, P427, DOI 10.1002/hep.1840130308; YAMASHITA Y, 1991, CANCER, V67, P385, DOI 10.1002/1097-0142(19910115)67:2<385::AID-CNCR2820670212>3.0.CO;2-Q; YODONO H, 1989, CANCER CHEMOTH PHARM, V23, pS42, DOI 10.1007/BF00647238; YU YQ, 1993, CANCER, V71, P62, DOI 10.1002/1097-0142(19930101)71:1<62::AID-CNCR2820710111>3.0.CO;2-8	37	684	688	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 11	1995	332	19					1256	1261						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW600	7708069				2023-01-03	WOS:A1995QW60000003
J	MCHUGH, PR				MCHUGH, PR			WITCHES, MULTIPLE PERSONALITIES, AND OTHER PSYCHIATRIC ARTIFACTS	NATURE MEDICINE			English	Editorial Material							SCHIZOPHRENIA	Contemporary psychiatric misdirections derived primarily from standard medical errors of oversimplification, misplaced emphasis, and invention are reviewed. These particular errors, however, were in part prompted and sustained by the sociocultural fads and fashions of the day. The results have been disastrous for everyone - patients, families, the public and psychiatry itself.			MCHUGH, PR (corresponding author), JOHNS HOPKINS MED INST,DEPT PSYCHIAT & BEHAV SCI,600 N WOLFE ST,MEYER 4-113,BALTIMORE,MD 21287, USA.							BARTA PE, 1990, AM J PSYCHIAT, V147, P1457; KENNY MG, 1986, PASSION A BOURNE MUL; MCHUGH PR, 1992, J ROY SOC MED, V85, P483; MCHUGH PR, 1992, AM SCHOLAR, V61, P497; MCHUGH PR, 1983, PERSPECTIVES PSYCHIA, P57; MCKENNA PJ, 1984, BRIT J PSYCHIAT, V145, P579, DOI 10.1192/bjp.145.6.579; Starkey Marion L, 1949, DEVIL MASSACHUSETTS; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; Szasz T.S., 1976, SCHIZOPHRENIA SACRED; TERR LC, 1983, AM J PSYCHIAT, V140, P1543; WERNICKE C, 1906, FUNDAMENTALS PSYCHIA	11	23	24	0	2	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	FEB	1995	1	2					110	114		10.1038/nm0295-110	http://dx.doi.org/10.1038/nm0295-110			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX558	7585001				2023-01-03	WOS:A1995QX55800014
J	MILLER, FG; QUILL, TE; BRODY, H; FLETCHER, JC; GOSTIN, LO; MEIER, DE				MILLER, FG; QUILL, TE; BRODY, H; FLETCHER, JC; GOSTIN, LO; MEIER, DE			REGULATING PHYSICIAN-ASSISTED DEATH	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EUTHANASIA; LIFE; SUICIDE; PATIENT; DOCTOR; AID		GENESEE HOSP,ROCHESTER,NY 14607; MICHIGAN STATE UNIV,E LANSING,MI 48824; GEORGETOWN JOHNS HOPKINS PROGRAM LAW & PUBL HLTH,WASHINGTON,DC 20001; CUNY MT SINAI SCH MED,NEW YORK,NY 10029	Michigan State University; Johns Hopkins University; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	MILLER, FG (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,BOX 348,CHARLOTTESVILLE,VA 22908, USA.		Brody, Howard/GQA-6310-2022					ANNAS GJ, 1990, JAMA-J AM MED ASSOC, V263, P858, DOI 10.1001/jama.263.6.858; BATTIN MP, 1994, LEAST WORST DEATH ES, P130; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CELOCRUZ MT, 1992, AM J LAW MED, V18, P369; EGAN T, 1994, NY TIMES        0307, pA1; Glantz L H, 1987, Law Med Health Care, V15, P231; GOMEZ CF, 1991, REGULATING DEATH; GOSTIN L, 1991, MILBANK Q, V69, P143, DOI 10.2307/3350124; Gostin Lawrence O, 1993, J Law Med Ethics, V21, P94, DOI 10.1111/j.1748-720X.1993.tb01234.x; Margolick David, 1994, N Y Times Web, pB8; McGough P M, 1993, Camb Q Healthc Ethics, V2, P63; MEIER D, 1994, PHYSICIAN ASSISTED D, P5; MILLER FG, 1993, PERSPECT BIOL MED, V36, P159; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; QUILL T. E., 1993, DEATH DIGNITY; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; TENHAVE HA, 1992, EUTHANASIA NORMAL ME, V22, P34; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; 1992, HARVARD LAW REV, V105, P2021	21	103	104	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 14	1994	331	2					119	123		10.1056/NEJM199407143310211	http://dx.doi.org/10.1056/NEJM199407143310211			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NW712	7516037				2023-01-03	WOS:A1994NW71200011
J	MUGA, A; GONZALEZMANAS, JM; LAKEY, JH; PATTUS, F; SUREWICZ, WK				MUGA, A; GONZALEZMANAS, JM; LAKEY, JH; PATTUS, F; SUREWICZ, WK			PH-DEPENDENT STABILITY AND MEMBRANE INTERACTION OF THE PORE-FORMING DOMAIN OF COLICIN-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIAL SCANNING CALORIMETRY; MITOCHONDRIAL PRECURSOR PROTEIN; C-TERMINAL DOMAIN; PHOSPHOLIPID-VESICLES; PSEUDOMONAS EXOTOXIN; INSERTION; TOXIN; TRANSLOCATION; BINDING; DENATURATION	Thermal stability of the pore-forming domain of colicin A was studied by high sensitivity differential scanning calorimetry and circular dichroism spectroscopy. In the pH range between 8 and 5, the thermal denaturation of the protein in solution occurs at 66-69-degrees-C and is characterized by the calorimetric enthalpy of approximately 90 kcal/M. At pH below 5, there is a rapid pH-dependent destabilization of the pore-forming domain resulting in the lowering of the midpoint denaturation temperature and a decrease in the calorimetric enthalpy of denaturation. Circular dichroism spectra in the near and far ultraviolet show that the thermotropic transition is associated with collapse of the native tertiary structure of the pore-forming domain, although a large proportion of the helical secondary structure remains preserved. The present data indicate some similarity also between acid-induced and temperature-induced denaturation of the pore-forming domain of colicin A. Association of the pore-forming domain with phospholipid vesicles of dioleoylphosphatidylglycerol results in total disappearance of the calorimetric transition, even at pH values as high as 7. Since lipid binding also induces collapse of the near ultraviolet circular dichroism spectrum, these data indicate that interaction with the membrane facilitates a conformational change within the pore-forming domain to a looser (denaturated-like) state. These findings are discussed in relation to the recent model (van der Goot, F. G., Gonzalez-Manas, J. M., Lakey, J. H., Pattus, F. (1991) Nature 354, 408-410) which postulates that a flexible ''molten globule'' state is an intermediate on the pathway to membrane insertion of colicin A.	NATL RES COUNCIL CANADA,INST BIOL SCI,OTTAWA K1A 0R6,ONTARIO,CANADA; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	National Research Council Canada; European Molecular Biology Laboratory (EMBL)			Muga, Arturo/N-1174-2014	Muga, Arturo/0000-0003-0345-6882; Lakey, Jeremy/0000-0003-4646-9085				CAVARD D, 1979, EUR J BIOCHEM, V96, P519, DOI 10.1111/j.1432-1033.1979.tb13065.x; DOLGIKH DA, 1981, FEBS LETT, V136, P311, DOI 10.1016/0014-5793(81)80642-4; ENDO T, 1989, FEBS LETT, V249, P173, DOI 10.1016/0014-5793(89)80618-0; ENDO T, 1989, J BIOL CHEM, V264, P2951; FARAHBAKHSH ZT, 1989, BIOCHEMISTRY-US, V28, P580, DOI 10.1021/bi00428a025; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; JIANG JX, 1990, J BIOL CHEM, V265, P8636; KONISKY J, 1982, ANNU REV MICROBIOL, V36, P125, DOI 10.1146/annurev.mi.36.100182.001013; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LAZDUNSKI CJ, 1988, BIOCHIM BIOPHYS ACTA, V947, P445, DOI 10.1016/0304-4157(88)90003-2; LOHNER K, 1991, BIOCHEMISTRY-US, V30, P6620, DOI 10.1021/bi00240a035; MARTINEZ MC, 1983, EMBO J, V2, P1501, DOI 10.1002/j.1460-2075.1983.tb01614.x; MASSOTTE D, 1989, BIOCHEMISTRY-US, V28, P7713, DOI 10.1021/bi00445a029; MENESTRINA G, 1989, BIOPHYS J, V55, P393, DOI 10.1016/S0006-3495(89)82833-4; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P5829, DOI 10.1021/bi00476a026; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; OLSNES S, 1988, TRENDS BIOCHEM SCI, V13, P348, DOI 10.1016/0968-0004(88)90105-3; PAIN R, 1991, NATURE, V354, P353, DOI 10.1038/354353a0; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; PATTUS F, 1990, EXPERIENTIA, V46, P180; PATTUS F, 1983, BIOCHEMISTRY-US, V22, P5698, DOI 10.1021/bi00294a003; RAMSAY G, 1989, BIOCHEMISTRY-US, V28, P529, DOI 10.1021/bi00428a018; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; TUCKER AD, 1986, J MOL BIOL, V190, P133, DOI 10.1016/0022-2836(86)90084-7; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; ZHAO JM, 1988, J BIOL CHEM, V263, P15369	28	68	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1993	268	3					1553	1557						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	KH620	7678407				2023-01-03	WOS:A1993KH62000011
J	CRUICKSHANK, JM				CRUICKSHANK, JM			THE CASES FOR AND AGAINST PRESCRIBING GENERIC DRUGS - DONT TAKE INNOVATIVE RESEARCH BASED PHARMACEUTICAL COMPANIES FOR GRANTED	BRITISH MEDICAL JOURNAL			English	Editorial Material											CRUICKSHANK, JM (corresponding author), ICI PHARMACEUT,MED RES DEPT,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND.							[Anonymous], 1987, Drug Ther Bull, V25, P93	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1988	297	6663					1597	1598		10.1136/bmj.297.6663.1597	http://dx.doi.org/10.1136/bmj.297.6663.1597			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R4933	3147090	Bronze, Green Published			2023-01-03	WOS:A1988R493300029
J	BRENNAN, TA				BRENNAN, TA			ETHICS COMMITTEES AND DECISIONS TO LIMIT CARE - THE EXPERIENCE AT THE MASSACHUSETTS-GENERAL-HOSPITAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	BRENNAN, TA (corresponding author), BRIGHAM & WOMENS HOSP,DIV GEN MED,75 FRANCIS ST,BOSTON,MA 02115, USA.							ANNAS G, 1979, AM J LAW MED, V4, P110; BEAUCHAMP R, 1985, THEORY HIST INFORMED, P11; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BRENNAN T, 1987, HARVARD LAW SCH COUR; Brennan T A, 1986, Law Med Health Care, V14, P13; CALLAHAN D, 1983, HASTINGS CENT REP, V13, P22, DOI 10.2307/3560573; CHARLSON ME, 1986, JAMA-J AM MED ASSOC, V255, P1316, DOI 10.1001/jama.255.10.1316; COHEN C, 1982, CRIT CARE MED, V10, P41; HILFIKER D, 1983, NEW ENGL J MED, V308, P716, DOI 10.1056/NEJM198303243081210; JONAS H, 1978, HASTINGS CENT REP, V8, P31, DOI 10.2307/3560975; JONSEN A, 1985, CLIN MED ETHICS, pCH4; KATZ J, 1985, SILENT WORLD DOCTORS; LEVINE C, 1977, HASTINGS CENT REP, V7, P25, DOI 10.2307/3560689; LO B, 1987, NEW ENGL J MED, V317, P46, DOI 10.1056/NEJM198707023170110; McCormick R A, 1984, Law Med Health Care, V12, P150; MICETICH KC, 1983, ARCH INTERN MED, V143, P975, DOI 10.1001/archinte.143.5.975; MOONEY CA, 1986, U ILLINOIS LAW REV, P1025; PONTOPPIDAN H, 1976, NEW ENGL J MED, V295, P362; RELMAN AS, 1978, NEW ENGL J MED, V298, P508, DOI 10.1056/NEJM197803022980910; SCHUCKING E, 1985, LAW MED HLTH CARE, V13, P22; SIEGLER M, 1986, HASTINGS CENT REP, V16, P22, DOI 10.2307/3563271; VEATCH R, 1977, HASTINGS CENT REP, V7, P20; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; 1983, DECIDING FOREGO LIFE, P440	27	80	80	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1988	260	6					803	807		10.1001/jama.260.6.803	http://dx.doi.org/10.1001/jama.260.6.803			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	P5232	3392811				2023-01-03	WOS:A1988P523200026
J	MULL, JD				MULL, JD			LIGHT IN THE AFTERNOON	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1988	260	3					393	393						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P1392	3379752				2023-01-03	WOS:A1988P139200036
J	SLOAND, EM; PITT, E; KLEIN, HG				SLOAND, EM; PITT, E; KLEIN, HG			SAFETY OF THE BLOOD-SUPPLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-IMMUNODEFICIENCY-VIRUS; HEPATITIS-C VIRUS; T-CELL LEUKEMIA; HTLV-II INFECTION; NON-B HEPATITIS; TRANSFUSION-ASSOCIATED HEPATITIS; POLYMERASE CHAIN-REACTION; INTRAVENOUS-DRUG-USERS; LYMPHOTROPIC VIRUS; TRYPANOSOMA-CRUZI		NIH, WARREN GRANT MAGNUSON CLIN CTR, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA	SLOAND, EM (corresponding author), NHLBI, 31 CTR DR, MSC 2490, BLDG 31, ROOM 4A11, BETHESDA, MD 20892 USA.							AACH RD, 1991, NEW ENGL J MED, V325, P1325, DOI 10.1056/NEJM199111073251901; Aach RD, 1978, VIRAL HEPATITIS, P383; ADLER SP, 1989, TRANSFUSION, V29, P667, DOI 10.1046/j.1537-2995.1989.29890020436.x; ALI AM, 1987, BLOOD S, V70, pA325; ALTER HJ, 1990, NEW ENGL J MED, V323, P1312, DOI 10.1056/NEJM199011083231905; ALTER HJ, 1966, BLOOD-J HEMATOL, V27, P297, DOI 10.1182/blood.V27.3.297.297; ALTER HJ, 1975, LANCET, V2, P838, DOI 10.1016/S0140-6736(75)90234-2; ALTER HJ, 1991, TRANSFUSION, V31, P771, DOI 10.1046/j.1537-2995.1991.31892023507.x; Alter HJ, 1987, TRANSFUSION TRANSMIT, P53; [Anonymous], 1995, JAMA, V274, P1374; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; APPLEMAN MD, 1993, TRANSFUSION, V33, P61, DOI 10.1046/j.1537-2995.1993.33193142312.x; BACKER U, 1988, 4TH P INT C AIDS STO, V2, P364; BARRETT BB, 1993, TRANSFUSION, V33, P228, DOI 10.1046/j.1537-2995.1993.33393174449.x; BLOCH M, 1982, REV I INVEST MED, V11, P148; BOWDEN R, 1990, TRANSFUSION, V30, P762, DOI 10.1046/j.1537-2995.1990.30891020340.x; BOWDEN RA, 1992, BLOOD SAFETY CURRENT, P201; BRAINE HG, 1986, TRANSFUSION, V26, P391, DOI 10.1046/j.1537-2995.1986.26486262752.x; BRECHOT C, 1985, NEW ENGL J MED, V312, P270, DOI 10.1056/NEJM198501313120503; BRYSON YJ, 1995, NEW ENGL J MED, V332, P833, DOI 10.1056/NEJM199503303321301; BUCHHOLZ DH, 1992, TRANSFUSION, V32, P667, DOI 10.1046/j.1537-2995.1992.32792391043.x; BUCHHOLZ DH, 1971, NEW ENGL J MED, V285, P429, DOI 10.1056/NEJM197108192850803; BUSCH M, 1994, SEP FOOD DRUG ADM C; BUSCH MP, 1990, NEW ENGL J MED, V323, P1308, DOI 10.1056/NEJM199011083231904; BUSCH MP, 1991, NEW ENGL J MED, V325, P1, DOI 10.1056/NEJM199107043250101; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; CARVALHO MR, 1993, TRANSFUSION, V33, P830, DOI 10.1046/j.1537-2995.1993.331094054620.x; CUMMING PD, 1989, NEW ENGL J MED, V321, P941, DOI 10.1056/NEJM198910053211405; DESCHRYVER A, 1990, TRANSFUSION, V30, P844; DODD RY, 1992, NEW ENGL J MED, V327, P419, DOI 10.1056/NEJM199208063270610; DODD RY, 1988, INFECT CONT HOSP EP, V9, P357; DOLL LS, 1991, TRANSFUSION, V31, P704, DOI 10.1046/j.1537-2995.1991.31892023494.x; DONAHUE JG, 1992, NEW ENGL J MED, V327, P369, DOI 10.1056/NEJM199208063270601; DONAHUE JG, 1990, NEW ENGL J MED, V323, P1709; DONDERO TJ, 1994, LANCET, V343, P1376, DOI 10.1016/S0140-6736(94)92517-8; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; DONEGAN E, 1990, TRANSFUSION, V30, P851, DOI 10.1046/j.1537-2995.1990.30991048798.x; ESTEBAN JI, 1985, LANCET, V2, P1083; ESTEBAN JI, 1990, NEW ENGL J MED, V323, P1107, DOI 10.1056/NEJM199010183231605; ESTEBAN JI, 1991, ANN INTERN MED, V115, P443, DOI 10.7326/0003-4819-115-6-443; FARCI P, 1991, NEW ENGL J MED, V325, P98, DOI 10.1056/NEJM199107113250205; FARZADEGAN H, 1988, ANN INTERN MED, V108, P785, DOI 10.7326/0003-4819-108-6-785; FEIGAL E, 1991, J INFECT DIS, V164, P36, DOI 10.1093/infdis/164.1.36; GILBERT GL, 1989, LANCET, V1, P1228, DOI 10.1016/S0140-6736(89)92330-1; GOLDMAN M, 1991, Transfusion Medicine Reviews, V5, P73, DOI 10.1016/S0887-7963(91)70194-6; GRANT IH, 1989, ANN INTERN MED, V111, P849, DOI 10.7326/0003-4819-111-10-849; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; HOOFNAGLE JH, 1990, TRANSFUSION, V30, P384, DOI 10.1046/j.1537-2995.1990.30590296367.x; HORSBURGH CR, 1989, LANCET, V2, P637; JACOBSON MA, 1988, ANN INTERN MED, V108, P585, DOI 10.7326/0003-4819-108-4-585; KALYANARAMAN VS, 1982, P NATL ACAD SCI-BIOL, V79, P1653, DOI 10.1073/pnas.79.5.1653; KERNDT PR, 1991, TRANSFUSION, V31, P814, DOI 10.1046/j.1537-2995.1991.31992094668.x; KHABBAZ RF, 1992, NEW ENGL J MED, V326, P375, DOI 10.1056/NEJM199202063260604; KHABBAZ RF, 1993, ANN INTERN MED, V118, P448; KIM DM, 1992, TRANSFUSION, V32, P221, DOI 10.1046/j.1537-2995.1992.32392213804.x; KLEINMAN S, 1991, Transfusion (Bethesda), V31, p41S; KORELITZ JJ, 1994, TRANSFUSION, V34, P870, DOI 10.1046/j.1537-2995.1994.341095026972.x; KOZIOL DE, 1986, ANN INTERN MED, V104, P488, DOI 10.7326/0003-4819-104-4-488; KRECH U, 1973, B WORLD HEALTH ORGAN, V49, P103; LANDER JJ, 1978, VOX SANG, V34, P77, DOI 10.1111/j.1423-0410.1978.tb03726.x; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; LEFRERE JJ, 1990, LANCET, V335, P1400, DOI 10.1016/0140-6736(90)91277-H; LEITMAN SF, 1989, NEW ENGL J MED, V321, P917, DOI 10.1056/NEJM198910053211401; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; LOIACONO BR, 1989, TRANSFUSION, V29, P823, DOI 10.1046/j.1537-2995.1989.29990070189.x; MACKINNON S, 1988, J CLIN PATHOL, V41, P948, DOI 10.1136/jcp.41.9.948; MANEZ R, 1993, TRANSFUSION, V33, P594, DOI 10.1046/j.1537-2995.1993.33793325057.x; MANNS A, 1992, INT J CANCER, V51, P886, DOI 10.1002/ijc.2910510609; MAURICE J, 1987, TROPICAL DISEASE RES, P89; MORDUCHOWICZ G, 1991, REV INFECT DIS, V13, P307; MORROW JF, 1991, JAMA-J AM MED ASSOC, V266, P555; MURPHY EL, 1993, LANCET, V341, P757, DOI 10.1016/0140-6736(93)90529-P; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; NELSON KE, 1992, ANN INTERN MED, V117, P554, DOI 10.7326/0003-4819-117-7-554; NICKERSON P, 1989, ANN INTERN MED, V111, P851, DOI 10.7326/0003-4819-111-10-851; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; PETERSEN LR, 1991, TRANSFUSION, V31, P698, DOI 10.1046/j.1537-2995.1991.31892023493.x; PETERSEN LR, 1994, TRANSFUSION, V34, P865, DOI 10.1046/j.1537-2995.1994.341095026971.x; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; PINDYCK J, 1985, TRANSFUSION, V25, P3, DOI 10.1046/j.1537-2995.1985.25185116497.x; ROBERTGUROFF M, 1982, SCIENCE, V215, P975, DOI 10.1126/science.6760397; ROY MJ, 1993, JAMA-J AM MED ASSOC, V269, P2876, DOI 10.1001/jama.269.22.2876; SARIN PS, 1989, P NATL ACAD SCI USA, V86, P2021, DOI 10.1073/pnas.86.6.2021; SAYERS MH, 1992, ANN INTERN MED, V116, P55, DOI 10.7326/0003-4819-116-1-55; SCHMIDT PJ, 1994, ARCH PATHOL LAB MED, V118, P454; SCHMUNIS GA, 1991, TRANSFUSION, V31, P547, DOI 10.1046/j.1537-2995.1991.31691306255.x; SCHOECHETMAN G, 1994, SEP FOOD DRUG ADM C; Selbie FR, 1943, BRIT J EXP PATHOL, V24, P150; SELIK RM, 1993, TRANSFUSION, V33, P890, DOI 10.1046/j.1537-2995.1993.331194082377.x; SHIH LN, 1990, J MED VIROL, V32, P257, DOI 10.1002/jmv.1890320412; SILVER H, 1970, Transfusion (Bethesda), V10, P315; SIMONS JN, 1995, P NATL ACAD SCI USA, V92, P3401, DOI 10.1073/pnas.92.8.3401; STARKEY JM, 1989, JAMA-J AM MED ASSOC, V262, P3452, DOI 10.1001/jama.262.24.3452; STEVENS CE, 1984, ANN INTERN MED, V101, P733, DOI 10.7326/0003-4819-101-6-733; SULLIVAN MT, 1991, ARCH INTERN MED, V151, P2043, DOI 10.1001/archinte.151.10.2043; TAYLOR PE, 1990, TRANSFUSION, V30, P783, DOI 10.1046/j.1537-2995.1990.30991048782.x; THIERS V, 1988, LANCET, V2, P1273; THOMPSON KS, 1992, TRANSFUSION, V32, pS65; TIPPLE MA, 1990, TRANSFUSION, V30, P207, DOI 10.1046/j.1537-2995.1990.30390194338.x; VISCIDI RP, 1991, J ACQ IMMUN DEF SYND, V4, P1190; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; WIKTOR SZ, 1991, LANCET, V338, P512, DOI 10.1016/0140-6736(91)90585-D; WRENN HE, 1974, TRANSFUSION, V14, P171, DOI 10.1111/j.1537-2995.1974.tb04512.x; ZIERDT CH, 1983, J CLIN MICROBIOL, V17, P628, DOI 10.1128/JCM.17.4.628-630.1983; 1993, ATTITUDES US ADULTS; 1991, MMWR-MORBID MORTAL W, V40, P176; 1991, TRANSFUSION S8S, V31, pS41	107	69	73	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 1	1995	274	17					1368	1373		10.1001/jama.274.17.1368	http://dx.doi.org/10.1001/jama.274.17.1368			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB278	7563562				2023-01-03	WOS:A1995TB27800028
J	NIGHTINGALE, SL				NIGHTINGALE, SL			CIDOFOVIR AVAILABLE UNDER TREATMENT IND FOR CMV RETINITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.								0	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2023-01-03	WOS:A1995RY05600008
J	BURNETTE, TC; HARRINGTON, JA; REARDON, JE; MERRILL, BM; DEMIRANDA, P				BURNETTE, TC; HARRINGTON, JA; REARDON, JE; MERRILL, BM; DEMIRANDA, P			PURIFICATION AND CHARACTERIZATION OF A RAT-LIVER ENZYME THAT HYDROLYZES VALACICLOVIR, THE L-VALYL ESTER PRODRUG OF ACYCLOVIR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE AMINOPEPTIDASE; PROTEINS; MITOCHONDRIA; CELLS	Valaciclovir is an oral prodrug of the antiherpetic agent acyclovir, An enzyme that hydrolyzes valaciclovir to acyclovir, valaciclovir hydrolase (VACVase), was purified from rat liver and characterized, VACVase was a basic (pI 9.4) protein associated with mitochondria, It was monomeric and had a molecular mass of 29 kDa, Amino acid sequences of six VACVase peptides, including its NH2 terminus (13 amino acids) and accounting for approximately 20% of its complete sequence, were not found in the SwissProt protein data base, VACVase hydrolyzed other amino acid esters of acyclovir in addition to valaciclovir (k(cat)/K-m = 58 mM(-1) s(-1)), with a preference for the L-alanyl (k(cat)/K-m = 226 mM(-1) S-1) and L-methionyl (k(cat)/K-m = 200 mM(-1) S-1) esters. It did not hydrolyze other types of esters or numerous di- and tripeptides and aminoacyl-beta-naphthylamides. Hydrolysis of valaciclovir by VACVase was not inhibited by amastatin, antipain, aprotinin, bestatin, chymostatin, E-64, EDTA, ebelactone A, ebelactone B, elastatinal, leupeptin, pepstatin, or phosphoramidon. It was neither inhibited nor activated by Ca2+, Co2+, Mg2+, Mn2+, or Zn2+. Therefore, this enzyme is not a typical esterase or peptidase and, to our knowledge, it has not been described previously. Its physiological function is not known; however, it may play a significant role in the biotransformation of valaciclovir to acyclovir.	BURROUGHS WELLCOME CO, DIV ORGAN CHEM, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund	BURNETTE, TC (corresponding author), BURROUGHS WELLCOME CO, DIV EXPTL THERAPY, RES TRIANGLE PK, NC 27709 USA.							Adibi S. A., 1981, PHYSL GASTROINTESTIN, V2, P1073; Beauchamp Lilia M., 1993, Drugs of the Future, V18, P619; BEAUCHAMP LM, 1992, ANTIVIR CHEM CHEMOTH, V3, P157, DOI 10.1177/095632029200300305; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burnette T. C., 1993, Antiviral Research, V20, P115; BURNETTE TC, 1994, DRUG METAB DISPOS, V22, P60; CROOKS RJ, 1994, ANTIVIR CHEM CHEMOTH, V5, P31; DEMIRANDA P, 1994, DRUG METAB DISPOS, V22, P55; DEMIRANDA P, 1994, 34TH INT C ANT AG CH; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Fleischer S, 1974, Methods Enzymol, V31, P6; FREITAS JO, 1981, INT J BIOCHEM, V13, P991, DOI 10.1016/0020-711X(81)90004-5; FRICK L, 1984, COMP BIOCHEM PHYS B, V77, P533, DOI 10.1016/0305-0491(84)90271-2; GROSS M, 1992, J BIOL CHEM, V267, P2080; JACOBSON MA, 1994, ANTIMICROB AGENTS CH, V38, P1534, DOI 10.1128/AAC.38.7.1534; KENDALL RL, 1992, J BIOL CHEM, V267, P20667; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADDEN EA, 1987, ANAL BIOCHEM, V163, P350, DOI 10.1016/0003-2697(87)90235-1; MEADOWS KC, 1990, PHARMACEUT RES, V7, P299, DOI 10.1023/A:1015890516119; MIRCHEFF AK, 1976, J MEMBRANE BIOL, V28, P309, DOI 10.1007/BF01869703; MOZDZANOWSKI J, 1990, CURRENT RES PROTEIN, P87; SMITH C, 1993, 33RD INT C ANT AG CH; STONE KL, 1989, TECHNIQUES PROTEIN C, P377; TERMIGNONI C, 1991, MOL CELL BIOCHEM, V102, P101; VISSER L, 1972, BIOCHIM BIOPHYS ACTA, V268, P257, DOI 10.1016/0005-2744(72)90223-9; WELLER S, 1993, CLIN PHARMACOL THER, V54, P595, DOI 10.1038/clpt.1993.196; WIEDHAUP K, 1981, TOP PHARM SCI, P307	28	36	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 30	1995	270	26					15827	15831		10.1074/jbc.270.26.15827	http://dx.doi.org/10.1074/jbc.270.26.15827			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RG538	7797586	hybrid			2023-01-03	WOS:A1995RG53800059
J	KANE, RL				KANE, RL			IMPROVING THE QUALITY OF LONG-TERM-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NURSING-HOME PATIENTS; OUTCOMES; IMPACT	Quality of long-term care can be improved by changing the strategies used to monitor it. Nursing home care has been the subject of intensive regulations, while it has been neglected by physicians. Newer forms of long-term care are coming under stricter oversight, which may stifle the innovations they offer. Greater but different attention is needed: more creativity can be fostered with better accountability by emphasizing long-term care outcomes. It is unrealistic to require that long-term care patients will improve; good outcomes are defined as doing as well as or better than expected. The Minimum Data Set for nursing homes offers a mechanism to generate data on many pertinent outcomes. An outcomes focus would encourage more collective action by the various parties involved in providing long-term care, including physicians. Clinicians are reluctant to assume responsibility for outcomes they feel unable to strongly influence, but they must recognize that part of their role is to engender cooperation from the myriad participants in long-term care, including patients and their families. Better-quality long-term care may cost more, but it may be possible to use less expensive personnel more creatively if current regulations are modified. Managed care arrangements offer one vehicle for reorganizing care and could provide the appropriate incentives to make positive changes. However, they could also lead to minimalist strategies. Accountability for realistic outcomes can provide the needed countervailing regulatory pressure.			KANE, RL (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,MINNESOTA CHAIR LONG TERM CARE & AGING,420 DELAWARE ST SE,BOX 197,MINNEAPOLIS,MN 55455, USA.				NATIONAL INSTITUTE ON AGING [K07AG000622] Funding Source: NIH RePORTER; NIA NIH HHS [5K07-AG00622] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		DONABEDIAN A, 1988, JAMA-J AM MED ASSOC, V260, P1743, DOI 10.1001/jama.260.12.1743; ELSTEIN AS, 1972, J MED EDUC, V47, P85; FOX PD, 1991, INITIATIVES SERVICE; FRIEDMAN B, 1993, J AM GERIATR SOC, V41, P1144, DOI 10.1111/j.1532-5415.1993.tb06465.x; GARRARD J, 1990, MED CARE, V28, P271, DOI 10.1097/00005650-199003000-00007; HARTMAIER SL, 1995, J GERONTOL A-BIOL, V50, pM128, DOI 10.1093/gerona/50A.2.M128; Institute of Medicine report, 1986, IMPROVING QUALITY CA; Kane R.A., 1981, ASSESSING ELDERLY; Kane R L, 1976, J Community Health, V2, P1, DOI 10.1007/BF01349487; Kane R L, 1976, J Community Health, V1, P233, DOI 10.1007/BF01324582; KANE RA, 1994, HEALTH CARE FINANC R, V16, P69; KANE RA, 1988, INQUIRY-J HEALTH CAR, V25, P132; Kane RA, 1993, ASSISTED LIVING US N; KANE RA, IN PRESS MILBANK Q; KANE RA, 1995, DELEGATION NURSING A; KANE RA, 1990, EVERYDAY ETHICS SOLV; KANE RL, 1983, GERONTOLOGIST, V23, P200, DOI 10.1093/geront/23.2.200; KANE RL, 1983, J GERONTOL, V38, P385, DOI 10.1093/geronj/38.4.385; KANE RL, 1989, AM J PUBLIC HEALTH, V79, P1271, DOI 10.2105/AJPH.79.9.1271; KANE RL, 1991, J AM GERIATR SOC, V39, P359, DOI 10.1111/j.1532-5415.1991.tb02900.x; KANE RL, 1993, ANNU REV PUBL HEALTH, V14, P545, DOI 10.1146/annurev.pu.14.050193.002553; KUROWSKI BD, 1982, HE222C182 US DEP HLT; MALONE JK, 1993, J HLTH CARE BENE JAN, P51; MANGEN DJ, 1984, HLTH PROGRAM EVALUAT; MANTON KG, 1988, J GERONTOL, V43, pS153, DOI 10.1093/geronj/43.5.S153; MENDELSON MA, 1974, TENDER LOVING GREED; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; MORRIS JN, 1994, J GERONTOL, V49, pM174, DOI 10.1093/geronj/49.4.M174; MORRIS R, 1974, GERONTOLOGIST, V14, P14, DOI 10.1093/geront/14.1.14; MORRIS R, 1980, AM J PUBLIC HEALTH, V70, P471, DOI 10.2105/AJPH.70.5.471; ROGERS A, 1989, PUBLIC HEALTH REP, V104, P222; RUTSTEIN DD, 1976, NEW ENGL J MED, V294, P582, DOI 10.1056/NEJM197603112941104; SCHNEIDER EL, 1990, JAMA-J AM MED ASSOC, V263, P2335, DOI 10.1001/jama.263.17.2335; SHAUGHNESSY PW, 1994, HEALTH CARE FINANC R, V16, P35; SIU AL, 1993, J CLIN EPIDEMIOL, V46, P1093, DOI 10.1016/0895-4356(93)90108-D; TERESI JA, 1992, GERONTOLOGIST, V32, P148, DOI 10.1093/geront/32.2.148; Vladeck B.C., 1980, UNLOVING CARE NURSIN; WEISSERT WG, 1989, HLTH CARE ELDERLY IN; 1990, MEDICARE STRATEGY QU; 1993, MEDICARE AM HLTH CAR	40	68	69	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 3	1995	273	17					1376	1380		10.1001/jama.273.17.1376	http://dx.doi.org/10.1001/jama.273.17.1376			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QV307	7715064				2023-01-03	WOS:A1995QV30700024
J	TERRIET, G; KESSELS, AGH; KNIPSCHILD, P				TERRIET, G; KESSELS, AGH; KNIPSCHILD, P			RANDOMIZED CLINICAL-TRIAL OF ULTRASOUND TREATMENT FOR PRESSURE ULCERS	BMJ-BRITISH MEDICAL JOURNAL			English	Article											TERRIET, G (corresponding author), UNIV LIMBURG, DEPT EPIDEMIOL, POB 616, 6200 MD MAASTRICHT, NETHERLANDS.		Riet, Gerben ter/A-6943-2011	Riet, Gerben ter/0000-0002-2231-7637				BERG W, 1990, LANCET, V335, P1445, DOI 10.1016/0140-6736(90)91459-N; McDiarmid T, 1985, PHYSIOTHERAPY, V71, P66; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P307; TERRIET G, 1992, CLIN EXP DERMATOL, V17, P328, DOI 10.1111/j.1365-2230.1992.tb00222.x; TERRIET G, 1994, THESIS U LIMBURG MAA, P77	5	18	19	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 22	1995	310	6986					1040	1041		10.1136/bmj.310.6986.1040	http://dx.doi.org/10.1136/bmj.310.6986.1040			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728058	Green Published			2023-01-03	WOS:A1995QV31300017
J	[Anonymous]				[Anonymous]			DYING FOR PALLIATIVE CARE	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1696	1699						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7529608				2023-01-03	WOS:A1994PY71700021
J	BAKKER, AJ; KOELEMAY, MJW; GORGELS, JPMC; VANVLIES, B; SMITS, R; TIJSSEN, JGP; HAAGEN, FDM				BAKKER, AJ; KOELEMAY, MJW; GORGELS, JPMC; VANVLIES, B; SMITS, R; TIJSSEN, JGP; HAAGEN, FDM			FAILURE OF NEW BIOCHEMICAL MARKERS TO EXCLUDE ACUTE MYOCARDIAL-INFARCTION AT ADMISSION	LANCET			English	Article							CREATINE-KINASE TYPE-2; CARDIAC TROPONIN-T; EARLY DIAGNOSIS; MASS CONCENTRATION; ISOENZYME-MB; CK-MB; MYOGLOBIN; SERUM; IMMUNOASSAY	In a substantial proportion of patients with suspected myocardial infarction, biochemical markers are needed for clinical decision-making at the time of admission, because electrocardiographic (ECG) recordings are inconclusive. We have assessed the usefulness for exclusion of myocardial infarction at admission of the newer markers creatine kinase MB (CK-MB) mass concentration, troponin T, and myoglobin in comparison with the routinely used markers creatine kinase (CK) and CK-MB activity. 290 consecutive patients were enrolled. Acute myocardial infarction was diagnosed on the basis of clinical history, ECG criteria, and time-dependent changes in CK and CK-MB activity. 153 patients had definite acute myocardial infarction. Troponin T had the highest sensitivity for prediction of acute myocardial infarction; high concentrations (above the upper reference limits) were found in 98 (64%) of the patients with infarctions compared with 92 (60%) for CK-MB mass concentration, 76 (50%) for myoglobin, 61 (40%) for CK activity, and 53 (35%) for CK-MB activity. However, troponin T also had the highest ''false-positive'' rate; of 137 patients without myocardial infarction, 36 (26%) had high troponin T concentrations. Sensitivity, specificity, and positive and negative predictive values were calculated in relation to time between onset of chest pain and hospital admission. Although CK-MB mass concentration was, by a small margin, the best marker in patients admitted within 8-10 h of onset of chest pain, all the markers had negative predictive values too low to allow exclusion of acute myocardial infarction at admission in patients with symptoms suggestive of myocardial infarction of less than 10 h duration.	MED CENTRUM LEEUWARDEN,DEPT CARDIOL,LEEUWARDEN,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN CHEM,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CARDIOL,1105 AZ AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,1105 AZ AMSTERDAM,NETHERLANDS	Medical Center Leeuwarden; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	BAKKER, AJ (corresponding author), KLIN CHEM LAB,DEPT CLIN CHEM,POB 850,8901 BR LEEUWARDEN,NETHERLANDS.							BACHEM MG, 1983, DEUT MED WOCHENSCHR, V108, P1190, DOI 10.1055/s-2008-1069720; BAKKER AJ, 1993, CLIN CHEM, V39, P653; BAKKER AJ, IN PRESS EUR J CLIN; BAR FW, 1987, AM J CARDIOL, V59, P6, DOI 10.1016/S0002-9149(87)80060-7; BRANDT DR, 1990, CLIN CHEM, V36, P375; CAIRNS JA, 1983, CLIN CHEM, V29, P469; COLLINSON PO, 1992, ANN CLIN BIOCHEM, V29, P43, DOI 10.1177/000456329202900105; DELANGHE JR, 1990, CLIN CHEM, V36, P149; GERHARDT W, 1991, CLIN CHEM, V37, P1405; GRIFFITHS PD, 1986, ANN CLIN BIOCHEM, V23, P238, DOI 10.1177/000456328602300303; HORDER M, 1991, EUR J CLIN CHEM CLIN, V29, P435; KAGEN LJ, 1978, CRC CR REV CL LAB SC, V9, P273, DOI 10.3109/10408367809150922; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1989, J MOL CELL CARDIOL, V21, P1349, DOI 10.1016/0022-2828(89)90680-9; KATUS HA, 1992, CLIN CHEM, V38, P386; LEE TH, 1987, ARCH INTERN MED, V147, P115, DOI 10.1001/archinte.147.1.115; MAIR J, 1991, AM J CARDIOL, V68, P1545, DOI 10.1016/0002-9149(91)90307-7; MCCOMB JM, 1985, ANN CLIN BIOCHEM, V22, P152, DOI 10.1177/000456328502200208; Moss D. W., 1986, TXB CLIN CHEM, P619; OHMAN EM, 1990, BRIT HEART J, V63, P335; ROGALSKY VY, 1985, CLIN BIOCHEM, V18, P338, DOI 10.1016/S0009-9120(85)80071-0; ROXIN LE, 1984, ACTA MED SCAND, V215, P417; RUDE RE, 1983, AM J CARDIOL, V52, P936, DOI 10.1016/0002-9149(83)90508-8; STEIN W, 1985, CLIN CHEM, V31, P1952	24	111	113	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1220	1222		10.1016/0140-6736(93)92192-V	http://dx.doi.org/10.1016/0140-6736(93)92192-V			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901536				2023-01-03	WOS:A1993MG27400016
J	THORPE, G				THORPE, G			FORTNIGHTLY REVIEW - ENABLING MORE DYING PEOPLE TO REMAIN AT HOME	BRITISH MEDICAL JOURNAL			English	Article							TERMINAL CARE; DEATH	When it comes to dying there is no place like home. Since earliest times most cultures have accepted that dying people should remain at home. But this was never possible for all. Some were destined to die in accidents, on battlefields, by execution, and from catastrophic illness, maybe many miles away. Nevertheless, with few exceptions people could expect to die in their own beds and in the bosom of their families. In Europe from the Middle Ages until a century ago there was a simplicity about dying. Aware that the end was approaching, people would take to their sickbeds and preside over the ritual. The family, including children, friends, and neighbours would congregate. The ceremony was public and doctors often complained about overcrowding. Death was not regarded as a frightening event and was accepted as an inevitable and integral part of life. Dramatic changes in attitudes to death have taken place since the mid-nineteenth century. The natural acceptance of a biological reality has been lost and people are now unable to come to terms with their own mortality. One consequence is that death has become institutionalised.1 This paper seeks to answer five questions. These refer to where people die, where they would choose to die, where they spend their last year of life, the reasons for admission for terminal care, and whether more dying people could remain at home. Discussion is restricted to adults in the United Kingdom. References are mostly from the past decade.			THORPE, G (corresponding author), MOORGREEN HOSP,COUNTESS MOUNTBATTEN HOUSE,WEST END,SOUTHAMPTON SO3 3JB,ENGLAND.							ADDINGTON-HALL J M, 1991, Palliative Medicine, V5, P207, DOI 10.1177/026921639100500305; ARIES P, 1976, WESTERN ATTITUDES DE; Beck-Friis Barbro, 1993, Palliative Medicine, V7, P93, DOI 10.1177/026921639300700202; CARTWRIGHT A, 1991, BRIT J GEN PRACT, V41, P271; CARTWRIGHT A, 1991, J PUBLIC HEALTH MED, V13, P81; CARTWRIGHT A, 1973, LIFE DEATH; DOYLE D, 1980, PRACTITIONER, V224, P575; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; FIELD D, 1993, FUTURE PALLIATIVE CA, P6; HAINES A, 1986, BRIT MED J, V292, P1051, DOI 10.1136/bmj.292.6527.1051; HERD EB, 1990, BRIT J GEN PRACT, V40, P248; JOHNSON IS, 1990, BRIT MED J, V300, P791, DOI 10.1136/bmj.300.6727.791; JONES R, 1992, EUR J CANCER CARE, V1, P9; JONES RVH, 1993, BRIT MED J, V306, P249, DOI 10.1136/bmj.306.6872.249; Levy B, 1976, J R Coll Gen Pract, V26, P303; PARKES CM, 1980, POSTGRAD MED J, V56, P685, DOI 10.1136/pgmj.56.660.685; Smith Anthony M., 1992, Palliative Medicine, V6, P277, DOI 10.1177/026921639200600403; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; WILKES E, 1984, LANCET, V1, P950; 1993, MAKING LONDON BETTER; 1992, JOINT REPORT PRINCIP; 1992, HLTH NATION SUMMARY; 1993, CHANGING CHILDBIRTH; 1993, OXFORD TXB PALLIATIV; 1989, CARING PEOPLE COMMUN; 1992, PATIENTS CHARTER	26	91	92	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1993	307	6909					915	918		10.1136/bmj.307.6909.915	http://dx.doi.org/10.1136/bmj.307.6909.915			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MB847	7694718	Green Published, Bronze			2023-01-03	WOS:A1993MB84700023
J	QUILL, TE				QUILL, TE			THE AMBIGUITY OF CLINICAL INTENTIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											QUILL, TE (corresponding author), UNIV ROCHESTER, SCH MED & DENT, ROCHESTER, NY 14607 USA.							ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BRODY H, 1993, J CLIN ETHIC, V4, P112; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; VANDERMAAS PJ, 1992, HLTH POLICY MONOGRAP, V2; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; 1992, JAMA-J AM MED ASSOC, V267, P2229	9	137	138	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	SEP 30	1993	329	14					1039	1040		10.1056/NEJM199309303291414	http://dx.doi.org/10.1056/NEJM199309303291414			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LY587	7690111				2023-01-03	WOS:A1993LY58700014
J	GRANT, WE; HOPPER, C; MACROBERT, AJ; SPEIGHT, PM; BOWN, SG				GRANT, WE; HOPPER, C; MACROBERT, AJ; SPEIGHT, PM; BOWN, SG			PHOTODYNAMIC THERAPY OF ORAL-CANCER - PHOTOSENSITIZATION WITH SYSTEMIC AMINOLEVULINIC ACID	LANCET			English	Note								Photodynamic therapy with intravenous photosensitising drugs has been shown to be effective in the ablation of superficial cancers, but long-lasting photosensitivity is a serious disadvantage. Similar photosensitivity is a feature of certain types of porphyria. We present the first report of tumour necrosis brought about by photodynamic activation of a temporary endogenous porphyrin accumulation, after an oral dose of the haem precursor, 5-aminolaevulinic acid. In 4 patients, quantitative fluorescence microscopy showed that accumulation of the photoactive intermediate protoporphyrin IX peaked after 4-6 h in 4 oral cavity squamous cell carcinomas, returning to background in 24 h. Irradiation with non-thermal red laser light caused tumour necrosis in 3 patients.	UNIV LONDON UNIV COLL, SCH MED, DEPT SURG, DIV MAXILLOFACIAL SURG, LONDON WC1E 6JJ, ENGLAND; UCL EASTMAN DENT HOSP, INST DENT SURG, DEPT ORAL PATHOL, LONDON WC1, ENGLAND	University of London; University College London; UCL Medical School; University College London Hospitals NHS Foundation Trust	GRANT, WE (corresponding author), UNIV LONDON UNIV COLL, SCH MED, DEPT SURG, NATL MED LASER CTR, LONDON WC1E 6JJ, ENGLAND.		Bown, Stephen G/C-5713-2009; Bown, Stephen/AAX-6573-2020					BARR H, 1987, BRIT J CANCER, V56, P111, DOI 10.1038/bjc.1987.166; BEDWELL J, 1992, BRIT J CANCER, V65, P818, DOI 10.1038/bjc.1992.175; DIVARIS DXG, 1990, AM J PATHOL, V136, P891; DOUGHERTY TJ, 1990, LASER SURG MED, V10, P485, DOI 10.1002/lsm.1900100514; DOUGHERTY TJ, 1966, ACTA MED SCAND, V179, P11; KENNEDY JC, 1992, J PHOTOCH PHOTOBIO B, V14, P275, DOI 10.1016/1011-1344(92)85108-7; LOH CS, 1993, BRIT J CANCER, V68, P41, DOI 10.1038/bjc.1993.284; LOH CS, 1992, BRIT J CANCER, V66, P452, DOI 10.1038/bjc.1992.295; MALIK Z, 1987, BRIT J CANCER, V56, P589, DOI 10.1038/bjc.1987.246; MEYER M, 1991, BRIT J CANCER, V64, P1093, DOI 10.1038/bjc.1991.470	10	228	235	1	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 17	1993	342	8864					147	148		10.1016/0140-6736(93)91347-O	http://dx.doi.org/10.1016/0140-6736(93)91347-O			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN042	7687318				2023-01-03	WOS:A1993LN04200013
J	PLATT, OS				PLATT, OS			IS THERE TREATMENT FOR SICKLE-CELL ANEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											PLATT, OS (corresponding author), CHILDRENS HOSP MED CTR,BOSTON,MA 02115, USA.							ALKHATTI A, 1987, NEW ENGL J MED, V317, P415, DOI 10.1056/NEJM198708133170704; CHARACHE S, 1987, BLOOD, V69, P109; CHARACHE S, 1985, NIH852117 PUBL; FORT AT, 1971, AM J OBSTET GYNECOL, V111, P324, DOI 10.1016/0002-9378(71)90772-1; GASTON MH, 1986, NEW ENGL J MED, V314, P1593, DOI 10.1056/NEJM198606193142501; KOSHY M, 1988, NEW ENGL J MED, V319, P1447, DOI 10.1056/NEJM198812013192204; LEY TJ, 1982, NEW ENGL J MED, V307, P1469, DOI 10.1056/NEJM198212093072401; LOCKARD CC, 1980, BLOOD PURE ELOQUENT, P319	8	9	10	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1988	319	22					1479	1480		10.1056/NEJM198812013192210	http://dx.doi.org/10.1056/NEJM198812013192210			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R1007	3054557				2023-01-03	WOS:A1988R100700010
J	FIELD, DR; GATES, EA; CREASY, RK; JONSEN, AR; LAROS, RK				FIELD, DR; GATES, EA; CREASY, RK; JONSEN, AR; LAROS, RK			MATERNAL BRAIN-DEATH DURING PREGNANCY - MEDICAL AND ETHICAL ISSUES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV CALIF SAN FRANCISCO, DEPT OBSTET GYNECOL & REPROD SCI, M-1485, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DIV ETH MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANNAS GJ, 1987, NEW ENGL J MED, V316, P1213, DOI 10.1056/NEJM198705073161909; [Anonymous], 1968, JAMA, V205, P337; ARTHUR RK, 1978, AM J OBSTET GYNECOL, V132, P175, DOI 10.1016/0002-9378(78)90921-3; BAEDER AJ, 1981, PRINCIPLES PRACTICE, V2, P1803; BARRETT JM, 1981, AM J OBSTET GYNECOL, V141, P153, DOI 10.1016/S0002-9378(16)32583-2; BERNAT JL, 1981, ANN INTERN MED, V94, P389, DOI 10.1001/archinte.94.3.389; BLACK PM, 1978, NEW ENGL J MED, V299, P338, DOI 10.1056/NEJM197808172990705; BLACK PM, 1978, NEW ENGL J MED, V299, P393, DOI 10.1056/NEJM197808242990805; COOPER DKC, 1982, S AFR MED J, V62, P933; COUSTAN DR, 1976, CONTEMPORARY OB GYN, V7, P27; COX KL, 1981, JPEN-PARENTER ENTER, V5, P246, DOI 10.1177/0148607181005003246; DEPACE NL, 1982, JAMA-J AM MED ASSOC, V248, P971, DOI 10.1001/jama.248.8.971; DILLON WP, 1982, JAMA-J AM MED ASSOC, V248, P1089, DOI 10.1001/jama.248.9.1089; DILLON WP, 1981, OBSTET GYNECOL, V58, P685; DOLLERY CT, 1975, BRIT J CLIN PHARMACO, V2, pP182; DRORY Y, 1975, CHEST, V67, P425, DOI 10.1378/chest.67.4.425; EDWARDS MJ, 1977, HDB TERATOLOGY, V1, P421; FLETCHER JC, 1985, SEMIN PERINATOL, V9, P130; FLETCHER JC, 1984, UNBORN PATIENT, P159; GALLAGHER TJ, 1978, CRIT CARE MED, V6, P323, DOI 10.1097/00003246-197809000-00005; GLUCKMAN PD, 1983, J PHYSIOL-LONDON, V343, P495, DOI 10.1113/jphysiol.1983.sp014905; GOLDBERG LI, 1974, NEW ENGL J MED, V291, P707, DOI 10.1056/NEJM197410032911405; GREISS FC, 1973, OBSTET GYNECOL, V2, P55; GRIEPP RB, 1971, SURG GYNECOL OBSTETR, V133, P792; HELLER L, 1968, SCAND J GASTROENTE S, V4, P4; HEW LR, 1980, OBSTET GYNECOL, V55, P464; Ingvar D H, 1978, Ann N Y Acad Sci, V315, P184; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1981, BRIT MED J, V283, P359, DOI 10.1136/bmj.283.6287.359; JENNETT B, 1981, BMJ-BRIT MED J, V282, P533, DOI 10.1136/bmj.282.6263.533; JOHNSEN DE, 1986, YALE LAW J, V95, P599, DOI 10.2307/796491; JORGENSEN EO, 1973, ACTA NEUROCHIR, V28, P259, DOI 10.1007/BF01405645; KATZ VL, 1986, OBSTET GYNECOL, V68, P571; KIRKLEY WH, 1980, AM J OBSTET GYNECOL, V137, P873; KLEIN RC, 1982, NEW ENGL J MED, V306, P1362; KOLDER VEB, 1987, NEW ENGL J MED, V316, P1192, DOI 10.1056/NEJM198705073161905; Korein J, 1978, Ann N Y Acad Sci, V315, P19, DOI 10.1111/j.1749-6632.1978.tb50327.x; LEVINSON G, 1974, ANESTHESIOLOGY, V40, P340, DOI 10.1097/00000542-197404000-00007; LYNN J, 1981, JAMA-J AM MED ASSOC, V246, P2184; MAIN ANH, 1981, BRIT MED J, V283, P1221, DOI 10.1136/bmj.283.6301.1221; MALLIANI A, 1972, CIRC RES, V30, P158, DOI 10.1161/01.RES.30.2.158; MURRAY TH, 1987, CLIN PERINATOL, V14, P329, DOI 10.1016/S0095-5108(18)30768-1; NELSON LJ, 1988, JAMA-J AM MED ASSOC, V95, P599; OUTWATER KM, 1984, NEUROLOGY, V34, P1243, DOI 10.1212/WNL.34.9.1243; PARISI JE, 1982, NEW ENGL J MED, V306, P14, DOI 10.1056/NEJM198201073060104; PLUM F, 1980, DIAGNOSIS STUPOR COM, P131; RIVERAALSINA ME, 1984, OBSTET GYNECOL, V64, P138; ROBERTSON JA, 1987, HASTINGS CENT REP, V17, P23, DOI 10.2307/3563180; SAFAR P, 1983, CARE CRITICALLY ILL, P751; SAMPSON MB, 1979, OBSTET GYNECOL, V53, pS2; SHAW MW, 1984, J LEGAL MED, V5, P63, DOI 10.1080/01947648409513403; SHELP E, 1986, BORN DIE; SHRADER D, 1986, HASTINGS CENT REP, V16, P12, DOI 10.2307/3562464; SIEGLER M, 1982, JAMA-J AM MED ASSOC, V248, P1101, DOI 10.1001/jama.248.9.1101; SMITH CV, 1981, AM J OBSTET GYNECOL, V141, P180, DOI 10.1016/S0002-9378(16)32588-1; SMITH DW, 1978, J PEDIATR-US, V92, P878, DOI 10.1016/S0022-3476(78)80352-7; THEODORE J, 1975, LANCET, V2, P749; VEATCH RM, 1982, JAMA-J AM MED ASSOC, V248, P1102, DOI 10.1001/jama.248.9.1102; WEBB GA, 1980, AM J OBSTET GYNECOL, V137, P263, DOI 10.1016/0002-9378(80)90783-8; WEINBERGER SE, 1980, AM REV RESPIR DIS, V121, P559, DOI 10.1164/arrd.1980.121.3.559; WINTER PM, 1972, ANESTHESIOLOGY, V37, P210, DOI 10.1097/00000542-197208000-00010; 1987, PATIENT CHOICE MATER; 1983, UNIFORM LAWS ANNOT A, V8, P15; 1981, DEFINING DEATH; 1975, BR MED J, V1, P251	65	89	90	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 12	1988	260	6					816	822		10.1001/jama.260.6.816	http://dx.doi.org/10.1001/jama.260.6.816			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P5232	3392814				2023-01-03	WOS:A1988P523200029
J	CANTWELL, BMJ; CARMICHAEL, J; GHANI, SE; HARRIS, AL				CANTWELL, BMJ; CARMICHAEL, J; GHANI, SE; HARRIS, AL			THROMBOSES AND THROMBOEMBOLI IN PATIENTS WITH LYMPHOMA DURING CYTO-TOXIC CHEMOTHERAPY	BRITISH MEDICAL JOURNAL			English	Article											CANTWELL, BMJ (corresponding author), UNIV NEW CASTLE UPON TYNE,NEWCASTLE GEN HOSP,DEPT CLIN ONCOL,NEWCASTLE TYNE NE4 6BE,ENGLAND.		Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409				LEVINE MN, 1988, NEW ENGL J MED, V318, P404, DOI 10.1056/NEJM198802183180703; NICOLSON GL, 1985, CANCER RES, V45, P331; RICKLES FR, 1983, BLOOD, V62, P14; SEIFTER EJ, 1985, CANCER TREAT REP, V69, P1011; WILSON JE, 1985, CECIL TXB MED, P426	5	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 16	1988	297	6642					179	180		10.1136/bmj.297.6642.179	http://dx.doi.org/10.1136/bmj.297.6642.179			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P2951	3408956	Bronze, Green Published			2023-01-03	WOS:A1988P295100021
J	YOUNG, FE; NORRIS, JA; LEVITT, JA; NIGHTINGALE, SL				YOUNG, FE; NORRIS, JA; LEVITT, JA; NIGHTINGALE, SL			THE FDAS NEW PROCEDURES FOR THE USE OF INVESTIGATIONAL DRUGS IN TREATMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									US FDA,OFF HLTH AFFAIRS,ROOM 14-95,5600 FISHERS LANE,ROCKVILLE,MD 20857	US Food & Drug Administration (FDA)								NIGHTINGALE SL, 1987, JAMA, V257, P1858; NIGHTINGALE SL, 1987, JAMA, V258, P179; 1987, FED REG         0522, V52, P19466; 1987, FED REG         0319, V52, P8798; 1987, FED REG         0319, V52, P8850	5	32	32	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 15	1988	259	15					2267	2270		10.1001/jama.259.15.2267	http://dx.doi.org/10.1001/jama.259.15.2267			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M8424	3280842				2023-01-03	WOS:A1988M842400030
J	BESSON, I; INGRAND, P; PERSON, B; BOUTROUX, D; HERESBACH, D; BERNARD, P; HOCHAIN, P; LARRICQ, J; GOURLAOUEN, A; RIBARD, D; KARA, NM; LEGOUX, JL; PILLEGAND, B; BECKER, MC; DICOSTANZO, J; METREAU, JM; SILVAIN, C; BEAUCHANT, M				BESSON, I; INGRAND, P; PERSON, B; BOUTROUX, D; HERESBACH, D; BERNARD, P; HOCHAIN, P; LARRICQ, J; GOURLAOUEN, A; RIBARD, D; KARA, NM; LEGOUX, JL; PILLEGAND, B; BECKER, MC; DICOSTANZO, J; METREAU, JM; SILVAIN, C; BEAUCHANT, M			SCLEROTHERAPY WITH OR WITHOUT OCTREOTIDE FOR ACUTE VARICEAL BLEEDING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ESOPHAGEAL-VARICES; CONTROLLED TRIAL; ENDOSCOPIC SCLEROTHERAPY; INJECTION SCLEROTHERAPY; PORTAL-HYPERTENSION; CIRRHOTIC-PATIENTS; EMERGENCY CONTROL; RANDOMIZED TRIAL; SOMATOSTATIN; HEMORRHAGE	Background. Sclerotherapy is considered the most effective way to stop bleeding from esophageal varices, but acute variceal bleeding is still associated with a high risk of rebleeding and death. We compared sclerotherapy alone with sclerotherapy and octreotide to control acute variceal bleeding and prevent early rebleeding in patients with cirrhosis. Methods. In a double-blind, prospective trial, 199 patients with cirrhosis and acute variceal bleeding who underwent emergency sclerotherapy were randomly assigned to receive a continuous infusion of octreotide (25 mu g per hour) or placebo for five days. The primary outcome measure was survival without rebleeding five days after sclerotherapy. Results. After five days, the proportion of patients who had survived without rebleeding was higher in the octreotide group (85 of 98 patients, or 87 percent) than in the placebo group (72 of 101, or 71 percent; 95 percent confidence interval for the difference, 4 to 27 percent; P = 0.009). The mean number of units of blood transfused within the first 24 hours after sclerotherapy was lower in the octreotide group (1.2 units; range, 0 to 7) than in the placebo group (2.0 units; range, 0 to 10; P=0.006). A logistic-regression analysis showed that the treatment assignment (P=0.003) and the number of blood units transfused before any other treatment was undertaken (P = 0.002) were the only two variables independently associated with survival without rebleeding. After adjustment for base-line differences between the two groups, the odds ratio for treatment failure in the placebo group, as compared with the octreotide group, was 3.3 (95 percent confidence interval, 1.5 to 7.3). The mean (+/-SD) 15-day cumulative survival rate (estimated by the Kaplan-Meier method) was 88+/-12 percent in both groups. Side effects were minor, and their incidence was similar in the two groups. Conclusions. In patients with cirrhosis, the combination of sclerotherapy and octreotide is more effective than sclerotherapy alone in controlling acute variceal bleeding, but there is no difference between the overall mortality rates associated with the two approaches to treatment.	CHU POITIERS,SERV HEPATOGASTROENTEROL,F-86021 POITIERS,FRANCE	CHU Poitiers; Universite de Poitiers								ALBILLOS A, 1993, GASTROENTEROLOGY, V104, P575, DOI 10.1016/0016-5085(93)90429-G; ARMITAGE P, 1987, STATISTICAL METHODS; AVGERINOS A, 1991, J HEPATOL, V13, P78, DOI 10.1016/0168-8278(91)90867-B; BARSOUM MS, 1982, BRIT J SURG, V69, P76, DOI 10.1002/bjs.1800690206; BURROUGHS AK, 1990, GASTROENTEROLOGY, V99, P1388, DOI 10.1016/0016-5085(90)91166-4; BURROUGHS AK, 1989, NEW ENGL J MED, V321, P857, DOI 10.1056/NEJM198909283211303; DEFRANCHIS R, 1992, J HEPATOL, V15, P256, DOI 10.1016/0168-8278(92)90044-P; DUDLEY FJ, 1992, GASTROENTEROLOGY, V103, P1973, DOI 10.1016/0016-5085(92)91459-H; FIACCADORI F, 1993, CURR THER RES CLIN E, V54, P519, DOI 10.1016/S0011-393X(05)80671-X; GRAHAM DY, 1981, GASTROENTEROLOGY, V80, P800; Huang C C, 1992, Changgeng Yi Xue Za Zhi, V15, P78; HWANG SJ, 1992, J HEPATOL, V16, P320, DOI 10.1016/S0168-8278(05)80663-4; MCCORMICK PA, 1990, EUR J GASTROEN HEPAT, V2, P489; MCKEE R, 1990, DIGESTION, V45, P60, DOI 10.1159/000200264; MOLLER S, 1992, J HEPATOL, V15, P184, DOI 10.1016/0168-8278(92)90034-M; PLANAS R, 1994, HEPATOLOGY, V20, P370, DOI 10.1016/0270-9139(94)90188-0; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; SHIELDS R, 1992, J HEPATOL, V16, P128, DOI 10.1016/S0168-8278(05)80105-9; SILVAIN C, 1993, HEPATOLOGY, V18, P61, DOI 10.1016/0270-9139(93)90507-J; SUNG JJY, 1993, LANCET, V342, P637, DOI 10.1016/0140-6736(93)91758-E; TERBLANCHE J, 1989, NEW ENGL J MED, V320, P1393, DOI 10.1056/NEJM198905253202107; THOMSEN BL, 1994, J HEPATOL, V21, P367, DOI 10.1016/S0168-8278(05)80315-0; 1987, SAS STAT GUIDE PERSO	23	212	219	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 31	1995	333	9					555	560		10.1056/NEJM199508313330904	http://dx.doi.org/10.1056/NEJM199508313330904			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RQ751	7623904	Bronze			2023-01-03	WOS:A1995RQ75100004
J	QUINEY, NF; DURKIN, MA				QUINEY, NF; DURKIN, MA			LESSON OF THE WEEK - ADRENOCORTICAL FAILURE IN INTENSIVE-CARE	BRITISH MEDICAL JOURNAL			English	Article							ACUTE MEDICAL ILLNESS				QUINEY, NF (corresponding author), GLOUCESTERSHIRE ROYAL HOSP,DEPT ANAESTHESIA & INTENS CARE,GLOUCESTER GL1 3NN,ENGLAND.							BALDWIN WA, 1993, ARCH SURG-CHICAGO, V128, P673; BETHUNE JE, 1989, ENDOCRINOLOGY, V2, P1647; BOUACHOUR G, 1994, INTENS CARE MED, V20, P138, DOI 10.1007/BF01707669; CLAYTON RN, 1989, BRIT MED J, V298, P271, DOI 10.1136/bmj.298.6669.271; DRUCKER D, 1986, CRIT CARE MED, V14, P789, DOI 10.1097/00003246-198609000-00006; DRUCKER D, 1985, CRIT CARE MED, V13, P477, DOI 10.1097/00003246-198506000-00007; JURNEY TH, 1987, CHEST, V92, P292, DOI 10.1378/chest.92.2.292; KNOWLTON AI, 1989, J INTENSIVE CARE MED, V4, P35, DOI DOI 10.1177/088506668900400104; LORIAUX DL, 1985, NEW ENGL J MED, V312, P1568, DOI 10.1056/NEJM198506133122409	9	6	6	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1253	1254		10.1136/bmj.310.6989.1253	http://dx.doi.org/10.1136/bmj.310.6989.1253			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767199	Green Published			2023-01-03	WOS:A1995QY87700026
J	BARBER, N				BARBER, N			WHAT CONSTITUTES GOOD PRESCRIBING	BRITISH MEDICAL JOURNAL			English	Article							DRUG	Drugs are the mainstay of medical treatment, yet there are few reports on what constitutes ''good prescribing.'' What is more, the existing guidance tends to imply that right answers exist, rather than recognising the complex trade offs that have to be made between conflicting aims. This paper proposes four aims that a prescriber should try to achieve, both on first prescribing a drug and on subsequently monitoring it. They are: to maximise effectiveness, minimise risks, minimise costs, and respect the patient's choices. This model of good prescribing brings together the traditional balancing of risks and benefits with the need to reduce costs and the right of the patient to make choices in treatment. The four aims are shown as a diagram plotting their commonest conflicts, which may be used as an aid to discussion and decision making.			BARBER, N (corresponding author), UNIV LONDON,SCH PHARM,29-39 BRUNSWICK SQ,LONDON WC1N 1AX,ENGLAND.							Barber N., 1991, PHARM J, V246, P671; BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; FINNEY DJ, 1965, J CHRON DIS, V18, P77, DOI 10.1016/0021-9681(65)90054-8; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; PARISH PA, 1973, J ROY SOC HEALTH, V4, P213; SCHWARTZ RK, 1989, SOC SCI MED, V28, P577, DOI 10.1016/0277-9536(89)90252-9; 1992, RISK ANAL PERCEPTION, P2	7	78	81	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					923	925		10.1136/bmj.310.6984.923	http://dx.doi.org/10.1136/bmj.310.6984.923			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719188	Green Published			2023-01-03	WOS:A1995QR97200032
J	RIAD, H; NICHOLLS, A				RIAD, H; NICHOLLS, A			AN ETHICAL DEBATE - ELECTIVE VENTILATION OF POTENTIAL ORGAN DONORS	BRITISH MEDICAL JOURNAL			English	Article							DONATION	Elective ventilation describes the procedure of transferring selected patients dying from rapidly progressive intracranial haemorrhage from general medical wards to intensive care units for a brief period of ventilation before confirmation of brain stem death and harvesting of organs. This approach in Exeter has led to a rate of kidney retrieval and transplant higher than has been achieved elsewhere in the United Kingdom, with a stabilisation of numbers on patients on dialysis. Recently doubt has been cast on the legality of our practice of elective ventilation on the grounds that relatives are not permitted to consent to treatment of an incompetent person when that treatment is not in the patient's best interests. We are thus faced with the dilemma of a protocol that is ethical, practical, and operates for the greater good but which may be illegal. This article explores various objections to the protocol and calls for public, medical, and legal debate on the issues.	UNIV BRISTOL,BRISTOL ROYAL INFIRM,INTENS THERAPY UNIT,BRISTOL BS2 8HW,AVON,ENGLAND; ROYAL LIVERPOOL UNIV HOSP,RENAL TRANSPLANT UNIT,LIVERPOOL,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,FAC LAW,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; THREE SERJEANTS INN,LONDON EC4Y 1BQ,ENGLAND	Bristol Royal Infirmary; University of Bristol; Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool; University of Liverpool	RIAD, H (corresponding author), ROYAL DEVON & EXETER HOSP,EXETER EX2 5DW,DEVON,ENGLAND.		Sano, Michael/E-1715-2011					COLLINS CH, 1992, CARE CRITICALLY ILL, V8, P57; Conference of Medical Royal Colleges and their Faculties in the UK, 1979, LANCET, Vi, P261; FEEST TG, 1990, LANCET, V335, P1133, DOI 10.1016/0140-6736(90)91134-V; NEW B, 1994, 18 KINGS FUND I RES; NICHOLLS A, 1994, BRIT J HOSP MED, V51, P555; NICHOLLS A, 1993, BRIT MED J, V306, P517, DOI 10.1136/bmj.306.6876.517-d; NIELSEN MS, 1994, J ROY COLL PHYS LOND, V28, P85; RIAD H, 1994, BRIT J HOSP MED, V51, P555; RIAD H, 1993, BRIT J HOSP MED, V50, P438; ROBSON JG, 1981, LANCET, V2, P365; ROBSON JG, 1981, BMJ-BRIT MED J, V283, P505, DOI 10.1136/bmj.283.6289.505-a; Routh G, 1992, CARE CRIT ILL, V8, P60; SOMMERVILLE A, 1993, MED ETHICS TODAY ITS; WILLATTS SM, 1994, BRIT J HOSP MED, V51, P554; WILLIAMS R, 1993, J ROY COLL PHYS LOND, V27, P214; 1983, CADAVERIC ORGANS TRA; 1979, BRIT MED J, V1, P332; 1993, ISSUES NURSING SOC, V19	18	38	38	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 18	1995	310	6981					714	715		10.1136/bmj.310.6981.714	http://dx.doi.org/10.1136/bmj.310.6981.714			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QN461	7711541	Green Published			2023-01-03	WOS:A1995QN46100024
J	THOMPSON, CB				THOMPSON, CB			APOPTOSIS IN THE PATHOGENESIS AND TREATMENT OF DISEASE	SCIENCE			English	Review							PROGRAMMED CELL-DEATH; AMYOTROPHIC-LATERAL-SCLEROSIS; CD4+ T-CELLS; B-CELLS; SUPEROXIDE-DISMUTASE; GROWTH-FACTORS; C-MYC; CAENORHABDITIS-ELEGANS; CHROMOSOMAL BREAKPOINT; PROTOONCOGENE BCL-2	In multicellular organisms, homeostasis is maintained through a balance between cell proliferation and cell death. Although much is known about the control of cell proliferation, less is known about the control of cell death. Physiologic cell death occurs primarily through an evolutionarily conserved form of cell suicide termed apoptosis. The decision of a cell to undergo apoptosis can be influenced by a wide variety of regulatory stimuli. Recent evidence suggests that alterations in cell survival contribute to the pathogenesis of a number of human diseases, including cancer, viral infections, autoimmune diseases, neurodegenerative disorders, and AIDS (acquired immunodeficiency syndrome). Treatments designed to specifically alter the apoptotic threshold may have the potential to change the natural progression of some of these diseases.	UNIV CHICAGO, GWEN KNAPP CTR LUPUS & IMMUNOL RES, HOWARD HUGHES MED INST, CHICAGO, IL 60637 USA	Howard Hughes Medical Institute; University of Chicago	THOMPSON, CB (corresponding author), UNIV CHICAGO, GWEN KNAPP CTR LUPUS & IMMUNOL RES, HOWARD HUGHES MED INST, DEPT MED, CHICAGO, IL 60637 USA.							ALDERSON MR, 1993, J EXP MED, V178, P2231, DOI 10.1084/jem.178.6.2231; AMEISEN JC, 1991, IMMUNOL TODAY, V12, P102; ARENAS E, 1994, NATURE, V367, P368, DOI 10.1038/367368a0; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; BANDA NK, 1992, J EXP MED, V176, P1099, DOI 10.1084/jem.176.4.1099; BEHL C, 1992, BIOCHEM BIOPH RES CO, V186, P944, DOI 10.1016/0006-291X(92)90837-B; BLACKWELL S, 1992, PHARMACOTHERAPY, V12, pS20; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BOYD JM, 1994, CELL, V79, P341, DOI 10.1016/0092-8674(94)90202-X; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CASTLE VP, 1993, AM J PATHOL, V143, P1543; CHANG GQ, 1993, NEURON, V11, P595, DOI 10.1016/0896-6273(93)90072-Y; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLARKE ML, UNPUB; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; CLEM RJ, 1991, SCIENCE, V254, P1388, DOI 10.1126/science.1962198; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; CLEMENT MV, 1994, J EXP MED, V180, P557, DOI 10.1084/jem.180.2.557; COHEN DA, 1993, CELL IMMUNOL, V151, P392, DOI 10.1006/cimm.1993.1248; COHEN JJ, 1993, HOSP PRACT, V28, P35, DOI 10.1080/21548331.1993.11442887; COHEN S, 1960, P NATL ACAD SCI USA, V46, P302, DOI 10.1073/pnas.46.3.302; COLOMBEL M, 1992, CANCER RES, V52, P4313; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; CYSTER JG, 1994, NATURE, V371, P389, DOI 10.1038/371389a0; DANCESCU M, 1992, J EXP MED, V176, P1319, DOI 10.1084/jem.176.5.1319; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; DUNSTAN CR, 1993, CALCIFIED TISSUE INT, V53, pS113, DOI 10.1007/BF01673417; ELLIS RE, 1991, GENETICS, V129, P79; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; EMLEN W, 1994, J IMMUNOL, V152, P3685; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FADOK VA, 1992, J IMMUNOL, V149, P4029; FADOK VA, 1992, J IMMUNOL, V148, P2207; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; FLEISCHMAN RA, 1993, AM J MED SCI, V305, P248, DOI 10.1097/00000441-199304000-00009; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; GARCHON HJ, 1994, EUR J IMMUNOL, V24, P380, DOI 10.1002/eji.1830240217; GENARO AM, 1994, EUR J IMMUNOL, V24, P2515, DOI 10.1002/eji.1830241038; GOLDIN RD, 1993, J PATHOL, V171, P73, DOI 10.1002/path.1711710115; GONZALEZGARCIA M, 1994, DEVELOPMENT, V120, P3033; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; GOUGEON ML, 1993, SCIENCE, V260, P1269, DOI 10.1126/science.8098552; GROUX H, 1992, J EXP MED, V175, P331, DOI 10.1084/jem.175.2.331; GUIOT AL, 1993, CR ACAD SCI III-VIE, V316, P1297; HAASE D, 1990, BLUT, V60, P192, DOI 10.1007/BF01720275; HAGUE A, 1994, ONCOGENE, V9, P3367; HALL SE, 1994, J IMMUNOL, V153, P3218; HEINTZ N, 1993, TRENDS BIOCHEM SCI, V18, P157, DOI 10.1016/0968-0004(93)90103-T; HENDERSON S, 1993, P NATL ACAD SCI USA, V90, P8479, DOI 10.1073/pnas.90.18.8479; HENDERSON S, 1991, CELL, V65, P1107, DOI 10.1016/0092-8674(91)90007-L; HENGARTNER MO, 1994, CELL, V76, P665, DOI 10.1016/0092-8674(94)90506-1; HENKART PA, 1994, IMMUNITY, V1, P343, DOI 10.1016/1074-7613(94)90063-9; HERRERO MT, 1993, NEUROSCIENCE, V56, P965, DOI 10.1016/0306-4522(93)90142-3; HEUSEL JW, 1994, CELL, V76, P977, DOI 10.1016/0092-8674(94)90376-X; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; HOFFMAN B, 1994, ONCOGENE, V9, P1807; HUNTER T, 1993, CURR OPIN GENET DEV, V3, P1, DOI 10.1016/S0959-437X(05)80333-8; ISACSON O, 1993, TRENDS NEUROSCI, V16, P306, DOI 10.1016/0166-2236(93)90104-T; ISHIZAKI Y, 1994, J CELL BIOL, V126, P1069, DOI 10.1083/jcb.126.4.1069; JACOBSON MD, 1994, EMBO J, V13, P1899, DOI 10.1002/j.1460-2075.1994.tb06459.x; KAGI D, 1994, NATURE, V369, P31, DOI 10.1038/369031a0; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; KELLEY LL, 1993, BLOOD, V82, P2340; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KOZOPAS KM, 1993, P NATL ACAD SCI USA, V90, P3516, DOI 10.1073/pnas.90.8.3516; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LAVAIL MM, 1992, P NATL ACAD SCI USA, V89, P11249, DOI 10.1073/pnas.89.23.11249; LEE JM, 1993, P NATL ACAD SCI USA, V90, P5742, DOI 10.1073/pnas.90.12.5742; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LEVINE B, 1993, NATURE, V361, P739, DOI 10.1038/361739a0; LEVY Y, 1994, J CLIN INVEST, V93, P424, DOI 10.1172/JCI116977; LIN EY, 1993, J IMMUNOL, V151, P1979; LITTMAN DR, 1994, CURR BIOL, V4, P618, DOI 10.1016/S0960-9822(00)00135-4; LOO DT, 1993, P NATL ACAD SCI USA, V90, P7951, DOI 10.1073/pnas.90.17.7951; LOTEM J, 1993, CELL GROWTH DIFFER, V4, P41; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MATTSON MP, 1993, ANN NY ACAD SCI, V679, P1, DOI 10.1111/j.1749-6632.1993.tb18285.x; MAY WS, 1994, J BIOL CHEM, V269, P26865; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MCDONNELL TJ, 1992, CANCER RES, V52, P6940; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; MINN A, UNPUB; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; MIYASHITA T, 1993, BLOOD, V81, P151; MOHR W, 1992, Z RHEUMATOL, V51, P35; MOUNTZ JD, 1994, ARTHRITIS RHEUM, V37, P1415, DOI 10.1002/art.1780371002; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; NEILAN JG, 1993, J VIROL, V67, P4391, DOI 10.1128/JVI.67.7.4391-4394.1993; NEIMAN PE, 1991, P NATL ACAD SCI USA, V88, P5857, DOI 10.1073/pnas.88.13.5857; NETA R, 1994, J IMMUNOL, V153, P4230; NEWELL MK, 1990, NATURE, V347, P286, DOI 10.1038/347286a0; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OHMORI T, 1993, BIOCHEM BIOPH RES CO, V192, P30, DOI 10.1006/bbrc.1993.1377; OKAMOTO M, 1994, BRAIN RES, V637, P57, DOI 10.1016/0006-8993(94)91217-3; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PARFITT AM, 1993, CALCIFIED TISSUE INT, V53, pS82, DOI 10.1007/BF01673408; RABIZADEH S, 1993, J NEUROCHEM, V61, P2318, DOI 10.1111/j.1471-4159.1993.tb07477.x; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RAFF MC, 1993, SCIENCE, V262, P695, DOI 10.1126/science.8235590; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAO VR, 1994, NATURE, V367, P639, DOI 10.1038/367639a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REED JC, 1990, CANCER RES, V50, P6565; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; ROEDERER M, 1993, PHARMACOLOGY, V46, P121, DOI 10.1159/000139037; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSENBAUM DM, 1994, STROKE, V25, P857, DOI 10.1161/01.STR.25.4.857; ROY N, 1995, CELL, V80, P167, DOI 10.1016/0092-8674(95)90461-1; ROZENGURT E, 1992, Current Opinion in Cell Biology, V4, P161, DOI 10.1016/0955-0674(92)90027-A; RUBIN LL, 1993, CURR BIOL, V3, P391, DOI 10.1016/0960-9822(93)90211-6; SACHS L, 1993, BLOOD, V82, P15, DOI 10.1182/blood.V82.1.15.bloodjournal82115; SHARKEY J, 1994, NATURE, V371, P336, DOI 10.1038/371336a0; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SINGER GG, 1994, IMMUNITY, V1, P365, DOI 10.1016/1074-7613(94)90067-1; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1990, NATURE, V348, P331, DOI 10.1038/348331a0; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGIMOTO A, 1994, EMBO J, V13, P2023, DOI 10.1002/j.1460-2075.1994.tb06475.x; TAKASHIMA A, 1993, P NATL ACAD SCI USA, V90, P7789, DOI 10.1073/pnas.90.16.7789; TANAKA M, 1994, CIRC RES, V75, P426, DOI 10.1161/01.RES.75.3.426; TROY CM, 1994, P NATL ACAD SCI USA, V91, P6384, DOI 10.1073/pnas.91.14.6384; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; UYAMA O, 1992, STROKE, V23, P75, DOI 10.1161/01.STR.23.1.75; VASCONCELOS AC, 1994, J GEN VIROL, V75, P1803, DOI 10.1099/0022-1317-75-7-1803; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1994, CELL, V76, P777, DOI 10.1016/0092-8674(94)90350-6; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; WILLIAMS GT, 1990, NATURE, V343, P76, DOI 10.1038/343076a0; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; YOSHIDA Y, 1993, LEUKEMIA, V7, P144; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533; ZIV I, 1994, NEUROSCI LETT, V170, P136, DOI 10.1016/0304-3940(94)90258-5	148	5966	6402	11	724	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	MAR 10	1995	267	5203					1456	1462		10.1126/science.7878464	http://dx.doi.org/10.1126/science.7878464			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QL497	7878464				2023-01-03	WOS:A1995QL49700026
J	RENSEN, PCN; VANDIJK, MCM; HAVENAAR, EC; BIJSTERBOSCH, MK; KRUIJT, JK; VANBERKEL, TJC				RENSEN, PCN; VANDIJK, MCM; HAVENAAR, EC; BIJSTERBOSCH, MK; KRUIJT, JK; VANBERKEL, TJC			SELECTIVE LIVER TARGETING OF ANTIVIRALS BY RECOMBINANT CHYLOMICRONS - A NEW THERAPEUTIC APPROACH TO HEPATITIS-B	NATURE MEDICINE			English	Article							LOW-DENSITY LIPOPROTEIN; ADENINE-ARABINOSIDE MONOPHOSPHATE; APOLIPOPROTEIN-E; RAT-LIVER; HEPATOCELLULAR-CARCINOMA; PARENCHYMAL-CELLS; VIRUS-INFECTION; REPLICATION; PROTEIN; DISTINCT	Hepatitis B virus (HBV) infection is the world's most important chronic virus infection. No safe and effective treatment is available at present, and clinical exploration of promising antiviral agents, such as nucleoside analogues is hampered because of significant side-effects due to their aspecific body distribution. We are exploring the possibility of the selective delivery of antiviral active drugs to liver parenchymal cells, the main site of infection and replication of HBV. Chylomicrons, which transport dietary lipids into the liver via apolipoprotein E-specific receptors, could serve as drug carriers. However, their endogenous nature hampers their application as pharmaceutical drug carriers. We report here that incorporation of a derivative of the nucleoside analogue iododeoxyuridine into recombinant chylomicrons leads to selective targeting to liver parenchymal cells. Potentially effective intracellular drug concentrations of 700 nM can be achieved, and we therefore anticipate that these drug carrier complexes represent a conceptual advance in the development of an effective and safe therapy for hepatitis B.	LEIDEN UNIV,LEIDEN AMSTERDAM CTR DRUG RES,DIV BIOPHARMACEUT,SYLVIUS LABS,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC			Van Berkel, Theo/ABD-7677-2021; Rensen, Patrick C.N./D-7176-2018	Rensen, Patrick C.N./0000-0002-8455-4988				BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; BEASLEY RP, 1981, LANCET, V2, P1129; BIJSTERBOSCH M K, 1990, Advanced Drug Delivery Reviews, V5, P231, DOI 10.1016/0169-409X(90)90018-N; BIJSTERBOSCH MK, 1994, BIOCHEMISTRY-US, V33, P14073, DOI 10.1021/bi00251a016; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; BLOUIN A, 1977, J CELL BIOL, V72, P441, DOI 10.1083/jcb.72.2.441; CHEN ZM, 1993, BMJ-BRIT MED J, V306, P890, DOI 10.1136/bmj.306.6882.890; HOEG JM, 1985, SCIENCE, V227, P759, DOI 10.1126/science.2982214; HOOFNAGLE JH, 1984, GASTROENTEROLOGY, V86, P150; HUETTINGER M, 1988, CLIN BIOCHEM, V21, P87, DOI 10.1016/S0009-9120(88)80093-6; LIN TS, 1994, J MED CHEM, V37, P798, DOI 10.1021/jm00032a013; LOK ASF, 1984, J ANTIMICROB CHEMOTH, V14, P93, DOI 10.1093/jac/14.1.93; Mahley R. W., 1991, CURR OPIN LIPIDOL, V2, P170; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; NAGELKERKE JF, 1983, J BIOL CHEM, V258, P2221; PERIGAUD C, 1992, NUCLEOS NUCLEOT NUCL, V11, P903, DOI 10.1080/07328319208021748; PRICE PM, 1989, P NATL ACAD SCI USA, V86, P8543; REDGRAVE TG, 1985, BIOCHIM BIOPHYS ACTA, V835, P104, DOI 10.1016/0005-2760(85)90036-0; SACKS SL, 1982, ANTIMICROB AGENTS CH, V21, P93, DOI 10.1128/AAC.21.1.93; SACKS SL, 1979, JAMA-J AM MED ASSOC, V241, P28, DOI 10.1001/jama.1979.03290270020010; SEEGER C, 1986, SCIENCE, V232, P477, DOI 10.1126/science.3961490; Shaw J. M., 1991, LIPOPROTEINS CARRIER; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; Tennant Bud C., 1994, P1455; TIOLLAIS P, 1985, NATURE, V317, P489, DOI 10.1038/317489a0; UEDA K, 1989, VIROLOGY, V169, P213, DOI 10.1016/0042-6822(89)90057-3; VANBERKEL TJC, 1983, BIOCHEM J, V216, P71, DOI 10.1042/bj2160071; VANBERKEL TJC, 1987, BIOCHEM J, V243, P715, DOI 10.1042/bj2430715; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WELLER IVD, 1983, J ANTIMICROB CHEMOTH, V11, P223, DOI 10.1093/jac/11.3.223; WINDLER E, 1980, J BIOL CHEM, V255, P8303; YOFFE B, 1992, DIGEST DIS SCI, V37, P1, DOI 10.1007/BF01308334	34	122	126	0	8	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					221	225		10.1038/nm0395-221	http://dx.doi.org/10.1038/nm0395-221			5	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585037				2023-01-03	WOS:A1995QX55900027
J	ALLEGRA, CJ				ALLEGRA, CJ			NEW THERAPEUTIC STRATEGIES FOR PATIENTS WITH GASTROINTESTINAL MALIGNANCIES USING BIOCHEMICAL MODULATION OF FLUOROURACIL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							HUMAN THYMIDYLATE SYNTHASE; ADVANCED COLORECTAL-CARCINOMA; HIGH-DOSE LEUCOVORIN; COLON-CARCINOMA; INTERFERON ALFA-2A; ADJUVANT THERAPY; FOLINIC ACID; PHASE-II; 5-FLUOROURACIL; CANCER				ALLEGRA, CJ (corresponding author), NATL NAVAL MED CTR, NCI,NAVY MED ONCOL BRANCH,8901 WISCONSIN AVE, BLDG 8, ROOM 5101, BETHESDA, MD 20889 USA.							BOBBIOPALLAVICINI E, 1993, J CHEMOTHERAPY, V5, P52; BORING CC, 1994, CA-CANCER J CLIN, V44, P7, DOI 10.3322/canjclin.44.1.7; CALVERT AH, 1986, J CLIN ONCOL, V4, P1245, DOI 10.1200/JCO.1986.4.8.1245; CHU E, 1990, CANCER RES, V50, P5834; CHU E, 1993, P NATL ACAD SCI USA, V90, P517, DOI 10.1073/pnas.90.2.517; CHU E, 1991, P NATL ACAD SCI USA, V88, P8977, DOI 10.1073/pnas.88.20.8977; CLARKE SJ, 1994, ANN ONCOL, V5, P5; DANENBERG PV, 1978, BIOCHEMISTRY-US, V17, P4018, DOI 10.1021/bi00612a022; EVANS RM, 1981, CANCER RES, V41, P3288; GREM JL, 1993, J CLIN ONCOL, V11, P1737, DOI 10.1200/JCO.1993.11.9.1737; GREM JL, 1991, J CLIN ONCOL, V9, P1811, DOI 10.1200/JCO.1991.9.10.1811; HOUGHTON JA, 1993, CANCER RES, V53, P4243; JACKMAN AL, 1990, CANCER RES, V50, P5212; JOHNSTON PG, 1991, CANCER RES, V51, P6668; JOHNSTON PG, 1992, CANCER RES, V52, P4306; JOHNSTON PG, 1993, BIOCHEM PHARMACOL, V45, P2483, DOI 10.1016/0006-2952(93)90230-T; JOHNSTON PG, 1993, P AN M AM SOC CLIN, V12, P202; KEMENY N, 1990, CANCER, V66, P2470, DOI 10.1002/1097-0142(19901215)66:12<2470::AID-CNCR2820661205>3.0.CO;2-Y; KEYOMARSI K, 1988, J BIOL CHEM, V263, P14402; LENZ HJ, 1993, P AN M AM SOC CLIN, V12, P199; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; PAZDUR R, 1990, J CLIN ONCOL, V8, P2027, DOI 10.1200/JCO.1990.8.12.2027; PETRELLI N, 1990, J CLIN ONCOL, V8, P491; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; POON MA, 1991, J CLIN ONCOL, V9, P1967, DOI 10.1200/JCO.1991.9.11.1967; SCHWARTZ EL, 1992, BIOCHEM BIOPH RES CO, V182, P1232, DOI 10.1016/0006-291X(92)91863-L; SMITH IE, 1994, ANN ONCOL, V5, P5; SORENSEN JM, 1993, P AN M AM SOC CLIN, V12, P158; SOTOS GA, 1994, CANCER TREAT REV, V20, P11, DOI 10.1016/0305-7372(94)90009-4; SWAIN SM, 1989, J CLIN ONCOL, V7, P890, DOI 10.1200/JCO.1989.7.7.890; ULLMAN B, 1978, P NATL ACAD SCI USA, V75, P980, DOI 10.1073/pnas.75.2.980; WADLER S, 1990, SEMIN ONCOL, V17, P16; WOLMARK N, 1993, J CLIN ONCOL, V11, P1879, DOI 10.1200/JCO.1993.11.10.1879; ZALCBERG J, 1994, ANN ONCOL, V5, P5	34	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					236	239		10.1001/jama.273.3.236	http://dx.doi.org/10.1001/jama.273.3.236			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807664				2023-01-03	WOS:A1995QB23400029
J	DAVIS, CL; HARDY, JR				DAVIS, CL; HARDY, JR			CURRENT ISSUES IN CANCER - PALLIATIVE CARE .10.	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARADOXICAL PAIN; NEBULIZED MORPHINE; BONE METASTASES; BREAST-CANCER; MORPHINE-6-GLUCURONIDE; PHARMACOKINETICS; PAMIDRONATE; OBSTRUCTION; OCTREOTIDE; KETOROLAC	Though many of the treatment strategies used in palliative care have never been subjected to clinical trial, it has been argued that advances in palliative care have outstripped those in many other specialties. This article is not a comprehensive review of therapeutic options, nor even of recent advances in this topic, but concentrates on the latest developments and controversies in the pharmacological treatment of four frequent and important symptoms: neuropathic pain, anorexia and cachexia, intestinal obstruction, and breathlessness. It is difficult to perform blinded, randomised trials in patients with advanced disease and poor performance status, yet it is these patients who may gain most from the adoption of new well evaluated treatment strategies.	ROYAL MARSDEN HOSP, LONDON SW3 6JJ, ENGLAND	Royal Marsden NHS Foundation Trust	DAVIS, CL (corresponding author), ROYAL MARSDEN HOSP, SUTTON SM2 5PT, SURREY, ENGLAND.		Hardy, Janet/F-2501-2012					AHMEDZAI S, 1990, ANN ONCOL, V1, P396, DOI 10.1093/oxfordjournals.annonc.a057788; AHMEDZAI S, 1993, OXFORD TXB PALLIATIV, P362; [Anonymous], 1989, NEW ENGL J MED, V321, P406; ASHBY M A, 1991, Palliative Medicine, V5, P147; BEAUFORD W, 1993, CHEST, V104, P175, DOI 10.1378/chest.104.1.175; Blackwell N., 1993, Palliative Medicine, V7, P63, DOI 10.1177/026921639300700110; BOONEKAMP PM, 1986, BONE MINER, V1, P27; BOWSHER D, 1993, BRIT MED J, V306, P473, DOI 10.1136/bmj.306.6876.473; CABOT PJ, 1993, 7TH P WORLD C PAIN, P330; CLARKE NW, 1991, BRIT J CANCER, V63, P420, DOI 10.1038/bjc.1991.97; DAVIS CL, 1993, BRIT MED J, V306, P793, DOI 10.1136/bmj.306.6880.793-c; DAVIS CL, 1992, BRIT J CANCER S16, V65, P12; DUNLOP R, 1988, LANCET, V1, P420; DUNLOP RJ, 1991, LANCET, V337, P1347; DYER C, 1992, BRIT MED J, V305, P731; FILSHIE J, 1988, CANCER SURV, V7, P161; GILLIES GWA, 1987, ANAESTHESIA, V42, P727, DOI 10.1111/j.1365-2044.1987.tb05317.x; GRAY JMB, 1981, POSTGRAD MED J, V57, P279, DOI 10.1136/pgmj.57.667.279; HANKS GWC, 1993, BRIT MED J, V306, P793, DOI 10.1136/bmj.306.6880.793-b; HANNA MH, 1990, BRIT J ANAESTH, V64, P547, DOI 10.1093/bja/64.5.547; HARDY PAJ, 1993, BRIT MED J, V306, P793, DOI 10.1136/bmj.306.6880.793-d; HOSKIN PJ, 1989, BRIT J CLIN PHARMACO, V27, P499, DOI 10.1111/j.1365-2125.1989.tb05399.x; JESSOP J, 1993, BRIT MED J, V306, P794, DOI 10.1136/bmj.306.6880.794; KHOO D, 1994, EUR J CANCER, V30A, P28, DOI 10.1016/S0959-8049(05)80012-7; LANGSTEIN HN, 1991, HEMATOL ONCOL CLIN N, V5, P103, DOI 10.1016/S0889-8588(18)30457-X; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LITVAK KM, 1990, CLIN PHARMACY, V9, P921; LOPRINZI CL, 1992, DRUGS, V43, P499, DOI 10.2165/00003495-199243040-00006; MacDonald Neil, 1993, Palliative Medicine, V7, P65; MERCADANTE S, 1992, J PAIN SYMPTOM MANAG, V7, P496, DOI 10.1016/0885-3924(92)90137-7; MORLEY JS, 1992, LANCET, V340, P1045, DOI 10.1016/0140-6736(92)93067-W; MORTON AR, 1991, BRIT J CANCER, V63, P556; MULVIHILL S, 1986, SURGERY, V100, P467; NOTT DM, 1990, GUT, V31, pA591; OSBORNE R, 1992, BRIT J CLIN PHARMACO, V34, P130, DOI 10.1111/j.1365-2125.1992.tb04121.x; OSBORNE R, 1990, CLIN PHARMACOL THER, V47, P12, DOI 10.1038/clpt.1990.2; PATERSON AHG, 1993, J CLIN ONCOL, V11, P59, DOI 10.1200/JCO.1993.11.1.59; PORTENOY RK, 1993, OXFORD TXB PALLIATIV, P187; TCHEKMEDYIAN NS, 1992, CANCER, V69, P1268; THIEBAUD D, 1991, EUR J CANCER, V27, P37, DOI 10.1016/0277-5379(91)90056-J; TWYCROSS R, 1993, BRIT MED J, V306, P793, DOI 10.1136/bmj.306.6880.793-a; WALSH TD, 1984, RECENT RESULTS CANC, V89, P115; YOSHIMURA H, 1969, BIOCHEM PHARMACOL, V18, P279; YOUNG IH, 1989, THORAX, V44, P387, DOI 10.1136/thx.44.5.387; 1990, WHO TECH REP SER, V804	45	14	14	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	MAY 21	1994	308	6940					1359	1362		10.1136/bmj.308.6940.1359	http://dx.doi.org/10.1136/bmj.308.6940.1359			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NM989	7517247	Green Published			2023-01-03	WOS:A1994NM98900031
J	FRANKS, NP; LIEB, WR				FRANKS, NP; LIEB, WR			MOLECULAR AND CELLULAR MECHANISMS OF GENERAL-ANESTHESIA	NATURE			English	Review							NICOTINIC ACETYLCHOLINE-RECEPTOR; RAT HIPPOCAMPAL-NEURONS; INHIBITORY POSTSYNAPTIC CURRENTS; AMINOBUTYRIC ACID(A) RECEPTORS; ANESTHETIC TARGET SITES; GH3 PITUITARY-CELLS; VOLATILE ANESTHETICS; XENOPUS OOCYTES; OPTICAL ISOMERS; CALCIUM CURRENT	General anaesthetics are much more selective than Is usually appreciated and may act by binding to only a small number of targets in the central nervous system. At surgical concentrations their principal effects are on ligand;gated (rather than voltage-gated) ion channels, with potentiation of postsynaptic inhibitory channel activity best fitting the pharmacological profile observed in general anaesthesia. Although the role of second messengers remains uncertain, it is now clear that anaesthetics act directly on proteins rather than on lipids.			FRANKS, NP (corresponding author), IMPERIAL COLL SCI TECHNOL & MED, BLACKETT LAB, BIOPHYS SECT, PRINCE CONSORT RD, LONDON SW7 2BZ, ENGLAND.			Franks, Nicholas/0000-0003-4874-4212				ABADJI VC, 1993, BIOCHIM BIOPHYS ACTA, V1147, P143, DOI 10.1016/0005-2736(93)90325-T; ABRAHAM MH, 1991, J PHARM SCI-US, V80, P719, DOI 10.1002/jps.2600800802; ADAM HK, 1983, BRIT J ANAESTH, V55, P97, DOI 10.1093/bja/55.2.97; AKESON MA, 1989, BIOCHEMISTRY-US, V28, P5120, DOI 10.1021/bi00438a032; ALIFIMOFF JK, 1989, BRIT J PHARMACOL, V96, P9, DOI 10.1111/j.1476-5381.1989.tb11777.x; ANDREWS PR, 1982, ANESTHESIOLOGY, V57, P314, DOI 10.1097/00000542-198210000-00014; ANIS NA, 1983, BRIT J PHARMACOL, V79, P565, DOI 10.1111/j.1476-5381.1983.tb11031.x; ARIMURA H, 1986, BRIT J PHARMACOL, V89, P573, DOI 10.1111/j.1476-5381.1986.tb11158.x; BANGHAM AD, 1980, ANESTHESIOLOGY, V53, P135, DOI 10.1097/00000542-198008000-00007; BAZIL CW, 1989, J PHARMACOL EXP THER, V248, P143; BAZIL CW, 1989, J NEUROCHEM, V53, P962, DOI 10.1111/j.1471-4159.1989.tb11799.x; BECKER KE, 1978, ANESTHESIOLOGY, V49, P192, DOI 10.1097/00000542-197809000-00008; BECKER KE, 1977, RES COMMUN CHEM PATH, V18, P23; BOWSERRILEY F, 1988, BRIT J PHARMACOL, V94, P1069, DOI 10.1111/j.1476-5381.1988.tb11624.x; BRADLEY RJ, 1984, BRAIN RES, V295, P101, DOI 10.1016/0006-8993(84)90820-5; BROCKERHOFF H, 1990, NEUROCHEM INT, V17, P15, DOI 10.1016/0197-0186(90)90062-X; BURCH PG, 1983, ANESTHESIOLOGY, V58, P146, DOI 10.1097/00000542-198302000-00008; CHIOU JS, 1992, BIOCHIM BIOPHYS ACTA, V1110, P225, DOI 10.1016/0005-2736(92)90363-Q; COCKSHOTT ID, 1992, XENOBIOTICA, V22, P369, DOI 10.3109/00498259209046648; COLLINS GGS, 1980, BRAIN RES, V190, P517, DOI 10.1016/0006-8993(80)90293-0; COOK CE, 1987, J PHARMACOL EXP THER, V241, P779; COTTRELL GA, 1987, BRIT J PHARMACOL, V90, P491, DOI 10.1111/j.1476-5381.1987.tb11198.x; CURRY S, 1990, BIOCHEMISTRY-US, V29, P4641, DOI 10.1021/bi00471a020; DANIELL LC, 1988, J PHARMACOL EXP THER, V245, P1; DESHMUKH DS, 1989, NEUROPHARMACOLOGY, V28, P1317, DOI 10.1016/0028-3908(89)90005-1; DICKINSON R, 1993, BIOPHYS J, V64, P1264, DOI 10.1016/S0006-3495(93)81491-7; DILDYMAYFIELD JE, 1992, J PHARMACOL EXP THER, V262, P487; DILGER JP, 1992, MOL PHARMACOL, V41, P127; DODSON BA, 1990, BRIT J PHARMACOL, V101, P710, DOI 10.1111/j.1476-5381.1990.tb14145.x; DOLIN SJ, 1986, BRIT J PHARMACOL, V88, P909, DOI 10.1111/j.1476-5381.1986.tb16265.x; EHRNEBO M, 1977, EUR J CLIN PHARMACOL, V11, P37, DOI 10.1007/BF00561786; ELBEHEIRY H, 1989, EXP BRAIN RES, V77, P87; ELLIOTT JR, 1989, BIOCHIM BIOPHYS ACTA, V988, P257, DOI 10.1016/0304-4157(89)90021-X; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; FIRESTONE LL, 1986, ANESTHESIOLOGY, V64, P694, DOI 10.1097/00000542-198606000-00004; FRANKS NP, 1987, TRENDS PHARMACOL SCI, V8, P169, DOI 10.1016/0165-6147(87)90160-X; FRANKS NP, 1986, P NATL ACAD SCI USA, V83, P5116, DOI 10.1073/pnas.83.14.5116; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; FRANKS NP, 1993, BRIT J ANAESTH, V71, P65, DOI 10.1093/bja/71.1.65; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; FRANKS NP, 1988, NATURE, V333, P662, DOI 10.1038/333662a0; FRANKS NP, 1991, ANN NY ACAD SCI, V625, P54, DOI 10.1111/j.1749-6632.1991.tb33829.x; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; FUJIWARA N, 1988, J PHYSIOL-LONDON, V402, P155, DOI 10.1113/jphysiol.1988.sp017198; GAGE PW, 1985, BRIT J PHARMACOL, V85, P229, DOI 10.1111/j.1476-5381.1985.tb08851.x; GAGE PW, 1985, BRIT J PHARMACOL, V85, P675, DOI 10.1111/j.1476-5381.1985.tb10563.x; GRUNER SM, 1991, ANN NY ACAD SCI, V625, P685, DOI 10.1111/j.1749-6632.1991.tb33902.x; GUNDERSEN CB, 1988, J PHARMACOL EXP THER, V247, P824; HALES TG, 1991, BRIT J PHARMACOL, V104, P619, DOI 10.1111/j.1476-5381.1991.tb12479.x; HARRIS B, 1992, EUR J PHARMACOL, V217, P215, DOI 10.1016/0014-2999(92)90875-5; HARRISON NL, 1987, J NEUROSCI, V7, P604; HASINOFF BB, 1989, BIOCHEM J, V258, P101, DOI 10.1042/bj2580101; HAYDON DA, 1986, J PHYSIOL-LONDON, V373, P311, DOI 10.1113/jphysiol.1986.sp016049; HERRINGTON J, 1991, J NEUROSCI, V11, P2226; HITZEMANN RJ, 1989, BIOCHIM BIOPHYS ACTA, V983, P205, DOI 10.1016/0005-2736(89)90235-6; HUANG LYM, 1980, SCIENCE, V207, P195, DOI 10.1126/science.7350656; HUNG OR, 1992, ANESTHESIOLOGY, V77, P237, DOI 10.1097/00000542-199208000-00003; JANES N, 1992, BIOCHEMISTRY-US, V31, P9467, DOI 10.1021/bi00154a020; JANOFF AS, 1981, BIOCHIM BIOPHYS ACTA, V649, P125, DOI 10.1016/0005-2736(81)90017-1; JONES MV, 1993, J NEUROPHYSIOL, V70, P1339, DOI 10.1152/jn.1993.70.4.1339; JONES MV, 1992, J PHYSIOL-LONDON, V449, P279, DOI 10.1113/jphysiol.1992.sp019086; JONG RHD, 1975, ANESTHESIOLOGY, V42, P384, DOI 10.1097/00000542-197504000-00003; KENDALL TJG, 1982, BRIT J PHARMACOL, V75, P219, DOI 10.1111/j.1476-5381.1982.tb08776.x; KENDIG JJ, 1993, EFFECTS HIGH PRESSUR; KISSIN I, 1983, ANESTHESIOLOGY, V58, P88, DOI 10.1097/00000542-198301000-00012; KLEMM WR, 1990, ALCOHOL, V7, P49, DOI 10.1016/0741-8329(90)90060-P; KRESS HG, 1991, ANESTHESIOLOGY, V74, P309, DOI 10.1097/00000542-199102000-00018; KRNJEVIC K, 1988, CAN J PHYSIOL PHARM, V66, P1570, DOI 10.1139/y88-257; KULLMANN DM, 1989, J PHYSIOL-LONDON, V412, P277, DOI 10.1113/jphysiol.1989.sp017615; LABELLA FS, 1993, CAN J PHYSIOL PHARM, V71, P48, DOI 10.1139/y93-007; LAMBERT JJ, 1990, CIBA F SYMP, V153, P56; LIN LH, 1992, J PHARMACOL EXP THER, V263, P569; LIN LH, 1993, J NEUROCHEM, V60, P1548, DOI 10.1111/j.1471-4159.1993.tb03320.x; LIU J, 1993, ANESTH ANALG, V77, P12; LODGE D, 1982, NEUROSCI LETT, V29, P281, DOI 10.1016/0304-3940(82)90330-5; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; LYON RC, 1981, J PHARMACOL EXP THER, V218, P669; MACDONALD RL, 1989, J PHYSIOL-LONDON, V417, P483, DOI 10.1113/jphysiol.1989.sp017814; MACIVER MB, 1991, ANN NY ACAD SCI, V625, P91, DOI 10.1111/j.1749-6632.1991.tb33832.x; MARSZALEC W, 1993, BRAIN RES, V608, P7, DOI 10.1016/0006-8993(93)90766-G; MAZE M, 1983, ANESTHESIOLOGY, V59, P327, DOI 10.1097/00000542-198310000-00010; MCFARLANE C, 1992, ANESTHESIOLOGY, V77, P1165, DOI 10.1097/00000542-199212000-00018; MILLER KW, 1989, P NATL ACAD SCI USA, V86, P1084, DOI 10.1073/pnas.86.3.1084; MINCHIN MCW, 1981, BRIT J PHARMACOL, V73, P681, DOI 10.1111/j.1476-5381.1981.tb16803.x; MORGAN WW, 1984, NEUROPHARMACOLOGY, V23, P773, DOI 10.1016/0028-3908(84)90110-2; MOSS GWJ, 1991, BIOPHYS J, V60, P1309, DOI 10.1016/S0006-3495(91)82168-3; MOSS GWJ, 1991, P NATL ACAD SCI USA, V88, P134, DOI 10.1073/pnas.88.1.134; MURRELL RD, 1991, J PHYSIOL-LONDON, V437, P431, DOI 10.1113/jphysiol.1991.sp018604; NAKAHIRO M, 1991, J PHARMACOL EXP THER, V259, P235; NAKAHIRO M, 1989, FASEB J, V3, P1850, DOI 10.1096/fasebj.3.7.2541038; NISHI K, 1983, BRIT J PHARMACOL, V79, P645, DOI 10.1111/j.1476-5381.1983.tb10001.x; PARKER I, 1986, J NEUROSCI, V6, P2290; POCOCK G, 1988, BRIT J PHARMACOL, V95, P209, DOI 10.1111/j.1476-5381.1988.tb16566.x; PRINGLE MJ, 1981, MOL PHARMACOL, V19, P49; PUIL E, 1990, J PHARMACOL EXP THER, V255, P955; RAINES DE, 1993, ANESTHESIOLOGY, V78, P918, DOI 10.1097/00000542-199305000-00017; RAMPIL IJ, 1993, ANESTHESIOLOGY, V78, P707, DOI 10.1097/00000542-199304000-00014; RAYMOND SA, 1991, ANN NY ACAD SCI, V625, P307, DOI 10.1111/j.1749-6632.1991.tb33857.x; RICHTER JA, 1982, PROG NEUROBIOL, V18, P275, DOI 10.1016/0301-0082(82)90013-2; ROBINSONWHITE AJ, 1990, ANESTHESIOLOGY, V72, P996, DOI 10.1097/00000542-199006000-00009; ROTH SH, 1989, MOL PHARMACOL, V36, P874; RYDER S, 1978, EUR J PHARMACOL, V49, P15, DOI 10.1016/0014-2999(78)90217-0; SAINT DA, 1992, BRIT J PHARMACOL, V107, P895, DOI 10.1111/j.1476-5381.1992.tb14543.x; SANDORFY C, 1990, Spectroscopy (Amsterdam), V8, P1; SAPP DW, 1992, J PHARMACOL EXP THER, V262, P801; SCHELLER MS, 1989, NEUROPHARMACOLOGY, V28, P677, DOI 10.1016/0028-3908(89)90150-0; SCHOLFIELD CN, 1980, PFLUG ARCH EUR J PHY, V383, P249, DOI 10.1007/BF00587527; SCHROEDER F, 1988, BIOCHIM BIOPHYS ACTA, V946, P85, DOI 10.1016/0005-2736(88)90460-9; SEGAL IS, 1988, ANESTHESIOLOGY, V69, P818, DOI 10.1097/00000542-198812000-00004; SERVIN F, 1988, ANESTHESIOLOGY, V69, P887, DOI 10.1097/00000542-198812000-00014; SILL JC, 1991, MOL PHARMACOL, V40, P1006; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SMITH EB, 1984, NATURE, V311, P56, DOI 10.1038/311056a0; STERN RC, 1991, J NEUROSCI, V11, P2217; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; TAKENOSHITA M, 1991, J NEUROSCI, V11, P1404; TAKENOSHITA M, 1987, BRAIN RES, V402, P303, DOI 10.1016/0006-8993(87)90037-0; TINKLENBERG JA, 1991, ANN NY ACAD SCI, V625, P532, DOI 10.1111/j.1749-6632.1991.tb33884.x; TORDA TA, 1977, BRIT J ANAESTH, V49, P771, DOI 10.1093/bja/49.8.771; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WAHLSTROM G, 1970, ACTA PHARMACOL TOX, V28, P493; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014, DOI 10.1152/jn.1991.66.6.2014; WANN KT, 1988, PROG NEUROBIOL, V30, P271, DOI 10.1016/0301-0082(88)90025-1; WERZ MA, 1985, MOL PHARMACOL, V28, P269; WHITE PF, 1985, BRIT J ANAESTH, V57, P197, DOI 10.1093/bja/57.2.197; WOOD SC, 1991, MOL PHARMACOL, V39, P332; YEH JZ, 1991, ANN NY ACAD SCI, V625, P155, DOI 10.1111/j.1749-6632.1991.tb33839.x; ZEILHOFER HU, 1992, EUR J PHARMACOL, V213, P155	129	1553	1611	2	123	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 17	1994	367	6464					607	614		10.1038/367607a0	http://dx.doi.org/10.1038/367607a0			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MW688	7509043				2023-01-03	WOS:A1994MW68800043
J	FEIX, JB; KALYANARAMAN, B; CHIGNELL, CF; HALL, RD				FEIX, JB; KALYANARAMAN, B; CHIGNELL, CF; HALL, RD			DIRECT OBSERVATION OF SINGLET OXYGEN PRODUCTION BY MEROCYANINE 540 ASSOCIATED WITH PHOSPHATIDYLCHOLINE LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note									NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	FEIX, JB (corresponding author), MED COLL WISCONSIN,DEPT RADIOL,NATL BIOMED ELECTRON SPIN RESONANCE CTR,MILWAUKEE,WI 53226, USA.				NATIONAL CANCER INSTITUTE [P01CA049089] Funding Source: NIH RePORTER; NCI NIH HHS [CA-49089] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON SM, 1973, PHOTOCHEM PHOTOBIOL, V18, P403, DOI 10.1111/j.1751-1097.1973.tb06440.x; [Anonymous], 1985, SINGLET O2; BLUM A, 1985, PHOTOCHEM PHOTOBIOL, V41, P27, DOI 10.1111/j.1751-1097.1985.tb03443.x; COHEN LB, 1974, J MEMBRANE BIOL, V19, P1, DOI 10.1007/BF01869968; DRAGSTEN PR, 1978, BIOCHEMISTRY-US, V17, P5228, DOI 10.1021/bi00617a024; EASTON TG, 1978, CELL, V13, P475, DOI 10.1016/0092-8674(78)90321-5; EMILIANI C, 1983, PHOTOCHEM PHOTOBIOL, V37, P487, DOI 10.1111/j.1751-1097.1983.tb04505.x; Foote C. S., 1979, SINGLET OXYGEN, P139; GOYAL GC, 1983, CANCER RES, V43, P5826; GROSSWEINER LI, 1982, PHOTOCHEM PHOTOBIOL, V36, P159, DOI 10.1111/j.1751-1097.1982.tb04358.x; HALL RD, 1987, PHOTOCHEM PHOTOBIOL, V45, P459, DOI 10.1111/j.1751-1097.1987.tb05403.x; HALL RD, 1987, PHOTOCHEM PHOTOBIOL, V46, P295, DOI 10.1111/j.1751-1097.1987.tb04769.x; HUMPHRIES GMK, 1983, BIOCHEM BIOPH RES CO, V111, P768, DOI 10.1016/0006-291X(83)90370-4; KALYANARAMAN B, 1987, P NATL ACAD SCI USA, V84, P2999, DOI 10.1073/pnas.84.9.2999; KAMINO K, 1978, JPN J PHYSIOL, V28, P225; KEENE JP, 1986, PHOTOCHEM PHOTOBIOL, V43, P117, DOI 10.1111/j.1751-1097.1986.tb09501.x; KHAN AU, 1979, P NATL ACAD SCI USA, V76, P6047, DOI 10.1073/pnas.76.12.6047; KINNALLY KW, 1978, BIOCHEMISTRY-US, V17, P3419; KRASNOVSKII AA, 1976, BIOFIZIKA+, V21, P748; KRASNOVSKY AA, 1979, PHOTOCHEM PHOTOBIOL, V29, P29, DOI 10.1111/j.1751-1097.1979.tb09255.x; KRASNOVSKY AA, 1981, CHEM PHYS LETT, V81, P443, DOI 10.1016/0009-2614(81)85647-3; MEAGHER RC, 1983, J CELL PHYSIOL, V116, P118, DOI 10.1002/jcp.1041160118; OGILBY PR, 1982, J AM CHEM SOC, V104, P2069, DOI 10.1021/ja00371a067; RODGERS MAJ, 1982, J AM CHEM SOC, V104, P5541, DOI 10.1021/ja00384a070; RODGERS MAJ, 1982, PHOTOCHEM PHOTOBIOL, V35, P473, DOI 10.1111/j.1751-1097.1982.tb02596.x; ROSS WN, 1974, BIOPHYS J, V14, P983, DOI 10.1016/S0006-3495(74)85963-1; ROSS WN, 1977, J MEMBRANE BIOL, V33, P141, DOI 10.1007/BF01869514; SIEBER F, 1987, PHOTOCHEM PHOTOBIOL, V46, P71, DOI 10.1111/j.1751-1097.1987.tb04738.x; SIEBER F, 1986, CANCER RES, V46, P2072; SIEBER F, 1984, P NATL ACAD SCI-BIOL, V81, P7584, DOI 10.1073/pnas.81.23.7584; Smith, 1981, CHOLESTEROL AUTOXIDA; SUWA K, 1977, BIOCHEM BIOPH RES CO, V75, P785, DOI 10.1016/0006-291X(77)91541-8; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; THOMAS JP, 1987, CANCER LETT, V35, P295, DOI 10.1016/0304-3835(87)90131-5; VALINSKY JE, 1978, CELL, V13, P487, DOI 10.1016/0092-8674(78)90322-7; VERKMAN AS, 1985, BIOCHEMISTRY-US, V24, P7117, DOI 10.1021/bi00346a015; Waggoner A S, 1977, Ann N Y Acad Sci, V303, P217; WEISHAUPT KR, 1976, CANCER RES, V36, P2326; WILLIAMSON P, 1983, BIOCHIM BIOPHYS ACTA, V732, P387, DOI 10.1016/0005-2736(83)90055-X; WILLIAMSON PL, 1981, MOL CELL BIOL, V1, P128, DOI 10.1128/MCB.1.2.128	40	43	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 25	1988	263	33					17247	17250						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	R0048	3182846				2023-01-03	WOS:A1988R004800012
J	BRAHAMS, D				BRAHAMS, D			RADIOTHERAPY OVERDOSE	LANCET			English	Editorial Material																		TOBIAS JS, 1988, BRIT MED J, V297, P372, DOI 10.1136/bmj.297.6645.372	1	1	1	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1988	2	8617					975	975						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q5795	2902427				2023-01-03	WOS:A1988Q579500055
J	URBAN, P; SCHEIDEGGER, D; BUCHMANN, B; BARTH, D				URBAN, P; SCHEIDEGGER, D; BUCHMANN, B; BARTH, D			CARDIAC-ARREST AND BLOOD IONIZED CALCIUM LEVELS	ANNALS OF INTERNAL MEDICINE			English	Article											URBAN, P (corresponding author), HOP CANTONAL UNIV, CTR CARDIOL, CH-1211 GENEVA 11, SWITZERLAND.							[Anonymous], 1986, JAMA-J AM MED ASSOC, V255, P2905, DOI [10.1001/jama.1986.03370210073024, DOI 10.1001/JAMA.1986.03370210073024]; BEST R, 1985, ANN EMERG MED, V14, P633, DOI 10.1016/S0196-0644(85)80876-3; BRISTOW MR, 1977, CIRC RES, V41, P565, DOI 10.1161/01.RES.41.4.565; CARDEN DL, 1985, AM J EMERG MED, V3, P120, DOI 10.1016/0735-6757(85)90033-6; CHEUNG JY, 1986, NEW ENGL J MED, V314, P1670; CONNOR TB, 1982, NEW ENGL J MED, V307, P869, DOI 10.1056/NEJM198209303071407; COOPER DJ, 1987, INTENS CARE MED, V13, P425; DEMBO DH, 1981, CRIT CARE MED, V9, P358, DOI 10.1097/00003246-198105000-00002; DROP LJ, 1975, ANESTHESIOLOGY, V43, P300, DOI 10.1097/00000542-197509000-00005; DROP LJ, 1980, J THORAC CARDIOV SUR, V79, P425; FYER AJ, 1984, BIOL PSYCHIAT, V19, P1437; GEFFIN GA, 1983, CARDIOVASC RES, V17, P415, DOI 10.1093/cvr/17.7.415; GINSBURG R, 1983, ANN INTERN MED, V98, P603, DOI 10.7326/0003-4819-98-5-603; HARRISON EE, 1983, AM J EMERG MED, V3, P267; HENRICH WL, 1984, NEW ENGL J MED, V310, P19, DOI 10.1056/NEJM198401053100105; KAY HJ, 1951, SURG GYNECOL OBSTET, V93, P97; KOSKI G, IN PRESS J THORAC AN; KRAUSE GS, 1986, AM HEART J, V111, P768, DOI 10.1016/0002-8703(86)90114-6; MARQUEZ J, 1986, ANESTHESIOLOGY, V65, P457, DOI 10.1097/00000542-198611000-00001; NAWAB ZM, 1984, T AM SOC ART INT ORG, V30, P184; OLIVA PB, 1970, AM J MED, V48, P209, DOI 10.1016/0002-9343(70)90117-8; PARASKOS JA, 1986, CIRCULATION, V74, P86; SCHEIDEGGER D, 1977, INTENS CARE MED, V3, P200; SCHEIDEGGER D, 1984, IONISIERTES KALZIUM; STEMPIEN A, 1986, ANN INTERN MED, V105, P603, DOI 10.7326/0003-4819-105-4-603; STUEVEN H, 1983, ANN EMERG MED, V12, P136, DOI 10.1016/S0196-0644(83)80551-4; STUEVEN HA, 1985, ANN EMERG MED, V14, P630, DOI 10.1016/S0196-0644(85)80875-1; STUEVEN HA, 1985, ANN EMERG MED, V14, P626, DOI 10.1016/S0196-0644(85)80874-X; URBAN P, 1985, CLIN CHEM, V31, P264; URBAN P, 1986, J THORAC CARDIOV SUR, V91, P303; 1980, JAMA, V244, P453	31	48	49	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 15	1988	109	2					110	113		10.7326/0003-4819-109-2-110	http://dx.doi.org/10.7326/0003-4819-109-2-110			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P3809	3382105				2023-01-03	WOS:A1988P380900007
J	SANDERCOCK, P				SANDERCOCK, P			THROMBOLYTIC THERAPY FOR ACUTE ISCHEMIC STROKE - PROMISING, PERILOUS, OR UNPROVED	LANCET			English	Editorial Material											SANDERCOCK, P (corresponding author), WESTERN GEN HOSP,NEUROSCI TRIALS UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.		sandercock, peter/GQI-3167-2022	sandercock, peter/0000-0001-8484-0135				BATH PMW, 1995, BRIT MED J, V311, P139, DOI 10.1136/bmj.311.6998.139; COUNSELL C, 1995, STROKE MODULE COCHRA; DONNAN GA, 1995, LANCET, V345, P578; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0; PETO R, 1995, J CLIN EPIDEMIOL, V48, P23, DOI 10.1016/0895-4356(94)00150-O; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; WARDLAW J, 1995, STROKE MODULE COCHRA	9	14	16	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1504	1505		10.1016/S0140-6736(95)92044-7	http://dx.doi.org/10.1016/S0140-6736(95)92044-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491040				2023-01-03	WOS:A1995TJ29100003
J	GLIKSON, M; ESPINOSA, RE; HAYES, DL				GLIKSON, M; ESPINOSA, RE; HAYES, DL			EXPANDING INDICATIONS FOR PERMANENT PACEMAKERS	ANNALS OF INTERNAL MEDICINE			English	Review							ORTHOTOPIC HEART-TRANSPLANTATION; LONG QT SYNDROME; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IDIOPATHIC DILATED CARDIOMYOPATHY; SHORT ATRIOVENTRICULAR DELAY; SINUS NODE DYSFUNCTION; CARDIAC TRANSPLANTATION; ATRIAL ARRHYTHMIAS; UNEXPLAINED SYNCOPE; VASOVAGAL SYNCOPE	Purpose: To review the current clinical experience with new and expanding indications for permanent cardiac pacing. Data Sources: A MEDLINE search was done of the English-language literature published from 1980 through 1994 about indications for permanent pacing. Five major areas were identified and searched: cardiomyopathies, atrial fibrillation, the long QT syndrome, cardiac transplantation, and vasovagal syncope. A manual search was then done for other contributions, including abstracts. Study Selection: Because published reports in these areas are scarce, all of the peer-reviewed articles and most of the relevant abstracts found were reviewed. Data Extraction: Data were manually extracted from the various sources, and the reports were classified and summarized according to specific indications. Results: Pacing is becoming an important option in the treatment of patients with symptomatic drug-resistant hypertrophic obstructive cardiomyopathy. Symptomatic and hemodynamic benefits have been shown in patients with pacing over various periods of follow-up. In patients with the long QT syndrome in whom medical therapy had failed, pacing at relatively fast rates markedly reduced symptoms and almost completely abolished fainting spells. Preliminary results suggest that pacing may be beneficial in dilated cardiomyopathy and in preventing episodes of paroxysmal atrial fibrillation. Further studies are needed to clarify the mechanisms of and to improve selection criteria for pacing in these conditions. Our ability to select cardiac transplant recipients for permanent pacing and our ability to optimize the timing of pacing in these patients have recently improved considerably. The role of pacing therapy in patients with neurally mediated (vasovagal) syncope remains incompletely understood. Better classification of these patients, made according to the sequence of hemodynamic events leading to syncope, is likely to clarify the potential benefit of pacing in these patients and improve the selection of patients for pacing. Conclusion: Few peer-reviewed clinical trial have been done, and further studies are needed to confirm the promising effects of pacing in patients with these newly recognized and expanding indications for pacing.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA	Mayo Clinic								Andersen H. R., 1993, European Heart Journal, V14, P252; ATTUEL P, 1988, PACE, V11, P1647, DOI 10.1111/j.1540-8159.1988.tb06289.x; AURICCHIO A, 1993, PACE, V16, P2034, DOI 10.1111/j.1540-8159.1993.tb00997.x; Barold S. Serge, 1992, Cardiology Clinics, V10, P573; BELLOCCI F, 1991, PACE, V14, P622; BENDITT DG, 1995, ANN INTERN MED, V122, P204, DOI 10.7326/0003-4819-122-3-199502010-00008; BEXTON RS, 1984, J AM COLL CARDIOL, V3, P712, DOI 10.1016/S0735-1097(84)80247-8; BEXTON RS, 1983, BRIT HEART J, V50, P555; BLANCHE C, 1992, J HEART LUNG TRANSPL, V11, P446; BONOW RO, 1983, AM J CARDIOL, V51, P1386, DOI 10.1016/0002-9149(83)90317-X; BRECKER SJD, 1992, LANCET, V340, P1308, DOI 10.1016/0140-6736(92)92492-X; BRINKER JA, 1993, NEW PERSPECTIVES CAR, P519; CANNON RO, 1992, J AM COLL CARDIOL, V19, pA120; CHANG AC, 1994, PACE, V17, P65, DOI 10.1111/j.1540-8159.1994.tb01352.x; COOPER MM, 1992, J THORAC CARDIOV SUR, V104, P812; COUMEL P, 1983, PACE, V6, P552, DOI 10.1111/j.1540-8159.1983.tb05295.x; DAUBERT C, 1993, NEW PERSPECTIVES CAR, P259; DAUBERT C, 1991, CIRCULATION S, V84, P453; DAUBERT C, 1993, PACE, V16, P885; DELUNA AB, 1988, EUR HEART J, V9, P1112, DOI 10.1093/oxfordjournals.eurheartj.a062407; DIBIASE A, 1991, AM J CARDIOL, V67, P1385, DOI 10.1016/0002-9149(91)90469-2; DISEGNI E, 1980, ARCH INTERN MED, V140, P1036, DOI 10.1001/archinte.140.8.1036; ELDAR M, 1992, J AM COLL CARDIOL, V20, P830, DOI 10.1016/0735-1097(92)90180-U; ELDAR M, 1987, J AM COLL CARDIOL, V10, P600, DOI 10.1016/S0735-1097(87)80203-6; ELLENBOGEN KA, 1988, AM HEART J, V116, P202, DOI 10.1016/0002-8703(88)90274-8; FAERESTRAND S, 1993, NEW PERSPECTIVES CAR, V3, P113; FANANAPAZIR L, 1992, CIRCULATION, V85, P2149, DOI 10.1161/01.CIR.85.6.2149; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; FELICIANO Z, 1993, CIRCULATION, V88, P19; FITZPATRICK A, 1991, PACE, V14, P13, DOI 10.1111/j.1540-8159.1991.tb04042.x; FITZPATRICK A, 1989, LANCET, V1, P658, DOI 10.1016/S0140-6736(89)92155-7; FITZPATRICK AP, 1990, PACE, V13, P619, DOI 10.1111/j.1540-8159.1990.tb02078.x; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; FREEDMAN RA, 1986, J AM COLL CARDIOL, V7, P595, DOI 10.1016/S0735-1097(86)80470-3; GARSON A, 1993, CIRCULATION, V87, P1866, DOI 10.1161/01.CIR.87.6.1866; Gilgenkrantz J M, 1968, Arch Mal Coeur Vaiss, V61, P439; GRAS D, 1994, J AM COLL CARDIOL, pA11; Gross Jay N., 1992, Cardiology Clinics, V10, P609; HARPER GR, 1991, PACE, V14, P1787, DOI 10.1111/j.1540-8159.1991.tb02767.x; HAYES DL, 1990, PACE, V13, P501; HEINZ G, 1990, CHEST, V97, P890, DOI 10.1378/chest.97.4.890; HEINZ G, 1993, J CARDIAC SURG, V8, P417, DOI 10.1111/j.1540-8191.1993.tb00386.x; HEINZ G, 1992, PACE, V15, P2061, DOI 10.1111/j.1540-8159.1992.tb03022.x; HESSELSON AB, 1992, J AM COLL CARDIOL, V19, P1542, DOI 10.1016/0735-1097(92)90616-U; HOCHLEITNER M, 1993, LANCET, V341, P629, DOI 10.1016/0140-6736(93)90387-V; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; HOCHLEITNER M, 1992, AM J CARDIOL, V70, P1320, DOI 10.1016/0002-9149(92)90769-U; JACQUET L, 1990, J AM COLL CARDIOL, V16, P832, DOI 10.1016/S0735-1097(10)80330-4; JANOSIK DL, 1989, J AM COLL CARDIOL, V14, P499, DOI 10.1016/0735-1097(89)90208-8; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; KACET S, 1991, PACE, V14, P1444, DOI 10.1111/j.1540-8159.1991.tb04062.x; KATO R, 1988, CURR CLIN P, V51, P15; LORIA K, 1988, J HEART TRANSPLANT, V7, P380; MABO P, 1991, PACE, V14, P648; MACKINTOSH AF, 1982, BRIT HEART J, V48, P584; MARKEWITZ A, 1993, J CARDIAC SURG, V8, P411, DOI 10.1111/j.1540-8191.1993.tb00385.x; MARKEWITZ A, 1988, PACE, V11, P1402, DOI 10.1111/j.1540-8159.1988.tb04987.x; MARTI V, 1991, PACE, V14, P1205, DOI 10.1111/j.1540-8159.1991.tb02855.x; MATSUMOTO K, 1993, CIRCULATION, V88, P210; MCAREAVEY D, 1992, AM J CARDIOL, V70, P651, DOI 10.1016/0002-9149(92)90207-F; MIYAMOTO Y, 1990, CIRCULATION, V82, P313; MONTERO JA, 1992, J HEART LUNG TRANSPL, V11, P799; MORGAN JM, 1991, PACE, V14, P667; MOSS AJ, 1991, CIRCULATION, V84, P1524, DOI 10.1161/01.CIR.84.4.1524; MOSS AJ, 1991, CIRCULATION, V84, P1136, DOI 10.1161/01.CIR.84.3.1136; PARRY G, 1992, BRIT HEART J, V68, P195; PAYNE ME, 1991, J HEART LUNG TRANSPL, V10, P738; RONASZEKI A, 1990, PACE, V13, P1728, DOI 10.1111/j.1540-8159.1990.tb06880.x; ROSENQVIST M, 1993, CIRCULATION, V88, P19; SCHMID C, 1993, THORAC CARDIOV SURG, V41, P101, DOI 10.1055/s-2007-1013830; SCHWARTZ PJ, 1990, CARDIAC ELECTROPHYSI, P589; SCOTT CD, 1991, PACE, V14, P1792, DOI 10.1111/j.1540-8159.1991.tb02768.x; SCOTT CD, 1993, J HEART LUNG TRANSPL, V12, P534; SCOTT CD, 1993, BRIT HEART J, V69, P399; SEIDELIN PH, 1992, LANCET, V340, P369, DOI 10.1016/0140-6736(92)91443-C; SLADE AKB, 1994, J AM COLL CARDIOL, pA10; SRA JS, 1993, NEW ENGL J MED, V328, P1085, DOI 10.1056/NEJM199304153281504; SUTTON R, 1990, PACE, V13, P1823, DOI 10.1111/j.1540-8159.1990.tb06897.x; SUTTON R, 1994, CARDIAC PACING ELECT, P15; Sutton R, 1992, EUR J CARDIAC PACING, V2, P180; WYNNE J, 1992, HEART DISEASE TXB CA, P1394; 1993, EUR J CARDIAC PACING, V3, P169	82	10	11	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 15	1995	123	6					443	451		10.7326/0003-4819-123-6-199509150-00009	http://dx.doi.org/10.7326/0003-4819-123-6-199509150-00009			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU437	7639445				2023-01-03	WOS:A1995RU43700008
J	BENTLEY, E; MACKIE, IC				BENTLEY, E; MACKIE, IC			TRENDS IN PRESCRIPTIONS OF PARACETAMOL FOR CHILDREN	BRITISH MEDICAL JOURNAL			English	Article							MEDICINES		UNIV MANCHESTER,HOSP DENT,DEPT DENT MED & SURG,MANCHESTER M15 6FH,LANCS,ENGLAND	University of Manchester								BENTLEY EM, 1993, HEALTH EDUC RES, V8, P519, DOI 10.1093/her/8.4.519; MACKIE IC, 1993, BRIT DENT J, V175, P93, DOI 10.1038/sj.bdj.4808242; 1979, BRIT MED J, V1, P1231	3	5	5	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					362	362		10.1136/bmj.311.7001.362	http://dx.doi.org/10.1136/bmj.311.7001.362			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640543	Green Published			2023-01-03	WOS:A1995RN46900017
J	OREOPOULOS, DG				OREOPOULOS, DG			WITHDRAWAL FROM DIALYSIS - WHEN LETTING DIE IS BETTER THAN HELPING TO LIVE	LANCET			English	Editorial Material							ATTITUDES; DECISIONS				OREOPOULOS, DG (corresponding author), TORONTO HOSP, DIV NEPHROL, WESTERN DIV, TORONTO, ON, CANADA.							AGODOA LY, 1995, AM J KIDNEY DIS, V25, P119, DOI 10.1016/0272-6386(95)90638-X; COHEN LM, 1995, ARCH INTERN MED, V155, P42, DOI 10.1001/archinte.155.1.42; COHEN LM, 1993, PSYCHOSOMATICS, V34, P395, DOI 10.1016/S0033-3182(93)71842-3; DISNEY APS, 1994, ANZDATA REPORT; KJELLSTRAND C, 1993, DEV NEPHROL, V34, P563; MOSS AH, 1993, J AM SOC NEPHROL, V4, P229; NELSON CB, 1994, J AM SOC NEPHROL, V4, P1608; OREOPOULOS DG, 1994, PERITON DIALYSIS INT, V14, P205; SCHNEIDERMAN LJ, 1994, AM J MED, V96, P110, DOI 10.1016/0002-9343(94)90130-9; SINGER PA, 1992, J AM SOC NEPHROL, V2, P1235; 1993, CANADIAN ORGAN REPLA; 1995, USRDS 1995 ANN DATA, P87	12	11	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUL 1	1995	346	8966					3	4		10.1016/S0140-6736(95)92645-3	http://dx.doi.org/10.1016/S0140-6736(95)92645-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603145				2023-01-03	WOS:A1995RF98500003
J	POUND, P; BURY, M; GOMPERTZ, P; EBRAHIM, S				POUND, P; BURY, M; GOMPERTZ, P; EBRAHIM, S			STROKE PATIENTS VIEWS ON THEIR ADMISSION TO HOSPITAL	BMJ-BRITISH MEDICAL JOURNAL			English	Article							HOME	Objective-To explore which components of care were valued by patients admitted to hospital following a stroke. Design-Qualitative study using in depth interviews 10 months after the stroke. Setting-Two adjacent districts in North Thames Regional Health Authority. Subjects-82 survivors of stroke taken consecutively from a stroke register, 40 of whom agreed to be interviewed. Results-Patients reported that during the acute stage of the stroke they wanted to put their faith in experienced and trusted experts who would help them make sense of the event, take all the actions necessary to ensure survival, and provide comfort and human warmth during the crisis. In addition to being reassured by the clinical tests and practical nursing help they received, patients valued feeling cared about by the staff, In most cases patients reported that their needs were met; however, the institutional nature of the hospital sometimes obstructed the fulfilment of their needs. Conclusion-Patients have important psychosocial needs during the acute stage of the stroke, which are often met by hospital admission. Patients gained benefits from their admission over and above those measurable in terms of morbidity or function. They used a combination of criteria to evaluate their care, focusing on the process as well as the outcome of care. Researchers and clinicians should do likewise.	UNIV LONDON, ROYAL HOLLOWAY & BEDFORD NEW COLL, DEPT SOCIAL POLICY & SOCIAL SCI, EGHAM TW20 0EX, SURREY, ENGLAND	University of London; Royal Holloway University London	POUND, P (corresponding author), ROYAL FREE HOSP, SCH MED, DEPT PUBL HLTH, LONDON NW3 2PF, ENGLAND.							Anderson R., 1992, AFTERMATH STROKE EXP; BAMFORD J, 1986, BRIT MED J, V292, P1369, DOI 10.1136/bmj.292.6532.1369; BENSIRA Z, 1980, J HEALTH SOC BEHAV, V21, P170, DOI 10.2307/2136736; BROCKLEHURST J C, 1978, Age and Ageing, V7, P100, DOI 10.1093/ageing/7.2.100; Bury M, 1994, Health Care Anal, V2, P240, DOI 10.1007/BF02251026; CHRISTIE D, 1978, SOC SCI MED, V12, P49; Fitzpatrick R, 1994, Qual Health Care, V3, P107; GOMPERTZ P, 1995, AGE AGEING, V24, P137, DOI 10.1093/ageing/24.2.137; HOFFMANN JE, 1974, URBAN LIFE CULT, V3, P50, DOI 10.1177/089124167400300103; Hunt SM, 1986, MEASURING HLTH STATU; ISAACS B, 1978, BRIT MED J, V2, P1640, DOI 10.1136/bmj.2.6152.1640; KAUFMAN SR, 1988, QUALITATIVE GERONTOL, P82; LUM O, 1982, CLIN GERONTOL, V1, P37; MAHONEY F I, 1965, Md State Med J, V14, P61; McKeown Thomas, 1979, ROLE MED; MULLEY G, 1978, BRIT MED J, V2, P1321, DOI 10.1136/bmj.2.6148.1321; Nouri FMLN., 1987, CLIN REHABIL, V1, P301, DOI DOI 10.1177/026921558700100409; Parker R., 1981, NEW LOOK PERSONAL SO, P17; Pound P, 1994, Qual Health Care, V3, P69, DOI 10.1136/qshc.3.2.69; POUND P, 1994, CLIN REHABIL, V8, P7, DOI DOI 10.1177/026921559400800102; WADE DT, 1987, BRIT J HOSP MED, V37, P200; WADE DT, 1985, LANCET, V1, P323; WADE DT, 1983, LANCET, V1, P807; WADE DT, 1985, J EPIDEMIOL COMMUN H, V39, P347, DOI 10.1136/jech.39.4.347; WILLIAMS SJ, 1991, SOC SCI MED, V33, P707, DOI 10.1016/0277-9536(91)90025-8; YOUNG J, 1994, BRIT MED J, V309, P1356, DOI 10.1136/bmj.309.6965.1356	26	54	55	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 1	1995	311	6996					18	22		10.1136/bmj.311.6996.18	http://dx.doi.org/10.1136/bmj.311.6996.18			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG975	7613315	Green Published			2023-01-03	WOS:A1995RG97500019
J	SPENCER, I; UNWIN, N; PLEDGER, G				SPENCER, I; UNWIN, N; PLEDGER, G			HOSPITAL INVESTIGATION OF MEN AND WOMEN TREATED FOR ANGINA	BRITISH MEDICAL JOURNAL			English	Article									UNIV NEWCASTLE UPON TYNE,DEPT MED,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; UNIV NEWCASTLE UPON TYNE,DEPT EPIDEMIOL & PUBL HLTH,NEWCASTLE TYNE NE2 4HH,TYNE & WEAR,ENGLAND; NEWCASTLE & N TYNESIDE HLTH AUTHOR,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND	Newcastle University - UK; Newcastle University - UK				Unwin, Nigel/0000-0002-1368-1648				CAMPEAU L, 1975, CIRCULATION, V54, P522; CLARKE KW, 1994, BMJ-BRIT MED J, V309, P563, DOI 10.1136/bmj.309.6954.563; JACKSON G, 1994, BRIT MED J, V309, P555, DOI 10.1136/bmj.309.6954.555; PETTICREW M, 1994, BRIT MED J, V306, P1164; Rose G, 1982, CARDIOVASCULAR SURVE	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 17	1995	310	6994					1576	1576		10.1136/bmj.310.6994.1576	http://dx.doi.org/10.1136/bmj.310.6994.1576			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE353	7787649	Green Published			2023-01-03	WOS:A1995RE35300024
J	COLDITZ, GA; HANKINSON, SE; HUNTER, DJ; WILLETT, WC; MANSON, JE; STAMPFER, MJ; HENNEKENS, C; ROSNER, B; SPEIZER, FE				COLDITZ, GA; HANKINSON, SE; HUNTER, DJ; WILLETT, WC; MANSON, JE; STAMPFER, MJ; HENNEKENS, C; ROSNER, B; SPEIZER, FE			THE USE OF ESTROGENS AND PROGESTINS AND THE RISK OF BREAST-CANCER IN POSTMENOPAUSAL WOMEN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HORMONE REPLACEMENT THERAPY; SEX-HORMONES; MORTALITY; WEIGHT; EPIDEMIOLOGY; PROGESTOGENS; SURVEILLANCE; HEIGHT	Background. The effect of adding progestins to estrogen therapy on the risk of breast cancer in postmenopausal women is controversial. Methods. To quantify the relation between the use of hormones and the risk of breast cancer in postmenopausal women, we extended our follow-up of the participants in the Nurses' Health Study to 1992. The women were asked to complete questionnaires every two years to update information on their menopausal status, use of estrogen and progestin preparations, and any diagnosis of breast cancer. During 725,550 person-years of follow-up, we documented 1935 cases of newly diagnosed invasive breastcancer. Results. The risk of breast cancer was significantly increased among women who were currently using estrogen alone (relative risk, 1.32; 95 percent confidence interval, 1.14 to 1.54) or estrogen plus progestin (relative risk, 1.41; 95 percent confidence interval, 1.15 to 1.74), as compared with postmenopausal women who had never used hormones. Women currently taking hormones who had used such therapy for 5 to 9 years had an adjusted relative risk of breast cancer of 1.46 (95 percent confidence interval, 1.22 to 1.74), as did those currently using hormones who had done so for a total of 10 or more years (relative risk, 1.46; 95 percent confidence interval, 1.20 to 1.76). The increased risk of breast cancer associated with five or more years of postmenopausal hormone therapy was greater among older women (relative risk for women 60 to 64 years old, 1.71; 95 percent confidence interval, 1.34 to 2.18). The relative risk of death due to breast cancer was 1.45 (95 percent confidence interval, 1.01 to 2.09) among women who had taken estrogen for five or more years. Conclusions. The addition of progestins to estrogen therapy does not reduce the risk of breast cancer among postmenopausal women, The substantial increase in the risk of breast cancer among older women who take hormones suggests that the trade-offs between risks and benefits should be carefully assessed.	BRIGHAM & WOMENS HOSP, DEPT MED, CHANNING LAB, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT NUTR, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	COLDITZ, GA (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [CA 40956] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; BRINTON LA, 1986, BRIT J CANCER, V54, P825, DOI 10.1038/bjc.1986.246; CAULEY JA, 1989, AM J EPIDEMIOL, V129, P1120, DOI 10.1093/oxfordjournals.aje.a115234; CHETKOWSKI RJ, 1986, NEW ENGL J MED, V314, P1615, DOI 10.1056/NEJM198606193142505; COLDITZ GA, 1993, AM J OBSTET GYNECOL, V168, P1473, DOI 10.1016/S0002-9378(11)90784-4; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COX DR, 1972, J R STAT SOC B, V34, P187; ETTINGER B, 1993, NEW ENGL J MED, V329, P1192, DOI 10.1056/NEJM199310143291610; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; FEINLEIB M, 1968, JNCI-J NATL CANCER I, V41, P315; FELSON DT, 1993, NEW ENGL J MED, V329, P1141, DOI 10.1056/NEJM199310143291601; GAMBRELL RD, 1983, OBSTET GYNECOL, V62, P435; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JURGENS RW, 1992, AM J OBSTET GYNECOL, V167, P459, DOI 10.1016/S0002-9378(11)91429-X; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; KEY TJA, 1988, EUR J CANCER CLIN ON, V24, P29, DOI 10.1016/0277-5379(88)90173-3; LEW EA, 1979, J CHRON DIS, V32, P563, DOI 10.1016/0021-9681(79)90119-X; LILIENFELD AM, 1956, CANCER, V9, P927, DOI 10.1002/1097-0142(195609/10)9:5<927::AID-CNCR2820090510>3.0.CO;2-3; LONDON SJ, 1989, JAMA-J AM MED ASSOC, V262, P2853; MORRISON AS, 1979, AM J EPIDEMIOL, V109, P709, DOI 10.1093/oxfordjournals.aje.a112734; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; PIKE MC, 1993, EPIDEMIOL REV, V15, P17, DOI 10.1093/oxfordjournals.epirev.a036102; ROMIEU I, 1989, JNCI-J NATL CANCER I, V81, P1313, DOI 10.1093/jnci/81.17.1313; ROSE DP, 1977, OBSTET GYNECOL, V49, P80; ROSNER B, 1994, AM J EPIDEMIOL, V139, P819, DOI 10.1093/oxfordjournals.aje.a117079; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STANFORD JL, 1993, EPIDEMIOL REV, V15, P98, DOI 10.1093/oxfordjournals.epirev.a036120; TRETLI S, 1989, INT J CANCER, V44, P23, DOI 10.1002/ijc.2910440105; WHITEHEAD MI, 1978, MATURITAS, V1, P87, DOI 10.1016/0378-5122(78)90015-4; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P209, DOI 10.1001/jama.257.2.209; WINGO PA, 1987, JAMA-J AM MED ASSOC, V257, P2438; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360; 1991, ORAL CONTRACEPTIVES	33	1283	1328	1	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1589	1593		10.1056/NEJM199506153322401	http://dx.doi.org/10.1056/NEJM199506153322401			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753136				2023-01-03	WOS:A1995RC19200001
J	COLLIS, RE; DAVIES, DWL; AVELING, W				COLLIS, RE; DAVIES, DWL; AVELING, W			RANDOMIZED COMPARISON OF COMBINED SPINAL-EPIDURAL AND STANDARD EPIDURAL ANALGESIA IN LABOR	LANCET			English	Article							FENTANYL; BUPIVACAINE	Epidural analgesia has a well-established role in labour, but has the drawbacks of delayed onset and motor blockade. The combined spinal-epidural technique may overcome these drawbacks. We carried out a randomised observational study to assess maternal satisfaction with the standard and combined techniques among 197 women in labour. For combined spinal-epidural analgesia, bupivacaine (2.5 mg) and fentanyl (25 mu g) were initially injected into the subarachnoid space, followed by top-ups of 15 mL 0.1% bupivacaine with 2 mu g/mL fentanyl into the epidural space, as required. For standard epidural analgesia, 25 mg (10 mL of 0.25%) bupivacaine was injected into the epidural space, followed by top-ups of 6-10 mL 0.25% bupivacaine, as required. Post partum, each woman completed a questionnaire about her labour and scored various items on a visual analogue scale (0=best, 100=worst outcome). Overall satisfaction was greater in the combined spinal-epidural group than in the standard epidural group (median [IQR] score 3 [2-10] vs 9 [3-22]; p=0.0002). Good analgesia was achieved in both groups, but the combined spinal-epidural had faster onset of analgesia and more of this group were satisfied with analgesia at 20 min (92/98 vs 68/99, p<0.0001). 12 women in the combined spinal-epidural group had leg weakness (as shown by an inability to raise the straight legs) at 20 min, but this initial motor block had resolved in most of these mothers by 1 h. In the standard epidural group 32 had leg weakness at 20 min (p=0.001), and the proportion of mothers with weakness increased in this group during labour. There were no differences in side-effects, except for mild pruritus, which was more common in the combined spinal-epidural group (42 vs 1%; p<0.0001). Overall, women seem to prefer the low-dose combined spinal-epidural technique to standard epidurals, perhaps because of the faster onset, less motor block, and feelings of greater self-control.	UCL HOSP, MIDDLESEX HOSP, DEPT SURG, DIV ANAESTHESIA, LONDON W1N 8AA, ENGLAND	University College London Hospitals NHS Foundation Trust; University of London; University College London				Collis, Rachel/0000-0003-2107-7990				CARRIE LES, 1990, ANAESTHESIA, V45, P1097, DOI 10.1111/j.1365-2044.1990.tb14932.x; CHESTNUT DH, 1991, ANESTHESIOLOGY, V74, P805, DOI 10.1097/00000542-199105000-00001; CHESTNUT DH, 1990, ANESTHESIOLOGY, V72, P613, DOI 10.1097/00000542-199004000-00006; COHEN SE, 1987, ANESTHESIOLOGY, V67, P403, DOI 10.1097/00000542-198709000-00020; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; COLLIS RE, 1993, LANCET, V341, P767, DOI 10.1016/0140-6736(93)90548-U; DAVIES MW, 1993, ANAESTHESIA, V48, P63; FLYNN AM, 1978, BRIT MED J, V2, P591, DOI 10.1136/bmj.2.6137.591; MCMANUS TJ, 1978, LANCET, V2, P72; MORGAN B, 1982, BMJ-BRIT MED J, V285, P689, DOI 10.1136/bmj.285.6343.689; MURPHY JD, 1991, BRIT MED J, V302, P564, DOI 10.1136/bmj.302.6776.564; PURDY G, 1987, BRIT J ANAESTH, V59, P319, DOI 10.1093/bja/59.3.319; STACEY RGW, 1993, BRIT J ANAESTH, V71, P499, DOI 10.1093/bja/71.4.499	13	203	211	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 3	1995	345	8962					1413	1416		10.1016/S0140-6736(95)92602-X	http://dx.doi.org/10.1016/S0140-6736(95)92602-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760614				2023-01-03	WOS:A1995RB44100014
J	ROLFE, S; HARPER, NJN				ROLFE, S; HARPER, NJN			ABILITY OF HOSPITAL DOCTORS TO CALCULATE DRUG DOSES	BRITISH MEDICAL JOURNAL			English	Article											ROLFE, S (corresponding author), MANCHESTER ROYAL INFIRM,DEPT ANAESTHESIA,OXFORD RD,MANCHESTER M13 9WL,LANCS,ENGLAND.							MULLER NF, 1992, EUROPEAN DRUG INDEX; SCRIMSHIRE JA, 1989, BRIT MED J, V298, P1497; 1994, AMPOULE LABELS NHS S; 1993, BRIT MED J, V306, P1589	4	66	68	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1173	1174		10.1136/bmj.310.6988.1173	http://dx.doi.org/10.1136/bmj.310.6988.1173			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX566	7767153	Green Published			2023-01-03	WOS:A1995QX56600023
J	BONADONNA, G; VALAGUSSA, P; MOLITERNI, A; ZAMBETTI, M; BRAMBILLA, C				BONADONNA, G; VALAGUSSA, P; MOLITERNI, A; ZAMBETTI, M; BRAMBILLA, C			CYCLOPHOSPHAMIDE, METHOTREXATE, AND FLUOROURACIL IN NODE-POSITIVE BREAST-CANCER - THE RESULTS OF 20 YEARS OF FOLLOW-UP	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ADJUVANT CHEMOTHERAPY; AXILLARY NODES; DOXORUBICIN; INTERVAL; THERAPY; TUMORS	Background. Adjuvant combination chemotherapy with cyclophosphamide, methotrexate, and fluorouracil was administered after radical mastectomy for primary breast cancer with histologically positive axillary lymph nodes to assess whether it would improve treatment outcome as compared with surgery alone. Here we report a 20-year follow-up of this investigation. Methods. In 1973 we began a trial involving 386 women who were randomly assigned to receive either no further treatment after radical mastectomy (179 women) or 12 monthly cycles of adjuvant combination chemotherapy (207 women). All patients were admitted to the Istituto Nazionale Tumori in Milan, Italy. Adjuvant chemotherapy was delivered in the outpatient clinic of the Division of Medical Oncology. Results. After a median follow-up of 19.4 years, the patients given adjuvant combination chemotherapy had significantly better rates of relapse-free survival (unadjusted relative risk of relapse, 0.71; 95 percent confidence interval, 0.56 to 0.90; P=0.004; adjusted relative risk, 0.65; 95 percent confidence interval, 0.51 to 0.83; P<0.001) and total survival (unadjusted relative risk of death, 0.78; 95 percent confidence interval, 0.62 to 0.99; P=0.04; adjusted relative risk, 0.76; 95 percent confidence interval, 0.60 to 0.97; P=0.03). With the exception of postmenopausal women, a benefit from adjuvant chemotherapy was evident in all subgroups of patients. Conclusions. The long-term results of this trial of adjuvant combination chemotherapy confirm our preliminary observations of the effectiveness of the treatment in women with node-positive breast cancer.			BONADONNA, G (corresponding author), IST NAZL TUMORI,DIV MED ONCOL,VIA VENEZIAN 1,I-20133 MILAN,ITALY.				NCI NIH HHS [N01-CM-33714] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BONADON G, 1975, P AM ASSOC CANC RES, V16, P254; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; BONADONNA G, 1995, JAMA-J AM MED ASSOC, V273, P542; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; BONADONNA G, 1977, CANCER-AM CANCER SOC, V39, P2904, DOI 10.1002/1097-0142(197706)39:6<2904::AID-CNCR2820390677>3.0.CO;2-8; BONADONNA G, IN PRESS CA CANCER J; BONADONNA G, 1981, MED ONCOLOGY CONTROV, P100; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; FISHER B, 1975, NEW ENGL J MED, V292, P117, DOI 10.1056/NEJM197501162920301; GOLDHIRSCH A, 1990, ANN ONCOL, V1, P183, DOI 10.1093/oxfordjournals.annonc.a057718; GOLDHIRSCH A, 1994, LANCET, V343, P377, DOI 10.1016/S0140-6736(94)91221-1; HENDERSON IC, 1990, CANCER, V65, P2132, DOI 10.1002/1097-0142(19900501)65:9+<2132::AID-CNCR2820651410>3.0.CO;2-4; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Miller R. G., 1981, SURVIVAL ANAL; MOLITERNI A, 1991, J CLIN ONCOL, V9, P1124, DOI 10.1200/JCO.1991.9.7.1124; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; VALAGUSSA P, 1994, ANN ONCOL, V5, P803, DOI 10.1093/oxfordjournals.annonc.a059008; Valagussa P, 1989, Recent Results Cancer Res, V115, P69; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801; 1992, LANCET, V399, P71; 1992, LANCET, V399, P1	22	756	785	0	18	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					901	906		10.1056/NEJM199504063321401	http://dx.doi.org/10.1056/NEJM199504063321401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877646	Bronze			2023-01-03	WOS:A1995QP89300001
J	WILLIAMS, JW; HOLLEMAN, DR; SAMSA, GP; SIMEL, DL				WILLIAMS, JW; HOLLEMAN, DR; SAMSA, GP; SIMEL, DL			RANDOMIZED CONTROLLED TRIAL OF 3 VS 10 DAYS OF TRIMETHOPRIM-SULFAMETHOXAZOLE FOR ACUTE MAXILLARY SINUSITIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ANTIMICROBIAL RESISTANCE; AMOXICILLIN-CLAVULANATE; HAEMOPHILUS-INFLUENZAE; COMPARATIVE EFFICACY; CEFUROXIME AXETIL; THERAPY; CLARITHROMYCIN; EQUIVALENCE; AMOXYCILLIN; BOOTSTRAP	Objective.-To compare 14-day outcomes and relapse and recurrence rates among patients with acute maxillary sinusitis randomized to 3-day (3D) vs 10-day (10D) treatment with trimethoprim/sulfamethoxazole (TMP/SMX). Setting.-University-affiliated Veterans Affairs general medical and acute care clinics. Patients.-Consecutive patients with sinus symptoms and radiographic evidence of maxillary sinusitis (complete opacity, air-fluid level, or greater than or equal to 6 mm of mucosal thickening). Patients were excluded for antibiotic use within the past week, TMP/ SMX allergy, symptoms for more than 30 days, or previous sinus surgery. Methods.-All subjects (n=80) received oxymetazoline nasal spray 0.05%, two sprays twice daily for 3 days. Subjects were randomly assigned to TMP/SMX double strength: one tablet twice daily for 10 days or one tablet twice daily for 3 days followed by 7 days of placebo, At 7 and 14 days, patients rated their overall sinus symptoms on a Likert scale. Radiographs were scored at baseline and 14 days by radiologists masked to clinical symptoms and treatment assignment. The primary outcome was number of days to ''cure'' or ''much improvement'' in sinus symptoms. Patients who were clinical successes by day 14 were assessed for symptomatic relapse or recurrence at 30 and 60 days, respectively, Results.-Groups were comparable at randomization: male, 100%; black, 53%; median age, 48 years (interquartile range, 41 to 63 years); symptom duration, 10 days (interquartile range, 6 to 17 days); bilateral maxillary disease, 51%; and radiograph score, 4 (interquartile range, 2 to 4). Outcome assessment was completed in 95% of patients at day 14(n=76). Medication side effects and use of nonstudy sinus medications were equal between groups. By 14 days, 77% of 3D subjects and 76% of 10D subjects rated their sinus symptoms as cured or much improved (95% confidence interval for difference, -15% to 17%). Median days to cure/much improvement were 5.0 and 4.5 for the 3D and 10D groups, respectively; distributions of time to cure were not different (P=.34). Radiograph scores improved in both groups compared with baseline (2 points; P<.001), but improvement did not differ between groups (P=.31). Eight percent of 3D subjects and 13% of 10D subjects missed work due to sinus symptoms. Of the 52 patients who were clinical successes at 14 days and completed follow-up, three (11%) of 27 3D subjects and one (4%) of 25 10D subjects relapsed symptomatically by day 30; one (4%) of 27 3D subjects and one (4%) of 25 10D subjects suffered symptomatic recurrence between days 30 and 60 (P=.45 for the relapse and recurrence rates combined). Conclusion.-At the 2-week follow-up, clinical symptoms and radiograph scores improved equally following 3 or 10 days of TMP/SMX plus oxymetazoline nasal spray. Symptomatic relapse and recurrence were similar between groups. Three days of antibiotics were as effective as 10 days and, because of the high disease prevalence, hold the potential for substantial cost savings.	AUDIE L MURPHY MEM VET ADM MED CTR,DIV GEN INTERNAL MED,SAN ANTONIO,TX; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX; LEXINGTON VET HOSP,MED SERV,LEXINGTON,KY; LEXINGTON VET HOSP,DIV GEN INTERNAL MED,LEXINGTON,KY; UNIV KENTUCKY,LEXINGTON,KY; VET AFFAIRS MED CTR,HLTH SERV RES FIELD PROGRAM,DURHAM,NC; VET AFFAIRS MED CTR,DIV GEN INTERNAL MED,DURHAM,NC; DUKE UNIV,MED CTR,DURHAM,NC	US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Lexington VA Medical Center; University of Kentucky; US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University	WILLIAMS, JW (corresponding author), AUDIE L MURPHY MEM VET ADM MED CTR,AMBULATORY CARE SERV 11C,7400 MERTON MINTON BLVD,SAN ANTONIO,TX 78284, USA.		Williams, John/AAM-4572-2020; Williams, John W/A-3696-2008	Williams, John/0000-0002-5267-5558; Williams, John W/0000-0002-5267-5558				ALTMAN DG, 1989, STAT MED, V8, P771, DOI 10.1002/sim.4780080702; AXELSSON A, 1970, ACTA OTO-LARYNGOL, V70, P71, DOI 10.3109/00016487009181861; AXELSSON A, 1988, ANN OTO RHINOL LARYN, V92, P75; AXELSSON A, 1970, ACTA OTOLARYNGOL STO, V69, P802; BERG O, 1988, ACTA OTO-LARYNGOL, V105, P343, DOI 10.3109/00016488809097017; BREIMAN RF, 1994, JAMA-J AM MED ASSOC, V271, P1831, DOI 10.1001/jama.271.23.1831; CAMACHO AE, 1992, AM J MED, V93, P271, DOI 10.1016/0002-9343(92)90232-Z; CASIANO RR, 1991, AM J MED, V91, pS27, DOI 10.1016/0002-9343(91)90398-H; DETSKY AS, 1985, ARCH INTERN MED, V145, P709, DOI 10.1001/archinte.145.4.709; DUNNETT CW, 1977, BIOMETRICS, V33, P593, DOI 10.2307/2529457; EFRON B, 1983, AM STAT, V37, P36, DOI 10.2307/2685844; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; Fascenelli F W, 1969, Arch Otolaryngol, V90, P190; Fleiss JL, 1981, STAT METHODS RATES P; GARLASCHI ML, 1993, EUR J EPIDEMIOL, V9, P64, DOI 10.1007/BF00463092; GWALTNEY JM, 1994, NEW ENGL J MED, V330, P25, DOI 10.1056/NEJM199401063300105; GWALTNEY JM, 1981, ANN OTO RHINOL LARYN, V90, P68, DOI 10.1177/00034894810903S216; HAMORY BH, 1979, J INFECT DIS, V139, P197, DOI 10.1093/infdis/139.2.197; HAVAS TE, 1988, ARCH OTOLARYNGOL, V114, P856; KARMA P, 1991, J ANTIMICROB CHEMOTH, V27, P83, DOI 10.1093/jac/27.suppl_A.83; KAYSER FH, 1990, EUR J CLIN MICROBIOL, V9, P810, DOI 10.1007/BF01967379; KIRSHNER B, 1991, J CLIN EPIDEMIOL, V44, P839, DOI 10.1016/0895-4356(91)90139-Z; MARCHI E, 1990, CURR MED RES OPIN, V12, P19, DOI 10.1185/03007999009111487; MATTHEWS BL, 1993, SOUTHERN MED J, V86, P329, DOI 10.1097/00007611-199303000-00016; MATTUCCI KF, 1986, ARCH OTOLARYNGOL, V112, P73; MELTZER EO, 1993, J ALLERGY CLIN IMMUN, V92, P812, DOI 10.1016/0091-6749(93)90058-N; MOSS AJ, 1986, VITAL HLTH STAT 10, V160, P66; NIELSEN RW, 1992, AM J MED, V92, pS70, DOI 10.1016/0002-9343(92)90611-E; NYFFENEGGER R, 1991, CLIN THER, V13, P589; ROVNER S, 1993, WASHINGTON POST 1130, P10; RUBIN RH, 1980, NEW ENGL J MED, V303, P426, DOI 10.1056/NEJM198008213030804; SANFORD JP, 1993, GUIDE ANTIMICROBIAL, P29; SCHELD WM, 1986, ANTIMICROB AGENTS CH, V30, P350, DOI 10.1128/AAC.30.3.350; SYDNOR A, 1989, ARCH OTOLARYNGOL, V115, P1430; VANDUIJN NP, 1992, BRIT MED J, V305, P684, DOI 10.1136/bmj.305.6855.684; WALD ER, 1986, PEDIATRICS, V77, P795; WILLIAMS JW, 1992, J GEN INTERN MED, V7, P481, DOI 10.1007/BF02599447; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WILLIAMS JW, 1993, CLIN RES, V41, pA566; WINTHER B, 1990, OTOLARYNG HEAD NECK, V103, P876, DOI 10.1177/01945998901030S507; [No title captured]; 1989, NATIONAL DISEASE THE, P487; 1993, J ANTIMICROB CHEMOTH, V31, P949; 1990, SAS STAT USERS GUIDE, P1027; 1992, P229 SAS I INC TECHN, P435; 1995, JAMA-J AM MED ASSOC, V273, P776; 1994, JAMA-J AM MED ASSOC, V272, P1926; 1994, REDBOOK DRUG TOPICS	48	96	94	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1015	1021		10.1001/jama.273.13.1015	http://dx.doi.org/10.1001/jama.273.13.1015			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP890	7897784				2023-01-03	WOS:A1995QP89000031
J	CRUMP, BJ; PANTON, R; DRUMMOND, MF; MARCHMENT, M; HAWKES, RA				CRUMP, BJ; PANTON, R; DRUMMOND, MF; MARCHMENT, M; HAWKES, RA			TRANSFERRING THE COSTS OF EXPENSIVE TREATMENTS FROM SECONDARY TO PRIMARY-CARE	BRITISH MEDICAL JOURNAL			English	Article								General practitioners, especially fundholders, are becoming increasingly concerned about being asked to prescribe treatments for their patients that are outside their therapeutic experience. They are concerned about the clinical responsibility for such prescribing and the effects on their budgets. In some specialties transferring the costs of expensive treatments from secondary to primary care (cost shifting) has become partly institutionalised because of the separate sources of funding for drugs prescribed in the two sectors. With increased efforts to control the rising costs of the drugs budget and the emergence of new expensive treatments, cost shifting will be a challenge to clinicians and purchasers as they strive for rational, cost effective prescribing. A review of the funding mechanisms for drugs prescribing and of the relation between the licensing process and the decision to support the use of a treatment in primary or secondary care is needed.	KEELE UNIV,NEWCASTLE LYME ST5 5BC,STAFFS,ENGLAND; UNIV YORK,YORK YO1 5DD,N YORKSHIRE,ENGLAND; PREMIER HLTH TRUST,BURTON TRENT DE14 2AU,STAFFS,ENGLAND	Keele University; University of York - UK	CRUMP, BJ (corresponding author), S BIRMINGHAM HLTH AUTHOR,BIRMINGHAM B15 3DP,W MIDLANDS,ENGLAND.							DRUMMOND M, 1993, PHARMACOECONOMICS, V4, P173, DOI 10.2165/00019053-199304030-00003; 1993, CRDC1 STAND GROUP HL	2	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					509	512		10.1136/bmj.310.6978.509	http://dx.doi.org/10.1136/bmj.310.6978.509			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888896	Green Published			2023-01-03	WOS:A1995QJ59800030
J	STREBEL, PM; IONNEDELCU, N; BAUGHMAN, AL; SUTTER, RW; COCHI, SL				STREBEL, PM; IONNEDELCU, N; BAUGHMAN, AL; SUTTER, RW; COCHI, SL			INTRAMUSCULAR INJECTIONS WITHIN 30 DAYS OF IMMUNIZATION WITH ORAL POLIOVIRUS VACCINE - A RISK FACTOR FOR VACCINE-ASSOCIATED PARALYTIC POLIOMYELITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENGLAND; SYSTEM; WALES	Background. In Romania the rate of vaccine-associated paralytic poliomyelitis is for unexplained reasons 5 to 17 times higher than in other countries. Long ago it was noted that intramuscular injections administered during the incubation period of wild-type poliovirus infection increased the risk of paralytic disease (a phenomenon known as ''provocation'' poliomyelitis). We conducted a case-control study to explore the association between intramuscular injections and vaccine-associated poliomyelitis in Romania. Methods. The patients were 31 young children in whom vaccine-associated paralytic poliomyelitis developed from 1988 through 1992. Eighteen were vaccine recipients, and 13 had acquired the disease by contact with vaccine recipients. Each of these children was matched with up to five controls according to health center, age, and in the case of vaccine recipients, history of receipt of the live attenuated oral poliovirus vaccine. Data were abstracted from medical records that documented the injections administered in the 30 days before the onset of paralysis. Results. Of the 31 children with vaccine-associated disease, 27 (87 percent) had received one or more intramuscular injections within 30 days before the onset of paralysis, as compared with 77 of the 151 controls (51 percent) (matched odds ratio, 31.2; 95 percent confidence interval, 4.0 to 244.2). Nearly all the intramuscular injections were of antibiotics, and the association was strongest for the patients who received 10 or more injections (matched odds ratio for greater than or equal to 10 injections as compared with no injections, 182.1; 95 percent confidence interval, 15.2 to 2186.4). The risk of paralytic disease was strongly associated with injections given after the oral poliovirus vaccine, but not with injections given before or at the same time as the vaccine (matched odds ratio, 56.7; 95 percent confidence interval, 8.9 to infinity). The attributable risk in the population for intramuscular injections given in the 30 days before the onset of paralysis was 86 percent (95 percent confidence interval, 66 to 95 percent); that is, we estimate that 86 percent of the cases of vaccine-associated paralytic poliomyelitis in this population might have been prevented by the elimination of intramuscular injections within 30 days after exposure to Oral poliovirus vaccine. Conclusions. Provocation paralysis, previously described only for wild-type poliovirus infection, may rarely occur in a child who receives multiple intramuscular injections shortly after exposure to oral poliovirus vaccine, either as a vaccine recipient or through contact with a recent recipient. This phenomenon may explain the high rate of vaccine-associated paralytic poliomyelitis in Romania, where the use of intramuscular injections of antibiotics in infants with febrile illness is common.	CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,DIV DATA MANAGEMENT,ATLANTA,GA 30333; MINIST HLTH,EXPANDED PROGRAMME IMMUNIZAT,BUCHAREST,ROMANIA	Centers for Disease Control & Prevention - USA	STREBEL, PM (corresponding author), CTR DIS CONTROL & PREVENT,NATL IMMUNIZATION PROGRAM,DIV EPIDEMIOL & SURVEILLANCE,MAILSTOP E-61,ATLANTA,GA 30333, USA.							ANDERSON GW, 1951, PEDIATRICS, V7, P741; ANDRUS JK, IN PRESS B WHO; BANKS HS, 1950, BRIT MED J, V2, P251, DOI 10.1136/bmj.2.4673.251; BODIAN D, 1954, AM J HYG, V60, P358, DOI 10.1093/oxfordjournals.aje.a119727; BRESLOW NE, 1980, IARC SCI PUBL, V32, P247; COCKBURN WC, 1988, B WORLD HEALTH ORGAN, V66, P143; COLLINGHAM KE, 1978, LANCET, V1, P976; CRAINIC R, 1983, INFECT IMMUN, V41, P1217, DOI 10.1128/IAI.41.3.1217-1225.1983; Deivanayagam N, 1993, Indian Pediatr, V30, P335; ESTEVES K, 1988, B WORLD HEALTH ORGAN, V66, P739; FLEISS JL, 1991, STATISTICAL METHODS; GREENBERG M, 1952, AM J PUBLIC HEALTH, V42, P142; GREENLAND S, 1987, STAT MED, V6, P701, DOI 10.1002/sim.4780060607; GUYER B, 1980, B WORLD HEALTH ORGAN, V58, P285; HERSH BS, 1993, AIDS, V7, P1617, DOI 10.1097/00002030-199312000-00012; HILL AB, 1950, BMJ-BRIT MED J, V2, P1; HIRJI KF, 1989, AM STAT, V43, P7, DOI 10.2307/2685158; HIRJI KF, 1988, BIOMETRICS, V44, P803, DOI 10.2307/2531592; Hollander M., 1973, NONPARAMETRIC STAT, P68; JOCE R, 1992, BRIT MED J, V305, P79, DOI 10.1136/bmj.305.6845.79; MCCLOSKEY BP, 1950, LANCET, V1, P659; NATHANSON N, 1961, B JOHNS HOPKINS HOSP, V108, P308; REN R, 1993, J INFECT DIS, V166, P747; ROSEN L, 1953, AM J HYG, V57, P237, DOI 10.1093/oxfordjournals.aje.a119571; SIMOES EAF, 1994, 34TH INT C ANT AG CH, P66; STREBEL PM, 1994, AM J EPIDEMIOL, V140, P1111, DOI 10.1093/oxfordjournals.aje.a117211; SUTTER RW, 1989, AM J PUBLIC HEALTH, V79, P495, DOI 10.2105/AJPH.79.4.495; SUTTER RW, 1992, J INFECT DIS, V165, P444, DOI 10.1093/infdis/165.3.444; TOWNSENDCOLES WF, 1953, T ROY SOC TROP MED H, V47, P77, DOI 10.1016/0035-9203(53)90027-3; Wyatt H V, 1986, Dev Biol Stand, V65, P123; WYATT HV, 1990, REV INFECT DIS, V12, P547; WYATT HV, 1984, SOC SCI MED, V19, P911, DOI 10.1016/0277-9536(84)90320-4; WYATT HV, 1985, T ROY SOC TROP MED H, V79, P355, DOI 10.1016/0035-9203(85)90379-7; YANG CF, 1991, VIRUS RES, V20, P159; 1981, INFECT DIS, P35; 1982, B WORLD HEALTH ORGAN, V60, P231; 1956, LANCET, V2, P1223; 1976, B WORLD HEALTH ORGAN, V53, P319; 1993, LOGXACT TURBO USER M; 1989, EXPANDED PROGRAMME I, P35	40	61	61	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 23	1995	332	8					500	506		10.1056/NEJM199502233320804	http://dx.doi.org/10.1056/NEJM199502233320804			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH288	7830731				2023-01-03	WOS:A1995QH28800004
J	BHAN, MK; WOO, EC; FONTAINE, O; MAULENRADOVAN, I; PIERCE, NF; RIBEIRO, H; RIBEIRO, T; PALMEIRA, C; REIS, Z; SINGH, KD; BHATNAGAR, S; MEJIA, HFV; BASTIDAS, MA; SALAZARLINDO, E; MIRANDALANGSCHWAGER, P				BHAN, MK; WOO, EC; FONTAINE, O; MAULENRADOVAN, I; PIERCE, NF; RIBEIRO, H; RIBEIRO, T; PALMEIRA, C; REIS, Z; SINGH, KD; BHATNAGAR, S; MEJIA, HFV; BASTIDAS, MA; SALAZARLINDO, E; MIRANDALANGSCHWAGER, P			MULTICENTER EVALUATION OF REDUCED-OSMOLARITY ORAL REHYDRATION SALTS SOLUTION	LANCET			English	Article							ACUTE DIARRHEA; THERAPY; INFANTS	In developed countries, use of oral rehydration salts (ORS) solution with osmolarity lower than that of plasma has been recommended because of the risk of hypernatraemia. We compared the clinical efficacy of reduced-osmolarity ORS and standard ORS solutions in children with acute diarrhoea in four developing countries. 447 boys aged 1-24 months, admitted to hospitals in four countries with acute diarrhoea and signs of dehydration, were randomly assigned either standard ORS (311 mmol/L) or reduced-osmolarity ORS (224 mmol/L) solution. Total stool output was 39% greater (95% CI 11-75), total ORS intake 18% greater (3-33), and duration of diarrhoea 22% longer (2-45) in the standard ORS group than in the reduced-osmolarity ORS group. The risk of requiring intravenous infusion after completion of the initial oral rehydration was greater in children given standard ORS solution than in those given reduced-osmolarity ORS solution in three of the four countries (all-country relative risk 1.4 [0.9-2.4]). This relative risk was significantly increased only in non-breastfed children (2.0 [1.0-3.8], p<0.05). in breastfed children, the relative risk of requiring intravenous infusion was not affected by the ORS solution (0.9 [0.4-2.0]). The mean sodium concentration 24 h after admission was significantly lower in the reduced-osmolarity ORS group than in the standard ORS group (135 [134-136] vs 138 [136-139] mmol/L, p<0.01). Reduced-osmolarity ORS solution has beneficial effects on the clinical course of acute diarrhoea. Our findings support the use of reduced-osmolarity ORS solution in children with acute non-cholera diarrhoea in developing countries. Further studies are needed to find the best formulation and whether such a solution would be satisfactory for the treatment of cholera.	WHO,DIARRHOEAL DIS CONTROL PROGRAMME,CH-1211 GENEVA,SWITZERLAND	World Health Organization								AVERY ME, 1990, NEW ENGL J MED, V323, P891, DOI 10.1056/NEJM199009273231307; ELLIOTT E J, 1989, Acta Paediatrica Scandinavica Supplement, P31; ELMOUGI M, 1994, J PEDIATR GASTR NUTR, V19, P83, DOI 10.1097/00005176-199407000-00013; Farthing M J, 1989, Acta Paediatr Scand Suppl, V364, P23; FINBERG L, 1973, NEW ENGL J MED, V289, P196, DOI 10.1056/NEJM197307262890407; GARDNER MJ, 1989, BMJ; HIRSCHHORN N, 1980, AM J CLIN NUTR, V33, P637, DOI 10.1093/ajcn/33.3.637; HUNT JB, 1992, GUT, V33, P1652, DOI 10.1136/gut.33.12.1652; MAHALANABIS D, 1970, PEDIATRICS, V45, P374; MANTEL N, 1959, J NATL CANCER I, V22, P719; PIZARRO D, 1986, J PEDIATR GASTR NUTR, V5, P6, DOI 10.1097/00005176-198601000-00003; POCOCK SJ, 1987, CLIN TRIALS PRACTICA, P123; RAHAMAN MM, 1979, LANCET, V2, P908; RAUTANEN T, 1993, ACTA PAEDIATR, V82, P52, DOI 10.1111/j.1651-2227.1993.tb12516.x; Sandhu B K, 1989, Acta Paediatr Scand Suppl, V364, P17; 1990, WHOCDDSER802REV2; 1992, J PEDIATR GASTROENTE, V14, P113	17	84	86	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 4	1995	345	8945					282	285						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QE731	7837862				2023-01-03	WOS:A1995QE73100009
J	JAMES, DK				JAMES, DK			CONTROVERSIES IN MANAGEMENT - SHOULD OBSTETRICIANS SEE WOMEN WITH NORMAL PREGNANCIES - OBSTETRICIANS SHOULD FOCUS ON PROBLEMS	BRITISH MEDICAL JOURNAL			English	Article							DELIVERY				JAMES, DK (corresponding author), QUEENS MED CTR,NOTTINGHAM NG7 2UH,ENGLAND.							HAVERCAMP A, 1982, PERINATOLOGY NEONATO, V6, P75; INCH S, 1985, J ROY SOC MED, V78, P683, DOI 10.1177/014107688507800821; JAMES D, 1991, HOSPITAL UPDATE, V18, P885; KLEIN M, 1983, BRIT J OBSTET GYNAEC, V90, P118, DOI 10.1111/j.1471-0528.1983.tb08894.x; MACVICAR J, 1993, BRIT J OBSTET GYNAEC, V100, P316, DOI 10.1111/j.1471-0528.1993.tb12972.x; PARSBOOSINGH J, 1990, EFFECTIVE CARE PREGN, V1, P192; REID M, 1990, EFFECTIVE CARE PREGN, V1, P131; REID M, 1986, PERINATAL CARE DELIV, P486; 1993, CHANGING CHILDBIRTH; 1992, 2ND HOUS COMM SEL CO	10	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					37	38		10.1136/bmj.310.6971.37	http://dx.doi.org/10.1136/bmj.310.6971.37			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB060	7827555	Green Published			2023-01-03	WOS:A1995QB06000032
J	WRIGHT, JD; PEARL, L				WRIGHT, JD; PEARL, L			KNOWLEDGE AND EXPERIENCE OF YOUNG-PEOPLE REGARDING DRUG MISUSE, 1969-94	BRITISH MEDICAL JOURNAL			English	Article							ABUSE	Objective-To monitor young people's knowledge and experience of illicit drugs between 1969 and 1994 at intervals of five years. Design-The same anonymously completed questionnaire was used throughout. Setting-Three Wolverhampton secondary schools representing three different socioeconomic groups. Subjects-392 pupils aged 14 to 15 completed the questionnaire in 1994. Previous sample sizes were 471 in 1969, 523 in 1974, 648 in 1979, 540 in 1984, and 380 in 1989. Main outcome measures-Self reported levels of knowledge and experience of illicit drugs. Results-Over 25 years the proportion of pupils who knew someone taking drugs more than quadrupled from 15% (71/471) to 65% (254/392), and the proportion who had been offered drugs increased ninefold from 5% (24) to 45% (175). Both of these proportions more than doubled over the past five years. In 1994 the proportions of pupils mentioning ''ecstasy'' (methylenedioxymethamphetamine), amphetamines, and crack cocaine increased significantly (P<0.01) and the proportion mentioning opiates decreased significantly (P<0.01). ''Poppers'' (amyl nitrite) were mentioned for the first time. ''To feel big, to show off, look grown up'' has continued to be the main perceived reason for taking drugs. Television has continued to be the main source of information. Conclusions-In the past five years in particular young people's exposure to illicit drugs has increased dramatically. Despite more education about drugs, pupils' knowledge remains limited. Social pressures remain the first perceived reason for taking drugs. The media have a responsibility not to glamorise drugs.	UNIV WOLVERHAMPTON,WOLVERHAMPTON WV1 1SB,ENGLAND	University of Wolverhampton								ALLEN FA, 1991, CRACK BROKEN PROMISE; BALDING J, 1994, YOUNG PEOPLE 1993; BEAN PT, 1988, HLTH ED J, V47, P79; BROWN C, 1988, ILLICIT DRUG USE POR; COHEN J, 1992, PSYCHOACTIVE DRUGS H; Davies OL, 1978, DESIGN ANAL IND EXPT; FRANCIS LJ, 1993, ADDICTION, V88, P665, DOI 10.1111/j.1360-0443.1993.tb02079.x; FRASER A, 1991, DRUG MISUSE LOCAL CO; Measham F., 1993, DRUGLINK, V8, P16; SMITH C, 1992, BRIT J ADDICT, V87, P227; Swadi Harith, 1992, Eur Child Adolesc Psychiatry, V1, P156, DOI 10.1007/BF02091901; WRIGHT JD, 1976, MED SCI LAW, V16, P252, DOI 10.1177/002580247601600408; WRIGHT JD, 1981, BRIT MED J, V282, P793, DOI 10.1136/bmj.282.6266.793; WRIGHT JD, 1986, BRIT MED J, V292, P179, DOI 10.1136/bmj.292.6514.179; WRIGHT JD, 1990, BRIT MED J, V300, P99, DOI 10.1136/bmj.300.6717.99; 1993, PHS6 ST GEORG HOSP M; 1993, DRUG ED SCH; 1993, HOME OFFICE STATISTI; 1993, DRUGS SOLVENTS YOU Y	19	61	62	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 7	1995	310	6971					20	24		10.1136/bmj.310.6971.20	http://dx.doi.org/10.1136/bmj.310.6971.20			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QB060	7755714	Green Published			2023-01-03	WOS:A1995QB06000022
J	KOSHY, M; BURD, L; WALLACE, D; MOAWAD, A; BARON, J				KOSHY, M; BURD, L; WALLACE, D; MOAWAD, A; BARON, J			PROPHYLACTIC RED-CELL TRANSFUSIONS IN PREGNANT PATIENTS WITH SICKLE-CELL DISEASE - A RANDOMIZED COOPERATIVE STUDY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV ILLINOIS HOSP & MED CTR,SICKLE CELL CLIN,HEMATOL SECT,CHICAGO,IL; UNIV ILLINOIS HOSP & MED CTR,DEPT MED,CHICAGO,IL; MICHAEL REESE HOSP & MED CTR,DEPT OBSTET & GYNECOL,CHICAGO,IL 60616; UNIV ILLINOIS,CTR PERINATAL,CHICAGO,IL 60612; UNIV ILLINOIS,DEPT MED,HEMATOL ONCOL SECT,CHICAGO,IL 60612; UNIV ILLINOIS,DEPT STAT,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois System; University of Illinois Chicago; Michael Reese Hospital & Medical Center; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NHLBI NIH HHS [HL-16005-09] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS JQ, 1953, OBSTET GYNECOL, V2, P335; BRUMFIELD CG, 1984, OBSTET GYNECOL, V63, pS13; CHARACHE S, 1980, OBSTET GYNECOL, V55, P407; CUNNINGHAM FG, 1983, OBSTET GYNECOL, V62, P419; EISENSTEIN MI, 1956, AM J OBSTET GYNECOL, V72, P622, DOI 10.1016/0002-9378(56)90387-8; FAIKPUI EZ, 1973, J REPROD MED, V11, P28; FORT AT, 1971, AM J OBSTET GYNECOL, V111, P324, DOI 10.1016/0002-9378(71)90772-1; HENDERSON A, 1961, NEW ENGL J MED, V264, P1276, DOI 10.1056/NEJM196106222642502; HENDRICKSE JP, 1972, J OBSTET GYN BR COMM, V79, P396; HORGER EO, 1972, OBSTET GYNECOL, V39, P873; Kobak AJ, 1941, AM J OBSTET GYNECOL, V41, P811, DOI 10.1016/S0002-9378(41)90869-4; KOSHY M, 1980, TEX REP BIOL MED, V40, P273; Koshy M, 1987, Prog Clin Biol Res, V240, P305; LAROS RK, 1971, OBSTET GYNECOL, V37, P67; MILNER PF, 1980, AM J OBSTET GYNECOL, V138, P239, DOI 10.1016/0002-9378(80)90241-0; MORRISON J C, 1979, Clinical Obstetrics and Gynecology, V22, P819, DOI 10.1097/00003081-197912000-00005; MORRISON JC, 1976, J PEDIATR-US, V89, P286, DOI 10.1016/S0022-3476(76)80469-6; MORRISON JC, 1972, SOUTHERN MED J, V65, P533, DOI 10.1097/00007611-197205000-00006; POWARS DR, 1986, OBSTET GYNECOL, V67, P217, DOI 10.1097/00006250-198602000-00012; PRITCHARD JA, 1973, AM J OBSTET GYNECOL, V117, P662, DOI 10.1016/0002-9378(73)90208-1; RICKS P, 1968, AM J OBSTET GYNECOL, V100, P1087, DOI 10.1016/S0002-9378(15)33407-4; ROBERTSON WM, 1947, T ROY SOC TROP MED H, V40, P435, DOI 10.1016/0035-9203(47)90006-0; TUCK SM, 1987, BRIT J OBSTET GYNAEC, V94, P121, DOI 10.1111/j.1471-0528.1987.tb02337.x	23	213	216	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 1	1988	319	22					1447	1452		10.1056/NEJM198812013192204	http://dx.doi.org/10.1056/NEJM198812013192204			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R1007	3054555				2023-01-03	WOS:A1988R100700004
J	BRIDGE, LR; BENSON, P; PIETRONI, PC; PRIEST, RG				BRIDGE, LR; BENSON, P; PIETRONI, PC; PRIEST, RG			RELAXATION AND IMAGERY IN THE TREATMENT OF BREAST-CANCER	BMJ-BRITISH MEDICAL JOURNAL			English	Article									ST MARYS HOSP, ACAD DEPT PSYCHIAT, LONDON W2 1NY, ENGLAND	Imperial College London								COOPER AF, 1979, BRIT J SURG, V66, P362; COX T, 1982, SOC SCI MED, V16, P381, DOI 10.1016/0277-9536(82)90048-X; EVERLY GS, 1981, NATURE TREATMENT STR, P131; FALLOWFIELD LJ, 1986, BMJ-BRIT MED J, V293, P1331, DOI 10.1136/bmj.293.6558.1331; FLEMING U, 1985, PRACTITIONER, V229, P471; FORESTER BM, 1978, AM J PSYCHIAT, V135, P960; GREER S, 1978, SOC SCI MED-MED SOC, V12, P129, DOI 10.1016/0160-7979(78)90170-4; GREER S, 1982, PSYCHOL MED, V12, P563, DOI 10.1017/S0033291700055665; GREER S, 1975, J PSYCHOSOM RES, V19, P147, DOI 10.1016/0022-3999(75)90062-8; GREER S, 1983, BRIT J PSYCHIAT, V143, P535, DOI 10.1192/bjp.143.6.535; HUGHES J, 1987, CANCER EMOTION; JACOBS TJ, 1980, PSYCHOSOM MED, V42, P11, DOI 10.1097/00006842-198001000-00002; JANSEN MA, 1984, J PSYCHOSOM RES, V28, P35, DOI 10.1016/0022-3999(84)90038-2; LESHAN LL, 1956, BRIT J MED PSYCHOL, V29, P49, DOI 10.1111/j.2044-8341.1956.tb01188.x; LYLES JN, 1982, J CONSULT CLIN PSYCH, V50, P509, DOI 10.1037/0022-006X.50.4.509; MAGUIRE GP, 1980, BRIT MED J, V281, P1179, DOI 10.1136/bmj.281.6249.1179; MAGUIRE P, 1981, RECENT ADV CLIN ONCO, P376; MAGUIRE P, 1984, BREAST CANCER DIAGNO, P303; MCLEAN J, 1986, PRACTITIONER, V230, P1079; McNair D. M., 1971, MANUAL PROFILE MOOD; PATEL C, 1981, BRIT MED J, V282, P2005, DOI 10.1136/bmj.282.6281.2005; PATEL C, 1985, BRIT MED J, V290, P1103, DOI 10.1136/bmj.290.6475.1103; PECK A, 1972, AM J ROENTGENOL, V114, P591, DOI 10.2214/ajr.114.3.591; PECK A, 1977, CANCER, V40, P180, DOI 10.1002/1097-0142(197707)40:1<180::AID-CNCR2820400129>3.0.CO;2-5; PLEWIS I, 1985, ANAL CHANGE; SCHONFIELD J, 1975, J PSYCHOSOM RES, V19, P229, DOI 10.1016/0022-3999(75)90018-5; SIMONTON OC, 1975, J TRANSPERSONAL PSYC, V7, P29; SIMONTON OC, 1978, GETTING WELL AGAIN; SIMS SER, 1987, J ADV NURS, V12, P583, DOI 10.1111/j.1365-2648.1987.tb03048.x; SNAITH RP, 1976, BRIT J PSYCHIAT, V128, P156, DOI 10.1192/bjp.128.2.156; SNOW HL, 1893, CANCER CANCER PROCES; SPIEGEL D, 1981, ARCH GEN PSYCHIAT, V38, P527; WORDEN JW, 1978, PSYCHOSOM MED, V40, P585; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1974, TNM CLASSIFICATION M; 1986, BR MED J, V293, P946; 1985, DH2 OFF POP CENS SUR	37	73	73	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	1988	297	6657					1169	1172		10.1136/bmj.297.6657.1169	http://dx.doi.org/10.1136/bmj.297.6657.1169			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q8250	3144333	Bronze, Green Published			2023-01-03	WOS:A1988Q825000021
J	BAKER, JA; LANT, AF; SUTTERS, CA				BAKER, JA; LANT, AF; SUTTERS, CA			17 YEARS EXPERIENCE OF A VOLUNTARILY BASED DRUG RATIONALIZATION PROGRAM IN HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article									RIVERSIDE HLTH AUTHOR,LONDON SW1 2AP,ENGLAND									ANDREWS PR, 1984, MED J AUSTRALIA, V141, P324, DOI 10.5694/j.1326-5377.1984.tb132792.x; AVORN J, 1982, AM J MED, V73, P4, DOI 10.1016/0002-9343(82)90911-1; BAKKE OM, 1984, HOSP FORMUL, V19, P411; Barrett C.W., 1982, CLIN PHARM HOSPITAL, P335; BROWN AW, 1975, BRIT MED J, V1, P323, DOI 10.1136/bmj.1.5953.323; CHEW R, 1985, PHARM 7 NATIONS, P36; COLLIER J, 1985, LANCET, V1, P331; CROOKS J, 1978, ADV PHARMACOL THER, V6, P189; DUNCAN A, 1980, BRIT MED J, V280, P300, DOI 10.1136/bmj.280.6210.300; GEORGE CF, 1983, WORLD DEV, V11, P229, DOI 10.1016/0305-750X(83)90030-X; GRANT GB, 1985, LANCET, V1, P1030; HARDING JM, 1985, BRIT MED J, V290, P450, DOI 10.1136/bmj.290.6466.450; HEMMINKI E, 1975, SOC SCI MED, V9, P111, DOI 10.1016/0037-7856(75)90103-1; JACKSON G, 1976, LANCET, V2, P1317; JONES SR, 1977, AM J MED SCI, V273, P79, DOI 10.1097/00000441-197701000-00008; KUNIN CM, 1973, ANN INTERN MED, V79, P555, DOI 10.7326/0003-4819-79-4-555; Maronde R F, 1971, Med Care, V9, P383, DOI 10.1097/00005650-197109000-00002; MCCARTHY MJ, 1974, LANCET, V2, P639; MIDDLEBROOK MJ, 1979, BRIT J PHARM PRACTIC, V1, P12; MITCHELL MW, 1985, J ROY COLL PHYS LOND, V19, P251; MOONEY GH, 1984, BRIT MED J, V288, P1817, DOI 10.1136/bmj.288.6433.1817; PETRIE JC, 1987, BRIT MED J, V294, P919, DOI 10.1136/bmj.294.6577.919; PLUMRIDGE R J, 1984, Australian Journal of Hospital Pharmacy, V14, P93; RIDLEY H, 1986, DRUGS CHOICE REPORT; SCHOLLENBERG E, 1980, CAN MED ASSOC J, V122, P49; SMITH T, 1985, BR MED J, V290, P533; SPECTOR R, 1983, J CLIN PHARMACOL, V23, P491, DOI 10.1002/j.1552-4604.1983.tb01795.x; SPOOR C, 1986, BRIT MED J, V292, P785, DOI 10.1136/bmj.292.6523.785; TOGNONI G, 1978, LANCET, V1, P1352; TURNER P, 1984, BRIT MED J, V288, P348, DOI 10.1136/bmj.288.6414.348; WICKINGS I, 1983, BRIT MED J, V286, P575, DOI 10.1136/bmj.286.6364.575; YELLOWLEES H, 1980, BRIT MED J, V280, P797, DOI 10.1136/bmj.280.6216.797-b; 1986, PHARM REPORT COMMITT, P64; 1978, BR MED J, V1, P1573; 1976, LANCET, V2, P351; 1982, REPORT SECRETARY STA; 1986, LANCET, V2, P1078; 1979, MIMS MAGAZINE   1101, P5; 1984, BR MED J, V289, P1388; 1984, EFFECT DRUG PRESCRIB	40	31	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 13	1988	297	6646					465	469		10.1136/bmj.297.6646.465	http://dx.doi.org/10.1136/bmj.297.6646.465			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P6653	3139150	Bronze, Green Published			2023-01-03	WOS:A1988P665300029
J	BULLIMORE, DW; FOSTER, P				BULLIMORE, DW; FOSTER, P			PROPHYLACTIC SCLEROTHERAPY FOR VARICES	BRITISH MEDICAL JOURNAL			English	Editorial Material											BULLIMORE, DW (corresponding author), ST JAMES HOSP,DEPT MED,LEEDS LS9 7TF,ENGLAND.							AOYAMA K, 1982, AUST PAEDIATR J, V18, P17; BACON BR, 1987, GASTROINTEST ENDOSC, V33, P311, DOI 10.1016/S0016-5107(87)71607-1; BARSOUM MS, 1982, BRIT J SURG, V69, P79, DOI 10.1002/bjs.1800690207; BARSOUM MS, 1982, BRIT J SURG, V69, P76, DOI 10.1002/bjs.1800690206; BEPPU K, 1981, GASTROINTEST ENDOSC, V27, P213, DOI 10.1016/S0016-5107(81)73224-3; BULLIMORE DW, 1985, J ROY COLL PHYS LOND, V19, P189; BURROUGHS AK, 1986, HEPATOLOGY, V6, P1407, DOI 10.1002/hep.1840060631; BURROUGHS AK, 1985, LANCET, V1, P1105; CONN HO, 1972, MEDICINE, V51, P27, DOI 10.1097/00005792-197201000-00002; DAGRADI AE, 1966, ARCH SURG-CHICAGO, V92, P944; DAGRADI AE, 1972, AM J GASTROENTEROL, V57, P520; GREGORY P, 1987, GASTROENTEROLOGY, V92, P1414; JACKSON FC, 1968, AM J SURG, V115, P22, DOI 10.1016/0002-9610(68)90127-X; KITANO S, 1987, HEPATOLOGY, V7, P810, DOI 10.1002/hep.1840070503; PAQUET KJ, 1982, ENDOSCOPY, V14, P4, DOI 10.1055/s-2007-1021560; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RESNICK RH, 1969, ANN INTERN MED, V70, P675, DOI 10.7326/0003-4819-70-4-675; SANTANGELO WC, 1988, NEW ENGL J MED, V318, P814, DOI 10.1056/NEJM198803313181304; SAUERBRUCH T, 1986, GASTROENTEROLOGY, V90, P1765; SEIDMAN E, 1984, HEPATOLOGY, V4, P950, DOI 10.1002/hep.1840040528; SMITH PM, 1982, J ROY COLL PHYS LOND, V16, P236; SORENSEN T, 1984, GUT, V25, P473, DOI 10.1136/gut.25.5.473; TERBLANCHE J, 1983, LANCET, V2, P1328; VANHOOTEGEM P, 1984, ENDOSCOPY, V16, P95, DOI 10.1055/s-2007-1018544; WEBB LJ, 1979, Q J MED, V48, P627; WESTABY D, 1985, HEPATOLOGY, V5, P827, DOI 10.1002/hep.1840050520; WESTABY D, 1986, HEPATOLOGY, V6, P673, DOI 10.1002/hep.1840060422; WESTABY S, 1978, DIGESTION, V17, P63, DOI 10.1159/000198095; WILLIAMS R, 1986, DIGEST DIS SCI, V31, pS108; WITZEL L, 1985, LANCET, V1, P773	30	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 6	1988	297	6645					370	371		10.1136/bmj.297.6645.370	http://dx.doi.org/10.1136/bmj.297.6645.370			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P5450	3044513	Green Published, Bronze			2023-01-03	WOS:A1988P545000002
J	HANCOCK, SL; HOPPE, RT; HORNING, SJ; ROSENBERG, SA				HANCOCK, SL; HOPPE, RT; HORNING, SJ; ROSENBERG, SA			INTERCURRENT DEATH AFTER HODGKIN DISEASE THERAPY IN RADIOTHERAPY AND ADJUVANT MOPP TRIALS	ANNALS OF INTERNAL MEDICINE			English	Article											HANCOCK, SL (corresponding author), STANFORD UNIV, DEPT RADIAT ONCOL, A089, STANFORD, CA 94305 USA.				NCI NIH HHS [CA 34244] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034244] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPELBAUM PC, 1979, NEW ENGL J MED, V300, P203; BJORKHOLM M, 1981, CANCER, V48, P2010, DOI 10.1002/1097-0142(19811101)48:9<2010::AID-CNCR2820480917>3.0.CO;2-V; BOOKMAN MA, 1986, CANCER TREAT REV, V13, P77, DOI 10.1016/0305-7372(86)90015-0; CADMAN E, 1978, NEW ENGL J MED, V299, P1317; CARBONE PP, 1971, CANCER RES, V31, P1860; CASTELLINO RA, 1974, ANN INTERN MED, V80, P593, DOI 10.7326/0003-4819-80-5-593; COHN KE, 1967, MEDICINE, V46, P281, DOI 10.1097/00005792-196705000-00003; COLEMAN CN, 1977, NEW ENGL J MED, V297, P1249, DOI 10.1056/NEJM197712082972303; COLEMAN CN, 1982, ANN INTERN MED, V96, P44, DOI 10.7326/0003-4819-96-1-44; DICKERMAN JD, 1976, J TRAUMA, V16, P662, DOI 10.1097/00005373-197608000-00012; DONALDSON SS, 1981, REV INFECT DIS, V3, pS133; EISENBERG AC, 1986, CANCER, V19, P385; FUKS Z, 1976, J CLIN INVEST, V58, P803, DOI 10.1172/JCI108532; GEHAN EA, 1965, BIOMETRIKA, V52, P203, DOI 10.1093/biomet/52.1-2.203; GLICKSMAN AS, 1982, CANCER TREAT REP, V66, P1035; GOTTDIENER JS, 1983, NEW ENGL J MED, V308, P569, DOI 10.1056/NEJM198303103081005; GREEN DM, 1987, J CLIN ONCOL, V5, P239, DOI 10.1200/JCO.1987.5.2.239; GUINEE VF, 1985, CANCER-AM CANCER SOC, V56, P642, DOI 10.1002/1097-0142(19850801)56:3<642::AID-CNCR2820560334>3.0.CO;2-N; HALPERIN EC, 1984, CANCER, V53, P232, DOI 10.1002/1097-0142(19840115)53:2<232::AID-CNCR2820530208>3.0.CO;2-F; HANCOCK EW, 1983, NEW ENGL J MED, V308, P588, DOI 10.1056/NEJM198303103081010; HOPPE RT, 1985, INT J RADIAT ONCOL, V11, P349, DOI 10.1016/0360-3016(85)90157-9; HOPPE RT, 1979, CANCER-AM CANCER SOC, V43, P472, DOI 10.1002/1097-0142(197902)43:2<472::AID-CNCR2820430211>3.0.CO;2-W; HOPPE RT, 1982, BLOOD, V59, P455; HOPPE RT, 1982, CANCER TREAT REP, V66, P743; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KAPLAN HS, 1980, HODGKINS DISEASE, P366; KING GW, 1979, ANN INTERN MED, V90, P892, DOI 10.7326/0003-4819-90-6-892; KRIKORIAN JG, 1979, NEW ENGL J MED, V300, P452, DOI 10.1056/NEJM197903013000902; KYONG K, 1979, NEW ENGL J MED, V301, P271; LIST AF, 1985, J CLIN ONCOL, V3, P215, DOI 10.1200/JCO.1985.3.2.215; LUKES RJ, 1966, CANCER RES, V26, P1063; MAUCH P, 1982, CANCER TREAT REP, V66, P809; MINOR DR, 1979, ANN INTERN MED, V90, P887, DOI 10.7326/0003-4819-90-6-887; MONSON RR, 1974, COMPUT BIOMED RES, V7, P325, DOI 10.1016/0010-4809(74)90010-X; NELSON DF, 1981, CANCER, V48, P2386, DOI 10.1002/1097-0142(19811201)48:11<2386::AID-CNCR2820481109>3.0.CO;2-B; POHJOLASINTONEN S, 1987, CANCER-AM CANCER SOC, V60, P31, DOI 10.1002/1097-0142(19870701)60:1<31::AID-CNCR2820600107>3.0.CO;2-D; PROSNITZ LR, 1978, INT J RADIAT ONCOL, V4, P781, DOI 10.1016/0360-3016(78)90036-6; ROSENBERG SA, 1985, INT J RADIAT ONCOL, V11, P5, DOI 10.1016/0360-3016(85)90357-8; SCHULTZ HP, 1975, INT J RADIAT ONCOL, V1, P1, DOI 10.1016/0360-3016(75)90003-6; SIBER GR, 1978, NEW ENGL J MED, V299, P442, DOI 10.1056/NEJM197808312990903; SIBER GR, 1986, ANN INTERN MED, V104, P467, DOI 10.7326/0003-4819-104-4-467; STEWART JR, 1984, PROG CARDIOVASC DIS, V27, P173; TESTER WJ, 1984, J CLIN ONCOL, V2, P762, DOI 10.1200/JCO.1984.2.7.762; TUCKER MA, 1985, ANN INTERN MED, V102, P37, DOI 10.7326/0003-4819-102-1-37; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; VALAGUSSA P, 1982, BLOOD, V59, P488; 1975, DHHS HRA751150 NAT C, P40; 1985, DHHS PHS8611515 NAT, P12	48	79	79	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1988	109	3					183	189		10.7326/0003-4819-109-3-183	http://dx.doi.org/10.7326/0003-4819-109-3-183			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P6065	3291657				2023-01-03	WOS:A1988P606500005
J	HAINER, BL; LAWLER, FH				HAINER, BL; LAWLER, FH			COMPARISON OF CRITICAL CARE PROVIDED BY FAMILY PHYSICIANS AND GENERAL INTERNISTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											HAINER, BL (corresponding author), E CAROLINA UNIV,SCH MED,DEPT FAMILY MED,GREENVILLE,NC 27858, USA.							ALCOFF J, 1981, J FAM PRACTICE, V12, P871; BERTAKIS KD, 1987, J FAM PRACTICE, V24, P305; BURKETT GL, 1982, MED CARE, V20, P1128, DOI 10.1097/00005650-198211000-00007; CHRISTIANSEN RG, 1986, JAMA-J AM MED ASSOC, V255, P2628, DOI 10.1001/jama.255.19.2628; CLINTON C, 1981, J FAM PRACTICE, V13, P361; COLWILL JM, 1986, JAMA-J AM MED ASSOC, V255, P2643, DOI 10.1001/jama.255.19.2643; COX DR, 1972, J R STAT SOC B, V34, P187; FRANKS P, 1986, MED CARE, V24, P941, DOI 10.1097/00005650-198610000-00007; GARBER AM, 1984, NEW ENGL J MED, V310, P1231, DOI 10.1056/NEJM198405103101906; GARG ML, 1976, AM J PUBLIC HEALTH, V66, P390, DOI 10.2105/AJPH.66.4.390; GEYMAN JP, 1986, JAMA-J AM MED ASSOC, V255, P2631, DOI 10.1001/jama.255.19.2631; GEYMAN JP, 1981, J FAM PRACTICE, V13, P325; GEYMAN JP, 1979, J FAM PRACTICE, V8, P911; GREENWALD HP, 1984, MED CARE, V22, P14, DOI 10.1097/00005650-198401000-00002; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MAGUIRE PH, 1979, J FAM PRACTICE, V8, P1019; MEDLEY ES, 1978, J FAM PRACTICE, V6, P817; MEZA F, 1981, J FAM PRACTICE, V13, P701; MORGAN CJ, 1986, BRIT MED J, V292, P1546, DOI 10.1136/bmj.292.6535.1546; NOREN J, 1980, NEW ENGL J MED, V302, P11, DOI 10.1056/NEJM198001033020103; ROSENBLATT RA, 1982, J FAM PRACTICE, V15, P681; SHANK JC, 1978, J FAM PRACTICE, V7, P547; SLABAUGH RC, 1980, J FAM PRACTICE, V11, P287; STERN TL, 1981, J FAM PRACTICE, V13, P1013; WEISS B, 1984, JAMA, V253, P549; WEISS BD, 1983, J FAM PRACTICE, V17, P693; WEISS BD, 1984, J FAM PRACTICE, V18, P747; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1985, SAS USERS GUIDE BASI	29	20	20	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 15	1988	260	3					354	358		10.1001/jama.260.3.354	http://dx.doi.org/10.1001/jama.260.3.354			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P1392	3379744				2023-01-03	WOS:A1988P139200026
J	MCCULLOUGH, J; STEEPER, TA; CONNELLY, DP; JACKSON, B; HUNTINGTON, S; SCOTT, EP				MCCULLOUGH, J; STEEPER, TA; CONNELLY, DP; JACKSON, B; HUNTINGTON, S; SCOTT, EP			PLATELET UTILIZATION IN A UNIVERSITY HOSPITAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV MINNESOTA HOSP & CLIN,QUAL ASSURANCE SERV,MINNEAPOLIS,MN 55455; AMER RED CROSS,BLOOD SERV,ST PAUL REG,MINNEAPOLIS,MN	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota Hospital; American Red Cross	MCCULLOUGH, J (corresponding author), UNIV MINNESOTA HOSP & CLIN,BLOOD BANK,DEPT LAB MED & PATHOL,BOX 198,HARVARD ST & E RIVER RD,MINNEAPOLIS,MN 55455, USA.			jackson, brooks/0000-0001-9458-135X	NLM NIH HHS [LM00160] Funding Source: Medline	NLM NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		ADERKA D, 1986, AM J MED SCI, V291, P147, DOI 10.1097/00000441-198603000-00001; BROWN CH, 1975, ANTIMICROB AGENTS CH, V7, P652, DOI 10.1128/AAC.7.5.652; BROWN CH, 1974, NEW ENGL J MED, V291, P265, DOI 10.1056/NEJM197408082910601; CARDAMONE JM, 1972, J AMER MED ASSOC, V221, P270, DOI 10.1001/jama.221.3.270; CAZENAVE JP, 1973, P SOC EXP BIOL MED, V142, P159; COHEN P, 1966, ARCH INTERN MED, V117, P113, DOI 10.1001/archinte.117.1.113; EKNOYAN G, 1969, NEW ENGL J MED, V280, P677, DOI 10.1056/NEJM196903272801301; FOLEY ME, 1977, LANCET, V1, P1230; FREEMAN G, 1954, BLOOD, V9, P586, DOI 10.1182/blood.V9.6.586.586; FREIREICH EJ, 1963, ANN INTERN MED, V59, P277, DOI 10.7326/0003-4819-59-3-277; GAETANO G, 1975, THROMB DIATH HAEMORR, V34, P284; GAYDOS LA, 1962, NEW ENGL J MED, V266, P905, DOI 10.1056/NEJM196205032661802; HABURCHAK DR, 1977, AM J SURG, V134, P630, DOI 10.1016/0002-9610(77)90451-2; HARKER LA, 1980, BLOOD, V56, P824; HARKER LA, 1972, NEW ENGL J MED, V287, P155, DOI 10.1056/NEJM197207272870401; HIGBY DJ, 1974, TRANSFUSION, V14, P440, DOI 10.1111/j.1537-2995.1974.tb04558.x; ILETT SJ, 1979, ACTA HAEMATOL-BASEL, V62, P86, DOI 10.1159/000207545; JANSON PA, 1980, NEW ENGL J MED, V303, P1318, DOI 10.1056/NEJM198012043032302; JOHNSON GJ, 1978, AM J PATHOL, V91, P85; Lindsay R M, 1976, Clin Nephrol, V6, P335; MENITOVE JE, 1982, WISC MED J, V81, P11; MIELKE CH, 1969, BLOOD-J HEMATOL, V34, P204, DOI 10.1182/blood.V34.2.204.204; MURPHY S, 1982, AM J HEMATOL, V12, P347, DOI 10.1002/ajh.2830120406; NELSON WR, 1975, SCAND J HAEMATOL, V15, P35; OBRIEN JR, 1968, LANCET, V1, P779; OBRIEN JR, 1970, J CLIN PATHOL, V23, P522, DOI 10.1136/jcp.23.6.522; PENNER JA, 1981, CLIN PRACTICE BLOOD, P514; ROY AJ, 1973, TRANSFUSION, V13, P283, DOI 10.1111/j.1537-2995.1973.tb05490.x; SATTLER FR, 1986, ANN INTERN MED, V105, P924, DOI 10.7326/0003-4819-105-6-924; SHATTIL SJ, 1980, J CLIN INVEST, V65, P329, DOI 10.1172/JCI109676; SLICHTER SJ, 1978, CLIN HAEMATOL, V7, P523; SLICHTER SJ, 1980, ANNU REV MED, V31, P509, DOI 10.1146/annurev.me.31.020180.002453; SOLOMON J, 1978, LANCET, V1, P267; STEINER RW, 1979, AM J HEMATOL, V7, P107, DOI 10.1002/ajh.2830070203; STRAUSS RG, 1986, PLASMA THER TRANSFUS, V7, P279; SWANSON JL, 1984, TRANSFUSION, V24, P141, DOI 10.1046/j.1537-2995.1984.24284173345.x; TOMASULO PA, 1981, CLIN PRACTICE BLOOD, P530; WEISS HJ, 1977, HAEMATOLOGY, P1377; WEITEKAMP MR, 1983, JAMA-J AM MED ASSOC, V249, P69, DOI 10.1001/jama.249.1.69; 1980, BLOOD SERVICES OPERA; 1987, JAMA, V257, P1777	41	57	57	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 22	1988	259	16					2414	2418		10.1001/jama.259.16.2414	http://dx.doi.org/10.1001/jama.259.16.2414			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M9670	3352130				2023-01-03	WOS:A1988M967000020
J	SURREY, T; JAHNIG, F				SURREY, T; JAHNIG, F			KINETICS OF FOLDING AND MEMBRANE INSERTION OF A BETA-BARREL MEMBRANE-PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; RECONSTITUTION; RENATURATION; INTERMEDIATE; OMPA	We have studied the kinetics of folding and membrane insertion of the outer membrane protein OmpA of Escherichia coli. In the native structure, its membrane-inserted domain forms a beta-barrel. The protein was unfolded in solubilized form in water/urea, and refolding was induced by dilution of urea and simultaneous addition of lipid vesicles, Three transitions along the folding pathway could be distinguished. Their characteristic times lie below a second, in the range of minutes, and in the range of an hour. The fast process corresponds to the transition from the unfolded state in water/urea to a misfolded state in water, the moderately slow process to a transition from the misfolded state to a partially folded state in the membrane, and the slow process to the transition from the partially folded to the native state. The partially folded state in the membrane is interpreted as the analogue of the molten globule state of soluble proteins.	MAX PLANCK INST BIOL, MEMBRANBIOCHEM ABT, D-72076 TUBINGEN, GERMANY	Max Planck Society			Surrey, Thomas/AAC-4608-2021	Surrey, Thomas/0000-0001-9082-1870				BOOTH PJ, 1995, NAT STRUCT BIOL, V2, P139, DOI 10.1038/nsb0295-139; CHRISTENSEN H, 1991, EUR BIOPHYS J, V19, P221, DOI 10.1007/BF00183530; DORNMAIR K, 1990, J BIOL CHEM, V265, P18907; EISELE JL, 1990, J BIOL CHEM, V265, P10217; Engelman DM, 1984, PROTEIN FOLDING PROB, P87; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FREUDL R, 1986, J BIOL CHEM, V261, P1355; Garel Jean-Renaud, 1992, P405; GOLDBERG ME, 1991, BIOCHEMISTRY-US, V30, P2790, DOI 10.1021/bi00225a008; HUANG KS, 1981, J BIOL CHEM, V256, P3802; PAULSEN H, 1990, PLANTA, V181, P204, DOI 10.1007/BF02411539; Schmid Franz X., 1992, P197; SCHWARZ G, 1987, BIOPHYS J, V52, P685, DOI 10.1016/S0006-3495(87)83263-0; SCHWEIZER M, 1978, EUR J BIOCHEM, V82, P211, DOI 10.1111/j.1432-1033.1978.tb12013.x; SCOTTO AW, 1985, BIOCHEMISTRY-US, V24, P4066, DOI 10.1021/bi00336a040; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SURREY T, 1992, P NATL ACAD SCI USA, V89, P7457, DOI 10.1073/pnas.89.16.7457; VANDERGOOT FG, 1991, NATURE, V354, P408, DOI 10.1038/354408a0; VOGEL H, 1986, J MOL BIOL, V190, P191, DOI 10.1016/0022-2836(86)90292-5; WEI J, 1995, BIOCHEMISTRY-US, V34, P6408, DOI 10.1021/bi00019a021	20	102	103	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 24	1995	270	47					28199	28203						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TG210	7499313				2023-01-03	WOS:A1995TG21000038
J	VANDEWERF, F; TOPOL, EJ; LEE, KL; WOODLIEF, LH; GRANGER, CB; ARMSTRONG, PW; BARBASH, GI; HAMPTON, JR; GUERCI, A; SIMES, RJ; ROSS, AM; CALIFF, RM				VANDEWERF, F; TOPOL, EJ; LEE, KL; WOODLIEF, LH; GRANGER, CB; ARMSTRONG, PW; BARBASH, GI; HAMPTON, JR; GUERCI, A; SIMES, RJ; ROSS, AM; CALIFF, RM			VARIATIONS IN PATIENT-MANAGEMENT AND OUTCOMES FOR ACUTE MYOCARDIAL-INFARCTION IN THE UNITED-STATES AND OTHER COUNTRIES - RESULTS FROM THE GUSTO TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CONSERVATIVE MANAGEMENT; PLASMINOGEN-ACTIVATOR; ANGIOPLASTY; ANGIOGRAPHY; THERAPY	Objective.-To examine differences in outcomes and patient management between patients in the United States and outside the United States undergoing thrombolysis for acute myocardial infarction. Design, Setting, and Patients.-Patients in the United States (n=23105) and 14 other countries (n=17916) were randomized to receive streptokinase plus either subcutaneous or intravenous (IV) heparin, accelerated recombinant tissue-type plasminogen activator (rt-PA) plus IV heparin, or combined streptokinase and rt-PA plus IV heparin. Outcome Measures.-Differences in 30-day mortality and patient management were compared among treatments and between US and non-US patients. Treatment-by-country interactions were assessed by logistic regression analyses. Expected mortality of US and non-US patients was estimated using a predictive model and was compared with observed mortality. Results.-Mortality reduction with accelerated rt-PA vs streptokinase was greater in the United States (1.2% absolute decrease vs 0.7% elsewhere), but the test for treatment-by-country interaction against streptokinase was not significant (P=.30). Benefits of accelerated rt-PA over combination therapy were observed in the United States, but not in other countries (P=.02). Despite differences in baseline characteristics and patient management, 30-day mortality was not significantly different: 6.8% in the United States vs 7.2% elsewhere (P=.09). After adjustment for baseline differences, observed vs predicted outcomes were slightly better in the United States (6.8% vs 7.0%) than elsewhere (7.2% vs 7.0%), indicating that enrollment in the United States was a marginally significant predictor of better survival (P=.047). Conclusions.-No significant evidence for a differentially greater benefit of accelerated rt-PA over streptokinase was found in US vs non-US patients, However, increased procedure and treatment use in the United States was associated with only a small decrease in short-term mortality. Long-term follow-up is required to clarify the relationship between survival and the more intensive US management approach.	CLEVELAND CLIN FDN, DEPT CARDIOL, CLEVELAND, OH 44195 USA; DUKE UNIV, MED CTR, DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT MED, DIV CARDIOL, DURHAM, NC 27710 USA; WALTER C MACKENZIE HLTH SCI CTR, DEPT MED, EDMONTON, AB, CANADA; TEL AVIV ELIAS SOURASKY HOSP, TEL AVIV, ISRAEL; QUEENS MED CTR, DEPT MED, NOTTINGHAM NG7 2UH, ENGLAND; ST FRANCIS HOSP, ROSLYN, NY USA; UNIV SYDNEY, NATL HLTH & MED RES COUNCIL CLIN TRIALS CTR, SYDNEY, NSW 2006, AUSTRALIA; GEORGE WASHINGTON UNIV, MED CTR, DIV CARDIOL, WASHINGTON, DC 20037 USA	Cleveland Clinic Foundation; Duke University; Duke University; University of Alberta; University of Nottingham; University of Sydney; George Washington University	VANDEWERF, F (corresponding author), UNIV HOSP GASTHUISBERG, DEPT CARDIOL, HERESTR 49, B-3000 LOUVAIN, BELGIUM.		Simes, Robert John/P-1497-2014; Granger, Christopher B/D-3458-2014	Granger, Christopher B/0000-0002-0045-3291; Topol, Eric/0000-0002-1478-4729; Armstrong, Paul/0000-0002-0460-3445				[Anonymous], 1989, NEW ENGL J MED, V320, P618; BARBASH GI, 1990, AM J CARDIOL, V66, P538, DOI 10.1016/0002-9149(90)90478-J; BARBASH GI, 1994, ARCH INTERN MED, V154, P2237, DOI 10.1001/archinte.154.19.2237; BARBASH GI, 1993, J AM COLL CARDIOL, V21, P281, DOI 10.1016/0735-1097(93)90664-M; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CALIFF RM, 1994, CIRCULATION, V90, P434; DEBONO DP, 1991, BMJ-BRIT MED J, V302, P555; ELLIS SG, 1992, CIRCULATION, V86, P1400, DOI 10.1161/01.CIR.86.5.1400; EVERY NR, 1993, NEW ENGL J MED, V329, P546, DOI 10.1056/NEJM199308193290807; HAMM CW, 1994, NEW ENGL J MED, V331, P1037, DOI 10.1056/NEJM199410203311601; HAMPTON J, 1993, LANCET, V342, P759; HOSMER EW, 1989, APPLIED LOGISTIC REG; KING SB, 1994, NEW ENGL J MED, V331, P1044, DOI 10.1056/NEJM199410203311602; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MARK DB, 1994, CIRCULATION, V89, P2015, DOI 10.1161/01.CIR.89.5.2015; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; RUOCCO NA, 1992, J AM COLL CARDIOL, V20, P1445, DOI 10.1016/0735-1097(92)90435-P; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; TUHEY JW, 1977, SCIENCE, V198, P679; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93	23	139	143	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 24	1995	273	20					1586	1591		10.1001/jama.273.20.1586	http://dx.doi.org/10.1001/jama.273.20.1586			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY541	7745771				2023-01-03	WOS:A1995QY54100025
J	TURNER, P; EDWARDS, R; WESTON, V; GAZIS, A; ISPAHANI, P; GREENWOOD, D				TURNER, P; EDWARDS, R; WESTON, V; GAZIS, A; ISPAHANI, P; GREENWOOD, D			SIMULTANEOUS RESISTANCE TO METRONIDAZOLE, CO-AMOXICLAV, AND IMIPENEM IN CLINICAL ISOLATE OF BACTEROIDES-FRAGILIS	LANCET			English	Note							SUSCEPTIBILITY	A blood-culture isolate of Bacteroides fragilis, taken from a woman after elective laparotomy, was resistant to metronidazole an had reduced susceptibility to imipenem and co-amoxiclav. After treatment with imipenem, pus drained from the pleural cavity yielded an identical isolate that had become highly resistant to imipenem and co-amoxiclav. Emergence of full resistance to the beta-lactam antibiotics was accompanied by a tenfold rise in the specific activity of a metallo-beta-lactamase. Clinicians need to be alert to simultaneous resistance to metronidazole, co-amoxiclav, and imipenem and development of high-level resistance to imipenem in B fragilis during treatment with this agent.	UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DIV MICROBIOL,NOTTINGHAM NG7 2UH,ENGLAND; UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DIV MED,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham; University of Nottingham	TURNER, P (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,NOTTINGHAM PUBL HTLH LAB,NOTTINGHAM NG7 2UH,ENGLAND.							CORNICK NA, 1990, J ANTIMICROB CHEMOTH, V25, P1011, DOI 10.1093/jac/25.6.1011; EDWARDS DI, 1993, J ANTIMICROB CHEMOTH, V31, P201, DOI 10.1093/jac/31.2.201; EDWARDS R, 1992, J MED MICROBIOL, V36, P89, DOI 10.1099/00222615-36-2-89; GOLDSTEIN EJC, 1993, J ANTIMICROB CHEMOTH, V31, P363, DOI 10.1093/jac/31.3.363; GREENWOOD D, 1991, ANAEROBES HUMAN DISE, P415; LIVERMORE DM, 1992, J ANTIMICROB CHEMOTH, V29, P609, DOI 10.1093/jac/29.6.609; PODGLAJEN I, 1992, FEMS MICROBIOL LETT, V91, P21, DOI 10.1016/0378-1097(92)90557-5; RASMUSSEN BA, 1993, CLIN INFECT DIS, V16, pS390, DOI 10.1093/clinids/16.Supplement_4.S390; TUNER K, 1993, CLIN INFECT DIS, V16, pS387, DOI 10.1093/clinids/16.Supplement_4.S387	9	51	54	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1275	1277		10.1016/S0140-6736(95)90927-3	http://dx.doi.org/10.1016/S0140-6736(95)90927-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746059				2023-01-03	WOS:A1995QY93300011
J	MOERTEL, CG; FLEMING, TR; MACDONALD, JS; HALLER, DG; LAURIE, JA; TANGEN, CM; UNGERLEIDER, JS; EMERSON, WA; TORMEY, DC; GLICK, JH; VEEDER, MH; MAILLIARD, JA				MOERTEL, CG; FLEMING, TR; MACDONALD, JS; HALLER, DG; LAURIE, JA; TANGEN, CM; UNGERLEIDER, JS; EMERSON, WA; TORMEY, DC; GLICK, JH; VEEDER, MH; MAILLIARD, JA			FLUOROURACIL PLUS LEVAMISOLE AS EFFECTIVE ADJUVANT THERAPY AFTER RESECTION OF STAGE-III COLON-CARCINOMA - A FINAL REPORT	ANNALS OF INTERNAL MEDICINE			English	Article							CANCER	Objective: To determine the effectiveness of two adjuvant therapy regimens in improving surgical cure rates in stage III (Dukes stage C) colon cancer. Design: Randomized, concurrently controlled clinical trial. Setting: Major cancer centers, universities, and community clinics affiliated with the North Cancer Treatment Group, the Southwest Oncology Group, and the Eastern Cooperative Oncology Group. Patients: Those who had had curative-intent resections of stage III colon cancer in the previous 1 to 5 weeks. Intervention: Patients were assigned to observation only, to levamisole alone (50 mg orally three times/d far 3 days, repeated every 2 weeks for 1 year), or to this regimen of levamisole plus fluorouracil (450 mg/m(2) body surface area intravenously daily for 5 days and then, beginning at 28 days, weekly for 48 weeks). Measurements: Rates of cancer recurrence and death. Early- and late-treatment side effects. Results: With all 929 eligible patients able to be followed for 5 years or more (median follow-up, 6.5 years), fluorouracil plus levamisole reduced the recurrence rate by 40% (P < 0.0001) and the death rate by 33% (P = 0.0007). Levamisole reduced the recurrence rate by only 2% and the death rate by only 6%. With few exceptions, toxicity was mild and patient compliance was excellent. No evidence of late side effects was seen. Conclusion: Fluorouracil plus levamisole is tolerable adjuvant therapy to surgery; it has been confirmed to substantially increase cure rates for patients with highrisk (stage III) colon cancer. It should be considered standard treatment for all such patients not entered into clinical trials.	MAYO CLIN & MAYO FDN, ROCHESTER, MN 55905 USA; FRED HUTCHINSON CANC RES CTR, SEATTLE, WA USA; TEMPLE UNIV, CTR CANC, PHILADELPHIA, PA 19140 USA; UNIV PENN, CTR CANC, PHILADELPHIA, PA 19104 USA; GRAND FORKS CLIN LTD, GRAND FORKS, ND 58201 USA; OHIO STATE UNIV, COLUMBUS, OH USA; ST LOUIS COMMUNITY CLIN ONCOL PROGRAM, ST LOUIS, MO USA; AMC, CANC RES CTR, DENVER, CO 80214 USA; ONCOL HEMATOL ASSOCIATES, PEORIA, IL 61602 USA; CREIGHTON UNIV, CTR CANC, MED ONCOL SERV, OMAHA, NE 68131 USA; ST JOSEPH HOSP, OMAHA, NE USA	Mayo Clinic; Fred Hutchinson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; University of Pennsylvania; University System of Ohio; Ohio State University; AMC Cancer Research Center; Creighton University					NATIONAL CANCER INSTITUTE [U10CA025224, U10CA037404, P01CA031224] Funding Source: NIH RePORTER; NCI NIH HHS [CA-31224, CA-25224, CA-37404] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNAUD JP, 1989, BRIT J SURG, V76, P284, DOI 10.1002/bjs.1800760322; BUYSE M, 1988, JAMA-J AM MED ASSOC, V259, P3571; COX DR, 1972, J R STAT SOC B, V34, P187; GREM JL, 1989, J NATL CANCER I, V81, P1413, DOI 10.1093/jnci/81.18.1413; HALL WH, 1990, JAMA-J AM MED ASSOC, V264, P1444; HOOK CC, 1992, ANN NEUROL, V31, P262, DOI 10.1002/ana.410310306; JANIK J, 1993, J CLIN ONCOL, V11, P125, DOI 10.1200/JCO.1993.11.1.125; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOVACH JS, 1992, J NATL CANCER I, V84, P515, DOI 10.1093/jnci/84.7.515; LAURIE JA, 1989, J CLIN ONCOL, V7, P1447, DOI 10.1200/JCO.1989.7.10.1447; MANTEL N, 1959, J NATL CANCER I, V22, P719; MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602; MOERTEL CG, 1993, J CLIN ONCOL, V11, P2386, DOI 10.1200/JCO.1993.11.12.2386; OCONNELL M, 1993, P AN M AM SOC CLIN, V12, P190; PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896; WOLMARK N, 1993, P AN M AM SOC CLIN, V12, P197; ZANIBONI A, 1993, P AN M AM SOC CLIN, V12, P191; 1992, SAS P229 I INC TECHN, P433	18	762	776	0	21	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					321	326		10.7326/0003-4819-122-5-199503010-00001	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00001			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847642				2023-01-03	WOS:A1995QJ08500001
J	WALDMANN, TA				WALDMANN, TA			HUMAN T-CELL LYMPHOTROPIC VIRUS TYPE-I ASSOCIATED ADULT T-CELL LEUKEMIA - THE JOSEPH-GOLDBERGER-CLINICAL-INVESTIGATOR-LECTURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Discussion							RECEPTOR GAMMA-CHAIN; ANTI-TAC-H; INTERLEUKIN-2 RECEPTOR; MONOCLONAL-ANTIBODY; PSEUDOMONAS EXOTOXIN; RADIOIMMUNOTHERAPY; LYMPHOMA; FEATURES; SURVIVAL; DOMAINS				WALDMANN, TA (corresponding author), NCI,METAB BRANCH,BLDG 10,ROOM 4N115,BETHESDA,MD 20892, USA.		Waldmann, Thomas/AAT-5972-2021	Waldmann, Thomas/0000-0003-4500-6660				BAMFORD RN, 1994, P NATL ACAD SCI USA, V91, P4940, DOI 10.1073/pnas.91.11.4940; BAZAN JF, 1990, P NATL ACAD SCI USA, V18, P6934; BROWN PS, 1991, P NATL ACAD SCI USA, V88, P2663, DOI 10.1073/pnas.88.7.2663; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0; JUNGHANS RP, 1990, CANCER RES, V50, P1495; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KOZAK RW, 1986, P NATL ACAD SCI USA, V83, P474, DOI 10.1073/pnas.83.2.474; KOZAK RW, 1989, CANCER RES, V49, P2639; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; QUEEN C, 1989, P NATL ACAD SCI USA, V86, P10029, DOI 10.1073/pnas.86.24.10029; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WALDMANN TA, 1993, BLOOD, V82, P1701; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WALDMANN TA, 1993, LEUKEMIA, V7, pS151; YAMAGUCI K, 1994, LANCET, V243, P213	24	5	6	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					735	737		10.1001/jama.273.9.735	http://dx.doi.org/10.1001/jama.273.9.735			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH814	7853633				2023-01-03	WOS:A1995QH81400034
J	DOWELL, JS; SNADDEN, D; DUNBAR, JA				DOWELL, JS; SNADDEN, D; DUNBAR, JA			CHANGING TO GENERIC FORMULARY - HOW ONE FUNDHOLDING PRACTICE REDUCED PRESCRIBING COSTS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To observe one general practice's attempt to reduce prescribing costs on becoming third wave fundholders through the introduction of a generic formulary applied to all new and repeat prescribing. To assess the impact on patients and prescribing patterns. Design-An observational study using interviews with patients and practitioners; questionnaires for patients and prescribing data. Setting-One urban general practice with five partners in Scotland. It became fundholding in April 1993. Subjects-71 searches of the register of repeat prescriptions identified 1274 potential changes in drugs. Questionnaires were sent to a stratified random sample of 280 patients four months after the changes were made; 33 interviews were conducted with 17 patients selected by local pharmacists to represent a wide range of opinion. Main outcome measures-Changes in prescribing and response and satisfaction of patients. Results-Of intended changes, 129 (70%) were in place after four months. Thirty three (20%) of the 167 patients who returned questionnaires were ''very unhappy,'' though interviews suggested that this was primarily with the communication they received rather than the change itself. Generic prescribing rose from one in three (37%) to over a half (58%). The volume of treatment dispensed (as treatment days) fell by 67 674 (10.7%), and the average cost per day's treatment fell by 3.1p from 32.3p per day in 1992 (9.4%), producing a total absolute saving of 24% (pound 137 712) over the first year. Conclusion-This practice has achieved a large reduction in prescribing costs rapidly. These were tolerated by patients, none of whom is thought to have left the practice for this reason. Great care must be taken to inform patients appropriately.	DOWNFIELD SURG,DUNDEE DD3 8NE,SCOTLAND		DOWELL, JS (corresponding author), WESTGATE HLTH CTR,TAYSIDE CTR GEN PRACTICE,DUNDEE DD2 4AD,SCOTLAND.		Dowell, Jonathan/M-6077-2019; Snadden, David/ABF-1586-2020; Dunbar, James A/G-3034-2012	Snadden, David/0000-0002-4818-1184; 				BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; DAY P, 1991, BRIT MED J, V303, P168, DOI 10.1136/bmj.303.6795.168; KEELEY D, 1994, BRIT MED J, V308, P206, DOI 10.1136/bmj.308.6922.206c; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; PANTON R, 1993, BRIT MED J, V306, P310, DOI 10.1136/bmj.306.6873.310; Patton M. Q., 1990, QUALITATIVE EVALUATI, P280; 1994, PRESCRIPTION IMPROVE	7	71	71	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					505	508		10.1136/bmj.310.6978.505	http://dx.doi.org/10.1136/bmj.310.6978.505			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7677830	Green Published			2023-01-03	WOS:A1995QJ59800028
J	ALTER, HJ; MOREL, PA; DORMAN, BP; SMITH, GC; CREAGAN, RP; WIESEHAHN, GP; CORASH, L; POPPER, H; EICHBERG, JW				ALTER, HJ; MOREL, PA; DORMAN, BP; SMITH, GC; CREAGAN, RP; WIESEHAHN, GP; CORASH, L; POPPER, H; EICHBERG, JW			PHOTOCHEMICAL DECONTAMINATION OF BLOOD COMPONENTS CONTAINING HEPATITIS-B AND NON-A, NON-B VIRUS	LANCET			English	Article									SAN ANTONIO COMMUNITY HOSP, DEPT CLIN MED, UPLAND, CA 91786 USA; ST MARYS HOSP & MED CTR, TRANSFUS SERV, SAN FRANCISCO, CA 94117 USA; DIAMOND SCI CO, DES MOINES, IA 50317 USA; ACROGEN INC, OAKLAND, CA 94606 USA; UNIV CALIF SAN FRANCISCO, DEPT LAB MED, SAN FRANCISCO, CA 94143 USA; SW FDN BIOMED RES, DEPT VIROL & IMMUNOL, SAN ANTONIO, TX 78284 USA; MT SINAI MED CTR, NEW YORK, NY 10029 USA	University of California System; University of California San Francisco; Texas Biomedical Research Institute; Icahn School of Medicine at Mount Sinai	ALTER, HJ (corresponding author), NIH, WARREN GRANT MAGNUSON CLIN CTR, DEPT TRANSFUS MED, BETHESDA, MD 20205 USA.				DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB077029] Funding Source: NIH RePORTER; NHLBI NIH HHS [1-HB-7-7029] Funding Source: Medline	DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTER HJ, 1985, INFECTION IMMUNITY B; [Anonymous], 1977, VOX SANG, V32, P346; CHANDRA P, 1966, Z NATURFORSCH PT B, VB 21, P663; DEWOLFF FA, 1986, CLIN PHARMACOKINET, V11, P62, DOI 10.2165/00003088-198611010-00004; EPSTEIN JH, 1970, J INVEST DERMATOL, V54, P350; FEINSTONE SM, 1981, J INFECT DIS, V144, P588, DOI 10.1093/infdis/144.6.588; HANSON CV, 1978, J GEN VIROL, V40, P345, DOI 10.1099/0022-1317-40-2-345; HEARST JE, 1977, NUCLEIC ACIDS RES, V4, P1339, DOI 10.1093/nar/4.5.1339; HYDE JE, 1978, BIOCHEMISTRY-US, V17, P1251, DOI 10.1021/bi00600a019; KANNE D, 1982, BIOCHEMISTRY-US, V21, P861, DOI 10.1021/bi00534a008; PECKLER S, 1982, J MOL BIOL, V162, P157, DOI 10.1016/0022-2836(82)90166-8; SEEFF LB, 1981, FRONTIERS LIVER DISE; SEIDL S, 1988, BLOOD TRANSFUSION; SHIMIZU YK, 1979, SCIENCE, V205, P197, DOI 10.1126/science.451589; SINDEN RR, 1978, J BACTERIOL, V136, P538, DOI 10.1128/JB.136.2.538-547.1978; WARD JW, 1988, NEW ENGL J MED, V318, P473, DOI 10.1056/NEJM198802253180803; WIESEHAHN GP, 1988, Patent No. 4748120; WIESEHAHN GP, 1988, Patent No. 4727027	18	60	70	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 24	1988	2	8626-7					1446	1450						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R5531	2904570				2023-01-03	WOS:A1988R553100003
J	DALEY, J; JENCKS, S; DRAPER, D; LENHART, G; THOMAS, N; WALKER, J				DALEY, J; JENCKS, S; DRAPER, D; LENHART, G; THOMAS, N; WALKER, J			PREDICTING HOSPITAL-ASSOCIATED MORTALITY FOR MEDICARE PATIENTS - A METHOD FOR PATIENTS WITH STROKE, PNEUMONIA, ACUTE MYOCARDIAL-INFARCTION, AND CONGESTIVE HEART-FAILURE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									CHARLES A DANA RES INST,BOSTON,MA; HLTH CARE FINANCING ADM,OFF RES,BALTIMORE,MD; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DEPT MED,DIV GEN MED & PRIMARY CARE,BOSTON,MA 02215; RAND CORP,DEPT ECON & STAT,SANTA MONICA,CA 90406	Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; RAND Corporation	DALEY, J (corresponding author), BAXTER HEALTHCARE CORP,INST HLTH DATA,LEXINGTON,MA, USA.							Fienberg S.E., 1980, ANAL CROSS CLASSIFIE, V2nd ed.; FLEISS JL, 1973, STATISTICAL METHODS; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Iezzoni LI, 1988, ABILITY MEDISGROUPS; JENCKS SF, 1987, NEW ENGL J MED, V317, P679, DOI 10.1056/NEJM198709103171106; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P3611, DOI 10.1001/jama.260.24.3611; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KAHN KL, 1988, JAMA-J AM MED ASSOC, V260, P3625, DOI 10.1001/jama.260.24.3625; KAHN KL, 1988, MED RECORD ABSTRACTI; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOSECOFF J, 1988, MED RECORD ABSTRACTI; Roth C.P., 1988, MED RECORD ABSTRACTI; RUBINSTEIN LV, 1988, MED RECORD ABSTRACTI; 1980, INT CLASSIFICATION D; 1986, SUGI SUPPLEMENTAL US	15	265	266	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1988	260	24					3617	3624		10.1001/jama.260.24.3617	http://dx.doi.org/10.1001/jama.260.24.3617			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R3644	3057251				2023-01-03	WOS:A1988R364400032
J	HORN, E				HORN, E			IRON AND FOLATE SUPPLEMENTS DURING PREGNANCY - SUPPLEMENTING EVERYONE TREATS THOSE AT RISK AND IS COST-EFFECTIVE	BRITISH MEDICAL JOURNAL			English	Article											HORN, E (corresponding author), UNIV NOTTINGHAM HOSP,DEPT THERAPEUT,NOTTINGHAM NG7 2UH,ENGLAND.							BAUMSLAG N, 1970, BMJ-BRIT MED J, V1, P16, DOI 10.1136/bmj.1.5687.16; BEISCHER NA, 1968, AM J OBSTET GYNECOL, V102, P819, DOI 10.1016/0002-9378(68)90509-7; BENTLEY DP, 1985, CLIN HAEMATOL, V14, P613; BONNAR J, 1969, LANCET, V1, P457; BUTLER NR, 1959, PERINATAL MORTALITY, P71; CHANARIN I, 1968, BRIT MED J, V2, P390, DOI 10.1136/bmj.2.5602.390; CHANARIN I, 1985, CLIN HAEMATOL, V14, P629; CHANARIN I, 1971, BRIT MED J, V2, P81, DOI 10.1136/bmj.2.5753.81; CHISHOLM M., 1966, Journal of Obstetrics and Gynaecology of the British Commonwealth, V73, P191; FENTON V, 1977, BRIT J HAEMATOL, V37, P145, DOI 10.1111/j.1365-2141.1977.tb08819.x; FLETCHER J, 1971, J OBSTET GYN BR COMM, V78, P781; GARN SM, 1981, AM J CLIN NUTR, V34, P115, DOI 10.1093/ajcn/34.1.115; HARRIS R, 1988, BRIT MED J, V296, P80, DOI 10.1136/bmj.296.6615.80-a; HEMMINKI E, 1978, BR J OBSTET GYNAECOL, V85, P410; HIBBARD BM, 1964, J OBSTET GYN BR COMM, V71, P529; JACOBS A, 1982, CLIN HAEMATOL, V11, P353; KALTREIDER DF, 1976, AM J OBSTET GYNECOL, V124, P251, DOI 10.1016/0002-9378(76)90152-6; KELLY AM, 1978, BRIT J OBSTET GYNAEC, V85, P338, DOI 10.1111/j.1471-0528.1978.tb14890.x; KULLANDER S, 1976, ACTA OBSTET GYN SCAN, V55, P287, DOI 10.3109/00016347609158500; McFee J G, 1973, Clin Obstet Gynecol, V16, P153, DOI 10.1097/00003081-197303000-00009; MORGAN EH, 1961, LANCET, V1, P9; MOSCOVITCH LF, 1973, AM J CLIN NUTR, V26, P707; NELSON MM, 1971, BRIT MED J, V1, P523, DOI 10.1136/bmj.1.5748.523; ROMSLO I, 1983, BRIT J OBSTET GYNAEC, V90, P101, DOI 10.1111/j.1471-0528.1983.tb08891.x; SCOTT JM, 1975, BRIT MED J, V1, P259, DOI 10.1136/bmj.1.5952.259; Smail S A, 1981, J R Coll Gen Pract, V31, P707; TAYLOR DJ, 1982, BRIT J OBSTET GYNAEC, V89, P1011, DOI 10.1111/j.1471-0528.1982.tb04656.x; WILLOUGHBY ML, 1967, BRIT J HAEMATOL, V13, P503, DOI 10.1111/j.1365-2141.1967.tb00760.x; 1978, BR MED J, V2, P1317; 1972, WHO TECH REP SER, V503, P29	30	24	24	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1988	297	6659					1325	&		10.1136/bmj.297.6659.1325	http://dx.doi.org/10.1136/bmj.297.6659.1325			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R0450	3144379	Green Published, Bronze			2023-01-03	WOS:A1988R045000034
J	BOWMAN, E; DOYLE, LW; MURTON, LJ; ROY, RND; KITCHEN, WH				BOWMAN, E; DOYLE, LW; MURTON, LJ; ROY, RND; KITCHEN, WH			INCREASED MORTALITY OF PRETERM INFANTS TRANSFERRED BETWEEN TERTIARY PERINATAL CENTERS	BRITISH MEDICAL JOURNAL			English	Article									UNIV MELBOURNE,DEPT OBSTET,PARKVILLE,VIC 3052,AUSTRALIA; UNIV MELBOURNE,DEPT GYNAECOL,PARKVILLE,VIC 3052,AUSTRALIA; ROYAL WOMENS HOSP,DIV PAEDIAT,MELBOURNE,AUSTRALIA; NEWBORN EMERGENCY TRANSPORT SERV,MELBOURNE,VIC,AUSTRALIA	University of Melbourne; University of Melbourne			Doyle, Lex/AAJ-5205-2021	Doyle, Lex/0000-0002-7667-7312				KITCHEN W, 1984, J PEDIATR-US, V104, P921, DOI 10.1016/S0022-3476(84)80500-4; KITCHEN WH, 1985, OBSTET GYNECOL, V66, P1079; LONG JG, 1980, PEDIATRICS, V65, P203, DOI 10.1542/peds.65.2.203; MANTEL N, 1959, J NATL CANCER I, V22, P719; Roy R N, 1977, Med J Aust, V2, P855; YU VYH, 1986, BRIT MED J, V293, P1200, DOI 10.1136/bmj.293.6556.1200	6	44	44	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 29	1988	297	6656					1098	1100		10.1136/bmj.297.6656.1098	http://dx.doi.org/10.1136/bmj.297.6656.1098			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q7868	3143439	Green Published, Bronze			2023-01-03	WOS:A1988Q786800020
J	WALSHAW, MJ; LIM, R; EVANS, CC; HIND, CRK				WALSHAW, MJ; LIM, R; EVANS, CC; HIND, CRK			PRESCRIPTION OF OXYGEN CONCENTRATORS FOR LONG-TERM OXYGEN TREATMENT - REASSESSMENT IN ONE DISTRICT	BRITISH MEDICAL JOURNAL			English	Article									UNIV LIVERPOOL,ROYAL LIVERPOOL HOSP,DEPT MED,LIVERPOOL L7 8XP,ENGLAND	Royal Liverpool & Broadgreen University Hospitals NHS Trust; Royal Liverpool University Hospital; University of Liverpool			Lim, Richard/J-7102-2012	Lim, Richard/0000-0002-4914-7244				[Anonymous], 1981, LANCET, V1, P681; BISWAS CK, 1982, BRIT MED J, V284, P923, DOI 10.1136/bmj.284.6320.923; Nocturnal Oxygen Therapy Trial Group, 1980, ANN INTERN MED, V93, P391; STARK RD, 1973, BRIT MED J, V3, P467, DOI 10.1136/bmj.3.5878.467; 1985, LANCET, V2, P365; 1985, NATIONAL HLTH SERVIC	6	46	46	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 22	1988	297	6655					1030	1032		10.1136/bmj.297.6655.1030	http://dx.doi.org/10.1136/bmj.297.6655.1030			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q6359	3142600	Green Published, Bronze			2023-01-03	WOS:A1988Q635900028
J	ADAMS, SL				ADAMS, SL			THE MEDICINAL LEECH - A PAGE FROM THE ANNELIDS OF INTERNAL MEDICINE	ANNALS OF INTERNAL MEDICINE			English	Article											ADAMS, SL (corresponding author), NORTHWESTERN UNIV, SCH MED,DEPT MED,EMERGENCY MED SECT, 1204 OLSON PAVILL, 233 E SUPER ST, CHICAGO, IL 60611 USA.							ALMALLAH Z, 1968, British Journal of Diseases of the Chest, V62, P215, DOI 10.1016/S0007-0971(68)80018-X; BASKOVA I P, 1984, Folia Haematologica (Leipzig), V111, P831; BASKOVA IP, 1984, B EXP BIOL MED+, V98, P1016, DOI 10.1007/BF01262447; BATCHELOR AGG, 1984, BRIT J PLAST SURG, V37, P358, DOI 10.1016/0007-1226(84)90079-1; BERGHAUS A, 1880, POP SCI MONTHLY, V17, P478; BUDZYNSKI AZ, 1981, P SOC EXP BIOL MED, V168, P266; BUDZYNSKI AZ, 1981, P SOC EXP BIOL MED, V168, P259; BUNKER TD, 1981, BR J ACCIDENT SURG, V12, P430; BUSING KH, 1953, ARCH MIKROBIOL, V19, P52, DOI 10.1007/BF00412315; CASTIGLIONI A, 1858, HIST MED, P698; Claude A, 1937, J EXP MED, V66, P353, DOI 10.1084/jem.66.3.353; COGHLAN CJ, 1980, ANAESTHESIA, V35, P520, DOI 10.1111/j.1365-2044.1980.tb03841.x; DACOSTA JC, 1907, MODERN SURGERY GENER, P73; DERGANC M, 1960, Br J Plast Surg, V13, P187; DICKSON WA, 1984, BRIT MED J, V289, P1727, DOI 10.1136/bmj.289.6460.1727; DIMITRIU V, 1931, PRESSE MED, V74, P1361; DIRCKX J, 1983, LANGUAGE MED ITS EVO, P28; Favilli G, 1940, NATURE, V145, P866, DOI 10.1038/145866a0; FRITZ H, 1971, 1970 P INT RES C PRO, V1, P271; GILLESPIE WA, 1834, BOSTON MED SURG, V10, P27; GLASSCHEIB HS, 1964, MARCH MED, P153; GLICK S, 1957, NEW ENGL J MED, V256, P409, DOI 10.1056/NEJM195702282560907; GRATTAN JHG, 1952, ANGLOSAXON MAGIC MED, P17; GREEN C, 1983, J ROY SOC HEALTH, V103, P42, DOI 10.1177/146642408310300112; HARE CJ, 1883, GOOD REMEDIES FASHIO, P30; HARVEY RP, 1986, P NATL ACAD SCI USA, V83, P1084, DOI 10.1073/pnas.83.4.1084; Haycraft J. B., 1884, P ROY SOC LOND B BIO, V36, P478, DOI [10.1098/rspl.1883.0135, DOI 10.1098/RSPL.1883.0135]; HEGNER RW, 1981, INVERTEBRATE ZOOLOGY, P420; HELDT T J, 1961, Henry Ford Hosp Med Bull, V9, P498; HENDERSON HP, 1983, BRIT J PLAST SURG, V36, P235, DOI 10.1016/0007-1226(83)90099-1; IWAKAWA A, 1986, CLIN EXP METASTAS, V4, P205, DOI 10.1007/BF00117933; KING J, 1870, AM DISPENSATORY, P424; KRETTER K, 1935, POLSKA GAZ LEK, V14, P796; LEGG JW, 1872, TREATISE HAEMOPHILIA, P43; LENGGENHAGER K, 1936, SCHWEIZ MED WOCHENSC, V9, P227; LENT C, 1986, NATURE, V323, P494, DOI 10.1038/323494a0; LENT CM, 1985, BRAIN RES BULL, V14, P643, DOI 10.1016/0361-9230(85)90114-5; LILIENTHAL H, 1943, J MT SINAI HOSP, V10, P135; LINDEMANN BRUNO ARTUR, 1939, ARCH EXP PATH U PHARMAKOL, V193, P490; LINKER A, 1960, J BIOL CHEM, V235, P924; LOEB L, 1913, JAMA-J AM MED ASSOC, V60, P1857; MANSONBAHR PEC, 1982, MANSONS TROPICAL DIS, P574; MARKWARDT F, 1985, BIOMED BIOCHIM ACTA, V44, P1007; MARSDEN PD, 1969, T ROY SOC TROP MED H, V63, P413, DOI 10.1016/0035-9203(69)90025-X; MAWSON COS, 1961, ROGETS INT THESAURUS, P460; MAYER L, 1930, BRUXELLES MED, V10, P312; METTLER CC, 1947, HIST MED, P334; PEREIRA J, 1854, ELEMENTS MATERIA MED, P1106; Randolph B M, 1935, Ann Med Hist, V7, P177; RIGBI M, 1987, COMP BIOCHEM PHYS C, V88, P95, DOI 10.1016/0742-8413(87)90052-1; RIGBI M, 1987, COMP BIOCHEM PHYS B, V87, P567, DOI 10.1016/0305-0491(87)90053-8; ROSS MS, 1983, ARCH DERMATOL, V119, P276, DOI 10.1001/archderm.1983.01650280004003; SATTERLEE HS, 1915, JAMA-J AM MED ASSOC, V23, P1781; SAWYER RT, 1986, LEECH BIOL BEHAVIOUR, V2, P467; SCHMUCKER JL, 1776, VERMISCHTE CHIRURGIS; SEEMULLER U, 1977, H-S Z PHYSIOL CHEM, V358, P1105, DOI 10.1515/bchm2.1977.358.2.1105; SHOPE RE, 1957, J EXP MED, V105, P373, DOI 10.1084/jem.105.4.373; SHRYOCK RH, 1966, MED AM HIST ESSAYS, P233; Shurtleff B., 1835, BOSTON MED SURG, V12, P322; SINGER C, 1962, SHORT HIST MED, P280; STILLE A, 1884, NATIONAL DISPENSARY, P766; WARING EJ, 1866, PRACTICAL THERAPEUTI, P754; WHITLOCK MR, 1983, BRIT J PLAST SURG, V36, P240, DOI 10.1016/0007-1226(83)90100-5; WOOD GB, 1843, DISPENSATORY US AM, P369; YUKI H, 1963, J BIOL CHEM, V238, P1877; 1986, BEHRING DIAG BIOL, V12; 1987, NEWSWEEK        0202, P58	67	66	67	2	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1988	109	5					399	405		10.7326/0003-4819-109-5-399	http://dx.doi.org/10.7326/0003-4819-109-5-399			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q0198	3044211				2023-01-03	WOS:A1988Q019800010
J	PALMER, FB; SHAPIRO, BK; WACHTEL, RC; ALLEN, MC; HILLER, JE; HARRYMAN, SE; MOSHER, BS; MEINERT, CL; CAPUTE, AJ				PALMER, FB; SHAPIRO, BK; WACHTEL, RC; ALLEN, MC; HILLER, JE; HARRYMAN, SE; MOSHER, BS; MEINERT, CL; CAPUTE, AJ			THE EFFECTS OF PHYSICAL THERAPY ON CEREBRAL-PALSY - A CONTROLLED TRIAL IN INFANTS WITH SPASTIC DIPLEGIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University	PALMER, FB (corresponding author), KENNEDY INST HANDICAPPED CHILDREN,CLIN RES UNIT,707 N BROADWAY,BALTIMORE,MD 21205, USA.		Hiller, Janet E./A-5633-2008	Hiller, Janet E./0000-0002-8532-4033	PHS HHS [17028] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BAX M, 1967, DEV MED CHILD NEUROL, V9, P1; Bayley N., 1969, BAYLEY SCALES INFANT; Bobath B, 1985, ABNORMAL POSTURAL RE; BOBATH K, 1964, Physiotherapy, V50, P246; BOBATH K, 1972, PHYSICAL THERAPY SER, P31; BOBATH K, 1980, CLIN DEV MED, V75; BROWNELL CA, 1985, INFANT INTERVENTION, P109; Doll EA, 1965, VINELAND SOCIAL MATU; DRILLIEN C, 1983, CLIN DEV MED, V86, P93; FERRY PC, 1981, PEDIATRICS, V67, P38; GOODMAN M, 1985, LANCET, V2, P1327; Hollingshead A.B., 1975, YALE J SOCIOLOGY; PARETTE HP, 1984, AM J OCCUP THER, V38, P462, DOI 10.5014/ajot.38.7.462; PEARSON PH, 1982, DEV MED CHILD NEUROL, V24, P417; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; PIPER MC, 1986, PEDIATRICS, V78, P216; PLESS IB, 1973, DEV MED CHILD NEUROL, V15, P256; PLESS IB, 1976, PEDIATRICS, V58, P7; PROVENCE S, 1985, J DEV BEHAV PEDIATR, V6, P363; SCHERZER AL, 1976, PEDIATRICS, V58, P47; SCRUTTON D, 1984, CLIN DEV MED, V90, P4; SHONKOFF JP, 1987, PEDIATRICS, V80, P650; SIMEONSSON RJ, 1982, PEDIATRICS, V69, P635; SPARLING J, 1979, LEARNINGAMES 1ST 3 Y; TAFT LT, 1972, DEV MED CHILD NEUROL, V14, P703; TERMAN LM, 1972, STANFORDBINET INTELL; THOMPSON S, 1979, 33RD ANN M AM AC CER; WRIGHT T, 1973, DEV MED CHILD NEUROL, V15, P146	29	201	203	0	20	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1988	318	13					803	808		10.1056/NEJM198803313181302	http://dx.doi.org/10.1056/NEJM198803313181302			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M7031	3280999				2023-01-03	WOS:A1988M703100002
J	LEVINE, MN; GENT, M; HIRSH, J; ARNOLD, A; GOODYEAR, MD; HRYNIUK, W; DEPAUW, S				LEVINE, MN; GENT, M; HIRSH, J; ARNOLD, A; GOODYEAR, MD; HRYNIUK, W; DEPAUW, S			THE THROMBOGENIC EFFECT OF ANTICANCER DRUG-THERAPY IN WOMEN WITH STAGE-II BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									MCMASTER UNIV,DEPT MED,HAMILTON L8S 4L8,ONTARIO,CANADA; MCMASTER UNIV,DEPT CLIN EPIDEMIOL & BIOSTAT,HAMILTON L8S 4L8,ONTARIO,CANADA	McMaster University; McMaster University	LEVINE, MN (corresponding author), ONTARIO CANC TREATMENT & RES FDN,HAMILTON REG CANC CTR,711 CONCESS ST,HAMILTON L8V 1C3,ONTARIO,CANADA.							ARANDA A, 1987, THROMB HAEMOSTASIS, V58, P110; COOPER RG, 1979, CANCER, V44, P793, DOI 10.1002/1097-0142(197909)44:3<793::AID-CNCR2820440302>3.0.CO;2-Y; COX DR, 1970, ANAL BINARY DATA, P14; DOLL DC, 1986, J CLIN ONCOL, V4, P1405, DOI 10.1200/JCO.1986.4.9.1405; ENCK RE, 1984, CANCER, V53, P2607, DOI 10.1002/1097-0142(19840615)53:12<2607::AID-CNCR2820531206>3.0.CO;2-T; FISHER B, 1981, NEW ENGL J MED, V305, P1, DOI 10.1056/NEJM198107023050101; Fleiss JL, 1981, STATISTICAL METHODS, P19; GALLUS A S, 1976, Seminars in Thrombosis and Hemostasis, V2, P203; GOODNOUGH LT, 1984, CANCER-AM CANCER SOC, V54, P1264, DOI 10.1002/1097-0142(19841001)54:7<1264::AID-CNCR2820540706>3.0.CO;2-R; HEALEY B, 1987, P AN M AM SOC CLIN, V6, P54; HENDRICK A, 1980, JAMA-J AM MED ASSOC, V243, P514, DOI 10.1001/jama.243.6.514; HULL R, 1982, HAEMOSTASIS THROMBOS, P844; HULL RD, 1983, ANN INTERN MED, V98, P891, DOI 10.7326/0003-4819-98-6-891; JORDAN VC, 1987, CANCER RES, V47, P4517; LEVINE M, 1983, P AN M AM SOC CLIN, V2, P101; LICCIARDELLO JTW, 1985, ONCOLOGY, V42, P296, DOI 10.1159/000226049; LIPTON A, 1984, CANCER TREAT REP, V68, P887; NEVASAARI K, 1978, LANCET, V2, P946; NICOLSON GL, 1985, CANCER RES, V45, P331; ORR FW, 1986, CANCER RES, V46, P891; Pizzo PA, 1985, CANCER PRINCIPLES PR, V2, P1963; RABINOV K, 1972, ARCH SURG-CHICAGO, V104, P134; RIBEIRO G, 1983, BRIT MED J, V286, P827, DOI 10.1136/bmj.286.6368.827; RICKLES FR, 1983, BLOOD, V62, P14; RUIZ MA, 1987, THROMB HAEMOSTASIS, V58, P110; WEISS RB, 1981, CANCER TREAT REP, V65, P677; 1983, LANCET, V1, P257	27	409	415	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 18	1988	318	7					404	407		10.1056/NEJM198802183180703	http://dx.doi.org/10.1056/NEJM198802183180703			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M0721	3340118				2023-01-03	WOS:A1988M072100003
J	TUMA, PL; COLLINS, CA				TUMA, PL; COLLINS, CA			DYNAMIN FORMS POLYMERIC COMPLEXES IN THE PRESENCE OF LIPID VESICLES - CHARACTERIZATION OF CHEMICALLY CROSS-LINKED DYNAMIN MOLECULES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEINS; SEA-URCHIN EGGS; CYTOPLASMIC DYNEIN; GTPASE; PURIFICATION; ACTIVATION; DOMAINS	Dynamin is a GTP-binding protein that is involved in the release of coated endocytic vesicles from the plasma membrane, We have been characterizing the enzymatic properties of purified rat brain dynamin to better understand how GTP binding and hydrolysis relate to its proposed function, Previously, we have demonstrated that activation of dynamin GTPase results from positive cooperative associations between dynamin molecules as they are bound to a polymeric surface, Our present report has extended these studies and has examined the structural features of dynamin self association. After treatment with the zero length protein cross-linking reagent, 1-ethyl-3-[3-(dimethylamino)propyl]carbo ide, dynamin in solution was found cross linked into dimers, This homodimer likely reflects the native soluble state of the molecule, After binding to brain vesicles, dynamin was cross-linked into higher order oligomers of greater than 800 kDa, Dynamin, copurified on brain membranous organelles, also formed multimeric complexes when cross-linked suggesting dynamin exists in polymeric form in vivo. No cross linked species other than homo-oligomers were observed, providing no evidence for close interactions between dynamin and membrane proteins, From experiments examining the effects of GTP, GDP, guanosine 5'-3-O-(thio)triphosphate, and 5'-guanylyl-beta,gamma-imidodiphosphate on cross-linking, we have determined that both dynamin membrane binding and self-association occur independently from the nucleotide-bound state of the enzyme, An 80-kDa dynamin fragment that is lacking its carboxyl-terminal domain is not cross-linked into higher order oligomers, suggesting that this domain is required for binding of dynamin to membranes and the subsequent enhancement of oligomerization, However, the dynamin fragment was found to form dimers indicating that this domain is not required for dynamin dimerization, Cross linked dynamin was able to cooperatively bind microtubules, but did not exhibit GTPase activation, We propose that intramolecular cross links in the dynamin monomer impart structural constraints that prevent the enhancement of GTP hydrolysis, We describe a model of the dynamin activation process to be considered in further investigations of the role for dynamin in endocytic vesicle formation.	NORTHWESTERN UNIV, SCH MED, DEPT CELL & MOLEC BIOL, CHICAGO, IL 60611 USA	Northwestern University								Collins C A, 1991, Trends Cell Biol, V1, P57, DOI 10.1016/0962-8924(91)90090-V; COLLINS CA, 1986, P NATL ACAD SCI USA, V83, P4799, DOI 10.1073/pnas.83.13.4799; COLLINS CA, 1989, CELL MOTIL CYTOSKEL, V14, P491, DOI 10.1002/cm.970140407; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HERSKOVITS JS, 1993, P NATL ACAD SCI USA, V90, P11468, DOI 10.1073/pnas.90.24.11468; HERSKOVITS JS, 1993, J CELL BIOL, V122, P565, DOI 10.1083/jcb.122.3.565; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU JP, 1994, J BIOL CHEM, V269, P21043; MAEDA K, 1992, MOL BIOL CELL, V3, P1181, DOI 10.1091/mbc.3.10.1181; NAKAYAMA M, 1993, J BIOL CHEM, V268, P15033; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; SCAIFE R, 1990, J CELL BIOL, V111, P3023, DOI 10.1083/jcb.111.6.3023; SHIMIZU T, 1989, BIOCHEMISTRY-US, V28, P7016, DOI 10.1021/bi00443a035; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; SHPETNER HS, 1989, CELL, V59, P421, DOI 10.1016/0092-8674(89)90027-5; STACHNIAK MC, 1989, J CELL BIOL, V111, pA291; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; TUMA PL, 1994, J BIOL CHEM, V269, P30842; TUMA PL, 1993, J BIOL CHEM, V268, P17240; VALLEE RB, 1986, METHOD ENZYMOL, V134, P89; VALLEE RB, 1986, METHOD ENZYMOL, V134, P116; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	28	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 3	1995	270	44					26707	26714		10.1074/jbc.270.44.26707	http://dx.doi.org/10.1074/jbc.270.44.26707			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TC978	7592898	hybrid			2023-01-03	WOS:A1995TC97800105
J	SCHWAB, TM; CALLAHAM, ML; MADSEN, CD; UTECHT, TA				SCHWAB, TM; CALLAHAM, ML; MADSEN, CD; UTECHT, TA			A RANDOMIZED CLINICAL-TRIAL OF ACTIVE COMPRESSION-DECOMPRESSION CPR VS STANDARD CPR IN OUT-OF-HOSPITAL CARDIAC-ARREST IN 2 CITIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERPOSED ABDOMINAL COMPRESSION; CARDIOPULMONARY-RESUSCITATION; RACIAL-DIFFERENCES; BLOOD-FLOW; SURVIVAL; DEFIBRILLATION; VENTILATION; PREDICTION; PERFUSION; PIGS	Objective.-To compare the effectiveness of active compression-decompression (ACD) cardiopulmonary resuscitation (CPR) with a handheld suction device vs standard manual CPR in victims of out-of-hospital cardiopulmonary arrest. Design.-Prospective randomized clinical trial with crossover group design. Setting.-Emergency medical services (EMS) of a large (San Francisco) and medium-sized (Fresno) city in California. Patients.-All normothermic adult victims of out-of-hospital, nontraumatic cardiac arrest on whom CPR was performed by first responders. Intervention.-Patients were randomized to receive either standard manual CPR according to American Heart Association guidelines or ACD CPR, on first-responder contact. Main Outcome Measures.-Return of spontaneous circulation, admission to the intensive care unit, survival to hospital discharge, and neurological function at hospital discharge. Results.-The ACD group (n=117 in Fresno; n=297 in San Francisco) and standard group (n=136 in Fresno; n=310 in San Francisco) were similar with regard to demographic and prognostic variables, such as age, witnessed arrest and bystander CPR frequency, and initial cardiac rhythm. Average interval from 911 call activation to EMS responder arrival was 6.4 minutes in Fresno and 4.0 minutes in San Francisco, In Fresno, there was no difference between the ACD group and standard CPR group in return of spontaneous circulation (17% vs 20%; P=.68), hospital admission (16% vs 20%; P=.56), hospital discharge (5% vs 7%; P=.64), or cerebral performance category score at discharge (1.5 vs 1.6; P=.90). Similarly, in San Francisco there was no difference between the ACD group and standard CPR group in return of spontaneous circulation (19% vs 21%; P=.65), hospital admission (13.5% vs 14.5%; P=.79), hospital discharge (4.7% vs 5.5%; P=.80), or cerebral performance category score at discharge (2.2 vs 2.6; P=.31). There was no increase in significant complications associated with the use of ACD CPR. Conclusion.-There was no improvement in outcome with ACD CPR in out-of-hospital cardiac arrest in these two cities. Differences in study design, demographics, EMS systems, response intervals, training, and technique performance may contribute to the lack of improvement in initial resuscitation with ACD CPR compared with previous studies. Future research needs to control these variables to determine the reason for these differences in outcome.	UNIV CALIF SAN FRANCISCO,DIV EMERGENCY MED,SAN FRANCISCO,CA	University of California System; University of California San Francisco	SCHWAB, TM (corresponding author), UNIV CALIF SAN FRANCISCO,VALLEY MED CTR,SAN JOSE MED EDUC PROGRAM,DEPT EMERGENCY MED,FRESNO,CA 93702, USA.			Callaham, Michael/0000-0003-2284-256X				BECKER LB, 1993, NEW ENGL J MED, V329, P600, DOI 10.1056/NEJM199308263290902; BECKER LB, 1993, ANN EMERG MED, V22, P86, DOI 10.1016/S0196-0644(05)80257-4; BERRYMAN CR, 1984, ANN EMERG MED, V13, P226, DOI 10.1016/S0196-0644(84)80467-9; CALLAHAM M, 1990, CRIT CARE MED, V18, P358, DOI 10.1097/00003246-199004000-00002; CHANDRA N, 1980, LANCET, V1, P175; CHANG MW, 1992, CIRCULATION, V86, P233; COHEN TJ, 1992, JAMA-J AM MED ASSOC, V267, P2916, DOI 10.1001/jama.267.21.2916; COHEN TJ, 1992, AM HEART J, V124, P1145, DOI 10.1016/0002-8703(92)90393-A; COHEN TJ, 1993, NEW ENGL J MED, V329, P1918, DOI 10.1056/NEJM199312233292603; CORDELL WH, 1994, ANN EMERG MED, V23, P1032, DOI 10.1016/S0196-0644(94)70099-0; COWIE MR, 1993, AM J PUBLIC HEALTH, V83, P955, DOI 10.2105/AJPH.83.7.955; CUMMINS RO, 1991, ANN EMERG MED, V20, P861; CUMMINS RO, 1990, ANN EMERG MED, V19, P1245, DOI 10.1016/S0196-0644(05)82282-6; DELGUERCIO LR, 1963, NEW ENGL J MED, V269, P1398, DOI 10.1056/NEJM196312262692603; EISENBERG MS, 1986, CIRCULATION, V74, P9; HALLSTROM A, 1993, AM J PUBLIC HEALTH, V83, P245, DOI 10.2105/AJPH.83.2.245; HOWARD M, 1987, ANN EMERG MED, V16, P253, DOI 10.1016/S0196-0644(87)80169-5; KERN KB, 1992, ANN EMERG MED, V21, P1066, DOI 10.1016/S0196-0644(05)80646-8; KRISCHER JP, 1989, CRIT CARE MED, V17, P1263, DOI 10.1097/00003246-198912000-00005; LINDNER KH, 1990, ANESTHESIOLOGY, V72, P675, DOI 10.1097/00000542-199004000-00017; LINDNER KH, 1993, CIRCULATION, V88, P1254, DOI 10.1161/01.CIR.88.3.1254; LOMBARDI G, 1994, JAMA-J AM MED ASSOC, V271, P678; LURIE KG, 1994, JAMA-J AM MED ASSOC, V271, P1405, DOI 10.1001/jama.271.18.1405; LURIE KG, 1990, JAMA-J AM MED ASSOC, V264, P1661, DOI 10.1001/jama.1990.03450130031020; MATEER JR, 1985, AM J EMERG MED, V3, P143, DOI 10.1016/0735-6757(85)90038-5; SACK JB, 1992, CIRCULATION, V86, P1692, DOI 10.1161/01.CIR.86.6.1692; SANDERS AB, 1984, JAMA-J AM MED ASSOC, V252, P3283, DOI 10.1001/jama.252.23.3283; SHULTZ JJ, 1994, CIRCULATION, V89, P684, DOI 10.1161/01.CIR.89.2.684; TUCKER KJ, 1993, J AM COLL CARDIOL, V22, P1485, DOI 10.1016/0735-1097(93)90561-E; TUCKER KJ, 1994, J AM COLL CARDIOL, V24, P201, DOI 10.1016/0735-1097(94)90564-9; 1992, JAMA-J AM MED ASSOC, V268, P2199; 1992, JAMA-J AM MED ASSOC, V268, P2184; 1992, JAMA-J AM MED ASSOC, V268, P2171; 1986, AM J EMERG MED, V4, P72	34	110	111	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 26	1995	273	16					1261	1268		10.1001/jama.273.16.1261	http://dx.doi.org/10.1001/jama.273.16.1261			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU571	7715038				2023-01-03	WOS:A1995QU57100028
J	OLIVIERI, NF; BRITTENHAM, GM; MATSUI, D; BERKOVITCH, M; BLENDIS, LM; CAMERON, RG; MCCLELLAND, RA; LIU, PP; TEMPLETON, DM; KOREN, G				OLIVIERI, NF; BRITTENHAM, GM; MATSUI, D; BERKOVITCH, M; BLENDIS, LM; CAMERON, RG; MCCLELLAND, RA; LIU, PP; TEMPLETON, DM; KOREN, G			IRON-CHELATION THERAPY WITH ORAL DEFERIPRONE IN PATIENTS WITH THALASSEMIA MAJOR	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE L1; SUBCUTANEOUS DEFEROXAMINE; EFFICACY; STORES; ANEMIA; TRIAL; DESFERRIOXAMINE; FERRITIN; TOXICITY; MICE	Background. To determine whether the orally active iron chelator deferiprone (1,2-dimethyl-3-hydroxypyridin-4-one) is efficacious in the treatment of iron overload in patients with thalassemia major, we conducted a prospective trial of deferiprone in 21 patients unable or unwilling to use standard chelation therapy with parenteral deferoxamine. Methods. Hepatic iron stores were determined yearly by chemical analysis of liver-biopsy specimens or magnetic-susceptibility measurements. Detailed clinical and laboratory studies were used to monitor safety and compliance. Results. The patients received deferiprone therapy for a mean (+/-SE) of 3.1+/-0.3 years. Ten patients in whom previous chelation therapy with deferoxamine had been ineffective had initial hepatic iron concentrations of at least 80 mu mol per gram of liver, wet weight - values associated with complications of iron overload. Hepatic iron concentrations decreased in all 10 patients, from 125.3+/-11.5 to 60.3+/-9.6 mu mol per gram (P<0.005), with values that were less than 80 mu mol per gram in 8 of the 10 patients (P<0.005). In all 11 patients in whom deferoxamine therapy had previously been effective, deferiprone maintained hepatic iron concentrations below 80 mu mol of iron per gram. Conclusions. Oral deferiprone induces sustained decreases in body iron to concentrations compatible with the avoidance of complications from iron overload. The risk of agranulocytosis associated with deferiprone may restrict its administration to patients who are unable or unwilling to use deferoxamine.	TORONTO HOSP,DEPT MED,TORONTO,ON M5T 2S8,CANADA; TORONTO HOSP,DEPT PATHOL,TORONTO,ON M5T 2S8,CANADA; UNIV TORONTO,DEPT CHEM,TORONTO,ON M5S 1A1,CANADA; UNIV TORONTO,DEPT CLIN BIOCHEM,TORONTO,ON,CANADA; CASE WESTERN RESERVE UNIV,CLEVELAND,OH 44106; METROHLTH MED CTR,DEPT MED,CLEVELAND,OH	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; Case Western Reserve University; MetroHealth System	OLIVIERI, NF (corresponding author), HOSP SICK CHILDREN,DEPT PEDIAT,HEMOGLOBINOPATHY PROGRAM,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.		Olivieri, Nancy/AAI-2250-2020	Templeton, Douglas/0000-0003-0693-662X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL042824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI035827] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 42824] Funding Source: Medline; NIAID NIH HHS [AI 35827] Funding Source: Medline; FDA HHS [FD-R-000532] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); FDA HHS		AGARWAL MB, 1992, BRIT J HAEMATOL, V82, P460, DOI 10.1111/j.1365-2141.1992.tb06445.x; ALREFAIE FN, 1992, BLOOD, V80, P593; BARRY M, 1974, BMJ-BRIT MED J, V2, P16, DOI 10.1136/bmj.2.5909.16; BERGERON RJ, 1992, BLOOD, V79, P1882; BERKOVITCH M, 1994, LANCET, V343, P1471, DOI 10.1016/S0140-6736(94)92585-2; BIESEMEIER JA, 1991, 14 DAY ORAL TOXICITY; BRITTENHAM GM, 1982, NEW ENGL J MED, V307, P1671, DOI 10.1056/NEJM198212303072703; BRITTENHAM GM, 1994, NEW ENGL J MED, V331, P567, DOI 10.1056/NEJM199409013310902; BRITTENHAM GM, 1993, AM J HEMATOL, V42, P81, DOI 10.1002/ajh.2830420116; BRONSPIEGELWEIN.N, 1990, NEW ENGL J MED, V323, P713; Cohen A, 1987, Hematol Oncol Clin North Am, V1, P521; COHEN A, 1984, BRIT J HAEMATOL, V58, P369, DOI 10.1111/j.1365-2141.1984.tb06096.x; COLLINS AF, 1994, BLOOD, V83, P2329; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V262, P1472; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; ENGLE MA, 1964, CIRCULATION, V30, P698, DOI 10.1161/01.CIR.30.5.698; FOSBURG MT, 1990, BLOOD, V76, P435; HOFFBRAND AV, 1989, LANCET, V2, P457; KONTOGHIORGHES GJ, 1987, INORG CHIM A-BIOINOR, V136, pL11, DOI 10.1016/S0020-1693(00)85549-8; KONTOGHIORGHES GJ, 1987, LANCET, V1, P1294; KONTOGHIORGHES GJ, 1990, BRIT J HAEMATOL, V76, P295, DOI 10.1111/j.1365-2141.1990.tb07887.x; MATSUI D, 1991, CLIN PHARMACOL THER, V50, P294, DOI 10.1038/clpt.1991.139; MEHTA J, 1991, INDIAN J HEMATOL BLO, V9, P33; OLIVIERI NF, 1992, AM J PEDIAT HEMATOL, V14, P48; OLIVIERI NF, 1986, NEW ENGL J MED, V314, P869, DOI 10.1056/NEJM198604033141402; OLIVIERI NF, 1990, SEMIN HEMATOL, V27, P101; OLIVIERI NF, 1994, NEW ENGL J MED, V331, P574, DOI 10.1056/NEJM199409013310903; OLIVIERI NF, 1994, BLOOD, V84, pA363; OLIVIERI NF, 1992, BLOOD, V79, P2741; OLIVIERI NF, 1990, LANCET, V336, P1275, DOI 10.1016/0140-6736(90)92962-H; Porter J B, 1989, Baillieres Clin Haematol, V2, P459, DOI 10.1016/S0950-3536(89)80027-7; PORTER JB, 1990, BLOOD, V76, P2389; PORTER JB, 1991, BLOOD, V78, P2727; SCHNEBLI HP, 1993, ERS6293 CEIB GEIG BI, P30; TONDURY P, 1990, BRIT J HAEMATOL, V76, P550; VREUGDENHIL G, 1990, ANN RHEUM DIS, V49, P956, DOI 10.1136/ard.49.11.956-b; WOLFE L, 1985, NEW ENGL J MED, V312, P1600, DOI 10.1056/NEJM198506203122503; ZURLO MG, 1989, LANCET, V2, P27, DOI 10.1016/S0140-6736(89)90264-X	38	257	268	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					918	922		10.1056/NEJM199504063321404	http://dx.doi.org/10.1056/NEJM199504063321404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7877649				2023-01-03	WOS:A1995QP89300004
J	JADHAV, S				JADHAV, S			THE GHOSTBUSTERS OF PSYCHIATRY	LANCET			English	Editorial Material											JADHAV, S (corresponding author), UCL, DEPT PSYCHIAT, LONDON, ENGLAND.		jadhav, sushrut/B-8249-2009	jadhav, sushrut/0000-0001-5325-8687				BLUE I, 1994, BRIT J PSYCHIAT, V165, P9, DOI 10.1192/bjp.165.1.9; COLEMAN J, 1994, TREATING SURVIVORS S; Good B.J., 1993, MED RATIONALITY EXPE, DOI 10.1017/cbo9780511811029; HALE AS, 1994, BRIT J PSYCHIAT, V165, P386, DOI 10.1192/bjp.165.3.386; JADHAV S, 1994, PSYCHIATR B, V18, P572; Kakar Sudhir., 1982, SHAMANS MYSTICS DOCT; LEWIS IM, 1966, MAN, V1, P307, DOI 10.2307/2796794; LITTLEWOOD R, 1991, LANCET, V337, P1013, DOI 10.1016/0140-6736(91)92668-R; MULHERN S, 1991, PSYCHIAT CLIN N AM, V14, P769; Turner V.W., 1964, MAGIC FAITH HEALING; Vitebsky, 1993, DIALOGUES DEAD DISCU; WEISS MG, 1992, BRIT J PSYCHIAT, V160, P819, DOI 10.1192/bjp.160.6.819	12	7	8	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 1	1995	345	8953					808	810		10.1016/S0140-6736(95)92959-2	http://dx.doi.org/10.1016/S0140-6736(95)92959-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QQ195	7898225				2023-01-03	WOS:A1995QQ19500004
J	LEE, TH; PEARSON, SD; JOHNSON, PA; GARCIA, TB; WEISBERG, MC; GUADAGNOLI, E; COOK, F; GOLDMAN, L				LEE, TH; PEARSON, SD; JOHNSON, PA; GARCIA, TB; WEISBERG, MC; GUADAGNOLI, E; COOK, F; GOLDMAN, L			FAILURE OF INFORMATION AS AN INTERVENTION TO MODIFY CLINICAL MANAGEMENT - A TIME-SERIES TRIAL IN PATIENTS WITH ACUTE CHEST PAIN	ANNALS OF INTERNAL MEDICINE			English	Article							LOW-RISK PATIENTS; ACUTE MYOCARDIAL-INFARCTION; EMERGENCY ROOM PATIENTS; ISCHEMIC-HEART-DISEASE; PREDICTIVE INSTRUMENT; PRACTICE GUIDELINES; INTENSIVE-CARE; MULTICENTER; IDENTIFICATION; COMPLICATIONS	Objective: To test whether a low-intensity, nonintrusive intervention improved the efficiency of management of patients with acute chest pain. Design: Time-series trial with six 14-week cycles, each including a 5-week intervention period and a 5-week control period separated by a-week ''washout'' periods. Setting: Urban teaching hospital. Patients: 1921 patients aged 30 years or older with acute chest pain unexplained by local trauma or chest radiograph. Intervention: Risk estimates and triage recommendations were made available to physicians at the time of emergency department evaluation and, for hospitalized patients, on a daily basis before morning rounds. Flowsheets and stickers, but no direct human contact, were used to transmit this information. at Measurements: Rates of admission to the hospital and coronary care unit, inpatient costs, and lengths of stay. Results: Rates of admission during intervention and control periods were similar in both the hospital (52% and 51 %, respectively) and the coronary care unit (10% and 10%, respectively). Total lengths of stay in the hospital were similar (4.9 +/- 5.9 days and 4.9 +/- 5.7 days, respectively), as were average total costs ($7822 +/- $13 217 and $7955 +/- $13 400, respectively). No differences in management were detected for the subgroup of patients with low clinical risk for acute myocardial infarction. Conclusions: The use of information alone without direct human contact-did not affect management of patients with acute chest pain at this hospital. Although this low-intensity intervention might be more effective for other conditions and in other settings, our data support the use of other strategies to affect physician decision making.	HARVARD UNIV, SCH MED, BOSTON, MA USA	Harvard University; Harvard Medical School	LEE, TH (corresponding author), BRIGHAM & WOMENS HOSP, 75 FRANCIS ST, BOSTON, MA 02115 USA.				AHRQ HHS [R01 HS06452] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006452] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BRUSH JE, 1985, NEW ENGL J MED, V312, P1137, DOI 10.1056/NEJM198505023121801; Coffey R J, 1992, Qual Manag Health Care, V1, P45; COREY GA, 1987, J FAM PRACTICE, V25, P127; GASPOZ JM, 1994, J AM COLL CARDIOL, V24, P1249, DOI 10.1016/0735-1097(94)90106-6; GOLDMAN L, 1988, NEW ENGL J MED, V318, P797, DOI 10.1056/NEJM198803313181301; GOLDMAN L, 1989, CLIN RES, V37, pA524; GRAFF L, 1992, ANN EMERG MED, V21, P967, DOI 10.1016/S0196-0644(05)82937-3; KOSECOFF J, 1987, JAMA-J AM MED ASSOC, V258, P2708, DOI 10.1001/jama.258.19.2708; LEE TH, 1985, ARCH INTERN MED, V145, P65, DOI 10.1001/archinte.145.1.65; LEE TH, 1991, NEW ENGL J MED, V324, P1239, DOI 10.1056/NEJM199105023241803; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MULLEY AG, 1980, NEW ENGL J MED, V302, P943, DOI 10.1056/NEJM198004243021704; PEARSON SD, 1994, J GEN INTERN MED, V9, P241, DOI 10.1007/BF02599648; POZEN MW, 1984, NEW ENGL J MED, V310, P1273, DOI 10.1056/NEJM198405173102001; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; TIERNEY WM, 1985, CRIT CARE MED, V13, P526, DOI 10.1097/00003246-198507000-00002; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WEINGARTEN S, 1990, ANN INTERN MED, V113, P283, DOI 10.7326/0003-4819-113-4-283; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	20	94	96	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					434	437		10.7326/0003-4819-122-6-199503150-00006	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM266	7856992				2023-01-03	WOS:A1995QM26600006
J	ELTON, A; HONIG, P; BENTOVIM, A; SIMONS, J				ELTON, A; HONIG, P; BENTOVIM, A; SIMONS, J			WITHHOLDING CONSENT TO LIFESAVING TREATMENT - 3 CASES	BRITISH MEDICAL JOURNAL			English	Article								The refusal of children or their parents to consent to treatment that professionals regard as essential always results in a dilemma. Responding to such refusals demands careful and sensitive clinical and ethicolegal intervention and close cooperation among professionals, in particular doctors and social workers. Since the introduction of the Children Act 1989 the number of cases in which children have withheld consent to Lifesaving treatment has risen, and it is now increasingly recognised that children have a right to have their views legally represented if a local authority or health authority seeks a court's leave to carry out treatment. Professionals have to consider which legal route, under either the Children Act or the Mental Health Act, is likely to be best for the individual child.	HOSP SICK CHILDREN,DEPT SOCIAL WORK,LONDON WC1N 3JH,ENGLAND	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	ELTON, A (corresponding author), HOSP SICK CHILDREN,DEPT PSYCHOL MED,GREAT ORMOND ST,LONDON WC1N 3JH,ENGLAND.							DEVEREUX JA, 1993, BRIT MED J, V306, P1459, DOI 10.1136/bmj.306.6890.1459; FREEMAN M, 1992, ADOPTION FOSTERING, V17, P14; LEWIS C, 1992, LAW SOC GAZETTE, V89, P27	3	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 11	1995	310	6976					373	377		10.1136/bmj.310.6976.373	http://dx.doi.org/10.1136/bmj.310.6976.373			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG721	7866216	Green Published			2023-01-03	WOS:A1995QG72100023
J	OGDEN, CW; REDDY, P; JOHNSON, H; RAMSAY, JWA; CARTER, SS				OGDEN, CW; REDDY, P; JOHNSON, H; RAMSAY, JWA; CARTER, SS			SHAM VERSUS TRANSURETHRAL MICROWAVE THERMOTHERAPY IN PATIENTS WITH SYMPTOMS OF BENIGN PROSTATIC BLADDER OUTFLOW OBSTRUCTION	LANCET			English	Article							TRANS-URETHRAL RESECTION; POSTOPERATIVE COMPLICATIONS; PROSTATECTOMY; HYPERTHERMIA; HYPERPLASIA	Transurethral microwave thermotherapy (TUMT) is a single-session, minimally invasive outpatient treatment for patients with symptoms of benign prostatic bladder outflow obstruction. We designed a prospective randomised trial to identify any placebo response. Patients with a Madsen symptom score over 8 for at least 6 months were eligible for study. Two measurements of urinary flow less than 15 mL/s and a residual urine of under 350 mL were also required for entry. Patients with renal dysfunction, upper urinary tract disease, co-existing bladder disease, and malignant prostatic change were excluded. 43 patients were studied: 21 were randomised to receive a sham treatment and 22 to thermotherapy. Sham treatments were done with the urethral applicator in situ. 40 patients were available for evaluation at 3 months. 2 patients had delayed follow-up and 1 patient randomised to TUMT has undergone transurethral resection. The thermotherapy group showed a 70% decrease (from 14.5 to 4.3) in the mean Madsen score, a 53% increase in flow-rate (8.5 to 13.0 mL/s), and 92% decrease in residual urine volume (147 to 12 mL). No significant change was seen in these mean indices in the sham group. There was no difference in the main complication of transient haematuria between the two groups. However, there was a 22% frequency of acute retention in the TUMT group. The results show little significant placebo component to the subjective and objective improvement that occurs in patients who have received TUMT.			OGDEN, CW (corresponding author), CHARING CROSS HOSP,DEPT UROL,PROSTATE UNIT,LONDON W6 8RP,ENGLAND.							BAERT L, 1990, J UROLOGY, V144, P1383, DOI 10.1016/S0022-5347(17)39748-3; BALL AJ, 1981, BRIT J UROL, V53, P613, DOI 10.1111/j.1464-410X.1981.tb03273.x; BRUSKEWITZ RC, 1986, J UROLOGY, V136, P613, DOI 10.1016/S0022-5347(17)44991-3; CARTER S S, 1991, Journal of Endourology, V5, P137, DOI 10.1089/end.1991.5.137; DEVONEC M, 1991, Journal of Endourology, V5, P129, DOI 10.1089/end.1991.5.129; EDWARDS LE, 1983, HIST NONSURGICAL TRE, P30; FABRICIUS P G, 1991, Journal of Urology, V145, p363A; GRAVERSEN PH, 1989, J UROLOGY, V141, P475, DOI 10.1016/S0022-5347(17)40864-0; LEPOR H, 1989, J UROLOGY, V141, P1283, DOI 10.1016/S0022-5347(17)41282-1; LEPOR H, 1992, J UROLOGY, V147, P639, DOI 10.1016/S0022-5347(17)37331-7; LEPOR H, 1990, J UROLOGY, V143, P533, DOI 10.1016/S0022-5347(17)40012-7; LIBMAN E, 1987, UROLOGY, V29, P467, DOI 10.1016/0090-4295(87)90031-8; LINDNER A, 1987, BRIT J UROL, V60, P567, DOI 10.1111/j.1464-410X.1987.tb05043.x; LUNDHUS E, 1987, SCAND J UROL NEPHROL, V21, P9, DOI 10.3109/00365598709180282; MADSEN PO, 1983, BENIGN PROSTATIC HYP, P763; MCLOUGHLIN J, 1990, BRIT J UROL, V65, P313, DOI 10.1111/j.1464-410X.1990.tb14746.x; MEBUST WK, 1989, J UROLOGY, V141, P243, DOI 10.1016/S0022-5347(17)40731-2; MELCHIOR J, 1974, J UROLOGY, V112, P634, DOI 10.1016/S0022-5347(17)59817-1; MOLLERNIELSON C, 1987, UROL INT, V40, P3; PETTERSSON S, 1992, J UROLOGY, V147, pA371; SAPOZINK MD, 1990, J UROLOGY, V143, P944, DOI 10.1016/S0022-5347(17)40146-7; STIRRAT GM, 1992, ANN ROY COLL SURG, V74, P80; YERUSHALMI A, 1985, J UROLOGY, V133, P873, DOI 10.1016/S0022-5347(17)49270-6; ZERBIB M, 1992, J UROLOGY, V147, P1048, DOI 10.1016/S0022-5347(17)37464-5	24	114	114	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JAN 2	1993	341	8836					14	17		10.1016/0140-6736(93)92482-9	http://dx.doi.org/10.1016/0140-6736(93)92482-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KF027	7678047				2023-01-03	WOS:A1993KF02700005
J	PRIMAKOFF, P; LATHROP, W; WOOLMAN, L; COWAN, A; MYLES, D				PRIMAKOFF, P; LATHROP, W; WOOLMAN, L; COWAN, A; MYLES, D			FULLY EFFECTIVE CONTRACEPTION IN MALE AND FEMALE GUINEA-PIGS IMMUNIZED WITH THE SPERM PROTEIN PH-20	NATURE			English	Article											PRIMAKOFF, P (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT PHYSIOL,FARMINGTON,CT 06032, USA.							ADA GL, 1985, NATURE, V317, P288, DOI 10.1038/317288b0; ANDERSON DJ, 1983, FERTIL STERIL, V40, P557; BRONSON R, 1984, FERTIL STERIL, V42, P171; CHEN C, 1986, ARCH ANDROLOGY, V16, P183, DOI 10.3109/01485018608986940; COWAN AE, 1986, J CELL BIOL, V103, P1289, DOI 10.1083/jcb.103.4.1289; CROSS NL, 1988, BIOL REPROD, V38, P235, DOI 10.1095/biolreprod38.1.235; GOLDBERG E, 1973, SCIENCE, V181, P458, DOI 10.1126/science.181.4098.458; GOLDBERG E, 1981, FERTIL STERIL, V35, P214; Goldberg E, 1983, Res Front Fertil Regul, V2, P1; HAAS GG, 1986, FERTIL STERIL, V46, P753; HALENDA RM, 1987, BIOL REPROD, V36, P491, DOI 10.1095/biolreprod36.2.491; JONES WR, 1982, IMMUNOLOGICAL FERTIL; KUMMERFELD HL, 1976, BIOL REPROD, V14, P300, DOI 10.1095/biolreprod14.3.300; LERUM JE, 1974, BIOL REPROD, V11, P108, DOI 10.1095/biolreprod11.1.108; MENGE AC, 1979, BIOL REPROD, V20, P931, DOI 10.1095/biolreprod20.4.931; MORALES P, 1988, J ANDROL, V9, P24; MORTON DB, 1979, J REPROD IMMUNOL, V1, P61, DOI 10.1016/0165-0378(79)90030-5; MUNOZ MG, 1978, BIOL REPROD, V18, P669, DOI 10.1095/biolreprod18.4.669; MYLES DG, 1984, J CELL BIOL, V99, P1634, DOI 10.1083/jcb.99.5.1634; MYLES DG, 1987, DEV BIOL, V121, P559, DOI 10.1016/0012-1606(87)90191-6; PRIMAKOFF P, 1985, J CELL BIOL, V101, P2239, DOI 10.1083/jcb.101.6.2239; PRIMAKOFF P, 1988, BIOL REPROD, V38, P921, DOI 10.1095/biolreprod38.4.921; PRIMAKOFF P, 1987, J CELL BIOL, V104, P141, DOI 10.1083/jcb.104.1.141; SINGER SL, 1985, GAMETE RES, V12, P29, DOI 10.1002/mrd.1120120104; SYNER FN, 1979, FERTIL STERIL, V32, P468; TUNG KSK, 1979, J REPROD IMMUNOL, V1, P145, DOI 10.1016/0165-0378(79)90015-9; TUNG KSK, 1986, REPRODUCTIVE IMMUNOL, P143	27	244	259	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	OCT 6	1988	335	6190					543	546		10.1038/335543a0	http://dx.doi.org/10.1038/335543a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q3412	3419530				2023-01-03	WOS:A1988Q341200054
J	DELASERNA, FJ; GILSANZ, F; RUILOPE, LM; PRAGA, M; RODICIO, JL; ALCAZAR, JM				DELASERNA, FJ; GILSANZ, F; RUILOPE, LM; PRAGA, M; RODICIO, JL; ALCAZAR, JM			IMPROVEMENT IN THE ERYTHROPOIESIS OF CHRONIC-HEMODIALYSIS PATIENTS WITH DESFERRIOXAMINE	LANCET			English	Article									HOSP 1 OCTUBRE, DEPT NEPHROL, E-28041 MADRID, SPAIN; HOSP 1 OCTUBRE, DEPT HAEMATOL, E-28041 MADRID, SPAIN	Hospital Universitario 12 de Octubre; Hospital Universitario 12 de Octubre			DE LA SERNA, JAVIER/B-1735-2012	DE LA SERNA, JAVIER/0000-0003-3904-1101; Ruilope, Luis M/0000-0001-6278-7951				ACKRILL P, 1985, CLIN NEPHROL, V24, pS94; ALTMANN P, 1987, NEW ENGL J MED, V317, P80, DOI 10.1056/NEJM198707093170204; ESCHBACH JW, 1985, KIDNEY INT, V28, P1, DOI 10.1038/ki.1985.109; GOKAL R, 1979, Q J MED, V48, P369; HERSHKO C, 1987, BRIT J HAEMATOL, V66, P149, DOI 10.1111/j.1365-2141.1987.tb01291.x; LI PK, 1982, CLIN CHEM, V28, P92; LOUACHE F, 1984, J BIOL CHEM, V259, P1576; MCCARTHY JT, 1986, AM J CLIN PATHOL, V86, P629; MCGONIGLE RJS, 1985, NEPHRON, V39, P1, DOI 10.1159/000183328; MOREB J, 1983, NEPHRON, V35, P196, DOI 10.1159/000183074; PALL H, 1986, LANCET, V2, P1279; PIOMELLI S, 1977, CLIN CHEM, V23, P264; PRAGA M, 1987, Nephrology Dialysis Transplantation, V2, P243; PRAGA M, 1987, NEW ENGL J MED, V316, P547; TESTA U, 1985, BRIT J HAEMATOL, V60, P491, DOI 10.1111/j.1365-2141.1985.tb07446.x; TIELEMANS C, 1985, CLIN NEPHROL, V24, P237; VANDEVYVER FL, 1984, KIDNEY INT, V26, P451, DOI 10.1038/ki.1984.195; WILLS MR, 1983, LANCET, V2, P29; 1985, LANCET, V1, P143	19	36	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 7	1988	1	8593					1009	1011						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N2401	2896866				2023-01-03	WOS:A1988N240100001
J	BION, JF; WILSON, IH; TAYLOR, PA				BION, JF; WILSON, IH; TAYLOR, PA			TRANSPORTING CRITICALLY ILL PATIENTS BY AMBULANCE - AUDIT BY SICKNESS SCORING	BRITISH MEDICAL JOURNAL			English	Note									PLYMOUTH GEN HOSP,INTENS CARE UNIT,PLYMOUTH PL4 8QQ,ENGLAND	University of Plymouth				Bion, Julian/0000-0003-0344-5403				BASKETT PJF, 1985, BRIT MED J, V290, P1531, DOI 10.1136/bmj.290.6481.1531; BION JF, 1985, BRIT MED J, V291, P432, DOI 10.1136/bmj.291.6493.432; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; WADDELL G, 1975, BRIT MED J, V1, P386, DOI 10.1136/bmj.1.5954.386	4	55	56	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1988	296	6616					170	170		10.1136/bmj.296.6616.170	http://dx.doi.org/10.1136/bmj.296.6616.170			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L7142	3122984	Bronze, Green Published			2023-01-03	WOS:A1988L714200013
J	STANNARD, VA; HUTCHINSON, A; MORRIS, DL; BYRNE, A				STANNARD, VA; HUTCHINSON, A; MORRIS, DL; BYRNE, A			GASTRIC EXOCRINE FAILURE IN CRITICALLY ILL PATIENTS - INCIDENCE AND ASSOCIATED FEATURES	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM HOSP,DEPT SURG & ANAESTHESIA,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								FIDDIANGREEN RG, 1983, GASTROENTEROLOGY, V85, P613; HASTINGS PR, 1978, NEW ENGL J MED, V298, P1041, DOI 10.1056/NEJM197805112981901; LUCAS CE, 1971, ARCH SURG-CHICAGO, V102, P266, DOI 10.1001/archsurg.1971.01350040028006; MENGUY R, 1974, GASTROENTEROLOGY, V66, P46; MORRIS DL, IN PRESS CRIT CARE M; PINILLA JC, 1985, CRIT CARE MED, V13, P646, DOI 10.1097/00003246-198508000-00007	6	55	57	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1988	296	6616					155	156		10.1136/bmj.296.6616.155	http://dx.doi.org/10.1136/bmj.296.6616.155			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L7142	3122979	Green Published			2023-01-03	WOS:A1988L714200007
J	RICH, MW; BECKHAM, V; WITTENBERG, C; LEVEN, CL; FREEDLAND, KE; CARNEY, RM				RICH, MW; BECKHAM, V; WITTENBERG, C; LEVEN, CL; FREEDLAND, KE; CARNEY, RM			A MULTIDISCIPLINARY INTERVENTION TO PREVENT THE READMISSION OF ELDERLY PATIENTS WITH CONGESTIVE-HEART-FAILURE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLUS ISOSORBIDE DINITRATE; GERIATRIC CONSULTATION; CONTROLLED TRIAL; HOSPITALIZATION; ENALAPRIL; REDUCTION; STAY; CARE	Background. Congestive heart failure is the most common indication for admission to the hospital among older adults. Behavioral factors, such as poor compliance with treatment, frequently contribute to exacerbations of heart failure, a fact suggesting that many admissions could be prevented. Methods. We conducted a prospective, randomized trial of the effect of a nurse-directed, multidisciplinary intervention on rates of readmission within 90 days of hospital discharge, quality of life, and costs of care for high-risk patients 70 years of age or older who were hospitalized with congestive heart failure. The intervention consisted of comprehensive education of the patient and family, a prescribed diet, social-service consultation and planning for an early discharge, a review of medications, and intensive follow-up. Results. Survival for 90 days without readmission, the primary outcome measure, was achieved in 91 of the 142 patients in the treatment group, as compared with 75 of the 140 patients in the control group, who received conventional care (P = 0.09). There were 94 readmissions in the control group and 53 in the treatment group (risk ratio, 0.56; P = 0.02). The number of readmissions for heart failure was reduced by 56.2 percent in the treatment group (54, vs. 24 in the control group; P = 0.04), whereas the number of readmissions for other causes was reduced by 28.5 percent (40 vs. 29, P not significant). In the control group, 23 patients (16.4 percent) had more than one readmission, as compared with 9 patients (6.3 percent) in the treatment group (risk ratio, 0.39; P = 0.01). In a subgroup of 126 patients, quality-of-life scores at 90 days improved more from base line for patients in the treatment group (P = 0.001). Because of the reduction in hospital admissions, the overall cost of care was $460 less per patient in the treatment group. Conclusions. A nurse-directed, multidisciplinary intervention can improve quality of life and reduce hospital use and medical costs for elderly patients with congestive heart failure.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DEPT PSYCHIAT,BEHAV MED SECT,ST LOUIS,MO 63110; WASHINGTON UNIV,DEPT ECON,ST LOUIS,MO 63130	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL)	RICH, MW (corresponding author), WASHINGTON UNIV,JEWISH HOSP ST LOUIS,DIV CARDIOL,GERIATR CARDIOL SECT,216 S KINGSHIGHWAY BLVD,ST LOUIS,MO 63110, USA.		Greiver, Michelle/N-8764-2015; Rich, Michael/AAD-6167-2022	Greiver, Michelle/0000-0001-8957-0285; Rich, Michael/0000-0002-4243-9391	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL044739] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL44739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS K, 1986, J AM GERIATR SOC, V34, P5, DOI 10.1111/j.1532-5415.1986.tb06333.x; CAMPION EW, 1983, J AM GERIATR SOC, V31, P792, DOI 10.1111/j.1532-5415.1983.tb03401.x; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; FISHER LD, 1993, BIOSTATISTICS METHOD, P188; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; GHALI JK, 1988, ARCH INTERN MED, V148, P2013, DOI 10.1001/archinte.148.9.2013; GHALI JK, 1990, ARCH INTERN MED, V150, P769, DOI 10.1001/archinte.150.4.769; GOODING J, 1985, J AM GERIATR SOC, V33, P595, DOI 10.1111/j.1532-5415.1985.tb06315.x; GRAVES EJ, 1991, ADV DATA VITAL HLTH, V199, P1; GUYATT GH, 1989, J GEN INTERN MED, V4, P101, DOI 10.1007/BF02602348; GUYATT GH, 1993, J AM COLL CARDIOL, V22, pA185, DOI 10.1016/0735-1097(93)90488-M; KENNEDY L, 1987, GERONTOLOGIST, V27, P577, DOI 10.1093/geront/27.5.577; KONSTAM M, 1994, CLIN PRACTICE GUIDEL, V11; LOEB HS, 1993, CIRCULATION, V87, P78; MOZES B, 1987, LANCET, V1, P968; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; PAUL SD, 1994, ARCH INTERN MED, V154, P1143, DOI 10.1001/archinte.154.10.1143; RECTOR TS, 1993, CIRCULATION, V87, P71; RICH MW, 1993, J GEN INTERN MED, V8, P585, DOI 10.1007/BF02599709; RICH MW, 1988, AM J PUBLIC HEALTH, V78, P680, DOI 10.2105/AJPH.78.6.680; ROGERS WJ, 1994, J AM COLL CARDIOL, V23, P393, DOI 10.1016/0735-1097(94)90426-X; SMITH DM, 1988, MED CARE, V26, P699, DOI 10.1097/00005650-198807000-00005; TOWNSEND J, 1988, BMJ-BRIT MED J, V297, P544, DOI 10.1136/bmj.297.6647.544; VANROSSUM E, 1993, BMJ-BRIT MED J, V307, P27, DOI 10.1136/bmj.307.6895.27; VINSON JM, 1990, J AM GERIATR SOC, V38, P1290, DOI 10.1111/j.1532-5415.1990.tb03450.x; WEINBERGER M, 1988, MED CARE, V26, P1092, DOI 10.1097/00005650-198811000-00007; WINOGRAD CH, 1993, ARCH INTERN MED, V153, P2017, DOI 10.1001/archinte.153.17.2017; 1991, NEW ENGL J MED, V325, P293; 1992, SAS P229 TECHN REP, P433	29	1607	1649	2	107	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 2	1995	333	18					1190	1195		10.1056/NEJM199511023331806	http://dx.doi.org/10.1056/NEJM199511023331806			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TB560	7565975				2023-01-03	WOS:A1995TB56000006
J	ALBERTI, W; ANDERSON, G; BARTOLUCCI, A; BELL, D; VILLALBA, JB; BRODIN, O; CARDIELLO, C; CARTEI, F; CARTEI, G; CELLERINO, R; CHASTANG, C; CORMIER, Y; COX, JD; CRINO, L; CROWLEY, J; DAUTZENBERG, B; DEPIERRE, A; DIETEMANN, A; DILLMAN, RO; DOI, O; FELD, R; FIGLIN, R; GANZ, PA; GREEN, MR; GREGOR, A; HELLE, PA; HERNDON, JE; HITOMI, S; HOST, H; IMAIZUMI, M; JETT, JR; JOHNSON, D; KAASA, S; KIMURA, H; KLASTERSKY, J; KONDO, H; KREISMAN, H; KRIS, MG; KUNISHIMA, K; KUWAHARA, O; LAD, TE; LAING, AH; MACBETH, F; MASAOKA, A; MATTSON, K; MINATEL, E; MIRA, JG; MORI, T; MOUNTAIN, CF; NIEDERLE, N; NIIRANEN, A; NOU, E; PAGE, W; PATER, J; PIANTADOSI, S; PISTERS, KMW; PYRHONEN, S; QUOIX, E; RAPP, E; ROWELL, NP; SAHMOUD, T; SAWAMURA, K; SCHALLIER, DCC; SCOTT, C; SIMPSON, J; STAGG, M; TERAMATSU, T; TROVO, MG; TSUCHIYA, R; TUMMARELLO, D; VANHOUTTE, P; VANZANDWIJK, N; VINCENT, RG; WADA, H; WHITE, JE; WILLIAMS, CJ; WOODS, RL; YAMAGUCHI, Y; ARRIAGADA, R; CARTMELLDAVIES, J; GIRLING, DJ; LECHEVALIER, T; MARSONI, S; PARMAR, MKB; PIGNON, JP; REKACEWICZ, C; SOUHAMI, RL; STEWART, LA; TARAYRE, M; TINAZZI, A; TONI, V				ALBERTI, W; ANDERSON, G; BARTOLUCCI, A; BELL, D; VILLALBA, JB; BRODIN, O; CARDIELLO, C; CARTEI, F; CARTEI, G; CELLERINO, R; CHASTANG, C; CORMIER, Y; COX, JD; CRINO, L; CROWLEY, J; DAUTZENBERG, B; DEPIERRE, A; DIETEMANN, A; DILLMAN, RO; DOI, O; FELD, R; FIGLIN, R; GANZ, PA; GREEN, MR; GREGOR, A; HELLE, PA; HERNDON, JE; HITOMI, S; HOST, H; IMAIZUMI, M; JETT, JR; JOHNSON, D; KAASA, S; KIMURA, H; KLASTERSKY, J; KONDO, H; KREISMAN, H; KRIS, MG; KUNISHIMA, K; KUWAHARA, O; LAD, TE; LAING, AH; MACBETH, F; MASAOKA, A; MATTSON, K; MINATEL, E; MIRA, JG; MORI, T; MOUNTAIN, CF; NIEDERLE, N; NIIRANEN, A; NOU, E; PAGE, W; PATER, J; PIANTADOSI, S; PISTERS, KMW; PYRHONEN, S; QUOIX, E; RAPP, E; ROWELL, NP; SAHMOUD, T; SAWAMURA, K; SCHALLIER, DCC; SCOTT, C; SIMPSON, J; STAGG, M; TERAMATSU, T; TROVO, MG; TSUCHIYA, R; TUMMARELLO, D; VANHOUTTE, P; VANZANDWIJK, N; VINCENT, RG; WADA, H; WHITE, JE; WILLIAMS, CJ; WOODS, RL; YAMAGUCHI, Y; ARRIAGADA, R; CARTMELLDAVIES, J; GIRLING, DJ; LECHEVALIER, T; MARSONI, S; PARMAR, MKB; PIGNON, JP; REKACEWICZ, C; SOUHAMI, RL; STEWART, LA; TARAYRE, M; TINAZZI, A; TONI, V			CHEMOTHERAPY IN NON-SMALL-CELL LUNG-CANCER - A METAANALYSIS USING UPDATED DATA ON INDIVIDUAL PATIENTS FROM 52 RANDOMIZED CLINICAL-TRIALS	BRITISH MEDICAL JOURNAL			English	Article							ADJUVANT CHEMOTHERAPY; SUPPORTIVE CARE; COMBINATION CHEMOTHERAPY; BRONCHOGENIC-CARCINOMA; PROLONG SURVIVAL; FINAL REPORT; RADIOTHERAPY; RADIATION; CYCLOPHOSPHAMIDE; CISPLATIN	Objective-To evaluate the effect of cytotoxic chemotherapy on survival in patients with non-small cell lung cancer. Design-Meta-analysis using updated data on individual patients from all available randomised trials, both published and unpublished. Subjects-9387 patients (7151 deaths) from 52 randomised clinical trials. Main outcome measure-Survival. Results-The results for modern regimens containing cisplatin favoured chemotherapy in all comparisons and reached conventional levels of significance when used with radical radiotherapy and with supportive care. Trials comparing surgery with surgery plus chemotherapy gave a hazard ratio of 0.87 (13% reduction in the risk of death, equivalent to an absolute benefit of 5% at five years). Trials comparing radical radiotherapy with radical radiotherapy plus chemotherapy gave a hazard ratio of 0.87 (13% reduction in the risk of death; absolute benefit of 4% at two years), and trials comparing supportive care with supportive care plus chemotherapy 0.73 (27% reduction in the risk of death; 10% improvement in survival at one year). The essential drugs needed to achieve these effects were not identified. No difference in the size of effect was seen in any subgroup of patients. In all but the radical radiotherapy setting, older trials using long term alkylating agents tended to show a detrimental effect of chemotherapy. This effect reached conventional significance in the adjuvant surgical comparison. Conclusion-At the outset of this meta-analysis there was considerable pessimism about the role of chemotherapy in non-small cell lung cancer. These results offer hope of progress and suggest that chemotherapy may have a role in treating this disease.	MRC,CANC TRIALS OFF,CAMBRIDGE CB2 2BW,ENGLAND				Rowell, Nick/AAA-3308-2020	Rowell, Nick/0000-0002-7836-9567; PIGNON, Jean-Pierre/0000-0003-2047-1582; Stewart, Lesley/0000-0003-0287-4724				ALBERTI W, 1990, Journal of Cancer Research and Clinical Oncology, V116, P503; ANDERSON G, 1985, SEMIN ONCOL, V12, P21; ANDERSON G, 1981, THORAX, V36, P190, DOI 10.1136/thx.36.3.190; ASOLA R, 1991, EUR J CANCER       S, V2, pA529; ASOLA R, 1991, EUR J CANCER       S, V2, pS91; BERGSAGEL DE, 1972, CANCER-AM CANCER SOC, V30, P621, DOI 10.1002/1097-0142(197209)30:3<621::AID-CNCR2820300305>3.0.CO;2-0; BRODEN O, 1991, LUNG CANCER S, V7, P165; BRUNNER KW, 1971, EUR J CANCER, V7, P285, DOI 10.1016/0014-2964(71)90071-5; CARDIELLO C, 1985, P AN M AM SOC CLIN, V4, pC692; CARTEI G, 1993, JNCI-J NATL CANCER I, V85, P794, DOI 10.1093/jnci/85.10.794; CELLERINO R, 1991, J CLIN ONCOL, V9, P1453, DOI 10.1200/JCO.1991.9.8.1453; CHASTANG CL, 1991, EUR J CANCER S2, V27, pA1017; CORMIER Y, 1982, CANCER, V50, P845, DOI 10.1002/1097-0142(19820901)50:5<845::AID-CNCR2820500507>3.0.CO;2-S; CRINO L, 1993, ANN ONCOL, V4, P847, DOI 10.1093/oxfordjournals.annonc.a058391; DERSIMONIAN R, 1980, CONTROL CLIN TRIALS, V7, P177; DILLMAN RO, 1990, NEW ENGL J MED, V323, P940, DOI 10.1056/NEJM199010043231403; Early Breast Cancer Trialists' Collaborative Group, 1990, TREATMENT EARLY BREA, V1; FELD R, 1993, JNCI-J NATL CANCER I, V85, P299, DOI 10.1093/jnci/85.4.299; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; GANZ PA, 1989, CANCER, V63, P1271, DOI 10.1002/1097-0142(19890401)63:7<1271::AID-CNCR2820630707>3.0.CO;2-6; GIRLING DJ, 1985, BRIT J CANCER, V52, P867, DOI 10.1038/bjc.1985.271; GREGOR A, 1993, J NATL CANCER I, V85, P997, DOI 10.1093/jnci/85.12.997; Holmes EC, 1991, LUNG CANCER, V7, P11; HOST H, 1973, CANCER CHEMOTH REP 3, V4, P161; ISRAEL L, 1982, RECENT RES CANCER, V80, P214; ISRAEL L, 1979, LUNG CANC PROGR THER, P443; JOHNSON DH, 1990, ANN INTERN MED, V113, P33, DOI 10.7326/0003-4819-113-1-33; KAASA S, 1991, CANCER, V67, P2443, DOI 10.1002/1097-0142(19910515)67:10<2443::AID-CNCR2820671008>3.0.CO;2-K; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARRER K, 1978, CANCER CHEMOTH PHARM, V1, P145; KAUNG DT, 1974, CANCER CHEMOTH REP 1, V58, P359; KIMURA H, 1991, LUNG CANCER S, V7, pA498; LAD T, 1988, J CLIN ONCOL, V6, P9; LAING AH, 1975, LANCET, V1, P1161; LECHEVALIER T, 1991, JNCI-J NATL CANCER I, V83, P417, DOI 10.1093/jnci/83.6.417; MATTSON K, 1988, EUR J CANCER CLIN ON, V24, P477, DOI 10.1016/S0277-5379(98)90020-7; MINET P, 1987, RADIOTHER ONCOL, V8, P217, DOI 10.1016/S0167-8140(87)80245-1; MORTON RF, 1991, ANN INTERN MED, V115, P681, DOI 10.7326/0003-4819-115-9-681; MOUNTAIN CF, 1979, LUNG CANCER PROGR TH, P421; NIIRANEN A, 1992, J CLIN ONCOL, V10, P1927, DOI 10.1200/JCO.1992.10.12.1927; OHTA M, 1993, J THORAC CARDIOV SUR, V106, P703, DOI 10.1016/S0022-5223(19)33714-6; Parkin DM, 1993, LUNG CANCER, V9, P1; PETO R, 1987, STAT MED, V6, P233, DOI 10.1002/sim.4780060306; PETROVICH Z, 1978, CANCER, V42, P1129, DOI 10.1002/1097-0142(197809)42:3<1129::AID-CNCR2820420315>3.0.CO;2-F; PISTERS KMW, 1994, J SURG ONCOL, V56, P236, DOI 10.1002/jso.2930560407; QUOIX E, 1991, B CANCER, V78, P341; Rankin EM, 1986, RANDOMISED TRIALS CA, P447; RAPP E, 1988, J CLIN ONCOL, V6, P633, DOI 10.1200/JCO.1988.6.4.633; Rudd R, 1991, RESP DIS PRACTICE, V7, P12; Sawamura K, 1988, LUNG CANCER, V4, pA166; SCHALLIER DC, 1988, CLIN EXP METASTAS, V6, P39, DOI 10.1007/BF01580405; SHIELDS TW, 1982, CANCER, V50, P1713, DOI 10.1002/1097-0142(19821101)50:9<1713::AID-CNCR2820500910>3.0.CO;2-B; SHIELDS TW, 1972, CANCER, V40, P2057; SIDOROWITZ E, 1985, 4TH P WORLD C LUNG C, pA277; SILVERBERG E, 1990, CA-CANCER J CLIN, V40, P9, DOI 10.3322/canjclin.40.1.9; SIMPSON JR, 1985, INT J RADIAT ONCOL, V11, P751, DOI 10.1016/0360-3016(85)90307-4; SLEVIN ML, 1990, BRIT MED J, V300, P1458, DOI 10.1136/bmj.300.6737.1458; SQUIRES TS, 1993, CA CANC J CLIN, V43, P7; STEWART THM, 1992, CELLULAR IMMUNE MECHANISMS AND TUMOR DORMANCY, P213; STOTT H, 1977, BRIT MED J, V2, P1513, DOI 10.1136/bmj.2.6101.1513; TERAMATSU T, 1991, LUNG CANCER, V7, pA462; Till J E, 1992, Qual Life Res, V1, P31, DOI 10.1007/BF00435433; TROVO MG, 1990, CANCER, V65, P400, DOI 10.1002/1097-0142(19900201)65:3<400::AID-CNCR2820650304>3.0.CO;2-H; Van Houtte P, 1988, Antibiot Chemother (1971), V41, P131; WHITE JE, 1982, CANCER TREAT REP, V66, P1113; WOODS RL, 1990, BRIT J CANCER, V61, P608, DOI 10.1038/bjc.1990.135; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1992, HAI GAN, V32, P481	68	2843	2898	0	93	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	OCT 7	1995	311	7010					899	909						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RZ237	7580546				2023-01-03	WOS:A1995RZ23700017
J	SMALLEY, WE; GRIFFIN, MR; FOUGHT, RL; SULLIVAN, L; RAY, WA				SMALLEY, WE; GRIFFIN, MR; FOUGHT, RL; SULLIVAN, L; RAY, WA			EFFECT OF A PRIOR-AUTHORIZATION REQUIREMENT ON THE USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS BY MEDICAID PATIENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PAYMENT; THERAPY	Background. Prior authorization - mandatory advance approval for the use of expensive medications - is now the primary method by which Medicaid programs control expenditures for drugs. However, whether this policy reduces expenditures for specific drugs without causing the unwanted substitution of other drugs or medical services has been largely unstudied. We evaluated the effects of a prior-authorization policy involving nongeneric nonsteroidal antiinflammatory drugs (NSAIDs) in the Medicaid program in Tennessee. Methods. We compared monthly Medicaid expenditures that were potentially affected by the policy change during the year before and the two years after its implementation. We studied prescriptions for NSAIDs, other analgesic or antiinflammatory drugs, and psychotropic drugs, as well as outpatient services and inpatient admissions for the management of pain or inflammation. Results. At the midpoint of the base-line year, 495,821 people were enrolled in Medicaid. During that year, mean annualized Medicaid expenditures for NSAID prescriptions amounted to $22.41. Expenditures decreased by 53 percent (95 percent confidence interval, 48 to 57 percent) during the next two years, for an estimated savings of $12.8 million. The reduction in expenditures resulted from the increased use of generic NSAIDs, as well as from a 19 percent decrease in overall NSAID use (95 percent confidence interval, 13 to 25 percent). There was no concomitant increase in Medicaid expenditures for other medical care. Regular users of nongeneric NSAIDs, those most affected by the policy change, had similar reductions in NSAID expenditures and use, with no increase in expenditures for other medical care. Conclusions. Prior-authorization requirements may be highly cost effective with regard to expenditures for NSAIDs, drugs that have very similar efficacy and safety but substantial variation in cost.	VANDERBILT UNIV,SCH MED,DEPT MED,DIV GASTROENTEROL,NASHVILLE,TN 37212; VANDERBILT UNIV,SCH MED,DEPT MED,DIV GEN INTERNAL MED,NASHVILLE,TN 37212; TENNESSEE STATE DEPT HLTH,BUR TENNCARE,NASHVILLE,TN	Vanderbilt University; Vanderbilt University; Tennessee Department Health	SMALLEY, WE (corresponding author), VANDERBILT UNIV,SCH MED,DEPT PREVENT MED,A-1124 MCN,NASHVILLE,TN 37232, USA.			Sullivan, Lisa/0000-0003-0726-7149	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007768] Funding Source: NIH RePORTER; AHRQ HHS [HS07768] Funding Source: Medline; FDA HHS [FD-U-0000073] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); FDA HHS		BATCHLOR EE, 1992, OSTEOARTHRITIS DIAGN, P465; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; BROOKS PM, 1991, NEW ENGL J MED, V324, P1716; Gondek K, 1994, Health Care Financ Rev, V15, P1; OLIN BR, 1992, DRUG FACTS COMP; POLLARD MR, 1991, HEALTH AFFAIR, V10, P196, DOI 10.1377/hlthaff.10.2.196; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; SMALLEY WE, 1995, AM J EPIDEMIOL, V141, P539, DOI 10.1093/oxfordjournals.aje.a117469; SOUMERAI SB, 1991, NEW ENGL J MED, V325, P1072, DOI 10.1056/NEJM199110103251505; SOUMERAI SB, 1993, MILBANK Q, V71, P217, DOI 10.2307/3350399; SOUMERAI SB, 1994, NEW ENGL J MED, V331, P650, DOI 10.1056/NEJM199409083311006; SOUMERAI SB, 1990, JAMA-J AM MED ASSOC, V263, P831, DOI 10.1001/jama.263.6.831; SOUMERAI SB, 1987, NEW ENGL J MED, V317, P550, DOI 10.1056/NEJM198708273170906; SOUMERAI SB, 1990, HEALTH AFFAIR, V9, P36, DOI 10.1377/hlthaff.9.3.36; TOMITA DK, 1988, PB89143325; WEINTRAUB M, 1991, JAMA-J AM MED ASSOC, V266, P2392, DOI 10.1001/jama.266.17.2392; 1980, INT CLASSIFICATION D; 1993, DRUG EVALUATIONS ANN; 1992, STAT B, V73, P25; 1994, SOCIAL SECURITY B AN, P325	20	137	137	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 15	1995	332	24					1612	1617		10.1056/NEJM199506153322406	http://dx.doi.org/10.1056/NEJM199506153322406			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC192	7753141	Bronze			2023-01-03	WOS:A1995RC19200006
J	DUNNE, DW; HAGAN, P; ABATH, FGC				DUNNE, DW; HAGAN, P; ABATH, FGC			PROSPECTS FOR IMMUNOLOGICAL CONTROL OF SCHISTOSOMIASIS	LANCET			English	Review							TRIOSE-PHOSPHATE ISOMERASE; GLUTATHIONE-S-TRANSFERASE; PROTECTIVE IMMUNITY; SURFACE-ANTIGEN; ATTENUATED CERCARIAE; RECOMBINANT FRAGMENT; MONOCLONAL-ANTIBODY; HUMAN RESISTANCE; LIFE-CYCLE; MANSONI		UNIV GLASGOW, INST BIOMED & LIFE SCI, DIV MOLEC & CELLULAR BIOL, GLASGOW, LANARK, SCOTLAND; FDN OSWALDO CRUZ, CTR PESQUISAS AGGEU MAGALHAES, DEPT IMMUNOL, RECIFE, PE, BRAZIL	University of Glasgow; Fundacao Oswaldo Cruz	DUNNE, DW (corresponding author), UNIV CAMBRIDGE, DEPT PATHOL, DIV MICROBIOL & PARASITOL, TENNIS COURT RD, CAMBRIDGE CB2 1QP, ENGLAND.		Dunne, David William/AAC-2530-2020	Dunne, David/0000-0002-8940-9886; Hagan, Paul/0000-0002-3516-2283	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALI PO, 1991, MOL BIOCHEM PARASIT, V45, P215, DOI 10.1016/0166-6851(91)90088-N; BALLOUL JM, 1987, NATURE, V326, P149, DOI 10.1038/326149a0; BALLOUL JM, 1987, J IMMUNOL, V138, P3448; BASCH PF, 1993, T ROY SOC TROP MED H, V87, P589, DOI 10.1016/0035-9203(93)90098-B; BOULANGER D, 1991, PARASITE IMMUNOL, V13, P473, DOI 10.1111/j.1365-3024.1991.tb00545.x; BUTTERWORTH A, 1988, BIOCHIMIE, V70, P1053, DOI 10.1016/0300-9084(88)90268-4; BUTTERWORTH AE, 1985, T ROY SOC TROP MED H, V79, P393, DOI 10.1016/0035-9203(85)90391-8; BUTTERWORTH AE, 1992, T ROY SOC TROP MED H, V86, P1, DOI 10.1016/0035-9203(92)90411-5; CAPRON A, 1987, SCIENCE, V238, P1065, DOI 10.1126/science.3317823; CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; COLLEY DG, 1986, T ROY SOC TROP MED H, V80, P952, DOI 10.1016/0035-9203(86)90268-3; CURRY AJ, 1995, J EXP MED, V181, P769, DOI 10.1084/jem.181.2.769; DEMEURE CE, 1993, J INFECT DIS, V168, P1000, DOI 10.1093/infdis/168.4.1000; DESSEIN AJ, 1988, J IMMUNOL, V140, P2727; DIN MSAN, 1994, AM J TROP MED HYG, V50, P585; DUNNE DW, 1992, EUR J IMMUNOL, V22, P1483, DOI 10.1002/eji.1830220622; DUNNE DW, 1988, EUR J IMMUNOL, V18, P123, DOI 10.1002/eji.1830180119; ELSHERBEINI M, 1991, MOL BIOCHEM PARASIT, V49, P83, DOI 10.1016/0166-6851(91)90132-P; FLANIGAN TP, 1989, J CLIN INVEST, V83, P1010, DOI 10.1172/JCI113942; GRZYCH JM, 1993, J IMMUNOL, V150, P527; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HARN DA, 1992, J IMMUNOL, V148, P562; HARN DA, IN PRESS MEM I O CRU; JAMES S L, 1987, Memorias do Instituto Oswaldo Cruz, V82, P121, DOI 10.1590/S0074-02761987000800020; KHALIFE J, 1986, J EXP MED, V164, P1626, DOI 10.1084/jem.164.5.1626; KHALIFE J, 1989, J IMMUNOL, V142, P4422; KNIGHT M, 1989, PARASITOL RES, V75, P280, DOI 10.1007/BF00931812; LANAR DE, 1986, SCIENCE, V234, P593, DOI 10.1126/science.3094144; LANGLEY JG, 1994, IMMUNOLOGY, V83, P651; LIESE B, 1986, PARASITOL TODAY, V2, P339, DOI 10.1016/0169-4758(86)90054-2; MATSUMOTO Y, 1988, NATURE, V333, P76, DOI 10.1038/333076a0; MAZZA G, 1990, PARASITE IMMUNOL, V12, P529, DOI 10.1111/j.1365-3024.1990.tb00986.x; MOSER D, 1991, J BIOL CHEM, V266, P8447; PEARCE EJ, 1988, P NATL ACAD SCI USA, V85, P5678, DOI 10.1073/pnas.85.15.5678; PEARCE EJ, 1986, J IMMUNOL, V137, P3593; PEARCE EJ, 1991, J EXP MED, V173, P159, DOI 10.1084/jem.173.1.159; REYNOLDS SR, 1994, J IMMUNOL, V152, P193; RIHET P, 1991, EUR J IMMUNOL, V21, P2679, DOI 10.1002/eji.1830211106; ROBERTS M, 1993, INFECT IMMUN, V61, P4984, DOI 10.1128/IAI.61.12.4984-4993.1993; SHOEMAKER C, 1992, P NATL ACAD SCI USA, V89, P1842, DOI 10.1073/pnas.89.5.1842; SMITH DB, 1986, P NATL ACAD SCI USA, V83, P8703, DOI 10.1073/pnas.83.22.8703; SMYTHIES LE, 1992, J IMMUNOL, V149, P3654; SOISSON LA, 1993, J IMMUNOL, V151, P4782; SOISSON LA, 1993, EXP PARASITOL, V77, P492, DOI 10.1006/expr.1993.1111; SOISSON LMA, 1992, J IMMUNOL, V149, P3612; TALLA I, 1990, ANN SOC BELG MED TR, V70, P173; TENDLER M, IN PRESS MEM I O CRU; WESTON D, 1993, MOL BIOCHEM PARASIT, V58, P161, DOI 10.1016/0166-6851(93)90100-C; WILKINS HA, 1987, T ROY SOC TROP MED H, V81, P29, DOI 10.1016/0035-9203(87)90273-2; WOLOWCZUK I, 1989, J IMMUNOL, V142, P1342; XU CB, 1993, J IMMUNOL, V150, P940	51	47	60	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 10	1995	345	8963					1488	1492						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC189	7769906				2023-01-03	WOS:A1995RC18900013
J	BOGOD, D				BOGOD, D			ADVANCES IN EPIDURAL ANALGESIA FOR LABOR - PROGRESS VERSUS PRUDENCE	LANCET			English	Editorial Material											BOGOD, D (corresponding author), CITY HOSP,DEPT ANAESTHESIA,NOTTINGHAM NG5 1PB,ENGLAND.							CHAMBERLAIN G, 1993, PAIN ITS RELIEF CHIL, P50; CHESTNUT DH, 1990, ANESTHESIOLOGY, V72, P613, DOI 10.1097/00000542-199004000-00006; Collis R E, 1994, Int J Obstet Anesth, V3, P75, DOI 10.1016/0959-289X(94)90173-2; GAMBLING DR, 1988, ANESTH ANALG, V33, P249; RUSSELL R, 1993, BRIT MED J, V306, P1299, DOI 10.1136/bmj.306.6888.1299; SMEDSTAD KG, 1988, CAN J ANAESTH, V35, P234, DOI 10.1007/BF03010616	6	10	10	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 6	1995	345	8958					1129	1130		10.1016/S0140-6736(95)90973-7	http://dx.doi.org/10.1016/S0140-6736(95)90973-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW622	7723541				2023-01-03	WOS:A1995QW62200005
J	LITTLE, P; KEEFE, M; WHITE, J				LITTLE, P; KEEFE, M; WHITE, J			SELF SCREENING FOR RISK OF MELANOMA - VALIDITY OF SELF MOLE COUNTING BY PATIENTS IN A SINGLE GENERAL-PRACTICE	BRITISH MEDICAL JOURNAL			English	Article							CUTANEOUS MALIGNANT-MELANOMA; DANISH CASE-CONTROL; MELANOCYTIC NEVI; SUNBURN; NAEVI; AUSTRALIA; EXPOSURE; WOMEN	Objective-To validate self screening by patients of high mole counts, assess the within family association of sun protection behaviour and mole counts, and estimate prevalence of risk factors for melanoma. Setting and subjects-Systematic sample of families from a single affluent general practice population in Wessex. Design-Subjects completed a questionnaire about risk factors for melanoma and counted their moles. Subsequently a mole count was done by a general practitioner trained at dermatology clinics. Main outcome measures-Validation of self counts by observer's count. Within family association of sun protection behaviour and mole counts; self reported risk factors. Results-199/237 subjects (84%) returned the questionnaire; 212/237 (89%) were examined, High counts by patients on the front of the trunk (>7 moles of greater than or equal to 2 mm) were reasonably sensitive (79%), predictive (75%), and specific (97%) of the observer's mole counts (kappa=0.74), unlike arm or total body counts. Sun protection behaviour correlated between individuals and other family members (Spearman's coefficient r=0.50, P<0.01), In the past three months 15/114 adults (13.2%, 95% confidence interval 7.0% to 19.1%) reported any change in a mole and 6/114 (5.3%, 2.0% to 11.1%) ''major'' changes; 6/109 adults (5.5%, 2.1% to 11.6%) had both high mole counts and freckling. Conclusions-Asking patients to count trunk moles could be a feasible way of identifying patients at high risk of melanoma. Concentrating on reported major changes in moles should avoid considerable workload in general practice. The generalisability of these findings and the adverse effects, net benefit in earlier diagnosis and prevention, and workload implications of such self screening need further research.	UNIV SOUTHAMPTON,DEPT DERMATOL,SOUTHAMPTON,HANTS,ENGLAND; HLTH CTR,THAME OX9 3JZ,OXON,ENGLAND	University of Southampton	LITTLE, P (corresponding author), UNIV SOUTHAMPTON,FAC MED,ALDERMOOR HLTH CTR,SOUTHAMPTON SO16 5ST,HANTS,ENGLAND.			Little, Paul/0000-0003-3664-1873				BAIN C, 1988, AM J EPIDEMIOL, V127, P703, DOI 10.1093/oxfordjournals.aje.a114851; BERAL V, 1983, BRIT J DERMATOL, V109, P165, DOI 10.1111/j.1365-2133.1983.tb07077.x; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; BONETT A, 1986, MED J AUSTRALIA, V144, P680, DOI 10.5694/j.1326-5377.1986.tb113693.x; BYLES JE, 1944, BRIT J DERMATOL, V130, P51; CLARK WM, 1988, ARCH DERMATOL, V114, P732; COOKE KR, 1989, CANCER, V63, P1240, DOI 10.1002/1097-0142(19890315)63:6<1240::AID-CNCR2820630635>3.0.CO;2-9; COOKE KR, 1985, J EPIDEMIOL COMMUNIT, V39, P52; DARCY C, 1994, J NATL CANCER I, V72, P257; ELDER DE, 1989, J INVEST DERMATOL S, V92, P297; ELWOOD JM, 1990, INT J EPIDEMIOL, V19, P801, DOI 10.1093/ije/19.4.801; ELWOOD JM, 1985, BRIT J CANCER, V51, P543, DOI 10.1038/bjc.1985.77; ELWOOD JM, 1994, INT J CANCER, V35, P427; ELWOOD JM, 1994, BRIT MED J, V288, P99; ENGLISH DR, 1988, BRIT MED J, V296, P1285, DOI 10.1136/bmj.296.6632.1285; ENGLISH JSC, 1988, BRIT J DERMATOL, V118, P641, DOI 10.1111/j.1365-2133.1988.tb02564.x; GREEN A, 1985, BRIT J CANCER, V51, P393, DOI 10.1038/bjc.1985.53; GREEN A, 1985, INT J CANCER, V35, P297, DOI 10.1002/ijc.2910350303; GROB JJ, 1990, CANCER, V66, P387, DOI 10.1002/1097-0142(19900715)66:2<387::AID-CNCR2820660232>3.0.CO;2-J; HOLLY EA, 1987, J AM ACAD DERMATOL, V17, P459, DOI 10.1016/S0190-9622(87)70230-8; JOHNSON N, 1994, BRIT J GEN PRACT, V44, P523; MACHIE R, 1985, BRIT J DERMATOL, V113, P167; MACKIE RM, 1982, BRIT J CANCER, V46, P955, DOI 10.1038/bjc.1982.307; MARKS R, 1994, BRIT MED J, V308, P75, DOI 10.1136/bmj.308.6921.75; MARTEAU T, 1991, BRIT MED J, V301, P26; NEWTON JA, 1994, BRIT MED BULL, V50, P677, DOI 10.1093/oxfordjournals.bmb.a072916; NEWTON JA, 1992, DIAGNOSIS MANAGEMENT, P53; NICHOLLS EM, 1973, CANCER, V32, P191, DOI 10.1002/1097-0142(197307)32:1<191::AID-CNCR2820320129>3.0.CO;2-W; OSTERLIND A, 1988, INT J CANCER, V42, P200, DOI 10.1002/ijc.2910420210; OSTERLIND A, 1988, INT J CANCER, V42, P319, DOI 10.1002/ijc.2910420303; PACK GT, 1952, AMA ARCH SURG, V65, P862, DOI 10.1001/archsurg.1952.01260020856010; ROBERTS DL, 1990, CLIN EXP DERMATOL, V15, P406, DOI 10.1111/j.1365-2230.1990.tb02132.x; ROUSH GC, 1988, PREV MED, V17, P273, DOI 10.1016/0091-7435(88)90003-5; SWERDLOW AJ, 1986, BRIT MED J, V292, P1555, DOI 10.1136/bmj.292.6535.1555; WEINSTOCK MA, 1989, PEDIATRICS, V84, P199; ZANETTI R, 1992, EUR J CANCER, V28A, P1172, DOI 10.1016/0959-8049(92)90480-P	36	38	38	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					912	916		10.1136/bmj.310.6984.912	http://dx.doi.org/10.1136/bmj.310.6984.912			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719184	Green Published			2023-01-03	WOS:A1995QR97200027
J	HARRIS, MA; SULLIVAN, CE				HARRIS, MA; SULLIVAN, CE			SLEEP PATTERN AND SUPPLEMENTARY OXYGEN REQUIREMENTS IN INFANTS WITH CHRONIC NEONATAL LUNG-DISEASE	LANCET			English	Note							AROUSAL RESPONSES	Seven infants with chronic neonatal lung disease and baseline oxygen saturation greater than 90% were studied with overnight polysomnography in their prescribed oxygen environment, and on a second night with 0.25 L/min additional oxygen. All had sleep fragmentation and decreased rapid-eye-movement (REM) sleep, which was reversed after the increased oxygen. Sleep duration (p<0.003), percentage REM sleep (p<0.001), and mean REM sleep period length (p<0.001) were increased, and arousals in REM sleep decreased (p<0.05), with improved oxygenation. We conclude that, in infants with chronic neonatal lung disease, arousal mechanisms minimise oxygen desaturation but induce sleep disruption.	ROYAL ALEXANDRA HOSP CHILDREN,DAVID READ PAEDIAT SLEEP DISORDERS CTR,MATL SIDS COUNCIL,SYDNEY,NSW,AUSTRALIA				Harris, Margaret-Anne/G-9627-2014					COONS S, 1987, SLEEP ITS DISORDERS, P17; ISSA FG, 1987, J APPL PHYSIOL, V62, P1832, DOI 10.1152/jappl.1987.62.5.1832; SCHER MS, 1992, SLEEP, V15, P195, DOI 10.1093/sleep/15.3.195; SELL EJ, 1988, BRONCHOPULMONARY DYS, P403; VOHR BR, 1982, AM J DIS CHILD, V136, P443, DOI 10.1001/archpedi.1982.03970410061015; WARD SLD, 1992, PEDIATRICS, V89, P860; WILLIAMS GR, 1989, AUST PAEDIATR J, V25, P370	7	33	35	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					831	832		10.1016/S0140-6736(95)92966-5	http://dx.doi.org/10.1016/S0140-6736(95)92966-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898231				2023-01-03	WOS:A1995QQ19500011
J	PAPHASSARANG, C; TOMSON, G; CHOPRAPAWON, C; WEERASURIYA, K				PAPHASSARANG, C; TOMSON, G; CHOPRAPAWON, C; WEERASURIYA, K			THE LAO NATIONAL DRUG POLICY - LESSONS ALONG THE JOURNEY	LANCET			English	Article									KAROLINSKA INST,DEPT INT HLTH & SOCIAL MED,INT HLTH CARE RES UNIT,S-17177 STOCKHOLM,SWEDEN; THAILAND HLTH RES INST,BANGKOK,THAILAND; UNIV COLOMBO,FAC MED,DEPT PHARMACOL,COLOMBO,SRI LANKA; MINIST PUBL HLTH,DEPT FOOD & DRUG,VIANGCHAN,LAOS	Karolinska Institutet; University of Colombo								CHETLEY A, 1994, LANCET, V343, P967; DUMOULIN J, 1994, LAO DRUG DATA BASE; FUNCK B, 1993, CHALLENGE EC REFORMM, P123; Hall P, 1975, CHANGE CHOICE CONFLI; HOGERZEIL HV, 1993, LANCET, V343, P1408; KINTANAR QL, 1992, PRESCRIPTION CHANGE, P32; MANGLA B, 1993, LANCET, V342, P608, DOI 10.1016/0140-6736(93)91424-K; PAPHASSARANG C, 1992, NATIONAL DRUG POLICY; PONGPRADITH S, 1993, DIARRHOEAL DISEASE C; REICH MR, 1994, HLTH POLICY PLANN, V9, P1; ROBLES A, 1992, PRESCRIPTION CHANGE; TOMSON G, 1986, LANCET, V2, P620; TOMSON G, 1992, NAIONAL DRUG POLICY; 1988, GUIDELINES DEV NATIO; 1994, REPORT BIENNIUM 1992; 1993, INVESTING HLTH WORLD; 1993, NATIONAL DRUG POLICY; 1994, LAO SOCIAL INDICATOR; 1992, ETHICAL CRITERIA MED	19	23	23	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					433	435		10.1016/S0140-6736(95)90408-5	http://dx.doi.org/10.1016/S0140-6736(95)90408-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QG904	7853957				2023-01-03	WOS:A1995QG90400016
J	TURNER, JA; DEYO, RA; LOESER, JD; VONKORFF, M; FORDYCE, WE				TURNER, JA; DEYO, RA; LOESER, JD; VONKORFF, M; FORDYCE, WE			THE IMPORTANCE OF PLACEBO-EFFECTS IN PAIN TREATMENT AND RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LOW-BACK-PAIN; EXPECTANCY; RESPONSES; ANALGESIA; SURGERY; MODEL	Objective.-To estimate the importance and implications of placebo effects in pain treatment and research from the existing literature, with emphasis on their magnitude and duration, the conditions influencing them, and proposed explanations. Data Sources.-English-language articles and books identified through MED-LINE (1980 through 1993) and PsycLIT (1967 through 1993) database searching, bibliography review, and expert consultation. Study Selection.-Articles were included if they pertained to the review objectives. Results.-Placebo response rates vary greatly and are frequently much higher than the often-cited one third. Placebos have time-effect curves, and peak, cumulative, and carryover effects similar to those of active medications. As with medication, surgery can produce substantial placebo effects, and this possibility is commonly overlooked in case series reports on back surgery. Individuals are not consistent in their placebo responses, and a placebo-responder personality has not been identified. Models advanced to explain placebo effects emphasize the role of anxiety, expectations, and learning. Conclusions.-Placebo effects influence patient outcomes after any treatment, including surgery, that the clinician and patient believe is effective. Placebo effects plus disease natural history and regression to the mean can result in high rates of good outcomes, which may be misattributed to specific treatment effects. The true causes of improvements in pain after treatment remain unknown in the absence of independently evaluated randomized controlled trials.	UNIV WASHINGTON, DEPT REHABIL MED, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA USA; UNIV WASHINGTON, DEPT HLTH SERV, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT NEUROL SURG, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT ANESTHESIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, CTR MULTIDISCIPLINARY PAIN, SEATTLE, WA USA; VET AFFAIRS MED CTR, HLTH SERV RES & DEV FIELD PROGRAM, SEATTLE, WA USA; GRP HLTH COOPERAT PUGET SOUND, CTR HLTH STUDIES, SEATTLE, WA 98101 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Group Health Cooperative	TURNER, JA (corresponding author), UNIV WASHINGTON, SCH MED, DEPT PSYCHIAT & BEHAV SCI RP10, SEATTLE, WA 98195 USA.			VonKorff, Michael/0000-0001-5386-8477	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS006344] Funding Source: NIH RePORTER; AHRQ HHS [HS 06344] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BEECHER HK, 1961, JAMA-J AM MED ASSOC, V176, P1102, DOI 10.1001/jama.1961.63040260007008; BEECHER HK, 1955, JAMA-J AM MED ASSOC, V159, P1602, DOI 10.1001/jama.1955.02960340022006; BLACKWELL B, 1972, LANCET, V1, P1279; BODEN SD, 1990, J BONE JOINT SURG AM, V72A, P403, DOI 10.2106/00004623-199072030-00013; Brody Howard, 1985, PLACEBO THEORY RES M, P37; BUCKALEW LW, 1982, J CLIN PSYCHOPHARM, V2, P245; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; COBB LA, 1959, NEW ENGL J MED, V260, P1115, DOI 10.1056/NEJM195905282602204; DePalma A F, 1968, Clin Orthop Relat Res, V59, P113; DEYO RA, 1990, NEW ENGL J MED, V322, P1627, DOI 10.1056/NEJM199006073222303; DEYO RA, 1993, SPINE, V18, P2153, DOI 10.1097/00007632-199311000-00002; DEYO RA, 1991, PHYS MED REHABIL, V5, P209; DIMOND EG, 1960, AM J CARDIOL, V5, P483, DOI 10.1016/0002-9149(60)90105-3; Evans F. J., 1985, PLACEBO THEORY RES M, P215; FISHER L, 1983, CIRCULATION, V68, P939, DOI 10.1161/01.CIR.68.5.939; FLATLEY TJ, 1985, CLIN ORTHOP RELAT R, P273; FULLENLOVE TM, 1957, RADIOLOGY, V68, P572, DOI 10.1148/68.4.572; GOODMAN P, 1976, J AM DENT ASSOC, V92, P755, DOI 10.14219/jada.archive.1976.0419; Gracely R H, 1987, Anesth Prog, V34, P113; GRACELY RH, 1985, LANCET, V1, P43; GREVERT P, 1985, PLACEBO THEORY RES M, P232; HOFFMAN RM, 1993, J GEN INTERN MED, V8, P487, DOI 10.1007/BF02600110; LASAGNA L, 1954, AM J MED, V16, P770, DOI 10.1016/0002-9343(54)90441-6; LASAGNA L, 1958, J CLIN INVEST, V37, P533, DOI 10.1172/JCI103635; LASKA E, 1973, HEADACHE, V13, P1, DOI 10.1111/j.1526-4610.1973.hed1301001.x; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; LIBERMAN R, 1964, J PSYCHIAT RES, V2, P233, DOI 10.1016/0022-3956(64)90010-X; LONG DM, 1989, STEREOT FUNCT NEUROS, V53, P149, DOI 10.1159/000099531; LUPARELLO TJ, 1970, PSYCHOSOM MED, V32, P509, DOI 10.1097/00006842-197009000-00009; MAGORA A, 1976, SCAND J REHABIL MED, V8, P115; MAX MB, 1987, NEUROLOGY, V37, P589, DOI 10.1212/WNL.37.4.589; McDonald C J, 1983, Stat Med, V2, P417; MILLER NE, 1989, NONSPECIFIC ASPECTS, P39; PECK C, 1991, THEOR MED, V12, P247, DOI 10.1007/BF00489609; POGGE RC, 1963, MED TIMES, V91, P1; REISS S, 1980, BEHAV THER, V11, P380, DOI 10.1016/S0005-7894(80)80054-2; ROBERTS AH, 1993, CLIN PSYCHOL REV, V13, P375, DOI 10.1016/0272-7358(93)90010-J; ROBERTS AH, 1993, 7TH WORLD C INT ASS; ROSENZWEIG P, 1993, CLIN PHARMACOL THER, V54, P578, DOI 10.1038/clpt.1993.190; Ross S, 1985, PLACEBO THEORY RES M, P67; SCHWEIGER A, 1981, PAVLOVIAN J BIOL SCI, V16, P140; Shapiro A, 1984, BEHAV HLTH HDB HLTH, P371; SHAPIRO AP, 1954, PSYCHOSOM MED, V16, P478, DOI 10.1097/00006842-195411000-00002; SOX HC, 1981, ANN INTERN MED, V95, P680, DOI 10.7326/0003-4819-95-6-680; SPANGFORT EV, 1972, ACTA ORTHOP SCAND, P1; Spiro HM, 1986, DOCTORS PATIENTS PLA; SPLITHOFF CA, 1953, JAMA-J AM MED ASSOC, V152, P1610, DOI 10.1001/jama.1953.03690170024008; STERNBACH RA, 1964, PSYCHOPHYSIOLOGY, V1, P67; THOMAS KB, 1987, BRIT MED J, V294, P1200, DOI 10.1136/bmj.294.6581.1200; THOMSON R, 1982, BRIT J PSYCHIAT, V140, P64, DOI 10.1192/bjp.140.1.64; TURNER JA, 1992, JAMA-J AM MED ASSOC, V268, P907, DOI 10.1001/jama.268.7.907; TURNER JA, 1992, SPINE, V17, P1, DOI 10.1097/00007632-199201000-00001; VOUDOURIS NJ, 1990, PAIN, V43, P121, DOI 10.1016/0304-3959(90)90057-K; VOUDOURIS NJ, 1989, PAIN, V38, P109, DOI 10.1016/0304-3959(89)90080-8; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WADDELL G, 1979, J BONE JOINT SURG AM, V61, P201, DOI 10.2106/00004623-197961020-00007; WALL PD, 1993, CIBA F SYMP, V174, P187; WEBER H, 1983, SPINE, V8, P131, DOI 10.1097/00007632-198303000-00003; WHITNEY CW, 1992, PAIN, V50, P281, DOI 10.1016/0304-3959(92)90032-7; Wickramasekera I., 1985, PLACEBO THEORY RES M, P255; WIESEL SW, 1984, SPINE, V9, P549, DOI 10.1097/00007632-198409000-00003	61	634	640	1	65	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 25	1994	271	20					1609	1614		10.1001/jama.271.20.1609	http://dx.doi.org/10.1001/jama.271.20.1609			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NL758	7880221				2023-01-03	WOS:A1994NL75800031
J	GARATTINI, S; GARATTINI, L				GARATTINI, S; GARATTINI, L			PHARMACEUTICAL PRESCRIPTIONS IN 4 EUROPEAN COUNTRIES	LANCET			English	Editorial Material											GARATTINI, S (corresponding author), MARIO NEGRI INST PHARMACOL RES,CTR ECON SANIT A VALENTI,I-20157 MILAN,ITALY.		Garattini, Silvio/AAA-6390-2020	Garattini, Silvio/0000-0003-0647-9297					0	36	36	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 13	1993	342	8881					1191	1192		10.1016/0140-6736(93)92181-R	http://dx.doi.org/10.1016/0140-6736(93)92181-R			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MG274	7901525				2023-01-03	WOS:A1993MG27400005
J	WENDOLOSKI, JJ; KIMATIAN, SJ; SCHUTT, CE; SALEMME, FR				WENDOLOSKI, JJ; KIMATIAN, SJ; SCHUTT, CE; SALEMME, FR			MOLECULAR-DYNAMICS SIMULATION OF A PHOSPHOLIPID MICELLE	SCIENCE			English	Article									PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	Princeton University	WENDOLOSKI, JJ (corresponding author), DUPONT CO,DEPT CENT RES & DEV,EXPTL STN,WILMINGTON,DE 19880, USA.							BAREMAN JP, 1988, PHYS REV LETT, V60, P2152, DOI 10.1103/PhysRevLett.60.2152; BROOKS BR, 1987, SUPERCOMPUTER RES CH, P123; CHEN SH, 1986, ANNU REV PHYS CHEM, V37, P351, DOI 10.1146/annurev.pc.37.100186.002031; DEKRUIJFF B, 1987, NATURE, V329, P587, DOI 10.1038/329587a0; DILL KA, 1984, MACROMOLECULES, V17, P380, DOI 10.1021/ma00133a022; DILL KA, 1981, P NATL ACAD SCI USA, V78, P676, DOI 10.1073/pnas.78.2.676; DILL KA, 1984, NATURE, V309, P42, DOI 10.1038/309042a0; DILL KA, 1980, P NATL ACAD SCI USA, V77, P3115, DOI 10.1073/pnas.77.6.3115; ELDER M, 1977, PROC R SOC LON SER-A, V354, P157, DOI 10.1098/rspa.1977.0062; HAILE JM, 1984, J PHYS CHEM-US, V88, P6363, DOI 10.1021/j150669a062; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; JONSSON B, 1986, J CHEM PHYS, V85, P2259, DOI 10.1063/1.451122; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; LUZZATI V, 1968, NATURE, V218, P1031, DOI 10.1038/2181031a0; OWENSON B, 1984, J PHYS CHEM-US, V84, P2906; SZLEIFER I, 1985, J CHEM PHYS, V83, P3612, DOI 10.1063/1.449167; SZLEIFER I, 1986, J CHEM PHYS, V85, P5345, DOI 10.1063/1.451679; WATANABE K, 1988, J PHYS CHEM-US, V92, P819, DOI 10.1021/j100314a045; WEINER PK, 1981, J COMPUT CHEM, V2, P287, DOI 10.1002/jcc.540020311; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WOODS MC, 1986, J PHYS CHEM-US, V90, P1875, DOI 10.1021/j100400a028; ZEMB T, 1982, CHEM PHYS LETT, V88, P68, DOI 10.1016/0009-2614(82)80072-9	22	102	104	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 3	1989	243	4891					636	638		10.1126/science.2916118	http://dx.doi.org/10.1126/science.2916118			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	T0483	2916118				2023-01-03	WOS:A1989T048300031
J	HOSKIN, PJ; HANKS, GW; WHITE, ID				HOSKIN, PJ; HANKS, GW; WHITE, ID			STERILE ABSCESS FORMATION BY CONTINUOUS SUBCUTANEOUS INFUSION OF DIAMORPHINE	BRITISH MEDICAL JOURNAL			English	Letter											HOSKIN, PJ (corresponding author), ROYAL MARSDEN HOSP,CONTINUING CARE UNIT,SUTTON SM2 5PT,SURREY,ENGLAND.			White, Isabel/0000-0003-3572-8969				Nicholson H, 1986, Nurs Times, V82, P49; Regnard C, 1983, Nurs Times, V79, P25	2	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1988	296	6636					1605	1605		10.1136/bmj.296.6636.1605-b	http://dx.doi.org/10.1136/bmj.296.6636.1605-b			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7292	3135034	Green Published			2023-01-03	WOS:A1988N729200046
J	KOZIELL, AB; LAURENSON, IF				KOZIELL, AB; LAURENSON, IF			WITCHDOCTORS IN AFRICA	BRITISH MEDICAL JOURNAL			English	Article									ROODLANDS GEN HOSP,HADDINGTON EH4 3PF,E LOTHIAN,SCOTLAND		KOZIELL, AB (corresponding author), QUEEN MARYS HOSP,DEPT MED,SIDCUP,KENT,ENGLAND.							MURRAY K, 1984, BR J UROL, V55, P379; TAPP A, 1987, NEUROUROL URODYNAM, V6, P254; WALTER S, 1978, UROL INT, V33, P135, DOI 10.1159/000280190	3	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1988	296	6616					179	181		10.1136/bmj.296.6616.179	http://dx.doi.org/10.1136/bmj.296.6616.179			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L7142	3122990	Green Published			2023-01-03	WOS:A1988L714200019
J	HORTON, R				HORTON, R			MAST-I - AGREEING TO DISAGREE	LANCET			English	Editorial Material																		HORTON R, 1995, LANCET, V346, P3, DOI 10.1016/S0140-6736(95)92644-5	1	13	13	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1504	1504		10.1016/S0140-6736(95)92043-9	http://dx.doi.org/10.1016/S0140-6736(95)92043-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491039				2023-01-03	WOS:A1995TJ29100002
J	DASGUPTA, B; BOWLES, J				DASGUPTA, B; BOWLES, J			SCINTIGRAPHIC LOCALIZATION OF STEROID INJECTION SITE IN PLANTAR FASCIITIS	LANCET			English	Note								Plantar fasciitis is a common cause of heel pain. We evaluated scintigraphic localisation of the inflammatory focus in 15 patients with this condition. Technetium-labelled bone scans precisely localised abnormal discrete areas of tracer uptake in 12 (80%) of patients in the medial and posterior aspect below the inferior surface of the calcaneum. Steroid injection at the inflammatory site abolished local tenderness and reduced pain in all 12. Our findings support an injection approach through the medial heel border posterior to the point of heel tenderness. Technetium scintigraphy may be a useful investigation to localise the steroid injection site in resistant cases of plantar fasciitis.			DASGUPTA, B (corresponding author), SOUTHEND HLTH CARE TRUST,WESTCLIFF ON SEA SS0 0RY,ESSEX,ENGLAND.		Bowles, Josephine/AAG-4903-2020	Bowles, Josephine/0000-0003-2867-7438				BEIKOWITZ JF, 1991, RADIOLOGY, V179, P665; INTENZO CM, 1991, CLIN NUCL MED, V16, P325, DOI 10.1097/00003072-199105000-00006; MAPP PI, 1993, OXFORD TXB RHEUMATOL; SCHEPSIS AA, 1991, CLIN ORTHOPAEDICS, V266, P185; SELMAN JR, 1994, FOOT ANKLE INT, V15, P376; Wall J R, 1993, Foot Ankle, V14, P465	6	29	29	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 25	1995	346	8987					1400	1401		10.1016/S0140-6736(95)92409-4	http://dx.doi.org/10.1016/S0140-6736(95)92409-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TG207	7475824				2023-01-03	WOS:A1995TG20700012
J	ROBINSON, RG; PRESTON, DF; SCHIEFELBEIN, M; BAXTER, KG				ROBINSON, RG; PRESTON, DF; SCHIEFELBEIN, M; BAXTER, KG			STRONTIUM-89 THERAPY FOR THE PALLIATION OF PAIN DUE TO OSSEOUS METASTASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							DOUBLE-BLIND CROSSOVER; PROSTATE-CANCER; BONE CANCER; SR-89 THERAPY; MANAGEMENT; CARCINOMA; EFFICACY; BREAST	Objective.-To present the current state of systemic radiopharmaceutical therapy for the palliation of pain in individuals with metastatic cancer and to evaluate the palliative effect and degree of hemotoxicity of strontium chloride 89 (Sr-89) in patients with painful osteoblastic metastases primarily from prostate and breast cancer. Data Sources and Study Selection.-A MEDLINE search through December 1994 was performed to identify English-language studies that met the following criteria. All eligible studies reported treatment of patients with painful osteoblastic bony metastases primarily from prostate or breast cancer treated with intravenous Sr-89. For study eligibility, evaluation of clinical response as assessed by the Karnofsky index, need for pain medication, or changes in mobility or sleep patterns was required. Hemotoxicity data were a requirement. A minimum of 10 prostate cancer cases was necessary for study inclusion. Only those studies assessing clinical response following one injection of Sr-89 were included. Preliminary reports of cooperative studies were not included. Doses of Sr-89 ranged from 0.6 MBq/kg (16 mu Ci/kg) to 400 MBq (10.8 mCi) per patient. Evaluation of patients for at least 3 months following Sr-89 treatment was required. In addition, two studies examining issues of cost with regard to Sr-89 treatment were identified. Data Extraction.-Baseline pain assessment and periodic pain estimates as measured by the Karnofsky index, medication diaries, changes in mobility, sleep patterns, and/or ability to work were the basis for assessment of response. Baseline and periodic complete blood cell counts were the basis for hemotoxicity evaluation. Data Synthesis.-Palliation and hemotoxicity data were analyzed separately for each study. Some improvement occurred in as many as approximately 80% of patients. Several studies demonstrated complete relief of pain in at least 10% of patients. The nadir of platelet and white blood cell counts appears at approximately 4 to 8 weeks following injection, with a partial return to baseline by 12 weeks. As many as 10 injections spaced 3 months apart have been given to some patients with repeated palliative effect and without serious hemotoxicity. Reinjection may be limited by a platelet count below 60x10(9)/L, a white blood cell count below 2.4x10(9)/L, or the absence of osteoblastic skeletal metastasis as seen on bone scan. Studies examining treatment costs suggest that Sr-89 may decrease costs associated with palliation of pain due to metastatic disease. Conclusions.-As many as 80% of selected patients with painful osteoblastic bony metastases from prostate or breast cancer may experience some pain relief following Sr-89 administration. In addition, as many as 10% or more may become pain free. Duration of clinical response may average 3 to 6 months in some cases. Hemotoxicity is mild. A decrease in treatment costs with administration of Sr-89 to patients with painful osteoblastic bony metastases from prostate cancer may occur. These observations reflect the preliminary nature of knowledge in this field and point to the need for larger clinical trials of the use of Sr-89 palliation.	UNIV KANSAS,MED CTR,DEPT RADIOL,DIV NUCL MED,KANSAS CITY,KS 66160	University of Kansas; University of Kansas Medical Center								ATKINS HL, 1993, RADIOLOGY, V186, P279, DOI 10.1148/radiology.186.1.7677974; BLAKE GM, 1986, EUR J NUCL MED, V12, P447, DOI 10.1007/BF00254749; BONICA JJ, 1990, MANAGEMENT PAIN, P400; CHEUNG A, 1980, RADIOLOGY, V134, P209, DOI 10.1148/radiology.134.1.6153129; CRANE VS, 1990, ANN PHARMACOTHER, V24, P524; Dearnaley D P, 1992, Clin Oncol (R Coll Radiol), V4, P101, DOI 10.1016/S0936-6555(05)80975-6; DEKLERK JMH, 1994, J NUCL MED, V35, P1423; DENIS L, 1993, CANCER-AM CANCER SOC, V71, P1050, DOI 10.1002/1097-0142(19930201)71:3+<1050::AID-CNCR2820711425>3.0.CO;2-#; Dickinson C.Z., 1993, J NUCL MED TECHNOL, V21, P133; DUSING RW, 1993, CLIN NUCL MED, V19, P624; FARHANGHI M, 1992, J NUCL MED, V33, P1451; HOLMES RA, 1993, SEMIN ONCOL, V20, P22; HOLMES RA, 1992, SEMIN NUCL MED, V22, P41, DOI 10.1016/S0001-2998(05)80156-4; HURST LC, 1986, CLIN ORTHOPAEDICS, V206, P290; JOHNSON DE, 1977, J UROLOGY, V9, P137; LAING AH, 1991, BRIT J RADIOL, V64, P816, DOI 10.1259/0007-1285-64-765-816; LEWINGTON VJ, 1991, EUR J CANCER, V27, P954, DOI 10.1016/0277-5379(91)90257-E; MAXON HR, 1991, J NUCL MED, V32, P1877; MAXON HR, 1992, SEMIN NUCL MED, V22, P33, DOI 10.1016/S0001-2998(05)80155-2; MCEWAN AJB, 1994, NUCL MED COMMUN, V15, P499, DOI 10.1097/00006231-199407000-00002; MCGOWAN D, 1994, ONCOLOGY S, V8, P30; NIELSEN OS, 1991, J CLIN ONCOL, V9, P509, DOI 10.1200/JCO.1991.9.3.509; PEREZ C, 1987, PRINCIPLES PRACTISE, P1276; Porter A T, 1994, Oncology (Williston Park), V8, P93; PORTER AT, 1993, INT J RADIAT ONCOL, V25, P805, DOI 10.1016/0360-3016(93)90309-J; PORTER AT, 1994, ONCOLOGY HUNTINGT S, V8, P25; QUILTY PM, 1994, RADIOTHER ONCOL, V31, P33, DOI 10.1016/0167-8140(94)90411-1; REDDY EK, 1986, J NATL MED ASSOC, V78, P27; Robinson R G, 1989, Radiographics, V9, P271; ROBINSON RG, 1993, SEMIN ONCOL, V20, P44; ROBINSON RG, 1992, SEMIN NUCL MED, V22, P28, DOI 10.1016/S0001-2998(05)80154-0; ROBINSON RG, 1990, J NUCL MED, V31, P1326; ROBINSON RG, 1993, APPL RADIOL, V22, P44; SILBERSTEIN EB, 1985, J NUCL MED, V26, P345; Twycross R G, 1981, Int Rehabil Med, V3, P135; TWYCROSS R G, 1991, Henry Ford Hospital Medical Journal, V39, P77; 1994, CLIN PRACTICE GUIDEL, V9; 1993, METASTRON PRESCRIBIN	38	137	160	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					420	424		10.1001/jama.274.5.420	http://dx.doi.org/10.1001/jama.274.5.420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7542352				2023-01-03	WOS:A1995RL41600030
J	BINDMAN, AB; GRUMBACH, K; OSMOND, D; KOMAROMY, M; VRANIZAN, K; LURIE, N; BILLINGS, J; STEWART, A				BINDMAN, AB; GRUMBACH, K; OSMOND, D; KOMAROMY, M; VRANIZAN, K; LURIE, N; BILLINGS, J; STEWART, A			PREVENTABLE HOSPITALIZATIONS AND ACCESS TO HEALTH-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; CITY; POOR	Objective. To examine whether the higher hospital admission rates for chronic medical conditions such as asthma, hypertension, congestive heart failure, chronic obstructive pulmonary disease, and diabetes in low-income communities resulted from community differences in access to care, prevalence of the diseases, propensity to seek care, or physician admitting style. Design.-Analysis of California hospital discharge data. We calculated the hospitalization rates for these five chronic conditions for the 250 ZIP code clusters that define urban California. We performed a random-digit telephone survey among adults residing in a random sample of 41 of these urban ZIP code clusters stratified by admission rates and a mailed survey of generalist and emergency physicians who practiced in the same 41 areas. Setting.-Community based. Participants.-A total of 6674 English- and Spanish-speaking adults aged 18 through 64 years residing in the 41 areas were asked about their access to care, their chronic medical conditions, and their propensity to seek health care. Physician admitting style was measured with written clinical vignettes among 723 generalist and emergency physicians practicing in the same communities. Main Outcome Measures.-We compared respondents' reports of access to medical care in an area with the area's cumulative admission rate for these five chronic conditions. We then tested whether access to medical care remained independently associated with preventable hospitalization rates after controlling for the prevalence of the conditions, health care seeking, and physician practice style. Results.-Access to care was inversely associated with the hospitalization rates for the five chronic medical conditions (R(2)=0.50; P<.001). In a multivariate analysis that included a measure of access, the prevalence of conditions, health care seeking, and physician practice style to predict cumulative hospitalization rates for chronic medical conditions, both self-rated access to care (P<.002) and the prevalence of the conditions (P<.03) remained independent predictors. Conclusion.-Communities where people perceive poor access to medical care have higher rates of hospitalization for chronic diseases. Improving access to care is more likely than changing patients' propensity to seek health care or eliminating variation in physician practice style to reduce hospitalization rates for chronic conditions.	SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94110; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA; UNIV CALIF SAN FRANCISCO,INST HLTH & AGING,SAN FRANCISCO,CA 94143; UNIV MINNESOTA,SCH MED,HENNEPIN CTY MED CTR,DEPT MED,MINNEAPOLIS,MN 55455; UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455; NYU,ROBERT F WAGNER GRAD SCH PUBL SERV,NEW YORK,NY 10003	San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; New York University	BINDMAN, AB (corresponding author), SAN FRANCISCO GEN HOSP,PRIMARY CARE RES CTR,WARD 95,1001 POTRERO AVE,SAN FRANCISCO,CA 94110, USA.		Grumbach, Kevin/L-9222-2016		AHRQ HHS [HSO7373] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		BILLINGS J, 1993, HEALTH AFFAIR, V12, P162, DOI 10.1377/hlthaff.12.1.162; CAPER P, 1993, HEALTH AFFAIR, V12, P174, DOI 10.1377/hlthaff.12.1.174; DIEHR P, 1990, HEALTH SERV RES, V24, P741; FREEMAN HE, 1987, HEALTH AFFAIR, V6, P6, DOI 10.1377/hlthaff.6.1.6; GRISWOLD PR, 1992, HLTH CARE COSTS MASS; GRUMBACH K, 1995, CALIFORNIA POLICY SE; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; KLEINMAN JC, 1981, MED CARE, V19, P1011, DOI 10.1097/00005650-198110000-00004; Komaromy Miriam, 1995, JGIM, V10, P70; MEUX E, 1994, HEALTH SERV RES, V29, P247; MEUX EF, 1990, REPORT RESULTS OSHPD; NEWACHECK PW, 1988, HEALTH SERV RES, V23, P401; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; SHEA S, 1992, NEW ENGL J MED, V327, P776, DOI 10.1056/NEJM199209103271107; SMELOFF EA, 1981, PUBLIC HEALTH REP, V96, P310; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; 1993, CD ROM SERIES 10, V4; 1990, STATISTICAL ANAL SAM; 1992, US DEPT HLTH HUMA 10, V4; 1992, 1990 CALIFORNIA HOSP	20	687	692	0	54	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 26	1995	274	4					305	311		10.1001/jama.274.4.305	http://dx.doi.org/10.1001/jama.274.4.305			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RJ898	7609259				2023-01-03	WOS:A1995RJ89800032
J	ROTHEN, HU; SPORRE, B; ENGBERG, G; WEGENIUS, G; REBER, A; HEDENSTIERNA, G				ROTHEN, HU; SPORRE, B; ENGBERG, G; WEGENIUS, G; REBER, A; HEDENSTIERNA, G			PREVENTION OF ATELECTASIS DURING GENERAL-ANESTHESIA	LANCET			English	Article							VENTILATION-PERFUSION RATIOS; CONTINUOUS DISTRIBUTIONS; ANESTHESIA; LUNG; HYPOXEMIA; O2	Atelectasis is an important cause of impaired gas exchange during general anaesthesia; it causes pulmonary shunting. We studied the effects of gas composition on the formation of atelectasis and on gas exchange during the induction of general anaesthesia. In 12 adult patients, the lungs were ventilated with 30% oxygen in nitrogen during anaesthesia induction, and in another 12, a conventional technique was used (100% oxygen during induction and 40% oxygen in nitrogen thereafter). Extent of atelectasis was estimated by computed tomography and the ventilation-perfusion relation (VA/Q) by the multiple inert gas elimination technique, After anaesthesia induction, there was little atelectasis in the 30% oxygen group (mean 0.2 [SD 0.4] cm(2)) and a significantly greater amount (4.2 [5.6] cm(2); p<0.001) in the 100% oxygen group. Patients in the 30% oxygen group were observed for another 40 min. 6 continued to receive 30% oxygen (subgroup A) and 6 were ventilated with 100% oxygen (subgroup B). During this time, the amount of atelectasis increased to 1.6 (1.6) cm(2) in subgroup A and to 4.7 (4.5) cm(2) in subgroup B (p=0.047 for difference between groups). In subgroup A, the shunt (VA/Q) <0.005) increased from 1.6 (2.0)% of cardiac output to 3.2 (2.7)%, but the arterial oxygen tension did not change. In subgroup B, the shunt increased from 2.6 (5.2)% to 9.8 (5.7)% of cardiac output. These results suggest that the composition of inspired gas is important in atelectasis formation during general anaesthesia. Use of a lower oxygen concentration than is now standard practice might prevent the early formation of atelectasis.	UNIV UPPSALA HOSP,DEPT CLIN PHYSIOL,S-75185 UPPSALA,SWEDEN; UNIV HOSP BERN,DEPT ANAESTHESIOL & INTENS CARE,BERN,SWITZERLAND; UNIV UPPSALA HOSP,DEPT ANAESTHESIOL & INTENS CARE,S-75185 UPPSALA,SWEDEN; UNIV UPPSALA HOSP,DEPT RADIOL,S-75185 UPPSALA,SWEDEN	Uppsala University; Uppsala University Hospital; University of Bern; University Hospital of Bern; Uppsala University; Uppsala University Hospital; Uppsala University; Uppsala University Hospital			Rothen, Hans Ulrich/H-7100-2018					BAKER AB, 1993, BRIT J ANAESTH, V70, P259, DOI 10.1093/bja/70.3.259; BENDIXEN HH, 1963, NEW ENGL J MED, V269, P991, DOI 10.1056/NEJM196311072691901; BRISMAR B, 1985, ANESTHESIOLOGY, V62, P422, DOI 10.1097/00000542-198504000-00009; COTE CJ, 1988, ANESTHESIOLOGY, V68, P184, DOI 10.1097/00000542-198802000-00002; DAMGAARDPEDERSE.K, 1980, PEDIATR RADIOL, V9, P145; DANTZKER DR, 1975, J APPL PHYSIOL, V38, P886, DOI 10.1152/jappl.1975.38.5.886; DAWSONSAUNDERS B, 1990, BASIC CLIN BIOSTATIS, P118; DON HF, 1972, ANESTHESIOLOGY, V36, P533, DOI 10.1097/00000542-197206000-00003; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; GUNNARSSON L, 1991, BRIT J ANAESTH, V66, P423, DOI 10.1093/bja/66.4.423; JOYCE CJ, 1993, J APPL PHYSIOL, V74, P1107, DOI 10.1152/jappl.1993.74.3.1107; LUNDQUIST H, IN PRESS ACTA RADIOL; MARSHALL BE, 1972, ANESTHESIOLOGY, V37, P178, DOI 10.1097/00000542-197208000-00009; MARSHALL BE, 1994, INTENS CARE MED, V20, P291, DOI 10.1007/BF01708968; MOLLER JT, 1991, BRIT J ANAESTH, V66, P437, DOI 10.1093/bja/66.4.437; NUNN JF, 1978, BRIT J ANAESTH, V50, P91, DOI 10.1093/bja/50.2.91; PRYSROBERTS C, 1967, LANCET, V2, P399; REBER A, 1994, NOV P ANN M SWED MED, P219; ROTHEN HU, 1995, ANESTHESIOLOGY, V82, P832, DOI 10.1097/00000542-199504000-00004; ROTHEN HU, 1993, BRIT J ANAESTH, V71, P788, DOI 10.1093/bja/71.6.788; TOKICS L, 1988, J APPL PHYSIOL, V64, P599, DOI 10.1152/jappl.1988.64.2.599; WAGNER PD, 1974, J APPL PHYSIOL, V36, P588, DOI 10.1152/jappl.1974.36.5.588; WAGNER PD, 1974, J CLIN INVEST, V54, P54, DOI 10.1172/JCI107750; WAGNER PD, 1985, J APPL PHYSIOL, V59, P376, DOI 10.1152/jappl.1985.59.2.376; WAGNER PD, 1980, PULMONARY GAS EXCHAN, V1, P233; WEBB SJS, 1967, ANAESTHESIA, V22, P69, DOI 10.1111/j.1365-2044.1967.tb02696.x; WILLENKIN RL, 1994, ANESTHESIA, P1045; 1992, LANCET, V339, P31	28	243	257	0	2	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1387	1391		10.1016/S0140-6736(95)92595-3	http://dx.doi.org/10.1016/S0140-6736(95)92595-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760608				2023-01-03	WOS:A1995RB44100007
J	HICKISH, TF; SMITH, IE; MIDDLETON, G; NICOLSON, M				HICKISH, TF; SMITH, IE; MIDDLETON, G; NICOLSON, M			PATIENT PREFERENCE FOR EXTENDED PALLIATIVE CHEMOTHERAPY FOR NONSMALL CELL LUNG-CANCER	LANCET			English	Letter									ROYAL MARSDEN HOSP,SUTTON SM2 5PT,SURREY,ENGLAND; ABERDEEN ROYAL INFIRM,ABERDEEN,SCOTLAND	Royal Marsden NHS Foundation Trust; University of Aberdeen				Hickish, Tamas/0000-0001-6770-7279				COATES A, 1993, LANCET, V342, P4, DOI 10.1016/0140-6736(93)91876-N; CULLEN MH, LUNG CANCER, V9, pS81; ELLIS PA, 1995, BRIT J CANCER, V71, P366, DOI 10.1038/bjc.1995.74; JAAKKIMAINEN L, 1990, J CLIN ONCOL, V8, P1301, DOI 10.1200/JCO.1990.8.8.1301; SOUQUET PJ, 1993, LANCET, V342, P19	5	9	7	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	APR 1	1995	345	8953					857	858		10.1016/S0140-6736(95)92993-2	http://dx.doi.org/10.1016/S0140-6736(95)92993-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7534859				2023-01-03	WOS:A1995QQ19500040
J	RINCK, G; KLEIJNEN, J; VANDENBOS, TGAM; DEHAES, HJCJM; SCHADE, E; VEENHOF, CHN				RINCK, G; KLEIJNEN, J; VANDENBOS, TGAM; DEHAES, HJCJM; SCHADE, E; VEENHOF, CHN			TRIALS IN PALLIATIVE CARE	BRITISH MEDICAL JOURNAL			English	Letter									ACAD MED CTR,INST SOCIAL MED,AMSTERDAM,NETHERLANDS; ACAD MED CTR,DEPT PSYCHOL MED,AMSTERDAM,NETHERLANDS; ACAD MED CTR,DEPT GEN FAMILY MED,AMSTERDAM,NETHERLANDS; ACAD MED CTR,DEPT INTERNAL MED,DIV MED ONCOL,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	RINCK, G (corresponding author), UNIV HOSP AMSTERDAM,ACAD MED CTR,DEPT CLIN EPIDEMIOL & BIOSTAT,POB 22700,1100 DE AMSTERDAM,NETHERLANDS.							MCWHINNEY IR, 1994, BRIT MED J, V309, P1340, DOI 10.1136/bmj.309.6965.1340; OVESEN L, 1993, J CLIN ONCOL, V11, P2043, DOI 10.1200/JCO.1993.11.10.2043	2	22	22	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 4	1995	310	6979					598	599		10.1136/bmj.310.6979.598c	http://dx.doi.org/10.1136/bmj.310.6979.598c			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK700	7534157	Green Published			2023-01-03	WOS:A1995QK70000053
J	MARSHALL, M; LOCKWOOD, A; GATH, D				MARSHALL, M; LOCKWOOD, A; GATH, D			SOCIAL-SERVICES CASE-MANAGEMENT FOR LONG-TERM MENTAL-DISORDERS - A RANDOMIZED CONTROLLED TRIAL	LANCET			English	Article							NEEDS; CARE; ILL	Case management arose in the USA as a solution to the difficulties of providing community care to people with severe mental disorders. The basic principle of the approach is that a case manager takes responsibility for a client; arranges an assessment of need, a comprehensive service plan, delivery of suitable services, and monitoring and assessment of services delivered. The case-management approach has been widely accepted, to the extent that recent legislation has made case-management the cornerstone of community care in the UK. We did a randomised controlled trial to evaluate a social services case-management team for people with long-term mental disorders. Subjects were referred from hostels for the homeless, night shelters, a general-practitioner clinic for the homeless, the Oxford City Council homelessness unit, and local voluntary-sector group homes. Of 103 subjects referred, 80 consented to be randomised to treatment or control groups. At 14-month follow-up, as assessed by standardised interviews, there were no significant differences between groups in number of needs, quality of life, employment status, quality of accommodation, social behaviour, or severity of psychiatric symptoms. In the case-management group there was a significant reduction in deviant behaviour on a standardised behaviour rating scale (REHAB) (mean=0.79; 95% CI 0.26-1.32). It is unfortunate, in view of the limited effectiveness we have shown, that social services case-management was not evaluated in randomised controlled trials before its implementation in the UK.			MARSHALL, M (corresponding author), UNIV OXFORD,WARNEFORD HOSP,DEPT PSYCHIAT,OXFORD OX3 7JX,ENGLAND.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Baker R., 1983, USERS MANUAL REHABIL; BREWIN CR, 1988, PSYCHOL MED, V18, P457, DOI 10.1017/S0033291700007996; BREWIN CR, 1987, PSYCHOL MED, V17, P971, DOI 10.1017/S0033291700000787; FORD R, 1993, IMPLEMENTING CASE MA; FRANKLIN JL, 1987, AM J PUBLIC HEALTH, V77, P674, DOI 10.2105/AJPH.77.6.674; Griffiths R, 1988, COMMUNITY CARE AGEND; Holloway F, 1991, Int J Soc Psychiatry, V37, P2, DOI 10.1177/002076409103700102; HOLLOWAY F, 1991, BRIT J PSYCHIAT, V159, P142, DOI 10.1192/bjp.159.1.142; KRAWIECKA M, 1977, ACTA PSYCHIAT SCAND, V55, P299, DOI 10.1111/j.1600-0447.1977.tb00174.x; Lear G, 1993, Nurs Times, V89, P26; LEHMAN AF, 1983, ARCH GEN PSYCHIAT, V40, P369; Marshall M., 1994, PHILOS PSYCHOL PSYCH, V1, P27; MARSHALL M, 1994, IN PRESS PSYCHOL MED; ROSSLER W, 1992, ACTA PSYCHIAT SCAND, V86, P445, DOI 10.1111/j.1600-0447.1992.tb03295.x; SEGAL S, 1977, COMMUNITY BASED SHEL; Shepherd G, 1990, Health Trends, V22, P59; THORNICROFT G, 1991, International Review of Psychiatry, V3, P125, DOI 10.3109/09540269109067527; 1986, MAKING REALITY COMMU	18	67	68	1	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 18	1995	345	8947					409	412		10.1016/S0140-6736(95)90399-2	http://dx.doi.org/10.1016/S0140-6736(95)90399-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QG904	7853949				2023-01-03	WOS:A1995QG90400007
J	ELLRODT, AG; CONNER, L; RIEDINGER, M; WEINGARTEN, S				ELLRODT, AG; CONNER, L; RIEDINGER, M; WEINGARTEN, S			MEASURING AND IMPROVING PHYSICIAN COMPLIANCE WITH CLINICAL-PRACTICE GUIDELINES - A CONTROLLED INTERVENTIONAL TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article							CARE; APPROPRIATENESS; DELAYS; TOOL	Objective: To determine factors that may lead physicians not to comply with clinical practice guidelines. Design: Retrospective analysis of patients whose physicians were not compliant with discharge recommendations from a prospective, controlled interventional trial of a guideline to reduce hospital length of stay for patients admitted for chest pain. Setting: A large community teaching hospital. Participants: Patients admitted with chest pain who were not discharged according to a practice guideline. Results: 79 (34%) of 230 patients with chest pain classified as being at low risk by concurrent or retrospective review were not discharged by day 3 (the guideline recommendation). Of these 79 patients, 33 (42%) were misclassified at concurrent review (10 were falsely classified as being at high risk and 23 were falsely classified as being at low risk). Of 46 correctly classified patients, 11 (14%) were classified as having noncompliant physicians because of health care system inefficiencies. The status of 7 (9%) patients was changed to high risk between initial classification and potential discharge. For 15 patients (19%), no obvious reason for delayed discharge was found, but they had a higher severity of illness than did low-risk patients discharged according to the guideline as measured by mean time-insensitive predictive instrument scores (41.3% +/- [SD] 14.1% compared with 31.5% +/- 14.3%; P = 0.017). In 13 patients (16%), physicians refused to follow the guideline recommendations. Conclusions: In measuring and attempting to improve physician compliance with a length-of-stay guideline, physician refusal accounts for a small percentage (16%) of noncompliance. Implementation issues, health care system inefficiency, and severity of illness were the predominant reasons why physicians did not comply with guidelines. Our study further supports the principle that clinical practice guidelines should complement rather than be a substitute for physician judgment.			ELLRODT, AG (corresponding author), CEDARS SINAI MED CTR, DEPT MED, 8700 BEVERLY BLVD, BECKER 113, LOS ANGELES, CA 90048 USA.							CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Ellrodt A G, 1992, QRB Qual Rev Bull, V18, P456; FRIEDMAN P, 1991, GB STAT VERSION 3 0; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; KASSIRER JP, 1993, NEW ENGL J MED, V329, P1263, DOI 10.1056/NEJM199310213291710; LAFFEL G, 1993, TXB TOTAL QUALITY HE, P40; PHELPS CE, 1993, NEW ENGL J MED, V329, P1241, DOI 10.1056/NEJM199310213291707; RELMAN AS, 1991, NEW ENGL J MED, V324, P922; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; SELKER HP, 1991, MED CARE, V29, P610, DOI 10.1097/00005650-199107000-00002; SELKER HP, 1989, MED CARE, V27, P112, DOI 10.1097/00005650-198902000-00003; SHENG A, 1993, J GEN INTERN MED, V8, P573, DOI 10.1007/BF02599642; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; WEINGARTEN S, 1993, AM J CARDIOL, V71, P259, DOI 10.1016/0002-9149(93)90787-D; WEINGARTEN SR, 1994, ANN INTERN MED, V120, P257, DOI 10.7326/0003-4819-120-4-199402150-00001; WILSON MC, 1991, MED DECIS MAKING, V11, P334; 1992, TRUE EPISTAT STATIST	17	138	139	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1995	122	4					277	282		10.7326/0003-4819-122-4-199502150-00007	http://dx.doi.org/10.7326/0003-4819-122-4-199502150-00007			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF769	7825764				2023-01-03	WOS:A1995QF76900007
J	SCHNEIDER, DL; BARRETTCONNOR, EL; MORTON, DJ				SCHNEIDER, DL; BARRETTCONNOR, EL; MORTON, DJ			THYROID-HORMONE USE AND BONE-MINERAL DENSITY IN ELDERLY WOMEN - EFFECTS OF ESTROGEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							L-THYROXINE THERAPY; PREMENOPAUSAL WOMEN; LEVOTHYROXINE; HYPOTHYROIDISM; METABOLISM	Objective.-To determine the effect of long-term use of thyroid hormone on bone mineral density (BMD) in elderly women and the potential mitigating effects of estrogen replacement therapy. Design.-Cross-sectional, community-based study. Setting.-Rancho Bernardo, Calif. Participants.-A total of 991 white women aged 50 to 98 years who participated in a study of osteoporosis. Main Outcome Measures.-Bone mineral density at the ultradistal radius and midshaft radius using single-photon absorptiometry and at the hip and lumbar spine using dual-energy x-ray absorptiometry. Results.-A total of 196 women taking thyroid hormone for a mean duration of 20.4 years were compared with 795 women who were not using thyroid hormone. Women taking daily thyroxine-equivalent doses of 200 mu g or more had significantly lower BMD levels at the midshaft radius and hip compared with those taking less than 200 mu g. Daily doses of 1.6 mu g/kg and greater were associated with lower bone mass at ail four sites compared with nonuse, whereas doses less than 1.6 mu g/kg were not associated with lower BMD levels. These associations were independent of age, body mass index, smoking status, and use of thiazides, corticosteroids, and estrogen. Women taking both estrogen and a thyroid hormone dose of 1.6 mu g/kg or greater had significantly higher BMD levels at all four sites than women taking the same thyroid hormone dose alone. Women taking both thyroid hormone and estrogen had BMD levels comparable with those observed in women taking only estrogen. Conclusions.-Long-term thyroid hormone use at thyroxine-equivalent doses of 1.6 mu g/kg or greater was associated with significant osteopenia at the ultradistal radius, midshaft radius, hip, and lumbar spine. Estrogen use appears to negate thyroid hormone-associated loss of bone density in postmenopausal women,	UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego					NATIONAL INSTITUTE ON AGING [R01AG007181, R37AG007181] Funding Source: NIH RePORTER; NIA NIH HHS [AG 07181] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLIN EV, 1991, AM J MED, V90, P360, DOI 10.1016/0002-9343(91)90577-K; AUWERX J, 1986, Q J MED, V60, P737; BAUER DC, 1993, ANN INTERN MED, V118, P657, DOI 10.7326/0003-4819-118-9-199305010-00001; CHRISTIANSEN C, 1991, OSTEOPOROSIS INT, V1, P7; CIVITELLI R, 1988, CALCIFIED TISSUE INT, V42, P77, DOI 10.1007/BF02556338; COLSTON KW, 1989, J BONE MINER RES, V4, P625; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; DIAMOND T, 1990, J CLIN ENDOCR METAB, V72, P1184; FISH LH, 1987, NEW ENGL J MED, V316, P764, DOI 10.1056/NEJM198703263161302; FRANKLYN JA, 1992, LANCET, V340, P9, DOI 10.1016/0140-6736(92)92423-D; GILMAN AG, 1980, GOODMAN GILMANS PHAR, P1406; GREENSPAN SL, 1991, AM J MED, V91, P5, DOI 10.1016/0002-9343(91)90066-7; KUNG AWC, 1991, JAMA-J AM MED ASSOC, V265, P2688, DOI 10.1001/jama.265.20.2688; MUNDY GR, 1976, J CLIN INVEST, V58, P529, DOI 10.1172/JCI108497; PAUL TL, 1988, JAMA-J AM MED ASSOC, V259, P3137, DOI 10.1001/jama.259.21.3137; RIBOT C, 1990, CLIN ENDOCRINOL, V33, P143, DOI 10.1111/j.1365-2265.1990.tb00477.x; ROSENBAUM RL, 1982, ANN INTERN MED, V96, P53, DOI 10.7326/0003-4819-96-1-53; ROSS DS, 1987, AM J MED, V82, P1167, DOI 10.1016/0002-9343(87)90219-1; SIMONSEN LLP, 1993, PHARM TIMES, V59, P29; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265; TAELMAN P, 1990, CLIN ENDOCRINOL, V33, P107, DOI 10.1111/j.1365-2265.1990.tb00471.x; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1988, SAS STAT USERS GUIDE	23	135	137	1	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 27	1994	271	16					1245	1249		10.1001/jama.271.16.1245	http://dx.doi.org/10.1001/jama.271.16.1245			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NG362	7848399				2023-01-03	WOS:A1994NG36200023
J	MOORE, RD; BONE, LR; GELLER, G; MAMON, JA; STOKES, EJ; LEVINE, DM				MOORE, RD; BONE, LR; GELLER, G; MAMON, JA; STOKES, EJ; LEVINE, DM			PREVALENCE, DETECTION, AND TREATMENT OF ALCOHOLISM IN HOSPITALIZED-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; BLADES CTR PRACTICE TEACHING & RES ALCOHOLISM,BALTIMORE,MD; JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University								BERNARDT MW, 1981, LANCET, V1, P325; CLARK WD, 1981, AM J MED, V71, P275, DOI 10.1016/0002-9343(81)90129-7; CYR MG, 1988, JAMA-J AM MED ASSOC, V259, P51, DOI 10.1001/jama.259.1.51; ECKARDT MJ, 1981, JAMA-J AM MED ASSOC, V246, P648, DOI 10.1001/jama.246.6.648; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; GREEN J R, 1965, Med J Aust, V1, P465; HNKIN J, 1979, ADM78661 DEP HLTH D; HOEPER EW, 1980, AM J PSYCHIAT, V137, P207; MAYFIELD D, 1974, AM J PSYCHIAT, V131, P1121; MIDANIK L, 1982, BRIT J ADDICT, V77, P357; NIVEN RG, 1984, JAMA-J AM MED ASSOC, V252, P1912, DOI 10.1001/jama.252.14.1912; SADLER D, 1984, AM MED NEWS, V27, P60; SELZER ML, 1975, J STUD ALCOHOL, V36, P117, DOI 10.15288/jsa.1975.36.117; SHERIN KM, 1982, J FAM PRACTICE, V15, P1091; SHRINER HA, 1981, CAN MED ASSOC J, V124, P1279; SOBELL LC, 1982, AM J PUBLIC HEALTH, V72, P823, DOI 10.2105/AJPH.72.8.823; WEST LJ, 1984, ANN INTERN MED, V100, P445; 1979, DHEW7955071 PUBL	18	424	429	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 20	1989	261	3					403	407		10.1001/jama.261.3.403	http://dx.doi.org/10.1001/jama.261.3.403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	R7677	2909780				2023-01-03	WOS:A1989R767700026
J	SHANN, F; GATCHALIAN, S; HUTCHINSON, R				SHANN, F; GATCHALIAN, S; HUTCHINSON, R			NASOPHARYNGEAL OXYGEN IN CHILDREN	LANCET			English	Article											SHANN, F (corresponding author), ROYAL CHILDRENS HOSP, INTENS CARE UNIT, PARKVILLE, VIC 3052, AUSTRALIA.		Shann, Frank/C-9510-2011					FAN LL, 1983, J PEDIATR-US, V103, P923, DOI 10.1016/S0022-3476(83)80717-3; Leowski J, 1986, World Health Stat Q, V39, P138; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; 1988, RESPIRATORY INFECTIO	4	27	27	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 26	1988	2	8622					1238	1240						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R0449	2903963				2023-01-03	WOS:A1988R044900013
J	COHEN, MM; DUNCAN, PG; TATE, RB				COHEN, MM; DUNCAN, PG; TATE, RB			DOES ANESTHESIA CONTRIBUTE TO OPERATIVE MORTALITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV MANITOBA,DEPT ANESTHESIA,WINNIPEG R3E 0W3,MANITOBA,CANADA; UNIV MANITOBA,BIOSTAT CONSULTING UNIT,WINNIPEG R3E 0W3,MANITOBA,CANADA; UNIV SASKATCHEWAN,DEPT ANESTHESIA,SASKATOON S7N 0W0,SASKATCHEWAN,CANADA	University of Manitoba; University of Manitoba; University of Saskatchewan	COHEN, MM (corresponding author), UNIV MANITOBA,DEPT COMMUNITY HLTH SCI,750 BANNATYNE AVE,WINNIPEG R3E 0W3,MANITOBA,CANADA.							ABBOTT RD, 1984, AM J EPIDEMIOL, V119, P830, DOI 10.1093/oxfordjournals.aje.a113803; BUNKER JP, 1966, JAMA, V197, P121; BURNHAM M, 1980, CAN ANAESTH SOC J, V27, P164, DOI 10.1007/BF03007781; CHARLSON ME, 1986, J CHRON DIS, V39, P439, DOI 10.1016/0021-9681(86)90111-6; COHEN MM, 1986, CAN J ANAESTH, V33, P22, DOI 10.1007/BF03010904; COHEN MM, 1988, J CLIN EPIDEMIOL, V41, P83, DOI 10.1016/0895-4356(88)90012-1; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; DAVIES JM, 1984, CAN MED ASSOC J, V131, P437; DERRINGTON MC, 1987, BRIT J ANAESTH, V59, P815, DOI 10.1093/bja/59.7.815; FARROW SC, 1982, BRIT J ANAESTH, V54, P811, DOI 10.1093/bja/54.8.811; FLOOD AB, 1984, MED CARE, V22, P115, DOI 10.1097/00005650-198402000-00003; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HARRISON GG, 1978, BRIT J ANAESTH, V50, P1041, DOI 10.1093/bja/50.10.1041; HUGHES EFX, 1972, SURGERY, V71, P315; Lubitz J, 1985, Health Care Financ Rev, V6, P103; LUFT HS, 1980, MED CARE, V18, P940, DOI 10.1097/00005650-198009000-00006; MAERKI SC, 1986, MED CARE, V24, P148, DOI 10.1097/00005650-198602000-00006; RILEY G, 1986, HLTH CARE FINANCE RE, V7, P37; Saklad M., 1941, ANESTHESIOLOGY, V2, P281, DOI [10.1097/00000542-194105000-00004, DOI 10.1097/00000542-194105000-00004]; TURNBULL KW, 1980, CAN ANAESTH SOC J, V27, P159, DOI 10.1007/BF03007780; UTTING JE, 1979, CAN ANAESTH SOC J, V26, P472, DOI 10.1007/BF03006159; VACANTI CJ, 1970, ANESTH ANAL CURR RES, V49, P564; WALKER SH, 1967, BIOMETRIKA, V54, P167, DOI 10.2307/2333860; WENNBERG JE, 1987, JAMA-J AM MED ASSOC, V257, P933, DOI 10.1001/jama.257.7.933; ZIFFREN SE, 1979, J AM GERIATR SOC, V27, P433, DOI 10.1111/j.1532-5415.1979.tb01722.x	25	155	159	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 18	1988	260	19					2859	2863		10.1001/jama.260.19.2859	http://dx.doi.org/10.1001/jama.260.19.2859			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q8739	3184350				2023-01-03	WOS:A1988Q873900024
J	BIANCO, AR; GALLO, C; MARINELLI, A; DISTRIA, M; DEPLACIDO, S; PAGLIARULO, C; PETRELLA, G; DELRIO, G				BIANCO, AR; GALLO, C; MARINELLI, A; DISTRIA, M; DEPLACIDO, S; PAGLIARULO, C; PETRELLA, G; DELRIO, G			ADJUVANT THERAPY WITH TAMOXIFEN IN OPERABLE BREAST-CANCER - 10 YEAR RESULTS OF THE NAPLES (GUN) STUDY	LANCET			English	Article									UNIV NAPLES, SCH MED 2, DIV SURG ONCOL, I-80131 NAPLES, ITALY; UNIV NAPLES, SCH MED 1, INST HLTH STAT, I-80131 NAPLES, ITALY; UNIV NAPLES, SCH MED 1, DEPT BIOL, I-80131 NAPLES, ITALY	University of Naples Federico II; University of Naples Federico II; University of Naples Federico II	BIANCO, AR (corresponding author), UNIV NAPLES, SCH MED 2, DIV MED ONCOL, VIA S PANSINI 5, I-80131 NAPLES, ITALY.		Gallo, Ciro/AAA-9241-2019	Gallo, Ciro/0000-0002-7939-3104				[Anonymous], 1984, Lancet, V2, P1205; BAUM M, 1985, LANCET, V1, P836; BIANCO AR, 1985, ANTIOESTROGENS ONCOL, P131; COX DR, 1972, J R STAT SOC B, V34, P187; CUMMINGS FJ, 1985, ANN INTERN MED, V103, P324, DOI 10.7326/0003-4819-103-3-324; FISHER B, 1986, J CLIN ONCOL, V4, P459, DOI 10.1200/JCO.1986.4.4.459; GOLDHIRSCH A, 1984, LANCET, V1, P1256; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kay R, 1983, Stat Med, V2, P41, DOI 10.1002/sim.4780020106; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MARSHALL JS, 1987, J LAB CLIN MED, V109, P300; MCGUIRE WL, 1977, CANCER RES, V37, P637; PALSHOF T, 1980, EJC SUPPL, V2, P183; PICHON MF, 1977, CANCER RES, V37, P464; PRITCHARD KI, 1984, ADJUVANT THERAPY CAN, V4, P339; RIBEIRO G, 1985, EUR J CANCER CLIN ON, V21, P897, DOI 10.1016/0277-5379(85)90104-X; ROSE C, 1985, LANCET, V1, P16; ROSE C, 1983, BREAST CANCER RES TR, V3, P77, DOI 10.1007/BF01806237; RUTQVIST LE, 1987, BREAST CANCER RES TR, V10, P255, DOI 10.1007/BF01805762; SENANAYAKE F, 1984, LANCET, V2, P1148; TAYLOR SG, 1985, J CLIN ONCOL, V3, P144, DOI 10.1200/JCO.1985.3.2.144; WALLGREN A, 1984, ADJUVANT THERAPY CAN, V4, P331	22	58	58	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	1988	2	8620					1095	1099						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q8569	2903322				2023-01-03	WOS:A1988Q856900001
J	CURSON, DA; PATEL, M; LIDDLE, PF; BARNES, TRE				CURSON, DA; PATEL, M; LIDDLE, PF; BARNES, TRE			PSYCHIATRIC MORBIDITY OF A LONG STAY HOSPITAL POPULATION WITH CHRONIC-SCHIZOPHRENIA AND IMPLICATIONS FOR FUTURE COMMUNITY CARE	BMJ-BRITISH MEDICAL JOURNAL			English	Article									SHENLEY HOSP, RADLETT, HERTS, ENGLAND; CHARING CROSS & WESTMINSTER MED SCH, LONDON, ENGLAND	Imperial College London	CURSON, DA (corresponding author), CHARTER CLIN CHELSEA, LONDON SW3 4PB, ENGLAND.		Liddle, Peter/AAU-7939-2020					ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; BARNES TRE, 1983, SOC PSYCHIATR, V18, P193, DOI 10.1007/BF00583530; Barton R., 1959, I NEUROSIS; CRUMPTON N, 1968, TREATMENT MENTAL DIS, P15; CURSON DA, 1985, BRIT J PSYCHIAT, V146, P464, DOI 10.1192/bjp.146.5.464; FALLOON I, 1978, PSYCHOL MED, V8, P59, DOI 10.1017/S0033291700006632; GAIND R, 1981, HDB BIOL PSYCHIATR 6, P149; Goffman Erving, 1961, ASYLUMS; Griffiths R, 1988, COMMUNITY CARE AGEND; Gruenberg E., 1966, EVALUATING EFFECTIVE; HIRSCH SR, 1973, BRIT MED J, V1, P633, DOI 10.1136/bmj.1.5854.633; JOHNSON DAW, 1976, BRIT J PSYCHIAT, V128, P246, DOI 10.1192/bjp.128.3.246; JONES M, 1952, SOCIAL PSYCHIATRY ST; LEFF JP, 1971, BRIT MED J, V3, P599, DOI 10.1136/bmj.3.5775.599; MCCREADIE RG, 1983, BRIT J PSYCHIAT, V143, P564, DOI 10.1192/bjp.143.6.564; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; MURPHY E, 1987, BRIT MED J, V295, P1505, DOI 10.1136/bmj.295.6612.1505-a; NIE NH, 1975, STATISTICAL PACKAGE; OWENS D G C, 1980, British Journal of Psychiatry, V136, P384; PASAMANICK B, 1964, JAMA-J AM MED ASSOC, V187, P177, DOI 10.1001/jama.1964.03060160005001; RENTON CA, 1963, ACTA PSYCHIAT SCAND, V39, P548, DOI 10.1111/j.1600-0447.1963.tb07482.x; STEVENS BC, 1973, PSYCHOL MED, V3, P141, DOI 10.1017/S0033291700048480; Wing J. K. C., 1974, MEASUREMENT CLASSIFI; WING JK, 1986, BRIT J PSYCHIAT, V149, P449, DOI 10.1192/bjp.149.4.449; WING JK, 1985, BRIT MED J, V291, P1219, DOI 10.1136/bmj.291.6504.1219; Wing JK, 1970, I SCHIZOPHRENIA; 1980, DIAGNOSTIC STATISTIC; 1971, BR MED J, V1, P189	28	47	47	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 1	1988	297	6652					819	822		10.1136/bmj.297.6652.819	http://dx.doi.org/10.1136/bmj.297.6652.819			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q4645	3140934	Green Published, Bronze			2023-01-03	WOS:A1988Q464500017
J	RIVKEES, SA; CRAWFORD, JD				RIVKEES, SA; CRAWFORD, JD			THE RELATIONSHIP OF GONADAL ACTIVITY AND CHEMOTHERAPY-INDUCED GONADAL DAMAGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School	RIVKEES, SA (corresponding author), MASSACHUSETTS GEN HOSP,CHILDRENS SERV,PEDIAT ENDOCRINE UNIT,BOSTON,MA 02114, USA.							ARNEIL GC, 1972, LANCET, V2, P1259; BAKER HWG, 1976, CLIN ENDOCRINOL, V5, P349, DOI 10.1111/j.1365-2265.1976.tb01964.x; BECK W, 1983, ACTA PAEDIATR SCAND, V72, P71, DOI 10.1111/j.1651-2227.1983.tb09666.x; BERRY CL, 1972, LANCET, V2, P1033; BLATT J, 1981, NEW ENGL J MED, V304, P1121, DOI 10.1056/NEJM198105073041901; BUCHANAN JD, 1975, LANCET, V2, P156; CHAPMAN RM, 1981, JAMA-J AM MED ASSOC, V245, P1323, DOI 10.1001/jama.245.13.1323; CHAPMAN RM, 1979, JAMA-J AM MED ASSOC, V242, P1882, DOI 10.1001/jama.242.17.1882; CHAPMAN RM, 1981, BLOOD, V58, P849; CHAPMAN RM, 1979, LANCET, V1, P285; CHAPMAN RM, 1982, SEMIN ONCOL, V9, P84; CHAPMAN RM, 1979, JAMA-J AM MED ASSOC, V242, P1177; DEGROOT GW, 1974, J PEDIATR-US, V84, P123, DOI 10.1016/S0022-3476(74)80572-X; DONALDSON SS, 1982, CANCER TREAT REP, V66, P977; ETTELDORF JN, 1976, J PEDIATR-US, V88, P206, DOI 10.1016/S0022-3476(76)80983-3; FAIRLEY KF, 1972, LANCET, V1, P568; GLODE LM, 1981, LANCET, V1, P1132; GRIFFIN JE, 1985, WILLIAMS TXB ENDOCRI, P2591; KING DJ, 1985, J CLIN PATHOL, V38, P1247, DOI 10.1136/jcp.38.11.1247; KIRKLAND RT, 1976, J PEDIATR-US, V89, P941, DOI 10.1016/S0022-3476(76)80600-2; KUMAR R, 1972, LANCET, V1, P1212; LENDON M, 1978, LANCET, V2, P439; LENTZ RD, 1977, J PEDIATR-US, V91, P385, DOI 10.1016/S0022-3476(77)81305-X; MAGUIRE LC, 1981, CANCER, V48, P1967, DOI 10.1002/1097-0142(19811101)48:9<1967::AID-CNCR2820480910>3.0.CO;2-0; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P12; MEHTA CR, 1986, J AM STAT ASSOC, V80, P969; PARRA A, 1978, J PEDIATR-US, V92, P117; PENNISI AJ, 1975, AM J DIS CHILD, V129, P315, DOI 10.1001/archpedi.1975.02120400027006; PENSO J, 1974, J PEDIATR-US, V84, P831, DOI 10.1016/S0022-3476(74)80758-4; PESCOVITZ OH, 1986, J PEDIATR-US, V108, P47, DOI 10.1016/S0022-3476(86)80767-3; QURESHI MSA, 1972, LANCET, V2, P1290; RAPOLA J, 1973, LANCET, V1, P98; SHALET SM, 1981, ARCH DIS CHILD, V56, P275, DOI 10.1136/adc.56.4.275; SHALET SM, 1977, J PEDIATR-US, V90, P920, DOI 10.1016/S0022-3476(77)80559-3; SHERINS RJ, 1978, NEW ENGL J MED, V299, P12, DOI 10.1056/NEJM197807062990103; SIRIS ES, 1976, NEW ENGL J MED, V294, P1143, DOI 10.1056/NEJM197605202942102; STYNE DM, 1985, J CLIN ENDOCR METAB, V61, P142, DOI 10.1210/jcem-61-1-142; SUTCLIFFE SB, 1979, JAMA-J AM MED ASSOC, V242, P1898, DOI 10.1001/jama.242.17.1898; SWIFT PGF, 1978, ARCH DIS CHILD, V53, P890, DOI 10.1136/adc.53.11.890; ULDALL PR, 1972, LANCET, V1, P693; VANMUHLENDAHL KE, 1976, HELV PAEDIATR ACTA, V31, P463; VIVIANI S, 1985, EUR J CANCER CLIN ON, V21, P601, DOI 10.1016/0277-5379(85)90088-4; WANG C, 1980, CANCER, V45, P2030, DOI 10.1002/1097-0142(19800415)45:8<2030::AID-CNCR2820450807>3.0.CO;2-S	44	195	199	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1988	259	14					2123	2125						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M7414	3162285				2023-01-03	WOS:A1988M741400028
J	SANTANGELO, WC; DUENO, MI; ESTES, BL; KREJS, GJ				SANTANGELO, WC; DUENO, MI; ESTES, BL; KREJS, GJ			PROPHYLACTIC SCLEROTHERAPY OF LARGE ESOPHAGEAL-VARICES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75230	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								BARSOUM MS, 1982, BRIT J SURG, V69, P76, DOI 10.1002/bjs.1800690206; BURROUGHS AK, 1983, NEW ENGL J MED, V309, P1539, DOI 10.1056/NEJM198312223092502; CONN HO, 1984, HEPATOLOGY, V4, P560, DOI 10.1002/hep.1840040333; CONN HO, 1968, NEW ENGL J MED, V279, P725, DOI 10.1056/NEJM196810032791401; DERSIMONIAN R, 1982, NEW ENGL J MED, V306, P1332, DOI 10.1056/NEJM198206033062204; FLEISS JL, 1981, STAT METHODS RATES P, P264; GARCEAU AJ, 1963, NEW ENGL J MED, V268, P469, DOI 10.1056/NEJM196302282680905; GREGORY P, 1987, GASTROENTEROLOGY, V92, P1414; JACKSON FC, 1965, ARCH SURG-CHICAGO, V91, P43; KOCH H, 1986, ENDOSCOPY, V18, P40, DOI 10.1055/s-2007-1018322; KORULA J, 1985, HEPATOLOGY, V5, P584, DOI 10.1002/hep.1840050410; KREJS GJ, 1987, NEW ENGL J MED, V316, P1618, DOI 10.1056/NEJM198706253162602; PAQUET KJ, 1982, ENDOSCOPY, V14, P4, DOI 10.1055/s-2007-1021560; PAQUET KJ, 1985, HEPATOLOGY, V5, P580, DOI 10.1002/hep.1840050409; RESNICK RH, 1969, ANN INTERN MED, V70, P675, DOI 10.7326/0003-4819-70-4-675; SAUERBRUCH T, 1986, JAN INT S PROPH VAR; SWAIN CP, 1986, LANCET, V1, P1113; TERBLANCHE J, 1983, LANCET, V2, P1328; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WESTABY D, 1985, HEPATOLOGY, V5, P827, DOI 10.1002/hep.1840050520; WITZEL L, 1985, LANCET, V1, P773; YASSIN YM, 1983, BRIT J SURG, V70, P20, DOI 10.1002/bjs.1800700107; ZAKIM D, 1982, HEPATOLOGY TXB LIVER; 1984, N ENGL J MED, V311, P1594	24	105	105	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 31	1988	318	13					814	818		10.1056/NEJM198803313181304	http://dx.doi.org/10.1056/NEJM198803313181304			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M7031	3281001				2023-01-03	WOS:A1988M703100004
J	JOSEPH, KS; BRAHMADATHAN, KN; ABRAHAM, S; JOSEPH, A				JOSEPH, KS; BRAHMADATHAN, KN; ABRAHAM, S; JOSEPH, A			DETECTING BACTERIURIA IN A PRIMARY MATERNAL AND CHILD HEALTH-CARE PROGRAM	BRITISH MEDICAL JOURNAL			English	Article									CHRISTIAN MED COLL & HOSP,DEPT MICROBIOL,VELLORE 632004,INDIA	Christian Medical College & Hospital (CMCH) Vellore	JOSEPH, KS (corresponding author), CHRISTIAN MED COLL & HOSP,DEPT COMMUNITY HLTH,VELLORE 632002,INDIA.			Joseph, K.S./0000-0003-2317-5607				BRUMFITT W, 1975, KIDNEY INT         S, V8, P113; COOKE CW, 1970, OBSTET GYNECOL, V36, P840; CZERWINSKI AW, 1971, AM J OBSTET GYNECOL, V110, P677, DOI 10.1016/0002-9378(71)90253-5; Fletcher R., 1982, CLIN EPIDEMIOLOGY ES; HARRIS R, 1984, GYNECOLOGY OBSTETRIC; ISENBERG HD, 1980, MANUAL CLIN MICROBIO; KUNIN CM, 1975, JAMA-J AM MED ASSOC, V231, P1349, DOI 10.1001/jama.231.13.1349; URRUTIA J, 1978, PERINATAL INFECTIONS; WAIT RB, 1984, POSTGRAD MED, V75, P153, DOI 10.1080/00325481.1984.11698643; Wait RB, 1984, POSTGRAD MED, V75, P161; WHALLEY P, 1967, AM J OBSTET GYNECOL, V97, P723, DOI 10.1016/0002-9378(67)90458-9; WILSON JMG, 1968, PUBLIC HLTH PAP, V34, P1	12	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1988	296	6626					906	907		10.1136/bmj.296.6626.906	http://dx.doi.org/10.1136/bmj.296.6626.906			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	M7851	3129069	Green Published			2023-01-03	WOS:A1988M785100019
J	RIOU, B; BARRIOT, P; RIMAILHO, A; BAUD, FJ				RIOU, B; BARRIOT, P; RIMAILHO, A; BAUD, FJ			TREATMENT OF SEVERE CHLOROQUINE POISONING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									SERV SANTE BRIGADE SAPEURS POMPIERS, PARIS, FRANCE; HOP PITIE, SERV REANIMAT MED, F-75651 PARIS 13, FRANCE; UNIV PARIS 07, HOP FERNAND WIDAL, TOXICOL CLIN, F-75475 PARIS 10, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	RIOU, B (corresponding author), UNIV PARIS 11, HOP BICETRE, SERV REANIMAT MED, 78 RUE GEN LECLERC, F-94275 LE KREMLIN BICETRE, FRANCE.							ARMAND J, 1971, MED LEG DOMMAGE CORPOR, V4, P19; BISMUTH C, 1983, CARE CRITICALLY ILL, P811; BONDURAND A, 1980, AFR MED, V19, P239; BRITTON WJ, 1978, MED J AUSTRALIA, V2, P407, DOI 10.5694/j.1326-5377.1978.tb76816.x; CANN HM, 1961, PEDIATRICS, V27, P95; CROUZETTE J, 1983, J TOXICOL-CLIN TOXIC, V20, P271, DOI 10.3109/15563658308990070; CZAJKA PA, 1978, CLIN TOXICOL, V13, P361, DOI 10.3109/15563657808988243; DIMAIO VJM, 1974, SOUTH MED J, V67, P1031, DOI 10.1097/00007611-197409000-00007; Don Michael T A, 1970, Am Heart J, V79, P831; Elmalem J, 1986, CONCOURS MED, V108, P2450; FRISKHOLMBERG M, 1983, BRIT J CLIN PHARMACO, V15, P502, DOI 10.1111/j.1365-2125.1983.tb01540.x; Gordon B, 1925, J CLIN INVEST, V1, P497, DOI 10.1172/JCI100027; Guillon C., 1982, SUICIDE MODE EMPLOI; HEATH A, 1983, J TOXICOL-CLIN TOXIC, V19, P1067; IFFTSITS-SIMON CLARA, 1968, ARCH TOXI KOL, V23, P204; IRWIN HM, 1972, FORENSIC SCI INT, V1, P249; KIEL FW, 1964, JAMA-J AM MED ASSOC, V190, P398; KLUG E, 1970, ARCH TOXIKOL, V26, P176; LOFASO F, 1987, PRESSE MED, V16, P22; LOOAREESUWAN S, 1986, BRIT J CLIN PHARMACO, V22, P31, DOI 10.1111/j.1365-2125.1986.tb02876.x; MEUNIER J, 1977, ACTA PHARMACOL TOX, V41, P228; MONDAIN J, 1979, B SOC PATHOL EXOT, V72, P86; NDRI KD, 1976, AFR MED, V15, P103; NOIRFALISE A, 1978, FORENSIC SCI, V11, P177, DOI 10.1016/S0379-0738(78)80054-1; Rakotoson L, 1973, Eur J Toxicol Hyg Environ, V6, P85; RIOU B, 1986, INTENS CARE MED, V12, pS175; RIOU B, 1987, REANIM SOINS INTENS, V3, P256; ROBINSON AE, 1970, J PHARM PHARMACOL, V22, P700, DOI 10.1111/j.2042-7158.1970.tb12756.x; SARVESVARAN R, 1979, MED SCI LAW, V19, P265, DOI 10.1177/002580247901900412; SOFOLA OA, 1983, CLIN PHYSIOL, V3, P75, DOI 10.1111/j.1475-097X.1983.tb00701.x; SOFOLA OA, 1980, CAN J PHYSIOL PHARM, V58, P836, DOI 10.1139/y80-129; STEAD AH, 1983, HUM TOXICOL, V2, P437, DOI 10.1177/096032718300200301; Van den Heede M, 1973, J Pharm Belg, V28, P556; Viala A, 1972, Eur J Toxicol, V5, P189; Vitris M, 1983, Dakar Med, V28, P593; Vitris M, 1983, Dakar Med, V28, P103; WEINGARTEN HL, 1981, CLIN TOXICOL, V18, P959, DOI 10.3109/15563658108990324; WILKEY IS, 1973, MED J AUSTRALIA, V1, P396; YERUSHALMY J, 1947, PUBLIC HEALTH REP, V62, P1432, DOI 10.2307/4586294	39	166	175	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1988	318	1					1	6		10.1056/NEJM198801073180101	http://dx.doi.org/10.1056/NEJM198801073180101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L5234	3336379				2023-01-03	WOS:A1988L523400001
J	JICK, H; JICK, SS; GUREWICH, V; MYERS, MW; VASILAKIS, C				JICK, H; JICK, SS; GUREWICH, V; MYERS, MW; VASILAKIS, C			RISK OF IDIOPATHIC CARDIOVASCULAR DEATH AND NONFATAL VENOUS THROMBOEMBOLISM IN WOMEN USING ORAL-CONTRACEPTIVES WITH DIFFERING PROGESTAGEN COMPONENTS	LANCET			English	Article							VASCULAR-DISEASE	Concern about the risks of cardiovascular illness in women using combined oral contraceptives (OC) containing the progestagens desogestrel and gestodene prompted two studies of data from the UK General Practice Research Database. We compared the risks of certain cardiovascular illnesses in otherwise healthy women exposed to one of three OCs containing <35 mu g oestrogen plus levonorgestrel, desogestrel, or gestodene. In the first study, based on some 470 general practices, there were 15 cases of unexpected idiopathic cardiovascular death among 303 470 women who were current users of one of the study OCs. The estimated incidence rates were 8/184 536 (4.3 per 100 000) woman-years at risk for users of combined OCs containing levonorgestrel, 2/135 567 (1.5 per 100 000) for desogestrel users, and 5/105 201 (4.8 per 100 000) for gestodene users. The relative risk (RR) estimates were 0.4 (95% CI 0.1-2.1) and 1.4 (CI 0.5-4.5) for desogestrel and gestodene, respectively, compared with levonorgestrel. In the second study, derived from some 370 general practices, there were 80 cases of nonfatal venous thromboembolism (VTE) in a cohort of 238 130 otherwise healthy women. The incidence rates of VTE per 100 000 woman-years at risk were 16.1 for levonorgestrel users, 29.3 for desogestrel, and 28.1 for gestodene. The adjusted RR estimates from the cohort analysis were 1.9 (1.1-3.2) and 1.8 (1.0-3.2) for desogestrel and gestodene users, respectively, compared with users of levonorgestrel. In a nested case-control analysis the adjusted matched RR estimates were 2.2 (1.1-4.4) and 2.1 (1.0-4.4) for desogestrel and gestodene users, respectively, compared with users of levonorgestrel. The excess risk for nonfatal VTE associated with the new generation of combined OCs containing low-dose oestrogen and the progestagens desogestrel or gestodene compared with levonorgestrel is estimated to be 16 per 100 000 woman-years.	HARVARD UNIV,DEACONESS HOSP,SCH MED,VASC RES LAB,CAMBRIDGE,MA 02138; HARVARD UNIV,SCH MED,DEPT MED,CAMBRIDGE,MA 02138	Harvard University; Harvard University	JICK, H (corresponding author), BOSTON UNIV,MED CTR,BOSTON COLLABORAT DRUG SURVEILLANCE PROGRAM,11 MUZZEY ST,LEXINGTON,MA 02173, USA.			Jick, Susan/0000-0002-2215-1067; Jick, Hershel/0000-0003-4270-5992				JICK H, 1991, BRIT MED J, V302, P766, DOI 10.1136/bmj.302.6779.766; Jick H., 1992, PHARMACOEPIDEM DR S, V1, P347, DOI DOI 10.1002/PDS.2630010607; JICK SS, 1995, BRIT MED J, V310, P215, DOI 10.1136/bmj.310.6974.215; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; PORTER JB, 1982, OBSTET GYNECOL, V59, P299; RODRIGUEZ LAG, 1994, LANCET, V343, P769, DOI 10.1016/S0140-6736(94)91843-0; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; Van Staa TP, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI DOI 10.1002/PDS.2630030106; VANDERVANGE N, 1988, CONTEMP OBSTET GYNEC, P317; 1995, LANCET, V346, P1582	10	623	631	0	19	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1589	1593		10.1016/S0140-6736(95)91928-7	http://dx.doi.org/10.1016/S0140-6736(95)91928-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500750	hybrid			2023-01-03	WOS:A1995TK48100009
J	OBRIEN, LA; GRISSO, JA; MAISLIN, G; LAPANN, K; KROTKI, KP; GRECO, PJ; SIEGERT, EA; EVANS, LK				OBRIEN, LA; GRISSO, JA; MAISLIN, G; LAPANN, K; KROTKI, KP; GRECO, PJ; SIEGERT, EA; EVANS, LK			NURSING-HOME RESIDENTS PREFERENCES FOR LIFE-SUSTAINING TREATMENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOPULMONARY-RESUSCITATION; DECISIONS; CARE	Objectives.-To determine life-sustaining treatment preferences among nursing home residents, whether information regarding cardiopulmonary resuscitation (CPR) affected these preferences, and with whom treatment preferences had been discussed, and to identify factors associated with CPR preferences. Design.-In-person survey. Setting.-Forty-nine randomly selected nursing homes. Subjects.-Four hundred twenty-one randomly selected nursing home residents capable of making decisions. Main Outcome Measures.-Preferences regarding CPR, hospitalization, and enteral tube feedings, and individual factors associated with CPR preferences. Results.-Of 1458 randomly selected nursing home residents assessed for the ability to participate in the study, 552 residents (38%) were eligible to participate and 421 agreed to be interviewed. Sixty percent of participants able to participate in the decision reported that they would elect CPR, 89% would choose hospitalization if seriously ill, and 33% would elect enteral tube feedings a no longer able to eat because of permanent brain damage. Individual factors associated with preferences for CPR included the following: African-American ethnicity, high self-reported physical mobility, belief that most important medical care decisions should be made by the doctor, moderate-to-severe impairment in daily decision-making skills, and not having a spouse. Fourteen percent changed their preference from preferring CPR to not preferring CPR after receiving additional information about CPR procedures. Twelve percent reported having discussed preferences with health care providers, and 31% discussed preferences with family members. Conclusions-More than half of nursing home residents capable of making decisions preferred the use of CPR. Few had discussed their preferences with health care providers. Individual preferences should be assessed when considering the use of life-sustaining treatments.	UNIV PENN,SCH NURSING,PHILADELPHIA,PA 19104; TEMPLE UNIV,INST SURVEY RES,PHILADELPHIA,PA 19122; CASE WESTERN RESERVE UNIV,SCH MED,CLEVELAND,OH; UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,CAMDEN,NJ 08103	University of Pennsylvania; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Case Western Reserve University; Rutgers State University New Brunswick; Rutgers State University Medical Center	OBRIEN, LA (corresponding author), UNIV PENN,SCH MED,CTR CLIN EPIDEMIOL & BIOSTAT,DIV GEN INTERNAL MED,PHILADELPHIA,PA 19104, USA.		Maislin, Greg/S-5322-2019		AHRQ HHS [1-R01-HS-06815] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; FILLENBAUM GG, 1980, J AM GERIATR SOC, V28, P381, DOI 10.1111/j.1532-5415.1980.tb01103.x; GERETY MB, 1993, J AM GERIATR SOC, V41, P953, DOI 10.1111/j.1532-5415.1993.tb06761.x; GRISSO JA, 1994, NEW ENGL J MED, V330, P1555, DOI 10.1056/NEJM199406023302202; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; JONSEN AR, 1986, CLIN ETHICS PRACTICA, P52; KISH L, 1965, SURVEY SAMPLING, P230; KOENIG HG, 1992, INT J PSYCHIAT MED, V22, P183, DOI 10.2190/M1F5-F40P-C4KD-YPA3; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; OUSLANDER JG, 1989, ARCH INTERN MED, V149, P1367, DOI 10.1001/archinte.149.6.1367; PFEIFFER E, 1975, J AM GERIATR SOC, V25, P433; SACHS GA, 1992, J AM GERIATR SOC, V42, P269; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; SHADLEN F, 1990, J AM GERIATR SOC, V38, pA55; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; SINGER PA, 1991, HASTINGS CTR REP S2, V21, P1; TENO J, 1991, CLIN RES, V39, pA632; UHLMANN RF, 1988, J GERONTOL, V43, pM115, DOI 10.1093/geronj/43.5.M115; 1993, SUDAAN VERSION 6 33; 1990, SAS P200 I INC TECHN, P194	23	134	135	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 13	1995	274	22					1775	1779		10.1001/jama.274.22.1775	http://dx.doi.org/10.1001/jama.274.22.1775			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TJ225	7500508				2023-01-03	WOS:A1995TJ22500027
J	FAIRLEY, CK; SMOLENIEC, JS; CAUL, OE; MILLER, E				FAIRLEY, CK; SMOLENIEC, JS; CAUL, OE; MILLER, E			OBSERVATIONAL STUDY OF EFFECT OF INTRAUTERINE TRANSFUSIONS ON OUTCOME OF FETAL HYDROPS AFTER PARVOVIRUS B19 INFECTION	LANCET			English	Note							DIAGNOSIS	The role of intrauterine transfusion for fetal hydrops arising from maternal paravirus B19 infection is unclear. 66 cases of fetal hydrops arising from B19 infection were reported in England and Wales between June, 1992, and September, 1994. In 29 cases the fetus was dead at the time of the first abnormal ultrasound or a therapeutic abortion as performed; 12 of the 38 alive at the first abnormal scan received intrauterine transfusions and 3 of the 12 died, 26 did not receive intrauterine transfusions and 13 died. After adjustment for the severity of the hydrops as assessed by the ultrasound and for gestational age, the odds of death among those who received an intrauterine transfusion was significantly less than among those who did not (odds ratio 0.14, 95% CI 0.02-0.96). These findings suggest that intrauterine transfusion will benefit some fetuses with hydrops arising from parvovirus B19 infection.	PUBL HLTH LAB SERV,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND; ST MICHAELS HOSP,BRISTOL,AVON,ENGLAND; BRISTOL PUBL HLTH LAB,REG VIRUS LAB,BRISTOL,AVON,ENGLAND	Public Health England				Christopher, Fairley/0000-0001-9081-1664				CHITKARA U, 1988, OBSTET GYNECOL, V71, P393; GLONING KP, 1990, BEHRING I MITT, V85, P79; Hall S. M., 1990, Reviews in Medical Microbiology, V1, P160; KILBY MD, 1995, OBSTET GYNAECOL REV, V7, P5; NAIDES SJ, 1989, PRENATAL DIAG, V9, P105, DOI 10.1002/pd.1970090205; PETERS MT, 1990, OBSTET GYNECOL, V75, P501; ROSENFELD SJ, 1993, VIRAL INFECTIONS DIA, P147; SMOLENIEC JS, 1994, BRIT J OBSTET GYNAEC, V101, P1079, DOI 10.1111/j.1471-0528.1994.tb13586.x; SMOLENIEC JS, 1995, OBSTET GYNECOL, V14, P142; TOROK TJ, 1992, CLIN INFECT DIS, V14, P149, DOI 10.1093/clinids/14.1.149	10	104	108	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 18	1995	346	8986					1335	1337		10.1016/S0140-6736(95)92346-2	http://dx.doi.org/10.1016/S0140-6736(95)92346-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE916	7475774				2023-01-03	WOS:A1995TE91600012
J	MCKENZIE, R; FRIED, MW; SALLIE, R; CONJEEVARAM, H; DIBISCEGLIE, AM; PARK, Y; SAVARESE, B; KLEINER, D; TSOKOS, M; LUCIANO, C; PRUETT, T; STOTKA, JL; STRAUS, SE; HOOFNAGLE, JH				MCKENZIE, R; FRIED, MW; SALLIE, R; CONJEEVARAM, H; DIBISCEGLIE, AM; PARK, Y; SAVARESE, B; KLEINER, D; TSOKOS, M; LUCIANO, C; PRUETT, T; STOTKA, JL; STRAUS, SE; HOOFNAGLE, JH			HEPATIC-FAILURE AND LACTIC-ACIDOSIS DUE TO FIALURIDINE (FIAU), AN INVESTIGATIONAL NUCLEOSIDE ANALOG FOR CHRONIC HEPATITIS-B	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PLACEBO-CONTROLLED TRIAL; MITOCHONDRIAL-DNA; ULTRASTRUCTURAL-CHANGES; ADENINE-ARABINOSIDE; ALPHA-INTERFERON; VIRUS-INFECTION; E-ANTIGEN; THERAPY; MYOPATHY	Background. We describe severe and unexpected multisystem toxicity that occurred during a study of the antiviral nucleoside analogue fialuridine (1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodouracil, or FIAU) as therapy for chronic hepatitis B virus infection. Methods. Fifteen patients with chronic hepatitis B were randomly assigned to receive fialuridine at a dose of either 0.10 or 0.25 mg per kilogram of body weight per day for 24 weeks and were monitored every 1 to 2 weeks by means of a physical examination, blood tests, and testing for hepatitis B virus markers. Results. During the 13th week lactic acidosis and liver failure suddenly developed in one patient. The study was terminated on an emergency basis, and all treatment with fialuridine was discontinued. Seven patients were found to have severe hepatotoxicity, with progressive lactic acidosis, worsening jaundice, and deteriorating hepatic synthetic function despite the discontinuation of fialuridine. Three other patients had mild hepatotoxicity. Several patients also had pancreatitis, neuropathy, or myopathy. Of the seven patients with severe hepatotoxicity, five died and two survived after liver transplantation. Histologic analysis of liver tissue revealed marked accumulation of microvesicular and macrovesicular fat, with minimal necrosis of hepatocytes or architectural changes. Electron microscopy showed abnormal mitochondria and the accumulation of fat in hepatocytes. Conclusions. In patients with chronic hepatitis B, treatment with fialuridine induced a severe toxic reaction characterized by hepatic failure, lactic acidosis, pancreatitis, neuropathy, and myopathy This toxic reaction was probably caused by widespread mitochondrial damage and may occur infrequently with other nucleoside analogues.	NIDDKD,DIGEST DIS BRANCH,LIVER DIS SECT,BETHESDA,MD 20892; NIAID,CLIN INVEST LAB,BETHESDA,MD; NCI,CTR CLIN,DEPT NURSING,BETHESDA,MD; NCI,DEPT PATHOL,BETHESDA,MD; NINCDS,ELECTROMYOG SECT,BETHESDA,MD 20892; UNIV VIRGINIA,MED CTR,DEPT SURG,CHARLOTTESVILLE,VA; LILLY RES LABS,INDIANAPOLIS,IN	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); University of Virginia; Eli Lilly			Kleiner, David E/N-2770-2013	Kleiner, David E/0000-0003-3442-4453				ALEXANDER GJM, 1987, J MED VIROL, V21, P81, DOI 10.1002/jmv.1890210111; ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5; Balistreri WF., 1990, PEDIAT HEPATOLOGY, P183; BISSUEL F, 1994, J INTERN MED, V235, P367, DOI 10.1111/j.1365-2796.1994.tb01088.x; CHATTHA G, 1993, ANN INTERN MED, V118, P37, DOI 10.7326/0003-4819-118-1-199301010-00007; CHEN CH, 1992, J BIOL CHEM, V267, P2856; CHEN CH, 1991, MOL PHARMACOL, V39, P625; COLACINO JM, 1994, ANTIMICROB AGENTS CH, V38, P1997, DOI 10.1128/AAC.38.9.1997; CUI LX, 1995, J CLIN INVEST, V95, P555, DOI 10.1172/JCI117698; DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602; DOONG SL, 1991, P NATL ACAD SCI USA, V88, P8495, DOI 10.1073/pnas.88.19.8495; Dusheiko G., 1991, OXFORD TXB CLIN HEPA, P571; FOUREL I, 1992, J MED VIROL, V37, P122, DOI 10.1002/jmv.1890370209; FREIMAN JP, 1993, AIDS, V7, P379, DOI 10.1097/00002030-199303000-00012; FRIED MW, 1992, HEPATOLOGY, V16, P861, DOI 10.1002/hep.1840160402; FRIED MW, 1994, J HEPATOL, V21, P145, DOI 10.1016/S0168-8278(05)80387-3; FRIED MW, 1992, HEPATOLOGY, V16, pA127; GARCIA G, 1987, ANN INTERN MED, V107, P278, DOI 10.7326/0003-4819-107-2-278; GOPINATH R, 1992, J AM SOC NEPHROL, V3, P1212; GRADON JD, 1992, J INTERN MED, V231, P317, DOI 10.1111/j.1365-2796.1992.tb00542.x; GREM JL, 1991, INVEST NEW DRUG, V9, P281; HODGE RAV, 1989, ANTIMICROB AGENTS CH, V33, P223, DOI 10.1128/AAC.33.2.223; HOOFNAGLE JH, 1988, GASTROENTEROLOGY, V95, P1318, DOI 10.1016/0016-5085(88)90367-8; JANSSEN HLA, 1993, HEPATOLOGY, V17, P383; KLECKER RW, 1994, MOL PHARMACOL, V46, P1204; KORBA BE, 1992, ANTIVIR RES, V19, P55, DOI 10.1016/0166-3542(92)90056-B; KORBA BE, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P663; KUHNS MC, 1989, J MED VIROL, V27, P274, DOI 10.1002/jmv.1890270404; LAI KK, 1991, ANN INTERN MED, V115, P283, DOI 10.7326/0003-4819-115-4-283; LEWIS LD, 1992, ANTIMICROB AGENTS CH, V36, P2061, DOI 10.1128/AAC.36.9.2061; LEWIS W, 1992, J CLIN INVEST, V89, P1354, DOI 10.1172/JCI115722; LOK ASF, 1992, GASTROENTEROLOGY, V102, P2091, DOI 10.1016/0016-5085(92)90337-X; MANNING FJ, 1995, REV FIALURIDE FIAU C; MAXSON CJ, 1992, AM J GASTROENTEROL, V87, P708; PAAR DP, 1992, 32ND INT C ANT AG CH, P264; PERRILLO RP, 1990, NEW ENGL J MED, V323, P295, DOI 10.1056/NEJM199008023230503; RICHARDSON FC, 1994, P NATL ACAD SCI USA, V91, P12003, DOI 10.1073/pnas.91.25.12003; SCULLARD GH, 1981, HEPATOLOGY, V1, P228, DOI 10.1002/hep.1840010306; SEITER K, 1993, CANCER, V71, P1875, DOI 10.1002/1097-0142(19930301)71:5<1875::AID-CNCR2820710526>3.0.CO;2-9; STASCHKE KA, 1994, J VIROL, V68, P8265, DOI 10.1128/JVI.68.12.8265-8269.1994; STEVENSON W, 1995, TRANSPLANT P, V27, P1219; SUSSMAN NL, 1992, HEPATOLOGY, V16, P60, DOI 10.1002/hep.1840160112; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	43	443	470	0	11	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 26	1995	333	17					1099	1105		10.1056/NEJM199510263331702	http://dx.doi.org/10.1056/NEJM199510263331702			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TA372	7565947	Bronze			2023-01-03	WOS:A1995TA37200002
J	TATARA, K				TATARA, K			ON PUTTING LIFE FIRST	LANCET			English	Editorial Material											TATARA, K (corresponding author), OSAKA UNIV,SCH MED,DEPT PUBL HLTH,OSAKA,JAPAN.							MIZUNO H, 1991, BRAIN DEATH ORGAN TR	1	3	3	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					327	328		10.1016/S0140-6736(95)92222-9	http://dx.doi.org/10.1016/S0140-6736(95)92222-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM713	7623528				2023-01-03	WOS:A1995RM71300005
J	LEAPE, LL; BATES, DW; CULLEN, DJ; COOPER, J; DEMONACO, HJ; GALLIVAN, T; HALLISEY, R; IVES, J; LAIRD, N; LAFFEL, G; NEMESKAL, R; PETERSEN, LA; PORTER, K; SERVI, D; SHEA, BF; SMALL, SD; SWEITZER, BJ; THOMPSON, BT; VANDERVLIET, M				LEAPE, LL; BATES, DW; CULLEN, DJ; COOPER, J; DEMONACO, HJ; GALLIVAN, T; HALLISEY, R; IVES, J; LAIRD, N; LAFFEL, G; NEMESKAL, R; PETERSEN, LA; PORTER, K; SERVI, D; SHEA, BF; SMALL, SD; SWEITZER, BJ; THOMPSON, BT; VANDERVLIET, M			SYSTEMS-ANALYSIS OF ADVERSE DRUG EVENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PREVENTION; FAILURES; COMPUTER; ERRORS	Objective.-To identify and evaluate the systems failures that underlie errors causing adverse drug events (ADEs) and potential ADEs. Design.-Systems analysis of events from a prospective cohort study. Participants.-All admissions to 11 medical and surgical units in two tertiary care hospitals over a 6-month period. Main Outcome Measures.-Errors, proximal causes, and systems failures. Methods.-Errors were detected by interviews of those involved. Errors were classified according to proximal cause and underlying systems failure by multidisciplinary teams of physicians, nurses, pharmacists, and systems analysts. Results.-During this period, 334 errors were detected as the causes of 264 preventable ADEs and potential ADEs. Sixteen major systems failures were identified as the underlying causes of the errors. The most common systems failure was in the dissemination of drug knowledge, particularly to physicians, accounting for 29% of the 334 errors. Inadequate availability of patient information, such as the results of laboratory tests, was associated with 18% of errors. Seven systems failures accounted for 78% of the errors; all could be improved by better information systems. Conclusions.-Hospital personnel willingly participated in the detection and investigation of drug use errors and were able to identify underlying systems failures. The most common defects were in systems to disseminate knowledge about drugs and to make drug and patient information readily accessible at the time it is needed. Systems changes to improve dissemination and display of drug and patient data should make errors in the use of drugs less likely.	HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DEPT PHARM, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT NURSING, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PHARM, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; APM INC, NEW YORK, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	LEAPE, LL (corresponding author), HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, 677 HUNTINGTON AVE, BOSTON, MA 02115 USA.				AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Ackoff R.L., 1974, REDESIGNING FUTURE; ALLNUTT MF, 1987, BRIT J ANAESTH, V59, P856, DOI 10.1093/bja/59.7.856; AVORN J, 1983, NEW ENGL J MED, V308, P1457, DOI 10.1056/NEJM198306163082406; Bates D W, 1994, Qual Manag Health Care, V2, P18; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bertalanffy Ludwig, 1968, GEN SYSTEM THEORY; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; Cook RI, 1994, HUMAN ERROR MED; COOPER JB, 1984, ANESTHESIOLOGY, V60, P34, DOI 10.1097/00000542-198401000-00008; Deming WE., 2018, OUT CRISIS; FOLLI HL, 1987, PEDIATRICS, V79, P718; Gaba D, 1994, HUMAN ERROR MED; GABA DM, 1987, ANESTHESIOLOGY, V66, P670, DOI 10.1097/00000542-198705000-00013; LANGLEY GJ, 1992, F IMPROVEMENT; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1976, ANN INTERN MED, V84, P162, DOI 10.7326/0003-4819-84-2-162; Moray N, 1994, HUMAN ERROR MED; Norman D.A., 1988, PSYCHOL EVERYDAY THI; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; Perrow C., 1984, NORMAL ACCIDENTS LIV; Rasmussen J., 1994, COGNITIVE SYSTEMS EN; REASON J, 1990, PHILOS T ROY SOC B, V327, P475, DOI 10.1098/rstb.1990.0090; Reason J., 1990, HUMAN ERROR; SOUMERAI SB, 1986, MED CARE, V24, P313, DOI 10.1097/00005650-198604000-00003; VANCOTT H, 1994, HUMAN ERROR MED; 1980, MED MALPRACTICE CLOS	31	1354	1409	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					35	43		10.1001/jama.1995.03530010049034	http://dx.doi.org/10.1001/jama.1995.03530010049034			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791256				2023-01-03	WOS:A1995RG23300028
J	HAOUARI, N; WOOD, C; GRIFFITHS, G; LEVENE, M				HAOUARI, N; WOOD, C; GRIFFITHS, G; LEVENE, M			THE ANALGESIC EFFECT OF SUCROSE IN FULL-TERM INFANTS - A RANDOMIZED CONTROLLED TRIAL	BRITISH MEDICAL JOURNAL			English	Article							NEWBORN; PAIN	Objective-To evaluate the effects of different sucrose concentrations on measures of neonatal pain, Design-Randomised, double blind, placebo controlled trial of sterile water (control) or one of three solutions of sucrose-namely, 12.5%, 25%, and 50% wt/vol. Setting-Postnatal ward, Patients-60 healthy infants of gestational age 37-42 weeks and postnatal age 1-6 days randomised to receive 2 ml of one of the four solutions on to the tongue two minutes before heel prick sampling for serum bilirubin concentrations. Main outcome measure-Duration of crying over the first three minutes after heel prick. Results-There was a significant reduction in overall crying time and heart rate after three minutes in the babies given 50% sucrose as compared with controls. This was maximal one minute after heel prick in the 50% sucrose group and became statistically significant in the 25% sucrose group at two minutes, There was a significant trend for a reduction in crying time with increasing concentrations of sucrose over the first three minutes. Conclusion-Concentrated sucrose solution seems to reduce crying and the autonomic effects of a painful procedure in healthy normal babies, Sucrose may be a useful and safe analgesic for minor procedures in neonates.	UNIV LEEDS,LEEDS GEN INFIRM,DIV PAEDIAT & CHILD HLTH,LEEDS LS2 9NS,W YORKSHIRE,ENGLAND	Leeds General Infirmary; University of Leeds								ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; BLASS E, 1987, PHARMACOL BIOCHEM BE, V26, P483, DOI 10.1016/0091-3057(87)90153-5; BLASS EM, 1991, PEDIATRICS, V87, P215; BLASS EM, 1989, ANN NY ACAD SCI, V575, P292; CUSIK J, 1985, STAT MED, V4, P87; FITZGERALD M, 1989, ARCH DIS CHILD-FETAL, V64, P441, DOI 10.1136/adc.64.4_Spec_No.441; LIEBLICH I, 1983, SCIENCE, V97, P871; PRECHTL HFR, 1974, BRAIN RES, V76, P185, DOI 10.1016/0006-8993(74)90454-5; RUSHFORTH JA, 1994, ARCH DIS CHILD-FETAL, V70, pF174, DOI 10.1136/fn.70.3.F174; RUSHFORTH JA, 1993, ARCH DIS CHILD, V69, P388, DOI 10.1136/adc.69.3.388	10	114	117	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 10	1995	310	6993					1498	1500		10.1136/bmj.310.6993.1498	http://dx.doi.org/10.1136/bmj.310.6993.1498			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD285	7787595	Green Published			2023-01-03	WOS:A1995RD28500020
J	CARLEN, PL; GORDON, M				CARLEN, PL; GORDON, M			CARDIOPULMONARY-RESUSCITATION AND NEUROLOGICAL COMPLICATIONS IN THE ELDERLY	LANCET			English	Editorial Material									UNIV TORONTO,BAYCREST CTR GERIATR CARE,TORONTO,ON,CANADA	University of Toronto; University Toronto Affiliates; Baycrest	CARLEN, PL (corresponding author), TORONTO HOSP,RES INST,PLAYFAIR NEUROSCI UNIT,TORONTO,ON M5T 2S8,CANADA.		Carlen, Peter Louis/GLN-7260-2022	Carlen, Peter/0000-0002-3339-8102				BEAL MF, 1993, TRENDS NEUROSCI, V16, P125, DOI 10.1016/0166-2236(93)90117-5; BEDELL SE, 1983, NEW ENGL J MED, V309, P570; DATZ DI, 1994, ARCH NEUROL-CHICAGO, V51, P661; DENNIS MS, 1993, STROKE, V24, P796, DOI 10.1161/01.STR.24.6.796; FINCH CE, 1993, TRENDS NEUROSCI, V16, P104, DOI 10.1016/0166-2236(93)90134-8; GORDON M, 1995, CARDIOL ELDER, V3, P53; JOHNSTON MV, 1994, NEUROBIOL AGING, V15, P235, DOI 10.1016/0197-4580(94)90119-8; KHACHATURIAN ZS, 1987, NEUROBIOL AGING, V8, P345, DOI 10.1016/0197-4580(87)90073-X; LANDFIELD PW, 1994, NEUROBIOL AGING, V15, P579, DOI 10.1016/0197-4580(94)90101-5; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; OLNEY JW, 1994, NEUROBIOL AGING, V15, P259, DOI 10.1016/0197-4580(94)90127-9; ROGOVE HJ, 1995, CRIT CARE MED, V23, P18, DOI 10.1097/00003246-199501000-00007; SMITH MA, 1995, TRENDS NEUROSCI, V18, P172, DOI 10.1016/0166-2236(95)93897-7; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TRESCH DD, 1989, AM J MED, V86, P145, DOI 10.1016/0002-9343(89)90259-3; WEST MJ, 1993, NEUROBIOL AGING, V14, P287, DOI 10.1016/0197-4580(93)90113-P	16	3	3	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1253	1254		10.1016/S0140-6736(95)90919-2	http://dx.doi.org/10.1016/S0140-6736(95)90919-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746051				2023-01-03	WOS:A1995QY93300003
J	MCCUE, JD				MCCUE, JD			THE NATURALNESS OF DYING	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							LIFE-SUPPORT; FUNCTIONAL STATUS; TERMINALLY ILL; DEATH ANXIETY; BODY-WEIGHT; BRAIN-DEATH; PHYSICIANS; MORTALITY; DEPRESSION; CARE	Evidence that dying occurs as a natural, final event in the wholeness of human life is culturally, artistically, and scientifically persuasive. Very elderly patients eventually undergo a process of functional declines, progressive apathy, and loss of willingness to eat and drink that culminates in death, even in the absence of acute illness or severe chronic disease. Despite clinical resemblances to depression and dementia, aging itself and a loss of will to live are the most probable explanations for natural dying. Acceptance of the naturalness of dying, however, directly conflicts with the medicalization and legalization of death that characterizes modern society's treatment of dying elderly patients. We prefer instead to believe that dying results from disease and injury, which may yield to advances in medical technology. The progressive move of the dying out of the home and into acute and long-term care facilities suggests that medicalization may be an irreversible process. Viewing dying as an independent diagnosis in patients who are obviously undergoing terminal declines from aging and chronic diseases can facilitate communication about spiritual and palliative care needs, which tend to be neglected in the medicalized view of dying. Physicians and nurses may need to assume the role of medical stewardship to help prevent the overtreatment and overtesting of modern medicine's approach to the dying. The emotional burdens of caring for the dying elderly, however, must be addressed openly through collaborative work, institutional policies on limitation of treatment, and support building among physicians and other caregivers.	UNIV MASSACHUSETTS, SCH MED, DEPT MED, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester	MCCUE, JD (corresponding author), BERKSHIRE MED CTR, 725 NORTH ST, PITTSFIELD, MA 01201 USA.							Aries Philippe, 2008, HOUR OUR DEATH; ARTISS KL, 1973, NEW ENGL J MED, V288, P1210, DOI 10.1056/NEJM197306072882305; AURELIUS M, MEDITATIONS MA ANTON; BAYER R, 1983, NEW ENGL J MED, V309, P1490, DOI 10.1056/NEJM198312153092405; BEAUVOIR SD, 1972, COMING OF AGE; BERLINGER WG, 1991, J AM GERIATR SOC, V39, P973, DOI 10.1111/j.1532-5415.1991.tb04043.x; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BLAZER D, 1989, NEW ENGL J MED, V320, P164, DOI 10.1056/NEJM198901193200306; BOCQUET H, 1987, REV EPIDEMIOL SANTE, V35, P151; BORTZ WM, 1990, J AM GERIATR SOC, V38, P146, DOI 10.1111/j.1532-5415.1990.tb03476.x; BOTWINICK J, 1978, J GERONTOL, V33, P755, DOI 10.1093/geronj/33.5.755; BRAITHWAITE S, 1986, ANN INTERN MED, V104, P711, DOI 10.7326/0003-4819-104-5-711; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; BRANCH WT, 1990, AM J MED, V88, P56, DOI 10.1016/0002-9343(90)90128-Z; BRURERA E, 1993, LANCET, V342, P13; BURGESS MM, 1993, J MED PHILOS, V18, P269, DOI 10.1093/jmp/18.3.269; CALLAHAN D, 1977, HASTINGS CENT REP, V7, P32, DOI 10.2307/3560692; CALLAHAN D, 1983, HASTINGS CENT REP, V13, P22, DOI 10.2307/3560573; Callahan D., 1987, SETTING LIMITS MED G; Callahan Daniel, 1993, TROUBLED DREAM LIFE; Callanan M, 1992, FINAL GIFTS; CHAMBERS CV, 1994, ARCH INTERN MED, V154, P541, DOI 10.1001/archinte.154.5.541; CLARK LP, 1990, J AM GERIATR SOC, V38, P967, DOI 10.1111/j.1532-5415.1990.tb04417.x; COOK ML, 1993, ARCH INTERN MED, V153, P2718, DOI 10.1001/archinte.153.24.2718; CRUM RM, 1993, JAMA-J AM MED ASSOC, V269, P2386, DOI 10.1001/jama.269.18.2386; DONTAS AS, 1991, J AM GERIATR SOC, V39, P641, DOI 10.1111/j.1532-5415.1991.tb03616.x; Dozor R B, 1992, Fam Med, V24, P538; Durand R P, 1990, Fam Pract Res J, V9, P123; DWYER JT, 1987, J GERONTOL, V42, P246, DOI 10.1093/geronj/42.3.246; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EMANUEL EJ, 1988, LANCET, V1, P106; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; ERIKSON EH, 1982, LIFE CYCLE COMPLETED, P60; FEIFEL H, 1973, J ABNORM PSYCHOL, V49, P278; FEIFEL H, 1967, 75TH P ANN CONV AM P, V2, P201; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; FORBES WF, 1993, J AM GERIATR SOC, V41, P1267, DOI 10.1111/j.1532-5415.1993.tb07313.x; FRIEDLAND RP, 1988, ANN INTERN MED, V109, P298, DOI 10.7326/0003-4819-109-4-298; GARLAND J, 1985, BRIT J MED PSYCHOL, V58, P267, DOI 10.1111/j.2044-8341.1985.tb02644.x; Gates M F, 1992, Hosp J, V8, P17; GLICK HR, 1992, RIGHT DIE; GRAHAM H, 1983, LANCET, V2, P670; Gruman G J, 1978, Omega (Westport), V9, P203, DOI 10.2190/1HPQ-G1GQ-TWVB-BWW5; GURALNIK JM, 1991, AM J PUBLIC HEALTH, V81, P443, DOI 10.2105/AJPH.81.4.443; HALEVY A, 1993, ANN INTERN MED, V119, P519, DOI 10.7326/0003-4819-119-6-199309150-00013; HILFIKER D, 1983, NEW ENGL J MED, V308, P716, DOI 10.1056/NEJM198303243081210; HOWELLS K, 1986, MED EDUC, V20, P502, DOI 10.1111/j.1365-2923.1986.tb01390.x; HULL FM, 1991, MED EDUC, V25, P491, DOI 10.1111/j.1365-2923.1991.tb00103.x; JARVIK LF, 1988, GERONTOLOGIST, V28, P739, DOI 10.1093/geront/28.6.739; Jennings B, 1988, Hastings Cent Rep, V18, P1; JOHANSSON B, 1989, J GERONTOL, V44, pP184, DOI 10.1093/geronj/44.6.P184; JONAS H, 1992, HASTINGS CENT REP, V22, P34, DOI 10.2307/3562722; KANE AC, 1985, OMEGA-J DEATH DYING, V16, P11; KAOTONA CLE, 1991, J MED GERONTOL, V1, P371; KELLER HH, 1993, J AM GERIATR SOC, V41, P1212, DOI 10.1111/j.1532-5415.1993.tb07305.x; KINSELLA TD, 1989, AM J MED, V86, P643, DOI 10.1016/0002-9343(89)90435-X; KITCHEN AD, 1986, J MED EDUC, V61, P760; KLONOFFCOHEN H, 1992, J CLIN EPIDEMIOL, V45, P207, DOI 10.1016/0895-4356(92)90080-7; KOENIG HG, 1990, ARCH INTERN MED, V150, P1349, DOI 10.1001/archinte.1990.00390180147035; KOENIG HG, 1989, J GEN INTERN MED, V4, P498, DOI 10.1007/BF02599548; KOENIG HG, 1989, J AM GERIATR SOC, V37, P599, DOI 10.1111/j.1532-5415.1989.tb01249.x; KRAKOWSKI AJ, 1982, PSYCHOTHER PSYCHOSOM, V38, P11, DOI 10.1159/000287609; KRAKOWSKI AJ, 1982, J PSYCHOSOM RES, V26, P91, DOI 10.1016/0022-3999(82)90068-X; Kubler-Ross E., 1975, DEATH FINAL STAGE GR; Larrabee GJ, 1986, DEV NEUROPSYCHOL, V2, P373, DOI 10.1080/87565648609540355; LASCH C, 1978, CULTURE NARCISSISM A, P207; LAUNER LJ, 1994, JAMA-J AM MED ASSOC, V271, P1093, DOI 10.1001/jama.271.14.1093; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LEE MA, 1990, J AM GERIATR SOC, V38, P710, DOI 10.1111/j.1532-5415.1990.tb01433.x; LO B, 1980, ANN INTERN MED, V93, P764, DOI 10.7326/0003-4819-93-5-764; LUDDINGTON AV, 1993, GERIATRICS, V48, P72; LYNN J, 1986, BY NO EXTRAORDINARY; MACKLIN R, 1993, ENEMIES PATIENTS; MAKSOUD A, 1993, ARCH INTERN MED, V153, P1249, DOI 10.1001/archinte.153.10.1249; MARTIN CA, 1987, STRESS BURNOUT PROVI, P121; MARTIN CA, 1987, STRESS BURNOUT PROVI; MATTHEWS DA, 1993, ANN INTERN MED, V118, P973, DOI 10.7326/0003-4819-118-12-199306150-00010; MCCUE JD, 1982, NEW ENGL J MED, V306, P458, DOI 10.1056/NEJM198202253060805; MENDEZ OE, 1993, CRIT CARE CLIN, V9, P613, DOI 10.1016/S0749-0704(18)30189-1; MERMANN AC, 1992, YALE J BIOL MED, V65, P137; MILES SH, 1989, NEW ENGL J MED, V321, P48, DOI 10.1056/NEJM198907063210110; Miller R. A., 1994, PRINCIPLES GERIATRIC, P3; MOEHLE KA, 1989, J GERONTOL, V44, pP176, DOI 10.1093/geronj/44.6.P176; MONMEYER RW, 1988, CONFRONTING DEATH; Mortimer J A, 1990, Adv Neurol, V51, P27; MOUNT BM, 1986, J CLIN ONCOL, V4, P1127, DOI 10.1200/JCO.1986.4.7.1127; MURPHY E, 1988, BRIT J PSYCHIAT, V152, P347, DOI 10.1192/bjp.152.3.347; MURPHY E, 1983, BRIT J PSYCHIAT, V142, P111, DOI 10.1192/bjp.142.2.111; Nuland S.B., 1994, HOW WE DIE; PALMORE E, 1976, J GERONTOL, V31, P76, DOI 10.1093/geronj/31.1.76; PAYER L, 1988, MED CULTURE; PERKINS HS, 1990, AM J MED, V89, P185, DOI 10.1016/0002-9343(90)90298-R; PERLS TT, 1993, J AM GERIATR SOC, V41, P1193, DOI 10.1111/j.1532-5415.1993.tb07302.x; PETERS AL, 1990, AM J MED, V89, P81, DOI 10.1016/0002-9343(90)90102-J; PHILLIPS DP, 1990, JAMA-J AM MED ASSOC, V263, P1947, DOI 10.1001/jama.263.14.1947; PHILLIPS PA, 1984, NEW ENGL J MED, V311, P753, DOI 10.1056/NEJM198409203111202; QUILL T, 1994, DEATH DIGNITY; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; QUILL TE, 1989, ANN INTERN MED, V111, P51, DOI 10.7326/0003-4819-111-1-51; REED HBC, 1963, J GERONTOL, V18, P271, DOI 10.1093/geronj/18.3.271; REUBEN DB, 1992, AM J MED, V93, P663, DOI 10.1016/0002-9343(92)90200-U; ROSENGREN A, 1993, BRIT MED J, V307, P1102, DOI 10.1136/bmj.307.6912.1102; ROVNER BW, 1991, JAMA-J AM MED ASSOC, V265, P993, DOI 10.1001/jama.265.8.993; RUDMAN D, 1987, J AM GERIATR SOC, V35, P496, DOI 10.1111/j.1532-5415.1987.tb01394.x; SAGER M, 1990, ARCH INTERN MED, V150, P1091, DOI 10.1001/archinte.150.5.1091; SANDMAN PO, 1987, J AM GERIATR SOC, V35, P31, DOI 10.1111/j.1532-5415.1987.tb01316.x; SCHMITZ P, 1994, PRINCIPLES GERIATRIC, P383; SCHNEIDERMAN ES, 1970, PSYCHOL TODAY, V5, P43; SCHNEIDERMAN ES, 1970, PSYCHOL TODAY, V4, P67; SCHULZ R, 1978, OMEGA, V9, P327; SERAVALLI EP, 1988, NEW ENGL J MED, V319, P1728, DOI 10.1056/NEJM198812293192609; SLOMKA J, 1992, SOC SCI MED, V35, P251, DOI 10.1016/0277-9536(92)90021-H; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SOUTHWICK F, 1993, ANN INTERN MED, V118, P146, DOI 10.7326/0003-4819-118-2-199301150-00011; STERN Y, 1994, JAMA-J AM MED ASSOC, V271, P1004, DOI 10.1001/jama.271.13.1004; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; TAYBACK M, 1990, ARCH INTERN MED, V150, P1065, DOI 10.1001/archinte.150.5.1065; THOMPSON MP, 1991, J AM GERIATR SOC, V39, P497, DOI 10.1111/j.1532-5415.1991.tb02496.x; TOLLE SW, 1983, ARCH INTERN MED, V143, P1447, DOI 10.1001/archinte.143.7.1447; Tolstoy L, 1981, DEATH I ILYICH; UEDA K, 1990, J AM GERIATR SOC, V38, P1332, DOI 10.1111/j.1532-5415.1990.tb03457.x; UHLMANN RF, 1987, ANN INTERN MED, V106, P879, DOI 10.7326/0003-4819-106-6-879; VICKIO CJ, 1985, J GERONTOL, V40, P347, DOI 10.1093/geronj/40.3.347; VONDRAS DD, 1992, J AM GERIATR SOC, V40, P285; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; WARREN WG, 1989, DEATH ED RES CLIN PE; WHITE N, 1988, J GERONTOL, V43, pP141, DOI 10.1093/geronj/43.6.P141; YARBOROUGH M, 1988, J AM GERIATR SOC, V36, P63, DOI 10.1111/j.1532-5415.1988.tb03435.x; YOUNGNER SJ, 1989, JAMA-J AM MED ASSOC, V261, P2205, DOI 10.1001/jama.261.15.2205; YOUNGNER SJ, 1983, ANN INTERN MED, V99, P252, DOI 10.7326/0003-4819-99-2-252	131	134	135	0	31	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 5	1995	273	13					1039	1043		10.1001/jama.273.13.1039	http://dx.doi.org/10.1001/jama.273.13.1039			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QP890	7897788				2023-01-03	WOS:A1995QP89000035
J	ESTEBAN, A; FRUTOS, F; TOBIN, MJ; ALIA, I; SOLSONA, JF; VALVERDU, I; FERNANDEZ, R; DELACAL, MA; BENITO, S; TOMAS, R; CARRIEDO, D; MACIAS, S; BLANCO, J				ESTEBAN, A; FRUTOS, F; TOBIN, MJ; ALIA, I; SOLSONA, JF; VALVERDU, I; FERNANDEZ, R; DELACAL, MA; BENITO, S; TOMAS, R; CARRIEDO, D; MACIAS, S; BLANCO, J			A COMPARISON OF 4 METHODS OF WEANING PATIENTS FROM MECHANICAL VENTILATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PRESSURE SUPPORT; WORK	Background. Weaning patients from mechanical ventilation is an important problem in intensive care units. Weaning is usually conducted in an empirical manner, and a standardized approach has not been developed. Methods. We carried out a prospective, randomized, multicenter study involving 546 patients who had received mechanical ventilation for a mean (+/-SD) of 7.5+/-6.1 days and who were considered by their physicians to be ready for weaning. One hundred thirty patients had respiratory distress during a two-hour trial of spontaneous breathing. These patients were randomly assigned to undergo one of four weaning techniques: intermittent mandatory ventilation, in which the ventilator rate was initially set at a mean (+/-SD) of 10.0+/-2.2 breaths per minute and then decreased, if possible, at least twice a day, usually by 2 to 4 breaths per minute (29 patients); pressure-support ventilation, in which pressure support was initially set at 18.0+/-6.1 cm of water and then reduced, it possible, by 2 to 4 cm of water at least twice a day (37 patients); intermittent trials of spontaneous breathing, conducted two or more times a day if possible (33 patients); or a once-daily trial of spontaneous breathing (31 patients). Standardized protocols were followed for each technique. Results. The median duration of weaning was 5 days for intermittent mandatory ventilation (first quartile, 3 days; third quartile, 11 days), 4 days for pressure-support ventilation (2 and 12 days, respectively), 3 days for intermittent (multiple) trials of spontaneous breathing (2 and 6 days, respectively), and 3 days for a once-daily trial of spontaneous breathing (1 and 6 days, respectively). After adjustment for other covariates, the rate of successful weaning was higher with a once-daily trial of spontaneous breathing than with intermittent mandatory ventilation (rate ratio, 2.83; 95 percent confidence interval, 1.36 to 5.89; P<0.006) or pressure-support ventilation (rate ratio, 2.05; 95 percent confidence interval, 1.04 to 4.04; P<0.04), There was no significant difference in the rate of success between once-daily trials and multiple trials of spontaneous breathing. Conclusions. A once-daily trial of spontaneous breathing led to extubation about three times more quickly than intermittent mandatory ventilation and about twice as quickly as pressure-support ventilation. Multiple daily trials of spontaneous breathing were equally successful.	LOYOLA UNIV, CHICAGO, IL 60611 USA; EDWARD HINES JR VET ADM HOSP, HINES, IL USA; HOSP DEL MAR, BARCELONA, SPAIN; HOSP SANTA CRUZ & SAN PABLO, E-08025 BARCELONA, SPAIN; HOSP PARC TAULI, SABADELL, SPAIN; HOSP GERMANS TRIAS & PUJOL, BADALONA, SPAIN; COMPLEJO HOSP LEON, LEON, SPAIN; HOSP GEN SEGOVIA, SEGOVIA, SPAIN; HOSP RIO ORTEGA, VALLADOLID, SPAIN	Loyola University Chicago; US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Institut Hospital del Mar d'Investigacions Mediques (IMIM); Hospital del Mar; Autonomous University of Barcelona; Parc Tauli Hospital Universitari; Hospital Germans Trias i Pujol; Universidad de Leon; Hospital de Leon	ESTEBAN, A (corresponding author), HOSP UNIV GETAFE, SERV CUIDADOS INTENS, CTRA TOLEDO KM 12500, E-28905 GETAFE, SPAIN.		Fernandez, Rafael/A-9586-2010	Fernandez, Rafael/0000-0001-5711-5317; benito, salvador/0000-0002-6333-5823; Frutos-Vivar, Fernando/0000-0002-4648-9636				ALTMAN DG, 1990, LANCET, V335, P149, DOI 10.1016/0140-6736(90)90014-V; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1991, ANESTHESIOLOGY, V75, P739, DOI 10.1097/00000542-199111000-00004; Brochard L, 1994, PRINCIPLES PRACTICE, P239; COX DR, 1972, J R STAT SOC B, V34, P187; DOWNS JB, 1973, CHEST, V64, P331, DOI 10.1378/chest.64.3.331; ESTEBAN A, 1994, CHEST, V106, P1188, DOI 10.1378/chest.106.4.1188; FAULKNER JA, 1985, LUNG BIOL HLTH DISEA, V29, P1329; GIBNEY RTN, 1982, CHEST, V82, P692, DOI 10.1378/chest.82.6.692; HASTINGS PR, 1980, ANESTHESIOLOGY, V53, P429; IMSAND C, 1994, ANESTHESIOLOGY, V80, P13, DOI 10.1097/00000542-199401000-00006; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUCE JM, 1981, CHEST, V79, P678, DOI 10.1378/chest.79.6.678; MARINI JJ, 1988, AM REV RESPIR DIS, V138, P1169, DOI 10.1164/ajrccm/138.5.1169; NATHAN SD, 1993, CHEST, V103, P1215, DOI 10.1378/chest.103.4.1215; ROCHESTER DF, 1988, AM REV RESPIR DIS, V138, P516, DOI 10.1164/ajrccm/138.3.516; SASSOON CSH, 1994, PRINCIPLES PRACTICE, P221; SCHACHTER EN, 1981, JAMA-J AM MED ASSOC, V246, P1210, DOI 10.1001/jama.246.11.1210; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; Tobin MJ, 1994, PRINCIPLES PRACTICE, P1177; TOMLINSON JR, 1989, CHEST, V96, P348, DOI 10.1378/chest.96.2.348; VENUS B, 1987, CRIT CARE MED, V15, P530, DOI 10.1097/00003246-198705000-00017	23	817	867	0	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1995	332	6					345	350		10.1056/NEJM199502093320601	http://dx.doi.org/10.1056/NEJM199502093320601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF300	7823995				2023-01-03	WOS:A1995QF30000001
J	ROBERTSON, DAF; AYRES, RCS; SMITH, CL; WRIGHT, R				ROBERTSON, DAF; AYRES, RCS; SMITH, CL; WRIGHT, R			ADVERSE CONSEQUENCES ARISING FROM MIS-DIAGNOSIS OF FOOD ALLERGY	BRITISH MEDICAL JOURNAL			English	Article											ROBERTSON, DAF (corresponding author), SOUTHAMPTON GEN HOSP,DEPT MED 2,SOUTHAMPTON SO9 4XY,HANTS,ENGLAND.							HUGHES M, 1986, BRIT MED J, V293, P366, DOI 10.1136/bmj.293.6543.366; KERR GR, 1979, J AM DIET ASSOC, V75, P29; MCEWEN LM, 1975, ANN ALLERGY, V35, P98; RIX KJB, 1984, BRIT J PSYCHIAT, V145, P121, DOI 10.1192/bjp.145.2.121; ROBERTSON D, 1987, BAILLIERE CLIN GASTR, V1, P473, DOI 10.1016/0950-3528(87)90043-1	5	16	16	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 17	1988	297	6650					719	720		10.1136/bmj.297.6650.719-a	http://dx.doi.org/10.1136/bmj.297.6650.719-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q1595	3147740	Bronze, Green Published			2023-01-03	WOS:A1988Q159500021
J	BRADLEY, JR; EVANS, DB; GORE, SM; COWLEY, AJ				BRADLEY, JR; EVANS, DB; GORE, SM; COWLEY, AJ			IS DIALYSIS HYPOTENSION CAUSED BY AN ABNORMALITY OF VENOUS TONE	BRITISH MEDICAL JOURNAL			English	Article									MRC CTR,BIOSTAT UNIT,CAMBRIDGE CB2 2BW,ENGLAND; UNIV NOTTINGHAM HOSP,DEPT MED,NOTTINGHAM NG7 2UH,ENGLAND	MRC Biostatistics Unit; MRC Laboratory Molecular Biology; University of Nottingham	BRADLEY, JR (corresponding author), ADDENBROOKES HOSP,DEPT RENAL MED,CAMBRIDGE CB2 2QQ,ENGLAND.			Bradley, John/0000-0002-7774-8805				ABBOUD FM, 1976, PROG CARDIOVASC DIS, V18, P371, DOI 10.1016/0033-0620(76)90003-7; BEVEGARD BS, 1965, J APPL PHYSIOL, V20, P1, DOI 10.1152/jappl.1965.20.1.1; GREENFIELD ADM, 1963, BRIT MED BULL, V19, P101, DOI 10.1093/oxfordjournals.bmb.a070026; HENRICH WL, 1986, KIDNEY INT, V30, P605, DOI 10.1038/ki.1986.228; HSU CH, 1984, NEPHRON, V38, P202, DOI 10.1159/000183308; KINET JP, 1982, KIDNEY INT, V21, P868, DOI 10.1038/ki.1982.111; MANSELL MA, 1983, BRIT MED J, V287, P308, DOI 10.1136/bmj.287.6388.308	7	29	30	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1988	296	6637					1634	1637		10.1136/bmj.296.6637.1634	http://dx.doi.org/10.1136/bmj.296.6637.1634			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N8341	3248129	Green Published, Bronze			2023-01-03	WOS:A1988N834100013
J	MILNER, PC; NICHOLL, JP; WILLIAMS, BT				MILNER, PC; NICHOLL, JP; WILLIAMS, BT			VARIABILITY IN REVIEWING ATTENDERS AT ACCIDENT AND EMERGENCY DEPARTMENTS IN ENGLAND	BRITISH MEDICAL JOURNAL			English	Note											MILNER, PC (corresponding author), UNIV SHEFFIELD,SCH MED,DEPT COMMUNITY MED,MED CARE RES UNIT,SHEFFIELD S10 2RX,S YORKSHIRE,ENGLAND.		Nicholl, Jon/B-8257-2008					CRAIG JA, 1981, OPCS STUDIES MED POP, V48; FAIRLEY J, 1969, BRIT MED J, V2, P375, DOI 10.1136/bmj.2.5653.375; GILL JS, 1985, LANCET, V1, P567; WEINERMAN ER, 1966, AM J PUBLIC HEALTH N, V56, P1037, DOI 10.2105/AJPH.56.7.1037; 1977, HLTH PERSONAL SOCIAL; 1973, HLTH PERSONAL SOCIAL; 1987, HLTH PERSONAL SOCIAL	7	1	1	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1988	296	6637					1645	1645		10.1136/bmj.296.6637.1645	http://dx.doi.org/10.1136/bmj.296.6637.1645			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N8341	3135057	Bronze, Green Published			2023-01-03	WOS:A1988N834100023
J	BEUTLER, JJ; ATTEVELT, JTM; SCHOUTEN, SA; FABER, JAJ; MEES, EJD; GEIJSKES, GG				BEUTLER, JJ; ATTEVELT, JTM; SCHOUTEN, SA; FABER, JAJ; MEES, EJD; GEIJSKES, GG			PARANORMAL HEALING AND HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article									STATE UNIV UTRECHT,INST MATH STAT,3508 TA UTRECHT,NETHERLANDS; STATE UNIV UTRECHT,DEPT SOCIAL SCI,3584 CA UTRECHT,NETHERLANDS	Utrecht University; Utrecht University	BEUTLER, JJ (corresponding author), STATE UNIV UTRECHT HOSP,DEPT NEPHROL & HYPERTENS,3511 GV UTRECHT,NETHERLANDS.		QQ, Simon/D-3888-2014					ATTEVELT JTM, 1988, THESIS STATE U UTREC, P47; BENSON H, 1977, LANCET, V1, P1152; BRENNAN PJ, 1982, BMJ-BRIT MED J, V285, P919, DOI 10.1136/bmj.285.6346.919; FULDER SJ, 1985, LANCET, V2, P542; HAGE H, 1986, TOEGEPASTE WETENSCHA, V2, P37; LIMBURGER HHB, 1981, TIJDSCHRIFT SOCIALE, V7, P219; MANCIA G, 1983, LANCET, V2, P695; REILLY DT, 1983, BRIT MED J, V287, P337, DOI 10.1136/bmj.287.6388.337; SHEPARD DS, 1983, PREV MED, V12, P304, DOI 10.1016/0091-7435(83)90239-6; 1985, LANCET, V2, P1177; 1978, WHO TECH REP SER, V628	11	31	31	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 28	1988	296	6635					1491	1494		10.1136/bmj.296.6635.1491	http://dx.doi.org/10.1136/bmj.296.6635.1491			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N6525	3134082	Green Published			2023-01-03	WOS:A1988N652500010
J	BUCHNESS, MR; LIM, HW; HATCHER, VA; SANCHEZ, M; SOTER, NA				BUCHNESS, MR; LIM, HW; HATCHER, VA; SANCHEZ, M; SOTER, NA			EOSINOPHILIC PUSTULAR FOLLICULITIS IN THE ACQUIRED IMMUNODEFICIENCY SYNDROME - TREATMENT WITH ULTRAVIOLET-B PHOTOTHERAPY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NYU, SCH MED, DEPT DERMATOL, NEW YORK, NY 10003 USA; BELLEVUE HOSP CTR, DEPT DERMATOL, NEW YORK, NY 10016 USA; CHARLES C HARRIS SKIN & CANC PAVIL, PHOTOMED SECT, NEW YORK, NY USA	New York University; Bellevue Hospital Center	BUCHNESS, MR (corresponding author), VET ADM MED CTR, DERMATOL SECT, 1ST AVE & E 24TH ST, NEW YORK, NY 10010 USA.		Lim, HW/GRY-3517-2022	Soter, Nicholas/0000-0003-3518-3209				COLTON AS, 1986, J AM ACAD DERMATOL, V14, P469, DOI 10.1016/S0190-9622(86)70059-5; DENMAN ST, 1986, J AM ACAD DERMATOL, V14, P375, DOI 10.1016/S0190-9622(86)70047-9; DINEHART SM, 1986, J AM ACAD DERMATOL, V14, P475, DOI 10.1016/S0190-9622(86)70060-1; GILCHREST BA, 1979, ANN INTERN MED, V91, P17, DOI 10.7326/0003-4819-91-1-17; JALIMAN HD, 1986, J AM ACAD DERMATOL, V14, P479, DOI 10.1016/S0190-9622(86)70061-3; OFUJI S, 1970, ACTA DERM-VENEREOL, V50, P195; SOEPRONO FF, 1986, J AM ACAD DERMATOL, V14, P1020, DOI 10.1016/S0190-9622(86)70126-6; SPIRA I, 1986, HAUTARZT, V37, P222; STEFFEN C, 1985, ARCH DERMATOL, V121, P921, DOI 10.1001/archderm.121.7.921; TAKEMATSU H, 1985, ARCH DERMATOL, V121, P917, DOI 10.1001/archderm.121.7.917	10	108	109	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 5	1988	318	18					1183	1186		10.1056/NEJM198805053181807	http://dx.doi.org/10.1056/NEJM198805053181807			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N1835	3362166				2023-01-03	WOS:A1988N183500007
J	VARDAS, PE; TRAVILL, CM; WILLIAMS, TDM; INGRAM, AM; LIGHTMAN, SL; SUTTON, R				VARDAS, PE; TRAVILL, CM; WILLIAMS, TDM; INGRAM, AM; LIGHTMAN, SL; SUTTON, R			EFFECT OF DUAL CHAMBER PACING ON RAISED PLASMA ATRIAL NATRIURETIC PEPTIDE CONCENTRATIONS IN COMPLETE ATRIOVENTRICULAR-BLOCK	BRITISH MEDICAL JOURNAL			English	Note									WESTMINSTER HOSP,CHARING CROSS & WESTMINSTER MED SCH,DEPT CARDIOL,LONDON SW1P 2AP,ENGLAND; WESTMINSTER HOSP,CHARING CROSS & WESTMINSTER MED SCH,DEPT MED,LONDON SW1P 2AP,ENGLAND	Imperial College London; Imperial College London			Vardas, Panos/AAP-5694-2021; vardas, panos/ABF-7144-2020; Vardas, Panos/AAD-5219-2022					ANDERSON JV, 1985, CLIN SCI, V69, pP39; NAKAOKA H, 1985, NEW ENGL J MED, V313, P892; OGAWA S, 1978, PACE, V1, P8, DOI 10.1111/j.1540-8159.1978.tb03435.x; WALSH KP, IN PRESS AM J PHYSL; YOMAH T, 1985, LANCET, V1, P1211	5	25	25	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 9	1988	296	6615					94	94		10.1136/bmj.296.6615.94	http://dx.doi.org/10.1136/bmj.296.6615.94			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L6207	2962695	Green Published, Bronze			2023-01-03	WOS:A1988L620700011
J	FAURISSON, F; CONTREPOIS, A; GROSSKOPF, C				FAURISSON, F; CONTREPOIS, A; GROSSKOPF, C			AEROSOL INHALATION BEFORE READING AGE	LANCET			English	Letter									ROCHE PROD LTD,NEUILLY SUR SEINE,FRANCE	Roche Holding	FAURISSON, F (corresponding author), INSERM,U13,F-75877 PARIS,FRANCE.								0	0	0	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	NOV 11	1995	346	8985					1298	1298		10.1016/S0140-6736(95)91898-1	http://dx.doi.org/10.1016/S0140-6736(95)91898-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TE145	7475739				2023-01-03	WOS:A1995TE14500048
J	BRITTO, J; NADEL, S; MACONOCHIE, I; LEVIN, M; HABIBI, P				BRITTO, J; NADEL, S; MACONOCHIE, I; LEVIN, M; HABIBI, P			MORBIDITY AND SEVERITY OF ILLNESS DURING INTERHOSPITAL TRANSFER - IMPACT OF A SPECIALIZED PEDIATRIC RETRIEVAL TEAM	BRITISH MEDICAL JOURNAL			English	Article							AIRWAY MANAGEMENT; TRANSPORT; STABILIZATION	Objective-To evaluate the morbidity and severity of illness during interhospital transfer of critically ill children by a specialised paediatric retrieval team. Design-Prospective, descriptive study. Setting-Hospitals without paediatric intensive care facilities in and around the London area, and a paediatric intensive care unit at a tertiary centre. Subjects-51 critically ill children transferred to the paediatric intensive care unit. Main outcome measures-Adverse events related to equipment and physiological deterioration during transfer. Paediatric risk of mortality score before and after retrieval. Therapeutic intervention score before and after arrival of retrieval team. Results-Two (4%) patients had preventable physiological deterioration during transport. There were no adverse events related to equipment. Severity of illness decreased during stabilisation and transport by the retrieval team, suggested by the difference between risk of mortality scores before and after retrieval (P < 0.001). The median (range) difference between the two scores was 3.0 (-6 to 17). Interventions during stabilisation by the retrieval team increased, demonstrated by the difference between intervention scores before and after retrieval, median (range) difference between the two scores being 6 (-8 to 38) (P < 0.001). Conclusions-Our study indicates that a specialised paediatric retrieval team can rapidly deliver intensive care to critically iu children awaiting transfer. Such children can be transferred to a paediatric intensive care unit with minimal morbidity and mortality related to transport. There was no deterioration in the clinical condition of most patients during transfer.			BRITTO, J (corresponding author), ST MARYS HOSP,DEPT PAEDIAT,PRAED ST,LONDON W2 1NY,ENGLAND.			Maconochie, Ian/0000-0001-6319-8550; Levin, Michael/0000-0003-2767-6919				BARRY PW, 1994, ARCH DIS CHILD, V71, P8, DOI 10.1136/adc.71.1.8; BLACK RE, 1982, NEW ENGL J MED, V307, P1465, DOI 10.1056/NEJM198212023072342; EDGE WE, 1994, CRIT CARE MED, V22, P1186, DOI 10.1097/00003246-199407000-00023; FULLER J, 1991, CAN J ANAESTH, V38, P252, DOI 10.1007/BF03008156; HENNING R, 1992, MED J AUSTRALIA, V156, P117; KANTER RK, 1989, PEDIATRICS, V84, P43; KANTER RK, 1993, CRIT CARE MED, V21, pS265; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; MACNAB AJ, 1991, J TRAUMA, V31, P205, DOI 10.1097/00005373-199131020-00009; MCCLOSKEY K A, 1991, Emergency Medicine Clinics of North America, V9, P475; MCDONALD TB, 1993, PEDIATR CLIN N AM, V40, P381; ORR RA, 1994, CRIT CARE MED, V22, P101, DOI 10.1097/00003246-199401000-00020; ORR RA, 1992, TXB PEDIATRIC INTENS, P1571; POLLACK MM, 1991, CRIT CARE MED, V19, P150, DOI 10.1097/00003246-199102000-00007; POLLACK MM, 1988, CRIT CARE MED, V16, P1110, DOI 10.1097/00003246-198811000-00006; ROBB HM, 1992, BRIT J INTENSIVE CAR, V2, P371; WETZEL RC, 1992, TXB PEDIATRIC INTENS, P563; WHITFIELD JM, 1993, PEDIATR EMERG CARE, V9, P69, DOI 10.1097/00006565-199304000-00002; 1995, CRD1 NHS CTR REV DIS; 1993, CARE CRITICALLY ILL	20	96	98	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					836	839		10.1136/bmj.311.7009.836	http://dx.doi.org/10.1136/bmj.311.7009.836			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580489	Green Published			2023-01-03	WOS:A1995RY19100019
J	MARCINKEVICIENE, JA; MAGLIOZZO, RS; BLANCHARD, JS				MARCINKEVICIENE, JA; MAGLIOZZO, RS; BLANCHARD, JS			PURIFICATION AND CHARACTERIZATION OF THE MYCOBACTERIUM-SMEGMATIS CATALASE-PEROXIDASE INVOLVED IN ISONIAZID ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; HORSERADISH-PEROXIDASE; TUBERCULOSIS; GENE; KATG; HEME; RESONANCE; ENZYME; SPECTROSCOPY	The unique antitubercular activity of isoniazid requires that the drug be oxidized by the katG-encoded mycobacterial catalase-peroxidase to an activated drug form. In order to quantitatively assess the catalytic capabilities of the enzyme, the native catalase-peroxidase from Mycobacterium smegmatis was purified over 200-fold to homogeneity. The enzyme was shown to exhibit both catalase and peroxidase activities, and in the presence of either hydrogen peroxide or t-butyl peroxide, was found 60 catalyze the oxidation of the reduced pyridine nucleotides, NADH and NADPH, as well as artificial peroxidase substrates, at rates between 2.7 and 20 s(-1). The homogeneous enzyme exhibited a visible absorbance spectrum typical of ferric heme-containing catalase-peroxidases, with a Soret maximum at 406 nm. Low temperature (10 K) electron paramagnetic resonance spectra in the presence of ethylene glycol revealed a high spin Fe(III) signal with g values of 5.9 and 5.6. The enzyme was very slowly (t(1/2) = similar to 20 min) reduced by dithionite, and the reduced form showed typical spectral changes when either KCN or CO were subsequently added, The M. smegmatis catalase-peroxidase was found to contain 2 heme molecules per tetramer, which were identified as iron protoporphyrin IX by the pyridine hemochromogen assay. The peroxidatic activity was inhibited by KCN, NaN3, isoniazid (isonicotinic acid hydrazide), and its isomer, nicotinic acid hydrazide, but not by 3-amino-1,2,4-triazole. The role of mycobacterial catalase-peroxidases in the oxidative activation of the antitubercular prodrug isoniazid is discussed.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA; YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT MOLEC PHARMACOL, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine					NCRR NIH HHS [RR02583] Funding Source: Medline; NIGMS NIH HHS [GM40168, GM33449] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002583] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM040168, R01GM033449, R01GM040168] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON LA, 1985, J BIOL CHEM, V260, P6080; BANERJEE A, 1994, SCIENCE, V263, P227, DOI 10.1126/science.8284673; BARTHOLOMEW WR, 1968, AM REV RESPIR DIS, V97, P710; BLUMBERG WE, 1968, J BIOL CHEM, V243, P1854; BROWNPETERSON NJ, 1993, J BACTERIOL, V175, P4197, DOI 10.1128/JB.175.13.4197-4202.1993; CLAIBORNE A, 1979, J BIOL CHEM, V254, P4245; Cleland W W, 1979, Methods Enzymol, V63, P103; COTTON ML, 1973, CAN J CHEM, V51, P582, DOI 10.1139/v73-088; DIAZ GA, 1974, AM REV RESPIR DIS, V110, P312, DOI 10.1164/arrd.1974.110.3.312; Falk J. E., 1964, PORPHYRINS METALLOPO, P804; GRUFT H, 1971, J CHROMATOGR, V56, P168, DOI 10.1016/S0021-9673(00)97797-5; HEYM B, 1995, MOL MICROBIOL, V15, P235, DOI 10.1111/j.1365-2958.1995.tb02238.x; HEYM B, 1993, J BACTERIOL, V175, P4255, DOI 10.1128/JB.175.13.4255-4259.1993; HOCHMAN A, 1991, BIOCHIM BIOPHYS ACTA, V1077, P299, DOI 10.1016/0167-4838(91)90544-A; JACKETT PS, 1978, J GEN MICROBIOL, V104, P37, DOI 10.1099/00221287-104-1-37; JOHNSSON K, 1995, J AM CHEM SOC, V117, P5009, DOI 10.1021/ja00122a038; JOHNSSON K, 1994, J AM CHEM SOC, V116, P7425, DOI 10.1021/ja00095a063; KALYANARAMAN B, 1985, J BIOL CHEM, V260, P4003; KIRKMAN HN, 1984, P NATL ACAD SCI-BIOL, V81, P4343, DOI 10.1073/pnas.81.14.4343; KIRKMAN HN, 1987, J BIOL CHEM, V262, P660; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; LEBEDEVA O V, 1977, Biokhimiya, V42, P1372; LEVY E, 1992, ARCH BIOCHEM BIOPHYS, V296, P321, DOI 10.1016/0003-9861(92)90579-L; LOEWEN PC, 1990, MOL GEN GENET, V224, P147, DOI 10.1007/BF00259461; LOEWEN PC, 1985, ARCH BIOCHEM BIOPHYS, V243, P144, DOI 10.1016/0003-9861(85)90782-9; LOPRASERT S, 1989, J BACTERIOL, V171, P4871, DOI 10.1128/jb.171.9.4871-4875.1989; MARGOLIASH E, 1960, BIOCHEM J, V74, P339, DOI 10.1042/bj0740339; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V70, P852; MORISHIMA I, 1977, BIOCHEMISTRY-US, V16, P5109, DOI 10.1021/bi00642a025; MORRIS SL, 1992, J GEN MICROBIOL, V138, P2363, DOI 10.1099/00221287-138-11-2363; MORSE PD, 1987, BIOPHYS J, V51, pA440; PEISACH J, 1971, J BIOL CHEM, V246, P3342; QUEMARD A, 1995, BIOCHEMISTRY-US, V34, P8235, DOI 10.1021/bi00026a004; SCHEJTER A, 1976, ARCH BIOCHEM BIOPHYS, V174, P36, DOI 10.1016/0003-9861(76)90321-0; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P399, DOI 10.1128/AAC.27.3.399; SHOEB HA, 1985, ANTIMICROB AGENTS CH, V27, P404, DOI 10.1128/AAC.27.3.404; SIEVERS G, 1983, BIOCHIM BIOPHYS ACTA, V742, P659, DOI 10.1016/0167-4838(83)90285-6; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TRIGGSRAINE BL, 1988, J BACTERIOL, V170, P4415, DOI 10.1128/jb.170.9.4415-4419.1988; WALLACE RJ, 1988, J INFECT DIS, V158, P52, DOI 10.1093/infdis/158.1.52; WELINDER KG, 1991, BIOCHIM BIOPHYS ACTA, V1080, P215; WILSON TM, 1995, MOL MICROBIOL, V15, P1009, DOI 10.1111/j.1365-2958.1995.tb02276.x; WITTENBERG BA, 1968, J BIOL CHEM, V243, P1863; YONETANI T, 1987, J BIOL CHEM, V262, P9547; YOUN HD, 1995, J BIOL CHEM, V270, P13740, DOI 10.1074/jbc.270.23.13740; YOUNG DB, 1994, CURR BIOL, V4, P351, DOI 10.1016/S0960-9822(00)00077-4; YUMOTO I, 1990, J BIOCHEM, V108, P583, DOI 10.1093/oxfordjournals.jbchem.a123246; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x	49	107	110	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 22	1995	270	38					22290	22295		10.1074/jbc.270.38.22290	http://dx.doi.org/10.1074/jbc.270.38.22290			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RW314	7673210	hybrid			2023-01-03	WOS:A1995RW31400037
J	BLACKHALL, LJ; MURPHY, ST; FRANK, G; MICHEL, V; AZEN, S				BLACKHALL, LJ; MURPHY, ST; FRANK, G; MICHEL, V; AZEN, S			ETHNICITY AND ATTITUDES TOWARD PATIENT AUTONOMY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER-PATIENT; TRUTH; CARE; PHYSICIANS; DISCLOSURE; DIAGNOSIS; PROXY	Objective.-To study differences in the attitudes of elderly subjects from different ethnic groups toward disclosure of the diagnosis and prognosis of a terminal illness and toward end-of-life decision making. Design.-Survey. Setting.-Thirty-one senior citizen centers within Los Angeles County, California. Respondents.-A stratified quota sample of 200 subjects aged 65 years and older self-identified as being from each of four ethnic groups: European American, African American, Korean American, or Mexican American (N=800). Main Outcome Measures and Results.-Korean Americans (47%) and Mexican Americans (65%) were significantly less likely than European Americans (87%) and African Americans (88%) to believe that a patient should be told the diagnosis of metastatic cancer. Korean Americans (35%) and Mexican Americans (48%) were less likely than African Americans (63%) and European Americans (69%) to believe that a patient should be told of a terminal prognosis and less likely to believe that the patient should make decisions about the use of life-supporting technology (28% and 41% vs 60% and 65%). Instead, Korean Americans and Mexican Americans tended to believe that the family should make decisions about the use of life support. On stepwise multiple logistic regression, ethnicity was the primary factor related to attitudes toward truth telling and patient decision making. Conclusions.-Korean-American and Mexican-American subjects were more likely to hold a family-centered model of medical decision making rather than the patient autonomy model favored by most of the African-American and European-American subjects. This finding suggests that physicians should ask their patients if they wish to receive information and make decisions or if they prefer that their families handle such matters.	UNIV SO CALIF,ANNENBERG SCH COMMUN,PACIFIC CTR HLTH POLICY & ETH,DEPT MED,LOS ANGELES,CA 90089; UNIV SO CALIF,DEPT OCCUPAT THERAPY,LOS ANGELES,CA; UNIV SO CALIF,DEPT PREVENT MED,LOS ANGELES,CA 90089	University of Southern California; University of Southern California; University of Southern California				FRANK, GELYA/0000-0002-7601-4236	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS007001] Funding Source: NIH RePORTER; AHRQ HHS [1 R01 HS07001 01A1] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ANNAS GJ, 1991, NEW ENGL J MED, V324, P1210, DOI 10.1056/NEJM199104253241711; [Anonymous], 1991, ANN INTERN MED, V115, P478; BEAUCHAMP TL, 1986, HIST THEORY INFORMED, P88; BEYENE Y, 1992, WESTERN J MED, V157, P328; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; DALLAVORGIA P, 1992, J MED ETHICS, V18, P67, DOI 10.1136/jme.18.2.67; Emanuel E J, 1990, J Clin Ethics, V1, P9; EMANUEL LL, 1989, AM J MED, V86, P87, DOI 10.1016/0002-9343(89)90234-9; ESTAPE J, 1992, ANN ONCOL, V3, P451, DOI 10.1093/oxfordjournals.annonc.a058233; FREEDMAN B, 1993, ARCH INTERN MED, V153, P572, DOI 10.1001/archinte.153.5.572; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; HOLLAND JC, 1987, CANCER INVEST, V5, P151, DOI 10.3109/07357908709018468; JAMES SA, 1984, AM J PUBLIC HEALTH, V74, P468, DOI 10.2105/AJPH.74.5.468; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; Levine R J, 1991, Law Med Health Care, V19, P207; MARIN G, 1987, HISPANIC J BEHAV SCI, V9, P183, DOI 10.1177/07399863870092005; MULLER JH, 1992, WESTERN J MED, V157, P323; NELSON JL, 1992, HASTINGS CENT REP, V22, P6; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; Oken Donald, 1961, JAMA-J AM MED ASSOC, V175, P86; ORONA CJ, 1994, CAMB Q HEALTHC ETHIC, V3, P338, DOI 10.1017/S0963180100005156; PEREZSTABLE EJ, 1992, JAMA-J AM MED ASSOC, V268, P3219, DOI 10.1001/jama.268.22.3219; SCHNEIDERMAN LJ, 1990, ANN INTERN MED, V112, P949, DOI 10.7326/0003-4819-112-12-949; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V277, P59; STEINBROOK R, 1984, NEW ENGL J MED, V310, P1598, DOI 10.1056/NEJM198406143102411; SURBONE A, 1992, JAMA-J AM MED ASSOC, V268, P1661; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; 1982, ETHICAL LEGAL IMPLIC, V1, P74; 1991, JAMA-J AM MED ASSOC, V265, P1868	30	681	689	0	53	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 13	1995	274	10					820	825		10.1001/jama.274.10.820	http://dx.doi.org/10.1001/jama.274.10.820			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RU324	7650806				2023-01-03	WOS:A1995RU32400030
J	[Anonymous]				[Anonymous]			CARE IN THE COMMUNITY	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 31	1995	376	6543					714	714						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RR836	7651524				2023-01-03	WOS:A1995RR83600002
J	STANFORD, JL; WEISS, NS; VOIGT, LF; DALING, JR; HABEL, LA; ROSSING, MA				STANFORD, JL; WEISS, NS; VOIGT, LF; DALING, JR; HABEL, LA; ROSSING, MA			COMBINED ESTROGEN AND PROGESTIN HORMONE REPLACEMENT THERAPY IN RELATION TO RISK OF BREAST-CANCER IN MIDDLE-AGED WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLIFERATION; SURVEILLANCE; PREVENTION; MODELS	Objective.-To determine the risk of breast cancer in relation to the use of combined estrogen and progestin hormone replacement therapy (HRT). Design.-A population-based case-control study. Setting.-The general female population of King County in western Washington State. Participants.-Middle-aged (50 to 64 years) women, including 537 patients with incident primary breast cancer diagnosed between January 1, 1988, and June 30, 1990, who were ascertained through the Seattle-Puget Sound Surveillance, Epidemiology, and End Results cancer registry and 492 randomly selected control women without a history of breast cancer. Main Outcome Measure,-Breast cancer risk in relation to use of menopausal hormones. Results.-Menopausal hormones of some type had been used by 57.6% of breast cancer cases and 61.0% of comparison women. The women who had ever taken combined estrogen-progestin HRT, representing 21.5% of cases and 21.3% of controls, were not at increased risk of breast cancer (relative odds [RO]=0.9; 95% confidence interval [CI], 0.7 to 1.3). Compared with nonusers of menopausal hormones, those who used estrogen-progestin HRT for 8 or more years had, if anything, a reduced risk of breast cancer (RO=0.4; 95% CI, 0.2 to 1.0). Conclusions.-On the whole, the use of estrogen with progestin HRT does not appear to be associated with an increased risk of breast cancer in middle-aged women. Nonetheless, since the use of combined estrogen-progestin HRT has only recently become prevalent, future investigations must assess whether breast cancer incidence is altered many years after estrogen-progestin HRT has been initiated, particularly among long-term users.	UNIV WASHINGTON,SCH PUBL HLTH & COMMUNITY MED,DEPT EPIDEMIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	STANFORD, JL (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV PUBL HLTH SCI,1124 COLUMBIA ST,MP-474,SEATTLE,WA 98104, USA.			Habel, Laurel/0000-0002-7230-587X	NCI NIH HHS [N01-CN-05230, R35-CA39779, K07-CA01364] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [K07CA001364, R35CA039779] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON TJ, 1989, HUM PATHOL, V20, P1139, DOI 10.1016/S0046-8177(89)80003-6; BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BERGKVIST L, 1990, NEW ENGL J MED, V322, P204; BERGKVIST L, 1989, NEW ENGL J MED, V321, P293, DOI 10.1056/NEJM198908033210505; Breslow NE, 1980, ANAL CASE CONTROL ST; Breslow NE Day NE, 1987, DESIGN ANAL COHORT S; BRINTON LA, 1993, EPIDEMIOL REV, V15, P66, DOI 10.1093/oxfordjournals.epirev.a036117; BRUZZI P, 1985, AM J EPIDEMIOL, V122, P904, DOI 10.1093/oxfordjournals.aje.a114174; CAULEY JA, 1990, AM J OBSTET GYNECOL, V163, P1438, DOI 10.1016/0002-9378(90)90602-4; CLARKE CL, 1990, ENDOCR REV, V11, P266, DOI 10.1210/edrv-11-2-266; COLDITZ GA, 1992, CANCER CAUSE CONTROL, V3, P433, DOI 10.1007/BF00051356; COX DR, 1972, J R STAT SOC B, V34, P187; CUTLER WB, 1990, NEW ENGL J MED, V322, P202; EWERTZ M, 1988, INT J CANCER, V42, P832, DOI 10.1002/ijc.2910420606; GAMBRELL RD, 1986, MATURITAS, V8, P169, DOI 10.1016/0378-5122(86)90023-X; GENALO MA, 1988, P SECTION SURVEY RES; GINSBURG KA, 1988, FERTIL STERIL, V49, pS16; GOING JJ, 1988, AM J PATHOL, V130, P193; HARLOW BL, 1988, AM J EPIDEMIOL, V127, P857, DOI 10.1093/oxfordjournals.aje.a114869; HARRIS RB, 1990, AM J PUBLIC HEALTH, V80, P1266, DOI 10.2105/AJPH.80.10.1266; HEMMINKI E, 1988, American Journal of Public Health, V78, P1479, DOI 10.2105/AJPH.78.11.1479; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JORDAN VC, 1993, CANCER, V71, P1501, DOI 10.1002/cncr.2820710415; KAUFMAN DW, 1991, AM J EPIDEMIOL, V134, P1375, DOI 10.1093/oxfordjournals.aje.a116041; NACHTIGALL LE, 1979, OBSTET GYNECOL, V54, P74, DOI 10.1097/00006250-197907000-00017; PALMER JR, 1991, AM J EPIDEMIOL, V134, P1386, DOI 10.1093/oxfordjournals.aje.a116042; POTTEN CS, 1988, BRIT J CANCER, V58, P163, DOI 10.1038/bjc.1988.185; PRENTICE RL, 1978, BIOMETRIKA, V65, P153, DOI 10.2307/2335290; RISCH HA, 1994, AM J EPIDEMIOL, V139, P670, DOI 10.1093/oxfordjournals.aje.a117057; SCHAIRER C, 1994, CANCER CAUSE CONTROL, V5, P491, DOI 10.1007/BF01831376; SEBOLD J, 1988, TELEPHONE SURVEY MET; STANFORD JL, 1993, EPIDEMIOL REV, V15, P98, DOI 10.1093/oxfordjournals.epirev.a036120; VOIGT LF, 1992, AM J EPIDEMIOL, V136, P1393, DOI 10.1093/oxfordjournals.aje.a116452; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; YANG CP, 1992, CANCER CAUSE CONTROL, V3, P475, DOI 10.1007/BF00051360	35	310	314	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 12	1995	274	2					137	142		10.1001/jama.274.2.137	http://dx.doi.org/10.1001/jama.274.2.137			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH222	7596001				2023-01-03	WOS:A1995RH22200026
J	SINGH, N; GAYOWSKI, T; YU, VL; WAGENER, MM				SINGH, N; GAYOWSKI, T; YU, VL; WAGENER, MM			TRIMETHOPRIM-SULFAMETHOXAZOLE FOR THE PREVENTION OF SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOSIS - A RANDOMIZED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Note							PROPHYLAXIS; INFECTION; ANTIBIOTICS; NORFLOXACIN; CIRRHOTICS	Objective: To assess the efficacy and safety of trimethoprim-sulfamethoxazole for the prevention of spontaneous bacterial peritonitis in patients with cirrhosis and ascites. Design: A randomized controlled trial. Setting: University-affiliate Veterans Affairs medical center. Patients: 60 consecutive patients with cirrhosis and ascites. Interventions: Consecutive patients were randomly assigned to receive either no prophylaxis or trimethoprim-sulfamethoxazole, one double-strength tablet daily, five times a week (Monday through Friday). Patient entry was stratified by serum bilirubin (>51 mu mol/L [>3 mg/dL]), ascitic fluid protein (<1 g/dL), and serum creatinine (>177 mu mol/L [>2 mg/dL]) levels to ensure that high-risk patients would be similarly distributed in the two groups. The median duration of follow-up for the study patients was 90 days. Main Outcome Measures: Spontaneous bacterial peritonitis or spontaneous bacteremia as defined by objective criteria. Results: Spontaneous bacterial peritonitis or spontaneous bacteremia developed in 27% (8 of 30) of patients who did not receive prophylaxis compared with 3% (1 of 30) of patients receiving trimethoprim-sulfamethoxazole (P = 0.025). Overall, infections developed in 9 of 30 patients (30%) not receiving prophylaxis and in 1 of 30 patients (3%) receiving trimethoprim-sulfamethoxazole (P = 0.012). Death occurred in 6 of 30 patients (20%) who did not receive prophylaxis and in 2 of 30 patients (7%) who received trimethoprim-sulfamethoxazole (P = 0.15). Side effects-particularly, hematologic toxicity-could not be attributed to trimethoprim-sulfamethoxazole in any patient. Conclusions: Trimethoprim-sulfamethoxazole was efficacious, safe, and cost-effective for the prevention of spontaneous bacterial peritonitis in patients with cirrhosis.	VET AFFAIRS MED CTR, INFECT DIS SECT, PITTSBURGH, PA 15240 USA; UNIV PITTSBURGH, PITTSBURGH, PA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh								BOCHUD PY, 1994, CLIN INFECT DIS, V18, P25, DOI 10.1093/clinids/18.1.25; BONTEN MJM, 1993, NEW ENGL J MED, V328, P209, DOI 10.1056/NEJM199301213280311; BOW EJ, 1988, AM J MED, V84, P847, DOI 10.1016/0002-9343(88)90062-9; COMETTA A, 1994, NEW ENGL J MED, V330, P1240, DOI 10.1056/NEJM199404283301717; DUPEYRON C, 1994, ANTIMICROB AGENTS CH, V38, P340, DOI 10.1128/AAC.38.2.340; FUNGTOMC J, 1993, ANTIMICROB AGENTS CH, V37, P1289, DOI 10.1128/AAC.37.6.1289; GINES P, 1990, HEPATOLOGY, V12, P716, DOI 10.1002/hep.1840120416; HOEFS JC, 1982, HEPATOLOGY, V2, P399; LLOVET JM, 1993, AM J GASTROENTEROL, V88, P388; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RIMOLA A, 1985, HEPATOLOGY, V5, P463, DOI 10.1002/hep.1840050320; RIMOLA A, 1988, J HEPATOL, V7, P72; RUNYON BA, 1988, HEPATOLOGY, V8, P171, DOI 10.1002/hep.1840080131; RUNYON BA, 1991, GASTROENTEROLOGY, V100, P1737, DOI 10.1016/0016-5085(91)90677-D; RUNYON BA, 1986, GASTROENTEROLOGY, V91, P1343, DOI 10.1016/0016-5085(86)90185-X; Schubert M L, 1991, Gastroenterology, V101, P550; SINGH N, 1994, DIAGN MICR INFEC DIS, V19, P1, DOI 10.1016/0732-8893(94)90042-6; SORIANO G, 1991, GASTROENTEROLOGY, V100, P477, DOI 10.1016/0016-5085(91)90219-B; TOLKOFFRUBIN NE, 1982, REV INFECT DIS, V4, P614	20	148	153	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	APR 15	1995	122	8					595	598		10.7326/0003-4819-122-8-199504150-00007	http://dx.doi.org/10.7326/0003-4819-122-8-199504150-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR525	7887554				2023-01-03	WOS:A1995QR52500007
J	FINNEGAN, LP; ROSSOUW, J; HARLAN, WR				FINNEGAN, LP; ROSSOUW, J; HARLAN, WR			A PEPPY RESPONSE TO PEPI RESULTS	NATURE MEDICINE			English	Editorial Material							ENDOMETRIAL CARCINOMA				FINNEGAN, LP (corresponding author), NIH,OFF DIS PREVENT,OFF RES WOMENS HLTH,BETHESDA,MD 20892, USA.							GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; SIMON JA, 1993, FERTIL STERIL, V60, P26; SMITH DC, 1975, NEW ENGL J MED, V293, P1164, DOI 10.1056/NEJM197512042932302; WENTZ WB, 1974, GYNECOL ONCOL, V2, P262; WOODRUFF JD, 1994, AM J OBSTET GYNECOL, V170, P1213; ZIEL HK, 1975, NEW ENGL J MED, V293, P1167, DOI 10.1056/NEJM197512042932303; 1995, JAMA-J AM MED ASSOC, V273, P199; 1992, ANN INTERN MED, V117, P1038; 1992, ACOG TECHNICAL B, V166	9	1	1	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					205	206		10.1038/nm0395-205	http://dx.doi.org/10.1038/nm0395-205			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585031				2023-01-03	WOS:A1995QX55900021
J	BENDITT, DG; PETERSEN, M; LURIE, KG; GRUBB, BP; SUTTON, R				BENDITT, DG; PETERSEN, M; LURIE, KG; GRUBB, BP; SUTTON, R			CARDIAC PACING FOR PREVENTION OF RECURRENT VASOVAGAL SYNCOPE	ANNALS OF INTERNAL MEDICINE			English	Review							NEURALLY MEDIATED SYNCOPE; TILT-TABLE TEST; UNEXPLAINED SYNCOPE; UPRIGHT TILT; YOUNG-PATIENTS; HEAD; REPRODUCIBILITY; ISOPROTERENOL; BRADYCARDIA; HYPERSENSITIVITY	Purpose: To review the status of cardiac pacing for the treatment of patients with recurrent vasovagal syncope. Data Sources: A MEDLINE search for English- and French-language articles published between 1980 and 1994 about cardiac pacing for prevention or treatment of vasovagal syncope. The term cardiac pacing was used in conjunction with the terms vasovagal, neurally mediated, or neurocardiogenic syncope, but not with the term carotid sinus hypersensitivity. Study Selection: Case reports and series from peer-reviewed journals were selected if they documented the presence of vasovagal syncope and assessed pacing effectiveness using tilt-table testing, clinical followup, or both. Four case reports and four series met these criteria. Data Extraction: Findings were summarized individually. Statistical analysis of combined data was inappropriate given differences among studies in patient selection, testing, and follow-up. Results: Pacing may be useful in selected patients with predominantly cardioinhibitory vasovagal responses. Pacing alone may eliminate symptoms in 25% of these patients and may prevent abrupt cardiovascular collapse in others (such as those in whom syncope occurs with minimal or no premonitory sensation). However, interpretation of most available reports has been limited both by the uncertainty associated with using the tilt-table technique to assess pacing effectiveness and by relatively short-term follow-up. Conclusions: The usefulness of cardiac pacing for patients with recurrent vasovagal syncope remains only partly understood. Randomized controlled trials are needed for this and other aspects of the treatment of this condition. Additionally, substantial room remains for innovation both in earlier recognition of imminent vasovagal syncope by implantable devices and in specifically designing cardiac pacing algorithms for treatment of this condition.	CHELSEA & WESTMINSTER HOSP, LONDON, ENGLAND; ROYAL BROMPTON & NATL HEART HOSP, LONDON SW3, ENGLAND; MED COLL OHIO, TOLEDO, OH 43699 USA	Imperial College London	BENDITT, DG (corresponding author), UNIV MINNESOTA, BOX 341 UMHC, MINNEAPOLIS, MN 55455 USA.							ALMQUIST A, 1985, CIRCULATION, V71, P927, DOI 10.1161/01.CIR.71.5.927; ALMQUIST A, 1989, NEW ENGL J MED, V320, P346, DOI 10.1056/NEJM198902093200603; BENDITT DG, 1991, PACE, V14, P1528, DOI 10.1111/j.1540-8159.1991.tb04074.x; BENDITT DG, 1993, CARDIOL REV, V1, P146; BLANC JJ, 1990, PRESSE MED, V19, P857; BRIGNOLE M, 1992, AM J CARDIOL, V70, P339, DOI 10.1016/0002-9149(92)90615-6; BROOKS R, 1993, AM J CARDIOL, V71, P1289, DOI 10.1016/0002-9149(93)90542-K; CALKINS H, 1993, AM J MED, V95, P473, DOI 10.1016/0002-9343(93)90329-N; CHEN MY, 1989, AM J CARDIOL, V63, P66, DOI 10.1016/0002-9149(89)91077-1; CHOSY JJ, 1965, J PSYCHOSOM RES, V9, P189, DOI 10.1016/0022-3999(65)90032-2; DAY SC, 1982, AM J MED, V73, P15, DOI 10.1016/0002-9343(82)90913-5; DEBUITLEIR M, 1993, AM J CARDIOL, V71, P304, DOI 10.1016/0002-9149(93)90795-E; DEMEY C, 1988, METHOD FIND EXP CLIN, V10, P57; DEMEY C, 1986, METHOD FIND EXP CLIN, V8, P449; DERMKSIAN G, 1958, JAMA-J AM MED ASSOC, V168, P1200, DOI 10.1001/jama.1958.03000090030007; FISH FA, 1992, AM J CARDIOL, V70, P605, DOI 10.1016/0002-9149(92)90199-9; Fitzpartick A., 1992, EUROPEAN J CARDIAC P, V2, P121; FITZPATRICK A, 1991, PACE, V14, P13, DOI 10.1111/j.1540-8159.1991.tb04042.x; FITZPATRICK A, 1991, EUR HEART J, V12, P389, DOI 10.1093/oxfordjournals.eurheartj.a059906; FITZPATRICK AP, 1991, J AM COLL CARDIOL, V17, P125, DOI 10.1016/0735-1097(91)90714-K; FITZPATRICK AP, 1990, PACE, V13, P619, DOI 10.1111/j.1540-8159.1990.tb02078.x; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; GRUBB BP, 1992, PACE, V15, P1477, DOI 10.1111/j.1540-8159.1992.tb02921.x; KAPOOR WN, 1990, MEDICINE, V69, P160, DOI 10.1097/00005792-199005000-00004; KAPOOR WN, 1992, ANN INTERN MED, V116, P358, DOI 10.7326/0003-4819-116-5-358; KOSINSKI D, 1994, J SEROTONIN RES, V1, P85; KUS T, 1989, CAN J CARDIOL, V5, P375; MACWILLIAM JA, 1987, J INT M C, V3, P253; MILSTEIN S, 1990, AM J CARDIOL, V65, P1339, DOI 10.1016/0002-9149(90)91324-Y; NEWMAN D, 1993, PACE, V16, P715, DOI 10.1111/j.1540-8159.1993.tb01650.x; PERRY JC, 1991, PACE, V14, P391, DOI 10.1111/j.1540-8159.1991.tb04084.x; PETERSEN M, 1994, BRIT HEART J, V71, P274; PONGIGLIONE G, 1990, J AM COLL CARDIOL, V16, P165, DOI 10.1016/0735-1097(90)90474-4; RAVIELE A, 1990, AM J CARDIOL, V65, P1322, DOI 10.1016/0002-9149(90)91321-V; ROSS RT, 1988, SYNCOPE; SAMOIL D, 1993, EUR J CARDIAC PACING, V1, P36; SAPIRE DW, 1983, AM HEART J, V106, P1406; SAVAGE DD, 1985, STROKE, V16, P626, DOI 10.1161/01.STR.16.4.626; SHELDON R, 1992, AM J CARDIOL, V69, P1300, DOI 10.1016/0002-9149(92)91225-S; SRA JS, 1992, J AM COLL CARDIOL, V19, P402, DOI 10.1016/0735-1097(92)90498-C; SRA JS, 1993, NEW ENGL J MED, V328, P1085, DOI 10.1056/NEJM199304153281504; Sutton R, 1992, EUR J CARDIAC PACING, V2, P180; VARDAS P, 1990, REV EUROPEENNE TECHN, V12, P910; VINGERHOETS AJJM, 1984, PSYCHOSOM MED, V46, P95; WAYNE HH, 1961, AM J MED, V30, P418, DOI 10.1016/0002-9343(61)90051-1; Weiss S, 1933, MEDICINE, V12, P297, DOI 10.1097/00005792-193309000-00003; XIAO CC, 1992, AM J CARDIOL, V69, P755	47	79	83	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1995	122	3					204	209		10.7326/0003-4819-122-3-199502010-00008	http://dx.doi.org/10.7326/0003-4819-122-3-199502010-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD733	7810939				2023-01-03	WOS:A1995QD73300008
J	MCWHINNEY, IR; BASS, MJ; DONNER, A				MCWHINNEY, IR; BASS, MJ; DONNER, A			EVALUATION OF A PALLIATIVE CARE SERVICE - PROBLEMS AND PITFALLS	BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CONTROLLED TRIAL; CANCER-PATIENTS; HOSPICE; INDEX	Objective-To evaluate a palliative care home support team based on an inpatient unit. Design-Randomised controlled trial with waiting list. Patients in the study group received the service immediately, those in the control group received it after one month. Main comparison point was at one month. Setting-A city of 300 000 people with a publicly funded home care service and about 200 general practitioners, most of whom provide home care. Main outcome measures-Pain and nausea levels were measured at entry to trial and at one month, as were quality of life for patients and care givers' health. Results-Because of early deaths, problems with recruitment, and a low compliance rate for completion of questionnaires, the required sample size was not attained. Conclusion-in designing evaluations of palliative care services, investigators should be prepared to deal with the following issues: attrition due to early death, opposition to randomisation by patients and referral sources, ethical problems raised by randomisation of dying patients, the appropriate timing of comparison points, and difficulties of collecting data from sick or exhausted patients and care givers. Investigators may choose to evaluate a service from various perspectives using different methods: controlled trials, qualitative studies, surveys, and audits. Randomised trials may prove to be impracticable for evaluation of palliative care.			MCWHINNEY, IR (corresponding author), UNIV WESTERN ONTARIO,CTR STUDIES FAMILY MED,THAMES VALLEY FAMILY PRACTICE RES UNIT,LONDON N6A 5C1,ON,CANADA.							ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; AIKEN LH, 1986, J CHRON DIS, V39, P1, DOI 10.1016/0021-9681(86)90101-3; BAUM M, 1993, LANCET, V341, P812, DOI 10.1016/0140-6736(93)90573-Y; BLOOM BS, 1980, J AM GERIATR SOC, V28, P451, DOI 10.1111/j.1532-5415.1980.tb01118.x; DUSH DM, 1984, HOSPICE J, V1, P55; EVANS C, 1985, LANCET, V1, P1204; Goldberg DP, 1972, DETECTION PSYCHIAT I; KANE RL, 1984, LANCET, V1, P890; MELZACK R, 1985, CAN MED ASSOC J, V133, P755; Melzack R, 1985, CAN MED ASSOC J, V133, P761; Melzack R., 1983, PAIN MEASUREMENT ASS; MOR V, 1987, HOSPICE CARE SYSTEMS; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; SILVERMAN WA, 1994, LANCET, V343, P1586, DOI 10.1016/S0140-6736(94)93053-8; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	16	178	179	0	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1340	1342		10.1136/bmj.309.6965.1340	http://dx.doi.org/10.1136/bmj.309.6965.1340			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7532501	Green Published			2023-01-03	WOS:A1994PT62500025
J	DIRNHOFER, S; KLIEBER, R; DELEEUW, R; BIDART, JM; MERZ, WE; WICK, G; BERGER, P				DIRNHOFER, S; KLIEBER, R; DELEEUW, R; BIDART, JM; MERZ, WE; WICK, G; BERGER, P			FUNCTIONAL AND IMMUNOLOGICAL RELEVANCE OF THE COOH-TERMINAL EXTENSION OF HUMAN CHORIONIC GONADOTROPIN-BETA - IMPLICATIONS FOR THE WHO BIRTH-CONTROL VACCINE	FASEB JOURNAL			English	Note						WHO; BIRTH CONTROL VACCINE; HCG; HCG-BETA-CTP	MONOCLONAL-ANTIBODIES; LUTEINIZING-HORMONE; HUMAN CHORIOGONADOTROPIN; ANTIFERTILITY VACCINES; GLYCOPROTEIN HORMONES; BIOLOGICAL-ACTIVITY; SUBUNIT; HCG	The World Health Organisation (WHO) Task Force on Birth Control Vaccines has selected the pregnancy hormone human chorionic gonadotropin (hCG) as a target molecule for a contraceptive vaccine. A synthetic peptide antigen corresponding to the amino acid sequence 109-145 of the carboxyl-terminal portion of the hCGbeta-subunit (hCGbetaCTP), which is supposed to elicit hCG-immunoneutralizing antibodies, has been submitted to clinical trails. Recent findings suggest that hCGbetaCTP does not play a role in the biological activity of hCG. This raises the question concerning the assumed mechanism of action of the hCGbetaCTP-based birth control vaccine. We therefore investigated the immunoneutralizing capacity of antibodies directed against hCGbetaCTP. Although it is possible to generate specific monoclonal and polyclonal antibodies for hCG by using hCGbetaCTP as an immunogen, it appeared that the biological response to hCG was not affected by such antibodies. The reason for this is that the hCG-antibody-complex is still able to bind to target cell receptors and therefore the intended contraceptive effect should not occur. In addition there is a risk of hazardous possible side effects such as an autoimmune reaction against the ovary because we found that at least one epitope is still accessible for antibody binding on receptor-bound hCG. We conclude from our results that both the efficacy and safety of the WHO vaccine are not yet ensured.	AUSTRIAN ACAD SCI, INST BIOMED AGING RES, RENNWEG 10, A-6020 INNSBRUCK, AUSTRIA; UNIV INNSBRUCK HOSP, DEPT OBSTET & GYNECOL, INNSBRUCK, AUSTRIA; ORGANON INT BV, DEPT ENDOCRINOL, OSS, NETHERLANDS; INST GUSTAVE ROUSSY, DEPT CLIN BIOL, F-94805 VILLEJUIF, FRANCE; UNIV HEIDELBERG, INST BIOCHEM 2, W-6900 HEIDELBERG, GERMANY; UNIV INNSBRUCK, INST GEN & EXPTL PATHOL, A-6020 INNSBRUCK, AUSTRIA	Austrian Academy of Sciences; Medical University of Innsbruck; UNICANCER; Gustave Roussy; Ruprecht Karls University Heidelberg; University of Innsbruck								BERGER P, 1987, NATURE, V326, P648, DOI 10.1038/326648a0; BERGER P, 1988, ENDOCRINOLOGY, V123, P2351, DOI 10.1210/endo-123-5-2351; BERGER P, 1990, J ENDOCRINOL, V125, P301, DOI 10.1677/joe.0.1250301; BERGER P, 1984, AM J REPROD IMMUNOL, V5, P157, DOI 10.1111/j.1600-0897.1984.tb00188.x; BERGER P, 1992, FOLLICLE STIMULATING, P319; BIDART JM, 1987, MOL IMMUNOL, V24, P339, DOI 10.1016/0161-5890(87)90175-1; BIRKEN S, 1982, ENDOCRINOLOGY, V110, P1555, DOI 10.1210/endo-110-5-1555; CAMPBELL RK, 1991, P NATL ACAD SCI USA, V88, P760, DOI 10.1073/pnas.88.3.760; CHEN F, 1991, J BIOL CHEM, V266, P6904; CHEN W, 1991, J BIOL CHEM, V266, P6264; GEYSEN HM, 1987, J IMMUNOL METHODS, V102, P259, DOI 10.1016/0022-1759(87)90085-8; GRIFFIN PD, 1991, STAT MED, V10, P177, DOI 10.1002/sim.4780100204; JONES WR, 1988, LANCET, V1, P1295; KOFLER R, 1982, AM J REPROD IMMUNOL, V2, P212, DOI 10.1111/j.1600-0897.1982.tb00168.x; KOFLER R, 1981, IMMUNOBIOLOGY, V160, P196, DOI 10.1016/S0171-2985(81)80047-2; MANNAERTS BMJ, 1987, NEUROENDOCRINOLOGY R, P49; MATZUK MM, 1990, ENDOCRINOLOGY, V126, P376, DOI 10.1210/endo-126-1-376; ROSE NR, 1991, VACCINES FERTILITY R, P121; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SCHWARZ S, 1986, ENDOCRINOLOGY, V118, P189, DOI 10.1210/endo-118-1-189; SCHWARZ S, 1988, J RECEPTOR RES, V8, P437, DOI 10.3109/10799898809049003; STAHLI C, 1980, J IMMUNOL METHODS, V32, P297, DOI 10.1016/0022-1759(80)90194-5; STEVENS VC, 1986, IMMUNOL TODAY, V7, P369, DOI 10.1016/0167-5699(86)90029-0; TALMADGE K, 1984, NATURE, V307, P37, DOI 10.1038/307037a0; YAMAMOTO Y, 1984, AM J REPROD IMMUNOL, V5, P164, DOI 10.1111/j.1600-0897.1984.tb00190.x	25	39	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	1993	7	14					1381	1385		10.1096/fasebj.7.14.7693535	http://dx.doi.org/10.1096/fasebj.7.14.7693535			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	MH008	7693535				2023-01-03	WOS:A1993MH00800011
J	ROSENBERG, SA; PACKARD, BS; AEBERSOLD, PM; SOLOMON, D; TOPALIAN, SL; TOY, ST; SIMON, P; LOTZE, MT; YANG, JC; SEIPP, CA; SIMPSON, C; CARTER, C; BOCK, S; SCHWARTZENTRUBER, D; WEI, JP; WHITE, DE				ROSENBERG, SA; PACKARD, BS; AEBERSOLD, PM; SOLOMON, D; TOPALIAN, SL; TOY, ST; SIMON, P; LOTZE, MT; YANG, JC; SEIPP, CA; SIMPSON, C; CARTER, C; BOCK, S; SCHWARTZENTRUBER, D; WEI, JP; WHITE, DE			USE OF TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 IN THE IMMUNOTHERAPY OF PATIENTS WITH METASTATIC MELANOMA - A PRELIMINARY-REPORT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									NCI,PATHOL LAB,BETHESDA,MD 20892; NIH,CTR CLIN,DEPT TRANSFUS MED,BETHESDA,MD 20205; DUPONT CO,GLENOLDEN LABS,WILMINGTON,DE 19898	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); DuPont	ROSENBERG, SA (corresponding author), NCI,SURG BRANCH,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.		wei, jiang/GRX-7907-2022					BELLDEGRUN A, 1988, CANCER RES, V48, P206; BERENDT MJ, 1980, J EXP MED, V151, P69, DOI 10.1084/jem.151.1.69; EBERLEIN TJ, 1982, J EXP MED, V156, P385; FISHER B, IN PRESS J CLIN ONCO; GRIMM EA, 1983, J EXP MED, V157, P884, DOI 10.1084/jem.157.3.884; ITOH K, 1986, CANCER RES, V46, P3011; KRADIN RL, 1987, CANCER IMMUNOL IMMUN, V24, P76; KURNICK JT, 1986, CLIN IMMUNOL IMMUNOP, V38, P367, DOI 10.1016/0090-1229(86)90247-3; LAFRENIERE R, 1985, CANCER RES, V45, P3735; LOTZE MT, 1986, JAMA-J AM MED ASSOC, V256, P3117, DOI 10.1001/jama.256.22.3117; MIESCHER S, 1987, J IMMUNOL, V138, P4004; MULE JJ, 1984, SCIENCE, V225, P1487, DOI 10.1126/science.6332379; MUUL LM, 1987, J IMMUNOL, V138, P989; RABINOWICH H, 1987, CANCER RES, V47, P173; ROSENBERG S, 1985, J NATL CANCER I, V75, P595; ROSENBERG SA, 1987, NEW ENGL J MED, V316, P889, DOI 10.1056/NEJM198704093161501; ROSENBERG SA, 1984, SCIENCE, V223, P1412, DOI 10.1126/science.6367046; ROSENBERG SA, 1985, NEW ENGL J MED, V313, P1485, DOI 10.1056/NEJM198512053132327; ROSENBERG SA, 1985, J EXP MED, V161, P1169, DOI 10.1084/jem.161.5.1169; ROSENBERG SA, 1986, SCIENCE, V233, P1318, DOI 10.1126/science.3489291; ROSENSTEIN M, 1984, CANCER RES, V44, P1946; ROSENSTEIN M, 1986, J IMMUNOL, V137, P1735; SHU S, 1985, J IMMUNOL, V135, P2895; SPIESS PJ, 1987, JNCI-J NATL CANCER I, V79, P1067; TOPALIAN SL, 1988, J CLIN ONCOL, V6, P839, DOI 10.1200/JCO.1988.6.5.839; TOPALIAN SL, 1987, J IMMUNOL METHODS, V102, P127, DOI 10.1016/S0022-1759(87)80018-2; YRON I, 1980, J IMMUNOL, V125, P238	27	1924	2095	4	106	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	1988	319	25					1676	1680		10.1056/NEJM198812223192527	http://dx.doi.org/10.1056/NEJM198812223192527			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R4575	3264384				2023-01-03	WOS:A1988R457500024
J	HUMMEL, RS; ORNATO, JP; WEINBERG, SM; CLARKE, AM				HUMMEL, RS; ORNATO, JP; WEINBERG, SM; CLARKE, AM			SPARK-GENERATING PROPERTIES OF ELECTRODE GELS USED DURING DEFIBRILLATION - A POTENTIAL FIRE HAZARD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV CARDIOL,BOX 525,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV BIOMED ENGN,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANESTHESIOL,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University; Virginia Commonwealth University								BABKA JC, 1983, NEW ENGL J MED, V309, P379; CONNELL PN, 1973, J ELECTROCARDIOL, V6, P313, DOI 10.1016/S0022-0736(73)80053-6; Dahl C F, 1976, Med Instrum, V10, P151; EWY GA, 1977, HEART LUNG, V6, P127; EWY GA, 1972, J APPL PHYSIOL, V32, P91, DOI 10.1152/jappl.1972.32.1.91; EWY GA, 1980, CRIT CARE MED, V8, P164, DOI 10.1097/00003246-198003000-00015; EWY GA, 1977, HEART LUNG, V6, P847; EWY GA, 1978, MED INSTRUM, V1, P47; GASCHO JA, 1979, CIRCULATION, V60, P231, DOI 10.1161/01.CIR.60.2.231; Geddes L A, 1975, Med Instrum, V9, P179; KERBER RE, 1981, CIRCULATION, V63, P676, DOI 10.1161/01.CIR.63.3.676; KERBER RE, 1980, MED INSTRUM, V14, P56; KERBER RE, 1983, AM J CARDIOL, V52, P739, DOI 10.1016/0002-9149(83)90408-3; KUHNEN R, 1985, DEUT MED WOCHENSCHR, V110, P37; PARKE JD, 1982, JAMA-J AM MED ASSOC, V248, P427, DOI 10.1001/jama.1982.03330040021016; PATEL AS, 1972, IEEE T BIO-MED ENG, VBM19, P228, DOI 10.1109/TBME.1972.324121; TACKER WA, 1983, HEART LUNG, V5, P510; THOMAS ED, 1977, AM HEART J, V93, P463, DOI 10.1016/S0002-8703(77)80409-2; 1971, HDB CHEM PHYSICS, pE43; 1988, BIOMED SAFETY STANDA, V18, P10; 1987, HLTH DEVICES, V16, P113; 1986, JAMA, V255, P2905; 1985, SAS USERS GUIDE STAT, P433	23	24	23	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1988	260	20					3021	3024		10.1001/jama.260.20.3021	http://dx.doi.org/10.1001/jama.260.20.3021			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q9245	3184368				2023-01-03	WOS:A1988Q924500029
J	KOSCOVE, EM; PARADIS, NA				KOSCOVE, EM; PARADIS, NA			SUCCESSFUL RESUSCITATION FROM CARDIAC-ARREST USING HIGH-DOSE EPINEPHRINE THERAPY - REPORT OF 2 CASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											KOSCOVE, EM (corresponding author), UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT EMERGENCY MED,1200 N STATE ST,LOS ANGELES,CA 90033, USA.							American Heart Association, 1986, JAMA-J AM MED ASSOC, V255, P2841; BENDIXEN HH, 1963, CIRC RES, V13, P64, DOI 10.1161/01.RES.13.1.64; BROWN CG, 1987, CIRCULATION, V75, P491, DOI 10.1161/01.CIR.75.2.491; BROWN CG, 1986, ANN EMERG MED, V15, P1138, DOI 10.1016/S0196-0644(86)80853-8; CHAMBERS W, 1977, CIRCULATION, V56, P183; Crile G.W., 1903, ST LOUIS MED SURG J, V84, P299; DOAN LA, 1984, ANN EMERG MED, V13, P784, DOI 10.1016/S0196-0644(84)80436-9; GREENBERG MI, 1984, ANN EMERG MED, V13, P789, DOI 10.1016/S0196-0644(84)80438-2; KOSNIK JW, 1985, ANN EMERG MED, V14, P204, DOI 10.1016/S0196-0644(85)80440-6; MANN DE, 1985, PACE, V8, P753, DOI 10.1111/j.1540-8159.1985.tb05888.x; MCCARTHY KC, 1958, JAMA-J AM MED ASSOC, V168, P2101, DOI 10.1001/jama.1958.03000160015005; MICHAEL JR, 1984, CIRCULATION, V69, P822, DOI 10.1161/01.CIR.69.4.822; OTTO CW, 1986, CIRCULATION, V74, P80; OTTO CW, 1985, AM J EMERG MED, V3, P285, DOI 10.1016/0735-6757(85)90048-8; OTTO CW, 1984, ANN EMERG MED, V13, P840, DOI 10.1016/S0196-0644(84)80455-2; PEARSON JW, 1963, ANESTH ANALG, V42, P599; RALSTON SH, 1985, ANN EMERG MED, V14, P1044, DOI 10.1016/S0196-0644(85)80916-1; REDDING JS, 1967, SOUTHERN MED J, V60, P926, DOI 10.1097/00007611-196709000-00004; REDDING JS, 1963, ANESTHESIOLOGY, V24, P203, DOI 10.1097/00000542-196303000-00008; REDDING JS, 1968, J AMER MED ASSOC, V203, P255; ROBERTS JR, 1979, JACEP-J AM COLL EMER, V8, P515, DOI 10.1016/S0361-1124(79)80298-1; TACKER WA, 1980, ELECTRICAL DEFIBRILL, P164; TODD GL, 1985, J MOL CELL CARDIOL, V17, P317, DOI 10.1016/S0022-2828(85)80132-2	23	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 27	1988	259	20					3031	3034		10.1001/jama.259.20.3031	http://dx.doi.org/10.1001/jama.259.20.3031			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N4536	3273478				2023-01-03	WOS:A1988N453600027
J	SCHNEIDERMAN, LJ; SPRAGG, RG				SCHNEIDERMAN, LJ; SPRAGG, RG			ETHICAL DECISIONS IN DISCONTINUING MECHANICAL VENTILATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											SCHNEIDERMAN, LJ (corresponding author), UNIV CALIF SAN DIEGO,LA JOLLA,CA 92093, USA.							BAYER EJ, 1986, NO EXTRAORDINARY MEA, P89; DANIELS N, 1986, NEW ENGL J MED, V314, P1380, DOI 10.1056/NEJM198605223142109; JONSEN AR, 1982, CLIN ETHICS; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; 1983, PRESIDENTS COMMISSIO, P83	5	63	63	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	1988	318	15					984	988		10.1056/NEJM198804143181509	http://dx.doi.org/10.1056/NEJM198804143181509			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	M8862	3352689				2023-01-03	WOS:A1988M886200009
J	KRISHNASWAMY, S; JONES, KC; MANN, KG				KRISHNASWAMY, S; JONES, KC; MANN, KG			PROTHROMBINASE COMPLEX ASSEMBLY - KINETIC MECHANISM OF ENZYME ASSEMBLY ON PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article											KRISHNASWAMY, S (corresponding author), UNIV VERMONT, HLTH SCI COMPLEX, DEPT BIOCHEM, BURLINGTON, VT 05405 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038337, R37HL034575, R01HL034575, P50HL035058] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-35058, HL-34575, HL-38337] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEATY NB, 1981, J BIOL CHEM, V256, P4611; BERG OG, 1985, BIOPHYS J, V47, P1, DOI 10.1016/S0006-3495(85)83870-4; Bevington P. R, 1969, DATA REDUCTION ERROR; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; DAVIE EW, 1975, ANNU REV BIOCHEM, V44, P729, DOI 10.1146/annurev.bi.44.070175.004055; DURBIN J, 1950, BIOMETRIKA, V37, P409, DOI 10.2307/2332391; ESMON CT, 1974, J BIOL CHEM, V249, P7782; FUJIKAWA K, 1972, BIOCHEMISTRY-US, V21, P2285; GUINTO ER, 1984, J BIOL CHEM, V259, P3986; HAMMES GG, 1978, PRINCIPLES CHEM KINE, P62; HELDEBRANT CM, 1973, J BIOL CHEM, V248, P7149; HIBBARD LS, 1980, J BIOL CHEM, V255, P638; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HIGGINS DL, 1985, J BIOL CHEM, V260, P3604; Jesty J, 1976, Methods Enzymol, V45, P95; KETTNER C, 1978, BIOCHEMISTRY-US, V17, P4778, DOI 10.1021/bi00615a027; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1987, THROMB HAEMOSTASIS, V58, P133; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1984, PROG HEMOST THROMB, V7, P1; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1981, BIOCHEMISTRY-US, V20, P28, DOI 10.1021/bi00504a005; MANN KG, 1986, BLOOD COAGULATION, P15; MORITA T, 1986, J BIOL CHEM, V261, P4015; NELSESTUEN GL, 1977, BIOCHEMISTRY-US, V16, P4164, DOI 10.1021/bi00638a005; NELSESTUEN GL, 1978, FED PROC, V37, P2621; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1981, J BIOL CHEM, V256, P6537; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; NESHEIM ME, 1981, J BIOL CHEM, V256, P9874; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; PAPAHADJOPOULOS D, 1964, BIOCHIM BIOPHYS ACTA, V90, P436, DOI 10.1016/0304-4165(64)90220-X; PUSEY ML, 1982, BIOCHEMISTRY-US, V21, P5262, DOI 10.1021/bi00264a022; PUSEY ML, 1984, BIOCHEMISTRY-US, V23, P6202, DOI 10.1021/bi00320a048; STENFLO J, 1977, ANNU REV BIOCHEM, V46, P157, DOI 10.1146/annurev.bi.46.070177.001105; SUTTIE JW, 1977, PHYSIOL REV, V57, P1, DOI 10.1152/physrev.1977.57.1.1; TRACY PB, 1983, P NATL ACAD SCI-BIOL, V80, P2380, DOI 10.1073/pnas.80.8.2380; TUCKER MM, 1983, J BIOL CHEM, V258, P1210; TUCKER MM, 1983, BIOCHEMISTRY-US, V22, P4540, DOI 10.1021/bi00288a029; VANDEWAART P, 1983, BIOCHEMISTRY-US, V22, P2427, DOI 10.1021/bi00279a019; WEI GJ, 1982, BIOCHEMISTRY-US, V21, P1949, DOI 10.1021/bi00537a039	44	154	161	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1988	263	8					3823	3834						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	M6037	3346225				2023-01-03	WOS:A1988M603700045
J	TINETTI, ME; GINTER, SF				TINETTI, ME; GINTER, SF			IDENTIFYING MOBILITY DYSFUNCTIONS IN ELDERLY PATIENTS - STANDARD NEUROMUSCULAR EXAMINATION OR DIRECT ASSESSMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											TINETTI, ME (corresponding author), YALE UNIV,SCH MED,DEPT MED,BOX 3333,333 CEDAR ST,NEW HAVEN,CT 06510, USA.							BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; BLAKE RL, 1981, J AM POD ASSOC, V71, P341, DOI 10.7547/87507315-71-6-341; BRANCH LG, 1984, AM J PUBLIC HEALTH, V74, P266, DOI 10.2105/AJPH.74.3.266; Finley F R, 1969, Arch Phys Med Rehabil, V50, P140; Guimaraes R M, 1980, Int Rehabil Med, V2, P177; HOPPENFELD S, 1976, PHYSICAL EXAMINATION; Imms F J, 1981, Age Ageing, V10, P147, DOI 10.1093/ageing/10.3.147; IMMS FJ, 1979, AGE AGEING, V8, P261, DOI 10.1093/ageing/8.4.261; JETTE AM, 1981, AM J PUBLIC HEALTH, V71, P1211, DOI 10.2105/AJPH.71.11.1211; KATZ S, 1970, GERONTOLOGIST, V10, P20, DOI 10.1093/geront/10.1_Part_1.20; KLAWANS HL, 1971, DIS NERV SYST, V32, P274; KOKEMON E, 1977, J GERONTOL, V32, P411; LINN MW, 1982, J AM GERIATR SOC, V30, P378, DOI 10.1111/j.1532-5415.1982.tb02835.x; MAHONEY F I, 1965, Md State Med J, V14, P61; MIKULIC MA, 1976, ARCH PHYS MED REHAB, V57, P143; NAGI SZ, 1976, MILBANK FUND Q, V54, P439, DOI 10.2307/3349677; NELSON AJ, 1974, PHYS THER, V54, P1059, DOI 10.1093/ptj/54.10.1059; OVERSTALL PW, 1977, BRIT MED J, V1, P261, DOI 10.1136/bmj.1.6056.261; ROBINSON JL, 1981, PHYS THER, V61, P351, DOI 10.1093/ptj/61.3.351; ROSOW I, 1966, J GERONTOL, V21, P556, DOI 10.1093/geronj/21.4.556; STANIC U, 1977, SCAND J REHABIL MED, V9, P95; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; TINETTI ME, 1986, J AM GERIATR SOC, V34, P119, DOI 10.1111/j.1532-5415.1986.tb05480.x; WOLFSON LI, 1986, J AM GERIATR SOC, V34, P845, DOI 10.1111/j.1532-5415.1986.tb07256.x; 1979, PHYSICIANS DESK REFE, P31; 1959, PUBLIC HLTH ASPECTS; 1979, CAN MED ASS J, V121, P1193	27	212	216	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	1988	259	8					1190	1193		10.1001/jama.259.8.1190	http://dx.doi.org/10.1001/jama.259.8.1190			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M1370	3339820				2023-01-03	WOS:A1988M137000017
J	BATES, DW; CULLEN, DJ; LAIRD, N; PETERSEN, LA; SMALL, SD; SERVI, D; LAFFEL, G; SWEITZER, BJ; SHEA, BF; HALLISEY, R; VANDERVLIET, M; NEMESKAL, R; LEAPE, LL				BATES, DW; CULLEN, DJ; LAIRD, N; PETERSEN, LA; SMALL, SD; SERVI, D; LAFFEL, G; SWEITZER, BJ; SHEA, BF; HALLISEY, R; VANDERVLIET, M; NEMESKAL, R; LEAPE, LL			INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOSPITALIZED-PATIENTS; HEALTH-CARE; MEDICATION	Objectives.-To assess incidence and preventability of adverse drug events (ADEs) and potential ADEs. To analyze preventable events to develop prevention strategies. Design.-Prospective cohort study. Participants.-All 4031 adult admissions to a stratified random sample of 11 medical and surgical units in two tertiary care hospitals over a 6-month period. Units included two medical and three surgical intensive care units and four medical and two surgical general care units. Main Outcome Measures.-Adverse drug events and potential ADEs. Methods.-Incidents were detected by stimulated self-report by nurses and pharmacists and by daily review of all charts by nurse investigators. Incidents were subsequently classified by two independent reviewers as to whether they represented ADEs or potential ADEs and as to severity and preventability. Results.-Over 6 months, 247 ADEs and 194 potential ADEs were identified. Extrapolated event rates were 6.5 ADEs and 5.5 potential ADEs per 100 nonobstetrical admissions, for mean numbers per hospital per year of approximately 1900 ADEs and 1600 potential ADEs. Of all ADEs, 1% were fatal (none preventable), 12% life-threatening, 30% serious, and 57% significant. Twenty-eight percent were judged preventable. Of the life-threatening and serious ADEs, 42% were preventable, compared with 18% of significant ADEs, Errors resulting in preventable ADEs occurred most often at the stages of ordering (56%) and administration (34%); transcription (6%) and dispensing errors (4%) were less common. Errors were much more likely to be intercepted if the error occurred earlier in the process: 48% at the ordering stage vs 0% at the administration stage, Conclusion.-Adverse drug events were common and often preventable; serious ADEs were more likely to be preventable. Most resulted from errors at the ordering stage, but many also occurred at the administration stage. Prevention strategies should target both stages of the drug delivery process.	BRIGHAM & WOMENS HOSP, DEPT PHARM, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT ANESTHESIA, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT PHARM, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA USA; HARVARD UNIV, SCH PUBL HLTH, DEPT BIOSTAT, BOSTON, MA 02115 USA; HARVARD UNIV, SCH PUBL HLTH, DEPT HLTH POLICY & MANAGEMENT, BOSTON, MA 02115 USA; APM INC, NEW YORK, NY USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	BATES, DW (corresponding author), BRIGHAM & WOMENS HOSP, DEPT MED, DIV GEN MED & PRIMARY CARE, 75 FRANCIS ST, BOSTON, MA 02115 USA.		Arán, Teodoro J Martínez/A-4568-2010	Arán, Teodoro J Martínez/0000-0002-5877-3941	AHRQ HHS [R01-HS07107-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bates D W, 1994, Qual Manag Health Care, V2, P18; BATES DW, 1993, J GEN INTERN MED, V8, P289, DOI 10.1007/BF02600138; BATES DW, 1994, J AM MED INFORM ASSN, V1, P404, DOI 10.1136/jamia.1994.95153428; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BERRY LL, 1988, AM J HOSP PHARM, V45, P1534, DOI 10.1093/ajhp/45.7.1534; BERWICK DM, 1989, NEW ENGL J MED, V320, P53, DOI 10.1056/NEJM198901053200110; BRENNAN TA, 1991, NEW ENGL J MED, V324, P370, DOI 10.1056/NEJM199102073240604; CLASSEN DC, 1991, JAMA-J AM MED ASSOC, V266, P2847, DOI 10.1001/jama.266.20.2847; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; EVANS RS, 1993, P ANN S COMPUT APPL, V17, P161; FAICH GA, 1986, NEW ENGL J MED, V314, P1589, DOI 10.1056/NEJM198606123142427; FAICH GA, 1991, ARCH INTERN MED, V151, P1645, DOI 10.1001/archinte.151.8.1645; FOLLI HL, 1987, PEDIATRICS, V79, P718; FORRESTER JW, 1971, MIT TECHNOL REV, V73, P2; FUCHSBERG A, 1978, TRIAL LAWYERS Q, V12, P9; GOSNEY M, 1984, LANCET, V2, P564; GRASELA TH, 1993, AM J HOSP PHARM, V50, P1889, DOI 10.1093/ajhp/50.9.1889; HODDINOTT BC, 1967, CAN MED ASSOC J, V97, P1001; HURWITZ N, 1969, BMJ-BRIT MED J, V1, P531, DOI 10.1136/bmj.1.5643.531; JICK H, 1984, J ALLERGY CLIN IMMUN, V74, P555, DOI 10.1016/0091-6749(84)90106-4; KARCH FE, 1975, JAMA-J AM MED ASSOC, V234, P1236, DOI 10.1001/jama.234.12.1236; KEITH MR, 1989, AM J HOSP PHARM, V46, P1809, DOI 10.1093/ajhp/46.9.1809; KESSLER DA, 1993, JAMA-J AM MED ASSOC, V269, P2765, DOI 10.1001/jama.269.21.2765; KOCH KE, 1990, AM J HOSP PHARM, V47, P1314, DOI 10.1093/ajhp/47.6.1314; LAFFEL G, 1989, JAMA-J AM MED ASSOC, V262, P2869; Leape L L, 1993, QRB Qual Rev Bull, V19, P144; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; LESAR TS, 1990, JAMA-J AM MED ASSOC, V263, P2329, DOI 10.1001/jama.263.17.2329; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; OGILVIE RI, 1967, CAN MED ASSOC J, V97, P1450; ONEIL AC, 1993, ANN INTERN MED, V119, P370, DOI 10.7326/0003-4819-119-5-199309010-00004; RIND DM, 1991, P ANN S COMPUT APPL, V15, P28; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; Wan T T, 1987, QRB Qual Rev Bull, V13, P61; 1985, INJURY AM; 1991, STATXACT USER MANUAL; 1988, SAS RELEASE 6 03; 1980, MED MALPRACTICE CLOS	41	2212	2300	3	125	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 5	1995	274	1					29	34		10.1001/jama.274.1.29	http://dx.doi.org/10.1001/jama.274.1.29			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RG233	7791255				2023-01-03	WOS:A1995RG23300027
J	ROCHON, PA; GURWITZ, JH				ROCHON, PA; GURWITZ, JH			DRUG-THERAPY	LANCET			English	Article							CLINICAL-TRIALS; ELDERLY PERSONS; NURSING-HOMES; HIP FRACTURE; RISK; AGE; OSTEOARTHRITIS; THROMBOLYSIS; KNEE; OLD	Drug therapy for individuals of any age is difficult but prescribing for older patients offers special challenges. Older people take about three times as many prescription medications as younger individuals do, mainly because of their increased prevalence of chronic medical conditions.(1) However, taking several drugs together substantially increases the risk of drug interactions, unwanted effects, and adverse reactions. Many medications need to be used with special caution because of age-related changes in pharmacokinetics and pharmacodynamics.(2) For some drugs, an increase in the volume of distribution (eg, diazepam) or a reduction in drug clearance (eg, digoxin) may lead to higher plasma concentrations in older than in younger patients.(2) Pharmacodynamic changes with ageing may result in an increased sensitivity to the effects of certain drugs (eg, opioids) for any given plasma concentration.(3) While a physician can usually do little to alter the characteristics of individual older patients to affect the kinetics or dynamics of drugs, the decision whether to prescribe anything at all, the choice of drug, and the manner in which it is to be used (eg, dose and duration of therapy) are all factors that are under control of the prescriber. Patient adherence to the regimen prescribed is important, and there should be a partnership between physician and patient in therapeutic decision making. We will discuss here mays of improving prescribing for older patients. Specifically, we will examine the scarcity of information to guide prescribing decisions, the general principles of prudent prescribing, and the opportunities to clarify and expand knowledge about drug therapy in the elderly.	UNIV TORONTO,MT SINAI HOSP,DEPT MED,DIV GERIATR MED,TORONTO,ON,CANADA; UNIV TORONTO,MT SINAI HOSP,DEPT PREVENT MED & BIOSTAT,TORONTO,ON,CANADA; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV GERONTOL,PROGRAM ANAL CLIN STRATEGIES,BOSTON,MA; BROCKTON W ROXBURY VET AFFAIRS MED CTR,BOSTON,MA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University	ROCHON, PA (corresponding author), BAYCREST CTR GERIATR CARE,3560 BATHURST ST,N YORK,ON M6A 2E1,CANADA.		Rochon, Paula A/J-2918-2016; McLaughlin, Thomas F/A-9416-2009	Rochon, Paula A/0000-0002-5973-4151; McLaughlin, Thomas F/0000-0002-2722-3066	NIA NIH HHS [K08 AG00510] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [K08AG000510] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], 1994, ARCH INTERN MED, V154, P1449; AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; BRADLEY JD, 1991, NEW ENGL J MED, V325, P87, DOI 10.1056/NEJM199107113250203; CHRISCHILLES EA, 1992, J GERONTOL, V47, pM137, DOI 10.1093/geronj/47.5.M137; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; DUDLEY NJ, 1992, AGE AGEING, V21, P95, DOI 10.1093/ageing/21.2.95; Fibrinolytic 'Therapy Trialists' (FTT) Collaborative Group, 1994, LANCET, V343, P311; GREENBLATT DJ, 1982, NEW ENGL J MED, V306, P1081; GREENBLATT DJ, 1991, NEW ENGL J MED, V324, P1691, DOI 10.1056/NEJM199106133242403; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; GRIFFIN MR, 1988, ANN INTERN MED, V114, P359; GRUWITZ JH, 1994, JAMA-J AM MED ASSOC, V272, P781; GURWITZ JH, 1991, JAMA-J AM MED ASSOC, V265, P1720, DOI 10.1001/jama.265.13.1720; GURWITZ JH, 1992, JAMA-J AM MED ASSOC, V268, P1417, DOI 10.1001/jama.1992.03490110055029; GURWITZ JH, 1990, JAMA-J AM MED ASSOC, V264, P471, DOI 10.1001/jama.264.4.471; JACOX A, 1994, AHCPR940593 AG HLTH; JOHNSON AG, 1994, ANN INTERN MED, V121, P289, DOI 10.7326/0003-4819-121-4-199408150-00011; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; LIANG MH, 1991, NEW ENGL J MED, V325, P125, DOI 10.1056/NEJM199107113250210; MONANE M, 1993, ARCH INTERN MED, V153, P633, DOI 10.1001/archinte.153.5.633; MULROW CD, 1994, JAMA-J AM MED ASSOC, V272, P1932, DOI 10.1001/jama.272.24.1932; RAY WA, 1993, ARCH INTERN MED, V153, P713, DOI 10.1001/archinte.153.6.713; RAY WA, 1993, NEW ENGL J MED, V329, P2029, DOI 10.1056/NEJM199312303292710; RAY WA, 1989, JAMA-J AM MED ASSOC, V262, P3303, DOI 10.1001/jama.262.23.3303; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; ROCHON PA, 1993, ARCH INTERN MED, V153, P243, DOI 10.1001/archinte.153.2.243; SALZMAN C, 1992, CLIN GERIATRIC PSYCH, V1, P363; SCOTT JC, 1987, J PHARMACOL EXP THER, V240, P159; SHORR RI, 1994, JAMA-J AM MED ASSOC, V271, P358; STEPHEN PJ, 1984, LANCET, V2, P1082; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; TOPOL EJ, 1992, NEW ENGL J MED, V327, P45, DOI 10.1056/NEJM199207023270109; TRIMBLE EL, 1994, CANCER, V74, P2208, DOI 10.1002/1097-0142(19941001)74:7+<2208::AID-CNCR2820741737>3.0.CO;2-#; WILLCOX SM, 1994, JAMA-J AM MED ASSOC, V272, P292, DOI 10.1001/jama.272.4.292; 1989, GUIDELINE STUDY DRUG, P16; 1991, CIRCULATION, V84, P527; 1986, BRIT MED J, V292, P614	38	87	92	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 1	1995	346	8966					32	36		10.1016/S0140-6736(95)92656-9	http://dx.doi.org/10.1016/S0140-6736(95)92656-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RF985	7603146				2023-01-03	WOS:A1995RF98500014
J	PEARSON, VAH; OWEN, MR; PHILLIPS, DR; GRAY, DJP; MARSHALL, MN				PEARSON, VAH; OWEN, MR; PHILLIPS, DR; GRAY, DJP; MARSHALL, MN			PREGNANT TEENAGERS KNOWLEDGE AND USE OF EMERGENCY CONTRACEPTION	BRITISH MEDICAL JOURNAL			English	Article									UNIV EXETER,INST POPULAT STUDIES,EXETER EX4 6DT,DEVON,ENGLAND; UNIV EXETER,POSTGRAD MED SCH,INST GEN PRACTICE,EXETER EX2 5DW,DEVON,ENGLAND	University of Exeter; University of Exeter	PEARSON, VAH (corresponding author), EXETER & N DEVON HLTH AUTHOR,SOUTHERNHAY E,EXETER EX1 1PQ,DEVON,ENGLAND.			PEREIRA GRAY, DENIS/0000-0001-7917-3841				BROMHAM DR, 1993, BRIT MED J, V306, P556, DOI 10.1136/bmj.306.6877.556; Bury J., 1984, TEENAGE PREGNANCY BR; DUNCAN G, 1990, BRIT J FAM PLANN, V15, P112; MELLANBY A, 1993, BRIT MED J, V307, P25, DOI 10.1136/bmj.307.6895.25; 1992, FMI21 OFF POP CENS S	5	47	49	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 24	1995	310	6995					1644	1644		10.1136/bmj.310.6995.1644	http://dx.doi.org/10.1136/bmj.310.6995.1644			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RF698	7795453	Green Published			2023-01-03	WOS:A1995RF69800025
J	KREISBERG, R				KREISBERG, R			WE BLEW IT	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							HUMAN-IMMUNODEFICIENCY-VIRUS; TRIMETHOPRIM-SULFAMETHOXAZOLE; CHOLESTASIS; INFECTION; DISEASE		UNIV ALABAMA,SCH MED,BIRMINGHAM,AL	University of Alabama System; University of Alabama Birmingham	KREISBERG, R (corresponding author), BAPTIST HLTH SYST,BIRMINGHAM,AL 35211, USA.							BACH N, 1992, SEMIN LIVER DIS, V12, P205, DOI 10.1055/s-2007-1007392; BONACINI M, 1992, AM J MED, V92, P404, DOI 10.1016/0002-9343(92)90271-C; CARSON JL, 1993, ANN INTERN MED, V119, P576, DOI 10.7326/0003-4819-119-7_Part_1-199310010-00005; CELLO JP, 1989, AM J MED, V86, P539, DOI 10.1016/0002-9343(89)90381-1; CHAN TYK, 1993, LANCET, V342, P1532, DOI 10.1016/S0140-6736(05)80091-1; DOWNER SM, 1994, BRIT MED J, V309, P86, DOI 10.1136/bmj.309.6947.86; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; EYSTER ME, 1993, J ACQ IMMUN DEF SYND, V6, P602; FREIMAN JP, 1993, AIDS, V7, P379, DOI 10.1097/00002030-199303000-00012; KOWDLEY KV, 1992, GASTROENTEROLOGY, V102, P2148, DOI 10.1016/0016-5085(92)90346-Z; MEDON PJ, 1984, J ETHNOPHARMACOL, V10, P235, DOI 10.1016/0378-8741(84)90005-9; MUNOZ SJ, 1990, HEPATOLOGY, V12, P342, DOI 10.1002/hep.1840120223; SCHWARZ ED, 1992, SEMIN LIVER DIS, V12, P142, DOI 10.1055/s-2007-1007386; Stein D. S., 1994, AIDS Clinical Care, V6, P17; STEIN DS, 1994, AIDS CLIN CARE, V6, P26; VANHERWEGHEM JL, 1993, LANCET, V341, P387, DOI 10.1016/0140-6736(93)92984-2; WOOLF GM, 1994, ANN INTERN MED, V121, P729, DOI 10.7326/0003-4819-121-10-199411150-00001	17	15	15	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 6	1995	332	14					945	949		10.1056/NEJM199504063321409	http://dx.doi.org/10.1056/NEJM199504063321409			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QP893	7661934				2023-01-03	WOS:A1995QP89300009
J	FISHER, RI; GAYNOR, ER; DAHLBERG, S; OKEN, MM; GROGAN, TM; MIZE, EM; GLICK, JH; COLTMAN, CA; MILLER, TP				FISHER, RI; GAYNOR, ER; DAHLBERG, S; OKEN, MM; GROGAN, TM; MIZE, EM; GLICK, JH; COLTMAN, CA; MILLER, TP			COMPARISON OF A STANDARD REGIMEN (CHOP) WITH 3 INTENSIVE CHEMOTHERAPY REGIMENS FOR ADVANCED NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DIFFUSE HISTIOCYTIC LYMPHOMA; SOUTHWEST-ONCOLOGY-GROUP; LARGE-CELL LYMPHOMA; MACOP-B CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; INTERMEDIATE-GRADE; M-BACOD; UNDIFFERENTIATED LYMPHOMA; AGGRESSIVE LYMPHOMAS; MALIGNANT-LYMPHOMAS	Background. CHOP is a first-generation, combination-chemotherapy regimen consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone that has cured approximately 30 percent of patients with advanced stages of intermediate-grade or high-grade non-Hodgkin's lymphoma in national cooperative-group trials. However, studies at single institutions have suggested that 55 to 65 percent of such patients might be cured by third-generation regimens such as ones consisting of low-dose methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone (m-BACOD); prednisone, doxorubicin, cyclophosphamide, and etoposide, followed by cytarabine, bleomycin, vincristine, and methotrexate with leucovorin rescue (ProMACE-CytaBOM); and methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide; vincristine, prednisone, and bleomycin (MACOP-B). Methods. To make a valid comparison of these regimens, the Southwest Oncology Group and the Eastern Cooperative Oncology Group initiated a prospective, randomized phase III trial. The study end points were the response rate, time to treatment failure, overall survival, and incidence of severe or life-threatening toxicity. Dose intensity was calculated and analyzed. Results. Of the 1138 patients registered for the trial, 899 were eligible. Each treatment group contained at least patients. Known prognostic factors were equally distributed among the groups. There were no significant differences among the groups in the rates of partial and complete response. At three years, 44 percent of all patients were alive without disease; there were no significant differences between the groups (41 percent in the CHOP and MACOP-B groups and 46 percent in the m-BACOD and ProMACE-CytaBOM groups; P = 0.35). Overall survival at three years was 52 percent (50 percent in the ProMACE-CytaBOM and MACOP-B groups, 52 percent in the m-BACOD group, and 54 percent in the CHOP group; P = 0.90). There was no subgroup of patients in which survival was improved by a third-generation regimen. Fatal toxic reactions occurred in 1 percent of the CHOP group, 3 percent of the ProMACE-CytaBOM group, 5 percent of the m-BACOD group, and 6 percent of the MACOP-B group (P = 0.09). Conclusions. CHOP remains the best available treatment for patients with advanced-stage intermediate-grade or high-grade non-Hodgkin's lymphoma.	LOYOLA UNIV, STRITCH SCH MED, MAYWOOD, IL 60153 USA; SW ONCOL GRP, CTR STAT, SEATTLE, WA USA; ABBOTT NW HOSP, VIRGINIA PIPER CANC INST, MINNEAPOLIS, MN USA; UNIV ARIZONA, TUCSON, AZ 85721 USA; UNIV PENN, PHILADELPHIA, PA 19104 USA; UNIV TEXAS, HLTH SCI CTR, SAN ANTONIO, TX 78284 USA	Loyola University Chicago; Southwest Oncology Group; University of Arizona; University of Pennsylvania; University of Texas System; University of Texas Health San Antonio					NCI NIH HHS [CA-13612, CA-37429, CA-46282] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U10CA046282, U10CA013612, U10CA037429] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARDE P, 1991, ANN ONCOL, V2, P431, DOI 10.1093/oxfordjournals.annonc.a057979; CHISESI T, 1991, LEUKEMIA, V5, P107; COIFFIER B, 1989, BLOOD, V74, P558; COLEMAN M, 1985, ANN INTERN MED, V103, P140, DOI 10.7326/0003-4819-103-1-140; COLTMAN CA, 1988, CANCER CHEMOTHERAPY, P194; CONNORS JM, 1988, SEMIN HEMATOL, V25, P41; COOPER IA, 1991, P AN M AM SOC CLIN, V10, P271; COX DR, 1975, BIOMETRIKA, V62, P269, DOI 10.1093/biomet/62.2.269; COX DR, 1972, J R STAT SOC B, V34, P187; DANA BW, 1990, J CLIN ONCOL, V8, P1155, DOI 10.1200/JCO.1990.8.7.1155; DANIEU L, 1986, CANCER RES, V46, P5372; DEVITA VT, 1975, LANCET, V1, P248; DIXON DO, 1986, J CLIN ONCOL, V4, P295, DOI 10.1200/JCO.1986.4.3.295; FEDERICO M, 1991, LEUKEMIA, V5, P95; FISHER RI, 1977, AM J MED, V63, P177, DOI 10.1016/0002-9343(77)90230-3; FISHER RI, 1981, BLOOD, V58, P45; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; FISHER RI, 1984, P AN M AM SOC CLIN, V3, P242; GAYNOR ER, 1985, J CLIN ONCOL, V3, P1596, DOI 10.1200/JCO.1985.3.12.1596; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; JAGANNATH S, 1985, J CLIN ONCOL, V3, P39, DOI 10.1200/JCO.1985.3.1.39; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; LAURENCE J, 1982, ANN INTERN MED, V97, P190, DOI 10.7326/0003-4819-97-2-190; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; LOWENTHAL DA, 1987, P AN M AM SOC CLIN, V6, P201; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MILLER TP, 1990, J CLIN ONCOL, V8, P1951, DOI 10.1200/JCO.1990.8.12.1951; MONTSERRAT E, 1991, BLOOD S, V78, pA127; ORADELL JN, 1992, DRUG TOPICS RED BOOK; ROSENBERG SA, 1982, CANCER, V49, P2112; SCHEIN PS, 1976, ANN INTERN MED, V85, P417, DOI 10.7326/0003-4819-85-4-417; SCHNEIDER AM, 1990, J CLIN ONCOL, V8, P94, DOI 10.1200/JCO.1990.8.1.94; SHIPP M, 1992, P AN M AM SOC CLIN, V11, P319; SHIPP MA, 1986, ANN INTERN MED, V104, P757, DOI 10.7326/0003-4819-104-6-757; SKARIN AT, 1983, J CLIN ONCOL, V1, P91, DOI 10.1200/JCO.1983.1.2.91; WEICK JK, 1991, J CLIN ONCOL, V9, P748, DOI 10.1200/JCO.1991.9.5.748	38	1760	1851	1	31	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 8	1993	328	14					1002	1006		10.1056/NEJM199304083281404	http://dx.doi.org/10.1056/NEJM199304083281404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KW282	7680764				2023-01-03	WOS:A1993KW28200004
J	RUARK, JE; RAFFIN, TA				RUARK, JE; RAFFIN, TA			INITIATING AND WITHDRAWING LIFE SUPPORT - PRINCIPLES AND PRACTICE IN ADULT MEDICINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									STANFORD UNIV,MED CTR,RM C-56,STANFORD,CA 94305	Stanford University								BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; Bok S., 1978, LYING MORAL CHOICE P; BRODY H, 1976, ETHICAL DECISIONS ME; EISENDRATH SJ, 1983, JAMA-J AM MED ASSOC, V249, P2054, DOI 10.1001/jama.249.15.2054; FUCHS VR, 1984, NEW ENGL J MED, V311, P1572, DOI 10.1056/NEJM198412133112411; GILFIX M, 1984, WESTERN J MED, V141, P387; GONDA TA, 1984, DYING DIGNIFIED HLTH; IVEY AE, 1978, MICROCOUNSELING INNO; JONSEN AR, 1978, CLIN RES, V26, P55; KNAUS WA, 1985, ANN SURG, V202, P685, DOI 10.1097/00000658-198512000-00004; SCHUSTER DP, 1983, AM J MED, V75, P402, DOI 10.1016/0002-9343(83)90340-6; YOUNG EWD, 1976, STANFORD MD, V15, P20	13	236	237	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1988	318	1					25	30		10.1056/NEJM198801073180106	http://dx.doi.org/10.1056/NEJM198801073180106			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L5234	3275889				2023-01-03	WOS:A1988L523400006
J	ALPERS, A; LO, B				ALPERS, A; LO, B			PHYSICIAN-ASSISTED SUICIDE IN OREGON - A BOLD EXPERIMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PATIENT; LIFE; CARE		UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	ALPERS, A (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,PROGRAM MED ETH,521 PARNASSUS AVE,ROOM C 126,SAN FRANCISCO,CA 94143, USA.				NIMH NIH HHS [MH42459] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANNAS GJ, 1993, NEW ENGL J MED, V328, P1573, DOI 10.1056/NEJM199305273282121; BEAUCHAMP TL, 1994, PRINCIPLES BIOMEDICA, P474; BELKIN L, 1993, NY TIMES MAGAZI 1114, P75; BELKIN L, 1993, NY TIMES MAGAZI 1114, P74; BELKIN L, 1993, NY TIMES MAGAZI 1114, P63; Belkin Lisa, 1993, N Y Times Mag, P48; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; BLUMENTHAL SJ, 1988, MED CLIN N AM, V72, P937, DOI 10.1016/S0025-7125(16)30754-4; CHRISTAKIS N, 1993, J GEN INTERN MED, V9, P314; COHEN JS, 1994, NEW ENGL J MED, V331, P89, DOI 10.1056/NEJM199407143310206; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Doyle D., 1993, OXFORD TXB PALLIATIV; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; LO B, 1995, RESOLVING ETHICAL DI, P168; MILES SH, 1994, JAMA-J AM MED ASSOC, V271, P1786, DOI 10.1001/jama.271.22.1786; MILLER FG, 1994, NEW ENGL J MED, V331, P119, DOI 10.1056/NEJM199407143310211; PIJNENBORG L, 1993, LANCET, V341, P1196, DOI 10.1016/0140-6736(93)91014-D; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; STEINBROOK R, 1992, NEW ENGL J MED, V326, P340, DOI 10.1056/NEJM199201303260511; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WOLF SM, 1991, NEW ENGL J MED, V325, P1666, DOI 10.1056/NEJM199112053252334	22	55	55	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					483	487		10.1001/jama.274.6.483	http://dx.doi.org/10.1001/jama.274.6.483			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RM699	7629958				2023-01-03	WOS:A1995RM69900029
J	ASAI, A; FUKUHARA, S; LO, B				ASAI, A; FUKUHARA, S; LO, B			ATTITUDES OF JAPANESE AND JAPANESE-AMERICAN PHYSICIANS TOWARDS LIFE-SUSTAINING TREATMENT	LANCET			English	Article								Doctors in different countries have different approaches to bioethical problems. We studied how attitudes to life-sustaining treatment for terminally ill patients differ in Japan and the USA by administering a questionnaire to Japanese (136) and Japanese-American (77) physicians. In a series of clinical scenarios the questionnaire asked what life-sustaining interventions the doctors would recommend to a patient with metastatic gastric cancer. Most Japanese physicians would recommend blood for transfusions for gastrointestinal bleeding (74%) total parenteral nutrition for malnutrition (67%) and vasopressors for life-threatening hypotension (61%) when the patient did not know of his diagnosis and outlook. Significantly fewer Japanese physicians would want these interventions for themselves: 29% would want transfusion, 36% would want total parenteral nutrition, and 25% would want vasopressors. 36% of Japanese physicians would override the explicit request of a competent moribund cancer patient to withdraw all life-support. By contrast, among Japanese-American physicians only 42% would recommend blood transfusions, 33% total parenteral nutrition, and 34% vasopressors to a terminally ill cancer patient who did not know of his diagnosis or outlook. Cross-cultural studies in medical ethics can help physicians and the public in different countries to take a fresh took at accepted practices and the ethical reasons behind them.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT GEN INTERNAL MED,PROGRAM MED ETH,SAN FRANCISCO,CA 94143; UNIV TOKYO,FAC MED,DIV INTERNAL HLTH,TOKYO,JAPAN	University of California System; University of California San Francisco; University of Tokyo					NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FRAMPTON MW, 1987, J GEN INTERN MED, V2, P394, DOI 10.1007/BF02596364; HADFIELD P, 1993, LANCET, V341, P1141, DOI 10.1016/0140-6736(93)93144-P; LO B, 1995, RESOLVING ETHICAL DI, P141; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; THOMSEN OO, 1993, LANCET, V341, P473, DOI 10.1016/0140-6736(93)90218-6; 1994, REPORT SURVEY JAPANE	7	81	83	0	5	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 5	1995	346	8971					356	359		10.1016/S0140-6736(95)92230-X	http://dx.doi.org/10.1016/S0140-6736(95)92230-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM713	7623536				2023-01-03	WOS:A1995RM71300013
J	CHIU, ES; AUSTIN, JHM				CHIU, ES; AUSTIN, JHM			ACUPUNCTURE NEEDLE FRAGMENTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											CHIU, ES (corresponding author), COLUMBIA UNIV,COLL PHYS & SURG,NEW YORK,NY 10032, USA.								0	10	10	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 2	1995	332	5					304	304		10.1056/NEJM199502023320505	http://dx.doi.org/10.1056/NEJM199502023320505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD396	7816066				2023-01-03	WOS:A1995QD39600005
J	COLLIER, J				COLLIER, J			THE CASES FOR AND AGAINST PRESCRIBING GENERIC DRUGS - GENERIC PRESCRIBING BENEFITS PATIENTS	BRITISH MEDICAL JOURNAL			English	Editorial Material											COLLIER, J (corresponding author), ST GEORGES HOSP,SCH MED,DEPT PHARMACOL & CLIN PHARMACOL,LONDON SW17 0RE,ENGLAND.							HAYWARD JL, 1986, BRIT MED J, V292, P762, DOI 10.1136/bmj.292.6522.762-b; LIS Y, 1988, PHARM J, V240, P176; MCEWEN J, 1987, GERIATRIC MED    DEC, P70; PANDYA SK, 1988, BRIT MED J, V297, P117, DOI 10.1136/bmj.297.6641.117; SANDERSON JH, 1986, LANCET, V1, P967; SMITH GT, 1986, PHARM J, V237, P242; STOUGHTON RB, 1987, ARCH DERMATOL, V123, P1312, DOI 10.1001/archderm.123.10.1312; TURNER P, 1987, LANCET, V2, P517; 1987, PHARM J, V239, P472	9	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1988	297	6663					1596	&		10.1136/bmj.297.6663.1596	http://dx.doi.org/10.1136/bmj.297.6663.1596			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R4933	3147089	Bronze, Green Published			2023-01-03	WOS:A1988R493300028
J	FIELD, JM				FIELD, JM			ANESTHETIC COMPLICATIONS OF A WEIGHT REDUCING REGIMEN	BRITISH MEDICAL JOURNAL			English	Article											FIELD, JM (corresponding author), QUEEN ELIZABETH MIL HOSP,DEPT ANAESTHET & RESUSCITAT,LONDON SE18 4QH,ENGLAND.							GLASER R, 1986, ANESTHESIOLOGY, V64, P408, DOI 10.1097/00000542-198603000-00029; MILLER RD, 1978, BRIT J ANAESTH, V50, P541, DOI 10.1093/bja/50.6.541; VAUGHAN RS, 1973, ANAESTHESIA, V28, P118, DOI 10.1111/j.1365-2044.1973.tb00303.x; VITEZ TS, 1985, ANESTHESIOLOGY, V63, P130, DOI 10.1097/00000542-198508000-00002; WEINER M, 1970, YALE J BIOL MED, V43, P76	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 26	1988	297	6660					1383	1383		10.1136/bmj.297.6660.1383	http://dx.doi.org/10.1136/bmj.297.6660.1383			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R0904	3146373	Bronze, Green Published			2023-01-03	WOS:A1988R090400024
J	BENZING, T; TJIVIKUA, T; WOLFE, J; REBEK, J				BENZING, T; TJIVIKUA, T; WOLFE, J; REBEK, J			RECOGNITION AND TRANSPORT OF ADENINE-DERIVATIVES WITH SYNTHETIC RECEPTORS	SCIENCE			English	Article									UNIV PITTSBURGH,DEPT CHEM,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh			Benzing, Thomas/X-5476-2019					BELL TW, 1988, J AM CHEM SOC, V110, P3673, DOI 10.1021/ja00219a060; CHANG SK, 1988, J AM CHEM SOC, V110, P1318, DOI 10.1021/ja00212a065; JEONG KS, 1988, J AM CHEM SOC, V110, P3327, DOI 10.1021/ja00218a068; KELLY TR, 1987, J AM CHEM SOC, V109, P6549, DOI 10.1021/ja00255a072; KEMP DS, 1981, J ORG CHEM, V46, P5140, DOI 10.1021/jo00338a014; KILBURN JD, 1988, J AM CHEM SOC, V110, P1307, DOI 10.1021/ja00212a058; PANT N, 1988, J AM CHEM SOC, V110, P2002, DOI 10.1021/ja00214a075; REBEK J, 1985, J AM CHEM SOC, V107, P6736, DOI 10.1021/ja00309a067; REBEK J, 1987, J AM CHEM SOC, V109, P2432, DOI 10.1021/ja00242a030; REBEK J, 1987, ANGEW CHEM INT EDIT, V26, P1244, DOI 10.1002/anie.198712441; REBEK J, 1986, J AM CHEM SOC, V108, P5637, DOI 10.1021/ja00278a052; REBEK J, 1985, J AM CHEM SOC, V107, P6738, DOI 10.1021/ja00309a068; REBEK J, 1987, J AM CHEM SOC, V109, P6866, DOI 10.1021/ja00256a059; REBEK J, 1987, J AM CHEM SOC, V109, P5033, DOI 10.1021/ja00250a051; REBEK J, 1987, J AM CHEM SOC, V109, P3479; SCHULTZ JS, 1974, AICHE J, V20, P417, DOI 10.1002/aic.690200302; VANSTAVEREN CJ, 1987, J AM CHEM SOC, V109, P3456, DOI 10.1021/ja00245a045; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	18	54	58	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	OCT 14	1988	242	4876					266	268		10.1126/science.3262924	http://dx.doi.org/10.1126/science.3262924			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	Q4368	3262924				2023-01-03	WOS:A1988Q436800037
J	WILLIAMS, EI; FITTON, F				WILLIAMS, EI; FITTON, F			FACTORS AFFECTING EARLY UNPLANNED READMISSION OF ELDERLY PATIENTS TO HOSPITAL	BRITISH MEDICAL JOURNAL			English	Article											WILLIAMS, EI (corresponding author), UNIV NOTTINGHAM HOSP,QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							AMOS G, 1973, CARE IS RARE; ARNOLD J, 1962, LANCET, V2, P551; BARIBEAUBRAUN J, 1979, J GERONTOL, V34, P351, DOI 10.1093/geronj/34.3.351; BROCKLEHURST JC, 1969, GERONTOL CLIN, V11, P115, DOI 10.1159/000245224; Burnside I G, 1976, Paraplegia, V14, P220; GAY P, 1979, I WENT HOME STUDY PA; GRAHAM H, 1983, LANCET, V1, P404; HIRST J, 1975, ELDERLY PATIENTS DIS; HOCKEY L, 1968, CARE BALANCE STUDY C; HODKINSON HM, 1980, J CLIN EXP GERONTOL, V2, P301; HOOD JC, 1978, HOSPITALS, V52, P79; HUNT A, 1978, ELDERLY HOME; MUNLEY PH, 1977, J CLIN PSYCHOL, V33, P1093, DOI 10.1002/1097-4679(197710)33:4<1093::AID-JCLP2270330438>3.0.CO;2-9; ROSIN A J, 1970, Gerontologia Clinica, V12, P40; SKEET M, 1974, HOME HOSPITAL; VICTOR CR, 1988, AGE AGEING, V17, P155, DOI 10.1093/ageing/17.3.155; VICTOR CR, 1985, AGE AGEING, V14, P37, DOI 10.1093/ageing/14.1.37; 1988, DISCHARGE PATIENTS H	18	131	132	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 24	1988	297	6651					784	787		10.1136/bmj.297.6651.784	http://dx.doi.org/10.1136/bmj.297.6651.784			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q2704	3142550	Green Published, Bronze			2023-01-03	WOS:A1988Q270400024
J	DAVIS, KH; HAWKS, RL; BLANKE, RV				DAVIS, KH; HAWKS, RL; BLANKE, RV			ASSESSMENT OF LABORATORY QUALITY IN URINE DRUG-TESTING - A PROFICIENCY TESTING PILOT-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,MCV STN,BOX 597,RICHMOND,VA 23298; RES TRIANGLE INST,RES TRIANGLE PK,NC 27709; NIDA,ROCKVILLE,MD	Virginia Commonwealth University; Research Triangle Institute; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)					PHS HHS [271-84-4134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		EDINGER SE, 1984, J MED TECHNOL, V1, P776; FRINGS CS, 1987, CLIN CHEM, V33, P1683; GORDON AJ, 1972, CHEM COMPANION, P485; HANSEN HJ, 1985, JAMA-J AM MED ASSOC, V253, P2382, DOI 10.1001/jama.253.16.2382; Hawks R, 1986, NIDA RES MONOGRAPH; WALSH JM, 1986, ADM861477 US DEP HLT; WILLETTE RE, 1986, NIDA RES MONOGRAPH, V73, P6; 1986, URINE TOXICOLOGY 198	8	25	25	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1988	260	12					1749	1754		10.1001/jama.260.12.1749	http://dx.doi.org/10.1001/jama.260.12.1749			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q1001	3411757				2023-01-03	WOS:A1988Q100100027
J	XIU, RJ				XIU, RJ			MICROCIRCULATION AND TRADITIONAL CHINESE-MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									PEKING UNION MED COLL, BEIJING, PEOPLES R CHINA	Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	XIU, RJ (corresponding author), CHINESE ACAD MED SCI, MICROCIRCULAT RES CTR, INST MICROCIRCULAT, 5 DONG DAN SAN TIAO, BEIJING, PEOPLES R CHINA.			Xiu, Ruijuan/0000-0002-1446-2711				DAI SW, 1984, J CHIN TRADITIONAL H, V15, P35; LU JS, 1976, CHINESE J INTERN MED, V4, P206; RUIJUAN X, 1982, JAMA-J AM MED ASSOC, V247, P1458, DOI 10.1001/jama.1982.03320350062033; XIU RJ, 1983, MICROVASC RES, V25, P262; XIU RJ, 1980, MICROVASC RES, V20, P371; XIU RJ, 1986, CHINESE MED J-PEKING, V99, P351; XIU RJ, 1975, CHIN MED J, V1, P216; XIU RJ, 1984, P INT S STUDIES CHIN, P553; XIU RJ, 1972, B MED RES, V6, P1; XIU RJ, 1984, J PROG APPL MICROCIR, V6, P141; XIU RJ, 1984, P INT S STUDIES CHIN, P558; XIU RJ, 1982, P ASPET SOT; XIU RJ, 1983, J PROG APPL MICROCIR, V3, P131; XIU RJ, IN PRESS CHIN MED J; XIU RJ, IN PRESS IMPROVEMENT; XU LN, 1976, J NEW MED, V5, P38; 1977, ENCY CHINESE TRADITI, P1933	17	25	28	1	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 23	1988	260	12					1755	1757		10.1001/jama.260.12.1755	http://dx.doi.org/10.1001/jama.260.12.1755			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q1001	3045357				2023-01-03	WOS:A1988Q100100028
J	TOPOL, EJ; BUREK, K; ONEILL, WW; KEWMAN, DG; KANDER, NH; SHEA, MJ; SCHORK, MA; KIRSCHT, J; JUNI, JE; PITT, B				TOPOL, EJ; BUREK, K; ONEILL, WW; KEWMAN, DG; KANDER, NH; SHEA, MJ; SCHORK, MA; KIRSCHT, J; JUNI, JE; PITT, B			A RANDOMIZED CONTROLLED TRIAL OF HOSPITAL DISCHARGE 3 DAYS AFTER MYOCARDIAL-INFARCTION IN THE ERA OF REPERFUSION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, DIV NUCL MED, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, DEPT PHYS MED & REHABIL, ANN ARBOR, MI 48109 USA; UNIV MICHIGAN, MED CTR, SCH PUBL HLTH, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	TOPOL, EJ (corresponding author), UNIV MICHIGAN, MED CTR,DEPT INTERNAL MED,DIV CARDIOL, CARDIAC CATHETERIZAT LAB, 1500 E MED CTR DR, ANN ARBOR, MI 48109 USA.			Juni, Jack/0000-0002-9230-6888				[Anonymous], 1987, Lancet, V2, P871; [Anonymous], 1986, LANCET, V1, P397; BRAUNWALD E, 1987, J AM COLL CARDIOL, V9, P467, DOI 10.1016/S0735-1097(87)80407-2; Buck C R Jr, 1977, Health Care Manage Rev, V2, P59; CALIFF RM, 1987, CIRCULATION, V76, P1; DEBUSK RF, 1980, CIRCULATION, V61, P738, DOI 10.1161/01.CIR.61.4.738; Derogatis L. R., 1983, BRIEF SYMPTOM INVENT; Derogatis LR, 1983, PSYCHOSOCIAL ADJUSTM; DOUBILET P, 1986, NEW ENGL J MED, V314, P253, DOI 10.1056/NEJM198601233140421; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; GUERCI AD, 1987, NEW ENGL J MED, V317, P1613, DOI 10.1056/NEJM198712243172601; GUNDLE MJ, 1980, AM J PSYCHIAT, V137, P1591; HAMM LF, 1986, PROG CARDIOVASC DIS, V28, P463, DOI 10.1016/0033-0620(86)90028-9; HARRISON DC, 1985, AM J CARDIOL, V56, pC10, DOI 10.1016/S0002-9149(85)80003-5; KLONER RA, 1983, AM HEART J, V106, P1009, DOI 10.1016/0002-8703(83)90645-2; LAFFEL GL, 1987, J AM COLL CARDIOL, V10, pB79, DOI 10.1016/S0735-1097(87)80432-1; LEW AS, 1987, AM J CARDIOL, V59, P1, DOI 10.1016/S0002-9149(87)80059-0; LEW AS, 1985, CIRCULATION, V72, P1321, DOI 10.1161/01.CIR.72.6.1321; LOWN B, 1967, AM J CARDIOL, V20, P494, DOI 10.1016/0002-9149(67)90027-6; MUELLER HS, 1987, J AM COLL CARDIOL, V10, P479, DOI 10.1016/S0735-1097(87)80188-2; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PRYOR DB, 1983, ANN INTERN MED, V99, P528, DOI 10.7326/0003-4819-99-4-528; RAFT D, 1985, AM J CARDIOL, V56, P395, DOI 10.1016/0002-9149(85)90873-2; ROSS RS, 1978, NEW ENGL J MED, V298, P275, DOI 10.1056/NEJM197802022980510; SCHRODER R, 1986, NEW ENGL J MED, V314, P1465; SIMOONS ML, 1988, LANCET, V1, P199; SIMOONS ML, 1985, LANCET, V2, P578; STERN RS, 1985, NEW ENGL J MED, V312, P621, DOI 10.1056/NEJM198503073121005; THOMPSON PL, 1988, LANCET, V1, P203; TOPOL EJ, 1987, NEW ENGL J MED, V317, P581, DOI 10.1056/NEJM198709033171001; TOPOL EJ, 1987, AM J CARDIOL, V60, P958, DOI 10.1016/0002-9149(87)90332-8; WHITE HD, 1987, NEW ENGL J MED, V317, P850, DOI 10.1056/NEJM198710013171402; 1980, HEART FACTS 1981; 1984, FED REG, V49, P234; 1987, LANCET, V1, P502	35	162	162	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 28	1988	318	17					1083	1088		10.1056/NEJM198804283181702	http://dx.doi.org/10.1056/NEJM198804283181702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N0896	3281014				2023-01-03	WOS:A1988N089600002
J	WRIGHT, IH; MCDONALD, JC; ROGERS, PN; LEDINGHAM, IM				WRIGHT, IH; MCDONALD, JC; ROGERS, PN; LEDINGHAM, IM			PROVISION OF FACILITIES FOR SECONDARY TRANSPORT OF SERIOUSLY ILL PATIENTS IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article									WESTERN INFIRM,DEPT SURG,GLASGOW G11 6NT,SCOTLAND; WESTERN INFIRM,INTENS THERAPY UNIT,GLASGOW G11 6NT,SCOTLAND									AITKENHEAD AR, 1980, BRIT MED J, V280, P1219, DOI 10.1136/bmj.280.6225.1219; ANDERSON IWR, 1987, BRIT MED J, V294, P228, DOI 10.1136/bmj.294.6566.228; BION JF, 1985, BRIT MED J, V291, P432, DOI 10.1136/bmj.291.6493.432; EHRENWERTH J, 1986, CRIT CARE MED, V14, P543, DOI 10.1097/00003246-198606000-00005; FINFER SR, 1987, ANAESTHESIA, V42, P900, DOI 10.1111/j.1365-2044.1987.tb04133.x; GENTLEMAN D, 1981, LANCET, V2, P853; GORIS RJA, 1982, J TRAUMA, V22, P141, DOI 10.1097/00005373-198202000-00011; JOHNSON CJH, 1985, ANAESTHESIA, V40, P471; LEDINGHAM IM, 1987, BRIT MED J, V294, P1095, DOI 10.1136/bmj.294.6579.1095; MACDONALD RC, 1981, INJURY, V12, P225; MARSH RHK, 1981, BRIT J HOSP MED, V25, P377; PARK GR, 1982, BRIT J ANAESTH, V54, P1081, DOI 10.1093/bja/54.10.1081; PRICE DG, 1981, LANCET, V2, P985; ROBERTSON C, 1985, LANCET, V2, P434; SMITH DF, 1983, CRIT CARE MED, V11, P10, DOI 10.1097/00003246-198301000-00004; THOMPSON RJ, 1985, ANAESTHESIA, V40, P604; WADDELL G, 1975, BRIT MED J, V4, P206, DOI 10.1136/bmj.4.5990.206; WADDELL G, 1975, BRIT MED J, V2, P417, DOI 10.1136/bmj.2.5968.417; WADDELL G, 1975, BRIT MED J, V1, P386, DOI 10.1136/bmj.1.5954.386	19	21	21	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1988	296	6621					543	545		10.1136/bmj.296.6621.543	http://dx.doi.org/10.1136/bmj.296.6621.543			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M2314	3126900	Green Published			2023-01-03	WOS:A1988M231400019
J	McGuire, WP; Hoskins, WJ; Brady, MF; Kucera, PR; Partridge, EE; Look, KY; ClarkePearson, DL; Davidson, M				McGuire, WP; Hoskins, WJ; Brady, MF; Kucera, PR; Partridge, EE; Look, KY; ClarkePearson, DL; Davidson, M			Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED TRIAL; COMBINATION CHEMOTHERAPY; FOLLOW-UP; CARCINOMA; TAXOL; DOXORUBICIN	Background. Chemotherapy combinations that include an alkylating agent and a platinum coordination complex have high response rates in women with advanced ovarian cancer. Such combinations provide longterm control of disease in few patients, however. We compared two combinations, cisplatin and cyclophosphamide and cisplatin and paclitaxel, in women with ovarian cancer. Methods. We randomly assigned 410 women with advanced ovarian cancer and residual masses larger than 1 cm after initial surgery to receive cisplatin (75 mg per square meter of body-surface area) with either cyclophosphamide (750 mg per square meter) or paclitaxel (135 mg per square meter over a period of 24 hours). Results. Three hundred eighty-six women met all the eligibility criteria. Known prognostic factors were similar in the two treatment groups. Alopecia, neutropenia, fever, and allergic reactions were reported more frequently in the cisplatin-paclitaxel group. Among 216 women with measurable disease, 73 percent in the cisplatin-paclitaxel group responded to therapy, as compared with 60 percent in the cisplatin-cyclophosphamide group (P=0.01), The frequency of surgically verified complete response was similar in the two groups, Progression-free survival was significantly longer (P<0.001) in the cisplatin-paclitaxel group than in the cisplatin-cyclophosphamide group (median, 18 vs, 13 months), Survival was also significantly longer (P<0.001) in the cisplatin-paclitaxel group (median, 38 vs. 24 months). Conclusions. Incorporating paclitaxel into first-line therapy improves the duration of progression-free survival and of overall survival in women with incompletely resected stage III and stage IV ovarian cancer. (C) 1996, Massachusetts Medical Society.	EMORY UNIV, DEPT MED, ATLANTA, GA 30322 USA; MEM SLOAN KETTERING CANC CTR, DEPT SURG, GYNECOL SERV, NEW YORK, NY 10021 USA; CORNELL UNIV, COLL MED, DEPT OBSTET & GYNECOL, NEW YORK, NY USA; ROSWELL PK CANC INST, GYNECOL ONCOL GRP STAT OFF, BUFFALO, NY USA; OREGON HLTH SCI UNIV, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, PORTLAND, OR USA; UNIV ALABAMA, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, BIRMINGHAM, AL USA; INDIANA UNIV, SCH MED, DIV OBSTET & GYNECOL, INDIANAPOLIS, IN USA; DUKE UNIV, SCH MED, DEPT OBSTET & GYNECOL, DIV GYNECOL ONCOL, DURHAM, NC USA; WALTER REED ARMY MED CTR, DEPT PATHOL & AREA LAB SCI, WASHINGTON, DC 20307 USA	Emory University; Memorial Sloan Kettering Cancer Center; Cornell University; Roswell Park Cancer Institute; Oregon Health & Science University; University of Alabama System; University of Alabama Birmingham; Indiana University System; Indiana University-Purdue University Indianapolis; Duke University; United States Department of Defense; United States Army; Walter Reed National Military Medical Center					NATIONAL CANCER INSTITUTE [U10CA027469, U10CA037517] Funding Source: NIH RePORTER; NCI NIH HHS [CA 37517, CA 27469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agresti A., 1990, CATEGORICAL DATA ANA; [Anonymous], 1979, WHO HDB REPORTING RE; BLESSING JA, 1990, CHEMOTHERAPY GYNECOL, P63; BOOKMAN MA, IN PRESS J CLIN ONCO; COX DR, 1972, J R STAT SOC B, V34, P187; EISENHAUER EA, 1994, J CLIN ONCOL, V12, P2654, DOI 10.1200/JCO.1994.12.12.2654; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583, DOI 10.1080/01621459.1952.10483441; LIEBMANN JE, 1993, BRIT J CANCER, V68, P1104, DOI 10.1038/bjc.1993.488; MANGIONI C, 1992, GYNECOL ONCOL, V45, P115; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCGUIRE WP, 1989, ANN INTERN MED, V111, P273, DOI 10.7326/0003-4819-111-4-273; MCGUIRE WP, 1995, J CLIN ONCOL, V13, P1589, DOI 10.1200/JCO.1995.13.7.1589; MCGUIRE WP, 1993, GYNECOL ONCOL, V51, P78, DOI 10.1006/gyno.1993.1250; NEIJT JP, 1984, LANCET, V2, P594; OMURA G, 1986, CANCER, V57, P1725, DOI 10.1002/1097-0142(19860501)57:9<1725::AID-CNCR2820570903>3.0.CO;2-J; OMURA GA, 1991, J CLIN ONCOL, V9, P1138, DOI 10.1200/JCO.1991.9.7.1138; ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1692, DOI 10.1200/JCO.1991.9.9.1692; ROWINSKY EK, 1991, J CLIN ONCOL, V9, P1704, DOI 10.1200/JCO.1991.9.9.1704; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; STEWART LA, 1991, BRIT MED J, V303, P884; SUTTON GP, 1989, J CLIN ONCOL, V7, P223, DOI 10.1200/JCO.1989.7.2.223; THIGPEN JT, 1989, SEMIN ONCOL, V16, P58; THIGPEN JT, 1994, J CLIN ONCOL, V12, P1748, DOI 10.1200/JCO.1994.12.9.1748; Williams C J, 1992, Semin Oncol, V19, P120; WILLIAMS CJ, 1985, J CLIN ONCOL, V3, P1455, DOI 10.1200/JCO.1985.3.11.1455	26	2477	2541	2	157	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					1	6		10.1056/NEJM199601043340101	http://dx.doi.org/10.1056/NEJM199601043340101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494563				2023-01-03	WOS:A1996TM48200001
J	ROBINSON, JC; CASALINO, LP				ROBINSON, JC; CASALINO, LP			THE GROWTH OF MEDICAL GROUPS PAID THROUGH CAPITATION IN CALIFORNIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							UNIVERSAL HEALTH-INSURANCE; MANAGED COMPETITION; PROMOTE QUALITY; ECONOMY; 1990S; PLAN	Background. In California, it is common for health maintenance organizations (HMOs) to contract with large medical groups that are paid through capitation and are responsible for managing a full spectrum of medical services. Methods. We studied six large medical groups in California - Bristol Park Medical, Friendly Hills HealthCare Network, HealthCare Partners Medical Group, Mullikin Medical Centers, Palo Alto Medical Foundation, and San Jose Medical Group - that are paid through capitation and that are growing as a result of contracts with managed-care organizations. We conducted interviews and obtained data on factors such as patient enrolment, capitation and other revenue, numbers of days spent by enrollees in the hospital, and numbers of visits to physicians per enrollee. Results Between 1990 and 1994, the number of HMO enrollees whose care was paid for through capitation in the six medical groups increased by 91 percent, from 398,359 to 759,474. In 1994, the mean number of hospital days per 1000 HMO enrollees ranged from 120 to 149 for non-Medicare patients and from 643 to 936 days for Medicare patients. By comparison, in 1993 the mean numbers of hospital days per 1000 HMO enrollees not covered by Medicare were 232 for California and 297 for the United States; for HMO enrollees covered by Medicare, the numbers were 1337 for California and 1698 for the United States. In 1994, the average annual number of visits to physicians for HMO patients in the six groups not covered by Medicare ranged from 3.1 to 3.9; for Medicare patients, it ranged from 6.8 to 9.3; these rates were slightly lower than statewide and national rates. Four of the groups have sold their assets (such as facilities, supplies, equipment, and patients' charts) to outside investors; the physicians remain employed by physician-owned professional corporations. Conclusions. Medical groups paid through capitation offer a model for the status of physicians in managed-care systems that differs from the employee status offered by staff-model HMOs and the subcontractor status offered by HMOs that negotiate directly with individual physicians. Despite their growth, such medical groups in California face substantial challenges, such as obtaining the financial assets necessary to sustain rapid growth.			ROBINSON, JC (corresponding author), UNIV CALIF BERKELEY,SCH PUBL HLTH,418 WARREN HALL,BERKELEY,CA 94720, USA.		Casalino, Lawrence/ABE-1245-2020	Casalino, Lawrence/0000-0002-7927-7859				ENTHOVEN A, 1989, NEW ENGL J MED, V320, P94, DOI 10.1056/NEJM198901123200205; ENTHOVEN A, 1989, NEW ENGL J MED, V320, P29, DOI 10.1056/NEJM198901053200106; ENTHOVEN AC, 1993, HEALTH AFFAIR, V12, P24, DOI 10.1377/hlthaff.12.suppl_1.24; HODAPP TE, 1994, HMOS 1995 RIGHT PLAC; KRONICK R, 1993, NEW ENGL J MED, V328, P148, DOI 10.1056/NEJM199301143280225; MORRISON EM, 1995, CONSOLIDATION PROVID; 1994, MARION MERRELL DOW M; 1994, CAPITATION STRATEGY	8	131	132	0	10	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 21	1995	333	25					1684	1687		10.1056/NEJM199512213332506	http://dx.doi.org/10.1056/NEJM199512213332506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TL401	7477222				2023-01-03	WOS:A1995TL40100006
J	BARKERCUMMINGS, C; MCCLELLAN, W; SOUCIE, JM; KRISHER, J				BARKERCUMMINGS, C; MCCLELLAN, W; SOUCIE, JM; KRISHER, J			ETHNIC-DIFFERENCES IN THE USE OF PERITONEAL-DIALYSIS AS INITIAL TREATMENT FOR END-STAGE RENAL-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY-OF-LIFE; RACIAL-DIFFERENCES; UNITED-STATES; RACE; TRANSPLANTATION; ACCESS; BLACK; EXPERIENCE; CANDIDATES; AMERICANS	Objective.-To evaluate the influence of ethnicity on the use of peritoneal dialysis (PD) as initial treatment for end-stage renal disease (ESRD) after controlling for other patient characteristics. Design.-Inception cohort analysis of incident ESRD patients. Patients.-All African-American and white patients (N=10726) who began treatment for ESRD at dialysis centers in North Carolina, South Carolina, and Georgia and reported to ESRD Network 6 between January 1, 1989, and December 31, 1991. Main Outcome Measure.-Odds ratios (ORs) of the association between ethnicity and PD as initial treatment modality. Results.-African-American patients were 56% less likely than whites to use PD (OR, 0.44; 95% confidence interval [CI], 0.40 to 0.49). This difference persisted (OR, 0.45; 95% CI, 0.38 to 0.52) after multivariable adjustment for age, education, social support, home ownership, functional status, albumin level, hypertension, history of myocardial infarction, peripheral neuropathy, and comorbid diabetes. Conclusions.-Ethnic differences in initial PD use cannot be explained by many demographic, socioeconomic, and comorbid factors associated with the use of PD as initial treatment for ESRD.	EMORY UNIV,ROLLINS SCH PUBL HLTH,CTR CLIN EVALUAT SCI,ATLANTA,GA 30322; EMORY UNIV,ROLLINS SCH PUBL HLTH,DEPT EPIDEMIOL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,DIV RENAL,ATLANTA,GA 30322; SE KIDNEY COUNCIL,ESRD NETWORK 6,RALEIGH,NC	Emory University; Rollins School Public Health; Emory University; Rollins School Public Health; Emory University								BLENDON RJ, 1989, JAMA-J AM MED ASSOC, V261, P278, DOI 10.1001/jama.261.2.278; BROGAN D, 1988, NEW ENGL J MED, V319, P55; BUTKUS DE, 1992, NEW ENGL J MED, V327, P840, DOI 10.1056/NEJM199209173271203; CHURCHILL DN, 1993, KIDNEY INT, V43, pS16; Dean A. G., 1990, EPI INFO VERSION 5 W; Dixon W. J., 1990, BMDP STATISTICAL SOF; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; FOX MP, 1993, AM J KIDNEY DIS, V22, P32, DOI 10.1016/0272-6386(93)70179-3; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HELD PJ, 1994, KIDNEY INT, V45, P1163, DOI 10.1038/ki.1994.154; HILL CE, 1988, COMMUNITY HLTH SYSTE, P60; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; JACKSON FLC, 1993, AM J KIDNEY DIS, V21, P10, DOI 10.1016/0272-6386(93)70070-F; JOHNSON PA, 1993, ANN INTERN MED, V118, P593, DOI 10.7326/0003-4819-118-8-199304150-00004; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; Kleinbaum DG., 1982, EPIDEMIOLOGIC RES PR; LEVINSON R, 1986, SOC PSYCHOL QUART, V49, P330, DOI 10.2307/2786772; LEVY DR, 1985, PEDIATRICS, V75, P639; MAIORCA R, 1993, KIDNEY INT, V43, pS4; MCCLELLAN WM, 1991, J CLIN EPIDEMIOL, V44, P83, DOI 10.1016/0895-4356(91)90204-M; NISSENSON AR, 1986, AM J KIDNEY DIS, V7, P229, DOI 10.1016/S0272-6386(86)80009-9; NOLPH KD, 1990, CONTEMP ISS NEPHROL, P127; OSBORNE NG, 1992, JAMA-J AM MED ASSOC, V267, P275, DOI 10.1001/jama.267.2.275; Rosenstock I.M., 1990, HLTH BEHAV HLTH ED T, P39; ROTELLAR C, 1991, AM J KIDNEY DIS, V17, P158, DOI 10.1016/S0272-6386(12)81122-X; Rothman K, 1986, MODERN EPIDEMIOLOGY; SANFILIPPO FP, 1992, JAMA-J AM MED ASSOC, V267, P247, DOI 10.1001/jama.267.2.247; SIMMONS RG, 1990, AM J KIDNEY DIS, V15, P201, DOI 10.1016/S0272-6386(12)80763-3; SNOW LF, 1974, ANN INTERN MED, V81, P82, DOI 10.7326/0003-4819-81-1-82; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; YERGAN J, 1987, MED CARE, V25, P592, DOI 10.1097/00005650-198707000-00003; 1992, AM J KIDNEY DIS S2, V20, P20; 1990, JAMA-J AM MED ASSOC, V263, P2344; 1992, AM J KIDNEY DIS S2, V20, P68; 1988, SAS PROCEDURES GUIDE; 1992, USRDS1992 NIH NAT I	40	41	41	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 20	1995	274	23					1858	1862						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK147	7500535				2023-01-03	WOS:A1995TK14700027
J	HIRSCHL, RB; PRANIKOFF, T; GAUGER, P; SCHREINER, RJ; DECHERT, R; BARTLETT, RH				HIRSCHL, RB; PRANIKOFF, T; GAUGER, P; SCHREINER, RJ; DECHERT, R; BARTLETT, RH			LIQUID VENTILATION IN ADULTS, CHILDREN, AND FULL-TERM NEONATES	LANCET			English	Note								We evaluated the safety and efficacy of partial liquid ventilation in a series of 19 adults, children, and neonates who were in respiratory failure and on extracorporeal life support. During partial liquid ventilation, the alveolar-arterial oxygen difference decreased from 590 (SE 25) to 471 (42) mm Hg (p=0 . 0002) and static pulmonary compliance increased from 0 . 18 (0 . 04) to 0 . 29 (0 . 04) mL cm H2O-1 kg(-1) (p=0 . 0002). 11 patients (58%) survived. These preliminary data suggest that partial liquid ventilation can be safely used in patients with severe respiratory failure and may improve lung function.	UNIV MICHIGAN, DEPT SURG, ANN ARBOR, MI 48109 USA	University of Michigan System; University of Michigan			Gauger, Paul/W-8176-2019		EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD015434] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD15434] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTLETT RH, 1990, CURR PROB SURG, V27, P623; FUHRMAN BP, 1991, CRIT CARE MED, V19, P712, DOI 10.1097/00003246-199105000-00019; GATTINONI L, 1993, JAMA-J AM MED ASSOC, V269, P2122, DOI 10.1001/jama.269.16.2122; GREENSPAN JS, 1990, J PEDIATR-US, V117, P106, DOI 10.1016/S0022-3476(05)82457-6; HIRSCHL RB, 1994, SURGERY, V116, P159; HIRSCHL RB, 1995, CHEST, V108, P500, DOI 10.1378/chest.108.2.500; LOWE CA, 1986, J APPL PHYSIOL, V60, P154, DOI 10.1152/jappl.1986.60.1.154; SHAFFER TH, 1992, PEDIATR PULM, V14, P102, DOI 10.1002/ppul.1950140208	8	157	162	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 4	1995	346	8984					1201	1202		10.1016/S0140-6736(95)92903-7	http://dx.doi.org/10.1016/S0140-6736(95)92903-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TC976	7475663				2023-01-03	WOS:A1995TC97600013
J	MATZEL, KE; STADELMAIER, U; HOHENFELLNER, M; GALL, FP				MATZEL, KE; STADELMAIER, U; HOHENFELLNER, M; GALL, FP			ELECTRICAL-STIMULATION OF SACRAL SPINAL NERVES FOR TREATMENT OF FECAL INCONTINENCE	LANCET			English	Article							CONTINENCE; MANAGEMENT; SPHINCTER	Functional deficits of the striated anal sphincteric muscles without any apparent gross defect often result in a lack of ability to postpone defaecation by intention or in faecal incontinence in response to increased intra-abdominal or intra-rectal pressure. We applied electrostimulation to the sacral spinal nerves to increase function of the striated muscles of the anal sphincter. Of three patients followed for 6 months, two gained full continence and one improved from gross incontinence to minor soiling. Closure pressure of the anal canal increased in all. Preliminary data indicate that anal closure pressure increases with the duration of stimulation. Continuous stimulation of sacral spinal nerves can help some patients with faecal incontinence. It may be possible to promote continence with intermittent stimulation.	UNIV WITTEN HERDECKE KLINIKUM, KLINIKUM WUPPERTAL, UROL & KINDERUROL KLIN, WUPPERTAL, GERMANY		MATZEL, KE (corresponding author), UNIV ERLANGEN NURNBERG, CHIRURG KLIN & POLIKLIN, W-8520 ERLANGEN, GERMANY.							BAETEN CGMI, 1991, LANCET, V338, P1163, DOI 10.1016/0140-6736(91)92030-6; CHRISTIANSEN J, 1989, DIS COLON RECTUM, V32, P432, DOI 10.1007/BF02563699; CORMAN ML, 1985, BRIT J SURG, V72, pS21, DOI 10.1002/bjs.1800721314; GASTON EA, 1948, SURG GYNECOL OBSTET, V87, P280; GOLIGHER JC, 1951, LANCET, V260, P543; LAURBERG S, 1990, BRIT J SURG, V77, P519, DOI 10.1002/bjs.1800770515; LONDONOSCHIMMER EE, 1994, INT J COLORECTAL DIS, V9, P110, DOI 10.1007/BF00699424; MATZEL KE, 1990, DIS COLON RECTUM, V33, P666, DOI 10.1007/BF02150742; PARKS A. G., 1962, DIS COLON AND RECTUM, V5, P407, DOI 10.1007/BF02616644; PERCY JP, 1981, LANCET, V1, P16; PETTE D, 1992, REV PHYSIOL BIOCH P, V120, P115, DOI 10.1007/BFb0036123; PICKRELL KL, 1952, ANN SURG, V135, P853, DOI 10.1097/00000658-195206000-00010; READ NW, 1983, GASTROENTEROLOGY, V85, P105; SALMONS S, 1981, MUSCLE NERVE, V4, P94, DOI 10.1002/mus.880040204; SCHMIDT RA, 1990, J UROLOGY, V143, P779, DOI 10.1016/S0022-5347(17)40092-9; SNOOKS SJ, 1986, ANN ROY COLL SURG, V68, P45; TANAGHO EA, 1988, J UROLOGY, V140, P1331, DOI 10.1016/S0022-5347(17)42038-6; TANAGHO EA, 1989, J UROLOGY, V142, P340, DOI 10.1016/S0022-5347(17)38751-7	18	396	410	3	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 28	1995	346	8983					1124	1127		10.1016/S0140-6736(95)91799-3	http://dx.doi.org/10.1016/S0140-6736(95)91799-3			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475602				2023-01-03	WOS:A1995TB54900009
J	COWEN, PJ; CLIFFORD, EM; WILLIAMS, C; WALSH, AES; FAIRBURN, CG				COWEN, PJ; CLIFFORD, EM; WILLIAMS, C; WALSH, AES; FAIRBURN, CG			WHY IS DIETING SO DIFFICULT	NATURE			English	Letter											COWEN, PJ (corresponding author), UNIV OXFORD,LITTLEMORE HOSP,DEPT PSYCHIAT,OXFORD OX4 4XN,ENGLAND.		Fairburn, Christopher/AAG-6234-2019; Fairburn, Christopher/AAM-9792-2020	Fairburn, Christopher/0000-0002-9673-9795; Cowen, Philip/0000-0001-5518-6138				ANDERSON IM, 1990, PSYCHOL MED, V20, P785, DOI 10.1017/S0033291700036473; BROWNELL KD, 1994, AM PSYCHOL, V49, P781, DOI 10.1037/0003-066X.49.9.781; COOPER Z, 1995, EATING DISORDERS OBE, P199; COWEN PJ, 1993, CLIN NEUROPHARMACOL, V16, pS6; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0	5	9	10	0	2	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	AUG 17	1995	376	6541					557	557		10.1038/376557a0	http://dx.doi.org/10.1038/376557a0			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	RP756	7637801				2023-01-03	WOS:A1995RP75600031
J	MITRAGOTRI, S; BLANKSCHTEIN, D; LANGER, R				MITRAGOTRI, S; BLANKSCHTEIN, D; LANGER, R			ULTRASOUND-MEDIATED TRANSDERMAL PROTEIN DELIVERY	SCIENCE			English	Article							INTERFERON-GAMMA; ERYTHROPOIETIN; PHONOPHORESIS; SKIN	Transdermal drug delivery offers a potential method of drug administration. However, its application has been limited to a few low molecular weight compounds because of the extremely low permeability of human skin. Low-frequency ultrasound was shown to increase the permeability of human skin to many drugs, including high molecular weight proteins, by several orders of magnitude, thus making transdermal administration of these molecules potentially feasible. It was possible to deliver and control therapeutic doses of proteins such as insulin, interferon gamma, and erythropoeitin across human skin. Low-frequency ultrasound is thus a potential noninvasive substitute for traditional methods of drug delivery, such as injections.	MIT, DEPT CHEM ENGN, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)								APFEL RE, 1986, IEEE T ULTRASON FERR, V33, P139, DOI 10.1109/T-UFFC.1986.26805; BOMMER J, 1988, LANCET, V2, P406; Bronaugh RL, 1989, PERCUTANEOUS ABSORPT, P27; BURNETTE RR, 1989, TRANSDERMAL DRUG DEL, P247; DAVIS JM, 1987, BIOCHEMISTRY-US, V26, P2633, DOI 10.1021/bi00383a034; ELIAS JJ, 1989, PERCUTANEOUS ABSORPT, P1; FRIDEMAN RM, 1981, INTERFERONS PRIMER; GAERTNER W, 1954, J ACOUST SOC AM, V26, P977, DOI 10.1121/1.1907464; GRUPS JW, 1989, BRIT J UROL, V64, P218, DOI 10.1111/j.1464-410X.1989.tb06000.x; Kost J, 1993, TOPICAL DRUG BIOAVAI, P91; KRALL LP, 1988, WORLD BOOK DIABETES, P160; MITRAGOTRI S, 1995, J PHARM SCI, V84, P697, DOI 10.1002/jps.2600840607; MORIMOTO Y, 1992, J PHARM PHARMACOL, V44, P634, DOI 10.1111/j.2042-7158.1992.tb05484.x; NEWMAN JT, 1992, J AM PODIAT MED ASSN, V82, P432, DOI 10.7547/87507315-82-8-432; PARKIN JM, 1987, BRIT MED J, V294, P1185, DOI 10.1136/bmj.294.6581.1185; PISHKO MV, 1991, ANAL CHEM, V63, P2268, DOI 10.1021/ac00020a014; PRAUSNITZ MR, 1993, P NATL ACAD SCI USA, V90, P10504, DOI 10.1073/pnas.90.22.10504; QUILLEN WS, 1980, ATHL TRAIN, V15, P109; ROSSEL J, 1988, IEEE T BIOMED ENG, V35, P649; SKAUEN DM, 1984, INT J PHARMACEUT, V20, P235, DOI 10.1016/0378-5173(84)90171-6; STRINGFELLOW D, 1986, CLIN APPLICATIONS IN, P1; TACHIBANA K, 1992, PHARMACEUT RES, V9, P952, DOI 10.1023/A:1015869420159; WALMSLEY AD, 1988, ULTRASOUND MED BIOL, V14; WALTERS KA, 1989, TRANSDERMAL DRUG DEL, P197; Wester R. C., 1993, TOPICAL DRUG BIOAVAI, P333	25	605	677	13	144	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 11	1995	269	5225					850	853		10.1126/science.7638603	http://dx.doi.org/10.1126/science.7638603			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	RN650	7638603				2023-01-03	WOS:A1995RN65000048
J	REJTO, PA; BINDEWALD, E; CHANDLER, D				REJTO, PA; BINDEWALD, E; CHANDLER, D			VISUALIZATION OF FAST ENERGY-FLOW AND SOLVENT CAGING IN UNIMOLECULAR DYNAMICS	NATURE			English	Article							CONFORMATIONAL ISOMERIZATION; TRANSITION-STATE; CYCLOHEXANE; LIQUIDS; RELAXATION; ACTIVATION	ENERGY flow in solution between physically or chemically evolving solute molecules and the surrounding solvent significantly affects the nature of chemical dynamics in liquids. It determines the extent to which the statistical theory of reaction rates(1,2) is valid; the transfer of energy between solute and solvent influences the ease with which the transition state evolves into the products-the process central to transition-state theory. But analysing the energy flow in liquid-phase dynamics is difficult because these systems are so complex, and the degrees of freedom are consequently so numerous. Here we present a way to address this challenge. We introduce an approach for visualizing the energy flow directly, and apply it to the isomerization of cyclohexane (between boat and chair conformations) in liquid carbon disulphide, a process for which detailed information about the molecular motions is available from molecular dynamics simulations(8). Our method reveals in pictorial form the formation and relaxation of a solvent cage, and shows that the relaxation has a strong effect on energy flow to and from the transition state on sub-picosecond timescales. We anticipate that this visualization approach will be generally useful for elucidating dynamical molecular processes in solution.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley			Rejto, Paul/M-4782-2019					ANDERSON JB, 1973, J CHEM PHYS, V58, P4684, DOI 10.1063/1.1679032; Bennett C. H., 1977, ACS SYM SER, V46, P63, DOI DOI 10.1021/BK-1977-0046.CH004; BORKOVEC M, 1986, J CHEM PHYS, V85, P146, DOI 10.1063/1.451651; CAMPBELL DM, 1992, J CHEM PHYS, V96, P2717, DOI 10.1063/1.462019; CHANDLER D, 1988, FARADAY DISCUSS, V85, P329, DOI 10.1039/dc9888500329; CHANDLER D, 1978, J CHEM PHYS, V68, P2959, DOI 10.1063/1.436049; CHANDLER D, 1983, SCIENCE, V220, P787, DOI 10.1126/science.220.4599.787; GERTNER BJ, 1991, J AM CHEM SOC, V113, P74, DOI 10.1021/ja00001a014; HANGGI P, 1990, REV MOD PHYS, V62, P251, DOI 10.1103/RevModPhys.62.251; HASHA DL, 1981, J CHEM PHYS, V75, P1571, DOI 10.1063/1.442193; HASHA DL, 1982, J AM CHEM SOC, V104, P2290, DOI 10.1021/ja00372a029; JIMENEZ R, 1994, NATURE, V369, P471, DOI 10.1038/369471a0; Johnston H.S., 1966, GAS PHASE REACTION R; Keck J. C., 1967, ADV CHEM PHYS, V13, P85, DOI 10.1002/9780470140154.ch5; MILLER WH, 1976, ACCOUNTS CHEM RES, V9, P306, DOI 10.1021/ar50104a005; PATRON F, 1991, CHEM PHYS, V152, P121, DOI 10.1016/0301-0104(91)80039-K; PICKETT HM, 1970, J AM CHEM SOC, V92, P7281; REJTO PA, 1994, J PHYS CHEM-US, V98, P12310, DOI 10.1021/j100098a028; SINGER SJ, 1986, J PHYS CHEM-US, V90, P6015, DOI 10.1021/j100280a111; STRAUSS HL, 1971, J CHEM EDUC, V48, P221, DOI 10.1021/ed048p221; Wigner E, 1938, T FARADAY SOC, V34, P0029, DOI 10.1039/tf9383400029; WILSON MA, 1990, CHEM PHYS, V149, P11, DOI 10.1016/0301-0104(90)80127-J	22	11	11	0	6	MACMILLAN MAGAZINES LTD	LONDON	4 LITTLE ESSEX STREET, LONDON, ENGLAND WC2R 3LF	0028-0836			NATURE	Nature	MAY 11	1995	375	6527					129	131		10.1038/375129a0	http://dx.doi.org/10.1038/375129a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	QX741	7753167				2023-01-03	WOS:A1995QX74100045
J	MAIR, P; KORNBERGER, E; HORMANN, C				MAIR, P; KORNBERGER, E; HORMANN, C			ACCIDENTAL HYPOTHERMIA	LANCET			English	Letter											MAIR, P (corresponding author), UNIV INNSBRUCK, SCH MED, DEPT ANAESTHESIA & INTENS CARE MED, A-6020 INNSBRUCK, AUSTRIA.							DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6	1	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 22	1995	345	8956					1048	1049						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QU573	7772186				2023-01-03	WOS:A1995QU57300039
J	HASSAN, N; WU, GY				HASSAN, N; WU, GY			GETTING TO THE CORE OF THE MATTER	NATURE MEDICINE			English	Editorial Material							VIRUS-DNA SYNTHESIS; ASIALOGLYCOPROTEIN RECEPTOR; HEPATOCYTES; ASIALOFETUIN; INHIBITION; DELIVERY; RESCUE; MODEL; CELLS				HASSAN, N (corresponding author), UNIV CONNECTICUT,CTR HLTH,DEPT MED,FARMINGTON,CT 06030, USA.							ASHWELL G, 1974, ADV ENZYMOL, V4, P99; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; CERENZIA MRT, 1994, J HEPATOL, V20, P307, DOI 10.1016/S0168-8278(05)80076-5; FIUME L, 1979, FEBS LETT, V103, P47, DOI 10.1016/0014-5793(79)81247-8; FIUME L, 1980, FEBS LETT, V116, P185, DOI 10.1016/0014-5793(80)80639-9; FLOREN CH, 1978, BIOCHEM J, V168, P493; GREGORIADIS G, 1993, DRUGS, V45, P15, DOI 10.2165/00003495-199345010-00003; HUBER BE, 1992, MOL PHARMACOL, V41, P639; MOMMAASKIENHUIS AM, 1985, EUR J CELL BIOL, V38, P42; MU JZ, 1993, AM J PHYSIOL, V264, pG752, DOI 10.1152/ajpgi.1993.264.4.G752; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; VANDERSLUIJS P, 1990, HEPATOLOGY, V6, P723; WU GY, 1985, HEPATOLOGY, V5, P709, DOI 10.1002/hep.1840050502; WU GY, 1983, P NATL ACAD SCI-BIOL, V80, P3078, DOI 10.1073/pnas.80.10.3078	14	3	3	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	MAR	1995	1	3					210	211		10.1038/nm0395-210	http://dx.doi.org/10.1038/nm0395-210			2	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	QX559	7585034				2023-01-03	WOS:A1995QX55900024
J	QUILL, TE; CASSEL, CK				QUILL, TE; CASSEL, CK			NONABANDONMENT - A CENTRAL OBLIGATION FOR PHYSICIANS	ANNALS OF INTERNAL MEDICINE			English	Article							INFORMED CONSENT; CARE; MODELS; ILL	Nonabandonment is one of a physician's central ethical obligations; it reflects a longitudinal commitment both to care about patients and to jointly seek solutions to problems with patients throughout their illnesses. The depth of this commitment may vary depending on the physician's and the patient's values and personalities, their shared experiences, and the patient's clinical circumstances. Traditional principled ethical analyses must balance the personal histories, values, motivations, and intentions of the participants with more general considerations. Such analyses often focus on a particular act, isolated in time, and yet the consequences of one decision immediately lead to a new set of choices. Nonabandonment places the physician's open-ended, long-term, caring commitment to joint problem solving at the core of medical ethics and clinical medicine. There is a world of difference between facing an uncertain future alone and facing it with a committed, caring, knowledgeable partner who will not shy away from difficult decisions when the path is unclear.	UNIV ROCHESTER, SCH MED, ROCHESTER, NY USA; UNIV CHICAGO, SCH MED, GEN INTERNAL MED SECT, CHICAGO, IL 60637 USA	University of Rochester; University of Chicago								BARON RJ, 1985, ANN INTERN MED, V103, P606, DOI 10.7326/0003-4819-103-4-606; Beauchamp TL, 1994, PRINCIPLES BIOMEDICA, V4th; BENSON JA, 1983, ANN INTERN MED, V99, P720, DOI 10.7326/0003-4819-99-5-720; BERNAT JL, 1993, ARCH INTERN MED, V153, P2723, DOI 10.1001/archinte.153.24.2723; Brody H., 1987, STORIES SICKNESS; Cassel, 1991, NATURE SUFFERING GOA; EDDY DM, 1994, JAMA-J AM MED ASSOC, V272, P179, DOI 10.1001/jama.272.3.179; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2221, DOI 10.1001/jama.267.16.2221; EMANUEL EJ, 1993, NEW ENGL J MED, V329, P879, DOI 10.1056/NEJM199309163291213; FOX RC, IN PRESS ENTRY US BI; Frankl Viktor E., 1946, MANS SEARCH MEANING; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; Gilligan C., 1982, DIFFERENT VOICE; GUSTAFSON JM, 1990, J MED PHILOS, V15, P125, DOI 10.1093/jmp/15.2.125; Jonsen Albert R., 1998, CLIN ETHICS, V4th; Jonsen Albert R., 1988, ABUSE CASUISTRY HIST; KATZ J, 1992, HUM MED, V8, P187; KRAUT AM, 1990, JAMA-J AM MED ASSOC, V263, P1807, DOI 10.1001/jama.263.13.1807; LIDZ CW, 1988, ARCH INTERN MED, V148, P1385, DOI 10.1001/archinte.148.6.1385; MacIntyre A., 1984, AFTER VIRTUE; MATTHEWS DA, 1993, ANN INTERN MED, V118, P973, DOI 10.7326/0003-4819-118-12-199306150-00010; MAY WF, 1983, PHYSICIANS COVENANT; Montgomery Hunter K, 1991, DOCTORS STORIES NARR; NOBLE J, 1987, TXB GENERAL MED PRIM, P3; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; Peabody FW, 1927, J AMER MED ASSOC, V88, P0877, DOI 10.1001/jama.1927.02680380001001; PELLEGRINO ED, 1993, JAMA-J AM MED ASSOC, V270, P874, DOI 10.1001/jama.270.7.874; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1991, ARCH INTERN MED, V151, P463; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; QUILL TE, 1993, JAMA-J AM MED ASSOC, V270, P870, DOI 10.1001/jama.270.7.870; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; QUILL TE, 1993, NEW ENGL J MED, V329, P1039, DOI 10.1056/NEJM199309303291414; Quill TE, 1993, DEATH DIGNITY MAKING; Ramsey P., 1970, PATIENT PERSON; Rogers C. R.., 1961, BECOMING PERSON; SEDLER RA, 1993, HASTINGS CENT REP, V23, P20, DOI 10.2307/3562062; Sherwin S., 1992, NO LONGER PATIENT FE; SHOWSTACK J, 1992, JAMA-J AM MED ASSOC, V267, P2497, DOI 10.1001/jama.267.18.2497; SINGER GR, 1975, NEW ENGL J MED, V293, P780; TOULMIN S, 1981, HASTINGS CENT REP, V11, P31, DOI 10.2307/3560542; TRUOG RD, 1992, NEW ENGL J MED, V327, P1678, DOI 10.1056/NEJM199212033272311; ZANER RM, 1970, WAY PHENOMENOLOGY; ZINN W, 1993, ARCH INTERN MED, V153, P306, DOI 10.1001/archinte.153.3.306; 1992, ANN INTERN MED, V117, P947; 1986, CURRENT OPINIONS 198, P8; 1992, JAMA-J AM MED ASSOC, V276, P2229	48	185	185	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1995	122	5					368	374		10.7326/0003-4819-122-5-199503010-00008	http://dx.doi.org/10.7326/0003-4819-122-5-199503010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ085	7847649				2023-01-03	WOS:A1995QJ08500008
J	GILBERT, RE; WIGFIELD, RE; FLEMING, PJ; BERRY, PJ; RUDD, PT				GILBERT, RE; WIGFIELD, RE; FLEMING, PJ; BERRY, PJ; RUDD, PT			BOTTLE-FEEDING AND THE SUDDEN-INFANT-DEATH-SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							SLEEPING POSITION; UNEXPECTED DEATH; RISK-FACTORS; BREAST-MILK; COT DEATH; EPIDEMIOLOGY; CHILDREN; PRETERM	Objective-To determine whether the risk of the sudden infant death syndrome is increased in bottle fed babies. Design-Population based case-control study matching for age and time. Subjects-All babies aged 1 week to 1 year dying of sudden infant death syndrome during November 1987 to April 1989 or February 1990 to June 1991 and two live controls. Setting-Avon and north Somerset. Main outcome measures-Breast or bottle feeding, sleeping position, maternal smoking, parental employment, and length of gestation. Results-Compared with being fully breast fed, the crude odds ratio for sudden infant death in fully bottle fed babies was 3.1 and for mixed breast and bottle fed babies 1.5. These odds ratios fell to 1.8 (95% confidence interval 0.7 to 4.8) and 1.2 (0.5 to 2.7) respectively after maternal smoking, parental employment, preterm gestation, and sleeping position had been adjusted for. Sleeping position partly masked the effect of being bottle fed on sudden infant death as breast fed babies were more likely to have slept prone than bottle fed babies. Conclusions-Bottle feeding is not a significant independent risk factor for the sudden infant death syndrome. Patterns of maternal smoking, preterm gestation, and parental employment status account for most of the apparent association with bottle feeding.	ST MICHAELS HOSP, DEPT CHILD HLTH, BRISTOL BS2 8EG, AVON, ENGLAND; ROYAL UNITED HOSP, BATH UNIT RES PAEDIAT, BATH BA1 3NG, AVON, ENGLAND; ST MICHAELS HOSP, DEPT PAEDIAT PATHOL, BRISTOL BS2 8EG, AVON, ENGLAND		GILBERT, RE (corresponding author), INST CHILD HLTH, DEPT EPIDEMIOL & BIOSTAT, LONDON WC1N 1EH, ENGLAND.		Fleming, Peter J/A-9081-2010; Fleming, Peter/O-3231-2019	Fleming, Peter J/0000-0003-2521-5764; Fleming, Peter/0000-0003-2521-5764; Gilbert, Ruth/0000-0001-9347-2709	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAL SM, 1986, AUST PAEDIATR J, V22, P13; BIERINGSORENSEN F, 1978, ACTA PAEDIATR SCAND, V67, P129, DOI 10.1111/j.1651-2227.1978.tb16292.x; BROOKS JG, 1994, PEDIATRICS, V94, P456; CARPENTE.RG, 1965, BRIT J PREV SOC MED, V19, P1; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; ENGELBERTS AC, 1991, THESIS; FEDRICK J, 1974, BRIT J PREV SOC MED, V28, P164; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FORD RPK, 1993, INT J EPIDEMIOL, V22, P885, DOI 10.1093/ije/22.5.885; FROGART P, 1971, BR J PREV SOC MED, V49, P119; HARRIS JDC, 1982, J EPIDEMIOL COMMUN H, V36, P162, DOI 10.1136/jech.36.3.162; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; KNOWELDEN J, 1984, MULTICENTRE STUDY PO; KRAUS AS, 1971, C J PUBLIC HEALTH, V62, P210; KRAUS JF, 1989, INT J EPIDEMIOL, V18, P113, DOI 10.1093/ije/18.1.113; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; LUCAS A, 1992, LANCET, V339, P261, DOI 10.1016/0140-6736(92)91329-7; LUCAS A, 1990, BRIT MED J, V300, P837, DOI 10.1136/bmj.300.6728.837; MCGLASHAN ND, 1989, SOC SCI MED, V29, P1015, DOI 10.1016/0277-9536(89)90059-2; MITCHELL EA, 1992, AUST J PUBLIC HEALTH, V16, P158; MURPHY JF, 1982, J EPIDEMIOL COMMUN H, V36, P17, DOI 10.1136/jech.36.1.17; POLLOCK JI, 1992, EFFECTS SMOKING FETU, P108; PROTESTOS CD, 1973, ARCH DIS CHILD, V48, P835, DOI 10.1136/adc.48.11.835; RHEAD WJ, 1973, BMJ-BRIT MED J, V4, P548, DOI 10.1136/bmj.4.5891.548-d; SAVAGE F, 1992, MIDIRS MIDWIFERY DIG, V2, P3; WATSON E, 1981, MED SCI LAW, V21, P78, DOI 10.1177/002580248102100202; WHITE AS, 1992, INFANT FEEDING 1990; WIGFIELD RE, 1992, BRIT MED J, V304, P282, DOI 10.1136/bmj.304.6822.282; WILLIAMS AF, 1994, ARCH DIS CHILD, V71, P376; 1993, REPORT CHIEF MED OFF	31	47	48	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 14	1995	310	6972					88	90		10.1136/bmj.310.6972.88	http://dx.doi.org/10.1136/bmj.310.6972.88			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC223	7833732	Green Published			2023-01-03	WOS:A1995QC22300018
J	JENCKS, SF; DALEY, J; DRAPER, D; THOMAS, N; LENHART, G; WALKER, J				JENCKS, SF; DALEY, J; DRAPER, D; THOMAS, N; LENHART, G; WALKER, J			INTERPRETING HOSPITAL MORTALITY DATA - THE ROLE OF CLINICAL RISK ADJUSTMENT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									CHARLES A DANA RES INST,BOSTON,MA; HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV GEN MED & PRIMARY CARE,BOSTON,MA 02215; BAXTER HEALTHCARE CORP,INST HLTH DATA,LEXINGTON,MA; HARVARD UNIV,THORNDIKE LAB,CAMBRIDGE,MA 02138	Harvard University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Baxter International Inc; Harvard University	JENCKS, SF (corresponding author), HLTH CARE FINANCING ADM,OFF RES,BALTIMORE,MD, USA.							DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; Deming W, 1982, OUT CRISIS; DUBOIS RW, 1987, NEW ENGL J MED, V317, P1674, DOI 10.1056/NEJM198712243172626; DUBOIS RW, 1988, ANN INTERN MED, V109, P582, DOI 10.7326/0003-4819-109-7-582; IEZZONI LI, 1987, ABILITY MEDISGROUPS; Juran J.M., 1988, JURAN PLANNING QUALI; LEONARD T, 1972, BIOMETRIKA, V59, P581; ROLPH J, 1974, J AM STAT ASS, V69, P880; TSUTAKAWA RK, 1985, BIOMETRICS, V41, P69, DOI 10.2307/2530644; 1988, MEDICARE IMPROVED PA; 1980, INT CLASSIFICATION D; 1987, MEDICARE HOSPITAL MO	12	173	173	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 23	1988	260	24					3611	3616		10.1001/jama.260.24.3611	http://dx.doi.org/10.1001/jama.260.24.3611			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R3644	3057250				2023-01-03	WOS:A1988R364400031
J	KRUPINSKI, J; RAJARAM, R; LAKONISHOK, M; BENOVIC, JL; CERIONE, RA				KRUPINSKI, J; RAJARAM, R; LAKONISHOK, M; BENOVIC, JL; CERIONE, RA			INSULIN-DEPENDENT PHOSPHORYLATION OF GTP-BINDING PROTEINS IN PHOSPHOLIPID-VESICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									CORNELL UNIV,NEW YORK STATE COLL VET MED,ITHACA,NY 14853; DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Cornell University; Duke University					NEI NIH HHS [EY0642901] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AKIYAMA T, 1985, BIOCHEM BIOPH RES CO, V131, P442, DOI 10.1016/0006-291X(85)91822-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; CERIONE RA, 1985, BIOCHEMISTRY-US, V24, P4499, DOI 10.1021/bi00338a002; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CERIONE RA, 1985, J BIOL CHEM, V260, P1493; CERIONE RA, 1986, RECEPTORS, P2; COHEN S, 1982, J BIOL CHEM, V257, P1523; COOPER JA, 1981, MOL CELL BIOL, V1, P165, DOI 10.1128/MCB.1.2.165; DAS M, 1977, P NATL ACAD SCI USA, V74, P2790, DOI 10.1073/pnas.74.7.2790; EVANS T, 1986, J BIOL CHEM, V261, P7052; FUKAMI Y, 1985, P NATL ACAD SCI USA, V82, P321, DOI 10.1073/pnas.82.2.321; GAWLER D, 1987, FEBS LETT, V216, P94, DOI 10.1016/0014-5793(87)80763-9; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P2674, DOI 10.1073/pnas.81.9.2674; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; GIERSCHIK P, 1984, FEBS LETT, V172, P321, DOI 10.1016/0014-5793(84)81149-7; GILMAN AG, 1984, CELL, V36, P577, DOI 10.1016/0092-8674(84)90336-2; GOMPERTS BD, 1983, NATURE, V306, P64, DOI 10.1038/306064a0; HEYWORTH CM, 1985, BIOCHEM J, V228, P593, DOI 10.1042/bj2280593; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ITOH H, 1986, P NATL ACAD SCI US, P2776; JOHNSON RM, 1986, P NATL ACAD SCI USA, V83, P2032, DOI 10.1073/pnas.83.7.2032; KAHN CR, 1985, ANNU REV MED, V36, P429; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KOLAND JG, 1988, J BIOL CHEM, V263, P2230; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFKOWITZ RJ, 1983, ANNU REV BIOCHEM, V52, P159, DOI 10.1146/annurev.bi.52.070183.001111; LITOSCH I, 1985, J BIOL CHEM, V260, P5464; MILLIGAN G, 1985, J BIOL CHEM, V260, P2057; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MURAYAMA T, 1985, J BIOL CHEM, V260, P7226; NEER EJ, 1984, J BIOL CHEM, V259, P4222; OBRIEN RM, 1987, FEBS LETT, V212, P281, DOI 10.1016/0014-5793(87)81361-3; PETRUZZELLI L, 1984, P NATL ACAD SCI-BIOL, V81, P3327, DOI 10.1073/pnas.81.11.3327; PIKE LJ, 1986, J BIOL CHEM, V261, P3782; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; ROTH RA, 1983, SCIENCE, V219, P299, DOI 10.1126/science.6849137; SALTIEL AR, 1986, SCIENCE, V233, P967, DOI 10.1126/science.3016898; SHIA MA, 1983, BIOCHEMISTRY-US, V22, P717, DOI 10.1021/bi00273a001; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRYER L, 1981, CURR TOP MEMBR TRANS, V15, P93; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; YU KT, 1984, J BIOL CHEM, V259, P5277; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	49	93	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1988	263	25					12333	12341						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	P8611	3137226				2023-01-03	WOS:A1988P861100030
J	COLQUHOUN, MC				COLQUHOUN, MC			USE OF DEFIBRILLATORS BY GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article																		ARMSTRONG A, 1972, BRIT HEART J, V34, P67; COBB LA, 1975, CIRCULATION       S3, V51, P223; CUMMINS RO, 1985, BRIT MED J, V291, P1401, DOI 10.1136/bmj.291.6506.1401; PAI GR, 1987, BRIT MED J, V294, P352, DOI 10.1136/bmj.294.6568.352; RAWLINS DC, 1981, BRIT MED J, V282, P1677, DOI 10.1136/bmj.282.6277.1677	5	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 30	1988	297	6644					336	336		10.1136/bmj.297.6644.336	http://dx.doi.org/10.1136/bmj.297.6644.336			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4527	3416166	Green Published, Bronze			2023-01-03	WOS:A1988P452700025
J	PENNEY, TM				PENNEY, TM			DELAYED COMMUNICATION BETWEEN HOSPITALS AND GENERAL-PRACTITIONERS - WHERE DOES THE PROBLEM LIE	BRITISH MEDICAL JOURNAL			English	Article									SUNDON MED CTR,LUTON,BEDS,ENGLAND									BADO W, 1984, BRIT MED J, V288, P1813, DOI 10.1136/bmj.288.6433.1813; Dover S B, 1984, Health Trends, V16, P48; MAGEEAN RJ, 1986, BRIT MED J, V293, P1283, DOI 10.1136/bmj.293.6557.1283; TULLOCH AJ, 1975, BRIT MED J, V4, P443, DOI 10.1136/bmj.4.5994.443	4	61	62	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 2	1988	297	6640					28	29		10.1136/bmj.297.6640.28-a	http://dx.doi.org/10.1136/bmj.297.6640.28-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P1000	3408904	Bronze, Green Published			2023-01-03	WOS:A1988P100000023
J	BRAHAMS, D				BRAHAMS, D			NO OBLIGATION TO RESUSCITATE A NON-VIABLE INFANT	LANCET			English	Editorial Material																			0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 21	1988	1	8595					1176	1176						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N4532	2897002				2023-01-03	WOS:A1988N453200062
J	GINSBERG, AL; BECK, LS; MCINTOSH, TM; NOCHOMOVITZ, LE				GINSBERG, AL; BECK, LS; MCINTOSH, TM; NOCHOMOVITZ, LE			TREATMENT OF LEFT-SIDED ULCERATIVE-COLITIS WITH 4-AMINOSALICYLIC ACID ENEMAS - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article									GEORGE WASHINGTON UNIV, SCH MED, DEPT PATHOL, WASHINGTON, DC 20037 USA	George Washington University	GINSBERG, AL (corresponding author), GEORGE WASHINGTON UNIV, SCH MED, DEPT MED, DIV GASTROENTEROL, 2150 PENN AVE NW, WASHINGTON, DC 20037 USA.							AZADKHAN AK, 1977, LANCET, V2, P892; BARON JH, 1964, BRIT MED J, V1, P89, DOI 10.1136/bmj.1.5375.89; BOWER G, 1964, AM REV RESPIR DIS, V89, P440; CAMPIERI M, 1984, DIGESTION, V29, P204, DOI 10.1159/000199034; CANNEMEYER W, 1955, BLOOD, V10, P62, DOI 10.1182/blood.V10.1.62.62; GANDOLFO J, 1987, DIGEST DIS SCI, V32, P700, DOI 10.1007/BF01296134; GINSBERG AL, 1985, GASTROENTEROLOGY, V88, P1395; HENSLER NM, 1957, AM REV TUBERC PULM, V76, P132; LEHMANN J, 1946, LANCET, V250, P15; LIGUMSKY M, 1981, GASTROENTEROLOGY, V81, P444; Lover M.J., 1984, US patent, Patent No. [44 40 763, 4440763]; SELBY WS, 1984, DIGESTION, V29, P231, DOI 10.1159/000199038; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; SIMPSON DG, 1960, AM J MED, V29, P297, DOI 10.1016/0002-9343(60)90026-7; STENSON WF, 1982, J CLIN INVEST, V69, P494, DOI 10.1172/JCI110474; VANHEES PAM, 1980, GUT, V21, P632, DOI 10.1136/gut.21.7.632	16	61	62	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB	1988	108	2					195	199		10.7326/0003-4819-108-2-195	http://dx.doi.org/10.7326/0003-4819-108-2-195			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L9765	3277506				2023-01-03	WOS:A1988L976500007
J	PARISI, VM; MEYER, BA				PARISI, VM; MEYER, BA			TO STAY OR NOT TO STAY - THAT IS THE QUESTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							DISCHARGE				PARISI, VM (corresponding author), SUNY STONY BROOK,MED CTR,STONY BROOK,NY 11794, USA.							ANNAS GJ, 1995, NEW ENGL J MED, V333, P1647, DOI 10.1056/NEJM199512143332420; CONRAD PD, 1989, AM J DIS CHILD, V143, P98, DOI 10.1001/archpedi.1989.02150130108026; WILLIAMS JW, 1912, JAMA-J AM MED ASSOC, V58, P7; WILLIAMS JW, 1912, JAMA-J AM MED ASSOC, V58, P4; YANOVER MJ, 1976, NEW ENGL J MED, V294, P702, DOI 10.1056/NEJM197603252941306; 1992, GUIDELINES PERINATAL; 1995, PEDIATRICS, V96, P788	7	30	30	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1635	1637		10.1056/NEJM199512143332412	http://dx.doi.org/10.1056/NEJM199512143332412			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477203				2023-01-03	WOS:A1995TK06500012
J	ELIA, M				ELIA, M			CHANGING CONCEPTS OF NUTRIENT-REQUIREMENTS IN DISEASE - IMPLICATIONS FOR ARTIFICIAL NUTRITIONAL SUPPORT	LANCET			English	Review							PARENTERAL-NUTRITION; ENERGY-EXPENDITURE; ENTERAL NUTRITION; BURNED CHILDREN				ELIA, M (corresponding author), DUNN CLIN NUTR CTR,HILLS RD,CAMBRIDGE CB2 2DH,ENGLAND.							ALLWOOD MC, 1992, CLIN NUTR, V11, P284, DOI 10.1016/0261-5614(92)90005-B; BOUGLE D, 1993, J PEDIATR GASTR NUTR, V17, P72, DOI 10.1097/00005176-199307000-00010; Byrne Theresa A., 1992, Surgical Forum, V43, P151; CARLSSON M, 1984, CLIN NUTR, V3, P103, DOI 10.1016/S0261-5614(84)80008-4; DALY JM, 1992, SURGERY, V112, P56; Elia M., 1992, International Journal of Food Sciences and Nutrition, V43, P47, DOI 10.3109/09637489209027532; Elia M., 1994, MED INT, V22, P411; ELIA M, 1992, CURR MED LIT CLIN NU, V1, P35; ELIA M, 1994, P NUTR SOC, V53, P114; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; FURST P, 1994, EUR J CLIN NUTR, V48, P681; GARIZ MB, 1993, J NUTR, V123, P238; GOLDIN BR, 1991, PROBIOTICS SCI BASIS, P355; GORAN MI, 1990, AM J PHYSIOL, V259, pE576, DOI 10.1152/ajpendo.1990.259.4.E576; HALLIWELL B, 1994, NUTR REV, V52, P253; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; HANNING RM, 1991, AM J CLIN NUTR, V54, P905; HERNDON DN, 1990, ANN SURG, V212, P424, DOI 10.1097/00000658-199010000-00005; HOWARD L, 1980, ANN INTERN MED, V93, P567; KLEIN GL, 1991, AM J CLIN NUTR, V53, P399, DOI 10.1093/ajcn/53.2.399; LAFRANCE RJ, 1991, TOTAL PARENTERAL NUT, P57; MIROWITZ SA, 1992, RADIOLOGY, V185, P535, DOI 10.1148/radiology.185.2.1410368; MIROWITZ SA, 1991, RADIOLOGY, V181, P117, DOI 10.1148/radiology.181.1.1909445; Moukarzel A., 1993, Clinical Nutrition (Edinburgh), V12, P59, DOI 10.1016/0261-5614(93)90154-V; MURRAY MJ, 1979, AM J CLIN NUTR, V32, P593, DOI 10.1093/ajcn/32.3.593; NAYLOR CD, 1987, GASTROENTEROLOGY, V97, P1033; NOVICK WM, 1988, SURGERY, P99; PLAUTH M, 1993, J HEPATOL, V17, P308, DOI 10.1016/S0168-8278(05)80210-7; PULLICINO E, CNAA DX96679 BRIT LE; PULLICINO E, 1992, METABOLISM, V42, P58; RUDMAN D, 1981, GASTROENTEROLOGY, V81, P1025; SAGAR P, 1995, CLIN NUTR, V14, P13, DOI 10.1016/S0261-5614(06)80004-X; SHENKIN A, 1986, CLIN NUTR, V5, P91, DOI 10.1016/0261-5614(86)90014-2; STANSFIELD SK, 1993, LANCET, V342, P578, DOI 10.1016/0140-6736(93)91410-N; STOBBAERTS RFJ, 1992, Z ERNAHRUNGSWISS, V31, P138, DOI 10.1007/BF01623072; THURNHAM DI, 1994, P NUTR SOC, V53, P557, DOI 10.1079/PNS19940065; WEEKES E, 1994, P NUTR SOC, V53, pA43; ZEIGLER TR, 1992, ANN INTERN MED, V116, P821; 1993, LANCET, V341, P1227; 1991, DIETARY REFERENCE VA; 1994, AM J HOSP PHARM, V51, P1427; 1979, J PARENTERAL ENTERAL, V3, P258; 1989, RECOMMENDED DIETARY; 1994, NEW ENGL J MED, V330, P1029	44	53	59	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 20	1995	345	8960					1279	1284		10.1016/S0140-6736(95)90929-X	http://dx.doi.org/10.1016/S0140-6736(95)90929-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY933	7746061				2023-01-03	WOS:A1995QY93300013
J	ASHTON, CM; KUYKENDALL, DH; JOHNSON, ML; WRAY, NP; WU, L				ASHTON, CM; KUYKENDALL, DH; JOHNSON, ML; WRAY, NP; WU, L			THE ASSOCIATION BETWEEN THE QUALITY OF INPATIENT CARE AND EARLY READMISSION	ANNALS OF INTERNAL MEDICINE			English	Article						PATIENT READMISSION; QUALITY OF HEALTH CARE; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); HOSPITALIZATION	DISEASE	Objective: To determine whether the quality of care during a hospital stay is associated with unplanned readmission within 14 days. Design: Case-control study. Setting: 12 Veterans Affairs hospitals. Patients: Men discharged after a hospitalization for diabetes (n = 593), chronic obstructive lung disease (n = 1172), or heart failure (n = 748). The ratio of controls (men without an unplanned readmission within 14 days to any Veterans Affairs hospital) to cases (men with such a readmission) was 3:1. Main Outcome Measures: Unplanned readmission to any of the 159 Veterans Affairs hospitals within 14 days of discharge. Quality of care during the index stay was assessed by chart review using disease-specific explicit criteria for the process of inpatient care, which were developed by panels composed of expert physicians. Adherence scores (the percentage of applicable criteria that were met) were calculated for the admission workup, evaluation and treatment, and readiness for discharge. Results: After adjustment was made for demographic characteristics, severity of illness, and need for care, adherence scores correlated with early unplanned readmission (P < 0.05). For patients with diabetes and heart failure, decreased readiness-for-discharge adherence scores correlated with increased risk for readmission (P = 0.001 and P = 0.016, respectively). In patients with obstructive lung disease, decreased admission-workup scores correlated with increased risk for readmission (P = 0.013). One of 7 readmissions in patients with diabetes, 1 of 5 readmissions in patients with heart failure, and 1 of 12 readmissions in patients with obstructive lung disease were attributable to substandard care. Conclusions: Lower quality of inpatient care increases the risk for unplanned early readmission in patients with heart failure, diabetes, or obstructive lung disease. Under certain circumstances, readmission is associated with remediable deficiencies in the process of inpatient care.	BAYLOR COLL MED, HOUSTON, TX 77030 USA	Baylor College of Medicine	ASHTON, CM (corresponding author), VET AFFAIRS MED CTR, 2002 HOLCOMBE BLVD, HOUSTON, TX 77030 USA.							ANDERSON GF, 1984, NEW ENGL J MED, V311, P1349, DOI 10.1056/NEJM198411223112105; ASHTON CM, 1994, J GEN INTERN MED, V9, P208, DOI 10.1007/BF02600126; ASHTON CM, 1994, MED CARE, V32, P755, DOI 10.1097/00005650-199408000-00001; ASHTON CM, 1987, MED CARE, V25, P1184, DOI 10.1097/00005650-198712000-00008; CAPLAN RA, 1991, JAMA-J AM MED ASSOC, V265, P1957, DOI 10.1001/jama.265.15.1957; FEINGLASS J, 1991, HEALTH SERV RES, V26, P183; Fleiss J. L., 1981, STAT METHODS RATES P, V2nd, P211, DOI DOI 10.2307/2530193; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; HAYWARD RA, 1993, MED CARE, V31, P394, DOI 10.1097/00005650-199305000-00002; Hosmer D., 2000, APPL LOGISTIC REGRES, V2; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P162; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LUDKE RL, 1993, INQUIRY-J HEALTH CAR, V30, P95; MANHEIM LM, 1990, MED CARE, V28, P29, DOI 10.1097/00005650-199001000-00005; REED RL, 1991, J GEN INTERN MED, V6, P223, DOI 10.1007/BF02598964; SANAZARO PJ, 1991, JAMA-J AM MED ASSOC, V265, P1977, DOI 10.1001/jama.265.15.1977; SIMMER TL, 1991, MED CARE, V29, pJS31; THOMAS JW, 1991, MED CARE, V29, P377, DOI 10.1097/00005650-199104000-00006; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; WILLIAMS EI, 1988, BRIT MED J, V297, P784, DOI 10.1136/bmj.297.6651.784; WRAY NP, 1995, MED CARE, V33, P75, DOI 10.1097/00005650-199501000-00007; 1989, ANAL READMISSIONS US; 1989, SAS UNIX 607	23	280	289	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					415	421		10.7326/0003-4819-122-6-199503150-00003	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QM266	7856989				2023-01-03	WOS:A1995QM26600003
J	PINK, G				PINK, G			THE PRICE OF TRUTH	BRITISH MEDICAL JOURNAL			English	Article																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1700	1705		10.1136/bmj.309.6970.1700	http://dx.doi.org/10.1136/bmj.309.6970.1700			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7819994	Green Published			2023-01-03	WOS:A1994PY71700023
J	MARTIN, MJ; HUNT, TK; HULLEY, SB				MARTIN, MJ; HUNT, TK; HULLEY, SB			THE COST OF HOSPITALIZATION FOR FIREARM INJURIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & INT HLTH,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	MARTIN, MJ (corresponding author), UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,CLIN EPIDEMIOL PROGRAM,BOX 0886,SAN FRANCISCO,CA 94143, USA.							ALEXANDER GR, 1985, AM J PUBLIC HEALTH, V75, P165, DOI 10.2105/AJPH.75.2.165; [Anonymous], 1987, Health Care Financ Rev, V8, P1; Baker S P, 1980, J Public Health Policy, V1, P224, DOI 10.2307/3342086; BAKER SP, 1984, INJURY FACT BOOK, P297; BRAY T, 1985, JAMA-J AM MED ASSOC, V254, P2452, DOI 10.1001/jama.254.17.2452; CARD JJ, 1974, OMEGA-J DEATH DYING, V5, P37, DOI 10.2190/K59M-Y0KN-PAKV-JFUV; ETTER IB, 1987, PUBLIC HEALTH REP, V102, P634; FISCHER RP, 1985, J TRAUMA, V25, P746, DOI 10.1097/00005373-198508000-00003; GOODMAN RA, 1986, AM J PUBLIC HEALTH, V76, P144, DOI 10.2105/AJPH.76.2.144; HARTUNIAN NS, 1980, AM J PUBLIC HEALTH, V70, P1249, DOI 10.2105/AJPH.70.12.1249; JETT HH, 1972, J TRAUM, V12, P577, DOI 10.1097/00005373-197207000-00005; LUNA GK, 1988, ARCH SURG-CHICAGO, V123, P825; MACLENNAN C, 1987, PUBLIC HEALTH REP, V102, P636; MUNOZ E, 1984, J TRAUMA, V24, P237; Rice D P, 1985, Health Care Financ Rev, V7, P61; SMITH GS, 1987, AM J PREV MED S, V3, P143; TARDIFF K, 1986, AM J PUBLIC HEALTH, V76, P139, DOI 10.2105/AJPH.76.2.139; 1984, HLTH CARE FINANCING, V5, P1	18	56	56	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 25	1988	260	20					3048	3050		10.1001/jama.260.20.3048	http://dx.doi.org/10.1001/jama.260.20.3048			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q9245	3184369				2023-01-03	WOS:A1988Q924500035
J	JENKINSON, D; DAVISON, J; JONES, S; HAWTIN, P				JENKINSON, D; DAVISON, J; JONES, S; HAWTIN, P			COMPARISON OF EFFECTS OF A SELF MANAGEMENT BOOKLET AND AUDIOCASSETTE FOR PATIENTS WITH ASTHMA	BRITISH MEDICAL JOURNAL			English	Article									UNIV NOTTINGHAM,SCH MED,DEPT COMMUNITY MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND	University of Nottingham								ANDERSON JE, 1980, BRIT MED J, V281, P924, DOI 10.1136/bmj.281.6245.924; BLUM ML, 1968, IND PSYCHOL THEORETI, P306; FIREMAN P, 1981, PEDIATRICS, V68, P341; HARDING JM, 1985, J ROY COLL GEN PRACT, V35, P226; HILTON S, 1986, LANCET, V1, P26; LEWIS CE, 1984, PEDIATRICS, V74, P478; LEY P, 1976, PSYCHOL MED, V6, P599, DOI 10.1017/S0033291700018237; MAIMAN LA, 1979, JAMA-J AM MED ASSOC, V241, P1919; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; MCCULLOCH DK, 1983, BRIT MED J, V287, P1858, DOI 10.1136/bmj.287.6408.1858; MODELL M, 1983, BRIT MED J, V286, P2027, DOI 10.1136/bmj.286.6383.2027; MORRELL DC, 1980, BRIT MED J, V280, P769, DOI 10.1136/bmj.280.6216.769	12	69	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1988	297	6643					267	270		10.1136/bmj.297.6643.267	http://dx.doi.org/10.1136/bmj.297.6643.267			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4266	3416147	Green Published, Bronze			2023-01-03	WOS:A1988P426600022
J	MAHER, ER; DUTOIT, SH; BAILLOD, RA; SWENY, P; MOORHEAD, JF				MAHER, ER; DUTOIT, SH; BAILLOD, RA; SWENY, P; MOORHEAD, JF			GASTROINTESTINAL COMPLICATIONS OF DIALYSIS RELATED AMYLOIDOSIS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL FREE HOSP & SCH MED,DEPT HISTOPATHOL,LONDON NW3 2QG,ENGLAND	University of London; University College London	MAHER, ER (corresponding author), ROYAL FREE HOSP & SCH MED,DEPT NEPHROL,LONDON NW3 2QG,ENGLAND.		Moorhead, John/M-7404-2014; Dutoit, Stephen Hamilton/E-1815-2013; MAHER, EAMONN R/A-9507-2008	MAHER, EAMONN R/0000-0002-6226-6918; Hamilton-Dutoit, Stephen/0000-0003-2158-3885				Bardin T, 1986, Nephrol Dial Transplant, V1, P151; BRANDT K, 1968, AM J MED, V44, P955, DOI 10.1016/0002-9343(68)90095-8; BROWN EA, 1986, BMJ-BRIT MED J, V292, P163, DOI 10.1136/bmj.292.6514.163; MUNOZGOMEZ J, 1985, ANN RHEUM DIS, V44, P729, DOI 10.1136/ard.44.11.729; THEAKER JM, 1987, J CLIN PATHOL, V40, P1247, DOI 10.1136/jcp.40.10.1247	5	53	53	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 23	1988	297	6643					265	266		10.1136/bmj.297.6643.265	http://dx.doi.org/10.1136/bmj.297.6643.265			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P4266	3416145	Bronze, Green Published			2023-01-03	WOS:A1988P426600020
J	DALZELL, GWN; PROUZINA, S; MAGEE, H; CUNNINGHAM, SR; ANDERSON, J; ADGEY, AAJ				DALZELL, GWN; PROUZINA, S; MAGEE, H; CUNNINGHAM, SR; ANDERSON, J; ADGEY, AAJ			ASSESSMENT OF A DEVICE FOR TRANS-TELEPHONIC CONTROL OF DEFIBRILLATION	LANCET			English	Article									ROYAL VICTORIA HOSP, REG MED CARDIOL CTR, BELFAST BT12 6BA, NORTH IRELAND; UNIV ULSTER, JORDANSTOWN, NORTH IRELAND; TEMTECH LTD, BANGOR, WALES	Ulster University								ADGEY AAJ, 1969, LANCET, V1, P1169; COBBE SM, 1985, BRIT MED J, V290, P93, DOI 10.1136/bmj.290.6462.93; COPLEY DP, 1977, CIRCULATION, V56, P901, DOI 10.1161/01.CIR.56.6.901; EISENBERG MS, 1985, AM J EMERG MED, V3, P568, DOI 10.1016/0735-6757(85)90174-3; GESSMAN LJ, 1979, AM J CARDIOL, V43, P422; KERBER RE, 1984, J AM COLL CARDIOL, V3, P815, DOI 10.1016/S0735-1097(84)80258-2; LESCH M, 1984, NEW ENGL J MED, V310, P255, DOI 10.1056/NEJM198401263100409; LIBERTHSON RR, 1974, CIRCULATION, V49, P790, DOI 10.1161/01.CIR.49.5.790; LUND I, 1976, LANCET, V2, P702; PAUL O, 1971, CIRCULATION, V43, P7, DOI 10.1161/01.CIR.43.1.7; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; SWENSON RD, 1987, CIRCULATION, V76, P463	12	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAR 26	1988	1	8587					695	697						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M6259	2895222				2023-01-03	WOS:A1988M625900013
J	FARLEY, TMM; MEIRIK, O; CHANG, CL; MARMOT, MG; POULTER, NR				FARLEY, TMM; MEIRIK, O; CHANG, CL; MARMOT, MG; POULTER, NR			EFFECT OF DIFFERENT PROGESTAGENS IN LOW ESTROGEN ORAL-CONTRACEPTIVES ON VENOUS THROMBOEMBOLIC DISEASE	LANCET			English	Article							CARDIOVASCULAR-DISEASE; PROSTATE-CANCER; LEVONORGESTREL; VASECTOMY; STEROIDS; SAFETY	A multinational hospital-based case-control study of the risk of venous thromboembolic disease associated with combined oral contraceptives (OCs) done in 1989-93 prompted a separate inquiry comparing the risk of venous thromboembolism (VTE) associated with low oestrogen (<35 mu g ethinyloestradiol) OCs containing levonorgestrel with risks in low oestrogen preparations containing the third-generation progestagens desogestrel or gestodene. This analysis of data from 9 countries, involved 769 cases and 1979 age matched hospital centre, 246 community controls general practice. 137 cases and 203 controls were current users of levonorgestrel (odds ratio [OR with 95% confidence interval] 3.5 [2.6-4.7]), with non-users as the reference; 28 controls were current users of [4.9-17.0]), and 36 cases and 28 controls were current users of gestodene (9.1 [4.9-16.7]). The ratios of these risks, compared with levonorgestrel, were 2.6 (1.4-4.8) for both products separately, Risk estimates adjusted for body mass index (BMI) were 3.4, 7.3, and 10.2 for levonorgestrel, desogestrel, and gestodene, respectively, compared with non-users, and 2.2 and 3.0 for desogestrel and gestodene, respectively, compared with levonorgestrel. 48 (68%) cases and 48 (86%) controls exposed to desogestrel or gestodene were from the UK (Oxford region). In this centre risk estimates compared with non-users, adjusted for BMI were 2.6, 5.3, and 5.7 for levonorgestrel, desogestrel, and gestodene, respectively. Current users of low oestrogen dose combined OCs containing desogestrel or gestodene appear to be at higher risk of VTE than users of combined OCs containing levonorgestrel. The possibility that these unexpected results on a secondary study objective are due to chance, bias, or residual confounding cannot be excluded entirely and the results need to be confirmed by independent studies. They are at variance with the apparently more favourable metabolic effects of the newer progestagens. Whether the new progestagens are associated with lower risk of arterial disease (stroke and myocardial infarction) must be evaluated further.	WHO,SPECIAL PROGRAMME RES DEV & RES TRAINING HUMAN RE,WORLD BANK,CH-1211 GENEVA 27,SWITZERLAND	The World Bank; World Health Organization			Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419				[Anonymous], 1995, LANCET, V346, P1575; BOTTIGER LE, 1980, LANCET, V1, P1097; BRESLOW NE, 1980, STATISTICAL METHODS; DARNEY PD, 1995, AM J MED, V98, pS104, DOI 10.1016/S0002-9343(99)80067-9; DIEBEN TOM, 1994, CONTRACEPTION, V50, P373, DOI 10.1016/0010-7824(94)90024-8; GERSTMAN BB, 1991, AM J EPIDEMIOL, V131, P32; GUESS HA, 1990, AM J EPIDEMIOL, V132, P1062, DOI 10.1093/oxfordjournals.aje.a115748; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; HIRJI KF, 1988, BIOMETRICS, V44, P803, DOI 10.2307/2531592; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JONES EE, 1995, AM J MED, V98, pS116, DOI 10.1016/S0002-9343(99)80069-2; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; MEADE TW, 1980, BRIT MED J, V280, P1157, DOI 10.1136/bmj.280.6224.1157; Newton JR, 1995, HUM REPROD UPDATE, V1, P231; NEWTON JR, 1994, OBSTET GYNECOL, V14, pS1; ROBINSON GE, 1994, BRIT J OBSTET GYNAEC, V101, P1036, DOI 10.1111/j.1471-0528.1994.tb13578.x; ROSENBERG L, 1990, AM J EPIDEMIOL, V132, P1051, DOI 10.1093/oxfordjournals.aje.a115746; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHAABAN MM, 1984, CONTRACEPTION, V30, P421, DOI 10.1016/0010-7824(84)90034-9; SHENFIELD GM, 1991, CLIN PHARMACOKINET, V20, P15, DOI 10.2165/00003088-199120010-00002; SINGH K, 1990, Advances in Contraception, V6, P23, DOI 10.1007/BF01849484; SPEROFF L, 1993, OBSTET GYNECOL, V81, P1034; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STANCZYK FZ, 1990, CONTRACEPTION, V42, P67, DOI 10.1016/0010-7824(90)90093-B; STUBBLEFIELD PG, 1993, AM J OBSTET GYNECOL, V168, P1047, DOI 10.1016/0002-9378(93)90336-H; Thorogood M., 1993, PHARMACOEPIDEMIOL DR, V2, P3; VANDERVANGE N, 1988, CONT OBSTETRICS GYNA, P315; 1988, POPUL REP A, P1; IN PRESS J CLIN EPID; 1989, MORTALITY STATIS DH5, V16	31	462	468	0	9	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1582	1588						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500749				2023-01-03	WOS:A1995TK48100008
J	CHONN, A; SEMPLE, SC; CULLIS, PR				CHONN, A; SEMPLE, SC; CULLIS, PR			BETA-2-GLYCOPROTEIN-I IS A MAJOR PROTEIN ASSOCIATED WITH VERY RAPIDLY CLEARED LIPOSOMES IN-VIVO, SUGGESTING A SIGNIFICANT ROLE IN THE IMMUNE CLEARANCE OF NON-SELF PARTICLES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE PHOSPHOLIPID ASYMMETRY; LARGE UNILAMELLAR LIPOSOMES; PERFUSED RAT-LIVER; ANTICARDIOLIPIN ANTIBODIES; APOLIPOPROTEIN-H; SCAVENGER RECEPTOR; BLOOD COMPONENTS; UPTAKE MECHANISM; RECOGNITION; MACROPHAGES	Liposomes recovered from the blood of liposome-treated CD1 mice were previously reported to have a complex protein profile associated with their mem branes (Chonn, A., Semple, S. C., and Cullis, P. R. (1992) J. Biol. Chem. 267, 18759-18765). In this study, we have further characterized and identified the major proteins associated with very rapidly cleared large unilamellar vesicles. These liposomes contained phosphatidylcholine, cholesterol, and anionic phospholipids (phosphatidylserine, phosphatidic acid, or cardiolipin) that dramatically enhance the clearance rate of Liposomes hom the circulation. These anionic phospholipids are normally found exclusively in the interior of cells but become expressed when cells undergo apoptosis or programmed cell death, and thus, they are believed to be markers of cell senescence, Analysis of the proteins associated with these liposomes by SDS-polyacrylamide gel electrophoresis revealed that two of the major proteins associated with the liposome membranes are proteins with electrophoretic mobilities corresponding to M(r) of 66,000 and 50,000-55,000. The 66-kDa protein was identified to be serum albumin by immunoblot analysis. Using various biochemical and immunological methods, we have identified the 50-55-kDa protein as the murine equivalent of human beta(2)-glycoprotein I. beta 2-glycoprotein I has a strong affinity for phosphatidylserine, phosphatidic acid, and cardiolipin inasmuch as the levels of beta 2-glycoprotein I associated with these anionic liposomes approach or even exceed those of serum albumin, which is present in serum at a concentration 200-fold greater than beta 2-glycoprotein I. Further, we demonstrate that the amount of beta 2-glycoprotein I associated with liposomes, as quantitated by an enzyme-linked immunosorbent assay, is correlated with their clearance rates; moreover, the circulation residency time of cardiolipin-containing liposomes is extended in mice pretreated with anti-beta 2-glycoprotein I antibodies. These findings strongly suggest that beta 2-glycoprotein I plays a primary role in mediating the clearance of liposomes and, by extension, senescent cells and foreign particles.	UNIV BRITISH COLUMBIA, DEPT BIOCHEM, VANCOUVER, BC V6P 6P2, CANADA	University of British Columbia								ALLEN TM, 1988, P NATL ACAD SCI USA, V85, P8067, DOI 10.1073/pnas.85.21.8067; ANDRADE JD, 1987, ANN NY ACAD SCI, V516, P158, DOI 10.1111/j.1749-6632.1987.tb33038.x; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BONTE F, 1986, CHEM PHYS LIPIDS, V40, P359, DOI 10.1016/0009-3084(86)90079-4; BONTE F, 1987, BIOCHIM BIOPHYS ACTA, V900, P1, DOI 10.1016/0005-2736(87)90271-9; CHONN A, 1991, BIOCHIM BIOPHYS ACTA, V1070, P215, DOI 10.1016/0005-2736(91)90167-7; CHONN A, 1992, J BIOL CHEM, V267, P18759; CONNOR J, 1994, J BIOL CHEM, V269, P2399; FADOK VA, 1992, J IMMUNOL, V148, P2207; FINLAYSO.JS, 1967, BIOCHIM BIOPHYS ACTA, V147, P413, DOI 10.1016/0005-2795(67)90001-3; GALLI M, 1990, LANCET, V335, P1544, DOI 10.1016/0140-6736(90)91374-J; GHARAVI AE, 1987, ANN RHEUM DIS, V46, P1, DOI 10.1136/ard.46.1.1; HARRIS EN, 1983, LANCET, V2, P1211; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; JULIANO RL, 1980, LIPOSOMES IMMUNOBIOL, P49; KIWADA H, 1987, CHEM PHARM BULL, V35, P1189; KIWADA H, 1986, CHEM PHARM BULL, V34, P1249; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; LEE KD, 1992, BIOCHIM BIOPHYS ACTA, V1111, P1, DOI 10.1016/0005-2736(92)90267-P; LEE NS, 1983, J BIOL CHEM, V258, P4765; LOZIER J, 1984, P NATL ACAD SCI-BIOL, V81, P3640, DOI 10.1073/pnas.81.12.3640; MCEVOY L, 1986, P NATL ACAD SCI USA, V83, P3311, DOI 10.1073/pnas.83.10.3311; MCNEIL HP, 1989, BRIT J HAEMATOL, V73, P506, DOI 10.1111/j.1365-2141.1989.tb00289.x; MCNEIL HP, 1990, P NATL ACAD SCI USA, V87, P4120, DOI 10.1073/pnas.87.11.4120; NISHIKAWA K, 1990, J BIOL CHEM, V265, P5226; NONAKA M, 1992, GENOMICS, V13, P1082, DOI 10.1016/0888-7543(92)90022-K; POLZ E, 1980, INT J BIOCHEM, V11, P265, DOI 10.1016/0020-711X(80)90229-3; POLZ E, 1979, FEBS LETT, V102, P183, DOI 10.1016/0014-5793(79)80955-2; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; SCHLEGEL RA, 1985, J CELL PHYSIOL, V123, P215, DOI 10.1002/jcp.1041230210; SCHROIT AJ, 1984, BIOL CELL, V51, P227, DOI 10.1111/j.1768-322X.1984.tb00303.x; SENIOR JH, 1987, CRC CR REV THER DRUG, V3, P123; SOMMERMAN EF, 1986, THESIS U BRIT COLUMB; STEIN Y, 1980, FEBS LETT, V111, P104, DOI 10.1016/0014-5793(80)80771-X; WURM H, 1982, METABOLISM, V31, P484, DOI 10.1016/0026-0495(82)90238-4; WURM H, 1984, INT J BIOCHEM, V16, P511, DOI 10.1016/0020-711X(84)90168-X	37	162	166	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 27	1995	270	43					25845	25849		10.1074/jbc.270.43.25845	http://dx.doi.org/10.1074/jbc.270.43.25845			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	TB466	7592769	hybrid			2023-01-03	WOS:A1995TB46600086
J	MARCHAND, S; LI, JX; CHAREST, J				MARCHAND, S; LI, JX; CHAREST, J			EFFECTS OF CAFFEINE ON ANALGESIA FROM TRANSCUTANEOUS ELECTRICAL NERVE-STIMULATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							PAIN; TENS				MARCHAND, S (corresponding author), UNIV QUEBEC ABITIBI TEMISCARMINGUE,ROUYN,PQ J9X 5E4,CANADA.			Marchand, Serge/0000-0002-4234-5977				DALY JW, 1981, LIFE SCI, V28, P2083, DOI 10.1016/0024-3205(81)90614-7; MARCHAND S, 1993, PAIN, V54, P99, DOI 10.1016/0304-3959(93)90104-W; MARCHAND S, 1991, CLIN J PAIN, V7, P122, DOI 10.1097/00002508-199106000-00008; SALTER MW, 1987, NEUROSCIENCE, V22, P631, DOI 10.1016/0306-4522(87)90359-9; SAWYNOK J, 1993, BRAIN RES, V610, P32, DOI 10.1016/0006-8993(93)91213-C	5	50	53	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 3	1995	333	5					325	326		10.1056/NEJM199508033330521	http://dx.doi.org/10.1056/NEJM199508033330521			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL694	7596392				2023-01-03	WOS:A1995RL69400034
J	MARK, DB; HLATKY, MA; CALIFF, RM; NAYLOR, CD; LEE, KL; ARMSTRONG, PW; BARBASH, G; WHITE, H; SIMOONS, ML; NELSON, CL; CLAPPCHANNING, N; KNIGHT, JD; HARRELL, FE; SIMES, J; TOPOL, EJ				MARK, DB; HLATKY, MA; CALIFF, RM; NAYLOR, CD; LEE, KL; ARMSTRONG, PW; BARBASH, G; WHITE, H; SIMOONS, ML; NELSON, CL; CLAPPCHANNING, N; KNIGHT, JD; HARRELL, FE; SIMES, J; TOPOL, EJ			COST-EFFECTIVENESS OF THROMBOLYTIC THERAPY WITH TISSUE-PLASMINOGEN ACTIVATOR AS COMPARED WITH STREPTOKINASE FOR ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OF-THE-NETHERLANDS; CORONARY THROMBOLYSIS; SURVIVAL; BENEFIT; FOLLOW; GUIDE	Background. Patients with acute myocardial infarction who were treated with accelerated tissue plasminogen activator (t-PA) (given over a period of 1 1/2 hours rather than the conventional 3 hours, and with two thirds of the dose given in the first 30 minutes) had a 30-day mortality that was 15 percent lower than that of patients treated with streptokinase in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary arteries (GUSTO) study, This was equivalent to an absolute decrease of 1 percent in 30-day mortality, We sought to assess whether the use of t-PA, as compared with streptokinase, is cost effective. Methods. Our primary, or base-case, analysis of cost effectiveness used data from the GUSTO study and life expectancy projected on the basis of the records of survivors of myocardial infarction in the Duke Cardiovascular Disease Database. In the primary analysis, we assumed that there were no additional treatment costs due to the use of t-PA after the first year and that the comparative survival benefit of t-PA was still evident one year after enrollment. Results. One year after enrollment, patients who received t-PA had both higher costs ($2,845) and a higher survival rate (an increase of 1.1 percent, or 11 per 1000 patients treated) than streptokinase-treated patients. On the basis of the projected life expectancy of each treatment group, the incremental cost-effectiveness ratio with both future costs and benefits discounted at 5 percent per year - was $32,678 per year of life saved, The use of t-PA was least cost effective in younger patients and most cost effective in older patients, At all ages, the use of t-PA in patients with anterior infarctions yielded more favorable cost-effectiveness values, In our secondary analyses, the cost-effectiveness values were most sensitive to a lowering of the projected long-term survival benefits of t-PA and to moderate or greater increases in the projected medical costs for patients in the t-PA group after the first year, In contrast, our results were not sensitive to even very unfavorable assumptions about the additional costs associated with the higher rate of disabling stroke that was noted in patients treated with t-PA in the GUSTO study. Conclusions. The cost effectiveness of treatment with accelerated t-PA rather than streptokinase compares favorably with that of other therapies whose added medical benefit for dollars spent is judged by society to be worthwhile.	DUKE UNIV, MED CTR,DEPT MED,DIV CARDIOL, CLIN TRIALS COORDINATING CTR, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT COMMUNITY & FAMILY MED, DIV BIOMETRY, DURHAM, NC 27710 USA; STANFORD UNIV, SCH MED, DEPT HLTH RES & POLICY, DIV HLTH SERV RES, PALO ALTO, CA 94304 USA; UNIV TORONTO, DEPT MED, TORONTO, ON, CANADA; INST CLIN EVALUAT SCI, TORONTO, ON, CANADA; UNIV ALBERTA, DEPT MED, EDMONTON, AB, CANADA; TEL AVIV SORASKY UNIV MED CTR, TEL AVIV, ISRAEL; GREEN LANE HOSP, DEPT CARDIOL, AUCKLAND 3, NEW ZEALAND; ERASMUS UNIV ROTTERDAM, ROTTERDAM, NETHERLANDS; UNIV SYDNEY, NATL HLTH & MED RES COUNCIL CLIN TRIALS CTR, SYDNEY, NSW 2006, AUSTRALIA; CLEVELAND CLIN, DEPT CARDIOL, CLEVELAND, OH 44106 USA	Duke University; Duke University; Stanford University; University of Toronto; University of Toronto; University of Alberta; Erasmus University Rotterdam; University of Sydney; Cleveland Clinic Foundation	MARK, DB (corresponding author), DUKE UNIV, MED CTR,DEPT MED,DIV CARDIOL, ECON & QUAL LIFE COORDINATING CTR, POB 3485, DURHAM, NC 27710 USA.			Mark, Daniel/0000-0001-6340-8087; Topol, Eric/0000-0002-1478-4729; Hlatky, Mark/0000-0003-4686-9441; Armstrong, Paul/0000-0002-0460-3445	AHRQ HHS [HS-05635, HS-06503] Funding Source: Medline; NHLBI NIH HHS [HL-36587] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R18HS005635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036587] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALGENT C, 1993, CIRCULATION S2, V88, P290; CERQUEIRA MD, 1992, J AM COLL CARDIOL, V20, P1452, DOI 10.1016/0735-1097(92)90436-Q; COX DR, 1972, J R STAT SOC B, V34, P187; DETSKY AS, 1990, ANN INTERN MED, V113, P147, DOI 10.7326/0003-4819-113-2-147; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P2879, DOI 10.1001/jama.262.20.2879; HLATKY MA, 1984, STAT MED, V3, P375, DOI 10.1002/sim.4780030415; LAFFEL GL, 1987, J AM COLL CARDIOL, V10, pB79, DOI 10.1016/S0735-1097(87)80432-1; LEE ET, 1980, STATISTICAL METHODS; LEE KL, 1995, CIRCULATION, V91, P1659, DOI 10.1161/01.CIR.91.6.1659; MARK DB, 1994, NEW ENGL J MED, V331, P1130, DOI 10.1056/NEJM199410273311706; MARK DB, 1994, TXB INTERVENTIONAL C, P1323; MARK DB, 1995, ACUTE CORONARY CARE, P167; NAYLOR CD, 1993, CAN J CARDIOL, V9, P553; PRYOR DB, 1988, TRENDS CORONARY HEAR, P76; ROSATI RA, 1975, ARCH INTERN MED, V135, P1017, DOI 10.1001/archinte.135.8.1017; SIFTON DW, 1993, RED BOOK PHARM FUNDA; SIMOONS ML, 1991, EUR HEART J, V12, P694, DOI 10.1093/eurheartj/12.6.694; SIMOONS ML, 1989, J AM COLL CARDIOL, V14, P1609, DOI 10.1016/0735-1097(89)90003-X; STEINBERG EP, 1988, J AM COLL CARDIOL, V12, pA58, DOI 10.1016/0735-1097(88)92642-3; TAYLOR GJ, 1992, AM J CARDIOL, V70, P26, DOI 10.1016/0002-9149(92)91384-G; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Torrance G W, 1989, Int J Technol Assess Health Care, V5, P559; Torrance GW, 1987, METHODS EC EVALUATIO; TSEVAT J, 1990, J CLIN EPIDEMIOL, V43, pS73, DOI 10.1016/0895-4356(90)90224-D; VERMEER F, 1988, BRIT HEART J, V59, P527; Weinstein MC, 1980, CLIN DECISION ANAL	26	451	453	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 25	1995	332	21					1418	1424		10.1056/NEJM199505253322106	http://dx.doi.org/10.1056/NEJM199505253322106			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY941	7723799	Green Published			2023-01-03	WOS:A1995QY94100006
J	TODD, CJ; FREEMAN, CJ; CAMILLERIFERRANTE, C; PALMER, CR; HYDER, A; LAXTON, CE; PARKER, MJ; PAYNE, BV; RUSHTON, N				TODD, CJ; FREEMAN, CJ; CAMILLERIFERRANTE, C; PALMER, CR; HYDER, A; LAXTON, CE; PARKER, MJ; PAYNE, BV; RUSHTON, N			DIFFERENCES IN MORTALITY AFTER FRACTURE OF HIP - THE EAST-ANGLIAN AUDIT	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate differences between hospitals in clinical management of patients admitted With fractured hip and to relate these to mortality at 90 days. Design-A prospective audit of process and outcome of care based on interviews with patients, abstraction from records with standard proforma, and follow up at three months. Data were analysed with chi(2) test and forward stepwise regression modelling of mortality. Setting-All eight hospitals in East Anglia with trauma orthopaedic departments. Patients-580 consecutive patients admitted for fracture of neck of femur. Main outcome measure-Mortality at 90 days. Results-Patients admitted to each hospital were similar with respect to age, sex, pre-existing illnesses, and activities of daily living before fracture. In all, 560 (97%) were treated surgically, by a range of grades of surgeon. Two hundred and sixty one patients (45%; range between hospitals 10-91%) received pharmaceutical thromboembolic prophylaxis, 502 (93%; 81-99%) perioperative antibiotic prophylaxis. The incidence of fatal pulmonary emboli differed between patients who received and those who did not receive prophylaxis against deep vein thrombosis (P=0.001). Mortality at 90 days was 18%, differing significantly between hospitals (5-23%). One hospital had significantly better survival than the others (odds ratio 0 .14; 95% confidence interval 0.04-0.48; P=0.0016). Conclusions-No single factor or aspect of practice accounted for this protective effect. Lower mortality may be associated with the cumulative effects of several aspects of the organisation of treatment and the management of fracture of the hip, including thromboembolic pharmaceutical prophylaxis, antibiotic prophylaxis, and early mobilisation.	ANGLIA & OXFORD REG HLTH AUTHOR,DIRECTORATE PUBL HLTH MED,CAMBRIDGE,ENGLAND; PETERBOROUGH DIST GEN HOSP,DEPT ORTHOPAED,PETERBOROUGH PE3 6DA,ENGLAND; NORFOLK & NORWICH HEALTHCARE NHS TRUST,NORWICH,NORFOLK,ENGLAND; UNIV CAMBRIDGE,ADDENBROOKES HOSP,SCH CLIN,ORTHOPAED RES UNIT,CAMBRIDGE,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	TODD, CJ (corresponding author), UNIV CAMBRIDGE,INST PUBL HLTH,DEPT COMMUNITY MED,HLTH SERV RES GRP,CAMBRIDGE CB2 2SR,ENGLAND.		Todd, Chris/A-7904-2010; Hyder, Adnan/AAT-9503-2021; Todd, Chris/AAD-8661-2022	Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Freeman, Carol/0000-0001-9751-0784				ALTMAN DG, 1980, BRIT MED J, V281, P1336, DOI 10.1136/bmj.281.6251.1336; FREEMAN CJ, 1995, E ANGLIAN AUDIT FRAC; HOLLINGWORTH W, IN PRESS J PUBLIC HL; PARKER MJ, 1993, J BONE JOINT SURG BR, V75, P797, DOI 10.1302/0301-620X.75B5.8376443; Parker MJ., 1993, HIP FRACTURE MANAGEM; Pearse M, 1992, Health Trends, V24, P134; RUSSELL IT, 1992, QUALITY HLTH CARE, V1, P52; SAINSBURY R, 1991, REV CLIN GERONTOL, V1, P67; TODD C, 1993, TIJDSCHRIFT SOCIALE, V71, P72; 1989, FRACTURED NECK FEMUR; 1990, REPORT E ANGLIAN REG; 1994, HOSPITAL EPISODE STA, V1; 1992, BRIT MED J, V305, P567; 1989, CMND555; 1994, HOSPITAL AMBULANCE S	15	246	248	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 8	1995	310	6984					904	908		10.1136/bmj.310.6984.904	http://dx.doi.org/10.1136/bmj.310.6984.904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QR972	7719180	Green Published			2023-01-03	WOS:A1995QR97200021
J	WATTS, GF				WATTS, GF			FAMILIAL HYPERCHOLESTEROLEMIA REGRESSION STUDY AND ITS IMPLICATIONS	LANCET			English	Editorial Material							CORONARY ATHEROSCLEROSIS; LIPOPROTEIN(A); DISEASE				WATTS, GF (corresponding author), UNIV WESTERN AUSTRALIA, DEPT MED, PERTH, WA, AUSTRALIA.			Watts, Gerald/0000-0003-2276-1524				ARMSTRONG VW, 1986, ATHEROSCLEROSIS, V62, P249, DOI 10.1016/0021-9150(86)90099-7; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; DAHLEN GH, 1994, ATHEROSCLEROSIS, V108, P111, DOI 10.1016/0021-9150(94)90106-6; GIBSON M, 1992, AM J CARDIOL, V69, P1286, DOI 10.1016/0002-9149(92)91222-P; GORDON BR, 1994, AM J CARDIOL, V74, P1109, DOI 10.1016/0002-9149(94)90461-8; Gordon Bruce R., 1994, Current Opinion in Lipidology, V5, P69, DOI 10.1097/00041433-199402000-00011; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; MARBURGER C, 1994, AM J CARDIOL, V73, P742, DOI 10.1016/0002-9149(94)90874-5; RIDKER PM, 1993, JAMA-J AM MED ASSOC, V270, P2195, DOI 10.1001/jama.270.18.2195; SEED M, 1990, NEW ENGL J MED, V322, P1494, DOI 10.1056/NEJM199005243222104; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WATTS GF, 1994, CLIN CHEM, V40, P2240	12	2	2	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 1	1995	345	8953					807	808		10.1016/S0140-6736(95)92958-4	http://dx.doi.org/10.1016/S0140-6736(95)92958-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QQ195	7898224				2023-01-03	WOS:A1995QQ19500003
J	BRYDEN, AA; ROTHWELL, PJN; OREILLY, PH				BRYDEN, AA; ROTHWELL, PJN; OREILLY, PH			URINARY RETENTION WITH MISUSE OF ECSTASY	BRITISH MEDICAL JOURNAL			English	Letter											BRYDEN, AA (corresponding author), STEPPING HILL HOSP,STOCKPORT SK2 7JE,CHESHIRE,ENGLAND.							GREER G, 1986, J PSYCHOACTIVE DRUGS, V18, P319, DOI 10.1080/02791072.1986.10472364; HENRY JA, 1992, BRIT MED J, V305, P5, DOI 10.1136/bmj.305.6844.5; STERNBACH GL, 1992, POSTGRAD MED, V91, P169; WORSEY J, 1989, BRIT J UROL, V64, P320, DOI 10.1111/j.1464-410X.1989.tb06028.x	4	22	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					504	504		10.1136/bmj.310.6978.504a	http://dx.doi.org/10.1136/bmj.310.6978.504a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QJ598	7888894	Green Published			2023-01-03	WOS:A1995QJ59800026
J	CHESSELLS, JM; BAILEY, C; RICHARDS, SM; EDEN, OB; BARBOR, PRH; BARRETT, A; BARTON, C; BROADBENT, V; DEMPSEY, SI; DURRANT, J; EMERSON, P; EVANS, DIK; FENNELLY, JJ; GALTON, DAG; GIBSON, B; GRAY, R; HANN, IM; HARDISTY, RM; HILL, FGH; KERNAHAN, J; KING, DJ; LILLEYMAN, JS; MANN, J; MARTIN, J; MCELWAIN, TJ; MELLOR, ST; JONES, PHM; OAKHILL, A; PETO, J; RADFORD, M; REES, JKH; STEVENS, RF; SUMMERFIELD, GP; THOMPSON, EN				CHESSELLS, JM; BAILEY, C; RICHARDS, SM; EDEN, OB; BARBOR, PRH; BARRETT, A; BARTON, C; BROADBENT, V; DEMPSEY, SI; DURRANT, J; EMERSON, P; EVANS, DIK; FENNELLY, JJ; GALTON, DAG; GIBSON, B; GRAY, R; HANN, IM; HARDISTY, RM; HILL, FGH; KERNAHAN, J; KING, DJ; LILLEYMAN, JS; MANN, J; MARTIN, J; MCELWAIN, TJ; MELLOR, ST; JONES, PHM; OAKHILL, A; PETO, J; RADFORD, M; REES, JKH; STEVENS, RF; SUMMERFIELD, GP; THOMPSON, EN			INTENSIFICATION OF TREATMENT AND SURVIVAL IN ALL CHILDREN WITH LYMPHOBLASTIC-LEUKEMIA - RESULTS OF UK MEDICAL-RESEARCH-COUNCIL TRIAL UKALL-X	LANCET			English	Article							PEDIATRIC-ONCOLOGY-GROUP; CANCER-STUDY-GROUP; PRESENTING FEATURES; PROGNOSTIC FACTORS; HIGH-RISK; NON-T; LEUKEMIA; CHILDHOOD; THERAPY; METHOTREXATE	The UK Medical Research Council trial MRC UKALL X was designed to investigate the benefit of one or two courses of additional intensification therapy in children with acute lymphoblastic leukaemia receiving standard treatment. From 1985 to 1990 1612 children, comprising more than 90% of eligible cases in the UK, were treated with intensive induction therapy, central nervous system directed therapy with cranial irradiation and intrathecal methotrexate, and continuing treatment for 2 years. 1171 children were randomised to receive additional intensification therapy at 5 weeks, 20 weeks, both, or neither. At follow-up of at least 3 years disease-free survival for all children at 5 years was 62% (95% confidence interval [Cl] 60.0-64.4), a significant improvement over the 56% (53.0.59.6) found in the preceding MRC UKALL trial. The 5-year disease-free survival was 71% (65.5-76.1) for children randomised to two blocks of intensification therapy, this being significantly better than the 62% (56.6-68.0), 61% (55.7-67.1), and 57% (50.9-62.7) rates for the groups randomised to one intensification block at 5 weeks, one at 20 weeks, and no intensification, respectively. The benefits of intensification therapy were seen irrespective of clinical factors known to influence outcome such as age, sex, and initial leucocyte count. We conclude that the addition of two courses of intensification therapy has produced a 14% improvement in disease-free survival and an 11% improvement in overall survival for the randomised patients. This additional treatment is of benefit to all children with acute lymphoblastic leukaemia, even those traditionally deemed at lower risk of relapse.	ST JAMES UNIV HOSP, PAEDIAT ONCOL DAY HOSP, LEEDS, W YORKSHIRE, ENGLAND; RADCLIFFE INFIRM, CLIN TRIAL SERV UNIT, OXFORD, ENGLAND	Saint James's University Hospital; Radcliffe Infirmary; University of Oxford	CHESSELLS, JM (corresponding author), INST CHILD HLTH, DEPT HAEMATOL & ONCOL, GUILFORD ST, LONDON WC1N 1EH, ENGLAND.							BLEYER WA, 1983, J CLIN ONCOL, V1, P317, DOI 10.1200/JCO.1983.1.5.317; BLOOMFIELD CD, 1986, BLOOD, V67, P415; CAMITTA B, 1989, J CLIN ONCOL, V7, P1539, DOI 10.1200/JCO.1989.7.10.1539; CHESSELLS JM, 1992, LANCET, V340, P565, DOI 10.1016/0140-6736(92)92103-M; CHESSELLS JM, IN PRESS BR J HAEMAT; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; COX D, 1991, CANCER, V67, P2428, DOI 10.1002/1097-0142(19910515)67:10<2428::AID-CNCR2820671004>3.0.CO;2-J; EDEN OB, 1991, BRIT J HAEMATOL, V78, P187, DOI 10.1111/j.1365-2141.1991.tb04415.x; EDEN OB, 1990, BRIT J HAEMATOL, V75, P496, DOI 10.1111/j.1365-2141.1990.tb07788.x; GAYNON PS, 1993, J CLIN ONCOL, V11, P2234, DOI 10.1200/JCO.1993.11.11.2234; GOLDIE JH, 1984, CANCER RES, V44, P3643; HALE JP, 1991, ARCH DIS CHILD, V66, P462, DOI 10.1136/adc.66.4.462; Henze G, 1990, Haematol Blood Transfus, V33, P483; KRANCE RA, 1991, CANCER-AM CANCER SOC, V67, P550, DOI 10.1002/1097-0142(19910201)67:3<550::AID-CNCR2820670303>3.0.CO;2-#; LIPSHULTZ SE, 1991, NEW ENGL J MED, V324, P808, DOI 10.1056/NEJM199103213241205; MILLER DR, 1989, J CLIN ONCOL, V7, P1807, DOI 10.1200/JCO.1989.7.12.1807; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; NIEMEYER CM, 1991, ANN ONCOL, V2, P745, DOI 10.1093/oxfordjournals.annonc.a057856; NORTON L, 1977, CANCER TREAT REP, V61, P1307; PETO J, 1986, LANCET, V1, P408; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINKERTON CR, 1987, ARCH DIS CHILD, V62, P12, DOI 10.1136/adc.62.1.12; PUI CH, 1989, NEW ENGL J MED, V321, P136, DOI 10.1056/NEJM198907203210302; Riehm H, 1987, Haematol Blood Transfus, V30, P139; RIVERA GK, 1994, BAILLIERE CLIN HAEM, V7, P273, DOI 10.1016/S0950-3536(05)80203-3; RIVERA GK, 1993, NEW ENGL J MED, V329, P1289, DOI 10.1056/NEJM199310283291801; RIVERA GK, 1991, LANCET, V337, P61, DOI 10.1016/0140-6736(91)90733-6; RIVERA GK, 1987, SEMIN HEMATOL, V24, P12; RUBIN CM, 1991, J CLIN ONCOL, V9, P2183, DOI 10.1200/JCO.1991.9.12.2183; TUBERGEN DG, 1993, J CLIN ONCOL, V11, P527, DOI 10.1200/JCO.1993.11.3.527; WHITE SJ, 1978, BRIT J CANCER, V37, P849, DOI 10.1038/bjc.1978.124	31	246	249	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	1995	345	8943					143	148		10.1016/S0140-6736(95)90164-7	http://dx.doi.org/10.1016/S0140-6736(95)90164-7			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823668				2023-01-03	WOS:A1995QC55000007
J	SCHEITHAUER, W; ROSEN, H; KORNEK, GV; SEBESTA, C; DEPISCH, D				SCHEITHAUER, W; ROSEN, H; KORNEK, GV; SEBESTA, C; DEPISCH, D			RANDOMIZED COMPARISON OF COMBINATION CHEMOTHERAPY PLUS SUPPORTIVE CARE WITH SUPPORTIVE CARE ALONE IN PATIENTS WITH METASTATIC COLORECTALCANCER	BRITISH MEDICAL JOURNAL			English	Article							CANCER-PATIENTS; FOLINIC ACID; CELL-LINES; 5-FLUOROURACIL; LEUCOVORIN; CISPLATIN; FLUOROURACIL; CARCINOMA; QUALITY; HEAD	Objectives-To compare the length of survival and quality of life in patients given combination chemotherapy in addition to supportive care and in patients given only supportive care. Design-Randomised study. Setting-Gastrointestinal oncology departments. Patients-40 previously untreated patients with histologically confirmed, measurable colorectal cancer that was locally recurrent or metastatic. Interventions-Patients were allocated randomly to receive chemotherapy or only supportive care in a ratio of 2:1 according to performance status, metastatic disease of the liver, and weight loss in the six months before entering the study. Chemotherapy consisted of four week cycles of intravenous leucovorin (200 mg/m2/day) followed by 5-fluorouracil (550 mg/m2/day) and cisplatin (20 mg/m2/day), each drug being given on the first four days of the cycle. Main outcome measures-Length of survival and quality of life score with an optimised functional living index-cancer scale. Results-Overall survival was significantly longer for patients given chemotherapy (11.0 months) than for those receiving supportive care alone (5.0 months; p=0.006). Despite common association of chemotherapy with mild to moderate gastrointestinal symptoms, there was no significant difference between the two groups in global or subgroup quality of life scores. In patients with abnormal scores before treatment, quality of life seemed better in the chemotherapy arm. Conclusions-In this sample of patients with disseminated colorectal cancer the chemotherapy regimen was an effective form of palliative treatment.	HANUSCH HOSP,DEPT GASTROENTEROL,A-1140 VIENNA,AUSTRIA; WEINER NEUSTADT GEN HOSP,DEPT SURG,A-2700 WIENER NEUSTADT,AUSTRIA	WGKK - Hanusch Hospital	SCHEITHAUER, W (corresponding author), UNIV VIENNA,DEPT INTERNAL MED 1,DIV ONCOL,A-1090 VIENNA,AUSTRIA.							ARBUCK SG, 1989, CANCER, V63, P1036, DOI 10.1002/1097-0142(19890315)63:6+<1036::AID-CNCR2820631309>3.0.CO;2-K; DAVIS HL, 1982, CANCER-AM CANCER SOC, V50, P2638; ERLICHMAN C, 1988, J CLIN ONCOL, V6, P469, DOI 10.1200/JCO.1988.6.3.469; ETIENNE MC, 1991, BRIT J CANCER, V63, P372, DOI 10.1038/bjc.1991.88; GANZ PA, 1989, CANCER, V63, P1271, DOI 10.1002/1097-0142(19890401)63:7<1271::AID-CNCR2820630707>3.0.CO;2-6; HART L, 1989, P AN M AM SOC CLIN, V8, P43; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAVIN P, 1980, CANCER, V46, P1536, DOI 10.1002/1097-0142(19801001)46:7<1536::AID-CNCR2820460707>3.0.CO;2-K; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; Moertel C.G., 1982, CANCER MED, P1830; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; POON MA, 1989, J CLIN ONCOL, V7, P1407, DOI 10.1200/JCO.1989.7.10.1407; PRESANT CA, 1990, J NATL CANCER I, V82, P322, DOI 10.1093/jnci/82.4.322; SCHEITHAUER W, 1991, CANCER, V67, P1294, DOI 10.1002/1097-0142(19910301)67:5<1294::AID-CNCR2820670504>3.0.CO;2-M; SCHEITHAUER W, 1989, ANTICANCER RES, V9, P1793; SCHEITHAUER W, 1992, P AN M AM SOC CLIN, V11, P195; SCHIPPER H, 1984, J CLIN ONCOL, V2, P472, DOI 10.1200/JCO.1984.2.5.472; VOKES EE, 1990, J CLIN ONCOL, V8, P241, DOI 10.1200/JCO.1990.8.2.241; 1992, J CLIN ONCOL, V6, P904	19	532	538	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 20	1993	306	6880					752	755		10.1136/bmj.306.6880.752	http://dx.doi.org/10.1136/bmj.306.6880.752			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KU173	7683942	Bronze, Green Published			2023-01-03	WOS:A1993KU17300021
J	FOGELFELD, L; WIVIOTT, MBT; SHOREFREEDMAN, E; BLEND, M; BEKERMAN, C; PINSKY, S; SCHNEIDER, AB				FOGELFELD, L; WIVIOTT, MBT; SHOREFREEDMAN, E; BLEND, M; BEKERMAN, C; PINSKY, S; SCHNEIDER, AB			RECURRENCE OF THYROID-NODULES AFTER SURGICAL REMOVAL IN PATIENTS IRRADIATED IN CHILDHOOD FOR BENIGN CONDITIONS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									MICHAEL REESE HOSP & MED CTR, DEPT MED, DIV ENDOCRINOL & METAB, LAKE SHORE DR 31ST ST, CHICAGO, IL 60616 USA; MICHAEL REESE HOSP & MED CTR, DEPT RADIOL, CHICAGO, IL 60616 USA	Michael Reese Hospital & Medical Center; Michael Reese Hospital & Medical Center				Fogelfeld, Leon/0000-0002-1303-7879; Shore-Freedman, Eileen/0000-0001-6194-1814	NCI NIH HHS [CA 21518] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA021518, R01CA021518] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AAGAARD J, 1984, ACTA CHIR SCAND, V150, P123; BANG U, 1985, ACTA ENDOCRINOL-COP, V109, P214, DOI 10.1530/acta.0.1090214; BERGFELT GOSTA, 1963, ACTA CHIR SCAND, V126, P531; CLARK OH, 1976, ENDOCRINOLOGY, V99, P988, DOI 10.1210/endo-99-4-988; COX DR, 1972, J R STAT SOC B, V34, P187; FAVUS MJ, 1976, NEW ENGL J MED, V294, P1019, DOI 10.1056/NEJM197605062941901; GEERDSEN JP, 1982, ACTA CHIR SCAND, V148, P225; GEERDSEN JP, 1986, ACTA MED SCAND, V220, P341; GEERDSEN JP, 1982, ACTA CHIR SCAND, V148, P221; GEERDSEN JP, 1984, CLIN ENDOCRINOL, V21, P529, DOI 10.1111/j.1365-2265.1984.tb01391.x; GHARIB H, 1987, NEW ENGL J MED, V317, P70, DOI 10.1056/NEJM198707093170202; HEDMAN I, 1986, ACTA CHIR SCAND, V152, P481; HEGEDUS L, 1987, BRIT MED J, V294, P801, DOI 10.1136/bmj.294.6575.801; JENNY H, 1966, ARCH SURG-CHICAGO, V92, P525; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LOGOTHETOPOULOS JH, 1955, BRIT J EXP PATHOL, V36, P617; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MATTE R, 1981, J CLIN ENDOCR METAB, V53, P377, DOI 10.1210/jcem-53-2-377; NOEL P, 1978, ANN ENDOCRINOL-PARIS, V39, P163; PERSSON CPA, 1982, WORLD J SURG, V6, P391, DOI 10.1007/BF01657664; PIERCY JE, 1957, LANCET, V1, P177; SCHNEIDER AB, 1986, ANN INTERN MED, V105, P405, DOI 10.7326/0003-4819-105-3-405; SCHNEIDER AB, 1985, MEDICINE, V64, P1; SCHNEIDER AB, 1986, J CLIN ENDOCR METAB, V63, P107, DOI 10.1210/jcem-63-1-107	24	61	61	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 30	1989	320	13					835	840		10.1056/NEJM198903303201304	http://dx.doi.org/10.1056/NEJM198903303201304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	T8530	2927450				2023-01-03	WOS:A1989T853000004
J	ALLON, M; DUNLAY, R; COPKNEY, C				ALLON, M; DUNLAY, R; COPKNEY, C			NEBULIZED ALBUTEROL FOR ACUTE HYPERKALEMIA IN PATIENTS ON HEMODIALYSIS	ANNALS OF INTERNAL MEDICINE			English	Article									UNIV OKLAHOMA, HLTH SCI CTR, SCH MED, OKLAHOMA CITY, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center	ALLON, M (corresponding author), VET ADM MED CTR, NEPHROL SECT 111G, 921 NE 13TH ST, OKLAHOMA CITY, OK 73104 USA.							ALVESTRAND A, 1984, AM J PHYSIOL, V246, pE174, DOI 10.1152/ajpendo.1984.246.2.E174; BLUMBERG A, 1988, AM J MED, V85, P507; BROWN MJ, 1983, NEW ENGL J MED, V309, P1414, DOI 10.1056/NEJM198312083092303; BROWN RS, 1986, KIDNEY INT, V30, P116, DOI 10.1038/ki.1986.160; CLAUSEN T, 1977, J PHYSIOL-LONDON, V270, P383, DOI 10.1113/jphysiol.1977.sp011958; CLAUSEN T, 1983, ACTA MED SCAND, P111; DEGOULET P, 1982, NEPHRON, V31, P103, DOI 10.1159/000182627; FERNANDEZ J, 1986, MINER ELECTROL METAB, V12, P125; HAALBOOM JRE, 1985, LANCET, V1, P1125; KAJI D, 1987, AM J PHYSIOL, V252, pF785, DOI 10.1152/ajprenal.1987.252.5.F785; LENS XM, 1987, KIDNEY INT, V32, P623; LIGHT RW, 1979, ARCH INTERN MED, V139, P639, DOI 10.1001/archinte.139.6.639; MONTOLIU J, 1987, ARCH INTERN MED, V147, P713, DOI 10.1001/archinte.147.4.713; NEVILLE A, 1977, BRIT MED J, V1, P413, DOI 10.1136/bmj.1.6058.413; SMITH SR, 1984, BRIT J CLIN PHARMACO, V18, P641, DOI 10.1111/j.1365-2125.1984.tb02520.x; TZAMALOUKAS AH, 1987, AM J NEPHROL, V7, P101, DOI 10.1159/000167443; VEA AM, 1982, P EUR DIAL TRANS, V19, P756; VESTAL RE, 1979, CLIN PHARMACOL THER, V26, P181; VINCENT HH, 1984, J CARDIOVASC PHARM, V6, P107	19	101	102	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1989	110	6					426	429		10.7326/0003-4819-110-6-426	http://dx.doi.org/10.7326/0003-4819-110-6-426			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	T7215	2919849				2023-01-03	WOS:A1989T721500004
J	CARMICHAEL, AJ; DICKINSON, F; MCHUGH, MI; MARTIN, AM; FARROW, M				CARMICHAEL, AJ; DICKINSON, F; MCHUGH, MI; MARTIN, AM; FARROW, M			MAGNESIUM FREE DIALYSIS FOR UREMIC PRURITUS	BRITISH MEDICAL JOURNAL			English	Article									ROYAL INFIRM,DEPT MED,SUNDERLAND SR2 7JE,ENGLAND; SUNDERLAND POLYTECH,DEPT MATH & COMP STUDIES,SUNDERLAND SR2 3SD,ENGLAND	Sunderland Royal Hospital; University of Sunderland								CARMICHAEL AJ, 1988, BRIT MED J, V296, P1575, DOI 10.1136/bmj.296.6636.1575; COBURN JW, 1969, ARCH INTERN MED, V124, P302, DOI 10.1001/archinte.124.3.302; GRAF H, 1979, BRIT MED J, V2, P1478, DOI 10.1136/bmj.2.6203.1478-a; NILSSON P, 1984, NEPHRON, V37, P25, DOI 10.1159/000183202; 1980, BR MED J, V281, P1025	5	26	26	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1988	297	6663					1584	1585		10.1136/bmj.297.6663.1584	http://dx.doi.org/10.1136/bmj.297.6663.1584			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R4933	3147085	Green Published, Bronze			2023-01-03	WOS:A1988R493300024
J	TYRER, P; MURPHY, S; KINGDON, D; BROTHWELL, J; GREGORY, S; SEIVEWRIGHT, N; FERGUSON, B; BARCZAK, P; DARLING, C; JOHNSON, AL				TYRER, P; MURPHY, S; KINGDON, D; BROTHWELL, J; GREGORY, S; SEIVEWRIGHT, N; FERGUSON, B; BARCZAK, P; DARLING, C; JOHNSON, AL			THE NOTTINGHAM STUDY OF NEUROTIC DISORDER - COMPARISON OF DRUG AND PSYCHOLOGICAL TREATMENTS	LANCET			English	Article									MAPPERLEY HOSP,NOTTINGHAM NG3 6AA,ENGLAND; MRC,BIOSTAT UNIT,CAMBRIDGE,ENGLAND	MRC Biostatistics Unit			Kingdon, David/B-8200-2009	Kingdon, David/0000-0002-8913-0906				ASBERG M, 1978, ACTA PSYCHIAT SCAND, P5; Beck A.T., 1979, COGNITIVE THERAPY DE; Beck A.T., 1985, ANXIETY DISORDERS PH; BIELSKI RJ, 1976, ARCH GEN PSYCHIAT, V33, P1479; BLACKBURN IM, 1981, BRIT J PSYCHIAT, V139, P181, DOI 10.1192/bjp.139.3.181; BUTLER G, 1987, BRIT J PSYCHIAT, V151, P535, DOI 10.1192/bjp.151.4.535; CATALAN J, 1984, BRIT J PSYCHIAT, V144, P593, DOI 10.1192/bjp.144.6.593; Greenblatt D. J., 1974, BENZODIAZEPINES CLIN; HOEHNSARIC R, 1981, ANXIETY NEW RES CHAN; JOHNSTONE EC, 1980, PSYCHOL MED, V10, P321, DOI 10.1017/S0033291700044081; KAHN RJ, 1986, ARCH GEN PSYCHIAT, V43, P79; KLEIN DF, 1962, AM J PSYCHIAT, V119, P432, DOI 10.1176/ajp.119.5.432; KLEIN DF, 1964, PSYCHOPHARMACOLOGIA, V5, P397, DOI 10.1007/BF02193476; KLEIN DF, IN PRESS PSYCHOPHARM; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; LIEBOWITZ MR, IN PRESS J PSYCHIATR; LIPMAN RS, 1986, ARCH GEN PSYCHIAT, V43, P68; MCNAIR DM, 1981, ANXIETY NEW RES CHAN, P69; MONTGOMERY SA, 1979, BRIT J PSYCHIAT, V134, P382, DOI 10.1192/bjp.134.4.382; PAYKEL ES, 1982, ARCH GEN PSYCHIAT, V39, P1041; PAYKEL ES, 1971, ARCH GEN PSYCHIAT, V25, P340, DOI 10.1001/archpsyc.1971.01750160052010; ROBINSON DS, 1973, ARCH GEN PSYCHIAT, V29, P407; Rush A. J., 1977, COGNITIVE THERAPY RE, V1, P17, DOI DOI 10.1007/BF01173502; Shader R I, 1982, J Clin Psychopharmacol, V2, p2S, DOI 10.1097/00004714-198212001-00001; SHEEHAN DV, 1982, NEW ENGL J MED, V307, P156, DOI 10.1056/NEJM198207153070304; SHEEHAN DV, 1980, ARCH GEN PSYCHIAT, V37, P51; SLOANE RB, 1975, AM J PSYCHIAT, V132, P373; Sloane RB, 1975, PSYCHOTHERAPY VS BEH; SPITZER RL, 1983, STRUCTURED CLIN INTE; TYRER P, 1985, LANCET, V1, P685; TYRER P, 1979, BRIT J PSYCHIAT, V135, P163, DOI 10.1192/bjp.135.2.163; TYRER P, 1984, BRIT J PSYCHIAT, V145, P9, DOI 10.1192/bjp.145.1.9; TYRER P, 1984, J NEUROL NEUROSUR PS, V47, P970, DOI 10.1136/jnnp.47.9.970; WADDELL MT, 1984, BEHAV RES THER, V22, P393, DOI 10.1016/0005-7967(84)90082-2; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; 1980, DIAGNOSTIC STATISTIC	36	140	141	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 30	1988	2	8605					235	240						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	P4528	2899234				2023-01-03	WOS:A1988P452800001
J	COLGAN, SM; WHORWELL, PJ; FARAGHER, EB				COLGAN, SM; WHORWELL, PJ; FARAGHER, EB			CONTROLLED TRIAL OF HYPNOTHERAPY IN RELAPSE PREVENTION OF DUODENAL ULCERATION	LANCET			English	Article									UNIV HOSP S MANCHESTER,DEPT MED,MANCHESTER M20 8LR,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital				Whorwell, Peter/0000-0002-5220-8474				Alexander F., 1950, PSYCHOSOMATIC MED; Beaumont W., 1833, EXPT OBSERVATIONS GA; BENNETT A, 1987, CURR OPIN GASTROEN, V3, P971, DOI 10.1097/00001574-198711000-00010; FELDMAN M, 1986, GASTROENTEROLOGY, V91, P1370, DOI 10.1016/0016-5085(86)90189-7; GOLDMAN MC, 1963, PSYCHOSOM MED, V25, P351, DOI 10.1097/00006842-196307000-00004; HAMILTON I, 1986, GUT, V27, P106, DOI 10.1136/gut.27.1.106; HANSKY J, 1980, GASTROENTEROLOGY, V78, P1179; KANG JY, 1982, DIGESTION, V23, P73, DOI 10.1159/000198690; KEHOE M, 1964, PSYCHOSOM MED, V26, P224, DOI 10.1097/00006842-196405000-00003; KIMBALL CP, 1979, PSYCHOTHER PSYCHOSOM, V31, P1, DOI 10.1159/000287307; LEE FI, 1985, LANCET, V1, P1299; LEVI L, 1987, SCAND J GASTROENTERO, V22, P120, DOI 10.3109/00365528709090979; MARTIN DF, 1981, LANCET, V1, P7; MILLER JP, 1986, BRIT MED J, V293, P1117, DOI 10.1136/bmj.293.6555.1117; NASIRY RW, 1987, GUT, V28, P533, DOI 10.1136/gut.28.5.533; PETERS MN, 1983, GASTROENTEROLOGY, V84, P114; PIPER DW, 1978, DIGESTION, V18, P303, DOI 10.1159/000198217; PIPER DW, 1981, GUT, V22, P1011, DOI 10.1136/gut.22.12.1011; PORRO GB, 1984, GUT, V25, pA565; SEGAWA K, 1987, DIGEST DIS SCI, V32, P449, DOI 10.1007/BF01296025; SHREEVE DR, 1983, DIGESTION, V28, P96, DOI 10.1159/000198970; STACHER G, 1975, GASTROENTEROLOGY, V68, P656; STANGHELLINI V, 1982, GASTROENTEROLOGY, V82, P1187; THOMAS J, 1980, GASTROENTEROLOGY, V78, P905; THOMPSON DG, 1983, GUT, V24, P277, DOI 10.1136/gut.24.4.277; WHORWELL PJ, 1987, GUT, V28, P423, DOI 10.1136/gut.28.4.423; WHORWELL PJ, 1987, STRESS MEDICINE, V3, P5, DOI 10.1002/smi.2460030104; WHORWELL PJ, 1984, LANCET, V2, P1232, DOI 10.1016/S0140-6736(84)92793-4; WORMSLEY KG, 1986, BRIT MED J, V293, P1501, DOI 10.1136/bmj.293.6560.1501; WORMSLEY KG, 1987, CURR OPIN GASTROEN, V3, P979, DOI 10.1097/00001574-198711000-00011; WORMSLEY KG, 1986, CURR OPIN GASTROEN, V2, P855, DOI 10.1097/00001574-198611000-00011; [No title captured]	32	42	43	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 11	1988	1	8598					1299	1300		10.1016/S0140-6736(88)92118-6	http://dx.doi.org/10.1016/S0140-6736(88)92118-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7289	2897556				2023-01-03	WOS:A1988N728900002
J	ALTMANN, P; PLOWMAN, D; MARSH, F; CUNNINGHAM, J				ALTMANN, P; PLOWMAN, D; MARSH, F; CUNNINGHAM, J			ALUMINUM CHELATION-THERAPY IN DIALYSIS PATIENTS - EVIDENCE FOR INHIBITION OF HEMOGLOBIN-SYNTHESIS BY LOW-LEVELS OF ALUMINUM	LANCET			English	Article									CHASE FARM HOSP, DEPT BIOCHEM, LONDON, ENGLAND	University of London; University College London; Royal Free London NHS Foundation Trust	ALTMANN, P (corresponding author), LONDON HOSP, DEPT NEUROL, LONDON E1 1BB, ENGLAND.							ADAMSON JW, 1968, AM J MED, V44, P725, DOI 10.1016/0002-9343(68)90254-4; ALTMANN P, 1987, KIDNEY INT, V32, P710, DOI 10.1038/ki.1987.264; ALTMANN P, 1987, NEW ENGL J MED, V317, P80, DOI 10.1056/NEJM198707093170204; ALTMANN P, 1987, NEW ENGL J MED, V317, P1605; ALTMANN P, 1987, 10TH INT C NEPHR; ARMITAGE P, 1987, STATISTICAL METHODS; BERLYNE GM, 1973, LANCET, V2, P1501; DHAESE PC, 1985, CLIN CHEM, V31, P24; ELLIOTT HL, 1978, BRIT MED J, V1, P1101, DOI 10.1136/bmj.1.6120.1101; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FELDMAN DS, 1986, GAGNON J STATVIEW 51; GRAF H, 1981, P EUR DIAL TRANS, V18, P674; HUBER CT, 1970, J BIOL CHEM, V245, P3979; KAISER L, 1984, KIDNEY INT, V26, P269, DOI 10.1038/ki.1984.169; MEREDITH PA, 1979, TOXICOL LETT, V4, P419, DOI 10.1016/0378-4274(79)90055-9; MEREDITH PA, 1977, ENZYME, V22, P22, DOI 10.1159/000458503; NAVARRO J, 1982, NEPHRON, V32, P301, DOI 10.1159/000182870; NORRIS KC, 1986, KIDNEY INT, V29, P199; OHARE JA, 1982, NEW ENGL J MED, V306, P654, DOI 10.1056/NEJM198203183061107; PRAGA M, 1987, Nephrology Dialysis Transplantation, V2, P243; Short A I, 1980, Proc Eur Dial Transplant Assoc, V17, P226; SWARTZ R, 1987, AM J KIDNEY DIS, V9, P217, DOI 10.1016/S0272-6386(87)80058-6; TIELEMANS C, 1985, CLIN NEPHROL, V24, P237; TOUAM M, 1983, CLIN NEPHROL, V19, P295; TRAPP GA, 1983, LIFE SCI, V33, P311, DOI 10.1016/S0024-3205(83)80002-2; WILLS MR, 1983, LANCET, V2, P29; WINEARLS CG, 1986, LANCET, V2, P1175, DOI 10.1016/S0140-6736(86)92192-6; 1983, LANCET, V1, P965	28	67	67	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 7	1988	1	8593					1012	1015						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N2401	2896867				2023-01-03	WOS:A1988N240100002
J	SIU, AL; LEIBOWITZ, A; BROOK, RH; GOLDMAN, NS; LURIE, N; NEWHOUSE, JP				SIU, AL; LEIBOWITZ, A; BROOK, RH; GOLDMAN, NS; LURIE, N; NEWHOUSE, JP			USE OF THE HOSPITAL IN A RANDOMIZED TRIAL OF PREPAID CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT MED,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,CTR HLTH SCI,DEPT PUBL HLTH,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; Los Angeles County Department of Public Health; University of California System; University of California Los Angeles	SIU, AL (corresponding author), RAND CORP,HLTH SCI PROGRAM,1700 MAIN ST,POB 2138,SANTA MONICA,CA 90406, USA.		Newhouse, Joseph/AAD-9763-2019; Newhouse, Joseph/AGJ-5632-2022					FRANCIS AM, 1984, MED CARE, V22, P418, DOI 10.1097/00005650-198405000-00006; GERTMAN PM, 1981, MED CARE, V19, P855, DOI 10.1097/00005650-198108000-00005; Johnson NL, 1969, DISTRIBUTIONS STAT D; LOGERFO JP, 1979, MED CARE, V17, P1, DOI 10.1097/00005650-197901000-00001; LUFT HS, 1978, NEW ENGL J MED, V298, P1336, DOI 10.1056/NEJM197806152982404; LUFT HS, 1981, HLTH MAINTENANCE ORG; MANNING WG, 1984, NEW ENGL J MED, V310, P1505, DOI 10.1056/NEJM198406073102305; MERRICK NJ, 1987, AM J PUBLIC HEALTH, V77, P187, DOI 10.2105/AJPH.77.2.187; Restuccia J D, 1984, Health Aff (Millwood), V3, P130, DOI 10.1377/hlthaff.3.2.130; RESTUCCIA JD, 1986, REDUCING INAPPROPRIA; SIU AL, 1986, NEW ENGL J MED, V315, P1259, DOI 10.1056/NEJM198611133152005; SLOSS EM, 1987, ANN INTERN MED, V106, P130, DOI 10.7326/0003-4819-106-1-130; WARE JE, 1986, LANCET, V1, P1017; YELIN EH, 1986, MED CARE, V24, P236, DOI 10.1097/00005650-198603000-00006; [No title captured]	15	52	52	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 4	1988	259	9					1343	1346		10.1001/jama.259.9.1343	http://dx.doi.org/10.1001/jama.259.9.1343			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M2548	3339839				2023-01-03	WOS:A1988M254800027
J	SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H; BROWN, SS				SURENDER, R; BRADLOW, J; COULTER, A; DOLL, H; BROWN, SS			PROSPECTIVE-STUDY OF TRENDS IN REFERRAL PATTERNS IN FUNDHOLDING AND NON-FUNDHOLDING PRACTICES IN THE OXFORD REGION, 1990-4	BRITISH MEDICAL JOURNAL			English	Article								Objective-To compare outpatient referral patterns in fundholding and non-fundholding practices before and after the NHS reforms in April 1991. Design-Prospective collection of data on general practitioners' referrals to specialist outpatient clinics between June 1990 and January 1994 and detailed comparisons of three phases-October 1990 to March 1991 (phase 1), October 1991 to March 1992 (phase 2), and October 1993 to January 1994 (phase 3). Setting-10 first wave fundholding practices and six non-fundholding practices in the Oxford region. Subjects-Patients referred to consultant outpatient clinics. Results-NHS referral rates increased in fundholding practices in phase 2 and phase 3 of the study by 8.1/1000 patients a year (95% confidence interval 5.7 to 10.5), an increase of 7.5% from phase 1 (107.3/1000) to phase 3 (115.4/1000). Non-fundholders' rates increased significantly, by 25.3/1000 patients (22.5-28.1), an increase of 26.6% from phase 1 (95.0/1000) to phase 3 (120.3/1000). The fundholders' referral rates to private clinics decreased by 8.8%, whereas those from non-fundholding practices increased by 12.2%. The proportion of referrals going outside district boundaries did not change significantly. Three of the four practices entering the third and fourth wave of fundholding increased their referral rates significantly in the year before becoming fundholders. Conclusions-No evidence existed that budgetary pressures caused first wave fundholders to reduce referral rates, although the method of budget allocation may have encouraged general practitioners to inflate their referral rates in the preparatory year. Despite investment in new practice based facilities, no evidence yet exists that fundholding encourages a shift away from specialist care.	KINGS FUND DEV CTR,LONDON W1M 0AN,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND; UNIV OXFORD,DEPT PUBL HLTH & PRIMARY CARE,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND	Radcliffe Infirmary; University of Oxford; University of Oxford			Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				BRADLOW J, 1992, PATTERNS REFERRAL; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; COULTER A, IN PRESS EUR J PUBLI; GARDINER M, 1990, BMJ; GLENNERSTER H, 1994, IMPLEMENTING GP FUND; Roland M, 1992, HOSPITAL REFERRALS; SHELDON TA, 1994, BRIT MED J, V309, P1059, DOI 10.1136/bmj.309.6961.1059	7	45	45	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 4	1995	311	7014					1205	1208		10.1136/bmj.311.7014.1205	http://dx.doi.org/10.1136/bmj.311.7014.1205			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TD768	7488902	Green Published			2023-01-03	WOS:A1995TD76800026
J	ANDERSON, HV				ANDERSON, HV			INTRAVENOUS THROMBOLYSIS IN REFRACTORY UNSTABLE ANGINA-PECTORIS	LANCET			English	Editorial Material							TRIAL; PLACEBO		HERMANN HOSP,HOUSTON,TX		ANDERSON, HV (corresponding author), UNIV TEXAS,HLTH SCI CTR,HOUSTON,TX 77225, USA.							ANDERSON HV, IN PRESS J AM COLL C; BAR FW, 1992, CIRCULATION, V86, P131, DOI 10.1161/01.CIR.86.1.131; DUVVURI S, 1994, J MYOCARD ISCHEMIA, V6, P11; FREEMAN MR, 1992, CIRCULATION, V85, P150, DOI 10.1161/01.CIR.85.1.150; GRAVES EJ, 1993, NATIONAL CTR HLTH 13, V114; GURKFINKEL E, 1995, J AM COLL CARDIOL, pA420; ROMEO F, 1995, J AM COLL CARDIOL, V25, P1295, DOI 10.1016/0735-1097(95)00002-L; SCHREIBER TL, 1992, CIRCULATION, V86, P1407, DOI 10.1161/01.CIR.86.5.1407; Theroux P, 1993, Curr Probl Cardiol, V18, P157	9	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	OCT 28	1995	346	8983					1113	1114						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TB549	7475596				2023-01-03	WOS:A1995TB54900003
J	MORRISON, RS; OLSON, E; MERTZ, KR; MEIER, DE				MORRISON, RS; OLSON, E; MERTZ, KR; MEIER, DE			THE INACCESSIBILITY OF ADVANCE DIRECTIVES ON TRANSFER FROM AMBULATORY TO ACUTE-CARE SETTINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ATTITUDES	Objective.-To investigate the accessibility of patients' previously executed advance directives during an acute hospitalization. Design.-Retrospective chart review. Setting.-A large metropolitan teaching hospital, a 514-bed skilled nursing facility, a geriatrics ambulatory care clinic, and a geriatrics group practice office. Patients.-One hundred fourteen geriatric patients who had previously executed an advance directive. Main Outcome Measures.-The medical records of 180 admissions over 3 years, 1991 through 1993, were reviewed for documentation of patients' advance directive status. Results.-Twenty-six percent of patients who had previously executed advance directives had their directives recognized during their hospitalization. Of the subgroup of patients who were judged not to have the capacity to make medical decisions during their admissions, 26% (14/53) had their directives recognized. When the advance directive was recognized, it appeared to influence treatment decisions in 12 (86%) of 14 cases. Conclusions.-Previously executed advance directives are not accessible when patients are admitted to hospitals for acute illness. When such directives are recognized, they are used to influence medical treatment decisions. Further research is needed to define and overcome barriers to this inaccessibility.	JEWISH HOME & HOSP AGED NEW YORK,NEW YORK,NY		MORRISON, RS (corresponding author), MT SINAI MED CTR,DEPT GERIATR & ADULT DEV,BOX 1070,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.							DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DAVIDSON KW, 1989, JAMA-J AM MED ASSOC, V262, P2415, DOI 10.1001/jama.262.17.2415; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; GHUSIN HF, 1993, J AM GERIATR SOC S, V41; HIGH DM, 1994, GERONTOLOGIST, V24, P409; LIBOW LS, 1978, GERIATRICS, V33, P92; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LYNN J, 1993, HASTINGS CENT REP, V23, P20, DOI 10.2307/3562275; MILLER MB, 1976, J AM GERIATR SOC, V24, P108, DOI 10.1111/j.1532-5415.1976.tb04281.x; MORRISON RS, 1994, ARCH INTERN MED, V154, P2311, DOI 10.1001/archinte.154.20.2311; OUSLANDER J, 1990, PRINCIPLES GERIATRIC, P331; PARIS B, 1992, J AM GERIATR SOC, V40, pA129; PARIS BEC, 1993, ARCH INTERN MED, V153, P1689, DOI 10.1001/archinte.153.14.1689; PFEIFER MP, 1994, J GEN INTERN MED, V9, P82, DOI 10.1007/BF02600206; RUBIN SM, 1994, JAMA-J AM MED ASSOC, V271, P209, DOI 10.1001/jama.271.3.209; SCHMERLING RH, 1988, J GEN INTERN MED, V3, P317; SUGARMAN J, 1994, J CLIN ETHIC, V5, P60; TENO JM, 1994, J CLIN ETHIC, V5, P23; 1992, Q PROGR REPORT ADV D	20	140	140	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 9	1995	274	6					478	482		10.1001/jama.274.6.478	http://dx.doi.org/10.1001/jama.274.6.478			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RM699	7629957				2023-01-03	WOS:A1995RM69900028
J	PROUDLER, AJ; AHMED, AIH; CROOK, D; FOGELMAN, I; RYMER, JM; STEVENSON, JC				PROUDLER, AJ; AHMED, AIH; CROOK, D; FOGELMAN, I; RYMER, JM; STEVENSON, JC			HORMONE REPLACEMENT THERAPY AND SERUM ANGIOTENSIN CONVERTING-ENZYME ACTIVITY IN POSTMENOPAUSAL WOMEN	LANCET			English	Note							DELETION POLYMORPHISM; HYPERTENSION; PLASMA; GENE	The mechanisms by which hormone replacement therapy (HRT) reduces the risk of coronary heart disease (CHD) are incompletely understood, but may include direct arterial effects. We examined the effect of oestrogen/progestagen HRT on serum angiotensin-converting-enzyme (ACE) activity in postmenopausal women. After 6 months, ACE activity was reduced by 20% (p<0.001) on average in 28 treated women but remained unchanged in 16 controls. Serum ACE activity is modifiable by gonadal steroids and changes in serum ACE may represent a novel mechanism by which HRT reduces CHD risk in women.	GUYS HOSP,DEPT NUCL MED,LONDON SE1 9RT,ENGLAND	Guy's & St Thomas' NHS Foundation Trust	PROUDLER, AJ (corresponding author), NATL HEART & LUNG INST,WYNN DEPT METAB MED,LONDON NW8 9SQ,ENGLAND.			Crook, David/0000-0002-9587-3730				ALHENCGELAS F, 1991, J LAB CLIN MED, V117, P33; BUTTERY JE, 1993, CLIN CHEM, V39, P312; CAMBIEN F, 1994, CIRCULATION, V90, P669, DOI 10.1161/01.CIR.90.2.669; CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; DUX S, 1984, ISRAEL J MED SCI, V20, P1138; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SASSANO P, 1987, AM J MED, V83, P227, DOI 10.1016/0002-9343(87)90690-5; STAMPFER MJ, 1991, PREV MED, V28, P47; STEVENSON JC, 1994, DRUGS, V47, P35, DOI 10.2165/00003495-199400472-00007	9	166	168	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 8	1995	346	8967					89	90		10.1016/S0140-6736(95)92114-1	http://dx.doi.org/10.1016/S0140-6736(95)92114-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RH220	7603219				2023-01-03	WOS:A1995RH22000012
J	VERNON, CC; VANDERZEE, J				VERNON, CC; VANDERZEE, J			HYPERTHERMIA IN CANCER-TREATMENT	LANCET			English	Letter									HAMMERSMITH HOSP, DEPT CLIN ONCOL, LONDON W12 0HS, ENGLAND; DR DANIEL DEN HOED CANC CTR, DEPT HYPERTHERMIA, ROTTERDAM, NETHERLANDS	Imperial College London; Erasmus University Rotterdam; Erasmus MC; Erasmus MC Cancer Institute								CORRY PM, 1988, INT J HYPERTHER, V4, P53, DOI 10.3109/02656738809032049; DAHL O, 1990, INTRO PRACTICAL ASPE, P108; KAPP D S, 1986, International Journal of Hyperthermia, V2, P139, DOI 10.3109/02656738609012390; SUIT HD, 1982, CANCER-AM CANCER SOC, V50, P1227, DOI 10.1002/1097-0142(19821001)50:7<1227::AID-CNCR2820500702>3.0.CO;2-J; VERNON CC, 1994, BR J CANCER S22, V70, P10	5	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 24	1995	345	8965					1636	1636						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE670	7783552				2023-01-03	WOS:A1995RE67000037
J	SHIFFMAN, ML; KAPLAN, GD; BRINKMANKAPLAN, V; VICKERS, FF				SHIFFMAN, ML; KAPLAN, GD; BRINKMANKAPLAN, V; VICKERS, FF			PROPHYLAXIS AGAINST GALLSTONE FORMATION WITH URSODEOXYCHOLIC ACID IN PATIENTS PARTICIPATING IN A VERY-LOW-CALORIE DIET PROGRAM	ANNALS OF INTERNAL MEDICINE			English	Article						DIET, REDUCING; CHOLELITHIASIS; CALORIC INTAKE; URSODEOXYCHOLIC ACID; WEIGHT LOSS	GASTRIC BYPASS-SURGERY; RAPID WEIGHT-LOSS; MORBID-OBESITY; SYMPTOMATIC GALLSTONES; CHOLESTEROL SATURATION; NATURAL-HISTORY; BILIARY SLUDGE; GALL-STONES; BILE; DISEASE	Objective: To determine whether prophylactic treatment with ursodeoxycholic acid can prevent gallstone formation in persons participating in a very-low-calorie weight reduction diet program. Design: Multicenter, double-blind, placebo-controlled, multidose clinical trial. Patients were treated with placebo or with 300 mg/d, 600 mg/d, or 1200 mg/d of ursodeoxycholic acid. Setting: 31 Health Management Resources weight management centers. Patients: 1004 patients were initially enrolled in a 16-week, 520-kcal/d, Health Management Resources liquid protein diet program. All patients had a body mass index of 38 kg/m(2) or more and a normal gallbladder ultrasonogram before study entry. Bile analysis was done in 32 patients. Measurements: Body weight and body mass index were measured before the diet was started and at 2-week intervals for 16 weeks. Gallbladder ultrasonography was done before enrollment and after 8 and 16 weeks of dieting. Bile was obtained by endoscopy and analyzed for cholesterol crystals and lipid levels. Results: Mean body weight for all patients at the start of dieting was 128.2 kg +/- 23.2 kg; mean initial body mass index was 44.2 kg/m(2) +/- 6.0 kg/m(2). Gallstones developed in 28% (95% CI, 22% to 35%) of patients receiving placebo, in 8% (CI, 5% to 13%) of patients treated with 300 mg/d of ursodeoxycholic acid, in 3% (CI, 1% to 7%) of patients treated with 600 mg/d of ursodeoxycholic acid, and in 2% (CI, 0.5% to 5%) of patients treated with 1200 mg/d of ursodeoxycholic acid. The differences between patients receiving placebo and patients receiving ursodeoxycholic acid were statistically significant. The percentage of ursodeoxycholic acid in bile increased stepwise with increasing doses of ursodeoxycholic acid. Conclusions: Ursodeoxycholic acid, 600 mg/d, is highly effective in preventing gallstone formation in patients having dietary-induced weight reduction.	HLTH MANAGEMENT RESOURCES, BOSTON, MA USA; CIBA GEIGY PHARMACEUT CORP, SUMMIT, NJ USA		SHIFFMAN, ML (corresponding author), VIRGINIA COMMONWEALTH UNIV MED COLL VIRGINIA, HEPATOL SECT, POB 980711, RICHMOND, VA 23298 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK043264] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43264] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMARAL JF, 1985, AM J SURG, V149, P551, DOI 10.1016/S0002-9610(85)80055-6; ANGELICO M, 1988, HEPATOLOGY, V8, P907; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BENNION LJ, 1978, NEW ENGL J MED, V299, P1221, DOI 10.1056/NEJM197811302992205; BENNION LJ, 1975, J CLIN INVEST, V56, P996, DOI 10.1172/JCI108180; BOLONDI L, 1985, GUT, V26, P734, DOI 10.1136/gut.26.7.734; BROOMFIELD PH, 1988, NEW ENGL J MED, V319, P1567, DOI 10.1056/NEJM198812153192403; CAREY MC, 1978, J LIPID RES, V19, P945; CAREY MC, 1988, GASTROENTEROLOGY, V95, P508, DOI 10.1016/0016-5085(88)90513-6; CRAIN K, 1990, CLIN THER, V12, P250; DIEHL AK, 1991, GASTROENTEROL CLIN N, V20, P1; EVERHART JE, 1993, ANN INTERN MED, V119, P1029, DOI 10.7326/0003-4819-119-10-199311150-00010; EVERSON GT, 1991, GASTROENTEROL CLIN N, V20, P85; FORGACS IC, 1984, GASTROENTEROLOGY, V87, P299; FRIEDMAN GD, 1966, J CHRON DIS, V19, P273, DOI 10.1016/0021-9681(66)90132-9; GRACIE WA, 1982, NEW ENGL J MED, V307, P798, DOI 10.1056/NEJM198209233071305; HAY DW, 1990, SEMIN LIVER DIS, V10, P159, DOI 10.1055/s-2008-1040470; HOY MK, 1994, AM J CLIN NUTR, V60, P249, DOI 10.1093/ajcn/60.2.249; INOUE K, 1992, ANN SURG, V215, P19, DOI 10.1097/00000658-199201000-00002; JORGENSEN T, 1989, GUT, V30, P528, DOI 10.1136/gut.30.4.528; KELLEY JE, 1993, AM SURGEON, V59, P23; KUROKI S, 1986, J LIPID RES, V27, P442; LEE SP, 1988, GASTROENTEROLOGY, V94, P170, DOI 10.1016/0016-5085(88)90626-9; LEGORRETA AP, 1993, JAMA-J AM MED ASSOC, V270, P1429, DOI 10.1001/jama.270.12.1429; LIDDLE RA, 1989, ARCH INTERN MED, V149, P1750, DOI 10.1001/archinte.149.8.1750; Luketic V A, 1994, Gastroenterologist, V2, P74; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MARKS JW, 1992, GASTROENTEROLOGY, V103, P566, DOI 10.1016/0016-5085(92)90848-S; MATON PN, 1977, LANCET, V2, P1297, DOI 10.1016/s0140-6736(77)90358-0; SALEN G, 1980, GASTROENTEROLOGY, V78, P1412; SHIFFMAN ML, 1991, AM J GASTROENTEROL, V86, P1000; SHIFFMAN ML, 1993, INT J OBESITY, V17, P153; SHIFFMAN ML, 1992, GASTROENTEROLOGY, V103, P214, DOI 10.1016/0016-5085(92)91115-K; SHIFFMAN ML, 1993, GASTROENTEROLOGY, V105, P1200, DOI 10.1016/0016-5085(93)90968-I; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; STONE BG, 1992, HEPATOLOGY, V15, P795, DOI 10.1002/hep.1840150508; SUGERMAN HJ, 1995, AM J SURG, V169, P91, DOI 10.1016/S0002-9610(99)80115-9; THIJS C, 1992, AM J EPIDEMIOL, V135, P274, DOI 10.1093/oxfordjournals.aje.a116281; TINT GS, 1982, ANN INTERN MED, V97, P351, DOI 10.7326/0003-4819-97-3-351; VONBERGMANN K, 1984, GASTROENTEROLOGY, V87, P136; WATTCHOW DA, 1983, BRIT MED J, V286, P763, DOI 10.1136/bmj.286.6367.763; WOROBETZ LJ, 1993, AM J GASTROENTEROL, V88, P1705; YANG HY, 1992, DIGEST DIS SCI, V37, P912, DOI 10.1007/BF01300390; ZEMAN RK, 1991, GASTROENTEROL CLIN N, V20, P127	44	95	100	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 15	1995	122	12					899	905		10.7326/0003-4819-122-12-199506150-00002	http://dx.doi.org/10.7326/0003-4819-122-12-199506150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC270	7755224				2023-01-03	WOS:A1995RC27000002
J	LOWE, CJ; RAYNOR, DK; COURTNEY, EA; PURVIS, J; TEALE, C				LOWE, CJ; RAYNOR, DK; COURTNEY, EA; PURVIS, J; TEALE, C			EFFECTS OF SELF-MEDICATION PROGRAM ON KNOWLEDGE OF DRUGS AND COMPLIANCE WITH TREATMENT IN ELDERLY PATIENTS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To determine whether a programme of self medication for inpatients improves compliance with treatment and knowledge of their drugs after discharge from hospital. Design-Patients were prospectively recruited from four wards: two with a self medication programme and two acting as controls. Ten days after discharge the patients were visited at home. They were questioned about their drugs, and a tablet count was undertaken. Setting-The pharmacy department and four medical wards with an interest in elderly patients at a district general hospital, and the patients' homes. Patients-88 patients discharged to their own homes who were regularly taking one or more drugs. Intervention-A hospital self medication programme in which patients are educated about their medicines and given increasing responsibility for taking them in hospital. Main outcome measure-Compliance with and knowledge of the purpose of their medicines 10 days after discharge from hospital. Results-The mean compliance score in patients taking part in the self medication programme was 95% compared with 83% in the control group (difference 12%, 95% confidence interval 4% to 21%; P<0.02). Of the patients in the self medication group, 90% (38/42) knew the purpose of their drugs compared with 46% (17/37) in the control group (difference 44%, 26% to 63%; P<0.001). Conclusion-A self medication programme is an effective aid for improving compliance with and knowledge of patients' drugs after discharge.	SEACROFT HOSP,PRACTICE DEV UNIT,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND; UNIV BRADFORD,PHARM PRACTICE RES UNIT,BRADFORD BD7 1DP,W YORKSHIRE,ENGLAND	University of Bradford	LOWE, CJ (corresponding author), SEACROFT HOSP,DEPT PHARM,LEEDS LS14 6UH,W YORKSHIRE,ENGLAND.							ASPLUND J, 1984, BRIT J CLIN PHARMACO, V17, P547, DOI 10.1111/j.1365-2125.1984.tb02388.x; BAXENDALEC, 1978, BRIT MED J, V2, P1278; Bird C, 1988, Nurs Times, V84, P28; FOSTER H, 1993, AGE AGEING S3, V22, P23; GARDNER MJ, 1989, CONFIDENCE INTERVAL; Ley P., 1988, COMMUNICATING PATIEN; MAZZUCA SA, 1982, J CHRON DIS, V35, P521, DOI 10.1016/0021-9681(82)90071-6; PARKIN DM, 1976, BMJ-BRIT MED J, V2, P686, DOI 10.1136/bmj.2.6037.686; RAYNOR DK, 1993, BRIT MED J, V306, P1158, DOI 10.1136/bmj.306.6886.1158; RUDD P, 1979, CLIN PHARMACOL THER, V25, P257; SACKET DL, 1979, COMPLIANCE HEALTHCAR; SANDLER DA, 1989, BRIT MED J, V298, P870, DOI 10.1136/bmj.298.6677.870; Webb C, 1990, Nurs Times, V86, P46; Wood SI, 1992, INT J PHARM PRAC, V1, P240; WRIGHT EC, 1993, LANCET, V342, P909, DOI 10.1016/0140-6736(93)91951-H	15	80	82	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 13	1995	310	6989					1229	1231		10.1136/bmj.310.6989.1229	http://dx.doi.org/10.1136/bmj.310.6989.1229			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QY877	7767193	Green Published			2023-01-03	WOS:A1995QY87700016
J	HEBERT, PC; WELLS, G; MARSHALL, J; MARTIN, C; TWEEDDALE, M; PAGLIARELLO, G; BLAJCHMAN, M				HEBERT, PC; WELLS, G; MARSHALL, J; MARTIN, C; TWEEDDALE, M; PAGLIARELLO, G; BLAJCHMAN, M			TRANSFUSION REQUIREMENTS IN CRITICAL CARE - A PILOT-STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK SURGICAL PATIENTS; OXYGEN DELIVERY; UNITED-STATES; BLOOD; MORTALITY; SEPSIS; SHOCK; HEMOGLOBIN; STRATEGIES; SEVERITY	Objective.-To evaluate the effects of a restrictive and a liberal red blood cell (RBC) transfusion strategy on mortality and morbidity in critically ill patients. Study Design.-Multicenter, prospective, randomized clinical trial. Patient Population.-Sixty-nine normovolemic critically ill patients admitted to one of five tertiary level intensive care units with hemoglobin values less than 90 g/L within 72 hours of admission. Interventions.-Patients were randomly allocated to one of two RBC transfusion strategies. Hemoglobin values were maintained between 100 and 120 g/L in the liberal transfusion group and between 70 and 90 g/L in the restrictive group. Results.-Primary diagnosis and mean+/-SD age (58.6+/-15 vs 59.0+/-21 years) and Acute Physiology and Chronic Health Evaluation II score (20+/-6.2 vs 21 +/-7.2) were similar in the restrictive and liberal groups, respectively. Daily hemoglobin values averaged 90 g/L in the restrictive group vs 109 g/L in the liberal group (P<.001). The restrictive group received 2.5 U per patient compared with 4.8 U per patient in the liberal group. This represents a 48% relative decrease (P<.001) in RBC units transfused per patient. The 30-day mortality rate was 24% in the restrictive group compared with 25% in the liberal group; the 95% confidence interval around the absolute difference was -19% to 21%. Similar observations were noted for intensive care unit mortality (P=.76) and 120-day mortality (P>.99). In addition, survival analysis comparing time until death in both groups did not reveal any significant difference (P=.93) between groups. Organ dysfunction scores were also similar (P=.44). Conclusion.-In this small randomized trial, neither mortality nor the development of organ dysfunction was affected by the transfusion strategy, which suggests that a more restrictive approach to the transfusion of RBCs may be safe in critically ill patients. However, the study lacked power to detect small but clinically significant differences. Therefore, further investigations of RBC transfusion strategies are warranted.	UNIV WESTERN ONTARIO, CRIT CARE PROGRAM, LONDON, ON, CANADA; UNIV TORONTO, CRIT CARE PROGRAM, TORONTO, ON, CANADA; UNIV OTTAWA, CRIT CARE PROGRAM, OTTAWA, ON, CANADA; UNIV BRITISH COLUMBIA, CRIT CARE PROGRAM, VANCOUVER, BC, CANADA; UNIV OTTAWA, CLIN EPIDEMIOL UNIT, OTTAWA, ON, CANADA; MCMASTER UNIV, DEPT PATHOL, HAMILTON, ON, CANADA	Western University (University of Western Ontario); University of Toronto; University of Ottawa; University of British Columbia; University of Ottawa; McMaster University			Martin, Claudio/G-3327-2011; Wells, George A/M-4549-2017	Wells, George A/0000-0002-2289-9139				ABEL FL, 1989, AM J PHYSIOL, V257, pR1265, DOI 10.1152/ajpregu.1989.257.6.R1265; ALEXIU O, 1975, ANAESTHESIA, V30, P609, DOI 10.1111/j.1365-2044.1975.tb00920.x; BAYER WL, 1980, ANN THORAC SURG, V29, P117, DOI 10.1016/S0003-4975(10)61648-7; BERNSTEIN MJ, 1988, JAMA-J AM MED ASSOC, V260, P2700; BIHARI D, 1987, NEW ENGL J MED, V317, P397, DOI 10.1056/NEJM198708133170701; BOYD O, 1993, JAMA-J AM MED ASSOC, V270, P2699, DOI 10.1001/jama.270.22.2699; CANE RD, 1990, CRIT CARE MED, V18, P1046, DOI 10.1097/00003246-199009000-00028; CARSON JL, 1988, LANCET, V1, P727; CROSBY ET, 1992, CAN J ANAESTH, V39, P695, DOI 10.1007/BF03008233; CZER LSC, 1978, SURG GYNECOL OBSTET, V147, P363; CZER LSC, 1980, CRIT CARE MED, V8, P710, DOI 10.1097/00003246-198012000-00002; Friedman LM, 1985, FUNDAMENTALS CLIN TR; FULLERTON WT, 1962, LANCET, V1, P75; GOLLUB S, 1966, JAMA-J AM MED ASSOC, V198, P149; GUTIERREZ G, 1986, Journal of Critical Care, V1, P45, DOI 10.1016/S0883-9441(86)80116-2; Hebert P. C., 1994, Clinical and Investigative Medicine, V17, pB22; HEBERT PC, 1993, CHEST, V104, P230, DOI 10.1378/chest.104.1.230; KAWAGUCHI A, 1984, CIRCULATION, V70, P30; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; Marshall JC, 1994, SEPSIS CURRENT PERSP, P38; Messmer K, 1972, ADV MICROCIRCULAT, V18, P1; NICHOLS RL, 1984, NEW ENGL J MED, V311, P1065, DOI 10.1056/NEJM198410253111701; SHOEMAKER WC, 1990, CRIT CARE MED, V18, pS19; SHOEMAKER WC, 1992, CHEST, V102, P208, DOI 10.1378/chest.102.1.208; SHOEMAKER WC, 1988, CHEST, V94, P1176, DOI 10.1378/chest.94.6.1176; SILBERSTEIN LE, 1989, JAMA-J AM MED ASSOC, V262, P1993, DOI 10.1001/jama.262.14.1993; SPENCE RK, 1990, AM J SURG, V159, P320, DOI 10.1016/S0002-9610(05)81227-9; STEHLING L, 1989, ANESTH ANALG, V68, pS1; STEHLING LC, 1982, INT ANESTHESIOL CLIN, V20, P45; STEHLING LC, 1987, VOX SANG, V52, P60, DOI 10.1111/j.1423-0410.1987.tb02990.x; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; SURGENOR DM, 1988, TRANSFUSION, V28, P513, DOI 10.1046/j.1537-2995.1988.28689059022.x; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; WEISEL RD, 1984, J THORAC CARDIOV SUR, V88, P26; WEISEL RD, 1984, J THORAC CARDIOVASC, V104, P308; WELCH HG, 1992, ANN INTERN MED, V116, P393, DOI 10.7326/0003-4819-116-5-393	37	120	124	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1439	1444		10.1001/jama.273.18.1439	http://dx.doi.org/10.1001/jama.273.18.1439			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723158				2023-01-03	WOS:A1995QW27900032
J	MAHER, DW; LIESCHKE, GJ; GREEN, M; BISHOP, J; STUARTHARRIS, R; WOLF, M; SHERIDAN, WP; KEFFORD, RF; CEBON, J; OLVER, I; MCKENDRICK, J; TONER, G; BRADSTOCK, K; LIESCHKE, M; CRUICKSHANK, S; TOMITA, DK; HOFFMAN, EW; FOX, RM; MORSTYN, G				MAHER, DW; LIESCHKE, GJ; GREEN, M; BISHOP, J; STUARTHARRIS, R; WOLF, M; SHERIDAN, WP; KEFFORD, RF; CEBON, J; OLVER, I; MCKENDRICK, J; TONER, G; BRADSTOCK, K; LIESCHKE, M; CRUICKSHANK, S; TOMITA, DK; HOFFMAN, EW; FOX, RM; MORSTYN, G			FILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED FEBRILE NEUTROPENIA - A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						FILGRASTIM; NEUTROPENIA; FEVER; TOBRAMYCIN; PIPERACILLIN	COLONY-STIMULATING FACTOR; CELL LUNG-CANCER; GRANULOCYTOPENIC PATIENTS; EMPIRIC THERAPY; FEVER; LEUKOPENIA; INFECTION; DURATION	Objective: To determine if filgrastim (recombinant human methionyl granulocyte colony-stimulating factor) used in addition to standard inpatient antibiotic therapy accelerated recovery from infection associated with chemotherapy-induced neutropenia. Design: Randomized, double-blind, placebo-controlled trial. Setting: Hematology and oncology wards of four teaching hospitals. Patients: 218 patients with cancer who had fever (temperature >38.2 degrees C) and neutropenia (neutrophil count <1.0 x 10(9)/L) after chemotherapy. Intervention: Patients were randomly assigned to receive filgrastim (12 mu g/kg of body weight per day) (n = 109) or placebo (n = 107) beginning within 12 hours of empiric therapy with tobramycin and piperacillin. Patients received treatment and remained in the study until the neutrophil count was greater than 0.5 x 10(9)/L and until 4 days without fever (temperature <37.5 degrees C) had elapsed. Measurements: Days of neutropenia and fever and days in the study (hospitalization); time to resolution of fever and febrile neutropenia; and frequency of the use of alternative antibiotics. Results: Compared with placebo, filgrastim reduced the median number of days of neutropenia (3.0 compared with 4.0 days of a neutrophil count of <0.5 x 10(9)/L; P = 0.005) and the time to resolution of febrile neutropenia (5.0 compared with 6.0 days; P = 0.01) but not days of fever (3.0 days for both groups). The frequency of the use of alternative antibiotics was similar in the two groups (46% compared with 41%; P = 0.48). The median number of days patients were hospitalized while on study was the same (8.0 days; P = 0.09); however, filgrastim decreased the risk for prolonged hospitalization (>11 days, 4th quartile) by half (relative risk, 2.1 [95% CI, 1.1 to 4.1]; P = 0.02). In exploratory subset analyses, filgrastim appeared to provide the greatest benefit in patients with documented infection and in patients presenting with neutrophil counts of less than 0.1 x 10(9)/L. Conclusions: Filgrastim treatment used with antibiotics at the onset of febrile neutropenia in patients with cancer who have received chemotherapy accelerated neutrophil recovery and shortened the duration of febrile neutropenia.	ROYAL MELBOURNE HOSP, DEPT CLIN HAEMATOL & MED ONCOL, MELBOURNE, VIC 3050, AUSTRALIA; PETER MACCALLUM CANC INST, DEPT HAEMATOL & MED ONCOL, MELBOURNE, VIC 3000, AUSTRALIA; AUSTIN HOSP, LUDWIG AUSTIN ONCOL UNIT, HEIDELBERG, VIC 3084, AUSTRALIA; WESTMEAD HOSP, DEPT MED ONCOL, WESTMEAD, NSW 2145, AUSTRALIA; WESTMEAD HOSP, DEPT HAEMATOL, WESTMEAD, NSW 2145, AUSTRALIA; AMGEN INC, AMGEN CTR, THOUSAND OAKS, CA 91320 USA	Royal Melbourne Hospital; Peter Maccallum Cancer Center; Austin Research Institute; Florey Institute of Neuroscience & Mental Health; Ludwig Institute for Cancer Research; University of Sydney; University of Sydney; Amgen	MAHER, DW (corresponding author), ROYAL MELBOURNE HOSP, LUDWIG INST CANC RES, MELBOURNE TUMOUR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA.		Olver, Ian/I-1518-2015; Toner, Guy C/G-1738-2011	Olver, Ian/0000-0001-5478-1576; Toner, Guy/0000-0001-9873-3592; Cebon, Jonathan/0000-0002-3898-950X; Lieschke, Graham/0000-0003-0325-798X; Kefford, Richard/0000-0001-9251-9229; Sheridan, William/0000-0001-8320-1323				BIESMA B, 1990, EUR J CANCER, V26, P932, DOI 10.1016/0277-5379(90)90613-X; BODEY GP, 1990, CANCER, V65, P9, DOI 10.1002/1097-0142(19900101)65:1<9::AID-CNCR2820650105>3.0.CO;2-C; BODEY GP, 1966, ANN INTERN MED, V64, P328, DOI 10.7326/0003-4819-64-2-328; BRONCHUD MH, 1987, BRIT J CANCER, V56, P809, DOI 10.1038/bjc.1987.295; CHABNER BA, 1989, CANCER PRINCIPLES PR, P349; COX DR, 1972, J R STAT SOC B, V34, P187; CRAWFORD J, 1991, NEW ENGL J MED, V325, P164, DOI 10.1056/NEJM199107183250305; CRAWFORD J, 1992, P AN M AM SOC CLIN, V11, P299; DEISSEROTH A, 1989, CANCER PRINCIPLES PR; GABRILOVE JL, 1988, NEW ENGL J MED, V318, P1414, DOI 10.1056/NEJM198806023182202; GERHARTZ HH, 1993, LEUKEMIA RES, V17, P175, DOI 10.1016/0145-2126(93)90063-Q; HOLLANDER M, 1973, NONPARAMETRIC STATIS; HUGHES WT, 1990, J INFECT DIS, V161, P381, DOI 10.1093/infdis/161.3.381; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P28; LYMAN GH, 1980, NEW ENGL J MED, V302, P257, DOI 10.1056/NEJM198001313020503; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; Metcalf D, 1988, MOL CONTROL BLOOD CE; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MORSTYN G, 1988, LANCET, V1, P667, DOI 10.1016/S0140-6736(88)91475-4; MORSTYN G, 1989, J CLIN ONCOL, V7, P1554, DOI 10.1200/JCO.1989.7.10.1554; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PIZZO PA, 1979, AM J MED, V67, P194, DOI 10.1016/0002-9343(79)90390-5; PIZZO PA, 1982, AM J MED, V72, P101, DOI 10.1016/0002-9343(82)90594-0; ROLSTON KVI, 1992, ARCH INTERN MED, V152, P283, DOI 10.1001/archinte.152.2.283; SCHIMPFF S, 1971, NEW ENGL J MED, V284, P1061, DOI 10.1056/NEJM197105132841904; SCHIMPFF SC, 1974, J INFECT DIS, V130, pS24, DOI 10.1093/infdis/130.Supplement.S24; SICKLES EA, 1975, ARCH INTERN MED, V135, P715, DOI 10.1001/archinte.135.5.715; SOUZA LM, 1986, SCIENCE, V232, P61, DOI 10.1126/science.2420009; TRILLETLENOIR V, 1993, EUR J CANCER, V29A, P319, DOI 10.1016/0959-8049(93)90376-Q; WINSTON DJ, 1982, ANN INTERN MED, V97, P509, DOI 10.7326/0003-4819-97-4-509; 1990, BMDP STATISTICAL SOF; 1992, SAS PROCEDURES GUIDE	34	171	172	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 1	1994	121	7					492	501		10.7326/0003-4819-121-7-199410010-00004	http://dx.doi.org/10.7326/0003-4819-121-7-199410010-00004			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PJ102	7520676				2023-01-03	WOS:A1994PJ10200004
J	MEYER, RM; QUIRT, IC; SKILLINGS, JR; CRIPPS, MC; BRAMWELL, VHC; WEINERMAN, BH; GOSPODAROWICZ, MK; BURNS, BF; SARGEANT, AM; SHEPHERD, LE; ZEE, B; HRYNIUK, WM				MEYER, RM; QUIRT, IC; SKILLINGS, JR; CRIPPS, MC; BRAMWELL, VHC; WEINERMAN, BH; GOSPODAROWICZ, MK; BURNS, BF; SARGEANT, AM; SHEPHERD, LE; ZEE, B; HRYNIUK, WM			ESCALATED AS COMPARED WITH STANDARD DOSES OF DOXORUBICIN IN BACOP THERAPY FOR PATIENTS WITH NON-HODGKINS-LYMPHOMA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LARGE-CELL LYMPHOMA; DIFFUSE HISTIOCYTIC LYMPHOMA; COMBINATION CHEMOTHERAPY; MALIGNANT-LYMPHOMA; ONCOLOGY-GROUP; SURVIVAL; TRIAL; CHOP; ADRIAMYCIN; INTENSITY	Background and Methods. In 1981 the Clinical Trials Group of the National Cancer Institute of Canada completed a pilot study in patients with advanced-stage non-Hodgkin's lymphoma with aggressive tumor histology. That study demonstrated the potential efficacy of escalating the dose of doxorubicin used in a regimen of bleomycin, doxorubicin, cyclophosphamide, vincristine, and prednisone (BACOP). In the present study, we compared standard BACOP (s-BACOP) with BACOP that included escalated doses of doxorubicin (esc-BACOP) in 238 patients 16 to 70 years old with previously untreated, advanced-stage intermediate- or high-grade non-Hodgkin's lymphoma. During the first 28-day cycle all patients received doxorubicin in a dose of 25 mg per square meter of body-surface area on days 1 and 8. Patients randomly assigned to receive s-BACOP subsequently received five identical cycles, whereas those assigned to receive esc-BACOP received 40 mg of doxorubicin per square meter on days 1 and 8 of five subsequent cycles if granulocytopenia (<1000 cells per cubic millimeter) had not developed during the first cycle. Results. The 119 patients assigned to the esc-BACOP regimen received doxorubicin at a significantly higher mean weekly dose intensity (13.5 vs. 10.4 mg per square meter per week, P<0.001) and mean total dose (296 vs. 231 mg per square meter, P<0.001). Because of granulocytopenia during the first cycle of therapy, only 56 of these patients (47 percent) received the escalated doses of doxorubicin. During a median follow-up of 65 months, there were no differences between the s-BACOP and esc-BACOP groups in response rate, overall survival, or survival without disease progression. When the patients who actually received the escalated doses of doxorubicin were compared with the patients in the s-BACOP group in whom neutropenia did not develop during the first treatment cycle, no difference between their outcomes was observed. Toxicity was greater in the esc-BACOP group. Conclusions. In patients with advanced-stage intermediate- or high-grade non-Hodgkin's lymphoma, escalating the dose of doxorubicin in the BACOP regimen increases toxicity but does not improve the rate of response or survival.	HAMILTON CIVIC HOSP, HAMILTON, ON, CANADA; MCMASTER UNIV, HAMILTON L8S 4L8, ONTARIO, CANADA; PRINCESS MARGARET HOSP, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, TORONTO M5S 1A1, ONTARIO, CANADA; NOVA SCOTIA CANC TREATMENT RES FDN, HALIFAX, NS, CANADA; DALHOUSIE UNIV, HALIFAX B3H 4H2, NS, CANADA; UNIV OTTAWA, OTTAWA REG CANC CTR, OTTAWA K1N 6N5, ONTARIO, CANADA; UNIV OTTAWA, OTTAWA CIVIC HOSP, OTTAWA K1N 6N5, ONTARIO, CANADA; LONDON REG CANC CTR, LONDON, ON, CANADA; UNIV WESTERN ONTARIO, LONDON N6A 3K7, ONTARIO, CANADA; UNIV MANITOBA, WINNIPEG R3T 2N2, MANITOBA, CANADA; MANITOBA CANC TREATMENT & RES FDN, WINNIPEG, MB, CANADA; NATL CANC INST CANADA, CLIN TRIALS GRP, KINGSTON, ON, CANADA; QUEENS UNIV, KINGSTON K7L 3N6, ONTARIO, CANADA; UNIV CALIF SAN DIEGO, GILDRED CANC CTR, LA JOLLA, CA 92093 USA	McMaster University; McMaster University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; Dalhousie University; University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Ottawa Hospital Research Institute; Western University (University of Western Ontario); Western University (University of Western Ontario); University of Manitoba; Queens University - Canada; Canadian Cancer Trials Group; Queens University - Canada; University of California System; University of California San Diego			Zee, Benny Chung Ying/G-5606-2017	Zee, Benny Chung Ying/0000-0002-7238-845X				CARBONE PP, 1971, CANCER RES, V31, P1860; COOPER IA, 1991, P AN M AM SOC CLIN, V10, P271; COX DR, 1972, J R STAT SOC B, V34, P187; DEVITA VT, 1975, LANCET, V1, P248; DEVITA VT, 1987, CANCER RES, V47, P5810; EPELBAUM R, 1988, ISRAEL J MED SCI, V24, P533; Fisher R I, 1990, Important Adv Oncol, P217; FISHER RA, 1970, STATISTICAL METHODS, P76; FISHER RI, 1993, NEW ENGL J MED, V328, P1002, DOI 10.1056/NEJM199304083281404; FISHER RI, 1983, ANN INTERN MED, V98, P304, DOI 10.7326/0003-4819-98-3-304; FLEISS JL, 1973, STATISTICAL METHODS; FRIEDMAN LM, 1985, FUNDAMENTALS CLIN TR, P196; GAMS RA, 1985, J CLIN ONCOL, V3, P1188, DOI 10.1200/JCO.1985.3.9.1188; GORDON LI, 1992, NEW ENGL J MED, V327, P1342, DOI 10.1056/NEJM199211053271903; HAGBERG H, 1985, EUR J CANCER CLIN ON, V21, P175, DOI 10.1016/0277-5379(85)90169-5; Hryniuk W M, 1988, Important Adv Oncol, P121; HRYNIUK WM, 1982, P AN M AM SOC CLIN, V1, P156; JONES SE, 1983, CANCER, V51, P1083, DOI 10.1002/1097-0142(19830315)51:6<1083::AID-CNCR2820510619>3.0.CO;2-M; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KARNOFSKY DA, 1948, CANCER-AM CANCER SOC, V1, P634, DOI 10.1002/1097-0142(194811)1:4<634::AID-CNCR2820010410>3.0.CO;2-L; KLIMO P, 1985, ANN INTERN MED, V102, P596, DOI 10.7326/0003-4819-102-5-596; KWAK LW, 1990, J CLIN ONCOL, V8, P963, DOI 10.1200/JCO.1990.8.6.963; LONGO, 1991, J CLIN ONCOL, V9, P710, DOI 10.1200/JCO.1991.9.4.710; LONGO DL, 1991, J CLIN ONCOL, V9, P25, DOI 10.1200/JCO.1991.9.1.25; MCKELVEY EM, 1976, CANCER, V38, P1484, DOI 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I; MEYER RM, 1991, J CLIN ONCOL, V9, P339, DOI 10.1200/JCO.1991.9.2.339; MOOD AM, 1973, INTRO THEORY STATIST; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; RAPPAPORT H, 1966, ATLAS TUMOR PATHOLOG; ROSENBERG SA, 1982, CANCER, V49, P2112; SACKETT DL, 1989, CHEST, V95, pS2, DOI 10.1378/chest.95.2.2S; SCHEIN PS, 1976, ANN INTERN MED, V85, P417, DOI 10.7326/0003-4819-85-4-417; SHIPP MA, 1993, NEW ENGL J MED, V329, P987, DOI 10.1056/nejm199309303291402; SKARIN AT, 1983, J CLIN ONCOL, V1, P91, DOI 10.1200/JCO.1983.1.2.91	35	58	59	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1993	329	24					1770	1776		10.1056/NEJM199312093292404	http://dx.doi.org/10.1056/NEJM199312093292404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK096	7694148				2023-01-03	WOS:A1993MK09600004
J	ADES, PA; GUNTHER, PGS; MEACHAM, CP; HANDY, MA; LEWINTER, MM				ADES, PA; GUNTHER, PGS; MEACHAM, CP; HANDY, MA; LEWINTER, MM			HYPERTENSION, EXERCISE, AND BETA-ADRENERGIC-BLOCKADE	ANNALS OF INTERNAL MEDICINE			English	Article									UNIV VERMONT, SCH MED, BURLINGTON, VT 05405 USA	University of Vermont					NCRR NIH HHS [RR109] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ADES PA, 1984, AM J CARDIOL, V54, P1337, DOI 10.1016/S0002-9149(84)80093-4; ADES PA, 1987, BRIT J CLIN PHARMACO, V24, pS29, DOI 10.1111/j.1365-2125.1987.tb03265.x; [Anonymous], 1984, ARCH INTERN MED, V144, P1045; BOYER JL, 1970, J AMER MED ASSOC, V211, P1668, DOI 10.1001/jama.211.10.1668; CADE R, 1984, AM J MED, V77, P785, DOI 10.1016/0002-9343(84)90513-8; EPSTEIN SE, 1965, J CLIN INVEST, V44, P1745, DOI 10.1172/JCI105282; EWY G, 1983, J CARDIAC REHABIL, V3, P25; FROELICHER VF, 1974, J APPL PHYSIOL, V36, P720, DOI 10.1152/jappl.1974.36.6.720; HAGBERG JM, 1983, AM J CARDIOL, V52, P763, DOI 10.1016/0002-9149(83)90412-5; HANSON JS, 1970, CIRC RES, V27, pI49; KOSTIS JB, 1987, CIRCULATION, V75, P204, DOI 10.1161/01.CIR.75.1.204; LIANG CS, 1979, J CLIN INVEST, V64, P613, DOI 10.1172/JCI109501; LUNDBORG P, 1981, CLIN SCI, V61, P299, DOI 10.1042/cs0610299; MARSH RC, 1983, J AM COLL CARDIOL, V2, P551, DOI 10.1016/S0735-1097(83)80284-8; MCLEOD AA, 1984, AM J CARDIOL, V53, P1656, DOI 10.1016/0002-9149(84)90597-6; NEILDWYER G, 1981, BRIT J CLIN PHARMACO, V11, P549, DOI 10.1111/j.1365-2125.1981.tb01169.x; RESSL J, 1977, ACTA CARDIOL, V32, P121; ROMAN O, 1981, CARDIOLOGY, V67, P230, DOI 10.1159/000173248; SABLE DL, 1982, CIRCULATION, V65, P679, DOI 10.1161/01.CIR.65.4.679; SAVIN WM, 1985, AM J CARDIOL, V55, pD101, DOI 10.1016/0002-9149(85)91063-X; SVEDENHAG J, 1984, ACTA PHYSIOL SCAND, V120, P77, DOI 10.1111/j.1748-1716.1984.tb07376.x; WILLIAMS ME, 1985, NEW ENGL J MED, V312, P823, DOI 10.1056/NEJM198503283121304; WOLFEL EE, 1986, CIRCULATION, V74, P664, DOI 10.1161/01.CIR.74.4.664; 1986, FDACDB86122 US DEP H	24	39	42	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	OCT 15	1988	109	8					629	634		10.7326/0003-4819-109-8-629	http://dx.doi.org/10.7326/0003-4819-109-8-629			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q6974	2901818				2023-01-03	WOS:A1988Q697400009
J	[Anonymous]				[Anonymous]			NEED WE POISON THE ELDERLY SO OFTEN	LANCET			English	Editorial Material																		ADAMS KRH, 1987, J ROY COLL PHYS LOND, V21, P39; BLACK AJ, 1984, J ROY COLL PHYS LOND, V18, P40; BROWNE M, 1987, BR J PHARM PRAC, V9, P250; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; Cartwright A, 1988, ELDERLY PEOPLE THEIR; GHOSE K, 1980, J ROY SOC MED, V73, P853, DOI 10.1177/014107688007301207; GOSNEY M, 1984, LANCET, V2, P564; HUWITZ N, 1969, BRIT MED J, V1, P536; KNOX JDE, 1980, J R COLL GEN PRAC S1, V30; MARTYS CR, 1982, BRIT MED J, V285, P1623, DOI 10.1136/bmj.285.6355.1623; PARISH P, 1983, ELDERLY THEIR USE ME; PAULET N, 1982, MED J AUSTRALIA, V1, P80, DOI 10.5694/j.1326-5377.1982.tb132165.x; SEIDL LG, 1966, B JOHNS HOPKINS HOSP, V119, P299; TALLIS RC, 1985, ADV GERIATRIC MED, P3; WILLIAMSON J, 1980, AGE AGEING, V9, P73, DOI 10.1093/ageing/9.2.73; 1985, DRUGS ELDERLY; 1984, J R COLL PHYS LOND, V18, P8	17	0	0	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUL 2	1988	2	8601					20	22						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P0493	2898624				2023-01-03	WOS:A1988P049300008
J	MCGAVOCK, H				MCGAVOCK, H			SOME PATTERNS OF PRESCRIBING BY URBAN GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article											MCGAVOCK, H (corresponding author), DEPT HLTH & SOCIAL SERV,PRESCRIBING INFORMAT UNIT,ROYSTON HOUSE,BELFAST BT1 6FT,NORTH IRELAND.							Anderson R M, 1980, J R Coll Gen Pract, V30, P609; BAIN DJG, 1981, BRIT MED J, V283, P585, DOI 10.1136/bmj.283.6291.585; Dunnell Karen, 1972, MED TAKERS PRESCRIBE; Elmes P C, 1976, Ulster Med J, V45, P166; HOWIE JGR, 1980, BR MED J, V282, P836; JONES DA, 1980, J EPIDEMIOL COMMUN H, V34, P119, DOI 10.1136/jech.34.2.119; Knox J D, 1980, J R Coll Gen Pract, V30, P1; LEE JAH, 1965, MILBANK FUND Q, V43, P285, DOI 10.2307/3348898; PARISH P, 1983, 40 KINGS FUND PROJ P; Parish P A, 1971, J R Coll Gen Pract, V21, P1; Reilly P M, 1978, J R Coll Gen Pract, V28, P525; Taylor R J, 1978, J R Coll Gen Pract, V28, P531	12	25	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1988	296	6626					900	902		10.1136/bmj.296.6626.900	http://dx.doi.org/10.1136/bmj.296.6626.900			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	M7851	3129067	Green Published, Bronze			2023-01-03	WOS:A1988M785100017
J	SCHLESSELMAN, JJ; STADEL, BV; MURRAY, P; LAI, SH				SCHLESSELMAN, JJ; STADEL, BV; MURRAY, P; LAI, SH			BREAST-CANCER IN RELATION TO EARLY USE OF ORAL-CONTRACEPTIVES - NO EVIDENCE OF A LATENT EFFECT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									NICHHD,CTR POPULAT RES,CONTRACEPT EVALUAT BRANCH,BETHESDA,MD 20205	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	SCHLESSELMAN, JJ (corresponding author), UNIFORMED SERV UNIV HLTH SCI,DEPT PREVENT MED & BIOMETR,4301 JONES BRIDGE RD,BETHESDA,MD 20814, USA.				NICHD NIH HHS [1-Y01-HD-61204] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [F32HD061204] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSON TJ, 1984, LANCET, V1, P99; [Anonymous], 1983, JAMA, V249, P1600; [Anonymous], 1983, JAMA, V249, P1596; [Anonymous], 1986, NEW ENGL J MED, V315, P405; ARMSTRONG BK, 1986, LANCET, V1, P552; BRINTON LA, 1982, INT J EPIDEMIOL, V11, P316, DOI 10.1093/ije/11.4.316; CRAMER DW, 1982, NEW ENGL J MED, V307, P1047, DOI 10.1056/NEJM198210213071703; DRIFE J, 1983, BRIT MED J, V287, P1397, DOI 10.1136/bmj.287.6403.1397; GILLMER MDG, 1983, LANCET, V2, P1145; HARRIS NV, 1982, AM J EPIDEMIOL, V116, P643, DOI 10.1093/oxfordjournals.aje.a113447; HULKA BS, 1982, JAMA-J AM MED ASSOC, V247, P475, DOI 10.1001/jama.247.4.475; JICK H, 1980, AM J EPIDEMIOL, V112, P577, DOI 10.1093/oxfordjournals.aje.a113030; KAUFMAN DW, 1980, NEW ENGL J MED, V303, P1045, DOI 10.1056/NEJM198010303031807; Kelsey JL, 1983, BREAST GYNECOLOGIC C; LIPNICK RJ, 1986, JAMA-J AM MED ASSOC, V255, P58, DOI 10.1001/jama.255.1.58; MCPHERSON K, 1986, LANCET, V1, P685; MCPHERSON K, 1986, BRIT MED J, V293, P709, DOI 10.1136/bmj.293.6549.709; MCPHERSON K, 1983, LANCET, V2, P1414; MCPHERSON K, 1986, J EPIDEMIOL COMMUN H, V40, P289, DOI 10.1136/jech.40.4.289; MEIRIK O, 1986, LANCET, V2, P650; MILLER DR, 1986, OBSTET GYNECOL, V68, P863; OLSSON H, 1985, LANCET, V1, P748; PAFFENBARGER RS, 1977, CANCER, V39, P1887, DOI 10.1002/1097-0142(197704)39:4+<1887::AID-CNCR2820390822>3.0.CO;2-I; PAFFENBARGER RS, 1979, REGULATION FERTILITY; PAUL C, 1986, BRIT MED J, V293, P723, DOI 10.1136/bmj.293.6549.723; PIKE MC, 1981, BRIT J CANCER, V43, P72, DOI 10.1038/bjc.1981.10; PIKE MC, 1983, LANCET, V2, P926; ROSENBERG L, 1982, JAMA-J AM MED ASSOC, V247, P3210, DOI 10.1001/jama.247.23.3210; ROSENBERG L, 1984, AM J EPIDEMIOL, V119, P167, DOI 10.1093/oxfordjournals.aje.a113735; SCHLESSELMAN JJ, IN PRESS CONTRACEPTI; Schlesselman JJ, 1982, CASE CONTROL STUDIES; SHAPIRO S, 1985, NEW ENGL J MED, V313, P969, DOI 10.1056/NEJM198510173131601; SITRUKWARE R, 1983, LANCET, V2, P1145; STADEL BV, 1986, LANCET, V1, P436; STADEL BV, 1986, AM J EPIDEMIOL, V123, P373, DOI 10.1093/oxfordjournals.aje.a114252; STADEL BV, 1985, LANCET, V2, P970; SWYER GIM, 1983, LANCET, V2, P1019; VESSEY M, 1983, BRIT J CANCER, V47, P455, DOI 10.1038/bjc.1983.74; VESSEY MP, 1982, BRIT J CANCER, V45, P327, DOI 10.1038/bjc.1982.58; WEISS NS, 1981, INT J CANCER, V28, P669, DOI 10.1002/ijc.2910280602; WEISS NS, 1979, JAMA-J AM MED ASSOC, V242, P261, DOI 10.1001/jama.242.3.261; 1979, MONOGRAPHS EVALUATIO, V21; 1981, BR MED J, V282, P2089	43	55	55	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 25	1988	259	12					1828	1833		10.1001/jama.259.12.1828	http://dx.doi.org/10.1001/jama.259.12.1828			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M5230	3343791				2023-01-03	WOS:A1988M523000024
J	PATEL, C; MARMOT, M				PATEL, C; MARMOT, M			CAN GENERAL-PRACTITIONERS USE TRAINING IN RELAXATION AND MANAGEMENT OF STRESS TO REDUCE MILD HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Article									MIDDLESEX HOSP, SCH MED, LONDON W1, ENGLAND	University of London; University College London; UCL Medical School	PATEL, C (corresponding author), UCL, DEPT COMMUNITY MED, LONDON WC1E 6EA, ENGLAND.		Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419				GAVRAS H, 1981, LANCET, V2, P543; GREENBERG G, 1986, BRIT MED J, V293, P988; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; JOHNSTON DW, 1985, J PSYCHOSOM RES, V29, P447, DOI 10.1016/0022-3999(85)90078-9; PATEL C, 1985, BRIT MED J, V290, P1103, DOI 10.1136/bmj.290.6475.1103; PATEL C, 1987, J HYPERTENSION S1, V5, P21; ROSE G, 1981, BMJ-BRIT MED J, V282, P1847, DOI 10.1136/bmj.282.6279.1847; STEPTOE A, 1987, STRESS MEDICINE, V3, P101, DOI 10.1002/smi.2460030206	8	54	55	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JAN 2	1988	296	6614					21	24		10.1136/bmj.296.6614.21	http://dx.doi.org/10.1136/bmj.296.6614.21			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L5704	3122919	Green Published, Bronze			2023-01-03	WOS:A1988L570400014
J	TOGNONI, G; RONCAGLIONI, MC				TOGNONI, G; RONCAGLIONI, MC			DISSENT - AN ALTERNATIVE INTERPRETATION OF MAST-I	LANCET			English	Note											TOGNONI, G (corresponding author), MARIO NEGRI INST PHARMACOL RES,DEPT CARDIOVASC RES,VIA ERITREA 62,I-20157 MILAN,ITALY.		roncaglioni, maria carla/AAB-1875-2020	roncaglioni, maria carla/0000-0002-2029-7847				DONNAN GA, 1995, LANCET, V345, P578; HACKE W, 1995, JAMA-J AM MED ASSOC, V284, P1017; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0	3	18	18	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 9	1995	346	8989					1515	1515		10.1016/S0140-6736(95)92050-1	http://dx.doi.org/10.1016/S0140-6736(95)92050-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491045				2023-01-03	WOS:A1995TJ29100009
J	DEVRIES, TPGM; HENNING, RH; HOGERZEIL, HV; BAPNA, JS; BERO, L; KAFLE, KK; MABADEJE, AFB; SANTOSO, B; SMITH, AJ				DEVRIES, TPGM; HENNING, RH; HOGERZEIL, HV; BAPNA, JS; BERO, L; KAFLE, KK; MABADEJE, AFB; SANTOSO, B; SMITH, AJ			IMPACT OF A SHORT-COURSE IN PHARMACOTHERAPY FOR UNDERGRADUATE MEDICAL-STUDENTS - AN INTERNATIONAL RANDOMIZED CONTROLLED-STUDY	LANCET			English	Article							PRESENTING CLINICAL-PHARMACOLOGY; THERAPEUTICS; CURRICULUM; SCHOOLS	Irrational prescribing is a habit which is difficult to cure. However, prevention is possible and for this reason the WHO Action Programme on Essential Drugs aims to improve the teaching of pharmacotherapy to medical students. The impact of a short problem-based training course in pharmacotherapy, using a WHO manual on the principles of rational prescribing, was measured in an international multi-centre controlled study of 219 undergraduate students in (Netherlands), Kathmandu (Nepal), Lagos Newcastle (Australia), New Delhi (India), San Francisco (USA), and Yogyakarta (Japan). The manual and the course presented the students, who were about to enter the clinical phase of their studies, with a normative model for pharmacotherapeutic reasoning in which they were taught to generate a ''standard'' pharmacotherapeutic approach to common disorders, resulting in a set of first-choice drugs called P(ersonal)-drugs. The students were then taught how to apply this set of P-drugs to specific patient problems on the symptomatic treatment of pain, using a six-step problem-solving routine. The impact of the course was measured by tests before training, immediately after, and six months later. After the course, students from the study group performed significantly better than controls in all patient problems presented (p<0.05). The students not only remembered how to solve old problems, but they could also apply their shills to new problems. Both retention and transfer effect were maintained at least six months after the training session in all seven medical schools. In view of the impossibiity of teaching students all basic knowledge on the thousands of drugs available, this approach seems to be an efficient way of teaching rational prescribing. However, the method should be accompanied by a change in teaching methods away from the habit of transferring knowledge about the drugs towards problem-based leaching of therapeutic reasoning.	WHO,ACT PROGRAMME ESSENTIAL DRUGS,CH-1211 GENEVA,SWITZERLAND; UNIV GRONINGEN,FAC MED,DEPT CLIN PHARMACOL,WHO,COLLABORATING CTR PHARMACOTHERAPY TEACHING TR,GRONINGEN,NETHERLANDS; MAULANA AZAD MED COLL,DEPT PHARMACOL,NEW DELHI,INDIA; UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; TRIBHUVAN UNIV,TEACHING HOSP,DEPT CLIN PHARMACOL,KATMANDU,NEPAL; UNIV LAGOS,COLL MED,DEPT PHARMACOL,LAGOS,NIGERIA; GADJAH MADA UNIV,DEPT CLIN PHARMACOL,YOGYAKARTA,INDONESIA; MATER MISERICORDIAE HOSP,DISCIPLINE CLIN PHARMACOL,WARATAH,NSW 2298,AUSTRALIA	World Health Organization; University of Groningen; World Health Organization; Maulana Azad Medical College; University of California System; University of California San Francisco; Tribhuvan University; Institute of Medicine (IoM) - Nepal; University of Lagos; Gadjah Mada University			Henning, Robert H/AAY-5222-2020; Smith, Ashley/GZB-0298-2022	Henning, Robert/0000-0002-5135-4621				BRODY J, 1985, KNOWLEDGE OBJECTIVES; DEVRIES TPG, 1995, WHODAP951 DOC; DEVRIES TPGM, 1993, BRIT J CLIN PHARMACO, V35, P591; DEVRIES TPGM, 1993, BRIT J CLIN PHARMACO, V35, P587; DEVRIES TPGM, 1993, BRIT J CLIN PHARMACO, V35, P581; DeVries TPGM., 1994, GUIDE GOOD PRESCRIBI; ELLISON MJ, 1990, J CLIN PHARMACOL, V30, P489, DOI 10.1002/j.1552-4604.1990.tb03613.x; FELDMAN RD, 1987, J CLIN PHARMACOL, V27, P682, DOI 10.1002/j.1552-4604.1987.tb03088.x; FISHER JW, 1980, J MED EDUC, V55, P168; HERXHEIMER A, 1983, MED TEACH, V5, P16, DOI 10.3109/01421598309145614; HOGERZEIL HV, 1995, BRIT J CLIN PHARMACO, V39, P1; NIERENBERG DW, 1986, CLIN PHARMACOL THER, V40, P488, DOI 10.1038/clpt.1986.213; NIERENBERG DW, 1990, CLIN PHARMACOL THER, V48, P603, DOI 10.1038/clpt.1990.200; ORME M, 1990, EUR J CLIN PHARMACOL, V38, P101; SNELL BF, 1992, MED J AUSTRALIA, V156, P352, DOI 10.5694/j.1326-5377.1992.tb139797.x; VESTAL RE, 1992, J CLIN PHARMACOL, V32, P779, DOI 10.1002/j.1552-4604.1992.tb03884.x; WILLIAMS PB, 1990, J CLIN PHARMACOL, V30, P1065, DOI 10.1002/j.1552-4604.1990.tb01847.x	17	69	73	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 2	1995	346	8988					1454	1457		10.1016/S0140-6736(95)92472-8	http://dx.doi.org/10.1016/S0140-6736(95)92472-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TH156	7490991				2023-01-03	WOS:A1995TH15600009
J	BEVERS, RFM; BAKKER, DJ; KURTH, KH				BEVERS, RFM; BAKKER, DJ; KURTH, KH			HYPERBARIC-OXYGEN TREATMENT FOR HEMORRHAGIC RADIATION CYSTITIS	LANCET			English	Article							THERAPY	Radiation-induced severe haemorrhagic cystitis is difficult to treat. Conventional treatments may decrease haematuria but do not affect the radiocystitis itself. Hyperbaric oxygen treatment has been reported to do both. We report the results of a prospective study of hyperbaric oxygen (20 sessions of 100% oxygen inhalation at 3 bar for 90 min in a multiplace hyperbaric chamber) to 40 patients with biopsy-proven radiation cystitis and severe haematuria. Haematuria disappeared completely or improved in 37 patients after treatment. Mean follow-up was 23.1 months (range 1-74); and the recurrence rate was 0.12/year. There were no adverse effects. Hyperbaric oxygen treatment should be considered for patients with severe radiation-induced haematuria.	UNIV AMSTERDAM,ACAD MED CTR,DEPT UROL,AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,DEPT SURG,AMSTERDAM,NETHERLANDS	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam								Akiyama A, 1994, Nihon Hinyokika Gakkai Zasshi, V85, P1269; FELDMEIER JJ, 1994, UNDERSEA HYPERBAR M, V21, P467; GABB G, 1987, CHEST, V92, P1074, DOI 10.1378/chest.92.6.1074; GRIM PS, 1990, JAMA-J AM MED ASSOC, V263, P2216; KINDWALL EP, 1993, CLIN PLAST SURG, P589; LEE HC, 1994, UNDERSEA HYPERBAR M, V21, P321; MOSS WT, 1979, RAD ONCOLOGY RATIONA, P246; NAKADA T, 1992, EUR UROL, V22, P294; Noordzij JW., 1993, INT UROGYNECOL J, V4, P160; NORKOOL DM, 1993, J UROLOGY, V150, P332, DOI 10.1016/S0022-5347(17)35476-9; PARSONS CL, 1986, J UROLOGY, V136, P813, DOI 10.1016/S0022-5347(17)45087-7; RIJKMANS BG, 1989, EUR UROL, V16, P354; SCHOENROCK GJ, 1986, UROLOGY, V27, P271, DOI 10.1016/0090-4295(86)90289-X; WEISS JP, 1994, J UROLOGY, V151, P1514, DOI 10.1016/S0022-5347(17)35289-8	14	131	138	0	4	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 23	1995	346	8978					803	805		10.1016/S0140-6736(95)91620-2	http://dx.doi.org/10.1016/S0140-6736(95)91620-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW258	7674746				2023-01-03	WOS:A1995RW25800011
J	GOULD, KL; ORNISH, D; SCHERWITZ, L; BROWN, S; EDENS, RP; HESS, MJ; MULLANI, N; BOLOMEY, L; DOBBS, F; ARMSTRONG, WT; MERRITT, T; PORTS, T; SPARLER, S; BILLINGS, J				GOULD, KL; ORNISH, D; SCHERWITZ, L; BROWN, S; EDENS, RP; HESS, MJ; MULLANI, N; BOLOMEY, L; DOBBS, F; ARMSTRONG, WT; MERRITT, T; PORTS, T; SPARLER, S; BILLINGS, J			CHANGES IN MYOCARDIAL PERFUSION ABNORMALITIES BY POSITRON EMISSION TOMOGRAPHY AFTER LONG-TERM, INTENSE RISK FACTOR MODIFICATION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-ARTERY DISEASE; ENDOTHELIUM-DEPENDENT RELAXATION; LOW-FAT DIET; STENOSIS SEVERITY; FLOW RESERVE; ATHEROSCLEROSIS-REGRESSION; NONINVASIVE ASSESSMENT; PHYSICAL EXERCISE; COLESTIPOL-NIACIN; HEART-DISEASE	Objective.-To quantify changes in size and severity of myocardial perfusion abnormalities by positron emission tomography (PET) in patients with coronary artery disease after 5 years of risk factor modification. Design.-Randomized controlled trial. Setting.-Outpatient community setting. Intervention.-Randomization of patients to risk factor modification consisting of very low-fat vegetarian diet, mild to moderate exercise, stress management, and group support (experimental group, n=20) or to usual care by their own physicians, consisting principally of antianginal therapy (control group, n=15). Main Outcome Measures.-Quantitative coronary arteriography and PET at baseline and 5 years after randomization. Automated, objective measures of size and severity of perfusion abnormalities on rest-dipyridamole PET images and of stenosis severity on arteriograms were made by computer algorithms. Results.-Size and severity of perfusion abnormalities on dipyridamole PET images decreased (improved) after risk factor modification in the experimental group compared with an increase (worsening) of size and severity in controls. The percentage of left ventricle perfusion abnormalities outside 2.5 SDs of those of normal persons (based on 20 disease-free individuals) on the dipyridamole PET image of normalized counts worsened in controls (mean+/-SE, +10.3%+/-5.6%) and imp roved in the experimental group (mean+/-SE, -5.1%+/-4.8%) (P=.02); the percentage of left ventricle with activity less than 60% of the maximum activity on the dipyridamole PET image of normalized counts worsened in controls (+13.5%+/-3.8%) and improved in the experimental group (-4.2%+/-3.8%) (P=.002); and the myocardial quadrant on the PET image with the lowest average activity expressed as a percentage of maximum activity worsened in controls (-8.8%+/-2.3%) and improved in the experimental group (+4.9%+/-13.3%) (P=.001). The size and severity of perfusion abnormalities on resting PET images were also significantly improved in the experimental group as compared with controls. The relative magnitude of changes in size and severity of PET perfusion abnormalities was comparable to or greater than the magnitude of changes in percent diameter stenosis, absolute stenosis lumen area, or stenosis flow reserve documented by quantitative coronary arteriography, Conclusions.-Modest regression of coronary artery stenoses after risk factor modification is associated with decreased size and severity of perfusion abnormalities on rest-dipyridamole PET images. Progression or regression of coronary artery disease can be followed noninvasively by dipyridamole PET reflecting the integrated flow capacity of the entire coronary arterial circulation.	UNIV TEXAS, SCH MED, CTR POSITRON DIAGNOST & RES, HOUSTON, TX 77030 USA; PREVENT MED RES INST, SAUSALITO, CA USA; CALIF PACIFIC MED CTR, SAN FRANCISCO, CA USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94143 USA	University of Texas System; California Pacific Medical Center; University of California System; University of California San Francisco	GOULD, KL (corresponding author), UNIV TEXAS, SCH MED,DEPT MED,DIV CARDIOL,ROOM 4258MSB, 6431 FANNIN, HOUSTON, TX 77030 USA.				NHLBI NIH HHS [HL 26885, HL 42554, R01 HL 26882] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026885, R01HL042554] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS HE, 1987, NATURE, V327, P237, DOI 10.1038/327237a0; [Anonymous], 1994, CIRCULATION, V89, P1329; BENZULY KH, 1994, CIRCULATION, V89, P1810, DOI 10.1161/01.CIR.89.4.1810; BLANKENHORN DH, 1993, ANN INTERN MED, V119, P969, DOI 10.7326/0003-4819-119-10-199311150-00002; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; BLANKENHORN DH, 1991, CORONARY ARTERY DIS, V2, P875; BROWN BG, 1993, CIRCULATION, V87, P1781, DOI 10.1161/01.CIR.87.6.1781; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1992, JAMA-J AM MED ASSOC, V268, P1429, DOI 10.1001/jama.268.11.1429; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; CASHINHEMPHILL L, 1990, JAMA-J AM MED ASSOC, V264, P3013, DOI 10.1001/jama.264.23.3013; CHILIAN WM, 1990, AM J PHYSIOL, V258, pH529, DOI 10.1152/ajpheart.1990.258.2.H529; COHEN RA, 1988, CIRC RES, V63, P903, DOI 10.1161/01.RES.63.5.903; DELORGERIL M, 1994, LANCET, V343, P1454, DOI 10.1016/S0140-6736(94)92580-1; DEMER L, 1988, PROG CARDIOVASC DIS, V30, P307, DOI 10.1016/0033-0620(88)90001-1; DEMER LL, 1989, CIRCULATION, V79, P825, DOI 10.1161/01.CIR.79.4.825; DEMER LL, 1990, J NUCL MED, V31, P259; FURBERG CD, 1994, CIRCULATION, V90, P1679, DOI 10.1161/01.CIR.90.4.1679; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Glantz SA., 1987, PRIMER BIOSTATISTICS; GOLDSTEIN RA, 1983, J NUCL MED, V24, P907; GORDON JB, 1989, J CLIN INVEST, V83, P1946, DOI 10.1172/JCI114103; GOULD KL, 1982, CIRCULATION, V66, P930, DOI 10.1161/01.CIR.66.5.930; GOULD KL, 1986, J AM COLL CARDIOL, V7, P775, DOI 10.1016/S0735-1097(86)80336-9; GOULD KL, 1991, J NUCL MED, V32, P579; GOULD KL, 1992, AM J CARDIOL, V69, P845, DOI 10.1016/0002-9149(92)90781-S; GOULD KL, 1994, CIRCULATION, V89, P1530, DOI 10.1161/01.CIR.89.4.1530; GOULD KL, 1990, J AM COLL CARDIOL, V15, P459, DOI 10.1016/S0735-1097(10)80078-6; GOULD KL, 1994, CIRCULATION, V90, P1558, DOI 10.1161/01.CIR.90.3.1558; GOULD KL, 1991, CIRCULATION, V84, pI22; GOULD KL, 1988, CIRCULATION, V78, P237, DOI 10.1161/01.CIR.78.2.237; Gould KL, 1991, CORONARY ARTERY STEN; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; HICKS K, 1989, J NUCL MED, V30, P1787; HODGSON JM, 1989, CIRCULATION, V79, P1043, DOI 10.1161/01.CIR.79.5.1043; HODGSON JM, 1993, J AM COLL CARDIOL, V21, P35, DOI 10.1016/0735-1097(93)90714-C; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KIRKEEIDE RL, 1986, J AM COLL CARDIOL, V7, P103, DOI 10.1016/S0735-1097(86)80266-2; KUO L, 1992, CIRC RES, V70, P465, DOI 10.1161/01.RES.70.3.465; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; MARCUS ML, 1988, J AM COLL CARDIOL, V11, P882, DOI 10.1016/0735-1097(88)90226-4; MARCUS ML, 1988, PROG CARDIOVASC DIS, V31, P39, DOI 10.1016/0033-0620(88)90010-2; MULLANI NA, 1983, J NUCL MED, V24, P898; OLIVER MF, 1994, LANCET, V344, P633; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; PEDERSEN TR, 1994, LANCET, V344, P1383; PITT B, 1994, J AM COLL CARDIOL, pA131; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; SCHULER G, 1992, J AM COLL CARDIOL, V19, P34, DOI 10.1016/0735-1097(92)90048-R; SEILER C, 1992, CIRCULATION, V85, P1987, DOI 10.1161/01.CIR.85.6.1987; SEILER C, 1993, J AM COLL CARDIOL, V21, P783, DOI 10.1016/0735-1097(93)90113-F; SELLKE FW, 1990, CIRCULATION, V81, P1586, DOI 10.1161/01.CIR.81.5.1586; SHIMOKAWA H, 1988, CIRCULATION, V78, P1421, DOI 10.1161/01.CIR.78.6.1421; SINGH RB, 1992, BRIT MED J, V304, P1015, DOI 10.1136/bmj.304.6833.1015; Snedecor G. W, 1989, STAT METHODS, VEighth; SPATZ C, 1984, BASIC STATISTICS; TAKAHASHI M, 1990, AM J PHYSIOL, V258, pH1, DOI 10.1152/ajpheart.1990.258.1.H1; TANNER FC, 1991, CIRCULATION, V83, P2012, DOI 10.1161/01.CIR.83.6.2012; TOMITA T, 1990, CIRC RES, V66, P18, DOI 10.1161/01.RES.66.1.18; UREN NG, 1993, J AM COLL CARDIOL, V22, P650, DOI 10.1016/0735-1097(93)90172-W; VERBEUREN TJ, 1986, CIRC RES, V58, P552, DOI 10.1161/01.RES.58.4.552; WACKERS F J T, 1992, American Journal of Cardiac Imaging, V6, P42; WATERS D, 1994, CIRCULATION, V89, P959, DOI 10.1161/01.CIR.89.3.959; WATERS D, 1993, CIRCULATION, V87, P1067, DOI 10.1161/01.CIR.87.4.1067; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WHITE CW, 1984, NEW ENGL J MED, V310, P819, DOI 10.1056/NEJM198403293101304; XU EZ, 1991, J NUCL MED, V32, P161; ZEIHER AM, 1991, CIRCULATION, V84, P1984, DOI 10.1161/01.CIR.84.5.1984; ZEIHER AM, 1991, CIRCULATION, V83, P391, DOI 10.1161/01.CIR.83.2.391; ZHAO XQ, 1993, CIRCULATION, V88, P2744, DOI 10.1161/01.CIR.88.6.2744; 1992, STAT VIEW	72	224	227	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 20	1995	274	11					894	901		10.1001/jama.274.11.894	http://dx.doi.org/10.1001/jama.274.11.894			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU603	7674504				2023-01-03	WOS:A1995RU60300029
J	ROTMAN, M; PAJAK, TF; CHOI, K; CLERY, M; MARCIAL, V; GRIGSBY, PW; COOPER, J; JOHN, M				ROTMAN, M; PAJAK, TF; CHOI, K; CLERY, M; MARCIAL, V; GRIGSBY, PW; COOPER, J; JOHN, M			PROPHYLACTIC EXTENDED-FIELD IRRADIATION OF PARAAORTIC LYMPH-NODES IN STAGE-IIB AND BULKY STAGE-IB AND STAGE-IIA CERVICAL CARCINOMAS - 10-YEAR TREATMENT RESULTS OF RTOG-79-20	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objectives.-To investigate whether irradiation to the standard pelvic field only improves the response rate and survival in comparison with pelvic plus para-aortic irradiation in patients with high-risk cervical carcinoma, and to investigate patterns of failure and treatment-related toxicity. Design.-Randomized controlled trial from November 1979 to October 1986, with stratification by histology, para-aortic nodal status, and International Federation of Gynecology and Obstetrics (FIGO) stage. Setting.-Radiation Therapy Oncology Group (RTOG) multicenter clinical trial. Patients.-A total of 367 patients with FIGO stage IB or IIA primary cervical cancers measuring 4 cm or greater in lateral diameter or with FIGO stage IIB cervical cancers were randomized to RTOG protocol 79-20 to receive either standard pelvic only irradiation or pelvic plus para-aortic irradiation. Intervention.-Pelvic only irradiation consisted of a midplane pelvic dose of 40 to 50 Gy in 4.5 to 6.5 weeks with daily fractions of 1.6 to 1.8 Gy for 5 d/wk. Pelvic plus para-aortic irradiation delivered 44 to 45 Gy in 4.5 to 6.5 weeks with daily fractions of 1.6 to 1.8 Gy for 5 d/wk. A total dose of 4000 to 5000 mg/h of radium equivalent or 30 to 40 Gy was provided by intracavitary brachytherapy to point A. Main Outcome Measures.-Response rate, overall and disease-free survival, patterns of failure, and treatment-related toxicities. Results.-Ten-year overall survival was 44% for the pelvic only irradiation arm and 55% for the pelvic plus para-aortic irradiation arm (P=.02). Cumulative incidence of death due to cervical cancer was estimated as significantly higher in the pelvic only arm at 10 years (P=.01). Disease-free survival was similar in both arms; 40% for the pelvic only arm and 42% for the pelvic plus para-aortic arm. Locoregional failures were similar at 10 years for both arms (pelvic only, 35%; pelvic plus para-aortic, 31%; P=.44). In complete responders, the patterns of locoregional failures were the same for both arms, but there was a lower cumulative incidence for first distant failure in the pelvic plus para-aortic irradiation arm (P=.053). Survival following first failure was significantly higher in the pelvic plus para-aortic arm (P=.007). A higher percentage of local failures were salvaged long-term on the pelvic plus para-aortic arm compared with the pelvic only arm (25% vs 8%). The cumulative incidence of grade 4 and 5 toxicities at 10 years in the pelvic plus para-aortic arm was 8%, compared with 4% in the pelvic only arm (P=.06). The death rate due to radiotherapy complications was higher in the pelvic plus para-aortic arm (four [2%] of 170) compared with the pelvic only arm (one [1%] of 167) (P=.38). The proportion of deaths due to radiotherapy complications in the pelvic plus para-aortic arm was higher than in the pelvic only arm (four [6%] of 67 vs one [1%] of 85; P=.24). If the patient had abdominal surgery prior to para-aortic irradiation, the estimated cumulative incidence of grade 4 and 5 complications was 11%, compared with 2% in the pelvic only arm. Conclusions.-The statistically significant difference in overall survival at 10 years for the pelvic plus para-aortic irradiation arm, without a difference in disease-free survival, can be explained by the following two factors: (1) a lower incidence of distant failure in complete responders and (2) a better salvage in the complete responders who later failed locally.	RADIAT THERAPY ONCOL GRP HEADQUARTERS, PHILADELPHIA, PA USA; RADIAT ONCOL CTR, SAN JUAN, PR USA; WASHINGTON UNIV, MALLINCKRODT INST RADIOL, ST LOUIS, MO 63110 USA; NYU, TISCH HOSP, NEW YORK, NY USA; KAWEAH DELTA CANC CARE CTR, VISALIA, CA USA	Radiation Therapy Oncology Group (RTOG); Washington University (WUSTL); New York University	ROTMAN, M (corresponding author), SUNY HLTH SCI CTR, DEPT RADIAT ONCOL, 450 CLARKSON AVE, BOX 1211, BROOKLYN, NY 11203 USA.				NATIONAL CANCER INSTITUTE [U10CA021661, U10CA032115] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		COX DR, 1972, J R STAT SOC B, V34, P187; GAYNOR JJ, 1993, J AM STAT ASSOC, V88, P400, DOI 10.2307/2290318; GELMAN R, 1990, J CLIN ONCOL, V8, P548, DOI 10.1200/JCO.1990.8.3.548; GRAY RJ, 1988, ANN STAT, V16, P1141, DOI 10.1214/aos/1176350951; GRISBY PW, 1984, INT J RADIAT ONCOL, V28, P451; HAIE C, 1988, RADIOTHER ONCOL, V11, P101, DOI 10.1016/0167-8140(88)90245-9; JAMPOLIS S, 1975, RADIOLOGY, V115, P681, DOI 10.1148/15.3.681; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; PAUNIER JP, 1967, RADIOLOGY, V88, P555, DOI 10.1148/88.3.555; ROTMAN M, 1979, INT J RADIAT ONCOL, V5, P2139, DOI 10.1016/0360-3016(79)90972-6; ROTMAN M, 1978, INT J RADIAT ONCOL, V4, P795, DOI 10.1016/0360-3016(78)90038-X; ROTMAN M, 1990, INT J RADIAT ONCOL, V19, P513, DOI 10.1016/0360-3016(90)90475-Y; ROTMAN M, 1981, CANCER-AM CANCER SOC, V48, P560, DOI 10.1002/1097-0142(19810715)48:1+<560::AID-CNCR2820481320>3.0.CO;2-T; ROTMAN M, 1994, SEMIN RADIAT ONCOL, V1, P23; RUTLEDGE FN, 1958, AM J OBSTET GYNECOL, V76, P321, DOI 10.1016/0002-9378(58)90221-7; SOTTO LSJ, 1960, AM J OBSTET GYNECOL, V80, P791, DOI 10.1016/0002-9378(60)90591-3; WILCOXON F, 1946, J ECON ENTOMOL, V39, P269, DOI 10.1093/jee/39.2.269; ZELEN M, 1974, J CHRON DIS, V27, P365, DOI 10.1016/0021-9681(74)90015-0	20	276	285	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 2	1995	274	5					387	393		10.1001/jama.274.5.387	http://dx.doi.org/10.1001/jama.274.5.387			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL416	7616634				2023-01-03	WOS:A1995RL41600024
J	DANZIG, LE; SHORT, LJ; COLLINS, K; MAHONEY, W; SEPE, S; BLAND, L; JARVIS, WR				DANZIG, LE; SHORT, LJ; COLLINS, K; MAHONEY, W; SEPE, S; BLAND, L; JARVIS, WR			BLOOD-STREAM INFECTIONS ASSOCIATED WITH A NEEDLELESS INTRAVENOUS-INFUSION SYSTEM IN PATIENTS RECEIVING HOME INFUSION THERAPY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.- To determine risk factors for bloodstream infections (BSIs) in an outbreak among patients receiving home intravenous infusion therapy. Design.- Case-control and retrospective cohort studies. Setting - Home health agency. Patients.- Patients receiving home intravenous infusion therapy from Rhode Island Home Therapeutics (RIHT) from January through December 1993. Main Outcome Measure.- Development of primary BSI. Methods.- We compared patients with BSI (ie, case patients) with randomly selected noninfected RIHT patients receiving intravenous therapy, conducted a cohort study of all RIHT patients receiving intravenous therapy via a central venous catheter (CVC), and conducted a culture survey of injection cap luminal fluid. Results.- Case patients were more likely than controls to have had therapy via a CVC (11/11 vs 14/32; odds ratio [OR] undefined; P<.001) or total parenteral nutrition and intralipid therapy (TPN/IL) (9/11 vs 3/32; OR, 43.5; 95% confidence interval [CI], 4.9 to 510.0). Among RIHT patients with CVCs, risk factors for BSI were receipt of TPN/IL (9/35 vs 2/67; rate ratio [RR], 8.6; 95% CI, 2.0 to 37.7) or use of a needleless infusion system (10/41 vs 1/61; RR, 14.9; 95% CI, 2.0 to 111.8). Only the combination of both exposures was significantly associated with development of a BSI (P<.001). Luminal fluid from injection caps of needleless devices was significantly more likely to be culture positive than fluid from protected-needle devices (5/23 vs 0/18; RR undefined; P=.04). Conclusions.- Our data suggest that a needleless device used for TPN/IL was associated with increased risk of BSI when injection caps were changed every 7 days.	RHODE ISL HOME THERAPEUT,E PROVIDENCE,RI		DANZIG, LE (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,1600 CLIFTON RD NE,ATLANTA,GA 30333, USA.		Mahoney, William/GQB-0802-2022					BENSON JS, 1992, FDA SAFETY ALERT NEE; DEAN AG, 1991, EPIINFO VERSION 5 01; GARNER JS, 1988, AM J INFECT CONTROL, V16, P128, DOI 10.1016/0196-6553(88)90053-3; GARTNER K, 1993, AM J INFECT CONTROL, V20, P75; GOLDMANN DA, 1993, CLIN MICROBIOL REV, V6, P176, DOI 10.1128/CMR.6.2.176-192.1993; GRAHAM DR, 1991, AM J MED, V91, pS95, DOI 10.1016/0002-9343(91)90351-W; IPPOLITO G, 1994, JAMA-J AM MED ASSOC, V272, P607, DOI 10.1001/jama.272.8.607; JARVIS WR, 1991, AM J MED, V91, pS101, DOI 10.1016/0002-9343(91)90352-X; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; MAKI DG, 1992, HOSP INFECT, P849; MENDELSON H, 1992, 33RD INT C ANT AG CH; SIMMONS BP, 1982, GUIDELINE PREVENTION; SKOLNICK R, 1993, AM J INFECT CONTROL, V21, P39, DOI 10.1016/0196-6553(93)90206-J; WILLIAMS WW, 1985, JPEN-PARENTER ENTER, V9, P735, DOI 10.1177/0148607185009006735; 1990, SAS PROCEDURES GUIDE	15	101	102	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 21	1995	273	23					1862	1864		10.1001/jama.273.23.1862	http://dx.doi.org/10.1001/jama.273.23.1862			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RD116	7776503				2023-01-03	WOS:A1995RD11600029
J	VELANDIA, M; FRIDKIN, SK; CARDENAS, V; BOSHELL, J; RAMIREZ, G; BLAND, L; IGLESIAS, A; JARVIS, W				VELANDIA, M; FRIDKIN, SK; CARDENAS, V; BOSHELL, J; RAMIREZ, G; BLAND, L; IGLESIAS, A; JARVIS, W			TRANSMISSION OF HIV IN DIALYSIS CENTER	LANCET			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; BENZALKONIUM CHLORIDE; HEMODIALYSIS; PREVALENCE; BLOOD	In August, 1993, 13 dialysis patients at one dialysis centre. in Colombia, South America, were found to be HIV positive, and this prompted an epidemiological investigation. We carried out a cohort study of all dialysis centre patients during January, 1992 to December, 1993 (epidemic period) to determine risk factors for HIV seroconversion. Haemodialysis and medical records were reviewed, dialysis centre staff and surviving patients were interviewed, and dialysis practices were observed. Stored sera from all dialysis centre patients were tested for HIV antibody. 12 (52%) of 23 patients tested positive for HIV antibody by enzyme immunoassay and western blot during the epidemic period. Of the 23 tested, 9 (39%) converted from HIV antibody negative to positive (seroconverters) and 10 (44%) remained HIV negative (seronegatives). The HIV seroconversion rate was higher among patients dialysed at the centre while a new patient, who was HIV seropositive, was dialysed there (90% vs 0%; p<0.01), or when the dialysis centre reprocessed access needles, dialysers, and bloodlines (60% vs 0%). While 2 of 9 HIV seroconverters had had sex with prostitutes, none had received unscreened blood products or had other HIV risk factors. No surgical or dental procedures were associated with HIV seroconversion. Dialysers were reprocessed separately with 5% formaldehyde and were labelled for use on the same patient. Access needles were reprocessed by soaking them in a common container with a low-level disinfectant, benzalkonium chloride; 4 pairs of needles were placed in one pan creating the potential for cross-contamination or use of one patient's needles on another patient. HIV transmission at the dialysis centre was confirmed, Improperly reprocessed patient-care equipment, most probably access needles, is the likely mechanism of transmission. This outbreak was discovered by accident and similar transmission may be occurring in many other countries where low-level disinfectants are used to sterilise critical patient-care equipment.	CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,HOSP INFECT PROGRAM,INVEST & PREVENT BRANCH,ATLANTA,GA 30333; CTR DIS CONTROL & PREVENT,EPIDEMIOL PROGRAM OFF,DIV FIELD EPIDEMIOL,ATLANTA,GA 30333; COLOMBIAN FIELD EPIDEMIOL TRAINING PROGRAM,BOGOTA,COLOMBIA; NATL INST HLTH,BOGOTA,COLOMBIA; IND UNIV SANTANDER,SCH MED,SANTANDER,SPAIN	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA				Velandia-Gonzalez, Martha/0000-0002-7636-3604				ARDUINO MJ, 1993, DIALYSIS TRANSPLANT, V22, P652; ARDUINO MJ, 1993, DIALYSIS TRANSPLANT, V22, P701; BLANK S, 1994, LANCET, V344, P512, DOI 10.1016/S0140-6736(94)91900-3; BURCHOVSKY G, 1988, 4TH INT C AIDS STOCK; CHANT K, 1994, LANCET, V342, P1548; CHIRGWIN K, 1989, AIDS, V3, P731, DOI 10.1097/00002030-198911000-00007; DEAN AG, 1991, EPI INFO VERSION 5 0; DYER E, 1993, BRIT MED J, V307, P584; FAVERO MS, 1989, ASPECTS RENAL CARE, P55; FAVERO MS, 1991, MANUAL CLIN MICROBIO, P183; Favero MS, 1992, HOSPITAL INFECTIONS, P375; HERSH BS, 1991, LANCET, V338, P645, DOI 10.1016/0140-6736(91)91230-R; KASLOW RA, 1976, JAMA-J AM MED ASSOC, V236, P2407, DOI 10.1001/jama.236.21.2407; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; MARCUS R, 1991, AM J MED, V90, P614, DOI 10.1016/S0002-9343(05)80014-2; MARTIN D, 1991, EPIDEMIOLOGY, V2, P359, DOI 10.1097/00001648-199109000-00008; NAKASHIMA AK, 1987, J CLIN MICROBIOL, V25, P1014, DOI 10.1128/JCM.25.6.1014-1018.1987; NAUS JI, 1965, J AM STAT ASSOC, V60, P532, DOI 10.2307/2282688; PETERSEN LR, 1994, TRANSFUSION, V34, P283, DOI 10.1046/j.1537-2995.1994.34494233574.x; PLOTT RT, 1990, ARCH DERMATOL, V126, P1441, DOI 10.1001/archderm.126.11.1441; POKROVSKY VV, 1988, 5TH INT C AIDS STOCK; RENGITO B, 1995, 7 C PAN AM INF CART; Rothman K, 1986, MODERN EPIDEMIOLOGY; Tokars J I, 1994, ASAIO J, V40, P1020, DOI 10.1097/00002480-199410000-00021; TSANG VCW, 1983, METHOD ENZYMOL, V92, P377; WAINBERG MA, 1990, J CLIN MICROBIOL, V28, P156, DOI 10.1128/JCM.28.1.156-158.1990; WALLENSTEIN S, 1980, AM J EPIDEMIOL, V111, P367, DOI 10.1093/oxfordjournals.aje.a112908; 1992, MMWR-MORBID MORTAL W, V41, P823; 1987, MMWR-MORBID MORTAL W, V36, pS1; 1993, REC PRACT REUSE HEMO; 1992, MMWR-MORBID MORTAL W, V41, P344; 1992, MMWR-MORBID MORTAL W, V41, P575	32	51	51	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUN 3	1995	345	8962					1417	1422		10.1016/S0140-6736(95)92603-8	http://dx.doi.org/10.1016/S0140-6736(95)92603-8			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB441	7760615	Bronze			2023-01-03	WOS:A1995RB44100015
J	KNIPSCHILD, P				KNIPSCHILD, P			LOOKING FOR GALL-BLADDER DISEASE IN THE PATIENTS IRIS	BRITISH MEDICAL JOURNAL			English	Article											KNIPSCHILD, P (corresponding author), STATE UNIV LIMBURG,DEPT EPIDEMIOL & HLTH CARE RES,POB 616,6200 MD MAASTRICHT,NETHERLANDS.							BERGGREN L, 1985, ACTA OPHTHALMOL, V63, P1; BRAND A, 1983, DEUT MED WOCHENSCHR, V108, P870, DOI 10.1055/s-2008-1069660; DERN N, 1984, THESIS PHILIPPS U MA; Feinstein AR, 1985, CLIN EPIDEMIOLOGY AR; GUYTON AC, 1981, TXB MED PHYSL, P603; JONGEDIJK J, 1973, BRES, V43, P38; KNIPSCHILD P, 1987, TIJDSCHRIFT SOCIALE, V65, P754; Schouten HJA, 1985, THESIS ERASMUS U ROT; SIMON A, 1979, JAMA-J AM MED ASSOC, V242, P1385, DOI 10.1001/jama.242.13.1385	9	35	36	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 17	1988	297	6663					1578	1581		10.1136/bmj.297.6663.1578	http://dx.doi.org/10.1136/bmj.297.6663.1578			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R4933	3147081	Green Published, Bronze			2023-01-03	WOS:A1988R493300020
J	MAVLIGIT, GM; CHARNSANGAVEJ, C; CARRASCO, CH; PATT, YZ; BENJAMIN, RS; WALLACE, S				MAVLIGIT, GM; CHARNSANGAVEJ, C; CARRASCO, CH; PATT, YZ; BENJAMIN, RS; WALLACE, S			REGRESSION OF OCULAR MELANOMA METASTATIC TO THE LIVER AFTER HEPATIC ARTERIAL CHEMOEMBOLIZATION WITH CISPLATIN AND POLYVINYL SPONGE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DIV DIAGNOST IMAGING,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center	MAVLIGIT, GM (corresponding author), UNIV TEXAS,MD ANDERSON HOSP & TUMOR INST,CTR CANC,DIV MED,BOX 41,1515 HOLCOMBE,HOUSTON,TX 77030, USA.							BEDIKIAN AY, 1981, SOUTHERN MED J, V74, P574, DOI 10.1097/00007611-198105000-00017; CARRASCO CH, 1986, JAMA-J AM MED ASSOC, V255, P3152, DOI 10.1001/jama.255.22.3152; DANIELS JR, 1986, P AM ASSOC CANC RES, V27, P404; EINHORN LH, 1974, CANCER, V34, P1001, DOI 10.1002/1097-0142(197410)34:4<1001::AID-CNCR2820340406>3.0.CO;2-Z; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; PATT YZ, 1983, CANCER, V51, P1359, DOI 10.1002/1097-0142(19830415)51:8<1359::AID-CNCR2820510807>3.0.CO;2-V; RAJPAL S, 1983, CANCER, V52, P334, DOI 10.1002/1097-0142(19830715)52:2<334::AID-CNCR2820520225>3.0.CO;2-E; RUIZ RS, 1985, CANCER B, V37, P6; WALLACE S, 1984, CURRENT PROBLEMS CAN, P4	9	117	120	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 19	1988	260	7					974	976		10.1001/jama.260.7.974	http://dx.doi.org/10.1001/jama.260.7.974			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P6566	3398202				2023-01-03	WOS:A1988P656600029
J	BUCKNALL, CE; ROBERTSON, C; MORAN, F; STEVENSON, RD				BUCKNALL, CE; ROBERTSON, C; MORAN, F; STEVENSON, RD			MANAGEMENT OF ASTHMA IN HOSPITAL - A PROSPECTIVE AUDIT	BRITISH MEDICAL JOURNAL			English	Article									GLASGOW ROYAL INFIRM,DEPT RESP MED,GLASGOW G4 0SF,SCOTLAND; STRATHCLYDE UNIV,DEPT MATH,GLASGOW G1 1XQ,SCOTLAND	University of Glasgow; University of Strathclyde								BELLAMY D, 1979, THORAX, V34, P36, DOI 10.1136/thx.34.1.36; BUCKNALL CE, 1988, LANCET, V1, P748; BUCKNALL CE, IN PRESS SCOTT MED J; BURNEY PGJ, 1986, LANCET, V2, P323; CUSHLEY MJ, 1983, J R SOC MED, V83, P662; ELLIS ME, 1985, BRIT J DIS CHEST, V79, P43, DOI 10.1016/0007-0971(85)90006-3; GRAHAM VAL, 1982, LANCET, V1, P418; MACDONALD JB, 1976, BRIT MED J, V2, P721, DOI 10.1136/bmj.2.6038.721; ORMEROD LP, 1980, BRIT MED J, V280, P687, DOI 10.1136/bmj.280.6215.687; OSMAN J, 1987, BRIT J DIS CHEST, V81, P232, DOI 10.1016/0007-0971(87)90155-0; REED S, 1985, THORAX, V40, P897, DOI 10.1136/thx.40.12.897; SEATON A, 1978, THORAX, V33, P1, DOI 10.1136/thx.33.1.1-a; STEWART CJ, 1985, BRIT J DIS CHEST, V79, P229, DOI 10.1016/S0007-0971(85)80023-1; 1982, BR MED J, V285, P1251	14	53	54	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 11	1988	296	6637					1637	1639		10.1136/bmj.296.6637.1637	http://dx.doi.org/10.1136/bmj.296.6637.1637			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N8341	3135048	Bronze, Green Published			2023-01-03	WOS:A1988N834100014
J	KOLLEF, MH; SHAPIRO, SD; FRASER, VJ; SILVER, P; MURPHY, DM; TROVILLION, E; HEARNS, ML; RICHARDS, RD; CRACCHILO, L; HOSSIN, L				KOLLEF, MH; SHAPIRO, SD; FRASER, VJ; SILVER, P; MURPHY, DM; TROVILLION, E; HEARNS, ML; RICHARDS, RD; CRACCHILO, L; HOSSIN, L			MECHANICAL VENTILATION WITH OR WITHOUT 7-DAY CIRCUIT CHANGES - A RANDOMIZED CONTROLLED TRIAL	ANNALS OF INTERNAL MEDICINE			English	Article						RESPIRATION, MECHANICAL; CROSS INFECTION; PNEUMONIA; COST SAVINGS	PROSPECTIVE PAYMENT SYSTEM; PROTECTED SPECIMEN BRUSH; CARE UNIT PATIENTS; NOSOCOMIAL PNEUMONIA; MULTIVARIATE-ANALYSIS; RESPIRATORY-FAILURE; RISK; INFECTIONS; PROGNOSIS; DIAGNOSIS	Objective: To determine whether a practice of not routinely changing ventilator circuits in patients who require prolonged mechanical ventilation is associated with an increased incidence of nosocomial pneumonia. Design: Randomized controlled trial. Setting: Intensive care units in two university-affiliated teaching hospitals. Patients: 300 patients admitted to an intensive care unit who required mechanical ventilation for more than 5 days. Intervention: Patients were randomly assigned to receive either no routine ventilator circuit changes or circuit changes every 7 days. Measurements: The primary outcome measure was the incidence of ventilator-associated pneumonia. Other outcome measures included duration of mechanical ventilation, length of hospital stay, and hospital mortality. Results: 147 patients were randomly assigned to receive no routine ventilator circuit changes, and 153 patients were randomly assigned to receive circuit changes every 7 days. The two groups were similar at the time of randomization with regard to demographic characteristics, intensive care unit admission diagnoses, and severity of illness, Ventilator-associated pneumonia was seen in 36 patients (24.5%) receiving no routine changes and in 44 patients (28.8%) receiving changes every 7 days (relative risk, 0.85 [95% CI, 0.55 to 1.17]). No statistically significant differences for hospital mortality, intensive care unit mortality, death during mechanical ventilation, death in patients with ventilator-associated pneumonia, or mortality directly attributed to ventitator-associated pneumonia were found between the two treatment groups (P greater than or equal to 0.11). Patients receiving changes every 7 days had 247 circuit changes costing a total of $7410; patients receiving no routine changes had a total of 11 circuit changes costing $330. Conclusion: The elimination of routine ventilator circuit changes can reduce medical care costs without increasing the incidence of nosocomial pneumonia in patients who require prolonged mechanical ventilation.	JEWISH HOSP ST LOUIS, DEPT INTERNAL MED, ST LOUIS, MO 63110 USA; BARNES HOSP, DEPT RESP THERAPY, ST LOUIS, MO 63110 USA; BARNES HOSP, DEPT INFECT CONTROL, ST LOUIS, MO 63110 USA	Barnes-Jewish Hospital	KOLLEF, MH (corresponding author), WASHINGTON UNIV, SCH MED, DIV PULM & CRIT CARE, BOX 8052, 660 S EUCLID AVE, ST LOUIS, MO 63110 USA.			Fraser, Victoria/0000-0001-6251-0733				ALFREDSON T, 1994, RESPIR CARE, V39, P1108; BOYCE JM, 1991, ARCH INTERN MED, V151, P1109, DOI 10.1001/archinte.151.6.1109; BOYCE JM, 1985, AM J INFECT CONTROL, V13, P228, DOI 10.1016/0196-6553(85)90063-X; Campbell R S, 1994, Respir Care, V39, P227; CANTRAL DE, 1993, AM J MED, V95, P601, DOI 10.1016/0002-9343(93)90356-T; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CHASTRE J, 1984, AM REV RESPIR DIS, V130, P924; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CRAVEN DE, 1982, NEW ENGL J MED, V306, P1505, DOI 10.1056/NEJM198206243062501; CRAVEN DE, 1991, AM J MED, V91, pS44, DOI 10.1016/0002-9343(91)90343-V; CRAVEN DE, 1988, ARCH INTERN MED, V148, P1161, DOI 10.1001/archinte.148.5.1161; CRAVEN DE, 1995, ANN INTERN MED, V122, P229, DOI 10.7326/0003-4819-122-3-199502010-00013; CRAVEN DE, 1984, AM REV RESPIR DIS, V129, P625; CRAVEN DE, 1986, AM REV RESPIR DIS, V133, P792; DREYFUSS D, 1991, AM REV RESPIR DIS, V143, P738, DOI 10.1164/ajrccm/143.4_Pt_1.738; ELNAGGAR M, 1976, ANESTH ANALG, V55, P195; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; FAGON JY, 1993, CHEST, V103, P547, DOI 10.1378/chest.103.2.547; GREENE R, 1994, AM J ROENTGENOL, V163, P1036, DOI 10.2214/ajr.163.5.7976872; HALEY RW, 1987, JAMA-J AM MED ASSOC, V257, P1611, DOI 10.1001/jama.257.12.1611; HESS D, 1994, RESPIR CARE, V94, P1149; Hess Dean, 1994, Chest, V106, p79S; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KOLLEF MH, 1994, AM J ROENTGENOL, V163, P1031, DOI 10.2214/ajr.163.5.7976871; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; KOLLEF MH, 1995, CHEST, V107, P1395, DOI 10.1378/chest.107.5.1395; LAREAU SC, 1978, AM REV RESPIR DIS, V118, P493; LEU HS, 1989, AM J EPIDEMIOL, V129, P1258, DOI 10.1093/oxfordjournals.aje.a115245; MEDURI GU, 1990, CHEST, V97, P1208, DOI 10.1378/chest.97.5.1208; MEDURI GU, 1992, CHEST, V102, pS551, DOI 10.1016/S0012-3692(16)34868-1; MEINERT CL, 1986, CLIN TRIALS DESIGN C, P194; MEUZIES R, 1989, CHEST, V95, P398; ORENS D, 1994, RESP CARE, V39, P1108; PINGLETON SK, 1992, CHEST, V102, pS553, DOI 10.1378/chest.102.5_Supplement_1.553S; ROTHMAN KJ, 1986, MODERN EPIDEMIOLOGY, P153; ROUBY JJ, 1992, AM REV RESPIR DIS, V146, P1059, DOI 10.1164/ajrccm/146.4.1059; RUBIN DB, 1990, J CLIN INVEST, V86, P474, DOI 10.1172/JCI114733; SALATA RA, 1987, AM REV RESPIR DIS, V135, P426; TABLAN OC, 1994, INFECT CONT HOSP EP, V15, P588, DOI 10.1086/646989; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TYRA JA, 1994, RESPIR CARE, V39, P1107; VALLES J, 1995, ANN INTERN MED, V122, P179, DOI 10.7326/0003-4819-122-3-199502010-00004; 1994, RESPIR CARE, V39, P797; 1990, SAS STAT USERS GUIDE, V2, P1071	44	134	142	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1995	123	3					168	174		10.7326/0003-4819-123-3-199508010-00002	http://dx.doi.org/10.7326/0003-4819-123-3-199508010-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RL104	7598297				2023-01-03	WOS:A1995RL10400002
J	PINGLETON, SK				PINGLETON, SK			PULMONARY AND CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ASTHMA; DEATH; RISK				PINGLETON, SK (corresponding author), UNIV KANSAS,MED CTR,KANSAS CITY,KS 66103, USA.							[Anonymous], 1992, CRIT CARE MED, V20, P864; BONE RC, 1994, JAMA-J AM MED ASSOC, V271, P1412; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAAHTELA T, 1993, NEW ENGL J MED, V331, P700; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; MALFMO NA, 1991, NEW ENGL J MED, V321, P285; MULLEN M, 1993, JAMA-J AM MED ASSOC, V270, P1842, DOI 10.1001/jama.270.15.1842; PEARLMAN DS, 1992, NEW ENGL J MED, V327, P1420, DOI 10.1056/NEJM199211123272004; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; RANGELFRAUSTO MS, 1995, JAMA-J AM MED ASSOC, V273, P117, DOI 10.1001/jama.273.2.117; ROUBY JJ, 1994, AM J RESP CRIT CARE, V150, P776, DOI 10.1164/ajrccm.150.3.8087352; SLY MS, 1994, ANN ALLERGY, V73, P259; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604, DOI 10.1164/ajrccm.149.3.8118625; SUR S, 1993, AM REV RESPIR DIS, V148, P713, DOI 10.1164/ajrccm/148.3.713; 1989, NATIONAL HEART LUNG; 1991, 913042 US DEP HLTH H	19	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1717	1718						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RB097	7752434				2023-01-03	WOS:A1995RB09700042
J	van der Maas, PJ; PIJNENBORG, L; VANDELDEN, JJM				van der Maas, PJ; PIJNENBORG, L; VANDELDEN, JJM			CHANGES IN DUTCH OPINIONS ON ACTIVE EUTHANASIA, 1966 THROUGH 1991	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL DECISIONS; LIFE; END		UNIV UTRECHT, CTR BIOETH & HLTH LAW, ROTTERDAM, NETHERLANDS	Utrecht University	van der Maas, PJ (corresponding author), ERASMUS UNIV ROTTERDAM, DEPT PUBL HLTH, POB 1738, 3000 DR ROTTERDAM, NETHERLANDS.							Adriaansens H. P. M., 1981, VRIJWILLIG INITIATIE; BLENDON RJ, 1992, JAMA-J AM MED ASSOC, V267, P2658, DOI 10.1001/jama.267.19.2658; Ester P., 1993, INDIVIDUALIZING SOC; Inglehart RonaldF., 1977, SILENT REVOLUTION; Mayer William G., 1992, CHANGING AM MIND WHY; PIJNENBORG L, 1994, BMJ-BRIT MED J, V309, P1209, DOI 10.1136/bmj.309.6963.1209; SCHUYT C, 1991, OP ZOEK NAAR HART VE; Seper F., 1980, DECLARATION EUTHANAS; Stimson J. A, 1991, PUBLIC OPINION AM MO; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; van der Maas PJ, 1992, HEALTH POLICY, V22, P1; VANDELDEN JJM, 1993, HASTINGS CENT REP, V23, P24, DOI 10.2307/3562919; 1994, 1994 SOC CULT PLANN; 1988, EUTHANASIE PASTORAAT; 1987, BIOETHICS, V1, P163	15	53	53	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 10	1995	273	18					1411	1414		10.1001/jama.273.18.1411	http://dx.doi.org/10.1001/jama.273.18.1411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QW279	7723147				2023-01-03	WOS:A1995QW27900010
J	BOZZETTE, SA; FINKELSTEIN, DM; SPECTOR, SA; FRAME, P; POWDERLY, WG; HE, WL; PHILLIPS, L; CRAVEN, D; VANDERHORST, C; FEINBERG, J				BOZZETTE, SA; FINKELSTEIN, DM; SPECTOR, SA; FRAME, P; POWDERLY, WG; HE, WL; PHILLIPS, L; CRAVEN, D; VANDERHORST, C; FEINBERG, J			A RANDOMIZED TRIAL OF 3 ANTIPNEUMOCYSTIS AGENTS IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; AEROSOLIZED PENTAMIDINE; TRIMETHOPRIM-SULFAMETHOXAZOLE; PRIMARY PROPHYLAXIS; SECONDARY PROPHYLAXIS; DAPSONE-PYRIMETHAMINE; PRIMARY PREVENTION; AIDS; COTRIMOXAZOLE; ZIDOVUDINE	Background. We evaluated the effectiveness of three treatment strategies for the prevention of a first episode of Pneumocystis carinii pneumonia in patients infected with the human immunodeficiency virus (HIV). Methods. In an open-label trial, 843 patients with HIV infection and fewer than 200 CD4+ cells per cubic millimeter received zidovudine plus one of three randomly assigned prophylactic agents, beginning with trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine and followed by a defined sequence of other drugs to be used in cases of intolerance. Results. The estimated 36-month cumulative risks of P. carinii pneumonia were 18 percent, 17 percent, and 21 percent in the trimethoprim-sulfamethoxazole, dapsone, and aerosolized-pentamidine groups, respectively (P = 0.22). The difference in risk among treatment strategies was negligible in patients entering the study with 100 or more CD4+ lymphocytes per cubic millimeter. In those entering with fewer than 100 CD4+ cells per cubic millimeter, the risk was 33 percent with aerosolized pentamidine, as compared with 19 percent with trimethoprim-sulfamethoxazole and 22 percent with dapsone (P=0.04). The lowest failure rates occurred in patients receiving trimethoprim-sulfamethoxazole, acid failures were more common with 50 mg of dapsone than with 100 mg. Toxoplasmosis developed in less than 3 percent of patients. Of the patients assigned to the two systemic therapies, only 23 percent were receiving their assigned drug and dose when they completed the study. The median survival was approximately 39 months in all three groups, and the mortality attributable to P. carinii pneumonia was only 1 percent. Conclusions. In patients with advanced HIV infection, the three treatment strategies we examined have similar effectiveness in preventing P. carinii pneumonia. Strategies that start with trimethoprim-sulfamethoxazole or with high-dose dapsone, rather than aerosolized pentamidine, are superior in patients with fewer than 100 CD4+ lymphocytes per cubic millimeter.	UNIV CALIF SAN DIEGO, LA JOLLA, CA 92093 USA; RAND CORP, SANTA MONICA, CA USA; HARVARD UNIV, SCH PUBL HLTH, BOSTON, MA 02115 USA; UNIV CINCINNATI, CINCINNATI, OH USA; WASHINGTON UNIV, SCH MED, ST LOUIS, MO USA; FRONTIER SCI TECHNOL & RES FDN, BUFFALO, NY USA; BOSTON UNIV, BOSTON, MA 02215 USA; UNIV N CAROLINA, CHAPEL HILL, NC USA; NIAID, BETHESDA, MD 20892 USA; JOHNS HOPKINS UNIV, BALTIMORE, MD USA	University of California System; University of California San Diego; RAND Corporation; Harvard University; Harvard T.H. Chan School of Public Health; University System of Ohio; University of Cincinnati; Washington University (WUSTL); Frontier Science Foundation; Boston University; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	BOZZETTE, SA (corresponding author), VET AFFAIRS MED CTR, MAIL CODE 111N-1, 3350 LA JOLLA VILLAGE DR, SAN DIEGO, CA 92161 USA.			feinberg, judith/0000-0003-4206-7214; Powderly, William/0000-0001-7808-3086				BLUM RN, 1992, J ACQ IMMUN DEF SYND, V5, P341; BOZZETTE SA, IN PRESS AM J MED; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CARR A, 1992, AIDS, V6, P165, DOI 10.1097/00002030-199202000-00004; CHAISSON RE, 1992, ARCH INTERN MED, V152, P2009, DOI 10.1001/archinte.152.10.2009; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; FREEDBERG KA, 1991, J ACQ IMMUN DEF SYND, V4, P521; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MALLOLAS J, 1993, AIDS, V7, P59, DOI 10.1097/00002030-199301000-00009; MASUR H, 1993, J ACQ IMMUN DEF SYND, V6, P46; MASUR H, 1992, NEW ENGL J MED, V327, P1853, DOI 10.1056/NEJM199212243272606; MAY T, 1994, J ACQ IMMUN DEF SYND, V7, P457; MOHLEBOETANI J, 1992, WESTERN J MED, V156, P303; PODZAMCZER D, 1993, AIDS, V7, P501, DOI 10.1097/00002030-199304000-00008; POWDERLY WG, 1995, NEW ENGL J MED, V332, P700, DOI 10.1056/NEJM199503163321102; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; SAAH AJ, 1994, J ACQ IMMUN DEF SYND, V7, P287; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; SLAVIN MA, 1992, AIDS, V6, P1169, DOI 10.1097/00002030-199210000-00017; TORRES RA, 1993, AM J MED, V95, P573, DOI 10.1016/0002-9343(93)90352-P	24	263	269	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 16	1995	332	11					693	699		10.1056/NEJM199503163321101	http://dx.doi.org/10.1056/NEJM199503163321101			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QL788	7854375				2023-01-03	WOS:A1995QL78800001
J	LARACH, MG				LARACH, MG			ACCIDENTAL HYPOTHERMIA	LANCET			English	Article							CARDIOPULMONARY BYPASS; CARDIAC-ARREST; RESUSCITATION; EXPERIENCE; EXPOSURE				LARACH, MG (corresponding author), PENN STATE UNIV,COLL MED,DEPT ANAESTHESIA,500 UNIV DR,POB 850,HERSHEY,PA 17033, USA.							ANDERSON S, 1970, BRIT J ANAESTH, V42, P653, DOI 10.1093/bja/42.7.653; ANTRETTER H, 1993, NEW ENGL J MED, V330, P219; BAUMGARTNER FJ, 1992, CAN J SURG, V35, P184; BOLTE RG, 1988, JAMA-J AM MED ASSOC, V260, P377, DOI 10.1001/jama.260.3.377; BURTON AC, 1955, MAN COLD ENV, P200; CHINARD FP, 1979, ANN INTERN MED, V90, P990, DOI 10.7326/0003-4819-90-6-990_2; DAANEN HAM, 1992, AVIAT SPACE ENVIR MD, V63, P1070; DANZL DF, 1989, CRIT CARE MED, V17, P227, DOI 10.1097/00003246-198903000-00005; DANZL DF, 1987, ANN EMERG MED, V16, P1042, DOI 10.1016/S0196-0644(87)80757-6; DAVIES DM, 1967, LANCET, V1, P1036; DUGUID H, 1961, LANCET, V2, P1213; FELL RH, 1968, LANCET, V1, P392; FITZGERALD FT, 1982, ADV INTERNAL MED, V27, P127; GENTILELLO LM, 1992, J TRAUMA, V32, P316, DOI 10.1097/00005373-199203000-00009; GIESBRECHT GG, 1994, AVIAT SPACE ENVIR MD, V65, P803; GREGORY JS, 1991, J TRAUMA, V31, P1247, DOI 10.1097/00005373-199109000-00008; Grossheim R L, 1973, Alaska Med, V15, P53; HARNETT RM, 1983, AVIAT SPACE ENVIR MD, V54, P425; HAUTY MG, 1987, J TRAUMA, V27, P1107, DOI 10.1097/00005373-198710000-00002; HERITY B, 1991, J EPIDEMIOL COMMUN H, V45, P19, DOI 10.1136/jech.45.1.19; HILL JG, 1992, ANN THORAC SURG, V54, P699, DOI 10.1016/0003-4975(92)91014-Z; IVERSEN RJ, 1990, ANN EMERG MED, V19, P1335, DOI 10.1016/S0196-0644(05)82300-5; JOLLY B T, 1992, Emergency Medicine Clinics of North America, V10, P311; KEATINGE WR, 1969, SURVIVAL COLD WATER, P73; Kugelberg J, 1967, Scand J Thorac Cardiovasc Surg, V1, P142, DOI 10.3109/14017436709131858; LASH RF, 1967, J AMER MED ASSOC, V201, P269, DOI 10.1001/jama.201.4.269; LEDINGHAM IM, 1980, BRIT MED J, V280, P1102, DOI 10.1136/bmj.280.6222.1102; LEE HA, 1965, BMJ-BRIT MED J, V1, P1217, DOI 10.1136/bmj.1.5444.1217; LETSOU GV, 1992, ARCH SURG-CHICAGO, V127, P525; LINTON AL, 1966, LANCET, V1, P24; LLOYD EL, 1973, BRIT J ANAESTH, V45, P41, DOI 10.1093/bja/45.1.41; LLOYD EL, 1972, SCOT MED J, V17, P83, DOI 10.1177/003693307201700302; LLOYD EL, 1986, HYPOTHERMIA COLD STR, P237; LOCHER T, 1991, SCHWEIZ MED WSCHR, V121, P1020; LONNING PE, 1986, ACTA ANAESTH SCAND, V30, P601, DOI 10.1111/j.1399-6576.1986.tb02485.x; MILLER JW, 1980, ANN EMERG MED, V9, P456, DOI 10.1016/S0196-0644(80)80304-0; MYERS RAM, 1979, JACEP-J AM COLL EMER, V8, P523, DOI 10.1016/S0361-1124(79)80300-7; NIELSEN HK, 1992, DAN MED BULL, V39, P190; OSBORNE L, 1984, BRIT MED J, V289, P881, DOI 10.1136/bmj.289.6449.881-a; RANKIN AC, 1984, BRIT MED J, V289, P874, DOI 10.1136/bmj.289.6449.874; REULER JB, 1978, ANN INTERN MED, V89, P519, DOI 10.7326/0003-4819-89-4-519; ROMET TT, 1988, AVIAT SPACE ENVIR MD, V59, P630; SCHALLER MD, 1990, JAMA-J AM MED ASSOC, V264, P1842, DOI 10.1001/jama.264.14.1842; SCHISSLER P, 1981, SOUTHERN MED J, V74, P474, DOI 10.1097/00007611-198104000-00024; SCHWAB RH, 1964, AM J MED SCI, V248, P290, DOI 10.1097/00000441-196409000-00006; SESSLER DI, 1990, ANESTHESIOLOGY, V73, P218, DOI 10.1097/00000542-199008000-00005; SHIELDS CP, 1990, ANN EMERG MED, V19, P1093, DOI 10.1016/S0196-0644(05)81510-0; SPLITTGERBER FH, 1986, AM SURGEON, V52, P407; STONEHAM MD, 1992, ANAESTHESIA, V47, P784, DOI 10.1111/j.1365-2044.1992.tb03257.x; VONSEGESSER LK, 1991, ANN THORAC SURG, V52, P560, DOI 10.1016/0003-4975(91)90929-K; WEYMAN AE, 1974, AM J MED, V56, P13, DOI 10.1016/0002-9343(74)90746-3; WHITE JD, 1982, ANN EMERG MED, V11, P417; YATES DW, 1979, RESUSCITATION, V7, P59, DOI 10.1016/0300-9572(79)90016-9; ZACHARY L, 1982, ANN PLAS SURG, V9, P238, DOI 10.1097/00000637-198209000-00008; ZELL SC, 1985, ANN EMERG MED, V14, P339, DOI 10.1016/S0196-0644(85)80101-3; Zingg W, 1966, Med Serv J Can, V22, P399; 1993, MMWR-MORBID MORTAL W, V42, P917; [No title captured]	58	92	95	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	FEB 25	1995	345	8948					493	498		10.1016/S0140-6736(95)90587-1	http://dx.doi.org/10.1016/S0140-6736(95)90587-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861878				2023-01-03	WOS:A1995QH92900014
J	HEBUTERNE, X; BROUSSARD, JF; RAMPAL, P				HEBUTERNE, X; BROUSSARD, JF; RAMPAL, P			ACUTE RENUTRITION BY CYCLIC ENTERAL NUTRITION IN ELDERLY AND YOUNGER PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTEIN-ENERGY MALNUTRITION; TOTAL PARENTERAL-NUTRITION; MEDICAL PATIENTS; METABOLISM; DISEASE; NECK; UNDERNUTRITION; INTERMITTENT; EXPENDITURE; FEEDINGS	Objective.-To evaluate the efficacy and tolerance of cyclic enteral nutrition (CyEN) in elderly compared with younger patients. Design.-Prospective case series. Setting.-University hospital nutritional support unit. Patients.-A total of 51 patients younger than 65 years (mean age, 45 years) and 45 patients 65 years of age and older (mean age, 77 years) referred for refeeding after having lost at least 20% of their body weight or at least 10% in 3 months. All patients were severely undernourished but were ambulatory. Intervention.-Cyclic enteral nutrition was administered via a nasogastric tube during the night; in the daytime patients were allowed to eat normally. Measurements.-Ten biological and anthropometric nutritional parameters and a global nutritional deficiency (GND) were measured at day 0, at day 15, and at the end of CyEN. Results.-Total energy intakes were 288% and 282% of resting energy expenditure in groups 1 and 2, respectively, and duration of CyEN was a mean of 27 days in both groups. Tolerance was generally good, although one patient in each group discontinued refeeding because of aspiration pneumonia. In both groups, seven nutritional parameters and the GND improved significantly; six parameters improved significantly more in younger than in elderly patients: body weight, serum albumin, serum prealbumin, serum transferrin, 24-hour urinary creatinine, and the GND (44.7% vs 35.4%; P=.006). After 1 year, the probability to be alive without relapse was 62% in the elderly and 76% in the younger patients (P=.18). Conclusions.-Cyclic enteral nutrition appears to be a well-tolerated and effective treatment of undernutrition in older malnourished ambulatory patients, although their response to CyEN was somewhat less than in younger patients.			HEBUTERNE, X (corresponding author), HOP ARCHET, CTR AGREE NUTR PARENTERALE DOMICILE, SERV GASTROENTEROL & NUTR, F-06202 NICE 03, FRANCE.							ABADLACRUZ A, 1990, JPEN-PARENTER ENTER, V14, P618, DOI 10.1177/0148607190014006618; ABBASI A, 1994, HDB NUTR AGED, P135; AIGES H, 1989, GASTROENTEROLOGY, V97, P905, DOI 10.1016/0016-5085(89)91496-0; ARORA S, 1989, GASTROENTEROLOGY, V96, P1560, DOI 10.1016/0016-5085(89)90527-1; ASHWORTH N, 1962, LANCET, V2, P685; BASTOW D, 1985, CLIN NUTR, V4, P7, DOI 10.1016/0261-5614(85)90031-7; BASTOW MD, 1983, BRIT MED J, V287, P1589, DOI 10.1136/bmj.287.6405.1589; BASTOW MD, 1983, LANCET, V1, P143; CALLOWAY DH, 1980, AM J CLIN NUTR, V33, P2088; CAMPBELL IT, 1983, AM J CLIN NUTR, V38, P870, DOI 10.1093/ajcn/38.6.870; CIOCON JO, 1988, ARCH INTERN MED, V148, P429, DOI 10.1001/archinte.148.2.429; CIOCON JO, 1992, JPEN-PARENTER ENTER, V16, P525, DOI 10.1177/0148607192016006525; CONSTANS T, 1992, J AM GERIATR SOC, V40, P263, DOI 10.1111/j.1532-5415.1992.tb02080.x; COSNES J, 1983, GASTROEN CLIN BIOL, V7, P1003; GREENE HL, 1976, NEW ENGL J MED, V294, P423, DOI 10.1056/NEJM197602192940805; GUENTER PA, 1991, JPEN-PARENTER ENTER, V15, P277, DOI 10.1177/0148607191015003277; HARRIS JA, 1982, ANNU REV NUTR, V2, P179; HEBUTERNE X, 1992, GASTROEN CLIN BIOL, V16, P227; HENDERSON CT, 1992, J AM COLL NUTR, V11, P309; JACKSON AA, 1977, AM J CLIN NUTR, V30, P1514, DOI 10.1093/ajcn/30.9.1514; JALLUT D, 1990, JPEN-PARENTER ENTER, V14, P563, DOI 10.1177/0148607190014006563; JEEJEEBHOY KN, 1986, GUT               S1, V27, pS25; JELLIFFE DB, 1966, WHO MONOGR SER, V53, P238; JUST B, 1990, AM J CLIN NUTR, V51, P107, DOI 10.1093/ajcn/51.1.107; KAMINSKI MV, 1982, J AM COLL NUTR, V1, P35; KLEIBEUKER JH, 1991, JPEN-PARENTER ENTER, V15, P80, DOI 10.1177/014860719101500180; LEHMANN AB, 1989, AGE AGEING, V18, P339, DOI 10.1093/ageing/18.5.339; LIPSCHITZ DA, 1982, J AM COLL NUTR, V1, P17; MASLOW K, 1988, JPEN-PARENTER ENTER, V12, P425, DOI 10.1177/0148607188012005425; MOHS ME, 1994, HDB NUTR AGED, P145; MORGAN DB, 1986, AGE AGEING, V15, P65, DOI 10.1093/ageing/15.2.65; PECK A, 1990, J AM GERIATR SOC, V38, P1195, DOI 10.1111/j.1532-5415.1990.tb01498.x; ROMIJN JA, 1993, AM J PHYSIOL, V265, pE380, DOI 10.1152/ajpendo.1993.265.3.E380; RUSSELL RM, 1992, AM J CLIN NUTR, V55, P1203; SCHWARTZ RS, 1990, METABOLISM, V39, P733, DOI 10.1016/0026-0495(90)90109-P; SHIZGAL HM, 1992, AM J CLIN NUTR, V55, P783, DOI 10.1093/ajcn/55.4.783; SIMKO V, 1989, ARCH INTERN MED, V149, P557, DOI 10.1001/archinte.149.3.557; SOLOMON SM, 1990, JPEN-PARENTER ENTER, V14, P90, DOI 10.1177/014860719001400190; SULLIVAN DH, 1990, AM J CLIN NUTR, V51, P749, DOI 10.1093/ajcn/51.5.749; TOMAIOLO PP, 1981, JPEN-PARENTER ENTER, V5, P46, DOI 10.1177/014860718100500146; UAUY R, 1978, J GERONTOL, V33, P663, DOI 10.1093/geronj/33.5.663; VOORRIPS LE, 1993, AM J CLIN NUTR, V58, P15, DOI 10.1093/ajcn/58.1.15; WALKER J, 1979, AM J CLIN NUTR, V32, P1397, DOI 10.1093/ajcn/32.7.1396; WEINSIER RL, 1979, AM J CLIN NUTR, V32, P418, DOI 10.1093/ajcn/32.2.418	44	66	66	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 22	1995	273	8					638	643		10.1001/jama.273.8.638	http://dx.doi.org/10.1001/jama.273.8.638			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QG748	7844874				2023-01-03	WOS:A1995QG74800029
J	LAROSA, JC				LAROSA, JC			HAS HRT COME OF AGE	LANCET			English	Editorial Material							POSTMENOPAUSAL WOMEN; ESTROGEN REPLACEMENT; HORMONE-THERAPY; DISEASE				LAROSA, JC (corresponding author), TULANE UNIV,MED CTR,NEW ORLEANS,LA, USA.							BAR J, 1993, OBSTET GYNECOL, V81, P261; CLARKSON RB, 1994, DRUGS S2, V47, P42; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRADY D, 1992, ANN INTERN MED, V117, P1038; KEANEY JF, 1994, CIRCULATION, V89, P2251, DOI 10.1161/01.CIR.89.5.2251; KUSHWAHA RS, 1992, CURR OPIN LIPIDOL, V3, P167; MENDOZA S, 1994, J LAB CLIN MED, V123, P837; SPAGNOLI LG, 1980, ATHEROSCLEROSIS, V82, P27; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; VANDERMOOREN MJ, 1994, METABOLISM, V43, P799, DOI 10.1016/0026-0495(94)90256-9; WAGNER JD, 1992, ARTERIOSCLER THROMB, V12, P717, DOI 10.1161/01.ATV.12.6.717; WHITCROFT SI, 1994, OBSTET GYNECOL, V84, P222; WILLIAMS JK, 1990, CIRCULATION, V81, P1680, DOI 10.1161/01.CIR.81.5.1680; 1985, VITAL STATISTICS US, V2, P258	15	14	14	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 14	1995	345	8942					76	77		10.1016/S0140-6736(95)90056-X	http://dx.doi.org/10.1016/S0140-6736(95)90056-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB804	7632206				2023-01-03	WOS:A1995QB80400003
J	JAGOX, A; CARR, DB; PAYNE, R				JAGOX, A; CARR, DB; PAYNE, R			NEW CLINICAL-PRACTICE GUIDELINES FOR THE MANAGEMENT OF PAIN IN PATIENTS WITH CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									MASSACHUSETTS GEN HOSP,CTR PAIN,DEPT ANESTHESIA,BOSTON,MA 02114; JOHNS HOPKINS UNIV,SCH NURSING,BALTIMORE,MD 21205; MD ANDERSON CANC CTR,HOUSTON,TX 77030	Harvard University; Massachusetts General Hospital; Johns Hopkins University; University of Texas System; UTMD Anderson Cancer Center								ARCANGELI G, 1989, RADIOTHER ONCOL, V14, P95, DOI 10.1016/0167-8140(89)90053-4; CLEELAND CS, 1994, NEW ENGL J MED, V330, P592, DOI 10.1056/NEJM199403033300902; FERRANTE FM, 1990, PATIENT CONTROLLED A; Field MJ, 1990, CLIN PRACTICE GUIDEL; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GALER BS, 1992, PAIN, V49, P87, DOI 10.1016/0304-3959(92)90192-E; GROSSMAN SA, 1991, J PAIN SYMPTOM MANAG, V6, P53, DOI 10.1016/0885-3924(91)90518-9; Jacox A, 1994, CLIN PRACTICE GUIDEL; JACOX AK, 1994, AHCPR940594 AG HLTH; JACOX AK, 1994, AHCPR940593 PUBL; JACOX AK, 1994, AHCPR940596 AG HLTH; JACOX AK, 1994, AHCPR940595 AG HLTH; KAIKO RF, 1983, ANN NEUROL, V13, P180, DOI 10.1002/ana.410130213; PATT RB, 1993, CANCER PAIN; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; 1986, CANCER PAIN RELIEF; 1994, CANCER FACTS FIGURES, P2	17	207	214	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					651	655		10.1056/NEJM199403033300926	http://dx.doi.org/10.1056/NEJM199403033300926			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	7508094	Bronze			2023-01-03	WOS:A1994MY57300037
J	REYNOLDS, HN; HAUPT, MT; THILLBAHAROZIAN, MC; CARLSON, RW				REYNOLDS, HN; HAUPT, MT; THILLBAHAROZIAN, MC; CARLSON, RW			IMPACT OF CRITICAL CARE PHYSICIAN STAFFING ON PATIENTS WITH SEPTIC SHOCK IN A UNIVERSITY HOSPITAL MEDICAL INTENSIVE-CARE UNIT	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV DETROIT,DETROIT RECEIVING HOSP,CTR HLTH,DEPT MED,4201 ST ANTOINE,DETROIT,MI 48201; WAYNE STATE UNIV,SCH MED,DEPT INTERNAL MED,DIV CRIT CARE MED,DETROIT,MI 48201	Detroit Receiving Hospital & University Health Center; University of Detroit Mercy; Wayne State University								BAILAR JC, 1984, NEW ENGL J MED, V311, P156, DOI 10.1056/NEJM198407193110306; BENSON JA, 1987, ANN INTERN MED, V106, P470, DOI 10.7326/0003-4819-106-3-470_1; BIRNBAUM ML, 1986, CRIT CARE MED, V14, P1068, DOI 10.1097/00003246-198612000-00017; BLOCK AJ, 1987, ANN INTERN MED, V107, P264, DOI 10.7326/0003-4819-107-2-264_3; CONNORS AF, 1983, NEW ENGL J MED, V308, P263, DOI 10.1056/NEJM198302033080508; CULLEN DJ, 1976, NEW ENGL J MED, V294, P982, DOI 10.1056/NEJM197604292941805; CULLEN DJ, 1984, CRIT CARE MED, V12, P106; FINKLER SA, 1982, ANN INTERN MED, V96, P102, DOI 10.7326/0003-4819-96-1-102; GILBERT R, 1974, AM REV RESPIR DIS, V109, P142; GRIMER PF, 1973, ANN INTERN MED, V78, P581; KELLEY MA, 1988, NEW ENGL J MED, V318, P1613, DOI 10.1056/NEJM198806163182410; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LI TCM, 1984, JAMA-J AM MED ASSOC, V252, P2023, DOI 10.1001/jama.252.15.2023; OLSEN GN, 1987, ANN INTERN MED, V106, P914, DOI 10.7326/0003-4819-106-6-914_2; SHEPARD DS, 1979, HRP0029335 NAT TECHN; SIEGEL JH, 1980, J TRAUMA, V20, P558, DOI 10.1097/00005373-198007000-00005; THIBAULT GE, 1980, NEW ENGL J MED, V302, P938, DOI 10.1056/NEJM198004243021703; TURNBULL AD, 1979, CRIT CARE MED, V7, P20, DOI 10.1097/00003246-197901000-00005	19	199	202	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 16	1988	260	23					3446	3450		10.1001/jama.260.23.3446	http://dx.doi.org/10.1001/jama.260.23.3446			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R2475	3210284				2023-01-03	WOS:A1988R247500022
J	GAYNON, PS; BLEYER, WA; ALBO, VC; GROSSMAN, NJ; NOVAK, LT; REAMAN, GH; STEINHERZ, PG; ABLIN, AR; FINKLESTEIN, JZ; LITTMAN, PS; PYESMANY, AF; SATHER, HN; HAMMOND, GD				GAYNON, PS; BLEYER, WA; ALBO, VC; GROSSMAN, NJ; NOVAK, LT; REAMAN, GH; STEINHERZ, PG; ABLIN, AR; FINKLESTEIN, JZ; LITTMAN, PS; PYESMANY, AF; SATHER, HN; HAMMOND, GD			INTENSIVE THERAPY FOR CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA AND UNFAVORABLE PRESENTING FEATURES - EARLY CONCLUSIONS OF STUDY CCG-106 BY THE CHILDRENS-CANCER-STUDY-GROUP	LANCET			English	Article									RHODE ISL HOSP,PROVIDENCE,RI 02902; RAINBOW BABIES & CHILDRENS HOSP,CLEVELAND,OH 44106; IZAAK WALTON KILLAM HOSP CHILDREN,HALIFAX B3J 3G9,NS,CANADA; CHILDRENS HOSP,NATL MED CTR,WASHINGTON,DC 20010; UNIV SO CALIF,SCH MED,LOS ANGELES,CA 90033; WYLER CHILDRENS HOSP,CHICAGO,IL; MEM SLOAN KETTERING CANC CTR,NEW YORK,NY 10021; CHILDRENS HOSP & MED CTR,SEATTLE,WA; UNIV CALIF SAN FRANCISCO,MED CTR,SAN FRANCISCO,CA 94143; CHILDRENS HOSP PITTSBURGH,PITTSBURGH,PA; UNIV CALIF LOS ANGELES,LOS ANGELES CTY HARBOR MED CTR,TORRANCE,CA 90509; CHILDRENS HOSP COLUMBUS,COLUMBUS,OH	Lifespan Health Rhode Island; Rhode Island Hospital; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Dalhousie University; Children's National Health System; University of Southern California; Memorial Sloan Kettering Cancer Center; Seattle Children's Hospital; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University System of Ohio; Ohio State University; Nationwide Childrens Hospital								AUR RJA, 1978, CANCER, V42, P2123, DOI 10.1002/1097-0142(197811)42:5<2123::AID-CNCR2820420507>3.0.CO;2-5; BAILAR JC, 1984, NEW ENGL J MED, V311, P156, DOI 10.1056/NEJM198407193110306; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BLEYER WA, 1986, MED PEDIATR ONCOL, V14, P271, DOI 10.1002/mpo.2950140506; BLEYER WA, 1983, J CLIN ONCOL, V1, P317, DOI 10.1200/JCO.1983.1.5.317; CAMITTA BM, 1980, MED PEDIATR ONCOL, V8, P383, DOI 10.1002/mpo.2950080410; CHESSELLS JM, 1982, SEMIN HEMATOL, V19, P155; CLAVELL LA, 1986, NEW ENGL J MED, V315, P657, DOI 10.1056/NEJM198609113151101; COCCIA PF, 1983, LEUKEMIA RES ADV CEL, P241; COX DR, 1972, J R STAT SOC B, V34, P187; DAHL GV, 1987, J CLIN ONCOL, V5, P1015, DOI 10.1200/JCO.1987.5.7.1015; DIEHL LF, 1986, J CLIN ONCOL, V4, P1114, DOI 10.1200/JCO.1986.4.7.1114; DUQUEHAMMERSHAIMB L, 1983, CANCER, V52, P39, DOI 10.1002/1097-0142(19830701)52:1<39::AID-CNCR2820520109>3.0.CO;2-S; EKERT H, 1978, BRIT J CANCER, V38, P619, DOI 10.1038/bjc.1978.258; FREI E, 1984, CANCER, V53, P2013, DOI 10.1002/1097-0142(19840515)53:10<2013::AID-CNCR2820531003>3.0.CO;2-2; GAYNON P, 1985, P AM SOC CLIN ONCOL, V4, P673; Gaynon P S, 1987, Haematol Blood Transfus, V30, P167; GREEN DM, 1982, CANCER, V50, P2722, DOI 10.1002/1097-0142(19821215)50:12<2722::AID-CNCR2820501204>3.0.CO;2-T; HAGHBIN M, 1980, CANCER, V46, P241, DOI 10.1002/1097-0142(19800715)46:2<241::AID-CNCR2820460203>3.0.CO;2-E; HAROUSSEAU JL, 1980, CANCER, V46, P1996, DOI 10.1002/1097-0142(19801101)46:9<1996::AID-CNCR2820460917>3.0.CO;2-R; HENZE G, 1982, KLIN PADIATR, V194, P195, DOI 10.1055/s-2008-1033805; HENZE G, 1983, KLIN PADIATR, V193, P145; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAMPERT F, 1984, RECENT RESULTS CANC, V93, P159; MASTRANGELO R, 1986, MED PEDIATR ONCOL, V14, P191, DOI 10.1002/mpo.2950140317; MAURER AM, 1980, BLOOD, V56, P1; Miller D R, 1981, Haematol Blood Transfus, V26, P77; MILLER DR, 1981, BRIT J HAEMATOL, V48, P199, DOI 10.1111/j.1365-2141.1981.tb08453.x; MILLER DR, 1983, CANCER, V51, P1041, DOI 10.1002/1097-0142(19830315)51:6<1041::AID-CNCR2820510612>3.0.CO;2-G; MURPHY SB, 1985, SEMIN ONCOL, V12, P192; NESBIT ME, 1981, LANCET, V1, P461; NESBIT ME, 1982, CANCER RES, V42, P674; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PINKEL D, 1979, CANCER, V43, P1128, DOI 10.1002/1097-0142(197903)43:3<1128::AID-CNCR2820430352>3.0.CO;2-Y; PULLEN DJ, 1982, BLOOD, V60, P1159; RIEHM H, 1980, AM J PEDIAT HEMATOL, V2, P299; RIEHM H, 1983, LEUKEMIA RES ADV CEL, P251; ROBISON LL, 1980, AM J PEDIAT HEMATOL, V2, P5; SALLAN SE, 1981, J PEDIATR-US, V99, P676, DOI 10.1016/S0022-3476(81)80384-8; SALLAN SE, 1983, CANCER RES, V43, P5601; SIEGEL SE, 1984, BLOOD S1, V64, pA173; SIMON R, 1982, CANCER TREAT REP, V66, P1083; STEINHERZ P, 1986, P AM SOC CLIN ONCOL, V5, P163; STEINHERZ PG, 1986, J CLIN ONCOL, V4, P744, DOI 10.1200/JCO.1986.4.5.744; WOLLNER N, 1976, CANCER, V37, P123, DOI 10.1002/1097-0142(197601)37:1<123::AID-CNCR2820370119>3.0.CO;2-7	45	82	82	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	OCT 22	1988	2	8617					921	924						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q5795	2902379				2023-01-03	WOS:A1988Q579500001
J	GOLDHIRSCH, A				GOLDHIRSCH, A			COMBINATION ADJUVANT CHEMOTHERAPY FOR NODE-POSITIVE BREAST-CANCER - INADEQUACY OF A SINGLE PERIOPERATIVE CYCLE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											GOLDHIRSCH, A (corresponding author), INSELSPITAL,LUDWIG INST CANC RES,CH-3010 BERN,SWITZERLAND.							[Anonymous], 1984, Lancet, V2, P1205; BAUM M, 1982, CLIN ONCOLOGY, V1, P649; BONADONNA G, 1985, BREAST CANCER RES TR, V5, P95, DOI 10.1007/BF01805984; BONADONNA G, 1981, ADJUVANT THERAPY CAN, V3, P435; COX DR, 1972, J R STAT SOC B, V34, P187; DAVIS BW, 1986, CANCER-AM CANCER SOC, V58, P2662, DOI 10.1002/1097-0142(19861215)58:12<2662::AID-CNCR2820581219>3.0.CO;2-Y; DEWYS WD, 1972, CANCER RES, V32, P374; FISHER B, 1975, SURG GYNECOL OBSTET, V140, P528; FISHER B, 1986, J CLIN ONCOL, V4, P459, DOI 10.1200/JCO.1986.4.4.459; FISHER B, 1983, CANCER RES, V43, P1488; FISHER B, 1987, ANN INTERN MED, V106, P649, DOI 10.7326/0003-4819-106-5-649; GELBER RD, 1985, RECENT RES CANCER, V98, P53; GELBER RD, 1985, MED ONCOL, P406; GOLDHIRSCH A, 1987, LANCET, V2, P151; GOLDHIRSCH A, 1986, NCI MONOGRAPHS, V1, P55; GOLDHIRSCH A, 1986, BREAST DISEASE, P123; GOLDIE JH, 1979, CANCER TREAT REP, V63, P1727; HENDERSON IC, 1986, NATL CANCER I MONOGR, V1, P95; HENDERSON IC, 1987, BREAST DISEASES, P324; HOUGHTON J, 1988, 3RD INT C ADJ THER P; HUBAY CA, 1984, SURGERY, V96, P61; INGLE J N, 1986, Proceedings American Society of Clinical Oncology Annual Meeting, V5, P70; JUNGI WF, 1981, ADJUVANT THERAPY CAN, V3, P395; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; NISSENMEYER R, 1985, RECENT RES CANCER, V98, P91; NISSENMEYER R, 1978, CANCER, V41, P2088, DOI 10.1002/1097-0142(197806)41:6<2088::AID-CNCR2820410604>3.0.CO;2-J; SCHABEL FM, 1977, CANCER, V39, P2875, DOI 10.1002/1097-0142(197706)39:6<2875::AID-CNCR2820390675>3.0.CO;2-7; TAYLOR SG, 1985, J CLIN ONCOL, V3, P144, DOI 10.1200/JCO.1985.3.2.144; 1987, LANCET, V2, P171; 1983, LANCET, V2, P542; 1984, LANCET, V1, P1256; 1985, CANCER RES, V45, P4454	32	89	89	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1988	319	11					677	683						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q0375	2901037				2023-01-03	WOS:A1988Q037500004
J	LAUPACIS, A; SACKETT, DL; ROBERTS, RS				LAUPACIS, A; SACKETT, DL; ROBERTS, RS			AN ASSESSMENT OF CLINICALLY USEFUL MEASURES OF THE CONSEQUENCES OF TREATMENT	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV WESTERN ONTARIO, DEPT MED, LONDON N6A 3K7, ONTARIO, CANADA; UNIV WESTERN ONTARIO, DEPT EPIDEMIOL & BIOSTAT, LONDON N6A 3K7, ONTARIO, CANADA; MCMASTER UNIV, DEPT MED, HAMILTON L8S 4L8, ONTARIO, CANADA; MCMASTER UNIV, DEPT IONOSPHERE RES, HAMILTON L8S 4L8, ONTARIO, CANADA	Western University (University of Western Ontario); Western University (University of Western Ontario); McMaster University; McMaster University								[Anonymous], 1982, Lancet, V2, P1173; [Anonymous], 1967, J AMER MED ASSOC, V202, P1028, DOI 10.1001/jama.1967.03130240070013; [Anonymous], 1972, CIRCULATION, V45, P991; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97; GUYATT G, 1986, NEW ENGL J MED, V314, P889, DOI 10.1056/NEJM198604033141406; HIRAYAMA T, 1981, BRIT MED J, V282, P183, DOI 10.1136/bmj.282.6259.183; LEVINE MN, 1985, CAN MED ASSOC J, V133, P977; MANTEL N, 1959, J NATL CANCER I, V22, P719; MOSTELLE.F, 1968, J AM STAT ASSOC, V63, P1, DOI 10.2307/2283825; MULLEY AG, 1982, NEW ENGL J MED, V307, P644, DOI 10.1056/NEJM198209093071103; OCONNOR AMC, 1987, J CHRON DIS, V40, P811, DOI 10.1016/0021-9681(87)90133-0; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; ROSMAN JB, 1984, LANCET, V2, P1291; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; SACKETT DL, 1986, CHEST, V89, pS2, DOI 10.1378/chest.89.2_Supplement.2S; STODDART GL, 1984, CAN MED ASSOC J, V130, P1542; SZMUNESS W, 1980, NEW ENGL J MED, V303, P833, DOI 10.1056/NEJM198010093031501; THOMAS DG, 1977, J AM STAT ASSOC, V72, P73, DOI 10.2307/2286908; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; WHITE LJ, 1984, ANN INTERN MED, V100, P149, DOI 10.7326/0003-4819-100-1-149; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; 1978, N ENGL J MED, V299, P53; 1979, CAN MED ASS J, V121, P1193	25	1226	1251	0	24	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 30	1988	318	26					1728	1733		10.1056/NEJM198806303182605	http://dx.doi.org/10.1056/NEJM198806303182605			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N9948	3374545				2023-01-03	WOS:A1988N994800005
J	RUSSO, D; ANDREUCCI, VE; IACCARINO, V; NIOLA, R; DALCANTON, A; CONTE, G				RUSSO, D; ANDREUCCI, VE; IACCARINO, V; NIOLA, R; DALCANTON, A; CONTE, G			PERCUTANEOUS RENAL EMBOLIZATION IN RENOVASCULAR HYPERTENSION	BRITISH MEDICAL JOURNAL			English	Note									UNIV NAPLES,FAC MED 2,DEPT RADIOL,I-80131 NAPLES,ITALY; UNIV REGGIO CALABRIA,CHAIR NEPHROL,CATANZARO,ITALY	University of Naples Federico II; Universita Mediterranea di Reggio Calabria	RUSSO, D (corresponding author), UNIV NAPLES,FAC MED 2,DEPT NEPHROL,I-80131 NAPLES,ITALY.		dal canton, antonio/G-4388-2013					DALCANTON A, 1984, CLIN NEPHROL, V21, P138; FLETCHER EWL, 1984, BRIT J RADIOL, V57, P279, DOI 10.1259/0007-1285-57-676-279; LIPUMA JP, 1981, AM J ROENTGENOL, V136, P603, DOI 10.2214/ajr.136.3.603; NANNI GS, 1983, RADIOLOGY, V148, P51, DOI 10.1148/radiology.148.1.6856864; REUTER SP, 1976, AM J ROENTGENOL, V127, P389	5	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 23	1988	296	6630					1160	1161		10.1136/bmj.296.6630.1160	http://dx.doi.org/10.1136/bmj.296.6630.1160			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N0662	3132246	Green Published, Bronze			2023-01-03	WOS:A1988N066200011
J	GAYLIN, W; KASS, LR; PELLEGRINO, ED; SIEGLER, M				GAYLIN, W; KASS, LR; PELLEGRINO, ED; SIEGLER, M			DOCTORS MUST NOT KILL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									UNIV CHICAGO,CTR CLIN MED ETH,ROOM W723,5841 S MARYLAND AVE,CHICAGO,IL 60637; HASTINGS CTR,BRIARCLIFF MANOR,NY; UNIV CHICAGO,COMM SOCIAL THOUGHT,CHICAGO,IL 60637; GEORGETOWN UNIV,KENNEDY INST ETH,WASHINGTON,DC 20007	University of Chicago; University of Chicago; Georgetown University								FENIGSEN R, 1987, EUTHANASIE EEN WELDA	1	121	121	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1988	259	14					2139	2140						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M7414	3346989				2023-01-03	WOS:A1988M741400031
J	RYLANCE, GW				RYLANCE, GW			NEW DRUGS - PRESCRIBING FOR INFANTS AND CHILDREN	BRITISH MEDICAL JOURNAL			English	Article											RYLANCE, GW (corresponding author), CHILDRENS HOSP,PAEDIAT,BIRMINGHAM B16 8ET,W MIDLANDS,ENGLAND.							ARANDA JV, 1974, J PEDIATR-US, V85, P534, DOI 10.1016/S0022-3476(74)80465-8; ARANT BS, 1978, J PEDIATR-US, V92, P705, DOI 10.1016/S0022-3476(78)80133-4; CHOONARA IA, 1984, ARCH DIS CHILD, V59, P578, DOI 10.1136/adc.59.6.578; EVANS NJ, 1985, BRIT J CLIN PHARMACO, V19, pP125; FRIISHA.B, 1961, PEDIATRICS, V28, P169; GLADTKE E, 1975, BASIC THERAPEUTIC AS, P393; HURWITZ ES, 1985, NEW ENGL J MED, V313, P849, DOI 10.1056/NEJM198510033131403; MILLER RP, 1976, CLIN PHARMACOL THER, V19, P284; MORSELLI PL, 1980, CLIN PHARMACOKINET, V5, P485, DOI 10.2165/00003088-198005060-00001; PARK MK, 1982, AM J DIS CHILD, V136, P418, DOI 10.1001/archpedi.1982.03970410036008; RANE A, 1980, EUR J CLIN PHARMACOL, V18, P9, DOI 10.1007/BF00561473; ROBERTS IF, 1979, BRIT MED J, V2, P14, DOI 10.1136/bmj.2.6181.14; RYLANCE GW, 1979, ARCH DIS CHILD, V54, P454, DOI 10.1136/adc.54.6.454; RYLANCE GW, 1986, TXB NEONATOLOGY, P223; SHOPE JT, 1981, PEDIATR CLIN N AM, V28, P5; WHYTE J, 1977, ACTA PAEDIATR SCAND, V66, P767, DOI 10.1111/j.1651-2227.1977.tb07987.x; WOODS CG, 1987, BRIT MED J, V294, P869, DOI 10.1136/bmj.294.6576.869-a; 1972, PEDIATR CLIN N AM, V19, P117	18	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 2	1988	296	6627					984	986		10.1136/bmj.296.6627.984	http://dx.doi.org/10.1136/bmj.296.6627.984			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M8425	3129119	Green Published			2023-01-03	WOS:A1988M842500022
J	SWIFT, CG				SWIFT, CG			PRESCRIBING IN OLD-AGE	BRITISH MEDICAL JOURNAL			English	Article											SWIFT, CG (corresponding author), UNIV LONDON KINGS COLL HOSP,SCH MED & DENT,LONDON SE5 8RX,ENGLAND.							CAIRD FI, 1985, J ROY COLL PHYS LOND, V19, P235; MOORE SR, 1985, GERIATRIC DRUG USE C; OMALLEY K, 1984, CLIN PHARM DRUG TREA; OMALLEY K, 1985, THERAPEUTICS ELDERLY; SWIFT CG, 1987, CLIN PHARM ELDERLY; VESTAL RE, 1984, DRUG TREATMENT ELDER; 1984, J R COLL PHYSICIANS, V18, P7	7	16	17	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1988	296	6626					913	915		10.1136/bmj.296.6626.913	http://dx.doi.org/10.1136/bmj.296.6626.913			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M7851	3129073	Green Published			2023-01-03	WOS:A1988M785100023
J	GOLDACRE, MJ; SIMMONS, H; HENDERSON, J; GILL, LE				GOLDACRE, MJ; SIMMONS, H; HENDERSON, J; GILL, LE			TRENDS IN EPISODE BASED AND PERSON BASED RATES OF ADMISSION TO HOSPITAL IN THE OXFORD RECORD LINKAGE STUDY AREA	BRITISH MEDICAL JOURNAL			English	Editorial Material											GOLDACRE, MJ (corresponding author), UNIV OXFORD,OXFORD REG HLTH AUTHOR,CLIN EPIDEMIOL UNIT,OLD RD,OXFORD OX3 7LF,ENGLAND.			Henderson, Jane/0000-0001-7527-694X				Acheson E.D., 1967, MED RECORD LINKAGE; [Anonymous], 1981, HLTH WEALTH INT STUD; Kohn Robert, 1976, HLTH CARE INT STUDY; MAYNARD A, 1986, PUBLIC EXPENDITURE N, P17; MCPHERSON K, 1985, BRIT MED J, V291, P797, DOI 10.1136/bmj.291.6498.797; 1982, DA8213 DEP HLTH SOC; 1986, DHSS1985 86 DEP HLTH, P31; 1985, GENERAL HOUSEHOLD SU, P151	8	69	69	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 20	1988	296	6621					583	585		10.1136/bmj.296.6621.583	http://dx.doi.org/10.1136/bmj.296.6621.583			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M2314	3126913	Green Published			2023-01-03	WOS:A1988M231400057
J	Andreotti, F; Pasceri, V; Hackett, DR; Davies, GJ; Haider, AW; Maseri, A				Andreotti, F; Pasceri, V; Hackett, DR; Davies, GJ; Haider, AW; Maseri, A			Preinfarction angina as a predictor of more rapid coronary thrombolysis in patients with acute myocardial infarction	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLASMINOGEN-ACTIVATOR; ANTECEDENT ANGINA; PECTORIS; THERAPY; STREPTOKINASE; THROMBOSIS; OCCLUSION; ARTERY; PREVENTION; MORTALITY	Background. When a myocardial infarction is preceded by angina, the infarct tends to be smaller than when there is no preinfarction angina. Prompt re canalization of the occluded infarct-related artery is crucial in limiting the size of the infarct. We prospectively studied the relation among preinfarction unstable angina, the speed of coronary reperfusion, and the size of the infarct in patients with acute myocardial infarction receiving thrombolytic therapy. Methods. We compared 14 patients who had unstable angina during the week before myocardial infarction with 9 patients who had no preinfarction angina. Coronary arteriograms were obtained at base line and 15, 35, 55, and 90 minutes and 24 hours after the start of thrombolytic therapy, The size of the infarct was estimated on the basis of creatine kinase and creatine kinase MB levels, which were measured every 4 hours during the first 24 hours. Results. Complete reperfusion (a flow of grade 3 according to the Thrombolysis in Myocardial Infarction classification) was achieved at 35 minutes in 64 percent of the patients with preinfarction angina but in none of those without preinfarction angina (P = 0.006); at 55 minutes in 86 percent and 38 percent, respectively (P = 0.05); and at 90 minutes in 86 percent and 50 percent, respectively (P = 0.14). The mean (+/-SD) time to reperfusion was 27+/-16 minutes in the group with preinfarction angina and 48+/-17 minutes in the group without preinfarction angina (P = 0.04); the peak creatine kinase levels were 1118+/-783 and 2395+/-1615 U per liter, respectively (P = 0.03); the peak creatine kinase MB levels were 102+/-67 and 251+/-186 U per liter, respectively (P = 0.009); and the 24-hour integrated creatine kinase MB levels were 1716+/-1171 and 4267+/-3252 U . liter(-1). 24 hours, respectively (P = 0.009). The time to reperfusion was positively correlated with the indexes of infarct size (r greater than or equal to 0.53, P less than or equal to 0.02). Conclusions. In patients with acute myocardial infarction preceded by unstable angina, as compared with those without preinfarction angina, thrombolytic therapy resulted in more rapid reperfusion and smaller infarcts. Earlier myocardial reperfusion may thus account for the smaller infarct size in patients with preinfarction angina. (C) 1996, Massachusetts Medical Society.	HAMMERSMITH HOSP, ROYAL POSTGRAD MED SCH, LONDON, ENGLAND	Imperial College London	Andreotti, F (corresponding author), CATHOLIC UNIV, INST CARDIOL, LARGO A GEMELLI 8, I-00168 ROME, ITALY.		Andreotti, Felicita/A-9962-2019	Andreotti, Felicita/0000-0002-1456-6430				BARBASH GI, 1992, J AM COLL CARDIOL, V20, P36, DOI 10.1016/0735-1097(92)90134-9; BEEBE DP, 1987, THROMB RES, V47, P123, DOI 10.1016/0049-3848(87)90249-0; BRAUNWALD E, 1995, CIRCULATION, V91, P1604, DOI 10.1161/01.CIR.91.5.1604; BRAUNWALD E, 1982, CIRCULATION, V66, P1146, DOI 10.1161/01.CIR.66.6.1146; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; COLLEN D, 1990, ANN INTERN MED, V112, P529, DOI 10.7326/0003-4819-112-7-529; Cox DR, 1974, THEORETICAL STATISTI; DAVIES GJ, 1984, NEW ENGL J MED, V311, P1488, DOI 10.1056/NEJM198412063112306; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; DEWOOD MA, 1980, NEW ENGL J MED, V303, P897, DOI 10.1056/NEJM198010163031601; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; FOX KAA, 1985, CIRCULATION, V72, P1346, DOI 10.1161/01.CIR.72.6.1346; FUJITA M, 1987, BRIT HEART J, V57, P139; GRANDE P, 1982, CIRCULATION, V65, P756, DOI 10.1161/01.CIR.65.4.756; HACKETT D, 1987, NEW ENGL J MED, V317, P1055, DOI 10.1056/NEJM198710223171704; HARPER RW, 1979, AM HEART J, V97, P178, DOI 10.1016/0002-8703(79)90353-3; INGERSLEV J, 1987, SCAND J CLIN LAB INV, V47, P143; JANG IK, 1989, CIRCULATION, V79, P920, DOI 10.1161/01.CIR.79.4.920; KAGEN L, 1977, AM J MED, V62, P86, DOI 10.1016/0002-9343(77)90353-9; KARAGOUNIS L, 1992, J AM COLL CARDIOL, V19, P1, DOI 10.1016/0735-1097(92)90043-M; KHAN MI, 1990, AM J CARDIOL, V65, P1051, DOI 10.1016/0002-9149(90)90313-P; KLONER RA, 1995, CIRCULATION, V91, P37, DOI 10.1161/01.CIR.91.1.37; KLONER RA, 1994, J AM COLL CARDIOL, V24, P1133, DOI 10.1016/0735-1097(94)90880-X; KUNITADA S, 1992, BLOOD, V79, P1420; LINCOFF AM, 1993, CIRCULATION, V87, P1792; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; MATSUDA Y, 1984, AM HEART J, V108, P955, DOI 10.1016/0002-8703(84)90460-5; MULLER DWM, 1990, AM HEART J, V119, P224, DOI 10.1016/S0002-8703(05)80008-0; OTTANI F, 1995, CIRCULATION, V91, P291, DOI 10.1161/01.CIR.91.2.291; PASCERI V, 1995, AM J CARDIOL, V75, P224, DOI 10.1016/0002-9149(95)80024-M; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PIERARD LA, 1988, AM J CARDIOL, V61, P984, DOI 10.1016/0002-9149(88)90111-7; Ridker, 1994, J Thromb Thrombolysis, V1, P35, DOI 10.1007/BF01061993; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; RUOCCO NA, 1992, J AM COLL CARDIOL, V20, P1445, DOI 10.1016/0735-1097(92)90435-P; SALAZAR AE, 1961, CIRC RES, V9, P1351, DOI 10.1161/01.RES.9.6.1351; VANLOON BJP, 1992, THROMB HAEMOSTASIS, V67, P101; VOGT A, 1993, J AM COLL CARDIOL, V21, P1391, DOI 10.1016/0735-1097(93)90314-Q; WALKER AM, 1995, NEW ENGL J MED, V332, P1091, DOI 10.1056/NEJM199504203321609	40	204	212	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 4	1996	334	1					7	12		10.1056/NEJM199601043340102	http://dx.doi.org/10.1056/NEJM199601043340102			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TM482	7494588				2023-01-03	WOS:A1996TM48200002
J	KUH, D; STIRLING, S				KUH, D; STIRLING, S			SOCIOECONOMIC VARIATION IN ADMISSION FOR DISEASES OF FEMALE GENITAL SYSTEM AND BREAST IN A NATIONAL COHORT AGED 15-43	BRITISH MEDICAL JOURNAL			English	Article							HYSTERECTOMY; WOMEN; EPIDEMIOLOGY; MENORRHAGIA	Objective-To investigate socioeconomic variation among young women in the risk of hospital admission for diseases (including neoplasms) of the female genital system and breast and for the common surgical procedures of dilatation and curettage and hysterectomy. Design-Large nationally representative cohort study with individual records of confirmed admissions to NHS and private hospitals since birth and data on occupational and educational experience. Setting-England, Scotland, and Wales. Patients-General population sample of 1628 women, 1549 of whom had a complete admissions record for the ages of 15-43 years. Main outcome measures-The percentage of women admitted for neoplasms or other diseases of the female genital system and breast or who had dilatation and curettage or hysterectomy between the ages of 15 and 43 years. Results-By the age of 43, 35% of women had been admitted, 17% had undergone dilatation and curettage at least once, and 10% had had a hysterectomy. There were significant inverse educational gradients, the risk of admission increasing more than twofold between the most and least educated women. The differential risk was most striking for disorders of menstruation, in which only 1% of those with the highest educational qualifications and 19% of those with minimal qualifications had been admitted to hospital. There was a significant educational gradient in the hysterectomy rate (from 1% to 15%) and a twofold difference in the risk of dilatation and curettage. There were also significant gradients in risk of admission and of hysterectomy according to partner's social class. Conclusions-Socioeconomic variations in the risk of dilatation and curettage and of hysterectomy were large. Lessening the socioeconomic gradient in risks of admissions and surgery for diseases of the female genital system. and breast, particularly for menstrual disorders, could have important resource implications.			KUH, D (corresponding author), UNIV LONDON UNIV COLL,SCH MED,DEPT EPIDEMIOL & PUBL HLTH,MED RES COUNCIL NATL SURVEY HLTH DEV,LONDON WC1E 6BT,ENGLAND.		Kuh, Diana/L-6019-2014	Kuh, Diana/0000-0001-7386-2857				BAYER LM, 1981, PRESENT PAST MIDDLE, P55, DOI DOI 10.1016/B978-0-12-233680-5.50009-5; BLAXTER M, 1987, LANCET, V2, P30; BLAXTER N, 1987, HLTH LIFESTYLE SURVE, P5; BOTO TCA, 1990, BRIT J HOSP MED, V44, P93; BRINTON LA, 1986, J CHRON DIS, V39, P1051, DOI 10.1016/0021-9681(86)90139-6; Buchan IC, 1973, TIME STUDY CONSULTAT; CARTWRIGHT A, 1976, SOCIOL REV MONOGR, V22, P77; CENTERWALL BS, 1981, AM J OBSTET GYNECOL, V139, P58, DOI 10.1016/0002-9378(81)90412-9; COLE SK, 1971, J OBSTET GYN BR COMM, V78, P933; COULTER A, 1993, BRIT MED J, V306, P236, DOI 10.1136/bmj.306.6872.236; COULTER A, 1994, FAM PRACT, V11, P67, DOI 10.1093/fampra/11.1.67; COULTER A, 1986, Q J SOC AFF, V2, P379; COULTER A, 1985, BRIT MED J, V291, P183, DOI 10.1136/bmj.291.6489.183; COULTER A, 1995, EUROPEAN J PUBLIC HL, V5, P123; GATH D, 1987, BMJ-BRIT MED J, V294, P213, DOI 10.1136/bmj.294.6566.213; GOLDBLATT P, 1990, 1971 1981 LONGITUDIN, P163; KJERULFF K, 1993, AM J PUBLIC HEALTH, V83, P106, DOI 10.2105/AJPH.83.1.106; MAGOS AL, 1991, LANCET, V337, P1074, DOI 10.1016/0140-6736(91)91718-A; MEILAHN EN, 1989, MATURITAS, V11, P319, DOI 10.1016/0378-5122(89)90028-5; Moser K., 1990, LONGITUDINAL STUDY M, P145; PENDLETON DA, 1980, SOC SCI MED, V36, P669; SIDDLE N, 1987, FERTIL STERIL, V47, P94; VESSEY MP, 1992, BRIT J OBSTET GYNAEC, V99, P402, DOI 10.1111/j.1471-0528.1992.tb13758.x; Wadsworth M E, 1987, Paediatr Perinat Epidemiol, V1, P95, DOI 10.1111/j.1365-3016.1987.tb00093.x; Wadsworth M. E. J., 1991, IMPRINT TIME CHILDHO; WADSWORTH MEJ, 1992, J EPIDEMIOL COMMUN H, V46, P300, DOI 10.1136/jech.46.3.300; 1977, MB4 DEP HLTH SOC SEC; 1972, 1968 1972 DEP HLTH S; 1986, MB5 OFF POP CENS SUR; 1994, INPATIENT TREATMENT; 1982, MB1 OFF POP CENS SUR; 1964, 1961 1966 MIN HLTH G; 1972, BURNHAM FURTHER ED C; 1977, 1973 DEP HLTH SOC SE; 1983, MB4 OFF POP CENS SUR	35	32	33	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 30	1995	311	7009					840	843		10.1136/bmj.311.7009.840	http://dx.doi.org/10.1136/bmj.311.7009.840			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY191	7580490	Green Published			2023-01-03	WOS:A1995RY19100021
J	RAVINA, JH; HERBRETEAU, D; CIRARUVIGNERON, N; BOURET, JM; HOUDART, E; AYMARD, A; MERLAND, JJ				RAVINA, JH; HERBRETEAU, D; CIRARUVIGNERON, N; BOURET, JM; HOUDART, E; AYMARD, A; MERLAND, JJ			ARTERIAL EMBOLIZATION TO TREAT UTERINE MYOMATA	LANCET			English	Note								Haemorrhage, probably related to hypervascularisation, is the commonest complication of uterine myomata and is difficult to treat. 16 patients, aged 34-48 years, with symptomatic uterine myomata, for which a major surgical procedure was planned after failure of medical treatment, were treated by selective free-flow arterial embolisation of the myomata with Ivalon particles. With a mean follow-up of 20 months (range 11-48) in the responders, symptoms resolved in 11 patients; menstrual cycles returned to normal in ten of these. Three patients had partial improvement. Two failures required surgery. In 14 cases embolisation caused pelvic pain, which required analgesia in all.	UNIV PARIS 07,HOP LARIBOISIERE,RADIOL INTERVENT SERV,F-75475 PARIS 10,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	RAVINA, JH (corresponding author), UNIV PARIS 07,HOP LARIBOISIERE,SERV GYNECOL OBSTET,F-75475 PARIS 10,FRANCE.							COHEN J, 1993, 3RD INT S GNRH AN CA, P25; FARRER-BROWN G, 1970, Journal of Obstetrics and Gynaecology of the British Commonwealth, V77, P967; HERBRETEAU D, 1993, ACTUALITE REANIMATIO, P17; RAVINA JH, 1994, PRESSE MED, V23, P1540; Sampson JA, 1912, SURG GYNECOL OBSTET, V14, P215	5	720	874	1	20	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 9	1995	346	8976					671	672		10.1016/S0140-6736(95)92282-2	http://dx.doi.org/10.1016/S0140-6736(95)92282-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU048	7544859				2023-01-03	WOS:A1995RU04800011
J	RICHARDS, JR				RICHARDS, JR			EUTHANASIA	NATURE MEDICINE			English	Editorial Material											RICHARDS, JR (corresponding author), OPEN UNIV,DEPT PHILOSOPHY,MILTON KEYNES MK7 6AA,BUCKS,ENGLAND.								0	0	0	0	0	NATURE PUBLISHING CO	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707	1078-8956			NAT MED	Nat. Med.	JUL	1995	1	7					618	620		10.1038/nm0795-618	http://dx.doi.org/10.1038/nm0795-618			3	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	RQ066	7585133				2023-01-03	WOS:A1995RQ06600026
J	KANE, RL; KANE, RA				KANE, RL; KANE, RA			LONG-TERM-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTH MAINTENANCE ORGANIZATIONS; NURSING-HOME; SERVICES				KANE, RL (corresponding author), UNIV MINNESOTA,SCH PUBL HLTH,MINNEAPOLIS,MN 55455, USA.							ARRAS J, 1995, BRINGING HOSPITAL HO; EUSTIS NN, 1992, GENERATIONS, V16, P17; HARRINGTON C, 1993, GERONTOLOGIST, V33, P790, DOI 10.1093/geront/33.6.790; HARRINGTON C, 1993, INQUIRY-J HEALTH CAR, V30, P429; Kane RA, 1993, ASSISTED LIVING US N; KANE RL, 1992, GERONTOLOGIST, V32, P771, DOI 10.1093/geront/32.6.771; KANE RL, 1983, J GERONTOL, V38, P385, DOI 10.1093/geronj/38.4.385; KANE RL, 1990, GERONTOLOGIST, V30, P291, DOI 10.1093/geront/30.3.291; KANE RL, 1994, GERONTOLOGIST, V34, P598, DOI 10.1093/geront/34.5.598; KANE RL, 1991, NEW ENGL J MED, V324, P627, DOI 10.1056/NEJM199102283240910; MANTON KG, 1994, MED CARE, V32, P277, DOI 10.1097/00005650-199403000-00007; MORRIS JN, 1990, GERONTOLOGIST, V30, P293, DOI 10.1093/geront/30.3.293; NEWCOMER R, 1990, GERONTOLOGIST, V30, P86, DOI 10.1093/geront/30.1.86; NEWCOMER R, 1990, HEALTH SERV RES, V25, P425; SIMONRUSINOWITZ L, 1993, GERONTOLOGIST, V33, P159, DOI 10.1093/geront/33.2.159; 1994, GAOHEHE94167 US GEN; 1994, GAOHEHS9526 US GEN A	17	10	10	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 7	1995	273	21					1690	1691		10.1001/jama.273.21.1690	http://dx.doi.org/10.1001/jama.273.21.1690			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	RB097	7752419				2023-01-03	WOS:A1995RB09700027
J	LOKKEN, P; STRAUMSHEIM, PA; TVEITEN, D; SKJELBRED, P; BORCHGREVINK, CF				LOKKEN, P; STRAUMSHEIM, PA; TVEITEN, D; SKJELBRED, P; BORCHGREVINK, CF			EFFECT OF HOMEOPATHY ON PAIN AND OTHER EVENTS AFTER ACUTE TRAUMA - PLACEBO-CONTROLLED TRIAL WITH BILATERAL ORAL-SURGERY	BRITISH MEDICAL JOURNAL			English	Article							ACETYLSALICYLIC-ACID; POSTOPERATIVE COURSE; SURGICAL REMOVAL; CLINICAL-TRIALS; DRUG EVALUATION; MOLAR TEETH; MODEL	Objective-To examine whether homoeopathy has any effect on pain and other inflammatory events after surgery. Design-Randomised double blind, placebo controlled crossover trial with ''identical'' oral surgical procedures performed on two separate occasions in 24 patients. Interventions-Treatment started 3 hours after surgery with either homoeopathy or placebo. Main outcome measures-Postoperative pain and preference for postoperative course assessed by patients on visual analogue scales. Measurements of postoperative swelling and reduction in ability to open mouth. Assessment of bleeding after surgery. Results-Pain after surgery was essentially the same whether treated with homoeopathy or placebo. Postoperative swelling was not significantly affected by homoeopathy, but treatment tended to give less reduction in ability to open mouth. No noticeable difference was seen in postoperative bleeding, side effects, or complaints. Thirteen of the 24 patients preferred the postoperative course with placebo. Conclusions-No positive evidence was found for efficacy of homoeopathic treatment on pain and other inflammatory events after an acute soft tissue and bone injury inflicted by a surgical intervention. Differences in the order of 30% to 40% would have been needed to show significant effects.	UNIV OSLO,DENT PHARMACOL & PHARMACOTHERAPEUT SECT,N-0316 OSLO,NORWAY; ST HANSHAUGEN MED CTR,N-0168 OSLO,NORWAY; NORWEGIAN INST NAT MED,N-1340 BEKKESTUA,NORWAY; OSLO CITY HOSP,MAXILLOFACIAL SURG SECT,N-0407 OSLO,NORWAY; UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO,NORWAY	University of Oslo; University of Oslo								Albertini H, 1985, J AM I HOMEOPATH, V3, P126; ALBUM B, 1977, INT J ORAL MAXILLOF, V6, P177, DOI 10.1016/S0300-9785(77)80051-3; BUCKMAN R, 1994, BRIT MED J, V309, P103, DOI 10.1136/bmj.309.6947.103; Campbell A., 1976, BR HOMOEOPATH J, V65, P154; FRISON L, 1992, STAT MED, V11, P1685, DOI 10.1002/sim.4780111304; GIBSON DM, 1972, BRIT HOMOEOPATHY J, V61, P167; IVES G, 1984, COMMUNICATIONS MIDLA, V11, P71; Jones B., 2015, DESIGN ANAL CROSS OV, V3rd; KAZIRO GSN, 1984, BRIT J ORAL MAX SURG, V22, P42, DOI 10.1016/0266-4356(84)90007-X; KLEIJNEN J, 1991, BRIT MED J, V302, P316, DOI 10.1136/bmj.302.6772.316; LESSELL CB, 1983, DENTAL PRESCRIBER; LOKKEN P, 1975, EUR J CLIN PHARMACOL, V8, P209, DOI 10.1007/BF00567117; LOKKEN P, 1980, BR J CLIN PHARM, V10, P27; MCIVOR EG, 1973, J AM I HOMOEOPATHY, V66, P81; MEURIS J, 1981, HEMEOPATHIE ODONTOST; PINSENT RJ, 1986, COMMUN BR HOMOEOPATH, V15, P3; Righetti M, 1988, FORSCHUNG HOMOOPATHI; SKJELBRED P, 1982, EUR J CLIN PHARMACOL, V21, P391, DOI 10.1007/BF00542325; SKJELBRED P, 1983, BRIT J CLIN PHARMACO, V15, P221, DOI 10.1111/j.1365-2125.1983.tb01489.x; SKJELBRED P, 1984, BRIT J CLIN PHARMACO, V17, P379, DOI 10.1111/j.1365-2125.1984.tb02361.x; SKJELBRED P, 1977, EUR J CLIN PHARMACOL, V12, P257, DOI 10.1007/BF00607424; SKJELBRED P, 1980, EUR J CLIN PHARMACOL, V18, P327, DOI 10.1007/BF00561390; 1991, HOMOOPATHISCHES ARZE	23	41	44	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 3	1995	310	6992					1439	1442		10.1136/bmj.310.6992.1439	http://dx.doi.org/10.1136/bmj.310.6992.1439			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RC105	7613277	Green Published			2023-01-03	WOS:A1995RC10500018
J	SANCHEZGUERRERO, J; LIANG, MH; KARLSON, EW; HUNTER, DJ; COLDITZ, GA				SANCHEZGUERRERO, J; LIANG, MH; KARLSON, EW; HUNTER, DJ; COLDITZ, GA			POSTMENOPAUSAL ESTROGEN THERAPY AND THE RISK FOR DEVELOPING SYSTEMIC LUPUS-ERYTHEMATOSUS	ANNALS OF INTERNAL MEDICINE			English	Note							LOW PLASMA ANDROGENS; PROSPECTIVE COHORT; WOMEN; GLOMERULONEPHRITIS; PATHOGENESIS; SURVIVAL; MICE	Objective: To examine the relation between postmenopausal hormone use and development of systemic lupus erythematosus. Design: Prospective cohort study. Setting: Nurses' Health Study. Patients: 69 435 women aged 30 to 55 years in 1976 who reported that they had completed menopause and did not have systemic lupus erythematosus or any connective tissue disease were followed every 2 years from 1976 to 1990. These women were classified as never- or ever-(current and past) users of postmenopausal hormones. Measurements: Incidence rates of systemic lupus erythematosus and classification criteria from the American College of Rheumatology that were confirmed by chart review. Results: With never-users of postmenopausal hormones as the reference group, age-adjusted relative risks for systemic lupus erythematosus (n = 45 women) were 2.1 (95% CI, 1.1 to 4.0) for ever-users, 2.5 (CI, 1.2 to 5.0) for current users, and 1.8 (CI, 0.8 to 4.1) for past users. A proportional increase in the risk for systemic lupus erythematosus was observed that was related to the duration of use of postmenopausal hormones (test for trend, P = 0.011). Conclusions: Postmenopausal hormone therapy is associated with an increased risk for developing systemic lupus erythematosus.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health			Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	FOGARTY INTERNATIONAL CENTER [F05TW004573] Funding Source: NIH RePORTER; FIC NIH HHS [5F05 TW04573-02] Funding Source: Medline; NCI NIH HHS [CA 40396] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALARCONSEGOVIA D, 1984, J RHEUMATOL, V11, P588; COHEN JHM, 1983, J IMMUNOL, V131, P2767; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; GOLDMAN L, 1991, NEW ENGL J MED, V325, P800, DOI 10.1056/NEJM199109123251108; HILL AB, 1965, P ROY SOC MED, V58, P295, DOI 10.1177/003591576505800503; JUNGERS P, 1982, ARTHRITIS RHEUM, V25, P454, DOI 10.1002/art.1780250415; KARLSON EW, 1995, IN PRESS ANN EPIDEMI; KELLEY VE, 1980, CLIN IMMUNOL IMMUNOP, V16, P142, DOI 10.1016/0090-1229(80)90198-1; LAHITA RG, 1981, J CLIN ENDOCR METAB, V53, P174, DOI 10.1210/jcem-53-1-174; LAHITA RG, 1987, ARTHRITIS RHEUM, V30, P241, DOI 10.1002/art.1780300301; MASI AT, 1978, ARTHRITIS RHEUM-US, V21, P480, DOI 10.1002/art.1780210413; ROTHMAN KJ, 1979, PHS NIH791649 PUBL; ROUBINIAN JR, 1979, J CLIN INVEST, V63, P902, DOI 10.1172/JCI109390; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; Silman AJ, 1993, EPIDEMIOLOGY RHEUMAT, P163; TAN EM, 1982, ARTHRITIS RHEUM, V25, P1271, DOI 10.1002/art.1780251101; Tosteson Anna N. A., 1994, P405	18	165	177	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572	0003-4819			ANN INTERN MED	Ann. Intern. Med.	MAR 15	1995	122	6					430	433		10.7326/0003-4819-122-6-199503150-00005	http://dx.doi.org/10.7326/0003-4819-122-6-199503150-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QM266	7856991				2023-01-03	WOS:A1995QM26600005
J	MISHRA, VK; PALGUNACHARI, MN; LUNDKATZ, S; PHILLIPS, MC; SEGREST, JP; ANANTHARAMAIAH, GM				MISHRA, VK; PALGUNACHARI, MN; LUNDKATZ, S; PHILLIPS, MC; SEGREST, JP; ANANTHARAMAIAH, GM			EFFECT OF THE ARRANGEMENT OF TANDEM REPEATING UNITS OF CLASS-A AMPHIPATHIC ALPHA-HELIXES ON LIPID INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHETIC PEPTIDE ANALOGS; APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; PERFORMANCE LIQUID-CHROMATOGRAPHY; CHOLESTEROL ACYLTRANSFERASE; PROTEIN INTERACTIONS; PLASMA LIPOPROTEINS; TRYPTOPHAN RESIDUES; SECONDARY STRUCTURE; WATER INTERFACE	Exchangeable apolipoproteins possess tandem repeating units of class A amphipathic helical segments and many of them are linked together by proline residues. To understand the optimal arrangement of the amphipathic helixes for lipid association, we have studied the interactions of three model class A amphipathic helical peptides with lipids. The three peptides are: 37pA, a dimer of 18A (DWLKAFYDKVAEKLKEAF) linked together by a Pro (18A-Pro-18A); 37aA, a dimer of 18A linked together by an Ala (18A-Ala-18A); and 36A, a dimer of 18A without any linker residue (18A-18A). Circular dichroism (CD) spectra showed that the peptides are predominantly alpha-helical in aqueous and lipid environments. Temperature dependent CD studies indicated that in buffer helix stability decreases in the order 36A > 37aA > 37pA; however, in the presence of dimyristoyl phosphatidylcholine (DMPC), the above order is reversed. The retention times of the peptides on a C-18 reversed-phase high performance liquid chromatography column decreased in the order 36A > 37aA > 37pA, consistent with the lengths of the nonpolar faces of the alpha-helixes being in the same order; the retention time of the parent 18A was shorter than 37pA. While 37pA adsorbed to egg phosphatidylcholine monolayers most strongly, the degree and rate of association of 36A were significantly lower. Differential scanning calorimetry indicated that, while 37pA was most effective in reducing the enthalpy of the gel to liquid-crystalline phase transition of DMPC multilamellar vesicles, 36A was least effective; 36A was even less effective than 18A. Fluorescence quenching experiments with iodide and acrylamide indicated that, in the presence of DMPC, Trp residues in 36A are most exposed to the quenchers while in 37pA they are least exposed. In the presence of DMPC, shielding of Trp in 18A from the quenchers was more than that observed with Trp residues in 36A. The results of this study suggest that the arrangement of tandem repeating amphipathic helical units which results in the formation of a class A amphipathic helix with a nonpolar face longer than five or six turns reduces the ability of the helix to associate with phospholipid.	UNIV ALABAMA,MED CTR,DEPT MED,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,DEPT BIOCHEM,BIRMINGHAM,AL 35294; UNIV ALABAMA,MED CTR,ATHEROSCLEROSIS RES INST,BIRMINGHAM,AL 35294; MED COLL PENN,DEPT BIOCHEM,PHILADELPHIA,PA 19129	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Drexel University			Mishra, Vinod/S-1151-2019	Mishra, Vinod/0000-0002-4527-1512; Phillips, Michael/0000-0002-7147-8007	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034343, P01HL022633] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34343, HL22633] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGUILAR MI, 1993, J CHROMATOGR, V646, P53, DOI 10.1016/S0021-9673(99)87007-1; ANANTHARAMAIAH GM, 1986, METHOD ENZYMOL, V128, P627; ANANTHARAMAIAH GM, 1990, ARTERIOSCLEROSIS, V10, P95, DOI 10.1161/01.ATV.10.1.95; ANANTHARAMAIAH GM, 1985, J BIOL CHEM, V260, P248; Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BLONDELLE SE, 1993, BIOCHIM BIOPHYS ACTA, V1202, P331, DOI 10.1016/0167-4838(93)90024-L; BRASSEUR R, 1991, J BIOL CHEM, V266, P16120; BROUILLETTE CG, 1984, BIOCHEMISTRY-US, V23, P359, DOI 10.1021/bi00297a027; CHUNG BH, 1985, J BIOL CHEM, V260, P256; CORIJN J, 1993, BIOCHIM BIOPHYS ACTA, V1170, P8, DOI 10.1016/0005-2760(93)90169-A; DEKROON AIP, 1990, BIOCHEMISTRY-US, V29, P8229, DOI 10.1021/bi00488a006; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; JORGENSEN EV, 1989, J BIOL CHEM, V264, P9215; KURZBAN GP, 1989, BIOCHEMISTRY-US, V28, P8537, DOI 10.1021/bi00447a040; Lakowicz J.R., 2006, PRINCIPLES FLUORESCE, VThird, DOI 10.1007/978-0-387-46312-4; LAU SYM, 1984, J CHROMATOGR, V317, P129, DOI 10.1016/S0021-9673(01)91653-X; LEVINE DM, 1993, P NATL ACAD SCI USA, V90, P12040, DOI 10.1073/pnas.90.24.12040; LIU DX, 1990, BIOCHEMISTRY-US, V29, P3637, DOI 10.1021/bi00467a008; Marsh D., 2013, HDB LIPID BILAYERS; MCLEAN LR, 1991, BIOCHEMISTRY-US, V30, P31, DOI 10.1021/bi00215a005; MISHRA VK, 1994, J BIOL CHEM, V269, P7185; MORRISET.JD, 1973, BIOCHEMISTRY-US, V12, P1290, DOI 10.1021/bi00731a008; MORRISETT JD, 1977, BIOCHIM BIOPHYS ACTA, V472, P93, DOI 10.1016/0304-4157(77)90015-6; NAKAGAWA SH, 1985, J AM CHEM SOC, V107, P7087, DOI 10.1021/ja00310a055; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; PONSIN G, 1986, J BIOL CHEM, V261, P9202; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; SEGREST JP, 1992, J LIPID RES, V33, P141; SONNICHSEN FD, 1992, BIOCHEMISTRY-US, V31, P8790, DOI 10.1021/bi00152a015; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; SPARROW JT, 1992, BIOCHEMISTRY-US, V31, P1065, DOI 10.1021/bi00119a015; THIAUDIERE E, 1993, BIOCHEMISTRY-US, V32, P12186, DOI 10.1021/bi00096a031; VENKATACHALAPATHI, 1993, PROTEINS, V15, P349; WESTERLUND JA, 1993, J BIOL CHEM, V268, P15745; Woody RW, 1985, PEPTIDES ANAL SYNTHE, P15; ZHOU N E, 1990, Peptide Research, V3, P8; [No title captured]	42	33	46	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 27	1995	270	4					1602	1611		10.1074/jbc.270.4.1602	http://dx.doi.org/10.1074/jbc.270.4.1602			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QD204	7829491	hybrid			2023-01-03	WOS:A1995QD20400021
J	MURRAY, JL; BERNFIELD, M				MURRAY, JL; BERNFIELD, M			THE DIFFERENTIAL EFFECT OF PRENATAL-CARE ON THE INCIDENCE OF LOW BIRTH-WEIGHT AMONG BLACKS AND WHITES IN A PREPAID HEALTH-CARE PLAN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									STANFORD UNIV,MED CTR,SCH MED,DEPT PEDIAT,DIV NEONATAL & DEV BIOL,STANFORD,CA 94305	Stanford University								ALLEN WR, 1981, PHYLON, V42, P26, DOI 10.2307/274882; BINKIN NJ, 1988, AM J DIS CHILD, V142, P434, DOI 10.1001/archpedi.1988.02150040088026; DAVID RJ, 1980, AM J PUBLIC HEALTH, V70, P964, DOI 10.2105/AJPH.70.9.964; ERICKSON JD, 1982, JAMA-J AM MED ASSOC, V247, P987; GORTMAKER SL, 1979, AM J PUBLIC HEALTH, V69, P653, DOI 10.2105/AJPH.69.7.653; GREENBERG RS, 1983, AM J OBSTET GYNECOL, V145, P797, DOI 10.1016/0002-9378(83)90681-6; HULKA BS, 1975, MED CARE, V13, P648, DOI 10.1097/00005650-197508000-00004; KESSEL SS, 1984, JAMA-J AM MED ASSOC, V251, P1978, DOI 10.1001/jama.251.15.1978; KESSNER DM, 1973, INFANT DEATH ANAL MA; KLEINMAN JC, 1987, NEW ENGL J MED, V317, P749, DOI 10.1056/NEJM198709173171207; KORENBROT CC, 1984, RES HIGHLIGHTS, V2; LIEBERMAN E, 1987, NEW ENGL J MED, V317, P743, DOI 10.1056/NEJM198709173171206; MCCORMICK MC, 1985, NEW ENGL J MED, V312, P82, DOI 10.1056/NEJM198501103120204; MOSES LE, 1984, NEW ENGL J MED, V311, P442, DOI 10.1056/NEJM198408163110705; PANETH N, 1982, NEW ENGL J MED, V307, P149, DOI 10.1056/NEJM198207153070303; PAPIERNIK E, 1984, CLIN OBSTET GYNECOL, V27, P614, DOI 10.1097/00003081-198409000-00010; PAPIERNIK E, 1985, PEDIATRICS, V76, P154; PENCHANSKY R, 1981, MED CARE, V19, P127, DOI 10.1097/00005650-198102000-00001; QUICK JD, 1981, AM J PUBLIC HEALTH, V71, P381, DOI 10.2105/AJPH.71.4.381; Scheffe H., 1959, WILEY SERIES PROBABI; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P48, DOI 10.1001/jama.255.1.48; SHOWSTACK JA, 1984, AM J PUBLIC HEALTH, V74, P1003, DOI 10.2105/AJPH.74.9.1003; THOMAS JW, 1984, MED CARE, V22, P553, DOI 10.1097/00005650-198406000-00006; VANSCOTTER RD, 1985, SOCIAL F ED; WALLACE HM, 1979, CLIN PEDIATR, V18, P213, DOI 10.1177/000992287901800404; WILLIAMS R, 1981, 1978 CALIFORNIA BIRT; WILLIAMS RL, 1982, NEW ENGL J MED, V306, P207, DOI 10.1056/NEJM198201283060404; WISE PH, 1985, NEW ENGL J MED, V313, P360, DOI 10.1056/NEJM198508083130605; [No title captured]; 1980, VITAL HLTH STATIS 21, V37; [No title captured]; 1985, CURRENT PRICE INDEX; 1986, CURRENT PRICE INDEX	33	142	144	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	1988	319	21					1385	1391		10.1056/NEJM198811243192105	http://dx.doi.org/10.1056/NEJM198811243192105			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	Q9919	3185649				2023-01-03	WOS:A1988Q991900005
J	MURPHY, DJ				MURPHY, DJ			DO-NOT-RESUSCITATE ORDERS - TIME FOR REAPPRAISAL IN LONG-TERM CARE INSTITUTIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									BETH ISRAEL HOSP,HEBREW REHABIL CTR AGED,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School					NIA NIH HHS [AG00599] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMUNDSEN DW, 1978, HASTINGS CENT REP, V8, P23, DOI 10.2307/3560974; ARENA FP, 1980, CRIT CARE MED, V8, P733, DOI 10.1097/00003246-198012000-00007; BACHMAN JW, 1986, JAMA-J AM MED ASSOC, V256, P477, DOI 10.1001/jama.256.4.477; BALL JR, 1984, J AM GERIATR SOC, V32, P528, DOI 10.1111/j.1532-5415.1984.tb02239.x; BAUM RS, 1974, CIRCULATION, V50, P1231, DOI 10.1161/01.CIR.50.6.1231; BAYER AJ, 1985, AGE AGEING, V14, P271, DOI 10.1093/ageing/14.5.271; BEDELL SE, 1984, NEW ENGL J MED, V310, P1089, DOI 10.1056/NEJM198404263101706; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BESDINE RW, 1983, J AM GERIATR SOC, V31, P602, DOI 10.1111/j.1532-5415.1983.tb04602.x; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRAITHWAITE S, 1986, ANN INTERN MED, V104, P711, DOI 10.7326/0003-4819-104-5-711; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; Callahan D, 1987, SETTING LIMITS; CHILDRESS JF, 1984, HASTINGS CENT REP, V14, P27, DOI 10.2307/3561094; CUMMINS RO, 1985, JAMA-J AM MED ASSOC, V253, P2408, DOI 10.1001/jama.253.16.2408; EMANUEL EJ, 1988, LANCET, V1, P170; FUSGEN I, 1978, GERONTOLOGY, V24, P37; GADOW S, 1980, GERONTOLOGIST, V20, P680, DOI 10.1093/geront/20.6.680; GORDON M, 1984, J AM GERIATR SOC, V32, P930, DOI 10.1111/j.1532-5415.1984.tb00895.x; GULATI RS, 1983, LANCET, V2, P267; HERSHEY CO, 1982, LANCET, V1, P31, DOI 10.1016/S0140-6736(82)92567-3; IMBUS SH, 1977, NEW ENGL J MED, V297, P308, DOI 10.1056/NEJM197708112970605; JONSEN AR, 1978, ANN INTERN MED, V88, P827, DOI 10.7326/0003-4819-88-6-827; JONSEN AR, 1982, CLIN ETHICS; KAPP MB, 1986, MILBANK Q, V64, P163, DOI 10.2307/3349962; LANTOS JD, 1988, NEW ENGL J MED, V318, P91, DOI 10.1056/NEJM198801143180206; LEVINSON W, 1987, J AM GERIATR SOC, V35, P1059, DOI 10.1111/j.1532-5415.1987.tb04921.x; LIBERTHSON RR, 1974, NEW ENGL J MED, V291, P317, DOI 10.1056/NEJM197408152910701; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LOEWY EH, 1987, NEW ENGL J MED, V317, P1465, DOI 10.1056/NEJM198712033172308; MARSH FH, 1986, CLIN GERIATRIC MED E; MESSERT B, 1976, LANCET, V2, P410; MILES SH, 1982, ANN INTERN MED, V96, P660, DOI 10.7326/0003-4819-96-5-660; MURPHY DJ, 1987, GERONTOLOGIST, V27, pA230; PEATFIELD RC, 1977, LANCET, V1, P1223; PERRY CB, 1985, J AM GERIATR SOC, V33, P353, DOI 10.1111/j.1532-5415.1985.tb07136.x; RABKIN MT, 1976, NEW ENGL J MED, V295, P364, DOI 10.1056/NEJM197608122950705; RAMSEY P, 1976, HASTINGS CENT REP, V6, P14, DOI 10.2307/3560354; RUARK JE, 1988, NEW ENGL J MED, V318, P25, DOI 10.1056/NEJM198801073180106; SAPHIR R, 1968, MEDICINE, V47, P73, DOI 10.1097/00005792-196801000-00004; SCHNEIDERMAN LJ, 1988, NEW ENGL J MED, V318, P984, DOI 10.1056/NEJM198804143181509; SCHRAM RB, 1978, NEW ENGL J MED, V299, P875, DOI 10.1056/NEJM197810192991608; STEINBROOK R, 1988, NEW ENGL J MED, V318, P286, DOI 10.1056/NEJM198802043180505; STEPHENS RL, 1986, JAMA-J AM MED ASSOC, V255, P240; THOMASMA DC, 1984, J AM GERIATR SOC, V32, P906, DOI 10.1111/j.1532-5415.1984.tb00892.x; THOMPSON RG, 1979, ANN INTERN MED, V90, P737, DOI 10.7326/0003-4819-90-5-737; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; UHLMANN RF, 1987, ANN INTERN MED, V106, P879, DOI 10.7326/0003-4819-106-6-879; VOLICER L, 1986, JAMA-J AM MED ASSOC, V256, P2210, DOI 10.1001/jama.256.16.2210; WAGNER A, 1984, NEW ENGL J MED, V310, P1129, DOI 10.1056/NEJM198404263101732; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; 1987, GUIDELINES TERMINATI; 1986, PHS871232 US DEP HLT; 1986, JAMA, V255, P2933; 1987, ACCREDITATION MANUAL; 1982, 03835158673 PUBL, V1; 1988, LONG TERM CARE STAND; 1983, 0402884 PUBL; 1987, OTABA306 US C OFF TE; 1986, CURRENT OPINIONS COU, P12	61	122	122	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2098	2101		10.1001/jama.260.14.2098	http://dx.doi.org/10.1001/jama.260.14.2098			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3138439				2023-01-03	WOS:A1988Q342100027
J	SUNDRAM, CJ				SUNDRAM, CJ			INFORMED CONSENT FOR MAJOR MEDICAL-TREATMENT OF MENTALLY-DISABLED PEOPLE - A NEW APPROACH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article											SUNDRAM, CJ (corresponding author), NEW YORK STATE COMMISS QUAL CARE MENTALLY DISABLED,99 WASHINGTON AVE,SUITE 1002,ALBANY,NY 12210, USA.							BRAKEL SJ, 1985, MENTALLY DISABLED LA, P447; EYMAN RK, 1986, MENT RETARD, V24, P301; GUTHEIL TG, 1983, HASTINGS CENT REP, V13, P8, DOI 10.2307/3561610; HALL RCW, 1982, HOSP COMMUNITY PSYCH, V33, P25; Marzen Thomas J, 1986, Issues Law Med, V1, P293; MCCARRICK AK, 1986, HOSP COMMUNITY PSYCH, V37, P289; ROSOFF AJ, 1981, INFORMED CONSENT GUI, P337; STAVIS PF, 1986, NY L J          0310, P1; WARREN JW, 1986, NEW ENGL J MED, V315, P1124, DOI 10.1056/NEJM198610303151804; 1978, ELECTROCONVULSIVE TH; 1982, 03835158673 PUBL; 1981, 3565399903 PUBL	12	15	15	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	1988	318	21					1368	1373		10.1056/NEJM198805263182105	http://dx.doi.org/10.1056/NEJM198805263182105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	N5438	3367937				2023-01-03	WOS:A1988N543800005
J	VAUX, KL				VAUX, KL			DEBBIES DYING - MERCY KILLING AND THE GOOD DEATH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											VAUX, KL (corresponding author), UNIV ILLINOIS,DEPT ETH MED,CHICAGO,IL 60680, USA.							[Anonymous], 1988, JAMA, V259, P272; RAMSEY P, 1983, PATIENTS PERSON, P163; 1983, DECISIONS FOREGO LIF, P294	3	26	26	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 8	1988	259	14					2140	2141		10.1001/jama.259.14.2140	http://dx.doi.org/10.1001/jama.259.14.2140			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M7414	3346990				2023-01-03	WOS:A1988M741400032
J	STEINBROOK, R; LO, B				STEINBROOK, R; LO, B			ARTIFICIAL FEEDING - SOLID GROUND, NOT A SLIPPERY SLOPE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV CALIF SAN FRANCISCO,DIV GEN INTERNAL MED,BOX 0320,RM A405,400 PARNASSUS AVE,SAN FRANCISCO,CA 94143; LOS ANGELES TIMES,LOS ANGELES,CA 90053	University of California System; University of California San Francisco								ANNAS GJ, 1986, MILBANK Q, V64, P95, DOI 10.2307/3349961; BUCHANAN A, 1986, MILBANK Q, V64, P17, DOI 10.2307/3349960; LO B, 1984, NEW ENGL J MED, V311, P402, DOI 10.1056/NEJM198408093110611; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LO B, 1986, ANN INTERN MED, V104, P869, DOI 10.7326/0003-4819-104-6-869; LYNN J, 1983, HASTINGS CENT REP, V13, P17, DOI 10.2307/3560572; MILLER A, 1985, WESTERN J MED, V143, P256; President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, 1983, DECIDING FOREGO LIFE; SCHNEIDERMAN LJ, 1985, ANN INTERN MED, V102, P693, DOI 10.7326/0003-4819-102-5-693; SIEGLER M, 1985, ARCH INTERN MED, V145, P129, DOI 10.1001/archinte.145.1.129; STEINBROOK R, 1986, ARCH INTERN MED, V146, P161, DOI 10.1001/archinte.146.1.161; STEINBROOK R, 1984, NEW ENGL J MED, V310, P1598, DOI 10.1056/NEJM198406143102411; STEINBROOK R, 1986, NEW ENGL J MED, V314, P457, DOI 10.1056/NEJM198602133140730; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; 1987, GUIDELINES REGARDING; 1986, WITHHOLDING WITHDRAW; 1986, LANCET, V1, P306; 1987, GUIDELINES TERMINATI; 1985, PRINCIPLES GUIDELINE; 1987, HDB LIVING WILL LAWS	20	73	73	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 4	1988	318	5					286	290		10.1056/NEJM198802043180505	http://dx.doi.org/10.1056/NEJM198802043180505			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L9231	3122046				2023-01-03	WOS:A1988L923100005
J	MACARTHUR, A; MACARTHUR, C; WEEKS, S				MACARTHUR, A; MACARTHUR, C; WEEKS, S			EPIDURAL-ANESTHESIA AND LOW-BACK-PAIN AFTER DELIVERY - A PROSPECTIVE COHORT STUDY	BRITISH MEDICAL JOURNAL			English	Article							LONG-TERM BACKACHE; CHILDBIRTH	Objective-To determine whether epidural anaesthesia during labour and delivery is a risk factor for postpartum back pain. Design-Prospective cohort study with follow up at one day, seven days, and six weeks after delivery. Setting-Teaching hospital in Montreal. Subjects-329 women who delivered a live infant(s) during the study period, Exclusion criteria were back pain before pregnancy and delivery by elective caesarean section. Intervention-Epidural anaesthesia during labour and delivery. Main outcome measures and results-The primary outcome variable was development of postpartum low back pain, Back pain was quantified with self reports (yes/no), a pain score (numeric rating scale), and degree of interference with daily activities. Of the 329 women, 164 received epidural anaesthesia during labour and 165 did not. The incidence of low back pain in epidural v non-epidural group was 53% v 43% on day one; 21% v 23% on day seven; and 14% v 7% at six weeks, The relative risk for low back pain (epidural v non-epidural) adjusted for parity, delivery, ethnicity, and weight was 1.76 (95% confidence interval 1.06 to 2.92) on day one; 1.00 (0.54 to 1.86) on day seven; and 2.22 (0.89 to 5.53) at six weeks. There were no differences between the two groups in pain scores or the frequency of interference with daily activities. Similar results were obtained in the subgroup of women with low back pain of new onset-that is, those women with no back pain during their pregnancy, Conclusions-Postpartum low back pain was common but decreased considerably over the short term, The association between epidural anaesthesia and postpartum low back pain was inconsistent over time with a significantly increased risk of low back pain (epidural v non-epidural) noted only on the first day after delivery.	ROYAL VICTORIA HOSP,DEPT ANAESTHESIA,MONTREAL,PQ H3A 1A1,CANADA; MCGILL UNIV,DEPT EPIDEMIOL & BIOSTAT,MONTREAL,PQ,CANADA	McGill University; Royal Victoria Hospital; McGill University			MacArthur, Christine/ABA-8601-2021	MacArthur, Christine/0000-0003-0434-2158				Alexander J T, 1993, Neurosurg Clin N Am, V4, P153; BREEN TW, 1994, ANESTHESIOLOGY, V81, P29, DOI 10.1097/00000542-199407000-00006; FRYMOYER JW, 1988, NEW ENGL J MED, V318, P291, DOI 10.1056/NEJM198802043180506; GREEN LW, 1970, PUBLIC HEALTH REP, V85, P815, DOI 10.2307/4593972; Hosmer D.W., 1989, APPL LOGISTIC REGRES, P1; JENSEN MP, 1986, PAIN, V27, P117, DOI 10.1016/0304-3959(86)90228-9; KITZINGER S, 1987, SOME WOMENS EXPERIEN; KRAMER MS, 1988, CLIN EPIDEMIOLOGY BI, P165; MACARTHUR C, 1990, BRIT MED J, V301, P9, DOI 10.1136/bmj.301.6742.9; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; RUSSELL R, 1993, BRIT MED J, V306, P1299, DOI 10.1136/bmj.306.6888.1299	11	52	54	1	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1336	1339		10.1136/bmj.311.7016.1336	http://dx.doi.org/10.1136/bmj.311.7016.1336			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496283	Green Published			2023-01-03	WOS:A1995TF90100020
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PROPOSED RULE RESTRICTING SALE OF TOBACCO PRODUCTS TO CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0811, V60, P41313	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2023-01-03	WOS:A1995RY05600007
J	NEWTON, JN; HENDERSON, J; GOLDACRE, MJ				NEWTON, JN; HENDERSON, J; GOLDACRE, MJ			WAITING LIST DYNAMICS AND THE IMPACT OF EARMARKED FUNDING	BRITISH MEDICAL JOURNAL			English	Article							MANAGEMENT	Objective-To determine how changes in the number of admissions from waiting lists and changes in the number of additions to the lists are related to list size and waiting times, in the context of local waiting list initiatives. Design-Review of national and Korner statistics. Setting-England (1987-94) and districts of the former Oxford region (1987-91). Main outcome measures-Correlation of quarterly changes in the number of admissions from waiting Lists in England with changes in total list size, numbers of patients waiting one to two, or over two years, and number of additions to the lists; examination of changes in waiting list statistics for individual district specialties in one region in relation to funding for waiting list initiatives. Results-Nationally, changes in the number of admissions to hospital from lists closely correlated with changes in the number of additions to lists (r=0.84; P<0.01). After adjusting for changes in the number of additions to lists, changes in the number of admissions correlated inversely with changes in List size (r=-0.62; P<0.001), Decreases in the number of patients waiting from one to two years were significantly associated with increases in the number of admissions (r=-0.52; P<0.01); locally, only six of 44 waiting list initiatives were followed by an increase in admissions and a fall in list size, although a further 11 were followed by a fall in list size without a corresponding increase in admissions. Conclusions-An increase in admissions improved waiting times but did not reduce list size because additions to the list tended to increase at the same time. The appropriateness of waiting list initiatives as a method of funding elective surgery should be reviewed.			NEWTON, JN (corresponding author), UNIV OXFORD,HLTH CARE EPIDEMIOL UNIT,OXFORD OX3 7LF,ENGLAND.		Newton, John/HCH-8693-2022	Newton, John/0000-0002-5641-6457; Henderson, Jane/0000-0001-7527-694X				Arnstein P M, 1991, Br J Plast Surg, V44, P553, DOI 10.1016/0007-1226(91)90029-J; Frankel S, 1989, Health Trends, V21, P56; GOLDACRE MJ, 1987, BRIT MED J, V295, P1105, DOI 10.1136/bmj.295.6606.1105; HEMINGWAY H, 1995, BRIT MED J, V310, P818, DOI 10.1136/bmj.310.6983.818; MILLS RP, 1991, J ROY SOC MED, V84, P405, DOI 10.1177/014107689108400709; Naylor C D, 1994, Qual Health Care, V3, P221, DOI 10.1136/qshc.3.4.221; PARMAR JR, 1993, ANN ROY COLL SURG, V75, P4; POPE C, 1991, SOCIOL HEALTH ILL, V13, P193, DOI 10.1111/1467-9566.ep11340798; POPE C, 1992, BRIT MED J, V305, P577, DOI 10.1136/bmj.305.6853.577; Umeh H N, 1994, Ann R Coll Surg Engl, V76, P4; WILLIAMS M, 1992, EPIDEMIOLOGICALLY BA; 1992, HLTH SERVICE CHARTER; 1994, EL9490 NHS EX; 1992, 4TH REPORT PROGR NHS; 1987, HOSPITAL WAITING STA; 1909, REVISED EXPANDED PAT; 1995, BRIT MED J, V310, P1045	17	27	27	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	SEP 23	1995	311	7008					783	785		10.1136/bmj.311.7008.783	http://dx.doi.org/10.1136/bmj.311.7008.783			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX107	7580440	Green Published			2023-01-03	WOS:A1995RX10700021
J	HARMER, M; DAVIES, KA; LUNN, JN				HARMER, M; DAVIES, KA; LUNN, JN			A SURVEY OF ACUTE PAIN SERVICES IN THE UNITED-KINGDOM	BRITISH MEDICAL JOURNAL			English	Article											HARMER, M (corresponding author), UNIV WALES COLL CARDIFF,COLL MED,DEPT ANAESTHET & INTENS CARE MED,HEATH PK,CARDIFF CF4 4XW,S GLAM,WALES.							CARTWRIGHT PD, 1991, ANAESTHESIA, V46, P188, DOI 10.1111/j.1365-2044.1991.tb09406.x; GOULD TH, 1992, BRIT MED J, V305, P1187, DOI 10.1136/bmj.305.6863.1187; WHEATLEY RG, 1991, BRIT J ANAESTH, V67, P353, DOI 10.1093/bja/67.3.353; 1990, PAIN SURGERY; 1992, PAIN DISCOMFORT PALL	5	29	29	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 5	1995	311	7001					360	361		10.1136/bmj.311.7001.360	http://dx.doi.org/10.1136/bmj.311.7001.360			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN469	7640541	Green Published			2023-01-03	WOS:A1995RN46900015
J	JAMES, SR; PATERSON, A; HARDEN, TK; DOWNES, CP				JAMES, SR; PATERSON, A; HARDEN, TK; DOWNES, CP			KINETIC-ANALYSIS OF PHOSPHOLIPASE C-BETA ISOFORMS USING PHOSPHOLIPID-DETERGENT MIXED MICELLES - EVIDENCE FOR INTERFACIAL CATALYSIS INVOLVING DISTINCT MICELLE BINDING AND CATALYTIC STEPS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNITS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ACTIVATION; C-DELTA-1; STIMULATION; HYDROLYSIS; VESICLES; ENZYMES; ASSOCIATION; BRAIN	Phosphatidylinositol 4,5-bisphosphate (PtdIns (4,5)P-2) hydrolysis by three different beta-isoforms of phospholipase C (PLC) was examined to investigate the catalytic action of these extracellular signal-regulated enzymes. Depletion of phospholipase C from solution by incubation with sucrose-loaded vesicles of differing compositions followed by ultracentrifugation demonstrated stable attachment of PLC to the vesicles from which an equilibrium association constant of PLC with PtdIns (4,5)P-2 could be determined. A mixed micellar system was established to assay PLC activity using dodecyl maltoside, which behaved as an essentially inert diluent of PtdIns (4,5)P-2 with respect to PLC beta activity. Kinetic analyses were performed to test whether PLC beta activity was dependent on both bulk PtdIns (4,5)P-2 concentration and surface concentration in the micelles as has been shown for other lipid metabolising enzymes. Each of the PLC beta isoforms behaved similarly in these analyses, which indicated the involvement of at least two binding events. Interfacial Michaelis constants were calculated to be between 0.1-0.2 mol fraction for all three enzymes, and K-s (the equilibrium dissociation constant of PLC for lipid) ranged between 100-200 mu M. The apparent multiple interfacial binding events did not appear to result from lipid-induced PLC beta oligomerization implying that PLC beta monomers possess more than one lipid-binding site, Surface dilution of PLC catalyzed PtdIns (4,5)P-2 hydrolysis was assessed in the presence of increasing concentrations of various nonsubstrate phospholipids, which profoundly reduced PLC activity, suggesting that these lipids may inhibit enzyme action. The data indicate that G protein-regulated isoforms of PLC operate with separate lipid binding and catalytic steps and imply that under physiological conditions, PLC beta isoforms operate under first-order conditions. These findings may have implications for the mechanisms of regulation of PLC beta s by G protein subunits.	UNIV N CAROLINA, SCH MED, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	JAMES, SR (corresponding author), UNIV DUNDEE, INST MED SCI, DEPT BIOCHEM, DUNDEE DD1 4HN, SCOTLAND.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029536, R01GM029536] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 29536] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERG OG, 1991, BIOCHEMISTRY-US, V30, P7283, DOI 10.1021/bi00243a034; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOGUSLAVSKY V, 1994, BIOCHEMISTRY-US, V33, P3032, DOI 10.1021/bi00176a036; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CAMPS M, 1992, EUR J BIOCHEM, V206, P821, DOI 10.1111/j.1432-1033.1992.tb16990.x; CARPENTER G, 1993, ADV SEC MESS PHOSPH, V28, P179; CIFUENTES ME, 1993, J BIOL CHEM, V268, P11586; CIFUENTES ME, 1994, J BIOL CHEM, V269, P1945; CREBA JA, 1983, BIOCHEM J, V212, P733, DOI 10.1042/bj2120733; DEEMS RA, 1975, J BIOL CHEM, V250, P9013; Dennis EA, 1983, ENZYMES, P307; EATON BR, 1976, ARCH BIOCHEM BIOPHYS, V176, P604, DOI 10.1016/0003-9861(76)90204-6; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FREMONT DH, 1993, P NATL ACAD SCI USA, V90, P342, DOI 10.1073/pnas.90.1.342; HANEL AM, 1993, BIOCHEMISTRY-US, V32, P5949, DOI 10.1021/bi00074a005; HARLAN JE, 1994, NATURE, V371, P168, DOI 10.1038/371168a0; HENDRICKSON HS, 1984, J BIOL CHEM, V259, P5734; HIRASAWA K, 1981, BIOCHEM J, V193, P607, DOI 10.1042/bj1930607; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAMES SR, 1994, BIOCHEM J, V298, P499, DOI 10.1042/bj2980499; JONES GA, 1993, J BIOL CHEM, V268, P20845; LEE KY, 1987, P NATL ACAD SCI USA, V84, P5540, DOI 10.1073/pnas.84.16.5540; LEE SB, 1993, J BIOL CHEM, V268, P25952; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; PARK DG, 1993, J BIOL CHEM, V268, P3710; PARKER PJ, 1994, TRENDS BIOCHEM SCI, V19, P54, DOI 10.1016/0968-0004(94)90031-0; PATERSON A, 1994, IN PRESS METHODS NEU, V6; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12742, DOI 10.1021/bi00166a005; REBECCHI M, 1992, BIOCHEMISTRY-US, V31, P12748, DOI 10.1021/bi00166a006; REBECCHI MJ, 1993, J BIOL CHEM, V268, P1735; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; RHEE SG, 1992, J BIOL CHEM, V267, P12393; ROBERTS MF, 1977, P NATL ACAD SCI USA, V74, P1950, DOI 10.1073/pnas.74.5.1950; SCHNABEL P, 1993, EUR J BIOCHEM, V217, P1109, DOI 10.1111/j.1432-1033.1993.tb18343.x; Segel IH, 1975, ENZYME KINETICS, P346; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; VANCE DE, 1985, BIOCH LIPIDS MEMBRAN, P242; VOLWERK JJ, 1994, BIOCHEMISTRY-US, V33, P3464, DOI 10.1021/bi00178a002; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALDO GL, 1994, METHOD ENZYMOL, V238, P195; WU DQ, 1993, J BIOL CHEM, V268, P3704	44	56	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 19	1995	270	20					11872	11881		10.1074/jbc.270.20.11872	http://dx.doi.org/10.1074/jbc.270.20.11872			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QY736	7744837	hybrid			2023-01-03	WOS:A1995QY73600033
J	LAPINLEIMU, H; VIIKARI, J; JOKINEN, E; SALO, P; ROUTI, T; LEINO, A; RONNEMAA, T; SEPPANEN, R; VALIMAKI, I; SIMELL, O				LAPINLEIMU, H; VIIKARI, J; JOKINEN, E; SALO, P; ROUTI, T; LEINO, A; RONNEMAA, T; SEPPANEN, R; VALIMAKI, I; SIMELL, O			PROSPECTIVE RANDOMIZED TRIAL IN 1062 INFANTS OF DIET LOW IN SATURATED FAT AND CHOLESTEROL	LANCET			English	Article							CORONARY HEART-DISEASE; RISK-FACTORS; CHILDREN	Interventions to avoid atherosclerosis might be more successful if launched early in life when eating and lifestyle patterns are formed, but dietary interventions have been limited by fears of diet-induced growth failure. We investigated the effects of a diet low in saturated fat and cholesterol on serum lipid concentrations and growth in 1062 healthy 7-month-old infants in a randomised study. Every 1-3 months, families in the intervention group received dietary advice aimed at adequate energy supply, with low fat intake (30-35% energy, polyunsaturated/ monounsaturated/saturated fatty acid ratio 1/1/1, and cholesterol intake <200 mg daily). Infants in control families consumed an unrestricted diet. 3-day food records were collected at ages 8 and 13 months. Growth was carefully monitored. Between 7 and 13 months serum cholesterol and non-high-density-lipoprotein cholesterol concentrations did not change significantly in the intervention group (mean change -0.03 [SD 0.72] mmol/L and 0.01 [0.67] mmol/L) but increased substantially in the control group (0.24 [0.64] mmol/L and 0.23 [0.60] mmol/L; p for difference in mean changes between groups <0 001). Daily intakes of energy and saturated fat were lower in the intervention than in the control group at 13 months (4065 [796] vs 4370 [748] kJ, p=0.033, and 9.3 [3.5] vs 14.5 [4.8] g, p<0.001, respectively), and intake of polyunsaturated fat was higher (5.8 [2.2] vs 4.4 [1.4] g, p<0.001). Growth did not differ between the groups and was as expected for children at this age. Serum cholesterol concentrations fell significantly in parents of intervention-group infants. The increases in serum cholesterol and non-high-density-lipoprotein cholesterol concentration that occur in infants between the ages of 7 and 13 months can be avoided by individualised diets, with no effect on the children's growth.	UNIV TURKU, DEPT PAEDIAT, TURKU, FINLAND; UNIV TURKU, DEPT MED, TURKU, FINLAND; SOCIAL INSURANCE INST, RES & DEV UNIT, TURKU, FINLAND	University of Turku; University of Turku	LAPINLEIMU, H (corresponding author), UNIV TURKU, CARDIORESP RES UNIT, KIINAMYLLYNKATU 10, SF-20520 TURKU, FINLAND.		Lapinleimu, Helena/AAT-8415-2021					DOUGHERTY RM, 1988, AM J CLIN NUTR, V48, P970, DOI 10.1093/ajcn/48.4.970; EHNHOLM C, 1982, NEW ENGL J MED, V307, P850, DOI 10.1056/NEJM198209303071403; ERKKOLA R, 1986, BIOL RES PREG PERIN, V7, P47; FRIEDMAN G, 1976, PEDIATRICS, V58, P655; GRUNDY SM, 1990, J LIPID RES, V31, P1149; KAPLAN RM, 1992, PREV MED, V21, P33, DOI 10.1016/0091-7435(92)90004-2; KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504; KNUIMAN JT, 1987, ARTERIOSCLEROSIS, V7, P612, DOI 10.1161/01.ATV.7.6.612; LAPINLEIMU H, 1994, ACTA PAEDIATR, V83, P383, DOI 10.1111/j.1651-2227.1994.tb18124.x; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; MCGILL HC, 1990, JAMA-J AM MED ASSOC, V264, P3018; NEWMAN TB, 1990, AM J DIS CHILD, V144, P851; NEWMAN WP, 1986, NEW ENGL J MED, V314, P138, DOI 10.1056/NEJM198601163140302; PESONEN E, 1990, EUR HEART J, V11, P53, DOI 10.1093/eurheartj/11.suppl_E.53; PYORALA K, 1985, CARDIOLOGY, V72, P35, DOI 10.1159/000173839; RASANEN L, 1991, ANN MED, V23, P73, DOI 10.3109/07853899109147934; RASANEN L, 1992, ACTA PAEDIATR, V81, P7, DOI 10.1111/j.1651-2227.1992.tb12069.x; ROSENTHAL SL, 1993, CLIN PEDIATR, V32, P135, DOI 10.1177/000992289303200302; SORVA R, 1990, ACTA PAEDIATR SCAND, V79, P490, DOI 10.1111/j.1651-2227.1990.tb11502.x; VARTIAINEN E, 1987, CARDIOVASCULAR RISK, P183; VIIKARI J, 1985, ACTA PAEDIATR SCAND, P103; WALTER HJ, 1988, NEW ENGL J MED, V318, P1093, DOI 10.1056/NEJM198804283181704; 1989, RECOMMENDED DIETARY; 1991, PEDIATRICS, V89, P495	24	169	171	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	FEB 25	1995	345	8948					471	476		10.1016/S0140-6736(95)90580-4	http://dx.doi.org/10.1016/S0140-6736(95)90580-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QH929	7861873				2023-01-03	WOS:A1995QH92900007
J	MALMIVAARA, A; HAKKINEN, U; ARO, T; HEINRICHS, ML; KOSKENNIEMI, L; KUOSMA, E; LAPPI, S; PALOHEIMO, R; SERVO, C; VAARANEN, V; HERNBERG, S				MALMIVAARA, A; HAKKINEN, U; ARO, T; HEINRICHS, ML; KOSKENNIEMI, L; KUOSMA, E; LAPPI, S; PALOHEIMO, R; SERVO, C; VAARANEN, V; HERNBERG, S			THE TREATMENT OF ACUTE LOW-BACK-PAIN - BED REST, EXERCISES, OR ORDINARY ACTIVITY	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CLINICAL-TRIAL; THERAPY	Background. Bed rest and back-extension exercises are often prescribed for patients with acute low back pain, but the effectiveness of these two competing treatments remains controversial. Methods. We conducted a controlled trial among employees of the city of Helsinki, Finland, who presented to an occupational health care center with acute, nonspecific low back pain. The patients were randomly assigned to one of three treatments: bed rest for two days (67 patients), back-mobilizing exercises (52 patients), or the continuation of ordinary activities as tolerated (the control group; 67 patients). Outcomes and costs were assessed after 3 and 12 weeks. Results. After 3 and 12 weeks, the patients in the control group had better recovery than those prescribed either bed rest or exercises. There were statistically significant differences favoring the control group in the duration of pain, pain intensity, lumbar flexion, ability to work as measured subjectively, Oswestry back-disability index, and number of days absent from work. Recovery was slowest among the patients assigned to bed rest. The overall costs of care did not differ significantly among the three groups. Conclusions. Among patients with acute low back pain, continuing ordinary activities within the limits permitted by the pain leads to more rapid recovery than either bed rest or back-mobilizing exercises.	NATL RES & DEV CTR WELF & HLTH,HELSINKI,FINLAND; CITY HELSINKI OCCUPAT HLTH CARE CTR,HELSINKI,FINLAND; INST OCCUPAT HLTH,DEPT EPIDEMIOL & BIOSTAT,HELSINKI,FINLAND	Finnish Institute of Occupational Health	MALMIVAARA, A (corresponding author), INST OCCUPAT HLTH,DEPT OCCUPAT MED,TOPELIUKSENKATU 41 AA,SF-00250 HELSINKI,FINLAND.							DEYO RA, 1986, NEW ENGL J MED, V315, P1064, DOI 10.1056/NEJM198610233151705; DEYO RA, 1987, SPINE, V12, P264, DOI 10.1097/00007632-198704000-00013; DEYO RA, 1991, CONT CONSERVATIVE CA, P169; DONELSON R, 1991, SPINE, V16, pS206, DOI 10.1097/00007632-199106001-00006; Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561; FAAS A, 1993, SPINE, V18, P1388; Fairbank J C, 1980, Physiotherapy, V66, P271; GILBERT JR, 1985, BRIT MED J, V291, P791, DOI 10.1136/bmj.291.6498.791; KOES BW, 1991, BRIT MED J, V302, P1572, DOI 10.1136/bmj.302.6792.1572; NACHEMSON A, 1991, ONT RYGGEN ORSAKER D; Sintonen H, 1992, QUALITY LIFE ASSESSM, P185; STANKOVIC R, 1990, SPINE, V15, P120, DOI 10.1097/00007632-199002000-00014; Torrance GW, 1987, METHODS EC EVALUATIO; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WIESEL SW, 1980, SPINE, V5, P324, DOI 10.1097/00007632-198007000-00006; 1993, EGRET INTUITIVE SOFT, P86; 1987, SPINE S, V12, pS22; 1987, SAS STAT GUIDE PERSO, P549	18	443	452	0	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 9	1995	332	6					351	355		10.1056/NEJM199502093320602	http://dx.doi.org/10.1056/NEJM199502093320602			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF300	7823996				2023-01-03	WOS:A1995QF30000002
J	[Anonymous]				[Anonymous]			GOING PRIVATE - TIME FOR CHANGE	BRITISH MEDICAL JOURNAL			English	Article																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1994	309	6970					1699	1700						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PY717	7772117				2023-01-03	WOS:A1994PY71700022
J	RON, E; MODAN, B; BOICE, JD; ALFANDARY, E; STOVALL, M; CHETRIT, A; KATZ, L				RON, E; MODAN, B; BOICE, JD; ALFANDARY, E; STOVALL, M; CHETRIT, A; KATZ, L			TUMORS OF THE BRAIN AND NERVOUS-SYSTEM AFTER RADIOTHERAPY IN CHILDHOOD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									CHAIM SHEBA MED CTR,DEPT CLIN EPIDEMIOL,IL-52621 TEL HASHOMER,ISRAEL; UNIV TEXAS,CTR CANC,HOUSTON,TX 77025; MINIST HLTH,ISRAEL CANC REGISTRY,JERUSALEM,ISRAEL	Chaim Sheba Medical Center; University of Texas System	RON, E (corresponding author), NCI,DIV CANC ETIOL,RADIAT EPIDEMIOL BRANCH,EXECUT PLAZA N,RM 408,BETHESDA,MD 20892, USA.							[Anonymous], 1976, INT CLASSIFICATION D; BELLER AJ, 1972, NEUROCHIRURGIA, V4, P135; BITHELL JF, 1975, BRIT J CANCER, V31, P271, DOI 10.1038/bjc.1975.62; Cox D.R., 1989, CONCISE ENCY STAT; DARBY SC, 1985, J NATL CANCER I, V75, P1; IACONO RP, 1981, J NEUROSURG, V55, P282, DOI 10.3171/jns.1981.55.2.0282; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; KUMAR PP, 1987, CANCER, V59, P1274, DOI 10.1002/1097-0142(19870401)59:7<1274::AID-CNCR2820590708>3.0.CO;2-H; LAND CE, 1986, RAD CARCINOGENESIS, P347; LEE W, 1970, BRHDBE704 FED DRUG A; LI FP, 1982, JAMA-J AM MED ASSOC, V247, P2692, DOI 10.1001/jama.247.19.2692; LIWNICZ BH, 1985, NEUROSURGERY, V17, P436, DOI 10.1227/00006123-198509000-00007; MIETTINEN OS, 1974, J AM STAT ASSOC, V69, P380, DOI 10.2307/2285664; MODAN B, 1974, LANCET, V1, P277; Monson R.R., 1984, RAD CARCINOGENESIS E, P97; PRESTON DL, 1987, RADIAT RES, V111, P151, DOI 10.2307/3577030; PRESTONMARTIN S, 1980, JNCI-J NATL CANCER I, V65, P67; PRESTONMARTIN S, 1983, J NATL CANCER I, V70, P863; RIMM IJ, 1987, CANCER, V59, P1506, DOI 10.1002/1097-0142(19870415)59:8<1506::AID-CNCR2820590819>3.0.CO;2-P; RON E, 1988, AM J EPIDEMIOL, V127, P713, DOI 10.1093/oxfordjournals.aje.a114852; RUBINSTEIN AB, 1984, J NEUROSURG, V61, P966, DOI 10.3171/jns.1984.61.5.0966; SCHOENBERG BS, 1982, CANCER EPIDEMIOL, P968; SCHULZ RJ, 1968, ARCH ENVIRON HEALTH, V17, P935, DOI 10.1080/00039896.1968.10665350; SEYAMA S, 1979, 1579 RAD EFF RES F T; SHORE RE, 1976, ARCH ENVIRON HEALTH, V31, P21, DOI 10.1080/00039896.1976.10667184; SHOREFREEDMAN E, 1983, CANCER, V51, P2159, DOI 10.1002/1097-0142(19830615)51:12<2159::AID-CNCR2820511202>3.0.CO;2-L; SIMONE JV, 1982, CANCER PRINCIPLES PR, P1254; SOFFER D, 1983, J NEUROSURG, V59, P1048, DOI 10.3171/jns.1983.59.6.1048; WERNER A, 1968, PHYS MED BIOL, V13, P247, DOI 10.1088/0031-9155/13/2/310; [No title captured]; [No title captured]	31	683	692	0	9	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 20	1988	319	16					1033	1039		10.1056/NEJM198810203191601	http://dx.doi.org/10.1056/NEJM198810203191601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q5315	3173432				2023-01-03	WOS:A1988Q531500001
J	HENDERSON, GE; MURPHY, EA; SOCKWELL, ST; ZHOU, JL; SHEN, QR; LI, ZM				HENDERSON, GE; MURPHY, EA; SOCKWELL, ST; ZHOU, JL; SHEN, QR; LI, ZM			HIGH-TECHNOLOGY MEDICINE IN CHINA - THE CASE OF CHRONIC RENAL-FAILURE AND HEMODIALYSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									SUN YATSEN UNIV MED SCI,GUANGZHOU,PEOPLES R CHINA	Sun Yat Sen University	HENDERSON, GE (corresponding author), UNIV N CAROLINA,SCH MED,CHAPEL HILL,NC 27514, USA.							AARON HJ, 1984, PAINFUL PRESCRIPTION; ALEXANDER S, 1977, ETHICAL ISSUES MODER, P409; Fox R., 1974, COURAGE FAIL SOCIAL; GORNICK M, 1985, HLTH CARE FINANC R S, V7, P13; HSIAO WC, 1984, NEW ENGL J MED, V310, P932, DOI 10.1056/NEJM198404053101428; LIAO LT, 1981, CHIN J INTERN MED, V20, P326; RELMAN AS, 1980, NEW ENGL J MED, V303, P996, DOI 10.1056/NEJM198010233031708; RUBIN RJ, 1984, PUBLIC HEALTH REP, V99, P492; SHEN QR, 1986, FAM PHYSICIAN, V11, P8; Starr P., 1982, SOCIAL TRANSFORMATIO; WANG DY, 1984, WUHAN MED J, V8, P117; XIE T, 1985, CHIN J ORG TRANSPLAN, V6, P1; XIE T, 1985, CHIN J ORG TRANSPLAN, V6, P2; 1985, GUANGZHOU YB 1985; 1986, BEIJING REV, V29, P32	15	7	7	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 14	1988	318	15					1000	1004		10.1056/NEJM198804143181528	http://dx.doi.org/10.1056/NEJM198804143181528			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M8862	3352684				2023-01-03	WOS:A1988M886200029
J	LLOYDTHOMAS, AR; WRIGHT, I; LISTER, TA; HINDS, CJ				LLOYDTHOMAS, AR; WRIGHT, I; LISTER, TA; HINDS, CJ			PROGNOSIS OF PATIENTS RECEIVING INTENSIVE-CARE FOR LIFE-THREATENING MEDICAL COMPLICATIONS OF HEMATOLOGICAL MALIGNANCY	BRITISH MEDICAL JOURNAL			English	Article									ST BARTHOLOMEWS HOSP,DEPT ANAESTHESIA,LONDON EC1A 7BE,ENGLAND; ST BARTHOLOMEWS HOSP,IMPERIAL CANC RES FUND,DEPT MED ONCOL,LONDON EC1A 7BE,ENGLAND	University of London; Queen Mary University London; Cancer Research UK; University of London; Queen Mary University London								BELL R, 1982, BRIT MED J, V284, P1221, DOI 10.1136/bmj.284.6324.1221; ESTOPA R, 1984, CRIT CARE MED, V12, P26, DOI 10.1097/00003246-198401000-00007; GOLDINER P, 1976, HODGKINS DISEASE, P371; HAUSER MJ, 1982, ARCH INTERN MED, V142, P527, DOI 10.1001/archinte.142.3.527; HORWICH A, 1983, SEMIN HEMATOL, V20, P35; JENNETT B, 1984, BRIT MED J, V289, P1709, DOI 10.1136/bmj.289.6460.1709; JOHNSON MH, 1986, CRIT CARE MED, V14, P693, DOI 10.1097/00003246-198608000-00006; KNAAUS WA, 1985, J CHRONIC DIS, V38, P295; KNAUS WA, 1986, ANN INTERN MED, V104, P410, DOI 10.7326/0003-4819-104-3-410; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; LISTER TA, 1982, SEMIN HEMATOL, V19, P172; LLOYDTHOMAS AR, 1986, INTENS CARE MED, V12, P317; SCHIMPFF SC, 1983, LEUKEMIA, P799; SCHUSTER DP, 1983, AM J MED, V75, P402, DOI 10.1016/0002-9343(83)90340-6; SNOW RM, 1979, JAMA-J AM MED ASSOC, V241, P2039, DOI 10.1001/jama.241.19.2039; TURNBULL AD, 1979, CRIT CARE MED, V7, P20, DOI 10.1097/00003246-197901000-00005	16	111	113	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 9	1988	296	6628					1025	1029		10.1136/bmj.296.6628.1025	http://dx.doi.org/10.1136/bmj.296.6628.1025			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M9668	3130123	Green Published			2023-01-03	WOS:A1988M966800006
J	BROCHARD, L; MANCEBO, J; WYSOCKI, M; LOFASO, F; CONTI, G; RAUSS, A; SIMONNEAU, G; BENITO, S; GASPARETTO, A; LEMAIRE, F; ISABEY, D; HARF, A				BROCHARD, L; MANCEBO, J; WYSOCKI, M; LOFASO, F; CONTI, G; RAUSS, A; SIMONNEAU, G; BENITO, S; GASPARETTO, A; LEMAIRE, F; ISABEY, D; HARF, A			NONINVASIVE VENTILATION FOR ACUTE EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE RESPIRATORY-FAILURE; POSITIVE PRESSURE VENTILATION; MECHANICAL VENTILATION; FACE MASK; SUPPORT VENTILATION; AIRWAY PRESSURE; COLD PATIENTS; NASAL MASK; SURVIVAL; COPD	Background. In patients with acute exacerbations of chronic obstructive pulmonary disease, noninvasive ventilation may be used in an attempt to avoid endotracheal intubation and complications associated with mechanical ventilation. Methods. We conducted a prospective, randomized study comparing noninvasive pressure-support ventilation delivered through a face mask with standard treatment in patients admitted to five intensive care units over a 15-month period, Results. A total of 85 patients were recruited from a larger group of 275 patients with chronic obstructive pulmonary disease admitted to the intensive care units in the same period. A total of 42 were randomly assigned to standard therapy and 43 to noninvasive ventilation. The two groups had similar clinical characteristics on admission to the hospital. The use of noninvasive ventilation significantly reduced the need for endotracheal intubation (which was dictated by objective criteria): 11 of 43 patients (26 percent) in the noninvasive-ventilation group were intubated, as compared with 31 of 42 (74 percent) in the standard-treatment group (P<0.001). In addition, the frequency of complications was significantly lower in the noninvasive-ventilation group (16 percent vs. 48 percent, P=0.001), and the mean (+/-SD) hospital stay was significantly shorter for patients receiving noninvasive ventilation (23+/-17 days vs. 35+/-33 days, P=0.005), The in-hospital mortality rate was also significantly reduced with noninvasive ventilation (4 of 43 patients, or 9 percent, in the noninvasive-ventilation group died in the hospital, as compared with 12 of 42, or 29 percent, in the standard-treatment group; P=0.02). Conclusions. in selected patients with acute exacerbations of chronic obstructive pulmonary disease, noninvasive ventilation can reduce the need for endotracheal intubation, the length of the hospital stay, and the in-hospital mortality rate.	HOP HENRI MONDOR,INSERM,U296,F-94010 CRETEIL,FRANCE; UNIV PARIS,INT HOSP,INTENS CARE UNIT,PARIS,FRANCE; HOP ANTOINE BECLERE,RESP INTENS CARE UNIT,CLAMART,FRANCE; ST PAU HOSP,MED INTENS CARE UNIT,BARCELONA,SPAIN; UNIV ROME LA SAPIENZA HOSP,INTENS CARE UNIT,ROME,ITALY; HOP HENRI MONDOR,MED INTENS CARE UNIT,F-94010 CRETEIL,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP; Sapienza University Rome; University Hospital Sapienza Rome; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP			Simonneau, Gerald/ABE-6614-2020; Lofaso, Frédéric/R-6100-2018; Conti, Giorgio/AAB-9546-2022	Conti, Giorgio/0000-0002-8566-9365				ALTMAN DG, 1991, PRACTICAL STATISTICS, P270; ASMUNDSSON T, 1974, ANN INTERN MED, V80, P54, DOI 10.7326/0003-4819-80-1-54; BENHAMOU D, 1992, CHEST, V102, P912, DOI 10.1378/chest.102.3.912; BERSTEN AD, 1991, NEW ENGL J MED, V325, P1825, DOI 10.1056/NEJM199112263252601; BOTT J, 1993, LANCET, V341, P1555, DOI 10.1016/0140-6736(93)90696-E; BROCHARD L, 1989, AM REV RESPIR DIS, V139, P513, DOI 10.1164/ajrccm/139.2.513; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1987, AM REV RESPIR DIS, V136, P411, DOI 10.1164/ajrccm/136.2.411; BROCHARD L, 1990, NEW ENGL J MED, V323, P1523, DOI 10.1056/NEJM199011293232204; BURK RH, 1973, ARCH INTERN MED, V132, P865, DOI 10.1001/archinte.132.6.865; CHEVROLET JC, 1991, CHEST, V100, P775, DOI 10.1378/chest.100.3.775; DERENNE JP, 1988, AM REV RESPIR DIS, V138, P1006, DOI 10.1164/ajrccm/138.4.1006; ELLIOTT M, 1994, PRINCIPLES PRACTICE, P427; ELLIOTT MW, 1990, BRIT MED J, V300, P358, DOI 10.1136/bmj.300.6721.358; FAGON JY, 1993, AM J MED, V94, P281, DOI 10.1016/0002-9343(93)90060-3; FERNANDEZ R, 1993, INTENS CARE MED, V19, P456, DOI 10.1007/BF01711087; FOGLIO C, 1992, CHEST, V101, P1533, DOI 10.1378/chest.101.6.1533; HILL NS, 1993, AM REV RESPIR DIS, V147, P1050, DOI 10.1164/ajrccm/147.4.1050; ISABEY D, 1989, J APPL PHYSIOL, V67, P771, DOI 10.1152/jappl.1989.67.2.771; KAELIN RM, 1987, CHEST, V92, P971, DOI 10.1378/chest.92.6.971; LEGALL JR, 1984, CRIT CARE MED, V12, P975; LEGER P, 1988, American Review of Respiratory Disease, V137, P63; MEDURI GU, 1989, CHEST, V95, P865, DOI 10.1378/chest.95.4.865; MEDURI GU, 1991, CHEST, V100, P445, DOI 10.1378/chest.100.2.445; MENZIES R, 1989, CHEST, V95, P398, DOI 10.1378/chest.95.2.398; PETTY TL, 1985, LUNG BIOL HLTH DISEA, V28, P389; PINGLETON SK, 1988, AM REV RESPIR DIS, V137, P1463, DOI 10.1164/ajrccm/137.6.1463; STAUFFER JL, 1981, AM J MED, V70, P65, DOI 10.1016/0002-9343(81)90413-7; VITACCA M, 1993, INTENS CARE MED, V19, P450, DOI 10.1007/BF01711086; WARREN PM, 1980, LANCET, V1, P467; WYSOCKI M, 1993, CHEST, V103, P907, DOI 10.1378/chest.103.3.907	31	1240	1294	0	22	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 28	1995	333	13					817	822		10.1056/NEJM199509283331301	http://dx.doi.org/10.1056/NEJM199509283331301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RW883	7651472	Bronze			2023-01-03	WOS:A1995RW88300001
J	GILL, PS; HARRINGTON, W; KAPLAN, MH; RIBEIRO, RC; BENNETT, JM; LIEBMAN, HA; BERNSTEINSINGER, M; ESPINA, BM; CABRAL, L; ALLEN, S; KORNBLAU, S; PIKE, MC; LEVINE, AM				GILL, PS; HARRINGTON, W; KAPLAN, MH; RIBEIRO, RC; BENNETT, JM; LIEBMAN, HA; BERNSTEINSINGER, M; ESPINA, BM; CABRAL, L; ALLEN, S; KORNBLAU, S; PIKE, MC; LEVINE, AM			TREATMENT OF ADULT T-CELL LEUKEMIA-LYMPHOMA WITH A COMBINATION OF INTERFERON-ALFA AND ZIDOVUDINE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VIRUS TYPE-I; HTLV-I; C RETROVIRUS; ANTIBODIES; LYMPHOCYTES; BETA; REPLICATION; INFECTION; PATIENT; THERAPY	Background. Infection with the human T-cell lymphotropic virus type I, a retrovirus, can cause a distinctive cancer, adult T-cell leukemia-lymphoma. The median survival of patients with the acute and lymphomatous forms of the disease is short, despite the use of cytotoxic chemotherapy. Methods: We treated 19 patients with acute or lymphomatous forms of adult T-cell leukemia-lymphoma with oral zidovudine (200 mg five times dairy) and interferon alfa (Intron A, 5 million to 10 million units subcutaneously each day). Seven of these patients had either relapsed after multiagent cytotoxic chemotherapy or failed to respond to that treatment. Results. Major responses were achieved in 58 percent of the patients (11 of 19), including complete remission in 26 percent (5 of 19). Four patients in whom prior cytotoxic therapy had failed had major responses, two of which were complete remissions. Six patients have survived for more than 12 months, with the longest remission since the discontinuation of treatment lasting more than 59 months. Conclusions. The combination of zidovudine and interferon alfa has activity against adult T-cell leukemia-lymphoma, even in patients in whom prior cytotoxic therapy has failed. This regimen should be evaluated further for its role in the treatment of adult T-cell leukemia-lymphoma.	UNIV SO CALIF, SCH MED, DEPT PREVENT MED, LOS ANGELES, CA 90033 USA; UNIV MIAMI, MIAMI, FL 33152 USA; N SHORE UNIV HOSP, DEPT MED, MANHASSET, NY 11030 USA; ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN USA; ST JUDE CHILDRENS RES HOSP, DEPT PEDIAT, MEMPHIS, TN USA; UNIV TENNESSEE, MEMPHIS, TN 38163 USA; UNIV ROCHESTER, MED CTR, DEPT MED, ROCHESTER, NY 14642 USA; KAISER PERMANENTE SUNSET HOSP, DEPT INTERNAL MED, LOS ANGELES, CA USA; UNIV TEXAS, MD ANDERSON CANC CTR, DIV MED, HOUSTON, TX USA	University of Southern California; University of Miami; Northwell Health; North Shore University Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Rochester; Kaiser Permanente; University of Texas System; UTMD Anderson Cancer Center	GILL, PS (corresponding author), UNIV SO CALIF, SCH MED,NORRIS CANC HOSP & RES INST, DEPT INTERNAL MED,1441 EASTLAKE AVE, RM 162, LOS ANGELES, CA 90033 USA.		Allen, Steven/N-6088-2019; Kornblau, Steven/A-9366-2009	Allen, Steven/0000-0002-3482-3182; 	NCI NIH HHS [P30-CA 21765, CA 20180] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765, P01CA020180] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLATTNER WA, 1982, INT J CANCER, V30, P257, DOI 10.1002/ijc.2910300302; BUNN PA, 1983, NEW ENGL J MED, V309, P257, DOI 10.1056/NEJM198308043090501; FRIEDMAN RL, 1984, CELL, V38, P745, DOI 10.1016/0092-8674(84)90270-8; FURMAN PA, 1986, P NATL ACAD SCI USA, V83, P8333, DOI 10.1073/pnas.83.21.8333; GENDELMAN HE, 1990, J IMMUNOL, V145, P2669; HANCHARD B, 1990, HUMAN RETROVIROLOGY : HTLV, P173; HINUMA Y, 1982, INT J CANCER, V29, P631, DOI 10.1002/ijc.2910290606; ICHIMARU M, 1988, JPN J CANC CHEMOTHER, V15, P2975; ISONO T, 1990, LEUKEMIA RES, V14, P841, DOI 10.1016/0145-2126(90)90172-6; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KAMIHIRA S, 1983, JPN J CANC CHEMOTHER, V10, P2188; KIMURA K, 1985, JPN J CANC CHEMOTHER, V12, P928; LOFTERS W, 1987, CANCER, V60, P2605, DOI 10.1002/1097-0142(19871201)60:11<2605::AID-CNCR2820601104>3.0.CO;2-T; MATSUSHIMA M, 1987, EUR J HAEMATOL, V39, P282; MEHTA CR, 1983, J AM STAT ASSOC, V78, P427, DOI 10.2307/2288652; MEYTES D, 1990, LANCET, V336, P1533, DOI 10.1016/0140-6736(90)93308-C; MORRIS A, 1987, J GEN VIROL, V68, P99, DOI 10.1099/0022-1317-68-1-99; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; REITZ MS, 1981, P NATL ACAD SCI-BIOL, V78, P1887, DOI 10.1073/pnas.78.3.1887; ROBERTGUROFF M, 1986, JAMA-J AM MED ASSOC, V255, P3133, DOI 10.1001/jama.255.22.3133; SAITO N, 1994, AM J HEMATOL, V47, P246, DOI 10.1002/ajh.2830470324; SAXINGER W, 1984, SCIENCE, V225, P1473, DOI 10.1126/science.6089348; SHIBATA D, 1989, ANN INTERN MED, V111, P871, DOI 10.7326/0003-4819-111-11-871; SHIMOYAMA M, 1991, BRIT J HAEMATOL, V79, P428, DOI 10.1111/j.1365-2141.1991.tb08051.x; SHIMOYAMA M, 1988, J CLIN ONCOL, V6, P128, DOI 10.1200/JCO.1988.6.1.128; TAJIMA K, 1990, HUMAN RETROVIROLOGY : HTLV, P267; TAMURA K, 1987, CANCER, V59, P1059, DOI 10.1002/1097-0142(19870315)59:6<1059::AID-CNCR2820590602>3.0.CO;2-M; TARONE RE, 1977, BIOMETRIKA, V64, P156, DOI 10.1093/biomet/64.1.156; TSUDA H, 1994, BRIT J CANCER, V70, P771, DOI 10.1038/bjc.1994.394; UCHIYAMA T, 1977, BLOOD, V50, P481, DOI 10.1182/blood.V50.3.481.481; WALDMANN TA, 1993, J ACQ IMMUN DEF SYND, V6, P671; WALDMANN TA, 1988, BLOOD, V72, P1805; 1993, NIH932770 NCI DIV CA; 1991, LEUKEMIA RES, V15, P81	35	278	291	1	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 29	1995	332	26					1744	1748		10.1056/NEJM199506293322603	http://dx.doi.org/10.1056/NEJM199506293322603			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RE667	7760890				2023-01-03	WOS:A1995RE66700003
J	TONKIN, SL; DAVIS, SL; GUNN, TR				TONKIN, SL; DAVIS, SL; GUNN, TR			NASAL ROUTE FOR INFANT RESUSCITATION BY MOTHERS	LANCET			English	Article							AIRWAY	In infants under 6 months of age air normally enters the trachea by the nose because the tongue fills the oral cavity, and the oral route is open only when the infant is making muscular efforts such as crying or gasping. The present recommendation for infant resuscitation is for the resuscitator's mouth to cover the mouth and nose of the baby. We set out to test whether this recommendation is feasible. We measured the dimensions of the faces of 28 babies aged between 2 and 4 months (the age when resuscitation is most often needed) and of the mouths of 25 of their mothers. Only 2 mothers would have been able to cover with their mouths the nose and closed mouth of 2 babies (not their own). The mannequins often used to teach adults to resuscitate infants are misleading because they present a wide open mouth, thus implying that that is the preferred route. We recommend that the nasal route of air entry be taught to parents for resuscitation of babies who have stopped breathing.	UNIV AUCKLAND,AUCKLAND,NEW ZEALAND	University of Auckland	TONKIN, SL (corresponding author), NEW ZEALAND COT DEATH ASSOC,POB 28-177,AUCKLAND,NEW ZEALAND.							GUNN TR, 1989, PEDIATRICS, V84, P73; SIEBERT J R, 1991, Pediatric Pathology, V11, P813; TONKIN S, 1975, PEDIATRICS, V55, P650; TONKIN SL, 1988, NEW ZEAL MED J, V101, P261; WILSON SL, 1980, J APPL PHYSIOL, V48, P500, DOI 10.1152/jappl.1980.48.3.500; 1992, JAMA-J AM MED ASSOC, V268, P2184; 1994, PUBLIC HLTH COMMISSI	7	25	25	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1353	1354		10.1016/S0140-6736(95)92543-0	http://dx.doi.org/10.1016/S0140-6736(95)92543-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752760				2023-01-03	WOS:A1995RA14800014
J	PODZAMCZER, D; SALAZAR, A; JIMENEZ, J; CONSIGLIO, E; SANTIN, M; CASANOVA, A; RUFI, G; GUDIOL, F				PODZAMCZER, D; SALAZAR, A; JIMENEZ, J; CONSIGLIO, E; SANTIN, M; CASANOVA, A; RUFI, G; GUDIOL, F			INTERMITTENT TRIMETHOPRIM-SULFAMETHOXAZOLE COMPARED WITH DAPSONE-PYRIMETHAMINE FOR THE SIMULTANEOUS PRIMARY PROPHYLAXIS OF PNEUMOCYSTIS PNEUMONIA AND TOXOPLASMOSIS IN PATIENTS INFECTED WITH HIV	ANNALS OF INTERNAL MEDICINE			English	Article						PNEUMONIA, PNEUMOCYSTIS CARINII; TOXOPLASMOSIS; TRIMETHOPRIM-SULFAMETHOX-AZOLE COMBINATION; DAPSONE; PYRIMETHAMINE	IMMUNODEFICIENCY-VIRUS INFECTION; CARINII PNEUMONIA; AEROSOLIZED PENTAMIDINE; CEREBRAL TOXOPLASMOSIS; CONTROLLED TRIAL; PREVENTION; AIDS; COTRIMOXAZOLE; ENCEPHALITIS; EFFICACY	Objective: To evaluate the efficacy and safety of two oral, intermittent drug regimens for the simultaneous primary prophylaxis of Pneumocystis carinii pneumonia and toxoplasmosis in patients with HIV infection. Design: Nonblinded randomized study: Patients received either 1) trimethoprim-sulfamethoxazole (160 mg-800 mg orally twice a day on a thrice weekly regimen) or 2) 100 mg of dapsone plus 50 mg of pyrimethamine orally twice weekly. Setting: University teaching hospital in Barcelona. Patients: 230 patients infected with HIV who had CD4 cell counts of less than 200 x 10(6)/L and who had not previously had P. carinii pneumonia or toxoplasmosis. Measurements: Clinical and biological evaluations; adverse reactions; and end points of P. carinii pneumonia, toxoplasmosis, and death. Results: After a median follow-up of 430 days, 6 (6.3%) of 96 evaluable patients receiving dapsone-pyrimethamine and 0 of 104 evaluable patients receiving trimethoprim-sulfamethoxazole developed P. carinii pneumonia (P < 0.0001). The cumulative rates of P carinii pneumonia at 12 and 24 months were 0% and 0% for patients receiving trimethoprim-sulfamethoxazole and 4% and 11% for patients receiving dapsone-pyrimethamine (Mantel-Cox, P = 0.014). However, only one episode of P. carinii pneumonia developed while patients were taking these drugs. No differences were observed for toxoplasmosis (one episode in the trimethopri m-sulfamethoxazole arm and two in the dapsone-pyrimethamine arm), with cumulative rates at 12 and 24 months of 0% and 4% for the trimethoprim-sulfamethoxazole arm and 2% and 7% for the dapsone-pyrimethamine arm (P = 0.65). Similar mortality rates were observed during follow-up (P = 0.85). Nineteen patients (9.5%) discontinued therapy with the drugs because of adverse effects: Ten were in the trimethoprim-sulfamethoxazole arm and 9 were in the dapsone-pyrimethamine arm (P = 0.95). Conclusions: Thrice-weekly trimethoprim-sulfamethoxazole is an effective and well-tolerated regimen for the simultaneous primary prophylaxis of P. carinii pneumonia and toxoplasmosis in patients infected with HIV. Twice-weekly dapsone-pyrimethamine appears to be a safe and effective alternative.			PODZAMCZER, D (corresponding author), UNIV BARCELONA, CIUTAT SANITARIA BELLVITGE, INFECT DIS SERV, C FEIXA LLARGA S-N, E-08907 BARCELONA, SPAIN.							ALLEGRA CJ, 1990, J CLIN INVEST, V85, P371, DOI 10.1172/JCI114448; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; ANTINORI A, 1992, LANCET, V340, P788, DOI 10.1016/0140-6736(92)92326-B; BEAMAN MH, 1992, ANN INTERN MED, V117, P163, DOI 10.7326/0003-4819-117-2-163; BLUM RN, 1992, J ACQ IMMUN DEF SYND, V5, P341; BOLAO F, 1991, 7 INT C AIDS, P252; BROUGHTON MC, 1991, ANTIMICROB AGENTS CH, V35, P1348, DOI 10.1128/AAC.35.7.1348; CARR A, 1992, ANN INTERN MED, V117, P106, DOI 10.7326/0003-4819-117-2-106; CLOTET B, 1991, AIDS, V5, P601, DOI 10.1097/00002030-199105000-00024; COKER RJ, 1992, LANCET, V340, P1099, DOI 10.1016/0140-6736(92)93120-C; CUSHION MT, 1985, ANTIMICROB AGENTS CH, V28, P796, DOI 10.1128/AAC.28.6.796; DEROUIN F, 1991, ANTIMICROB AGENTS CH, V35, P252, DOI 10.1128/AAC.35.2.252; ELIASZEWICZ M, 1992, 6TH INT C AIDS, P242; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GALLANT JE, 1994, ANN INTERN MED, V120, P932, DOI 10.7326/0003-4819-120-11-199406010-00006; GIRARD PM, 1993, NEW ENGL J MED, V328, P1514, DOI 10.1056/NEJM199305273282102; GONZALEZ AH, 1989, J ANTIMICROB CHEMOTH, V24, P19, DOI 10.1093/jac/24.1.19; GRAHAM NMH, 1992, NEW ENGL J MED, V326, P1037, DOI 10.1056/NEJM199204163261601; GRANT IH, 1990, AIDS, V4, P519, DOI 10.1097/00002030-199006000-00004; Hardy W. D., 1994, AIDS (Philadelphia), V8, pS15, DOI 10.1097/00002030-199411004-00059; HARDY WD, 1992, NEW ENGL J MED, V327, P1842, DOI 10.1056/NEJM199212243272604; HOROWITZ HW, 1992, LANCET, V339, P747, DOI 10.1016/0140-6736(92)90649-N; HUGHES WT, 1990, LANCET, V336, P1066, DOI 10.1016/0140-6736(90)92533-N; HUGHES WT, 1988, ANTIMICROB AGENTS CH, V32, P623, DOI 10.1128/AAC.32.5.623; JORDE UP, 1993, AIDS, V7, P355, DOI 10.1097/00002030-199303000-00008; MACGREGOR RR, 1992, AM J MED, V92, P227, DOI 10.1016/0002-9343(92)90122-R; MAY T, 1994, J ACQ IMMUN DEF SYND, V7, P457; METROKA CE, 1991, NEW ENGL J MED, V325, P737; MIRO JM, 1994, MED CLIN-BARCELONA, V102, P566; OFARRELL N, 1991, LANCET, V337, P986, DOI 10.1016/0140-6736(91)91629-9; OPRAVIL M, 1994, ANTIMICROB AGENTS CH, V38, P1197, DOI 10.1128/AAC.38.5.1197; OPRAVIL M, 1993, 33RD INT C ANT AG CH, P316; OPRAVIL M, 1993, 9TH INT C AIDS, P373; PERTEL P, 1994, CLIN INFECT DIS, V18, P630, DOI 10.1093/clinids/18.4.630; PODZAMCZER D, 1993, AIDS, V7, P501, DOI 10.1097/00002030-199304000-00008; RUSKIN J, 1991, LANCET, V337, P468, DOI 10.1016/0140-6736(91)93402-U; SCHNEIDER MME, 1992, NEW ENGL J MED, V327, P1836, DOI 10.1056/NEJM199212243272603; TORRES RA, 1993, AM J MED, V95, P573, DOI 10.1016/0002-9343(93)90352-P; WORMSER GP, 1991, ARCH INTERN MED, V151, P688, DOI 10.1001/archinte.151.4.688; ZANGERLE R, 1991, LANCET, V337, P1232, DOI 10.1016/0140-6736(91)92910-T	40	98	100	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 15	1995	122	10					755	761		10.7326/0003-4819-122-10-199505150-00004	http://dx.doi.org/10.7326/0003-4819-122-10-199505150-00004			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QX147	7717598				2023-01-03	WOS:A1995QX14700004
J	BERNINI, JC; FORT, DW; GRIENER, JC; KANE, BJ; CHAPPELL, WB; KAMEN, BA				BERNINI, JC; FORT, DW; GRIENER, JC; KANE, BJ; CHAPPELL, WB; KAMEN, BA			AMINOPHYLLINE FOR METHOTREXATE-INDUCED NEUROTOXICITY	LANCET			English	Article							CHILDHOOD LEUKEMIA; ADENOSINE; FOLATE; ACCUMULATION; INHIBITOR; THERAPY; TISSUE; BRAIN; ACID	Methotrexate, a mainstay treatment for children with acute lymphoblastic leukaemia, can cause neurotoxicity, with paralysis, seizures, somnolence, anorexia, and headaches. The pathophysiology of this reaction is unknown. It has been suggested that the anti-inflammatory effect of methotrexate in patients with arthritis is due to adenosine release brought on by inhibition of purine synthesis. Since adenosine is a central nervous system depressant, we wondered whether adenosine release in the central nervous system could account for some of the neurotoxicity due to methotrexate, and whether that toxicity could be lessened by displacement of adenosine from its receptor by aminophylline. 6 patients (age 3-16 years) who had methotrexate-induced neurotoxicity unresponsive to standard treatment received 2.5 mg/kg aminophylline. In addition, the concentration of adenosine in the cerebrospinal fluid (CSF) from 11 children completing a 24-h systemic methotrexate protocol was compared with that in 8 newly diagnosed patients and 12 who had not received any treatment for at least a week. 4 of 6 patients with toxic signs and symptoms attributed to methotrexate and unrelieved by steroids, epidural blood patch, promethazine, 5-hydroytryptamine antagonists, paracetamol, and narcotics, had complete resolution of neurotoxicity after or during a l-h infusion of aminophylline; 2 others had a pronounced improvement but persistent nausea. CSF adenosine concentrations of patients receiving methotrexate, even when there was very slight or no toxicity, were greatly increased compared with control subjects (mean values of 217 and 51 nmol/L, median 175 and 52 nmol/L). Subacute methotrexate neurotoxicity may be mediated by adenosine and relieved by aminophylline.	UNIV TEXAS,SW MED CTR,DEPT PEDIAT,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; CHILDRENS MED CTR,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas								ALLEGRA CJ, 1985, P NATL ACAD SCI USA, V82, P4881, DOI 10.1073/pnas.82.15.4881; BAKER WJ, 1991, J CLIN ONCOL, V9, P679, DOI 10.1200/JCO.1991.9.4.679; BEARDSLEY GP, 1989, J BIOL CHEM, V264, P328; BERTINO JR, 1993, J CLIN ONCOL, V11, P5, DOI 10.1200/JCO.1993.11.1.5; BLEYER WA, 1981, CANCER TREAT REP, V65, P89; BRATTSTROM LE, 1988, SCAND J CLIN LAB INV, V48, P215, DOI 10.3109/00365518809167487; CAMITTA B, 1989, J CLIN ONCOL, V7, P1539, DOI 10.1200/JCO.1989.7.10.1539; CASH JM, 1994, NEW ENGL J MED, V330, P1368; CHEN LS, 1992, J CHROMATOGRPAHY, V16, P2791; CRONSTEIN BN, 1993, J CLIN INVEST, V92, P2675, DOI 10.1172/JCI116884; GREGORIOS JB, 1990, BRAIN RES, V516, P20, DOI 10.1016/0006-8993(90)90892-F; HEDQVIST P, 1978, CIRC RES, V43, P592, DOI 10.1161/01.RES.43.4.592; HERRMANN SC, 1992, J CHROMATOGR-BIOMED, V574, P247, DOI 10.1016/0378-4347(92)80036-P; JACOBSON KA, 1991, BIOCHEM PHARMACOL, V41, P1399, DOI 10.1016/0006-2952(91)90555-J; JONSSON OG, 1991, CANCER INVEST, V9, P53, DOI 10.3109/07357909109032800; KAMEN BA, 1984, CANCER RES, V44, P5092; KAMEN BA, 1986, NEUROTOXICOLOGY, V7, P209; KAMEN BA, 1987, METABOLISM ACTION AN, P141; KANE BJ, 1992, ANN PHARMACOTHER, V26, P939, DOI 10.1177/106002809202600718; KREMER JM, 1992, ARTHRITIS RHEUM, V35, P138, DOI 10.1002/art.1780350203; LUCOCK MD, 1993, NEUROCHEM RES, V18, P617, DOI 10.1007/BF00966940; Mastrangelo R, 1983, CENTRAL NERVOUS SYST, P71; MCINTOSH S, 1976, CANCER-AM CANCER SOC, V37, P853, DOI 10.1002/1097-0142(197602)37:2<853::AID-CNCR2820370234>3.0.CO;2-Q; MCLEAN AM, 1990, J PHARM SCI, V79, P1005, DOI 10.1002/jps.2600791112; OCHS JJ, 1989, AM J PEDIAT HEMATOL, V11, P93; OLNEY JW, 1981, NATURE, V292, P165, DOI 10.1038/292165a0; RALL T W, 1990, P618; SOLLEVI A, 1986, PROG NEUROBIOL, V27, P319, DOI 10.1016/0301-0082(86)90005-5; WINICK N, 1990, CANCER THER CONTROL, V1, P245; WINICK NJ, 1987, CANC DRUG DEL, V4, P25, DOI 10.1089/cdd.1987.4.25	30	111	116	0	6	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					544	547		10.1016/S0140-6736(95)90464-6	http://dx.doi.org/10.1016/S0140-6736(95)90464-6			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776773				2023-01-03	WOS:A1995QK44400009
J	OVERGAARD, J; GONZALEZ, DG; HULSHOF, MCCM; ARCANGELI, G; DAHL, O; MELLA, O; BENTZEN, SM				OVERGAARD, J; GONZALEZ, DG; HULSHOF, MCCM; ARCANGELI, G; DAHL, O; MELLA, O; BENTZEN, SM			RANDOMIZED TRIAL OF HYPERTHERMIA AS ADJUVANT TO RADIOTHERAPY FOR RECURRENT OR METASTATIC MALIGNANT-MELANOMA	LANCET			English	Article							COMBINED RADIATION-THERAPY; ONCOLOGY-GROUP; COMPLICATIONS; IRRADIATION	The value of hyperthermia as an adjuvant to radiotherapy in patients with malignant melanoma was studied in European multicentre trial. 134 metastatic or recurrent lesions of malignant melanoma in 70 patients were randomly assigned to receive radiotherapy (three fractions of 8 Gy or 9 Gy in 8 days) alone or followed by hyperthermia (43 degrees C for 60 min). Overall, the 2-year actuarial local tumour control was 37(SE 5)%. Univariate analysis showed a beneficial effect of hyperthermia (radiation alone 28% vs combined treatment 46%, p=0.008) and radiation dose (24 Gy 25% vs 27 Gy 56%, p=0.02), but no effect of tumour size (less than or equal to 4 cm 42% vs >4 cm 29%, p=021). Cox multivariate regression analysis showed the most important prognostic variables to be hyperthermia (odds ratio for 2-year local control 1.73 [95% CI 1.07-2.78], p=0.023), tumour size (0.91 [0.85-0.99], p=0.05), and radiation dose (1.17 [1.01-1.36], p=0.05). Addition of heat did not significantly increase acute or late radiation reactions. Heating was well tolerated, but because of difficulties with equipment only 14% of treatments achieved the protocol objective. The overall 5-year survival rate was 19%, but 38% of the patients for whom all known disease was controlled survived 5 years. Adjuvant hyperthermia significantly improved local tumour control when applied in association with radiation in treatment of malignant melanoma. Successful local treatment of patients with a single or a few metastatic malignant melanoma lesions has significant curative potential.	AARHUS UNIV HOSP,DEPT ONCOL,DK-8000 AARHUS,DENMARK; ACAD MED CTR,DEPT RADIOTHERAPY,AMSTERDAM,NETHERLANDS; G PORFIRI ONCOL CTR,DEPT RADIOTHERAPY,LATINA,ITALY; HAUKELAND HOSP,DEPT ONCOL,N-5021 BERGEN,NORWAY	Aarhus University; University of Amsterdam; Academic Medical Center Amsterdam; University of Bergen; Haukeland University Hospital	OVERGAARD, J (corresponding author), DANISH CANC SOC,DEPT EXPTL CLIN ONCOL,RADIUMSTN,NORREBROGADE 44,DK-8000 AARHUS C,DENMARK.		Bentzen, Søren M/E-3997-2012; Bentzen, Soren M/O-7787-2019	Bentzen, Søren M/0000-0002-7444-7564; Bentzen, Soren M/0000-0002-7444-7564; Hulshof, Maarten CCM/0000-0001-5240-3467				BENTZEN SM, 1989, RADIOTHER ONCOL, V16, P169, DOI 10.1016/0167-8140(89)90017-0; BENYOSEF R, 1992, INT J HYPERTHER, V8, P733, DOI 10.3109/02656739209005021; BERDEAUX DH, 1985, CANCER TREAT REP, V69, P397; BLOIS MS, 1983, CANCER-AM CANCER SOC, V52, P1330, DOI 10.1002/1097-0142(19831001)52:7<1330::AID-CNCR2820520732>3.0.CO;2-M; COX RS, 1992, INT J HYPERTHER, V8, P719, DOI 10.3109/02656739209005020; DEWHIRST MW, 1993, J NATL CANCER I, V85, P951, DOI 10.1093/jnci/85.12.951; ENGIN K, 1992, INT J RADIAT ONCOL, V25, P87; GONZALEZ DG, 1986, RADIOTHER ONCOL, V6, P105, DOI 10.1016/S0167-8140(86)80016-0; HAND JW, 1989, INT J HYPERTHER, V5, P421, DOI 10.3109/02656738909140469; KIM JH, 1982, CANCER-AM CANCER SOC, V50, P478, DOI 10.1002/1097-0142(19820801)50:3<478::AID-CNCR2820500316>3.0.CO;2-6; LEE YTNM, 1980, CANCER TREAT REV, V7, P59; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; OVERETT TK, 1985, CANCER, V56, P1222, DOI 10.1002/1097-0142(19850901)56:5<1222::AID-CNCR2820560544>3.0.CO;2-A; OVERGAARD J, 1989, INT J RADIAT ONCOL, V16, P535, DOI 10.1016/0360-3016(89)90470-7; OVERGAARD J, 1986, INT J RADIAT ONCOL, V12, P867, DOI 10.1016/0360-3016(86)90378-0; OVERGAARD J, 1987, INT J HYPERTHER, V3, P483, DOI 10.3109/02656738709140422; OVERGAARD J, 1986, RADIOTHER ONCOL, V5, P183, DOI 10.1016/S0167-8140(86)80048-2; OVERGAARD J, 1987, STRAHLENTHER ONKOL, V163, P453; OVERGAARD J, 1990, INTRO PRACTICAL ASPE, P213; OVERGAARD J, 1990, PIGMENT CELL, V10, P14; OVERGAARD M, 1987, RADIOTHER ONCOL, V9, P1, DOI 10.1016/S0167-8140(87)80213-X; PEREZ CA, 1991, AM J CLIN ONCOL-CANC, V14, P133, DOI 10.1097/00000421-199104000-00008; PEREZ CA, 1989, INT J RADIAT ONCOL, V16, P551, DOI 10.1016/0360-3016(89)90471-9; 1978, ICRU29 INT COMM RAD	24	459	468	0	8	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAR 4	1995	345	8949					540	543		10.1016/S0140-6736(95)90463-8	http://dx.doi.org/10.1016/S0140-6736(95)90463-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QK444	7776772				2023-01-03	WOS:A1995QK44400008
J	FISHWICK, D; PRASAN, A; ADAMS, P				FISHWICK, D; PRASAN, A; ADAMS, P			THROMBOLYSIS AND LOW-BACK-PAIN	BRITISH MEDICAL JOURNAL			English	Letter							STREPTOKINASE				FISHWICK, D (corresponding author), ROYAL VICTORIA INFIRM TRUST,DEPT CARDIOL & GEN MED,NEWCASTLE TYNE,TYNE & WEAR,ENGLAND.			Fishwick, David/0000-0001-5941-090X				[Anonymous], 1986, Lancet, V1, P397; BOURKE J, 1992, NEW ZEAL MED J, V105, P482; LEAR J, 1992, LANCET, V340, P851, DOI 10.1016/0140-6736(92)92726-V; SHAH M, 1990, BRIT MED J, V301, P1219, DOI 10.1136/bmj.301.6762.1219-a; 1991, BRIT MED J, V302, P111	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	FEB 25	1995	310	6978					504	504		10.1136/bmj.310.6978.504	http://dx.doi.org/10.1136/bmj.310.6978.504			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QJ598	7888893	Green Published			2023-01-03	WOS:A1995QJ59800025
J	BURNS, JP; REARDON, FE; TRUOG, RD				BURNS, JP; REARDON, FE; TRUOG, RD			USING NEWLY DECEASED PATIENTS TO TEACH RESUSCITATION PROCEDURES	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							CONSENT; INFANTS		HASSAN & REARDON, BOSTON, MA 02116 USA; CHILDRENS HOSP, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital	BURNS, JP (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, DIV PEDIAT CRIT CARE, NEMC 93, 750 WASHINGTON ST, BOSTON, MA 02111 USA.		Burns, Jeffrey P/AAW-8474-2021					ABRAMSON NS, 1981, JAMA-J AM MED ASSOC, V246, P2828; BENFIELD DG, 1991, JAMA-J AM MED ASSOC, V265, P2360, DOI 10.1001/jama.265.18.2360; BRATTEBO G, 1988, LANCET, V2, P1078; Clayton M., 1992, DRAWINGS COLLECTION; FEINBERG J, 1985, HASTINGS CENT REP, V15, P31, DOI 10.2307/3561915; Iserson K V, 1991, J Emerg Med, V9, P509, DOI 10.1016/0736-4679(91)90225-5; ISERSON KV, 1986, HASTINGS CENT REP, V16, P28, DOI 10.2307/3563273; MAY WF, 1985, HASTINGS CENT REP, V15, P38, DOI 10.2307/3561916; MORHAIM D K, 1991, Journal of Emergency Medicine, V9, P515, DOI 10.1016/0736-4679(91)90233-6; Orlowski J P, 1990, J Clin Ethics, V1, P201; ORLOWSKI JP, 1988, NEW ENGL J MED, V319, P439, DOI 10.1056/NEJM198808183190710; ROELS L, 1991, TRANSPLANT P, V23, P903; ROSNER F, 1991, MODERN MED JEWISH ET, P313; TACHAKRA SS, 1991, JAMA-J AM MED ASSOC, V266, P1649, DOI 10.1001/jama.1991.03470120051027; 1991, JAMA-J AM MED ASSOC, V266, P2837; 1993, AM MED NEWS     0322, P10	16	46	46	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 15	1994	331	24					1652	1655		10.1056/NEJM199412153312411	http://dx.doi.org/10.1056/NEJM199412153312411			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PW446	7772111				2023-01-03	WOS:A1994PW44600011
J	MARTIN, MA; PFALLER, MA; WENZEL, RP				MARTIN, MA; PFALLER, MA; WENZEL, RP			COAGULASE-NEGATIVE STAPHYLOCOCCAL BACTEREMIA - MORTALITY AND HOSPITAL STAY	ANNALS OF INTERNAL MEDICINE			English	Article									UNIV IOWA, COLL MED, DEPT MED, DIV CLIN EPIDEMIOL, IOWA CITY, IA 52242 USA	University of Iowa								[Anonymous], 1978, INT CLASSIFICATION D; BATTISTI O, 1981, ARCH DIS CHILD, V56, P775, DOI 10.1136/adc.56.10.775; BENDER JW, 1980, JOHNS HOPKINS MED J, V146, P13; BURCHARD KW, 1984, ARCH SURG-CHICAGO, V119, P96; CHRISTENSEN GD, 1982, ANN INTERN MED, V96, P1, DOI 10.7326/0003-4819-96-1-1; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P363; CONOVER WJ, 1980, PRACTICAL NONPARAMET, P280; DELEON SP, 1984, AM J MED, V77, P639, DOI 10.1016/0002-9343(84)90354-1; DIXON RE, 1978, ANN INTERN MED, V89, P749, DOI 10.7326/0003-4819-89-5-749; DONOWITZ LG, 1987, AM J INFECT CONTROL, V15, P141, DOI 10.1016/0196-6553(87)90137-4; FEINSTEIN AR, 1988, J CLIN INVEST, V81, P1, DOI 10.1172/JCI113279; FEWINSTEIN AR, 1985, CLIN EPIDEMIOLOGY AR, P225; Fleiss J, 1981, STAT METHODS RATES P, V2nd, P113; FORSE RA, 1979, SURGERY, V86, P507; KAUFFMAN CA, 1984, ANN INTERN MED, V101, P60, DOI 10.7326/0003-4819-101-1-60; KELSEY JL, 1986, METHODS OBSERVATIONA, P128; KIRCHHOFF LV, 1985, INFECT CONT HOSP EP, V6, P479, DOI 10.1017/S0195941700063591; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P143; KLOOS WE, 1982, J CLIN MICROBIOL, V16, P509, DOI 10.1128/JCM.16.3.509-516.1982; KREGER BE, 1980, AM J MED, V68, P332, DOI 10.1016/0002-9343(80)90101-1; LANGLEY J, 1988, PEDIATR INFECT DIS J, V7, P34, DOI 10.1097/00006454-198801000-00008; LORENTZEN JE, 1985, SURGERY, V98, P81; LOWDER JN, 1982, ARCH INTERN MED, V142, P1456, DOI 10.1001/archinte.142.8.1456; MacMahon B., 1970, EPIDEMIOLOGY PRINCIP, P43; MAKI DG, 1977, NEW ENGL J MED, V296, P1305, DOI 10.1056/NEJM197706092962301; MARTIN MA, 1987, INTERSCIENCE C ANTIM; MCCABE WR, 1962, ARCH INTERN MED, V110, P856, DOI 10.1001/archinte.1962.03620240038007; MCCABE WR, 1962, ARCH INTERN MED, V110, P847, DOI 10.1001/archinte.1962.03620240029006; MORRISON AJ, 1986, INFECT CONT HOSP EP, V7, P550, DOI 10.1017/S0195941700065309; MOYER MA, 1983, ARCH INTERN MED, V143, P66, DOI 10.1001/archinte.143.1.66; PFALLER M A, 1988, Clinical Microbiology Reviews, V1, P281; PRESS OW, 1984, MEDICINE, V63, P189, DOI 10.1097/00005792-198407000-00001; ROSE R, 1977, SOUTHERN MED J, V70, P1267, DOI 10.1097/00007611-197711000-00005; Schlesselman JJ., 1982, CASE CONTROL STUDIES, P160; SECHZER PH, 1963, ANESTHESIOLOGY, V24, P779, DOI 10.1097/00000542-196311000-00005; SEIGEL DG, 1973, J CHRON DIS, V26, P219, DOI 10.1016/0021-9681(73)90102-1; SHERERTZ RJ, 1983, ARCH INTERN MED, V143, P52, DOI 10.1001/archinte.143.1.52; SITGESSERRA A, 1980, SURG GYNECOL OBSTET, V151, P481; SMITH IM, 1958, ARCH INTERN MED, V102, P375, DOI 10.1001/archinte.1958.00030010375005; SMITH IM, 1981, STAPHYLOCOCCI STAPHY, P765; SPENGLER RF, 1978, JOHNS HOPKINS MED J, V142, P77; SPENGLER RF, 1978, JAMA-J AM MED ASSOC, V240, P2455, DOI 10.1001/jama.240.22.2455; STILLMAN RI, 1987, INFECT CONT HOSP EP, V8, P108, DOI 10.1017/S0195941700067278; TOWNSEND TR, 1981, AM J EPIDEMIOL, V114, P73, DOI 10.1093/oxfordjournals.aje.a113176; WADE JC, 1982, ANN INTERN MED, V97, P503, DOI 10.7326/0003-4819-97-4-503; WENZEL RP, 1976, AM J EPIDEMIOL, V103, P251, DOI 10.1093/oxfordjournals.aje.a112223; WEY SB, 1988, IN PRESS ARCH INTERN; WILSON WR, 1982, MAYO CLIN PROC, V57, P155; WINSTON DJ, 1983, ARCH INTERN MED, V143, P32, DOI 10.1001/archinte.143.1.32; WOLFF SM, 1974, NEW ENGL J MED, V291, P733, DOI 10.1056/NEJM197410032911411; 1984, PHYSICIANS DRG WORKI; 1972, DEFINITIONS USED NAT, P261; 1984, CDC SURVEILLANCE SUM, V33, P955	53	295	296	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 1	1989	110	1					9	16		10.7326/0003-4819-110-1-9	http://dx.doi.org/10.7326/0003-4819-110-1-9			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R7361	2908834				2023-01-03	WOS:A1989R736100004
J	HASHIZUME, M; KITANO, S; YAMAGA, H; SUGIMACHI, K				HASHIZUME, M; KITANO, S; YAMAGA, H; SUGIMACHI, K			HAPTOGLOBIN TO PROTECT AGAINST RENAL DAMAGE FROM ETHANOLAMINE OLEATE SCLEROSANT	LANCET			English	Letter											HASHIZUME, M (corresponding author), KYUSHU UNIV,FAC MED,DEPT SURG 2,FUKUOKA 812,JAPAN.							HERMAN EC, 1961, J LAB CLIN MED, V57, P834; KITANO S, 1987, HEPATOLOGY, V7, P810, DOI 10.1002/hep.1840070503; LALICH JJ, 1955, ARCH PATHOL, V60, P389; MALING TJB, 1975, NEW ZEAL MED J, V82, P269; WITZEL L, 1985, LANCET, V1, P773	5	72	74	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	AUG 6	1988	2	8606					340	341						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P5449	2899760				2023-01-03	WOS:A1988P544900058
J	SAUERBRUCH, T; WOTZKA, R; KOPCKE, W; HARLIN, M; HELDWEIN, W; BAYERDORFFER, E; SANDER, R; ANSARI, H; STARZ, I; PAUMGARTNER, G				SAUERBRUCH, T; WOTZKA, R; KOPCKE, W; HARLIN, M; HELDWEIN, W; BAYERDORFFER, E; SANDER, R; ANSARI, H; STARZ, I; PAUMGARTNER, G			PROPHYLACTIC SCLEROTHERAPY BEFORE THE 1ST EPISODE OF VARICEAL HEMORRHAGE IN PATIENTS WITH CIRRHOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									STUDY GRP PROPHYLAXIS VARICEAL BLEEDING,MUNICH,FED REP GER									BAKER LA, 1959, AM J MED, V26, P228, DOI 10.1016/0002-9343(59)90311-0; BEPPU K, 1981, GASTROINTEST ENDOSC, V27, P213, DOI 10.1016/S0016-5107(81)73224-3; BURROUGHS AK, 1986, HEPATOLOGY, V6, P1407, DOI 10.1002/hep.1840060631; CELLO JP, 1987, NEW ENGL J MED, V316, P11, DOI 10.1056/NEJM198701013160103; CONN HO, 1969, AM J SURG, V117, P656, DOI 10.1016/0002-9610(69)90401-2; CONN HO, 1965, NEW ENGL J MED, V272, P1255, DOI 10.1056/NEJM196506172722402; Cox D. R, 1977, ANAL BINARY DATA; EFRON B, 1971, BIOMETRIKA, V58, P403, DOI 10.1093/biomet/58.3.403; GREGORY P, 1987, GASTROENTEROLOGY, V92, P1414; HERMOS JA, 1984, ALCOHOL CLIN EXP RES, V8, P314, DOI 10.1111/j.1530-0277.1984.tb05518.x; INOKUCHI K, 1984, ANN SURG, V200, P61, DOI 10.1097/00000658-198407000-00010; JACKSON FC, 1971, ANN SURG, V174, P672, DOI 10.1097/00000658-197110000-00012; JACKSON FC, 1968, AM J SURG, V115, P22, DOI 10.1016/0002-9610(68)90127-X; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOCH H, 1986, ENDOSCOPY, V18, P40, DOI 10.1055/s-2007-1018322; LEBREC D, 1986, GASTROENTEROLOGY, V90, P1740; LEBREC D, 1980, GASTROENTEROLOGY, V79, P1139; MACDOUGALL BRD, 1982, LANCET, V1, P124; MANTEL N, 1959, J NATL CANCER I, V22, P719; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PAGLIARO L, 1986, NEW ENGL J MED, V314, P244; PAQUET KJ, 1982, ENDOSCOPY, V14, P4, DOI 10.1055/s-2007-1021560; PASCAL JP, 1987, NEW ENGL J MED, V317, P856, DOI 10.1056/NEJM198710013171403; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; RESNICK RH, 1969, ANN INTERN MED, V70, P675, DOI 10.7326/0003-4819-70-4-675; REYNOLDS TB, 1981, GASTROENTEROLOGY, V80, P1005; RUEFF B, 1976, LANCET, V1, P655; SANTANGELO WC, 1988, NEW ENGL J MED, V318, P814, DOI 10.1056/NEJM198803313181304; SAUERBRUCH T, 1985, SCAND J GASTROENTERO, V20, P51, DOI 10.3109/00365528509089632; TERBLANCHE J, 1983, LANCET, V2, P1328; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WESTABY D, 1984, GUT, V25, P129, DOI 10.1136/gut.25.2.129; WITZEL L, 1985, LANCET, V1, P773; WORDEHOFF D, 1987, DEUT MED WOCHENSCHR, V112, P947, DOI 10.1055/s-2008-1068172; 1984, N ENGL J MED, V311, P1594	36	134	136	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 7	1988	319	1					8	15		10.1056/NEJM198807073190102	http://dx.doi.org/10.1056/NEJM198807073190102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P0947	3288871				2023-01-03	WOS:A1988P094700002
J	MURCIANO, D; BOCZKOWSKI, J; LECOCGUIC, Y; EMILI, JM; PARIENTE, R; AUBIER, M				MURCIANO, D; BOCZKOWSKI, J; LECOCGUIC, Y; EMILI, JM; PARIENTE, R; AUBIER, M			TRACHEAL OCCLUSION PRESSURE - A SIMPLE INDEX TO MONITOR RESPIRATORY MUSCLE FATIGUE DURING ACUTE RESPIRATORY-FAILURE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article									HOP BEAUJON, FAC X BICHAT,INSERM,U220,PNEUMOL CLIN, 100 BD GEN LECLERC, F-92110 CLICHY, FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Boczkowski, Jorge/S-7474-2018	Boczkowski, Jorge/0000-0001-6619-5785				AUBIER M, 1981, J APPL PHYSIOL, V50, P538, DOI 10.1152/jappl.1981.50.3.538; AUBIER M, 1980, AM REV RESPIR DIS, V122, P747, DOI 10.1164/arrd.1980.122.5.747; AUBIER M, 1980, AM REV RESPIR DIS, V122, P191; BARNARD PA, 1986, J APPL PHYSIOL, V60, P1067, DOI 10.1152/jappl.1986.60.3.1067; BEGIN R, 1982, AM REV RESPIR DIS, V125, P312; COHEN CA, 1982, AM J MED, V73, P308, DOI 10.1016/0002-9343(82)90711-2; DERENNE JP, 1978, AM REV RESPIR DIS, V118, P581; DERENNE JP, 1978, AM REV RESPIR DIS, V118, P373; DERENNE JP, 1978, AM REV RESPIR DIS, V118, P119; FLEURY B, 1985, AM REV RESPIR DIS, V131, P822; GELB AF, 1977, AM REV RESPIR DIS, V116, P9; GRASSINO A, 1979, B EUR PHYSIOPATH RES, V15, P105; GROSS D, 1979, J APPL PHYSIOL, V46, P1, DOI 10.1152/jappl.1979.46.1.1; HOLLE RHO, 1984, J APPL PHYSIOL, V57, P1150, DOI 10.1152/jappl.1984.57.4.1150; KAISER E, 1963, Electromyography, V3, P5; KIMBALL WR, 1982, AM REV RESPIR DIS, V126, P991; MILICEMILI J, 1980, ANESTH ANALG, V59, P865; MURCIANO D, 1982, AM REV RESPIR DIS, V126, P113; ROSSI A, 1985, AM REV RESPIR DIS, V131, P672; ROUSSOS C, 1979, B EUR PHYSIOPATH RES, V15, P117; ROUSSOS CS, 1977, J APPL PHYSIOL, V43, P189, DOI 10.1152/jappl.1977.43.2.189; SASSOON CSH, 1987, AM REV RESPIR DIS, V135, P107; SORLI J, 1978, CLIN SCI MOL MED, V54, P295, DOI 10.1042/cs0540295; WHITELAW WA, 1975, RESP PHYSIOL, V23, P181, DOI 10.1016/0034-5687(75)90059-6; WILSON SH, 1984, THORAX, V39, P535, DOI 10.1136/thx.39.7.535; 1961, AIDE MEMOIRE PRATIQU	26	89	91	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN	1988	108	6					800	805		10.7326/0003-4819-108-6-800	http://dx.doi.org/10.7326/0003-4819-108-6-800			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7293	3369770				2023-01-03	WOS:A1988N729300004
J	FALK, JL; RACKOW, EC; WEIL, MH				FALK, JL; RACKOW, EC; WEIL, MH			END-TIDAL CARBON-DIOXIDE CONCENTRATION DURING CARDIOPULMONARY RESUSCITATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV HLTH SCI CHICAGO MED SCH,DEPT MED,DIV CRIT CARE MED,3333 GREEN BAY RD,N CHICAGO,IL 60064; UNIV HLTH SCI CHICAGO MED SCH,DEPT MED,DIV CARDIOL,N CHICAGO,IL 60064	Chicago Medical School; Chicago Medical School								BARSAN WG, 1981, ANN EMERG MED, V10, P135, DOI 10.1016/S0196-0644(81)80377-0; BIRCHER N, 1980, CRIT CARE MED, V8, P147, DOI 10.1097/00003246-198003000-00012; BISHOP RL, 1976, JAMA-J AM MED ASSOC, V235, P506, DOI 10.1001/jama.235.5.506; CHANDRA N, 1980, LANCET, V1, P175; DELGUERCIO LR, 1963, NEW ENGL J MED, V269, P1398, DOI 10.1056/NEJM196312262692603; DUBOIS AB, 1952, J APPL PHYSIOL, V4, P526, DOI 10.1152/jappl.1952.4.7.526; ECKENHOFF JE, 1963, BRIT J ANAESTH, V35, P750, DOI 10.1093/bja/35.12.750; FREEMAN J, 1963, CLIN SCI, V24, P135; GARNETT AR, 1987, JAMA-J AM MED ASSOC, V257, P512, DOI 10.1001/jama.257.4.512; GERST PH, 1959, J CLIN INVEST, V38, P524, DOI 10.1172/JCI103830; GRUNDLER W, 1986, CIRCULATION, V74, P1071, DOI 10.1161/01.CIR.74.5.1071; GUDIPATI CV, 1988, CIRCULATION, V77, P234, DOI 10.1161/01.CIR.77.1.234; GUDIPATI CV, 1986, CRIT CARE MED, V14, P432, DOI 10.1097/00003246-198604000-00241; GUDIPATI CV, 1986, CHEST, V89, pS446; KALENDA Z, 1978, RESUSCITATION, V6, P259, DOI 10.1016/0300-9572(78)90006-0; KOUWENHOVEN WB, 1960, JAMA-J AM MED ASSOC, V173, P1064, DOI 10.1001/jama.1960.03020280004002; MACKENZIE GJ, 1964, LANCET, V1, P1342; MAIER GW, 1984, CIRCULATION, V70, P86, DOI 10.1161/01.CIR.70.1.86; MCASLAN TC, 1976, CRIT CARE MED, V4, P255, DOI 10.1097/00003246-197609000-00008; NIEMANN JT, 1984, AM J CARDIOL, V53, P269, DOI 10.1016/0002-9149(84)90438-7; RALSTON SH, 1982, ANESTH ANALG, V61, P645; REDDING J S, 1971, Anesthesia and Analgesia, V50, P668; Relman A S, 1986, N Engl J Med, V315, P188, DOI 10.1056/NEJM198607173150310; RIKER JB, 1976, CRIT CARE MED, V4, P223, DOI 10.1097/00003246-197609000-00002; RILEY RL, 1946, AM J PHYSIOL, V147, P191, DOI 10.1152/ajplegacy.1946.147.1.191; ROSBOROUGH JP, 1981, CIRCULATION, V64, P303; SAUNDERS AB, 1985, ANN EMERG MED, V14, P948; SIKAND R, 1966, J APPL PHYSIOL, V21, P1331, DOI 10.1152/jappl.1966.21.4.1331; Smallhout B, 1975, ATLAS CAPNOGRAPHY, V1, P28; STEENBLOCK U, 1976, RESPIRATION, V33, P133, DOI 10.1159/000193726; TREVINO RP, 1985, CRIT CARE MED, V13, P910, DOI 10.1097/00003246-198511000-00012; VOORHEES WD, 1980, CRIT CARE MED, V8, P134, DOI 10.1097/00003246-198003000-00008; WEIL MH, 1985, CRIT CARE MED, V13, P907, DOI 10.1097/00003246-198511000-00011; WEIL MH, 1986, NEW ENGL J MED, V315, P153, DOI 10.1056/NEJM198607173150303; WEIL MH, 1985, CRIT CARE MED, V13, P888, DOI 10.1097/00003246-198511000-00005; WEISER M, 1962, AM J CARDIOL, V10, P555; 1980, JAMA, V244, P453; 1986, JAMA, V255, P2905	38	294	300	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 10	1988	318	10					607	611		10.1056/NEJM198803103181005	http://dx.doi.org/10.1056/NEJM198803103181005			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M3891	3125432				2023-01-03	WOS:A1988M389100005
J	ANAND, KJS; SIPPELL, WG; SCHOFIELD, NM; AYNSLEYGREEN, A				ANAND, KJS; SIPPELL, WG; SCHOFIELD, NM; AYNSLEYGREEN, A			DOES HALOTHANE ANESTHESIA DECREASE THE METABOLIC AND ENDOCRINE STRESS RESPONSES OF NEWBORN-INFANTS UNDERGOING OPERATION	BRITISH MEDICAL JOURNAL			English	Article									UNIV KIEL,KINDERKLIN,ALLGEMEINE PADIAT ABT,D-2300 KIEL 1,FED REP GER; JOHN RADCLIFFE HOSP,NUFFIELD DEPT ANAESTHET,OXFORD OX3 9DU,ENGLAND; ROYAL VICTORIA INFIRM,DEPT CHILD HLTH,NEWCASTLE TYNE NE1 4LP,TYNE & WEAR,ENGLAND	University of Kiel; University of Oxford; Newcastle University - UK	ANAND, KJS (corresponding author), HARVARD UNIV,CHILDRENS HOSP,DEPT ANESTHESIA,BOSTON,MA 02115, USA.		Anand, Kanwaljeet/B-3287-2014	Anand, Kanwaljeet/0000-0001-6498-1483				ALBANO JDM, 1972, ACTA ENDOCRINOL-COP, V70, P487, DOI 10.1530/acta.0.0700487; Altman DG., 1982, STATISTICS PRACTICE, P6; ANAND KJS, 1987, LANCET, V1, P243; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; ANAND KJS, 1985, HORM RES, V22, P115, DOI 10.1159/000180083; AYNSLEYGREEN A, 1973, DIABETOLOGIA, V9, P274, DOI 10.1007/BF01221854; Bergmeyer HU, 1974, METHOD ENZYMAT AN, P1196; BESSEY PQ, 1984, ANN SURG, V200, P264, DOI 10.1097/00000658-198409000-00004; BIEBUYCK JF, 1972, BIOCHEM J, V128, P711, DOI 10.1042/bj1280711; BROMAGE PR, 1971, SURG GYNECOL OBSTETR, V132, P1051; BROWN MJ, 1981, CLIN SCI, V61, P591, DOI 10.1042/cs0610591; BURGOYNE JL, 1982, CLIN SCI, V63, P421, DOI 10.1042/cs0630421; DIAZ J H, 1979, Anesthesiology (Hagerstown), V51, pS313; DIERDORF SF, 1981, ANESTH ANALG, V60, P204, DOI 10.1213/00000539-198160040-00007; GELMAN S, 1984, ANESTHESIOLOGY, V61, P726, DOI 10.1097/00000542-198412000-00017; GHATEI MA, 1983, ENDOCRINOLOGY, V112, P917, DOI 10.1210/endo-112-3-917; Gilles F. H., 1983, GROWTH EPIDEMIOL NEU, P117, DOI [10.1016/b978-0-7236-7017-9.50018-1, DOI 10.1016/B978-0-7236-7017-9.50018-1]; GREGORY GA, 1969, ANESTHESIOLOGY, V30, P488, DOI 10.1097/00000542-196905000-00003; GREGORY GA, 1982, CAN ANAESTH SOC J, V29, P105, DOI 10.1007/BF03007985; HADJIAN AJ, 1975, PEDIATR RES, V9, P40, DOI 10.1203/00006450-197509010-00008; IM MJC, 1979, J SURG RES, V10, P459; INKSTER JS, 1977, RECENT ADV ANAESTH A, V12, P59; LERMAN J, 1983, ANESTHESIOLOGY, V59, P421, DOI 10.1097/00000542-198311000-00010; MURRAY AJ, 1981, ANAL BIOCHEM, V116, P537, DOI 10.1016/0003-2697(81)90399-7; NICODEMUS HF, 1969, ANESTHESIOLOGY, V31, P344, DOI 10.1097/00000542-196910000-00011; OBARA H, 1984, CAN ANAESTH SOC J, V31, P24, DOI 10.1007/BF03011479; PERRY LB, 1974, ANESTHESIOLOGY, V40, P465, DOI 10.1097/00000542-197405000-00014; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; ROIZEN MF, 1974, ANESTHESIOLOGY, V41, P432, DOI 10.1097/00000542-197411000-00005; ROIZEN MF, 1981, ANESTHESIOLOGY, V54, P390, DOI 10.1097/00000542-198105000-00008; SALEM MR, 1980, CRIT CARE MED, V8, P541, DOI 10.1097/00003246-198010000-00003; SIPPELL WG, 1978, J STEROID BIOCHEM, V9, P63, DOI 10.1016/0022-4731(78)90104-8; SPERLING MA, 1982, MONOGR PAEDIATR, V16, P39; SRINIVASAN G, 1986, J PEDIATR SURG, V21, P718, DOI 10.1016/S0022-3468(86)80395-5; UOZUMI T, 1972, ACTA ENDOCRINOL-COP, V69, P517, DOI 10.1530/acta.0.0690517; Williamson D. H, 1982, BIOCH DEV FETUS NEON, P621	36	92	93	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 5	1988	296	6623					668	672		10.1136/bmj.296.6623.668	http://dx.doi.org/10.1136/bmj.296.6623.668			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M4461	3128362	Green Published			2023-01-03	WOS:A1988M446100007
J	DUNEA, G				DUNEA, G			LETTER FROM CHICAGO - MATTERS OF TURF	BRITISH MEDICAL JOURNAL			English	Editorial Material											DUNEA, G (corresponding author), COOK CTY HOSP,CHICAGO,IL 60612, USA.							DUNEA G, 1979, BRIT MED J, V1, P795, DOI 10.1136/bmj.1.6166.795; WHITTINGTON HG, 1987, AM MED NEWS     0515, P32	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 23	1988	296	6617					277	278		10.1136/bmj.296.6617.277	http://dx.doi.org/10.1136/bmj.296.6617.277			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L8774	3124910	Green Published			2023-01-03	WOS:A1988L877400024
J	POULTER, NR; CHANG, CL; FARLEY, TMM; MEIRIK, O; MARMOT, MG; DEBERTRIBEIRO, M; MEDINA, E; ARTIGAS, J; HE, S; ZHONG, YH; ZHANG, DW; ZHAO, WJ; ROJAS, O; VESSEY, MP; HEINEMANN, L; DONNAN, S; HO, S; BARTFAI, G; KISJANTO, J; WILKS, R; AGWANDA, R; RUIZ, R; KOZUHNOVAK, M; DUSITSIN, N; VIRUTAMASEN, P; PHANTHUMCHINDA, K; KOETSAWANG, S; PIYAANANT, M; DEMIROVIC, J; BELKIC, K; MWANDILA, WS; MUTALE, CM; MATENGA, J; WILSON, A; PETITTI, D; HOLCK, S; LAWLEY, S; SMITH, S; SHIPLEY, M; OLSEN, J; THOROGOOD, M; KELAGHAN, J				POULTER, NR; CHANG, CL; FARLEY, TMM; MEIRIK, O; MARMOT, MG; DEBERTRIBEIRO, M; MEDINA, E; ARTIGAS, J; HE, S; ZHONG, YH; ZHANG, DW; ZHAO, WJ; ROJAS, O; VESSEY, MP; HEINEMANN, L; DONNAN, S; HO, S; BARTFAI, G; KISJANTO, J; WILKS, R; AGWANDA, R; RUIZ, R; KOZUHNOVAK, M; DUSITSIN, N; VIRUTAMASEN, P; PHANTHUMCHINDA, K; KOETSAWANG, S; PIYAANANT, M; DEMIROVIC, J; BELKIC, K; MWANDILA, WS; MUTALE, CM; MATENGA, J; WILSON, A; PETITTI, D; HOLCK, S; LAWLEY, S; SMITH, S; SHIPLEY, M; OLSEN, J; THOROGOOD, M; KELAGHAN, J			VENOUS THROMBOEMBOLIC DISEASE AND COMBINED ORAL-CONTRACEPTIVES - RESULTS OF INTERNATIONAL MULTICENTER CASE-CONTROL STUDY	LANCET			English	Article							NONFATAL VASCULAR-DISEASE; MU-G ETHINYLESTRADIOL; CARDIOVASCULAR-DISEASE; ETHINYL ESTRADIOL; SERUM LEVELS; 12 CYCLES; THROMBOSIS; WOMEN; FORMULATIONS; DESOGESTREL	The composition and use of oral contraceptives (OCs) have changed since their cardiovascular side-effects were established 20 years ago. This report describes the risk of idiopathic venous thromboembolic (VTE) events (deep vein thrombosis [DVT] and/or pulmonary embolism [PEI]) in association with current use of combined OCs among 1143 cases aged 20-44 and 2998 age-matched controls, as evaluated in a hospital-based, case-control study in 21 centres in Africa, Asia, Europe, and Latin America. OC use was associated with an increased risk of VTE in Europe (odds ratio 4.15 [95% CI 3.09-5.57]) and in non-European (''developing'') countries (3.25 [2.59-4.08]). Risk estimates were generally higher for DVT than for PE but no consistent trend by certainty of diagnosis (definite, probable, possible) was found. Increased risk was apparent within 4 months of starting OCs, was unaffected by duration of current episode of OC use, and had disappeared within 3 months of stopping OCs. Relative risk estimates of VTE associated with OC use were unaffected by age of user, by history of hypertension (excluding hypertension in pregnancy), or in any consistent way by smoking. However, in both groups of countries increased body mass index (BMI) was an independent risk factor for VTE, and OC-associated odds ratios were higher among those with a BMI above 25 kg/m(2) than among those with smaller BMIs. OC-associated risk estimates were high among women in Europe with a history of hypertension in pregnancy. Odds ratios associated with the use of OCs containing a third-generation progestagen observed with progestagens type) and second (norgestrel group) generation. Odds ratios associated with first and second generation progestagens tended to be lower, though not significantly, when used in combination with low (<50 mu g oestrogen) rather than higher oestrogen doses. This study confirms an association between OC use and VTE in Europe and the developing countries, although overall risk estimates associated with use were lower than demonstrated in most previous studies of non-fatal idiopathic VTE.	ESCOLA PAULISTA MED, SAO PAULO, BRAZIL; ESCUELA MED, VALPARAISO, CHILE; SHANGHAI INST PLANNED PARENTHOOD RES, SHANGHAI, PEOPLES R CHINA; UNIV VALLE, FAC SALUD, CALI, COLOMBIA; UNIV OXFORD, OXFORD, ENGLAND; ZENTRUM EPIDEMIOL & GESUNDHEITFORSCH, BERLIN, GERMANY; CHINESE UNIV HONG KONG, HONG KONG, HONG KONG; ALBERT SZENT GYORGYI MED UNIV, H-6701 SZEGED, HUNGARY; UNIV INDONESIA, FAC MED, JAKARTA, INDONESIA; UNIV W INDIES, TROP METAB RES UNIT, KINGSTON 7, JAMAICA; KENYA GOVT MED RES CTR, NAIROBI, KENYA; GRP INTERUNIV MEXICANO INVEST EPIDEMIOL SALUD REP, DURANGO, MEXICO; UNIV LJUBLJANA, INST PUBL HLTH, LJUBLJANA, SLOVENIA; CHULALONGKORN HOSP, BANGKOK, THAILAND; SIRIRAJ HOSP, SIRIRAJ FAMILY HLTH RES CTR, BANGKOK, THAILAND; UNIV BELGRADE, SCH MED, BELGRADE, YUGOSLAVIA; UNIV LUSAKA, TEACHING HOSP, LUSAKA, ZAMBIA; UNIV ZIMBABWE, HARARE, ZIMBABWE	Universidade Federal de Sao Paulo (UNIFESP); Universidad del Valle; University of Oxford; Chinese University of Hong Kong; Szeged University; University of Indonesia; University West Indies Mona Jamaica; Kenya Medical Research Institute; University of Ljubljana; Chulalongkorn University; Mahidol University; University of Belgrade; University of Zimbabwe			Marmot, M G/Y-3920-2019	Marmot, M G/0000-0002-2431-6419	Medical Research Council [G8802774] Funding Source: researchfish	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)		[Anonymous], 1973, Lancet, V1, P1399; [Anonymous], 1967, J R Coll Gen Pract, V13, P267; BOTTIGER LE, 1971, ACTA MED SCAND, V190, P455; Breslow N.E., 1980, STAT METHODS CANC RE, P192; FARLEY TMM, 1995, LANCET, V346, P1582; GERSTMAN BB, 1990, INT J EPIDEMIOL, V19, P931, DOI 10.1093/ije/19.4.931; GODSLAND IF, 1990, NEW ENGL J MED, V323, P1375, DOI 10.1056/NEJM199011153232003; GREENE GR, 1972, AM J PUBLIC HEALTH N, V62, P680, DOI 10.2105/AJPH.62.5.680; HELMRICH SP, 1987, OBSTET GYNECOL, V69, P91; HUMPEL M, 1990, AM J OBSTET GYNECOL, V163, P329; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JORDAN WM, 1961, LANCET, V2, P1146, DOI DOI 10.1016/S0140-6736(61)91061-3; KUHL H, 1988, CONTRACEPTION, V38, P381, DOI 10.1016/0010-7824(88)90110-2; KUHL H, 1988, CONTRACEPTION, V38, P477, DOI 10.1016/0010-7824(88)90088-1; KUHNZ W, 1990, HORM RES, V33, P40, DOI 10.1159/000181446; LAROSA JC, 1988, AM J OBSTET GYNECOL, V158, P1621, DOI 10.1016/0002-9378(88)90200-1; LAWSON DH, 1977, BRIT MED J, V2, P729, DOI 10.1136/bmj.2.6089.729; MAGUIRE MG, 1979, AM J EPIDEMIOL, V110, P188, DOI 10.1093/oxfordjournals.aje.a112803; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; NICOLAIDES AN, 1995, THROMBOEMBOLISM, P193; PERLMAN JA, 1985, J CHRON DIS, V38, P857, DOI 10.1016/0021-9681(85)90110-9; PETITTI DB, 1978, AM J EPIDEMIOL, V108, P480, DOI 10.1093/oxfordjournals.aje.a112646; POLLER L, 1978, BRIT MED BULL, V34, P151, DOI 10.1093/oxfordjournals.bmb.a071485; PORTER JB, 1985, OBSTET GYNECOL, V66, P1; PORTER JB, 1982, OBSTET GYNECOL, V59, P299; POULOSE KP, 1970, BRIT MED J, V3, P67, DOI 10.1136/bmj.3.5714.67; RAMCHARAN S, 1981, NIH81564 CTR POP RES; REALINI JP, 1985, AM J OBSTET GYNECOL, V152, P729, DOI 10.1016/S0002-9378(85)80001-6; ROYAL COLLEGE OF GENERAL PRACTITIONERS' ORAL CONTRACEPTION STUDY, 1978, Journal of the Royal College of General Practitioners, V28, P393; SARTWELL PE, 1969, AM J EPIDEMIOL, V90, P365, DOI 10.1093/oxfordjournals.aje.a121082; STADEL BV, 1981, NEW ENGL J MED, V305, P612, DOI 10.1056/NEJM198109103051104; STADEL BV, 1981, NEW ENGL J MED, V305, P672, DOI 10.1056/NEJM198109173051205; STOLLEY PD, 1975, AM J EPIDEMIOL, V102, P197, DOI 10.1093/oxfordjournals.aje.a112148; THOROGOOD M, 1992, INT J EPIDEMIOL, V21, P48, DOI 10.1093/ije/21.1.48; THOROGOOD M, 1990, BRIT J FAMILY PLANNI, V0016; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526; VESSEY M P, 1980, British Journal of Family Planning, V6, P1; VESSEY MP, 1968, BMJ-BRIT MED J, V2, P199, DOI 10.1136/bmj.2.5599.199; VESSEY MP, 1970, BMJ-BRIT MED J, V3, P123, DOI 10.1136/bmj.3.5715.123; VESSEY MP, 1969, BRIT MED J, V2, P651, DOI 10.1136/bmj.2.5658.651; VESSEY MP, 1990, ORAL CONTRACEPTIVES, P121; VREIM CE, 1990, JAMA-J AM MED ASSOC, V263, P2753; WACHOLDER S, 1992, AM J EPIDEMIOL, V135, P1019, DOI 10.1093/oxfordjournals.aje.a116396; WELLS PS, 1995, LANCET, V345, P1326, DOI 10.1016/S0140-6736(95)92535-X; WESSLER S, 1976, JAMA-J AM MED ASSOC, V236, P2179, DOI 10.1001/jama.236.19.2179; 1991, EPIDEMIOLOGICAL GRAP; IN PRESS J EPIDEMIOL; IN PRESS J CLIN EPID	48	554	559	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 16	1995	346	8990					1575	1582						8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500748				2023-01-03	WOS:A1995TK48100007
J	WILSON, RPH; BUCHAN, I; WALLEY, T				WILSON, RPH; BUCHAN, I; WALLEY, T			ALTERATIONS IN PRESCRIBING BY GENERAL-PRACTITIONER FUNDHOLDERS - AN OBSERVATIONAL STUDY	BRITISH MEDICAL JOURNAL			English	Article							COSTS	Objectives-To compare prescribing in general practices before and after they become fundholders to assess whether this affected prescribing patterns. Design-Analysis of prescribing data (PACT) for one year before and one year after practices become first, second, or third wave fundholders and comparison with practices that were not fundholders during any part of the study. Main outcome measures-Prescribing costs (net ingredient cost per prescribing unit), prescribing volume (items per 1000 prescribing units), net ingredient cost per item, and percentage of generic prescribing. Setting-Former Mersey Regional Health Authority. Subjects-100 fundholders (20 first wave, 31 second wave, 49 third wave) and 312 non-fundholders. Results-Prescribing costs and volume rose throughout the study in all groups. In all three fundholding waves the rate of increase of prescribing costs was significantly lower than for non-fundholders. Both cost per item and prescribing volume tended to decrease, the former probably because of a significant increase in generic prescribing: Fundholding and non-fundholding practices differed in several respects. Conclusion-Fundholding has altered practice prescribing patterns compared with those of non-fundholders, increasing generic prescribing and reducing the rate of increase of prescribing costs.	UNIV LIVERPOOL,DEPT THERAPEUT & PHARMACOL,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND; UNIV LIVERPOOL,DEPT MED,LIVERPOOL L69 3BX,MERSEYSIDE,ENGLAND	University of Liverpool; University of Liverpool			Buchan, Iain E/H-5767-2013	Buchan, Iain E/0000-0003-3392-1650				BOGLE SM, 1994, BRIT MED J, V308, P637, DOI 10.1136/bmj.308.6929.637; BRADLOW J, 1993, BRIT MED J, V307, P1186, DOI 10.1136/bmj.307.6913.1186; BRITTEN N, 1995, BRIT MED J, V310, P1067, DOI 10.1136/bmj.310.6986.1067c; CHEW R, 1995, OHE COMPENDIUM HLTH; DOWELL JS, 1995, BRIT MED J, V310, P505, DOI 10.1136/bmj.310.6978.505; GILLIGAN JD, 1991, 54 ROYAL COLL GEN PR; GLENNERSTER H, 1994, EVALUATING NHS REFOR; KEELEY D, 1994, BRIT MED J, V308, P206, DOI 10.1136/bmj.308.6922.206c; LLOYD DCEF, 1995, BRIT MED J, V310, P165, DOI 10.1136/bmj.310.6973.165; MAXWELL M, 1993, BRIT MED J, V307, P1190, DOI 10.1136/bmj.307.6913.1190; ROBERTS SJ, 1993, BRIT MED J, V307, P485, DOI 10.1136/bmj.307.6902.485; SHINE C, 1995, BRIT MED J, V310, P1070, DOI 10.1136/bmj.310.6986.1070a; WALLEY T, 1995, PHARMACOECONOMICS, V7, P320, DOI 10.2165/00019053-199507040-00006; 1994, PRESCRIPTION IMPROVE; 1994, PRIORITY SETTING NHS; 1995, BRIEFING GP FUNDHOLD; [No title captured]	17	48	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 18	1995	311	7016					1347	1350		10.1136/bmj.311.7016.1347	http://dx.doi.org/10.1136/bmj.311.7016.1347			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TF901	7496289	Green Published			2023-01-03	WOS:A1995TF90100027
J	KOGAN, MD; ALEXANDER, GR; TEITELBAUM, MA; JACK, BW; KOTELCHUCK, M; PAPPAS, G				KOGAN, MD; ALEXANDER, GR; TEITELBAUM, MA; JACK, BW; KOTELCHUCK, M; PAPPAS, G			THE EFFECT OF GAPS IN HEALTH-INSURANCE ON CONTINUITY OF A REGULAR SOURCE OF CARE AMONG PRESCHOOL-AGED CHILDREN IN THE UNITED-STATES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE; AMERICAN CHILDREN; ACCESS; TERMINATION; SERVICES; POOR	Objective.-To estimate the prevalence and length of gaps in health insurance coverage and their effect on having a regular source of care in a national sample of preschool-aged children. Design.-Follow-up survey of a nationally representative sample of 3-year-old children in the US population by phone or personal interview. Participants.-A total of 8129 children whose mothers were interviewed for the 1991 Longitudinal Follow-up to the National Maternal and Infant Health Survey. Main Outcome Measures.-Report of any gap in health insurance for the children, the length of the gap, and the number of different sites where the children were taken for medical care as a measure of continuity of a regular source of care. Results.-About one quarter of US children were without health insurance for at least 1 month during their first 3 years of life, Over half of these children had a health insurance gap of more than 6 months. Less than half of US children had only one site of care during their first 3 years. Children with health insurance gaps of longer than 6 months were at increased risk of having more than one care site (odds ratio = 1.52; 95% confidence interval, 1.19 to 1.96). This risk further increased when an emergency treatment was discounted as a multiple site of care. Conclusions.-Having a gap in health insurance coverage is an important determinant for not having a regular source of care for preschool-aged children. This finding is of concern, given the sizable percentage of children in the United States who lacked continuous health care coverage during a critical period of development.	CHILDRENS DEF FUND,WASHINGTON,DC; BROWN UNIV,SCH MED,DEPT FAMILY MED,PROVIDENCE,RI 02912; UNIV N CAROLINA,DEPT MATERNAL & CHILD HLTH,CHAPEL HILL,NC; UNIV ALABAMA,DEPT MATERNAL & CHILD HLTH,BIRMINGHAM,AL	Brown University; University of North Carolina; University of North Carolina Chapel Hill; University of Alabama System; University of Alabama Birmingham	KOGAN, MD (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR HLTH STAT,6525 BELCREST RD,ROOM 840,HYATTSVILLE,MD 20782, USA.			Jack, Brian/0000-0002-6497-2437				ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; ALPERT JJ, 1976, PEDIATRICS, V57, P917; [Anonymous], 1994, CURRENT POPULATION S; ATKINSON WL, 1992, ANNU REV MED, V43, P451, DOI 10.1146/annurev.med.43.1.451; BENNIFIELD RL, 1994, DYNAMICS EC WELL BEI, P70; BRAVEMAN P, 1989, NEW ENGL J MED, V321, P508, DOI 10.1056/NEJM198908243210805; BUTLER JA, 1985, PEDIATRICS, V76, P495; CORNELIUS LJ, 1993, J NATL MED ASSOC, V85, P281; Cunningham P J, 1994, Future Child, V4, P24, DOI 10.2307/1602433; CUNNINGHAM PJ, 1990, HLTH AFF MILLWOOD, V90, P76; DAVIS K, 1981, ANNU REV PUBL HEALTH, V2, P159, DOI 10.1146/annurev.pu.02.050181.001111; HAYWARD RA, 1988, NEW ENGL J MED, V318, P1507, DOI 10.1056/NEJM198806093182305; HUBBELL FA, 1989, AM J MED, V87, P127; Johansen A. S, 1994, ANAL CONCEPT PRIMARY; KOGAN MD, 1994, JAMA-J AM MED ASSOC, V272, P1025, DOI 10.1001/jama.272.13.1025; LURIE N, 1984, NEW ENGL J MED, V311, P480, DOI 10.1056/NEJM198408163110735; LURIE N, 1986, NEW ENGL J MED, V314, P1266, DOI 10.1056/NEJM198605083141934; MARQUIS MS, 1992, JAMA-J AM MED ASSOC, V268, P3473; MAURER HM, 1993, AM J DIS CHILD, V147, P529, DOI 10.1001/archpedi.1993.02160290035015; MCDANIEL DB, 1975, PEDIATRICS, V56, P504; MONHEIT AC, 1984, FUTURE CHILD, V74, P1331; MOSCOVICE I, 1987, MED CARE, V25, P413, DOI 10.1097/00005650-198705000-00005; NEWACHECK PW, 1994, MATERNAL CHILD HLTH; ORR ST, 1991, MED CARE, V29, P283, DOI 10.1097/00005650-199103000-00009; PETER G, 1994, 1994 REDBOOK; RASK KJ, 1994, JAMA-J AM MED ASSOC, V271, P1931, DOI 10.1001/jama.271.24.1931; REICHEL W, 1981, JAMA-J AM MED ASSOC, V246, P2065, DOI 10.1001/jama.246.18.2065; SANDERSON M, 1991, BIRTH-ISS PERINAT C, V18, P26, DOI 10.1111/j.1523-536X.1991.tb00050.x; SPILLMAN BC, 1992, INQUIRY-J HEALTH CAR, V29, P457; Starfield B., 1992, PRIMARY CARE CONCEPT; SWARTZ K, 1990, INQUIRY-J HEALTH CAR, V27, P281; SWARTZ K, 1993, INQUIRY, V80, P64; SZILAGYI PG, 1993, PEDIATRICS, V91, P1; WEISSMAN JS, 1991, ANN INTERN MED, V114, P325, DOI 10.7326/0003-4819-114-4-325; 1993, 1991 LONGITUDINAL FO; 1993, SURVEY DATA ANAL VER; 1994, MMWR MORB MORTAL WKL, V43; 1991, JAMA-J AM MED ASSOC, V266, P1547	38	129	129	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 8	1995	274	18					1429	1435		10.1001/jama.274.18.1429	http://dx.doi.org/10.1001/jama.274.18.1429			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	TC477	7474188				2023-01-03	WOS:A1995TC47700024
J	HACKE, W; KASTE, M; FIESCHI, C; TONI, D; LESAFFRE, E; VONKUMMER, R; BOYSEN, G; BLUHMKI, E; HOXTER, G; MAHAGNE, MH; HENNERICI, M				HACKE, W; KASTE, M; FIESCHI, C; TONI, D; LESAFFRE, E; VONKUMMER, R; BOYSEN, G; BLUHMKI, E; HOXTER, G; MAHAGNE, MH; HENNERICI, M			INTRAVENOUS THROMBOLYSIS WITH RECOMBINANT TISSUE-PLASMINOGEN ACTIVATOR FOR ACUTE HEMISPHERIC STROKE - THE EUROPEAN COOPERATIVE ACUTE STROKE STUDY (ECASS)	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MIDDLE CEREBRAL-ARTERY; ACUTE ISCHEMIC STROKE; LOCAL INTRAARTERIAL THROMBOLYSIS; EMBOLIC STROKE; MYOCARDIAL-INFARCTION; FIBRINOLYTIC THERAPY; TERRITORY STROKE; RANDOMIZED TRIAL; CLINICAL-TRIALS; BRAIN EDEMA	Objective.-To evaluate the efficacy and safety of intravenous thrombolysis using recombinant tissue plasminogen activator (rt-PA) in patients with acute ischemic stroke. Design.-Randomized, prospective, multicenter, double-blind, placebo-controlled clinical trial. Setting.-A total of 75 hospitals in 14 European countries. Patients.-A total of 620 patients with acute ischemic hemispheric stroke and moderate to severe neurologic deficit and without major early infarct signs on initial computed tomography (CT). Intervention.-Patients were randomized to treatment with 1.1 mg per kilogram of body weight of rt-PA (alteplase) or placebo within 6 hours from the onset of symptoms. Outcome Measures.-Primary end points included Barthel Index (BI) and modified Rankin Scale (RS) at 90 days. Secondary end points included combined BI and RS, Scandinavian Stroke Scale (SSS) at 90 days, and 30-day mortality. Tertiary end points included early neurologic recovery (SSS) and duration of in-hospital stay. Safety parameters included mortality and incidence of intracranial or extracranial hemorrhage. Results.-The distribution of demographic variables was similar among patients in the rt-PA and placebo treatment arms in both the intention-to-treat (ITT) analysis and the explanatory analysis for the target population (TP). A total of 109 patients (17.4%) were included in the trial despite major protocol violations but excluded from the TP. There was no difference in the primary end points in the ITT analysis, while the TP analysis revealed a significant difference in the RS in favor of rt-PA-treated patients (P=.035). Of the secondary end points, the combined BI and RS showed a difference in favor of rt-PA-treated patients in both analyses (P<.001). Neurologic recovery at 90 days was significantly better for rt-PA-treated patients in the TP (P=.03). The speed of neurologic recovery assessed by the SSS was significantly better up to 7 days in the ITT analysis and up to 30 days for the TP in the rt-PA treatment arm. In-hospital stay was significantly shorter in the rt-PA treatment arm in both analyses. There were no statistically significant differences in the mortality rate at 30 days or in the overall incidence of intracerebral hemorrhages among the rt-PA and placebo treatment arms in either analysis. However, the occurrence of large parenchymal hemorrhages was significantly more frequent in the rt-PA-treated patients. Conclusions.-Intravenous thrombolysis in acute ischemic stroke is effective in improving some functional measures and neurologic outcome in a defined subgroup of stroke patients with moderate to severe neurologic deficit and without extended infarct signs on the initial CT scan. However, the identification of this subgroup is difficult and depends on recognition of early major CT signs of early infarction. Therefore, since treating ineligible patients is associated with an unacceptable increase of hemorrhagic complications and death, intravenous thrombolysis cannot currently be recommended for use in an unselected population of acute ischemic stroke patients.	UNIV HEIDELBERG, DEPT NEURORADIOL, HEIDELBERG, GERMANY; HELSINKI UNIV, DEPT NEUROL, HELSINKI, FINLAND; UNIV ROME, DEPT NEUROL, ROME, ITALY; UNIV LEUVEN, BIOSTAT CTR CLIN TRIALS, LOUVAIN, BELGIUM; UNIV COPENHAGEN, HVIDOVRE HOSP, DEPT NEUROL, COPENHAGEN, DENMARK; DR KARL THOMAE GMBH, BIBERACH, GERMANY; BOEHRINGER INGELHEIM KG, BIBERACH, GERMANY; INNOVEX BIODESIGN GMBH, FREIBURG, GERMANY; UNIV NICE, DEPT NEUROL, NICE, FRANCE; UNIV HEIDELBERG, KLINIKUM MANNHEIM, DEPT NEUROL, HEIDELBERG, GERMANY	Ruprecht Karls University Heidelberg; University of Helsinki; Sapienza University Rome; KU Leuven; University of Copenhagen; Boehringer Ingelheim; UDICE-French Research Universities; Universite Cote d'Azur; Ruprecht Karls University Heidelberg	HACKE, W (corresponding author), UNIV HEIDELBERG, DEPT NEUROL, NEUENHEIMER FELD 400, D-69120 HEIDELBERG, GERMANY.		Hacke, Werner/ABE-8661-2020; von Kummer, Rüdiger/AAA-4478-2019; Toni, Danilo/K-3151-2016	von Kummer, Rüdiger/0000-0003-0119-4604; Toni, Danilo/0000-0003-2735-8427				ARGENTINO C, 1989, STROKE, V20, P1143, DOI 10.1161/01.STR.20.9.1143; ASPLUND K, 1986, ACTA NEUROL SCAND, V73, P530; BABIKIAN VL, 1989, STROKE, V20, P1500, DOI 10.1161/01.STR.20.11.1500; BASTIANELLO S, 1991, NEURORADIOLOGY, V33, P207, DOI 10.1007/BF00588219; BOCKENHEIMER S, 1991, RADIOLOGE, V31, P210; Boysen G, 1995, Eur J Neurol, V1, P213, DOI 10.1111/j.1468-1331.1995.tb00074.x; BOZZAO L, 1989, STROKE, V20, P735, DOI 10.1161/01.STR.20.6.735; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; CASTO L, 1992, ACTA NEUROL SCAND, V86, P308, DOI 10.1111/j.1600-0404.1992.tb05091.x; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DELZOPPO GJ, 1988, STROKE, V19, P307, DOI 10.1161/01.STR.19.3.307; DELZOPPO GJ, 1991, SEMIN NEUROL, V11, P368, DOI 10.1055/s-2008-1041241; FIESCHI C, 1988, ANN NY ACAD SCI, V522, P662; FIESCHI C, 1989, J NEUROL SCI, V91, P311, DOI 10.1016/0022-510X(89)90060-9; FORSTING M, 1993, THROMBOLYTIC THERAPY, V2, P160; GORE JM, 1991, CIRCULATION, V83, P448, DOI 10.1161/01.CIR.83.2.448; GRANGER CV, 1989, ARCH PHYS MED REHAB, V70, P100; GROTTA JC, 1989, STROKE, V20, P317; GROTTA JC, 1987, NEW ENGL J MED, V317, P1505, DOI 10.1056/NEJM198712103172405; GUPTA SS, 1963, ANN MATH STAT, V34, P792, DOI 10.1214/aoms/1177704004; HACKE W, 1994, CEREBROVASC DIS, V4, P385, DOI 10.1159/000108517; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HACKE W, 1994, FIBRINOLYSIS, V8, P216, DOI 10.1016/0268-9499(94)90719-6; HACKE W, 1993, THROMBOLYTIC THERAPY, V2, P151; HALEY EC, 1993, STROKE, V24, P1000, DOI 10.1161/01.STR.24.7.1000; HENNERICI M, 1991, CEREBROVASC DIS, V1, P124, DOI 10.1159/000108907; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0; HORNIG CR, 1986, STROKE, V17, P179, DOI 10.1161/01.STR.17.2.179; KASTE M, 1994, STROKE, V25, P1348, DOI 10.1161/01.STR.25.7.1348; KASTE M, 1995, STROKE, V26, P249, DOI 10.1161/01.STR.26.2.249; KOUDSTAAL PJ, 1988, BRIT MED J, V297, P1571, DOI 10.1136/bmj.297.6663.1571; LESAFFRE E, 1993, STAT MED, V12, P1063; LEVY DE, 1994, STROKE, V25, P291, DOI 10.1161/01.STR.25.2.291; LEYS D, 1992, STROKE, V23, P317, DOI 10.1161/01.STR.23.3.317; LINDENSTROM E, 1991, CEREBROVASC DIS, V1, P103, DOI 10.1159/000108825; MAHONEY F I, 1965, Md State Med J, V14, P61; Matsumoto K, 1991, THROMBOLYTIC THERAPY, P207; MOBIUS E, 1989, AKTUEL NEUROL, V16, P184, DOI 10.1055/s-2007-1020608; MOHR JP, 1994, CEREBROVASC DIS, V4, P197, DOI 10.1159/000108482; MORI E, 1992, NEUROLOGY, V42, P976, DOI 10.1212/WNL.42.5.976; MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802; NENCI GG, 1983, ANGIOLOGY, V34, P561, DOI 10.1177/000331978303400901; OKADA Y, 1989, STROKE, V20, P598, DOI 10.1161/01.STR.20.5.598; ORGOGOZO JM, 1991, CEREBROVASC DIS, V1, P100, DOI 10.1159/000108904; PESSIN MS, 1990, CLIN NEUROPHARMACOL, V13, P271, DOI 10.1097/00002826-199008000-00001; POCOCK SJ, 1987, BIOMETRICS, V43, P487, DOI 10.2307/2531989; RANKIN J, 1957, Scott Med J, V2, P200; RINGELSTEIN EB, 1992, NEUROLOGY, V42, P289, DOI 10.1212/WNL.42.2.289; ROPPER AH, 1984, ARCH NEUROL-CHICAGO, V41, P26, DOI 10.1001/archneur.1984.04050130032017; SENN S, 1994, STAT MED, V13, P1715, DOI 10.1002/sim.4780131703; SILVER FL, 1984, STROKE, V15, P492, DOI 10.1161/01.STR.15.3.492; SMALLING RW, 1990, J AM COLL CARDIOL, V15, P915, DOI 10.1016/0735-1097(90)90216-C; TAUB NA, 1994, STROKE, V25, P352, DOI 10.1161/01.STR.25.2.352; TOMSICK TA, 1989, NEURORADIOLOGY, V31, P312, DOI 10.1007/BF00344173; TONI D, 1995, ARCH NEUROL-CHICAGO, V52, P670, DOI 10.1001/archneur.1995.00540310040014; TONI D, IN PRESS NEUROLOGY; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; VONKUMMER R, 1992, STROKE, V23, P646, DOI 10.1161/01.STR.23.5.646; VONKUMMER R, 1994, AM J NEURORADIOL, V15, P9; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; WOLPERT SM, 1993, AM J NEURORADIOL, V14, P3; YAMAGUCHI T, 1993, CEREBROVASC DIS, V3, P269, DOI 10.1159/000108714; ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977; ZEUMER H, 1983, AM J NEURORADIOL, V4, P401; ZEUMER H, 1989, NEURORADIOLOGY, V31, P336, DOI 10.1007/BF00344178; ZEUMER H, 1985, J NEUROL, V231, P287, DOI 10.1007/BF00313704; 1991, STROKE, V22, P153	68	2532	2647	3	167	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 4	1995	274	13					1017	1025		10.1001/jama.274.13.1017	http://dx.doi.org/10.1001/jama.274.13.1017			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RX108	7563451				2023-01-03	WOS:A1995RX10800023
J	BAZZATO, G; FRACASSO, A; GAMBARO, G; BAGGIO, B				BAZZATO, G; FRACASSO, A; GAMBARO, G; BAGGIO, B			USE OF GLYCOSAMINOGLYCANS TO INCREASE EFFICIENCY OF LONG-TERM CONTINUOUS PERITONEAL-DIALYSIS	LANCET			English	Note							CELL-PROLIFERATION; HEPARIN	Long-term continuous ambulatory peritoneal dialysis (CAPD) frequently induces progressive structural changes in the peritoneal membrane, leading to dialysis failure. Because heparin and glycosaminoglycans favourably remodel anatomical barriers exposed to injury, we studied the effect of intraperitoneal administration of glycosaminoglycans on peritoneal dialysis efficiency. 16 CAPD patients received glycosaminoglycans for 30 days followed by a 30-day wash-out. Glycosaminoglycans in urea and creatinine dialysate-to-plasma ratios significantly increased (means 0.86 and 0.78 at baseline, 0.92 and 0.82 at 30 days, respectively). Peritoneal protein loss was reduced, and serum albumin concentration increased. We now need to assess whether glycosaminoglycans can postpone dialysis failure in the long term.	UNIV PADUA,INST INTERNAL MED,PADUA,ITALY; UNIV PADUA,DIV NEPHROL,PADUA,ITALY; UMBERTO I GEN HOSP,DIV NEPHROL,MESTRE,ITALY	University of Padua; University of Padua; ULSS 3 Serenissima								BREBOROWICZ A, 1994, NEPHRON, V67, P346, DOI 10.1159/000187991; CAENAZZO C, 1995, NEPHROL DIAL TRANSPL, V10, P175; CHAIMOVITZ C, 1994, KIDNEY INT, V45, P1226, DOI 10.1038/ki.1994.163; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; COFFEY AK, 1985, AM J PATHOL, V120, P248; GAMBARO G, 1992, KIDNEY INT, V42, P285, DOI 10.1038/ki.1992.288; GAMBARO G, 1994, KIDNEY INT, V46, P797, DOI 10.1038/ki.1994.335; GAMBARO G, 1994, J AM SOC NEPHROL, V5, P448; LANTZ M, 1991, J CLIN INVEST, V88, P2026, DOI 10.1172/JCI115530; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369	10	48	49	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	SEP 16	1995	346	8977					740	741						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RU810	7658876				2023-01-03	WOS:A1995RU81000012
J	ANDERSON, NE; BROAD, JB; BONITA, R				ANDERSON, NE; BROAD, JB; BONITA, R			DELAYS IN-HOSPITAL ADMISSION AND INVESTIGATION IN ACUTE STROKE	BRITISH MEDICAL JOURNAL			English	Article							TIME		AUCKLAND HOSP,AUCKLAND,NEW ZEALAND; SCH MED AUCKLAND,GERIATR MED SECT,AUCKLAND,NEW ZEALAND	Auckland City Hospital; University of Auckland			Broad, Joanna B/D-1194-2010	Broad, Joanna B/0000-0003-0157-7031				ALBERTS MJ, 1990, JAMA-J AM MED ASSOC, V263, P65, DOI 10.1001/jama.263.1.65; BARSAN WG, 1993, ARCH INTERN MED, V153, P2558, DOI 10.1001/archinte.153.22.2558; BONITA R, 1995, INT J EPIDEMIOL, V24, P535, DOI 10.1093/ije/24.3.535; BONITA R, 1993, LANCET, V342, P470; HARPER GD, 1992, STROKE, V23, P835, DOI 10.1161/01.STR.23.6.835	5	51	53	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 15	1995	311	6998					162	162		10.1136/bmj.311.6998.162	http://dx.doi.org/10.1136/bmj.311.6998.162			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RK159	7613428	Green Published			2023-01-03	WOS:A1995RK15900022
J	ELIA, M				ELIA, M			AN INTERNATIONAL PERSPECTIVE ON ARTIFICIAL NUTRITIONAL SUPPORT IN THE COMMUNITY	LANCET			English	Review							HOME PARENTERAL-NUTRITION; SMALL-BOWEL TRANSPLANTATION; GASTROSTOMY; MANAGEMENT				ELIA, M (corresponding author), DUNN CLIN NUTR CTR,HILLS RD,CAMBRIDGE CB2 2DH,ENGLAND.							ABUELMAGD, 1994, J AM COLL SURGEONS, V179, P385; ALLISON S, IN PRESS CLIN NUTR S, V1; AUGUST DA, 1991, JPEN-PARENTER ENTER, V15, P323, DOI 10.1177/0148607191015003323; BROVIAC JW, 1974, SURG GYNECOL OBSTET, V139, P24; CARTER DM, 1993, CLIN NUTR, V12, P208, DOI 10.1016/0261-5614(93)90016-W; CLARK CLI, 1992, BRIT J SURG, V79, P676, DOI 10.1002/bjs.1800790728; DEFRANCESCO A, IN PRESS CLIN NUTR S, V1; ELIA M, 1993, J ROY COLL PHYS LOND, V27, P8; ELIA M, 1994, NUTRITION, V10, P1; ELIA M, 1994, ENTERAL PARENTERAL N; Fallowfield L., 1991, QUALITY LIFE MISSING; GAGGIOTTI G, IN PRESS CLIN NUTR S, V1; GAUDERER MWL, 1980, J PEDIATR SURG, V15, P872, DOI 10.1016/S0022-3468(80)80296-X; HERMANNZAIDINS M, 1989, NUTRITION SUPPORT HO, P25; HOLDEN CE, 1991, ARCH DIS CHILD, V66, P148, DOI 10.1136/adc.66.1.148; HOWARD L, 1993, CANCER, V72, P3531, DOI 10.1002/1097-0142(19931201)72:11+<3531::AID-CNCR2820721621>3.0.CO;2-6; HOWARD L, 1991, JPEN-PARENTER ENTER, V15, P384, DOI 10.1177/0148607191015004384; KELLY G, 1950, THEOL STUD, V12, P550; KING D, 1989, NUTRITION SUPPORT HO, P229; MESSING B, 1989, CLIN NUTR, V8, P3, DOI 10.1016/0261-5614(89)90018-6; MESSING B, 1988, PRESSE MED, V17, P845; MUGHAL M, 1986, LANCET, V2, P383; OHANRAHAN T, 1992, CLIN NUTR, V11, P331, DOI 10.1016/0261-5614(92)90083-3; PARIS JJ, 1993, CLIN NUTR S1, P12; PARKER T, IN PRESS J R COLL PH; PAYNEJAMES J, 1990, BRIT MED J, V301, P1, DOI 10.1136/bmj.301.6742.1; PERL M, 1980, JPEN-PARENTER ENTER, V4, P554, DOI 10.1177/0148607180004006554; ROBINOVITCH AE, 1981, JPEN-PARENTER ENTER, V5, P522, DOI 10.1177/0148607181005006522; SCHRAUT WH, 1988, GASTROENTEROLOGY, V94, P525, DOI 10.1016/0016-5085(88)90449-0; SCRIBNER BH, 1970, J AMER MED ASSOC, V212, P457, DOI 10.1001/jama.212.3.457; SHILS ME, 1970, NEW ENGL J MED, V283, P341, DOI 10.1056/NEJM197008132830705; SMITH CE, 1993, JPEN-PARENTER ENTER, V17, P501, DOI 10.1177/0148607193017006501; TAYLOR CA, 1992, MAYO CLIN PROC, V67, P1042, DOI 10.1016/S0025-6196(12)61118-5; TILSON MD, 1980, SURG CLIN N AM, V60, P1273; TODO S, 1995, 15TH WORLD C TRANSPL, V27, P1355; WEEKES E, 1992, J HUM NUTR DIET, V5, P41; WHEATLEY C, 1994, MED INT, V22, P407; Wilcock H, 1991, Health Trends, V23, P93; WOOD S, 1994, MED INT, V22, P406; 1994, STATISTICAL YB 1994, P216; IN PRESS CLIN NUTR S, V1; 1993, 1985 1991 OL F ANN R; 1988, NUTR CLIN PRACTICE, V5, P202; 1992, POSITIVE APPROACH TR; 1992, 1985 1990 OL F ANN R	45	57	59	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	MAY 27	1995	345	8961					1345	1349		10.1016/S0140-6736(95)92541-4	http://dx.doi.org/10.1016/S0140-6736(95)92541-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RA148	7752759				2023-01-03	WOS:A1995RA14800012
J	LARUE, F; COLLEAU, SM; BRASSEUR, L; CLEELAND, CS				LARUE, F; COLLEAU, SM; BRASSEUR, L; CLEELAND, CS			MULTICENTER STUDY OF CANCER PAIN AND ITS TREATMENT IN FRANCE	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE	Objective-To describe the treatment of cancer pain in France and to evaluate the predictive factors for inadequate management. Design-Multicentre, representative cross sectional survey. Setting-20 treatment centres, including cancer centres, university hospitals, state hospitals, private clinics, and one homecare setting (in which patients are supported at home). Subjects-605 patients with cancer. Main measures-Patients rated prevalence and severity of pain and functional impairment related to pain. Doctors reported patients' cancer characteristic, performance status, pain severity, and analgesic drugs ordered. Results-57% (340/601) of patients with cancer reported pain due to their disease, and, of those with pain, 69% (224/325) rated their worst pain at a level that impaired their ability to function. 30% (84/279) were reported as receiving no drugs for their pain. Of the 270 patients in pain for whom information on treatment was available 51% (137/270) were not receiving adequate pain relief, according to an index based on the World Health Organisation's guidelines. French doctors were found to underestimate the severity of their patients' pain. Younger patients, patients without metastatic disease, patients with a better performance status, and patients who rated their pain as more severe than their doctors did were at greater risk for undertreatment of their pain. Conclusions-In the light of the high prevalence and the severity of pain among patients with cancer, the assessment and treatment of cancer pain in France remain inadequate, emphasising the need for changes in patient care.	UNIV WISCONSIN,SCH MED,PAIN RES GRP,MADISON,WI 53706; UNIV WISCONSIN,SCH MED,WHO,COLLABORATING CTR SYMPTOM EVALUAT CANC CARE,MADISON,WI 53706; HOP AMBROISE PARE,F-92104 BOULOGNE,FRANCE	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; World Health Organization; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP	LARUE, F (corresponding author), HOP INT UNIV PARIS,PAIN CONSULTAT,F-75674 PARIS,FRANCE.							Boureau F, 1988, PRATIQUE TRAITEMENT; BRASSEUR L, 1993, J PAIN SYMPTOM MANAG, V8, P412, DOI 10.1016/0885-3924(93)90066-5; CLEELAND C, 1991, CANCER, V67, P823, DOI 10.1002/1097-0142(19910201)67:3+<823::AID-CNCR2820671412>3.0.CO;2-S; Cleeland CS, 1991, EFFECT CANC QUALITY, P294; Cleeland CS, 1989, ISSUES PAIN MEASUREM, P391; CLELLAND CS, 1994, NEW ENGL J MED, V330, P592; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GREENWALD HP, 1987, CANCER, V60, P2563, DOI 10.1002/1097-0142(19871115)60:10<2563::AID-CNCR2820601036>3.0.CO;2-L; PICHARDLEANDRI E, 1989, DOULEUR CHEZ ENFANT; VONROENN JH, 1993, ANN INTERN MED, V119, P121, DOI 10.7326/0003-4819-119-2-199307150-00005; 1986, 8632B B OFF MIN AFF; 1990, CANCER PAIN RELIEF P; 1986, SOIGNER ACCOMPAGNER; 1986, CANCER PAIN RELIEF	15	251	258	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	APR 22	1995	310	6986					1034	1037		10.1136/bmj.310.6986.1034	http://dx.doi.org/10.1136/bmj.310.6986.1034			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QV313	7728056	Green Published			2023-01-03	WOS:A1995QV31300015
J	COOK, DJ; GUYATT, GH; JAESCHKE, R; REEVE, J; SPANIER, A; KING, D; MOLLOY, DW; WILLAN, A; STREINER, DL				COOK, DJ; GUYATT, GH; JAESCHKE, R; REEVE, J; SPANIER, A; KING, D; MOLLOY, DW; WILLAN, A; STREINER, DL			DETERMINANTS IN CANADIAN HEALTH-CARE WORKERS OF THE DECISION TO WITHDRAW LIFE-SUPPORT FROM THE CRITICALLY ILL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTENSIVE-CARE; RESOURCE-ALLOCATION; RATIONING DECISIONS; RESUSCITATE ORDERS; MEDICAL-CARE; INEVITABILITY; VARIABILITY; TECHNOLOGY; DIRECTIVES; ATTITUDES	Objective.-To examine the attitudes of health care workers regarding the withdrawal or life support. Design.-Cross-sectional survey. Participants.-Attending staff, house staff, and intensive care unit (ICU) nurses in 37 Canadian university-affiliate hospitals. Main Outcome Measures.-Health care workers' ratings of the importance of 17 factors considered in the decision to withdraw life support, and their ratings of five levels of care ranging from comfort measures to intensive care in two of 12 different clinical scenarios. Results.-We surveyed 1361 respondents (149 of 167 potentially eligible ICU attending staff, 142 of 173 ICU house staff, and 1070 of 1455 ICU nurses, with response rates of 89%, 82% and 74%, respectively). The most important factors were likelihood of surviving the current episode, likelihood of long-term survival, premorbid cognitive function, and age of the patient. In choosing the level of care for the patient scenarios, the same option was chosen by more than 50% of respondents in only one of 12 scenarios; opposite extremes of care were chosen by more than 10% of the respondents in eight of 12 scenarios. Respondent characteristics affecting choices included the number of years since graduation, the city and province in which they worked, the number of beds in their ICU, and their assessment of the likelihood that they would withdraw life support in comparison with their colleagues (P<.001 for all comparisons). Conclusions.-While ICU health care workers consistently identify a number of patient factors as important in decisions to withdraw care, there is extreme variability, which may be explained in part by the values of individual health care providers.	MCMASTER UNIV, FAC HLTH SCI, DEPT MED, HAMILTON, ON L8N 3Z5, CANADA; MCMASTER UNIV, FAC HLTH SCI, DEPT CLIN EPIDEMIOL & BIOSTAT, HAMILTON, ON, CANADA; MCGILL UNIV, JEWISH GEN HOSP, DEPT SURG, MONTREAL, PQ H3T 1E2, CANADA	McMaster University; McMaster University; McGill University			Embrett, Mark G./H-4466-2014; Streiner, David/E-6563-2011	Embrett, Mark G./0000-0002-3969-0219; Streiner, David/0000-0003-0610-6271				ALEMAYEHU E, 1991, CAN MED ASSOC J, V144, P1133; BONE RC, 1990, CHEST, V97, P949, DOI 10.1378/chest.97.4.949; BYTH PL, 1990, ETHICAL ATTITUDES ME; COOK DJ, 1992, CURRENT PULMONOLOGY; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2047; Feinstein AR, 1987, CLINIMETRICS, P141, DOI DOI 10.2307/J.CTT1XP3VBC.13; GUYATT G, 1992, JAMA-J AM MED ASSOC, V268, P2420, DOI 10.1001/jama.1992.03490170092032; GUYATT GH, 1986, CAN MED ASSOC J, V134, P889; JAVITT JC, 1991, NEW ENGL J MED, V325, P1418, DOI 10.1056/NEJM199111143252005; LOEWY EH, 1987, NEW ENGL J MED, V317, P1465, DOI 10.1056/NEJM198712033172308; LUCE JM, 1988, CHEST, V94, P621, DOI 10.1378/chest.94.3.621; MCCRARY SV, 1989, JAMA-J AM MED ASSOC, V265, P2411; MOLLOY DW, 1993, HUM MED, V9, P70; MOLLOY DW, 1991, CAN MED ASSOC J, V145, P307; PEARLMAN RA, 1982, ANN INTERN MED, V97, P420, DOI 10.7326/0003-4819-97-3-420; SCHROEDER SA, 1979, NEW ENGL J MED, V300, P1306, DOI 10.1056/NEJM197906073002304; SINGER DE, 1983, NEW ENGL J MED, V309, P1155, DOI 10.1056/NEJM198311103091905; SMEDIRA NG, 1990, NEW ENGL J MED, V322, P309, DOI 10.1056/NEJM199002013220506; SPRUNG CL, 1992, CRIT CARE MED, V20, P320; SPRUNG CL, 1990, JAMA-J AM MED ASSOC, V263, P2211, DOI 10.1001/jama.263.16.2211; VINCENT JL, 1990, INTENS CARE MED, V16, P256, DOI 10.1007/BF01705162; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; ZIMMERMAN JE, 1986, JAMA-J AM MED ASSOC, V255, P351, DOI 10.1001/jama.255.3.351; ZOOK CJ, 1980, NEW ENGL J MED, V302, P996, DOI 10.1056/NEJM198005013021804	28	304	309	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 1	1995	273	9					703	708		10.1001/jama.273.9.703	http://dx.doi.org/10.1001/jama.273.9.703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QH814	7853627				2023-01-03	WOS:A1995QH81400028
J	RYTOMAA, M; KINNUNEN, PKJ				RYTOMAA, M; KINNUNEN, PKJ			REVERSIBILITY OF THE BINDING OF CYTOCHROME-C TO LIPOSOMES - IMPLICATIONS FOR LIPID-PROTEIN INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FERRICYTOCHROME-C; PHOSPHOLIPID MONOLAYERS; CONFORMATIONAL-CHANGES; CARDIOLIPIN BILAYERS; NMR MEASUREMENTS; RESONANCE RAMAN; KINASE-C; MEMBRANES; FLUORESCENCE; ASSOCIATION	Studies on the membrane binding of cytochrome c revealed liposome-associated and soluble cytochrome c not to be in rapid equilibrium, In brief, cytochrome c attached to pyrene phospholipid labeled, fluorescent liposomes containing either 17.6 mol % cardiolipin (CL) or 30 mol % egg phosphatidylglycerol (PG) is practically not at all or very slowly, respectively, detached by a subsequently added excess (up to 20-fold) of nonlabeled liposomes containing these acidic lipids, Cytochrome c was fully dissociated from PG-containing liposomes by increasing the ionic strength by NaCl, whereas dissociation from CL-containing membranes was less complete, presumably because of the scavenging of the protein within inverted intramembrane micelles, Importantly, the apparent irreversibility of the binding of cytochrome c to liposomes is strongly dependent on the structure of the acidic phospholipid. Cytochrome c bound to lyso-PG/PC liposomes could be dissociated with an excess of nonlabeled PG-containing liposomes, Cytochrome c was also efficiently bound to membranes containing the negatively charged dicetylphosphate yet could be readily dissociated by nonlabeled PG-containing liposomes. We conclude both proper geometry of the phosphate group and the presence of two acyl chains to be required for the tight binding of cytochrome c to acidic phospholipids, These data provide evidence for the membrane association of cytochrome c by an acidic phospholipid in the extended conformation (Kinnunen, P. K. J., Koiv, A., Lehtonen, J, Y, A., Rytomaa, M., and Mustonen P, (1994) Chem, Phys. Lipids 73, 181-207) in which one of the acyl chains of the lipid becomes accommodated within a hydrophobic cavity of the protein, Based on the crystal structure of cytochrome c we putatively assign the invariant Asn-52 (horse heart cytochrome c) as the site liganding the protonated phosphate of the lipid, whereas Lys-72 and -73 should bind the deprotonated form.	UNIV HELSINKI, INST BIOMED, DEPT MED CHEM, SF-00014 HELSINKI, FINLAND	University of Helsinki								BAZZI MD, 1991, BIOCHEMISTRY-US, V30, P7970, DOI 10.1021/bi00246a014; BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; DEKRUIJFF B, 1980, BIOCHIM BIOPHYS ACTA, V602, P477, DOI 10.1016/0005-2736(80)90327-2; DEMEL RA, 1989, J BIOL CHEM, V264, P3988; DICKERSON RE, 1971, J BIOL CHEM, V246, P1511; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FORSTER T, 1948, ANN PHYS-BERLIN, V2, P55, DOI 10.1002/andp.19484370105; HAUSER H, 1988, BIOCHEMISTRY-US, V27, P9166, DOI 10.1021/bi00426a014; HEIMBURG T, 1991, BIOCHEMISTRY-US, V30, P9084, DOI 10.1021/bi00101a025; HONDA Z, 1991, NATURE, V349, P342, DOI 10.1038/349342a0; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; JORI G, 1974, PHOTOCHEM PHOTOBIOL, V19, P337, DOI 10.1111/j.1751-1097.1974.tb06521.x; KABACK HR, 1993, J BIOENERG BIOMEMBR, V25, P627; KAHANA E, 1992, BIOCHEM J, V282, P75, DOI 10.1042/bj2820075; KAIHOVAARA P, 1991, BIOCHEMISTRY-US, V30, P8380, DOI 10.1021/bi00098a015; KIMELBERG HK, 1969, BIOCHEM BIOPH RES CO, V34, P784, DOI 10.1016/0006-291X(69)90248-4; KINNUNEN PKJ, 1992, CHEM PHYS LIPIDS, V63, P251, DOI 10.1016/0009-3084(92)90041-M; KINNUNEN PKJ, 1991, CHEM PHYS LIPIDS, V57, P375, DOI 10.1016/0009-3084(91)90087-R; KINNUNEN PKJ, 1994, CHEM PHYS LIPIDS, V73, P181, DOI 10.1016/0009-3084(94)90181-3; KINNUNEN PKJ, 1993, CHEM PHYS LIPIDS, V66, P75, DOI 10.1016/0009-3084(93)90033-Y; KINNUNEN PKJ, 1993, FLUORESCENCE SPECTRO, P159; KOIV A, 1994, CHEM PHYS LIPIDS, V70, P1, DOI 10.1016/0009-3084(94)90042-6; KOZARAC Z, 1988, FEBS LETT, V229, P372, DOI 10.1016/0014-5793(88)81159-1; LANDOLTMARTICORENA C, 1993, J MOL BIOL, V229, P602, DOI 10.1006/jmbi.1993.1066; LEE MH, 1989, J BIOL CHEM, V264, P14797; LETELLIER L, 1973, EUR J BIOCHEM, V40, P507, DOI 10.1111/j.1432-1033.1973.tb03220.x; MACDONALD RC, 1991, BIOCHIM BIOPHYS ACTA, V1061, P297, DOI 10.1016/0005-2736(91)90295-J; MEERS P, 1994, BIOCHEMISTRY-US, V33, P5829, DOI 10.1021/bi00185a022; MUGA A, 1991, BIOCHEMISTRY-US, V30, P7219, DOI 10.1021/bi00243a025; MUSTONEN P, 1987, BIOCHEMISTRY-US, V26, P2991, DOI 10.1021/bi00385a006; MUSTONEN P, 1993, BIOCHEMISTRY-US, V32, P5373, DOI 10.1021/bi00071a012; MUSTONEN P, 1993, J BIOL CHEM, V268, P1074; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; PACHENCE JM, 1991, BIOPHYS J, V59, P894, DOI 10.1016/S0006-3495(91)82302-5; PINHEIRO TJT, 1994, BIOCHEMISTRY-US, V33, P2451, DOI 10.1021/bi00175a013; QI PX, 1994, NAT STRUCT BIOL, V1, P378, DOI 10.1038/nsb0694-378; QUINN PJ, 1969, BIOCHEM J, V115, P65, DOI 10.1042/bj1150065; QUINN PJ, 1969, BIOCHEM J, V113, P791, DOI 10.1042/bj1130791; RYTOMAA M, 1992, J BIOL CHEM, V267, P22243; RYTOMAA M, 1994, J BIOL CHEM, V269, P1770; SCHLAME M, 1990, BIOCHEM J, V265, P79, DOI 10.1042/bj2650079; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; SPECK SH, 1983, FEBS LETT, V164, P379, DOI 10.1016/0014-5793(83)80321-4; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3871, DOI 10.1021/bi00230a010; SPOONER PJR, 1991, BIOCHEMISTRY-US, V30, P3880, DOI 10.1021/bi00230a011; SPOONER PJR, 1992, BIOCHEMISTRY-US, V31, P10129, DOI 10.1021/bi00156a037; STEINEMANN A, 1971, J MEMBRANE BIOL, V4, P74, DOI 10.1007/BF02431963; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; TEISSIE J, 1981, BIOCHEMISTRY-US, V20, P1554, DOI 10.1021/bi00509a023; THUREN T, 1985, CLIN CHEM, V31, P714; VANDERKOOI J, 1973, ARCH BIOCHEM BIOPHYS, V154, P219, DOI 10.1016/0003-9861(73)90052-0; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P1456, DOI 10.1073/pnas.78.3.1456; VINCENT JS, 1986, J AM CHEM SOC, V108, P3551, DOI 10.1021/ja00273a001; VINCENT JS, 1987, BIOCHEMISTRY-US, V26, P2312, DOI 10.1021/bi00382a036; WALTHAM MC, 1986, BIOCHIM BIOPHYS ACTA, V862, P451, DOI 10.1016/0005-2736(86)90250-6	56	234	236	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 17	1995	270	7					3197	3202		10.1074/jbc.270.7.3197	http://dx.doi.org/10.1074/jbc.270.7.3197			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	QG471	7852404	hybrid			2023-01-03	WOS:A1995QG47100048
J	BONADONNA, G; ZAMBETTI, M; VALAGUSSA, P				BONADONNA, G; ZAMBETTI, M; VALAGUSSA, P			SEQUENTIAL OR ALTERNATING DOXORUBICIN AND CMF REGIMENS IN BREAST-CANCER WITH MORE THAN 3 POSITIVE NODES - 10-YEAR RESULTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADJUVANT CHEMOTHERAPY; COMBINATION CHEMOTHERAPY; AXILLARY NODES; CYCLOPHOSPHAMIDE; METHOTREXATE; FLUOROURACIL	Objective.-To improve current adjuvant results in patients with resectable mammary carcinoma and more than three positive axillary lymph nodes. Design.-A prospective randomized study was carried out to compare the effectiveness of four courses of doxorubicin hydrochloride followed by eight courses of cyclophosphamide, methotrexate, and fluorouracil (CMF) (sequential regimen) vs two courses of CMF alternated with one course of doxorubicin for a total of 12 courses (alternating regimen). All drug courses were recycled every 3 weeks. The median duration of follow-up at the time of current analysis was 9 years. Setting.-The study was conducted on patients operated on for primary unilateral breast cancer at the Istituto Nazionale Tumori of Milan, Italy. Adjuvant chemotherapy was delivered in the outpatient clinic of the Division of Medical Oncology. Patients.-A total of 405 women were entered into the study, 403 of whom met the protocol criteria. Patient characteristics were fairly well balanced between the two treatment groups, with the exception of extent of nodal involvement: 38% with more than 10 positive nodes were randomized to the alternating regimen compared with 29% in the sequential regimen (P=.08). Main Outcome Measure.-Relapse-free and total survival at 10 years after surgery estimated according to the Kaplan-Meier product limit method. Results.-Treatment outcome was significantly superior for patients who received the sequential regimen compared with those given the alternating chemotherapy. The relapse-free survival was 42% vs 28% (P=.002) and total survival was 58% vs 44% (P=.002), respectively. The benefit of the sequential regimen was evident in all patient subsets. Treatment was fairly well tolerated, but we documented four cases of congestive heart failure, which was fatal in two patients. Conclusions.-Current findings indicate that in women with extensive nodal involvement, sequential chemotherapy with doxorubicin followed by CMF yields superior results compared with the alternating administration of the same regimens or with classical CMF.			BONADONNA, G (corresponding author), IST NAZL TUMORI,DEPT MED,DIV MED ONCOL,VIA VENEZIAN 1,I-20133 MILAN,ITALY.				NCI NIH HHS [N01-CM-07338] Funding Source: Medline; DIVISION OF CANCER TREATMENT [N01CM007338] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); DIVISION OF CANCER TREATMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)NIH National Cancer Institute- Division of Cancer Treatment & Diagnosis)		BONADONNA G, 1985, BREAST CANCER RES TR, V5, P95, DOI 10.1007/BF01805984; BONADONNA G, 1992, CANCER RES, V52, P2127; BONADONNA G, 1986, ANN INTERN MED, V104, P739, DOI 10.7326/0003-4819-104-6-739; BONADONNA G, 1976, NEW ENGL J MED, V294, P405, DOI 10.1056/NEJM197602192940801; BONADONNA G, 1975, CANCER CHEMOTH REP 3, V6, P381; BONADONNA G, 1981, NEW ENGL J MED, V304, P10, DOI 10.1056/NEJM198101013040103; BONADONNA G, IN PRESS N ENGL J ME; BONFANTE V, 1986, EUR J CANCER CLIN ON, V22, P1379, DOI 10.1016/0277-5379(86)90149-5; BUZZONI R, 1991, J CLIN ONCOL, V9, P2134, DOI 10.1200/JCO.1991.9.12.2134; COX DR, 1972, J R STAT SOC B, V34, P187; FISHER B, 1992, CANCER RES, V52, P2371; HARRIS JR, 1991, BREAST DISEASES; HENDERSON IC, 1994, CANCER, V74, P401; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Miller R. G., 1981, SURVIVAL ANAL; MOLITERNI A, 1991, J CLIN ONCOL, V9, P1124, DOI 10.1200/JCO.1991.9.7.1124; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; TANCINI G, 1983, J CLIN ONCOL, V1, P2, DOI 10.1200/JCO.1983.1.1.2; VALAGUSSA P, 1994, ANN ONCOL, V5, P209, DOI 10.1093/oxfordjournals.annonc.a058795; VALAGUSSA P, 1994, ANN ONCOL, V5, P803, DOI 10.1093/oxfordjournals.annonc.a059008; VALAGUSSA P, 1990, BREAST CANCER RES TR, V15, P137, DOI 10.1007/BF01806351; VERONESI U, 1990, EUR J CANCER, V26, P68; WOD WC, 1994, NEW ENGL J MED, V330, P1253; 1992, LANCET, V399, P71; 1992, LANCET, V399, P1	25	298	301	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 15	1995	273	7					542	547						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QF686	7837388				2023-01-03	WOS:A1995QF68600023
J	ARNOW, P; CHAMBERLIN, W				ARNOW, P; CHAMBERLIN, W			DEBUGGING COMPUTER-ASSISTED ANTIBIOTIC PRESCRIBING	LANCET			English	Editorial Material									MICHAEL REESE HOSP & MED CTR,CHICAGO,IL 60616	Michael Reese Hospital & Medical Center	ARNOW, P (corresponding author), UNIV CHICAGO HOSP & CLIN,DEPT MED,CHICAGO,IL 60637, USA.							EVANS RS, 1994, ARCH INTERN MED, V154, P878, DOI 10.1001/archinte.154.8.878; GARDNER FT, 1979, ARCH SURG-CHICAGO, V114, P883; GROSS PA, 1994, CLIN INFECT DIS, V18, P421, DOI 10.1093/clinids/18.3.421; HIRSCHMAN SZ, 1988, ARCH INTERN MED, V148, P2001, DOI 10.1001/archinte.148.9.2001; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; MOSS FM, 1981, LANCET, V2, P407; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418, DOI 10.1164/ajrccm/148.5.1418; STURM AW, 1988, J ANTIMICROB CHEMOTH, V22, P257, DOI 10.1093/jac/22.2.257; YU VI, 1976, JAMA-J AM MED ASSOC, V242, P1279; YU VL, 1991, AM J MED SCI, V301, P165, DOI 10.1097/00000441-199103000-00003; 1994, J ANTIMICROB CHEMOTH, V34, P21	11	6	6	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JAN 28	1995	345	8944					207	208		10.1016/S0140-6736(95)90219-8	http://dx.doi.org/10.1016/S0140-6736(95)90219-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD532	7823711				2023-01-03	WOS:A1995QD53200005
J	FROST, H; MOFFETT, JAK; MOSER, JS; FAIRBANK, JCT				FROST, H; MOFFETT, JAK; MOSER, JS; FAIRBANK, JCT			RANDOMIZED CONTROLLED TRIAL FOR EVALUATION OF FITNESS PROGRAM FOR PATIENTS WITH CHRONIC LOW-BACK-PAIN	BRITISH MEDICAL JOURNAL			English	Article							FUNCTIONAL RESTORATION; OUTPATIENT TREATMENT; CLINICAL-TRIAL; FOLLOW-UP; DISABILITY; VALIDITY	Objective-To evaluate a progressive fitness programme for patients with chronic low back pain. Design-Single blind randomised controlled trial. Assessments were carried out before and after treatment by an observer blinded to the study and included a battery of validated measures. All patients were followed up by postal questionnaire six months after treatment. Setting-Physiotherapy department of orthopaedic hospital. Subjects-81 patients with chronic low back pain referred from orthopaedic consultants for physiotherapy. The patients were randomly allocated to a fitness programme or control group. Intervention-Both groups were taught specific exercises to carry out at home and referred to a back-school for education in back care. Patients allocated to the fitness class attended eight exercise classes over four weeks in addition to the home programme and backschool. Results-Significant differences between the groups were shown in the changes before and after treatment in scores on the Oswestry low back pain disability index (P<0.005), pain reports (sensory P<0.05 and affective P<0.005), self efficacy reports (P<0.05), and walking distance (P<0.005). No significant differences between the groups were found by the general health questionnaire or questionnaire on pain locus of control. A benefit of about 6 percentage points on the disability index was maintained by patients in the fitness group at six months. Conclusion-There is a role for supervised fitness programmes in the management of moderately disabled patients with chronic low back pain. Further clinical trials, however, need to be established in other centres to confirm these findings.			FROST, H (corresponding author), NUFFIELD ORTHOPAED CTR,OXFORD OX3 7LD,ENGLAND.		Fairbank, Jeremy/AAA-3411-2019	Frost, Helen/0000-0001-9241-8970				ASTRAND PO, 1987, ARCH PHYS MED REHAB, V68, P305; Baker DJ, 1989, BACK PAIN NEW APPROA, P174; BANDURA A, 1982, AM PSYCHOL, V37, P122, DOI 10.1037/0003-066X.37.2.122; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; DOLCE JJ, 1986, PAIN, V24, P365, DOI 10.1016/0304-3959(86)90122-3; FLOR H, 1991, 6TH P WORLD C PAIN A, P4229; GOLDBERG DP, 1978, MANUAL GENERAL HLTH; HARKAPAA K, 1989, SCAND J REHABIL MED, V21, P81; HAZARD RG, 1989, SPINE, V14, P157, DOI 10.1097/00007632-198902000-00003; JENSEN MP, 1993, PAIN, V55, P195, DOI 10.1016/0304-3959(93)90148-I; KEIJSERS J F E M, 1991, Physiotherapy Theory and Practice, V7, P177, DOI 10.3109/09593989109106969; KELLETT KM, 1991, PHYS THER, V71, P283, DOI 10.1093/ptj/71.4.283; KOES BW, 1992, BRIT MED J, V304, P601, DOI 10.1136/bmj.304.6827.601; KOHLES S, 1990, SPINE, V15, P1321, DOI 10.1097/00007632-199012000-00016; KORES RC, 1990, BEHAV RES THER, V28, P165, DOI 10.1016/0005-7967(90)90029-I; LINDSTROM I, 1992, PHYS THER, V72, P279, DOI 10.1093/ptj/72.4.279; MAIN CJ, 1991, PAIN, V46, P287, DOI 10.1016/0304-3959(91)90112-B; MANNICHE C, 1991, PAIN, V47, P53, DOI 10.1016/0304-3959(91)90011-L; MAYER TG, 1985, SPINE, V10, P482, DOI 10.1097/00007632-198507000-00002; MCQUADE KJ, 1988, CLIN ORTHOP RELAT R, V233, P198; MEADE TW, 1990, BRIT MED J, V300, P1431, DOI 10.1136/bmj.300.6737.1431; MOFFETT JAK, 1986, SPINE, V111, P120; NICHOLAS MK, 1992, PAIN, V48, P339, DOI 10.1016/0304-3959(92)90082-M; NUTTER P, 1987, SPINE, V21, P137; POCOCK SJ, 1987, CLIN TRIALS PRACTICA; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; SUTTON JR, 1990, EXERCISE, FITNESS, AND HEALTH, P217; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B	29	196	200	1	25	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 21	1995	310	6973					151	154		10.1136/bmj.310.6973.151	http://dx.doi.org/10.1136/bmj.310.6973.151			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QD201	7833752	Green Published			2023-01-03	WOS:A1995QD20100018
J	WEST, S; MUNOZ, B; LYNCH, M; KAYONGOYA, A; CHILANGWA, Z; MMBAGA, BBO; TAYLOR, HR				WEST, S; MUNOZ, B; LYNCH, M; KAYONGOYA, A; CHILANGWA, Z; MMBAGA, BBO; TAYLOR, HR			IMPACT OF FACE-WASHING ON TRACHOMA IN KONGWA, TANZANIA	LANCET			English	Article							RISK	Observational studies have suggested that the prevalence of trachoma is lower in children with clean faces than in those with ocular or nasal discharge or flies on the face. We carried out a community-based randomised trial in three pairs of villages to assess the impact on trachoma of a face-washing intervention programme following a mass topical antibiotic treatment campaign. Six villages in Kongwa, Tanzania, were randomly assigned mass treatment plus the face-washing programme or treatment only. 1417 children aged 1-7 years in these villages were randomly selected and followed up for trachoma status and observations of facial cleanliness at baseline and 2, 6, and 12 months. At 12 months, children in the intervention villages were 60% more likely to have bad clean faces at two or more follow-up visits than children in the control villages. The odds of having severe trachoma in the intervention villages were 0.62 (95% CI 0.40-0.97) compared with control villages. A clean face at two or more follow-up visits was protective for any trachoma (odds ratio 0.58 [0.47-0.72]) and severe trachoma (0.35 [0.21-0.59]). This community-based participatory approach to face-washing intervention had variable penetration rates in the villages and was labour intensive. However, we found that, combined with topical treatment, community-based strategies for improving hygiene in children in trachoma-endemic villages can reduce the prevalence of trachoma.	JOHNS HOPKINS UNIV, DANA CTR PREVENT OPHTHALMOL, BALTIMORE, MD USA; CENT EYE HLTH FDN, DODOMA, TANZANIA; UNIV MELBOURNE, DEPT OPHTHALMOL, MELBOURNE, VIC, AUSTRALIA	Johns Hopkins University; University of Melbourne				Taylor, Hugh/0000-0002-9437-784X				LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LYNCH M, 1994, T ROY SOC TROP MED H, V88, P513, DOI 10.1016/0035-9203(94)90141-4; MABEY DCW, 1991, ANN TROP PAEDIATR, V11, P295, DOI 10.1080/02724936.1991.11747518; RAPOZA PA, 1991, INT OPHTHALMOL, V15, P123, DOI 10.1007/BF01046432; STANTON BF, 1987, AM J EPIDEMIOL, V125, P292, DOI 10.1093/oxfordjournals.aje.a114529; TAYLOR HR, 1989, ARCH OPHTHALMOL-CHIC, V107, P1821, DOI 10.1001/archopht.1989.01070020903037; THYLEFORS B, 1987, B WORLD HEALTH ORGAN, V65, P477; WEST S, 1993, INVEST OPHTH VIS SCI, V34, P3194; WEST S, 1994, INT OPHTHALMOL, V18, P105, DOI 10.1007/BF00919249; WEST SK, 1991, ARCH OPHTHALMOL-CHIC, V109, P855, DOI 10.1001/archopht.1991.01080060119038; WEST SK, 1991, INT J EPIDEMIOL, V20, P1088, DOI 10.1093/ije/20.4.1088	11	170	175	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JAN 21	1995	345	8943					155	158		10.1016/S0140-6736(95)90167-1	http://dx.doi.org/10.1016/S0140-6736(95)90167-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QC550	7823670	hybrid			2023-01-03	WOS:A1995QC55000010
J	MCCARTHY, M				MCCARTHY, M			UNLOCKING THE DATASETS	LANCET			English	Editorial Material											MCCARTHY, M (corresponding author), CAMDEN & ISLINGTON HLTH AUTHOR,DEPT PUBL HLTH,LONDON,ENGLAND.							[Anonymous], HIGH TECHNOLOGY MED; CHALMERS I, 1991, NEW ENGL J MED, V325, P1514; COX TM, 1993, LANCET, V342, P694, DOI 10.1016/0140-6736(93)91703-O; HELLMAN S, 1991, NEW ENGL J MED, V324, P1585, DOI 10.1056/NEJM199105303242208; 1989, LANCET, V2, P195; 1993, ASSESSING EFFECTS HL	6	1	1	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 20	1993	342	8882					1252	1253		10.1016/0140-6736(93)92355-W	http://dx.doi.org/10.1016/0140-6736(93)92355-W			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH566	7901579				2023-01-03	WOS:A1993MH56600005
J	DODWELL, D; BOND, M; ELWELL, C; GILDERSLEVE, J; PARMAR, S; OWENS, J; BULMAN, A; CRELLIN, A; ASH, D				DODWELL, D; BOND, M; ELWELL, C; GILDERSLEVE, J; PARMAR, S; OWENS, J; BULMAN, A; CRELLIN, A; ASH, D			EFFECT OF MEDICAL AUDIT ON PRESCRIPTION OF PALLIATIVE RADIOTHERAPY	BRITISH MEDICAL JOURNAL			English	Article											DODWELL, D (corresponding author), COOKRIDGE HOSP,YORKSHIRE REG CTR CANC TREATMENT,LEEDS LS16 6QB,W YORKSHIRE,ENGLAND.							CRELLIN AM, 1990, CLIN ONCOLOGY, V1, P63; Maher E J, 1990, Health Trends, V22, P78; PRICE P, 1986, RADIOTHER ONCOL, V6, P247, DOI 10.1016/S0167-8140(86)80191-8; Priestman T J, 1989, Clin Oncol (R Coll Radiol), V1, P39, DOI 10.1016/S0936-6555(89)80010-X; 1991, BRIT J CANCER, V63, P265	5	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					24	25		10.1136/bmj.307.6895.24	http://dx.doi.org/10.1136/bmj.307.6895.24			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	7688252	Green Published, Bronze			2023-01-03	WOS:A1993LL36900021
J	CHENEY, FW; POSNER, K; CAPLAN, RA; WARD, RJ				CHENEY, FW; POSNER, K; CAPLAN, RA; WARD, RJ			STANDARD OF CARE AND ANESTHESIA LIABILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									VIRGINIA MASON MED CTR,SEATTLE,WA 98101	Virginia Mason Medical Center	CHENEY, FW (corresponding author), UNIV WASHINGTON,SCH MED,DEPT ANESTHESIOL,RN-10,SEATTLE,WA 98195, USA.							BRUNNER EA, 1984, INT ANESTHESIOL CLIN, V22, P17, DOI 10.1097/00004311-198408000-00004; Caplan R A, 1988, QRB Qual Rev Bull, V14, P363; CAPLAN RA, 1988, ANESTHESIOLOGY, V68, P5, DOI 10.1097/00000542-198801000-00003; CHARLES SC, 1985, AM J PSYCHIAT, V142, P437; DANZON PM, 1985, MED MALPRACTICE THEO, P40; KEATS AS, 1988, ANESTHESIOLOGY, V68, P2; 1988, PROPOSED ALTERNATIVE	7	184	184	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 17	1989	261	11					1599	1603		10.1001/jama.261.11.1599	http://dx.doi.org/10.1001/jama.261.11.1599			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	T5890	2918653				2023-01-03	WOS:A1989T589000021
J	FERENCHICK, GS				FERENCHICK, GS			SANITATION, SPIRITS, AND MEDICINE - HEALTH-CARE IN THE AFRICAN BUSH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											FERENCHICK, GS (corresponding author), MICHIGAN STATE UNIV,E LANSING,MI 48824, USA.							KAPLAN I, 1985, AREA HDB LIBERIA, P116; TAKYI DA, 1983, THESIS U IOWA IOWA C; 1987, MMWR, V36, P1	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 24	1989	261	8					1201	1202						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	T2747	2915445				2023-01-03	WOS:A1989T274700037
J	SHAW, IH; EVANS, JM				SHAW, IH; EVANS, JM			HOSPITAL ANESTHESIA AND GENERAL-PRACTICE	BMJ-BRITISH MEDICAL JOURNAL			English	Article									RADCLIFFE INFIRM, NUFFIELD DEPT ANAESTHET, OXFORD OX2 6HE, ENGLAND	Radcliffe Infirmary; University of Oxford								BAULD HW, 1974, BRIT J ANAESTH, V46, P273, DOI 10.1093/bja/46.4.273; BLACHER RS, 1984, ANESTHESIOLOGY, V61, P1; EDELIST G, 1964, ANESTH ANALG, V43, P227; EDWARDS R, 1985, BMJ-BRIT MED J, V291, P423, DOI 10.1136/bmj.291.6493.423; FISHER A, 1975, ANAESTHESIA, V30, P633, DOI 10.1111/j.1365-2044.1975.tb00924.x; GOLDMAN L, 1979, ANESTHESIOLOGY, V50, P285, DOI 10.1097/00000542-197904000-00002; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GRONERT GA, 1980, ANESTHESIOLOGY, V53, P395, DOI 10.1097/00000542-198011000-00007; GUILLEBAUD J, 1985, BRIT MED J, V291, P498, DOI 10.1136/bmj.291.6494.498; JONES RM, 1987, ANAESTHESIA, V42, P1, DOI 10.1111/j.1365-2044.1987.tb02935.x; JONES RM, 1985, RECENT ADV ANAESTHES, P89; KERR MG, 1964, BRIT MED J, V1, P532; LOW JM, 1986, BRIT J ANAESTH, V58, P471, DOI 10.1093/bja/58.5.471; MACDONALD AG, 1985, RECENT ADV ANAESTHES, P107; MILLEDGE JS, 1980, GENERAL ANAESTHESIA, P511; MOIR D, 1986, OBSTETRIC ANAESTHESI; NEUBERGER J, 1984, BRIT MED J, V289, P1136, DOI 10.1136/bmj.289.6452.1136; PANTUCK EJ, 1966, BRIT J ANAESTH, V38, P406, DOI 10.1093/bja/38.5.406; PRYSROBERTS C, 1973, BRIT J ANAESTH, V45, P671, DOI 10.1093/bja/45.7.671; PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P531, DOI 10.1093/bja/43.6.531; PRYSROBERTS C, 1971, BRIT J ANAESTH, V43, P112; 1987, 1987 MED DEF UN ANN, P18	22	2	2	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 3	1988	297	6661					1461	1464		10.1136/bmj.297.6661.1461	http://dx.doi.org/10.1136/bmj.297.6661.1461			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R2187	3147018	Green Published, Bronze			2023-01-03	WOS:A1988R218700033
J	YOUNGER, SJ				YOUNGER, SJ			WHO DEFINES FUTILITY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,SCH MED,CTR BIOMED ETHICS,DEPT MED,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland	YOUNGER, SJ (corresponding author), CASE WESTERN RESERVE UNIV,UNIV HOSP CLEVELAND,SCH MED,CTR BIOMED ETHICS,DEPT PSYCHIAT,CLEVELAND,OH 44106, USA.							ANGELL M, 1985, JAMA-J AM MED ASSOC, V254, P1203, DOI 10.1001/jama.254.9.1203; BLENDON RJ, 1984, NEW ENGL J MED, V311, P613, DOI 10.1056/NEJM198408303110938; BLENDON RJ, 1988, JAMA-J AM MED ASSOC, V259, P3587, DOI 10.1001/jama.259.24.3587; CALLAHAN D, 1988, HASTINGS CENT REP, V18, P14, DOI 10.2307/3562403; Callahan D., 1987, SETTING LIMITS MED G; Childress JF., 1970, SOUNDINGS, V53, P339; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2208, DOI 10.1001/jama.249.16.2208; EVANS RW, 1983, JAMA-J AM MED ASSOC, V249, P2047; MCQUILLEN MP, 1988, NEW ENGL J MED, V318, P1756; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; NOLAN K, 1987, HASTINGS CENT REP, V17, P9, DOI 10.2307/3562663; RESCHER N, 1969, ETHICS, V79, P173, DOI 10.1086/291723; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109	13	227	228	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 14	1988	260	14					2094	2095		10.1001/jama.260.14.2094	http://dx.doi.org/10.1001/jama.260.14.2094			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q3421	3418875				2023-01-03	WOS:A1988Q342100025
J	HAAK, H; HARDON, AP				HAAK, H; HARDON, AP			INDIGENIZED PHARMACEUTICALS IN DEVELOPING-COUNTRIES - WIDELY USED, WIDELY NEGLECTED	LANCET			English	Article									UNIV AMSTERDAM,CTR ANTHROPOL SOCIOL,OUDEZIJDS ACHTERBURGWAL 185,1012 DK AMSTERDAM,NETHERLANDS	University of Amsterdam								BLEDSOE CH, 1985, SOC SCI MED, V21, P275, DOI 10.1016/0277-9536(85)90101-7; BURGHART R, 1988, CONTEXT MED DEV COUN, P289; HAAK H, IN PRESS SOC SCI MED; HARDON AP, 1987, SOC SCI MED, V25, P277, DOI 10.1016/0277-9536(87)90231-0; HARDON AP, 1987, PRELIMINARY FINDINGS; VANDERGEEST S, 1985, TETRACYCLINE CHILDRE; WOLFFERS I, 1988, CONTEXT MED DEV COUN, P47	7	38	38	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	SEP 10	1988	2	8611					620	621						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q1374	2900991				2023-01-03	WOS:A1988Q137400016
J	OATES, S; WILLIAMS, GL; REES, GAD				OATES, S; WILLIAMS, GL; REES, GAD			CARDIOPULMONARY RESUSCITATION IN LATE PREGNANCY	BMJ-BRITISH MEDICAL JOURNAL			English	Article											OATES, S (corresponding author), UNIV HOSP WALES, OBSTET & GYNAECOL, CARDIFF CF4 4XW, S GLAM, WALES.							ARCHER GW, 1974, BRIT J ANAESTH, V46, P358, DOI 10.1093/bja/46.5.358; DEPACE NL, 1982, JAMA-J AM MED ASSOC, V248, P971, DOI 10.1001/jama.248.8.971; HOFFENBERG R, 1987, J R COLL PHYSICIANS, V21, P175; KASTEN GW, 1986, ANESTH ANALG, V65, P341; KATZ VL, 1986, OBSTET GYNECOL, V68, P571; KERR MG, 1964, BRIT MED J, V1, P532; KILLAM A, 1985, CLIN OBSTET GYNECOL, V28, P32, DOI 10.1097/00003081-198528010-00005; MARX GF, 1982, ANESTHESIOLOGY, V56, P156, DOI 10.1097/00000542-198202000-00018; MASSON RG, 1979, AM REV RESPIR DIS, V120, P187; MORGAN M, 1979, ANAESTHESIA, V34, P20, DOI 10.1111/j.1365-2044.1979.tb04862.x; REES GAD, 1988, ANAESTHESIA, V43, P347, DOI 10.1111/j.1365-2044.1988.tb09009.x; TURNBULL AC, 1986, 29 DEP HLTH SOC SEC; UELAND K, 1969, AM J OBSTET GYNECOL, V104, P856, DOI 10.1016/0002-9378(69)90637-1; UELAND K, 1969, AM J OBSTET GYNECOL, V103, P8, DOI 10.1016/S0002-9378(16)34334-4; WEBER CE, 1971, AM J OBSTET GYNECOL, V110, P158, DOI 10.1016/0002-9378(71)90600-4; WEIL AM, 1957, AM J OBSTET GYNECOL, V73, P754, DOI 10.1016/0002-9378(57)90383-6	16	35	36	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	AUG 6	1988	297	6645					404	405		10.1136/bmj.297.6645.404	http://dx.doi.org/10.1136/bmj.297.6645.404			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P5450	3408984	Green Published, Bronze			2023-01-03	WOS:A1988P545000026
J	IMPERIALE, TF; SIEGAL, AP; CREDE, WB; KAMENS, EA				IMPERIALE, TF; SIEGAL, AP; CREDE, WB; KAMENS, EA			PREADMISSION SCREENING OF MEDICARE PATIENTS - THE CLINICAL IMPACT OF REIMBURSEMENT DISAPPROVAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									CLEVELAND METROPOLITAN GEN HOSP,HAMANN 331,3395 SCRANTON RD,CLEVELAND,OH 44109; YALE UNIV,SCH MED,DEPT INTERNAL MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT PSYCHIAT,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YALE NEW HAVEN HOSP,NEW HAVEN,CT 06504; VET ADM MED CTR,W HAVEN,CT 06516; CONNECTICUT PEER REVIEW ORG,MERIDEN,CT	MetroHealth System; Yale University; Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System				Imperiale, Thomas/0000-0001-7586-1073				DANS PE, 1985, NEW ENGL J MED, V313, P1131, DOI 10.1056/NEJM198510313131806; FLEISS JL, 1981, STATISTICAL METHODS, P13; GERTMAN PM, 1981, MED CARE, V19, P855, DOI 10.1097/00005650-198108000-00005; Restuccia J D, 1984, Health Aff (Millwood), V3, P130, DOI 10.1377/hlthaff.3.2.130; RESTUCCIA JD, 1986, REDUCING INAPPROPRIA; RESTUCCIA JD, 1982, METHOD DETERMINE INA; 1986, ANN INTERN MED, V105, P454	7	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 17	1988	259	23					3418	3421						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7295	3286913				2023-01-03	WOS:A1988N729500022
J	BLOEMENKAMP, KWM; ROSENDAAL, FR; HELMERHORST, FM; BULLER, HR; VANDENBROUCKE, JP				BLOEMENKAMP, KWM; ROSENDAAL, FR; HELMERHORST, FM; BULLER, HR; VANDENBROUCKE, JP			ENHANCEMENT BY FACTOR-V LEIDEN MUTATION OF RISK OF DEEP-VEIN THROMBOSIS ASSOCIATED WITH ORAL-CONTRACEPTIVES CONTAINING 3RD-GENERATION PROGESTAGEN	LANCET			English	Article							THROMBOEMBOLIC DISEASE; VENOUS THROMBOSIS	Recent concern about the safety of combined oral contraceptives (OCs) with third-generation progestagens prompted an examination of data from a population-based case-control study (Leiden Thrombophilia Study). We compared the risk of deep-vein thrombosis (DVT) during use of the newest OCs, containing a third-generation progestagen, with the risk of ''older'' products. We also investigated the influence of family history of thrombosis, previous pregnancy, age, and the thrombogenic factor V Leiden mutation. We selected 126 women with DVT and 159 controls aged 15-49 (mean 34.9) and premenopausal found, as compared non-users, the highest adjusted relative risks to be that for an OC containing desogestrel and 30 mu g ethinyloestradiol (relative risk [RR] 8.7, 95% CI 3.9-19.3). We found lower relative risks for ail other types of OC, ranging from 2.2 to 3.8. In a direct comparison, users of the desogestrel-containing oral contraceptive had a 2.5-fold higher risk (95% CI 1.2-5.2) than users of all other OC types combined. The relative risk for the desogestrel-containing OC was similar among women with and without a family history--ie, preferential prescription because of family history cannot explain our findings. Nor could the excess risk be explained by previous pregnancy, and it was highest in the youngest age categories, where we would expect most new users. The age-adjusted RR for the desogestrel-containing contraceptive was 9.2 (3.9-21.4) among non-carriers of the factor V Leiden mutation and 6.0 (1.9-19.0) among carriers of the mutation. This latter risk is superimposed on the 8-fold increased risk of venous thrombosis for carriers of the factor V Leiden mutation. The risk of carriers using the desogestrel-containing OC as compared with noncarrier non-users will therefore be increased almost 50-fold. Use of low-dose OCs with a third-generation progestagen carries a higher risk of DVT than the previous generation of OCs. The absolute risk of DVT associated with these OCs seems to be especially high among carriers of the factor V Leiden mutation and among women with a family history of thrombosis. However, the higher risk associated with OC with a third-generation progestagen compared with previous generations was also present in women without factor V Leiden and with no family history.	LEIDEN UNIV HOSP,DEPT CLIN EPIDEMIOL,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,DEPT OBSTET GYNAECOL & REPROD MED,2300 RC LEIDEN,NETHERLANDS; LEIDEN UNIV HOSP,THROMBOSIS & HAEMOSTASIS RES CTR,2300 RC LEIDEN,NETHERLANDS; UNIV AMSTERDAM,ACAD MED CTR,CTR HEMOSTASIS THROMBOSIS ATHEROSCLEROSIS & INFLA,1105 AZ AMSTERDAM,NETHERLANDS	Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); Leiden University; Leiden University Medical Center (LUMC); University of Amsterdam; Academic Medical Center Amsterdam			Rosendaal, Frits/Q-3842-2017; Vandenbroucke, Jan/AAM-3928-2020	Rosendaal, Frits/0000-0003-2558-7496; Vandenbroucke, Jan/0000-0001-5668-6716				BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BOTTIGER LE, 1980, LANCET, V1, P1097; CARTER JC, 1994, PROGR CARDIOVASC DIS, V6, P423; FOTHERBY K, 1994, CONTRACEPTION, V49, P1, DOI 10.1016/0010-7824(94)90106-6; GERSTMAN BB, 1991, AM J EPIDEMIOL, V133, P32, DOI 10.1093/oxfordjournals.aje.a115799; INMAN WHW, 1970, BMJ-BRIT MED J, V2, P203, DOI 10.1136/bmj.2.5703.203; JANSSEN HF, 1987, SURGERY, V101, P205; KOSTER T, 1993, LANCET, V342, P1503, DOI 10.1016/S0140-6736(05)80081-9; LIDEGAARD O, 1993, BRIT MED J, V306, P956, DOI 10.1136/bmj.306.6883.956; ROBINSON GE, 1994, BRIT J OBSTET GYNAEC, V101, P1036, DOI 10.1111/j.1471-0528.1994.tb13578.x; SHAPIRO S, 1979, LANCET, V1, P743; SPEROFF L, 1993, OBSTET GYNECOL, V1, P1034; VANDENBROUCKE JP, 1994, LANCET, V344, P1453, DOI 10.1016/S0140-6736(94)90286-0; VESSEY M, 1986, BRIT MED J, V292, P526, DOI 10.1136/bmj.292.6519.526	14	535	541	0	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	DEC 16	1995	346	8990					1593	1596		10.1016/S0140-6736(95)91929-5	http://dx.doi.org/10.1016/S0140-6736(95)91929-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK481	7500751	Bronze			2023-01-03	WOS:A1995TK48100010
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PATIENT EDUCATION-PROGRAM PROPOSED	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0823, V60, P44182	1	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2023-01-03	WOS:A1995RY05600009
J	COVARRUBIAS, M; VYAS, TB; ESCOBAR, L; WEI, A				COVARRUBIAS, M; VYAS, TB; ESCOBAR, L; WEI, A			ALCOHOLS INHIBIT A CLONED POTASSIUM CHANNEL AT A DISCRETE SATURABLE SITE - INSIGHTS INTO THE MOLECULAR-BASIS OF GENERAL-ANESTHESIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SQUID GIANT-AXON; K+ CHANNEL; XENOPUS-OOCYTES; SUBUNIT STOICHIOMETRY; ION CHANNELS; TEA BLOCKADE; RECEPTOR; SHAKER; DROSOPHILA; BINDING	The molecular basis of general anesthetic action on membrane proteins that control ion transport is not yet understood, In a previous report (Covarrubias, M., and Rubin, E. (1993) Proc. Natl. Acad. Sci. 90, 6957-6960), we found that low concentrations of ethanol (17-170 mM) selectively inhibited a noninactivating cloned K+ channel encoded by Drosophila Shaw2. Here, we have conducted equilibrium dose-inhibition experiments, single channel recording, and mutagenesis in vitro to study the mechanism underlying the inhibition of Shaw2 K+ channels by a homologous series of n-alkanols (ethanol to 1-hexanol), The results showed that: (i) these alcohols inhibited Shaw2 whole-cell currents, the equilibrium dose-inhibition relations were hyperbolic, and competition experiments revealed the presence of a discrete site of action, possibly a hydrophobic pocket; (ii) this pocket may be part of the protein because n-alkanol sensitivity can be transferred to novel hybrid K+ channels composed of Shaw2 subunits and homologous ethanol-insensitive subunits; (iii) moreover, a hydrophobic point mutation within a cytoplasmic loop of an ethanol-insensitive K+ channel (human Kv3.4) was sufficient to allow significant inhibition by n-alkanols, with a dose-inhibition relation that closely resembled that of wildtype Shaw2 channels; and (iv) 1-butanol selectively inhibited long duration single channel openings in a manner consistent with a direct effect on channel gating. These results strongly suggest that a discrete site within the ion channel protein is the primary locus of alcohol and general anesthetic action.	WASHINGTON UNIV,SCH MED,DEPT ANAT & NEUROBIOL,ST LOUIS,MO 63110	Washington University (WUSTL)	COVARRUBIAS, M (corresponding author), THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT PATHOL ANAT & CELL BIOL,1020 LOCUST ST,JAH 25,PHILADELPHIA,PA 19107, USA.			Covarrubias, Manuel/0000-0002-0881-4143	NIAAA NIH HHS [AA07463, AA07186-07] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007186, T32AA007463] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALIFIMOFF JK, 1989, BRIT J PHARMACOL, V96, P9, DOI 10.1111/j.1476-5381.1989.tb11777.x; ANANTHARAM V, 1992, MOL PHARMACOL, V42, P499; Ausubel FM., 2006, ENZYMATIC MANIPULATI; AVEYARD R, 1969, T FARADAY SOC, V65, P2645, DOI 10.1039/tf9696502645; BRAHM J, 1983, J GEN PHYSIOL, V81, P283, DOI 10.1085/jgp.81.2.283; BRAU ME, 1995, J GEN PHYSIOL, V105, P485, DOI 10.1085/jgp.105.4.485; CHOI KL, 1993, NEURON, V10, P533, DOI 10.1016/0896-6273(93)90340-W; COVARRUBIAS M, 1994, NEURON, V13, P1403, DOI 10.1016/0896-6273(94)90425-1; COVARRUBIAS M, 1991, NEURON, V7, P763, DOI 10.1016/0896-6273(91)90279-9; COVARRUBIAS M, 1993, P NATL ACAD SCI USA, V90, P6957, DOI 10.1073/pnas.90.15.6957; DIETRICH RA, 1989, PHARMACOL REV, V41, P489; DILGER JP, 1994, ANESTHESIOLOGY, V81, P431, DOI 10.1097/00000542-199408000-00022; DURELL SR, 1992, BIOPHYS J, V62, P238, DOI 10.1016/S0006-3495(92)81809-X; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; Franks N P, 1991, Alcohol Alcohol Suppl, V1, P197; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1991, SCIENCE, V254, P427, DOI 10.1126/science.1925602; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; FROEMMEL C, 1984, Journal of Theoretical Biology, V111, P247; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P279; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAYDON DA, 1988, J PHYSIOL-LONDON, V402, P363, DOI 10.1113/jphysiol.1988.sp017209; HAYDON DA, 1988, J PHYSIOL-LONDON, V402, P375, DOI 10.1113/jphysiol.1988.sp017210; HAYDON DA, 1983, J PHYSIOL-LONDON, V341, P411, DOI 10.1113/jphysiol.1983.sp014813; HAYDON DA, 1986, J PHYSIOL-LONDON, V373, P311, DOI 10.1113/jphysiol.1986.sp016049; HEIGENBOTHAM L, 1992, NEURON, V8, P483; HERRINGTON J, 1991, J NEUROSCI, V11, P2226; ISACOFF EY, 1991, NATURE, V353, P86, DOI 10.1038/353086a0; KAVANAUGH MP, 1992, NEURON, V8, P493, DOI 10.1016/0896-6273(92)90277-K; Ledwell J. L., 1995, Biophysical Journal, V68, pA32; LI CY, 1994, P NATL ACAD SCI USA, V91, P8200, DOI 10.1073/pnas.91.17.8200; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACKINNON R, 1990, SCIENCE, V250, P276, DOI 10.1126/science.2218530; MACKINNON R, 1991, NATURE, V350, P232, DOI 10.1038/350232a0; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; MCCORMACK K, 1993, BIOPHYS J, V63, P1740; MCPHEE JC, 1994, P NATL ACAD SCI USA, V91, P12346, DOI 10.1073/pnas.91.25.12346; Meyer H, 1901, ARCH EXP PATHOL PHAR, V46, P338, DOI 10.1007/BF01978064; MILLER KW, 1986, ANN NY ACAD SCI, V492, P71; MOSS GWJ, 1991, P NATL ACAD SCI USA, V88, P134, DOI 10.1073/pnas.88.1.134; MURRELL RD, 1991, J PHYSIOL-LONDON, V437, P431, DOI 10.1113/jphysiol.1991.sp018604; PRESS WH, 1989, NUMERICAL RECIPES PA, P473; RUDY B, 1991, J NEUROSCI RES, V29, P401, DOI 10.1002/jnr.490290316; SINE SM, 1987, BIOPHYS J, V52, P1047; SLATER SJ, 1993, NATURE, V364, P82, DOI 10.1038/364082a0; SLESINGER PA, 1993, NEURON, V11, P739, DOI 10.1016/0896-6273(93)90083-4; SOLC CK, 1988, J NEUROSCI, V8, P2556; STUEHMER W, 1992, METHOD ENZYMOL, V207, P319; Tanford C., 1973, HYDROPHOBIC EFFECT; TEEM JL, 1993, CELL, V73, P335, DOI 10.1016/0092-8674(93)90233-G; TSUNODA S, 1995, J NEUROSCI, V15, P1741, DOI 10.1523/JNEUROSCI.15-03-01741.1995; WAFFORD KA, 1991, NEURON, V7, P27, DOI 10.1016/0896-6273(91)90071-7; WEI A, 1990, SCIENCE, V248, P599, DOI 10.1126/science.2333511; WEIGHT FF, 1992, ADV BIOCHEM PSYCHOPH, V47, P335; WEIGHT FF, 1992, INT REV NEUROBIOL, V33, P289, DOI 10.1016/S0074-7742(08)60694-7; WOOD SC, 1995, MOL PHARMACOL, V47, P121; YELLEN G, 1991, SCIENCE, V251, P939, DOI 10.1126/science.2000494; ZAGOTTA WN, 1988, J NEUROSCI, V8, P4765; ZORN L, NEUROSCI LETT, V161, P81	59	79	79	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 18	1995	270	33					19408	19416		10.1074/jbc.270.33.19408	http://dx.doi.org/10.1074/jbc.270.33.19408			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	RP703	7642622	hybrid			2023-01-03	WOS:A1995RP70300036
J	MURPHY, JA; ROSS, LM; GIBSON, BES				MURPHY, JA; ROSS, LM; GIBSON, BES			VINCRISTINE TOXICITY IN 5 CHILDREN WITH ACUTE LYMPHOBLASTIC-LEUKEMIA	LANCET			English	Letter							PHARMACOKINETICS				MURPHY, JA (corresponding author), ROYAL HOSP SICK CHILDREN,DEPT HAEMATOL,GLASGOW G3 8SJ,LANARK,SCOTLAND.							CHESSELLS JM, 1995, LANCET, V345, P143, DOI 10.1016/S0140-6736(95)90164-7; COMO JA, 1994, NEW ENGL J MED, V330, P263, DOI 10.1056/NEJM199401273300407; FEDELI L, 1989, CANCER, V64, P1805, DOI 10.1002/1097-0142(19891101)64:9<1805::AID-CNCR2820640908>3.0.CO;2-D; TSURUO T, 1982, CANCER RES, V42, P4730; VANDENBERG HW, 1982, CANCER CHEMOTH PHARM, V8, P215, DOI 10.1007/BF00255487	5	31	33	0	1	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	AUG 12	1995	346	8972					443	443		10.1016/S0140-6736(95)92816-2	http://dx.doi.org/10.1016/S0140-6736(95)92816-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RN656	7623589				2023-01-03	WOS:A1995RN65600046
J	DONZELLI, GP; PRATESI, S; RAPISARDI, G; AGATI, G; FUSI, F; PRATESI, R				DONZELLI, GP; PRATESI, S; RAPISARDI, G; AGATI, G; FUSI, F; PRATESI, R			1-DAY PHOTOTHERAPY OF NEONATAL JAUNDICE WITH BLUE-GREEN LAMP	LANCET			English	Letter									UNIV FLORENCE,DEPT PHYS,FLORENCE,ITALY; CNR,INST QUANTUM ELECTR,FLORENCE,ITALY	University of Florence; Consiglio Nazionale delle Ricerche (CNR)	DONZELLI, GP (corresponding author), UNIV FLORENCE,OSPED MEYER,DEPT PEDIAT,I-50132 FLORENCE,ITALY.		Pratesi, Simone/M-6697-2016; Agati, Giovanni/F-5572-2013; fusi, franco/K-4637-2013	Pratesi, Simone/0000-0002-8943-7246; fusi, franco/0000-0002-4349-0842; AGATI, GIOVANNI/0000-0003-0855-9389				AGATI G, 1993, J PHOTOCH PHOTOBIO B, V18, P197, DOI 10.1016/1011-1344(93)80063-F; DONZELLI GP, 1994, SPIE, V2084, P332; PRATESI R, 1983, LANCET, V2, P859; SISSON T R C, 1970, Birth Defects Original Article Series, V6, P100; VECCHI C, 1982, LANCET, V2, P390	5	16	18	0	3	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0099-5355			LANCET	Lancet	JUL 15	1995	346	8968					184	185						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RJ031	7603251				2023-01-03	WOS:A1995RJ03100045
J	MILLER, VT; LAROSA, J; BARNABEI, V; KESSLER, C; LEVIN, G; SMITHROTH, A; GRIFFIN, M; STOY, DB; BUSH, T; ZACUR, H; FOSTER, D; ANDERSON, J; MCKENZIE, A; MILLER, S; WOOD, PD; STEFANICK, ML; MARCUS, R; AKANA, A; HEINRICHS, L; KIRCHNER, C; OHANLAN, K; RUYLE, M; SHEEHAN, M; JUDD, HL; GREENDALE, G; BAYALOS, R; LOZANO, K; KAWAKAMI, K; BARRETTCONNOR, E; LANGER, R; KRITZSILVERSTEIN, D; CARRIONPETERSEN, ML; CAVERO, C; SCHROTT, HG; JOHNSON, SR; FEDDERSEN, DA; KRUTZFELDT, DL; BENDA, JA; PAUERSTEIN, C; TRABAL, J; SCHENKEN, R; STERN, MP; RODRIGUEZSIFUENTES, M; EASTON, C; WELLS, HB; ESPELAND, M; HOWARD, G; BYINGTON, R; LEGAULT, C; SHUMAKER, S; HOGAN, P; HIRE, D; WASILAUSKAS, C; JAMES, M; LANE, K; TERRELL, T; REECE, S; PIERCE, J; SNOW, M; ANTHONY, S; MEBANESIMS, IL; EINHORN, P; HUNSBERGER, S; WACLAWIW, M; LIPPEL, K; LUCAS, D; VERTER, J; JACKSON, S; KELAGHAN, J; PERLMAN, J; WOLF, P; MCGOWAN, J; GORDON, S; HEYSE, S; FRADKIN, J; SHERMAN, S; PAGE, L; SORENSON, A; HULKA, B; BRODY, B; BURKMAN, R; HEANEY, R; KRAUSS, R; ROBERTS, H; WITTES, J; RIGGS, L; MOSS, R; ALBERS, J; MARCOVINA, S; FINEBERG, SE; TRACY, RP; MERINO, M; SCULLY, R; LIVOLSI, V; KESSLER, G				MILLER, VT; LAROSA, J; BARNABEI, V; KESSLER, C; LEVIN, G; SMITHROTH, A; GRIFFIN, M; STOY, DB; BUSH, T; ZACUR, H; FOSTER, D; ANDERSON, J; MCKENZIE, A; MILLER, S; WOOD, PD; STEFANICK, ML; MARCUS, R; AKANA, A; HEINRICHS, L; KIRCHNER, C; OHANLAN, K; RUYLE, M; SHEEHAN, M; JUDD, HL; GREENDALE, G; BAYALOS, R; LOZANO, K; KAWAKAMI, K; BARRETTCONNOR, E; LANGER, R; KRITZSILVERSTEIN, D; CARRIONPETERSEN, ML; CAVERO, C; SCHROTT, HG; JOHNSON, SR; FEDDERSEN, DA; KRUTZFELDT, DL; BENDA, JA; PAUERSTEIN, C; TRABAL, J; SCHENKEN, R; STERN, MP; RODRIGUEZSIFUENTES, M; EASTON, C; WELLS, HB; ESPELAND, M; HOWARD, G; BYINGTON, R; LEGAULT, C; SHUMAKER, S; HOGAN, P; HIRE, D; WASILAUSKAS, C; JAMES, M; LANE, K; TERRELL, T; REECE, S; PIERCE, J; SNOW, M; ANTHONY, S; MEBANESIMS, IL; EINHORN, P; HUNSBERGER, S; WACLAWIW, M; LIPPEL, K; LUCAS, D; VERTER, J; JACKSON, S; KELAGHAN, J; PERLMAN, J; WOLF, P; MCGOWAN, J; GORDON, S; HEYSE, S; FRADKIN, J; SHERMAN, S; PAGE, L; SORENSON, A; HULKA, B; BRODY, B; BURKMAN, R; HEANEY, R; KRAUSS, R; ROBERTS, H; WITTES, J; RIGGS, L; MOSS, R; ALBERS, J; MARCOVINA, S; FINEBERG, SE; TRACY, RP; MERINO, M; SCULLY, R; LIVOLSI, V; KESSLER, G			EFFECTS OF ESTROGEN OR ESTROGEN/PROGESTIN REGIMENS ON HEART-DISEASE RISK-FACTORS IN POSTMENOPAUSAL WOMEN - THE POSTMENOPAUSAL ESTROGEN/PROGESTIN INTERVENTIONS (PEPI) TRIAL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HORMONE-REPLACEMENT THERAPY; DENSITY LIPOPROTEIN CHOLESTEROL; ATHEROSCLEROTIC VASCULAR-DISEASE; ACUTE MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; PROGESTOGEN REPLACEMENT; CARBOHYDRATE-METABOLISM; PLASMA-LIPOPROTEIN; INSULIN-RESISTANCE; SERUM-LIPIDS	Objective.-To assess pairwise differences between placebo, unopposed estrogen, and each of three estrogen/progestin regimens on selected heart disease risk factors in healthy postmenopausal women. Design.-A 3-year, multicenter, randomized, double-blind, placebo-controlled trial. Participants.-A total of 875 healthy postmenopausal women aged 45 to 64 years who had no known contraindication to hormone therapy. Intervention.-Participants were randomly assigned in equal numbers to the following groups: (1) placebo; (2) conjugated equine estrogen (CEE), 0.625 mg/d; (3) CEE, 0.625 mg/d plus cyclic medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo; (4) CEE, 0.625 mg/d plus consecutive MPA, 2.5 mg/d; or (5) CEE, 0.625 mg/d plus cyclic micronized progesterone (MP), 200 mg/d for 12 d/mo. Primary Endpoints.-Four endpoints were chosen to represent four biological systems related to the risk of cardiovascular disease: (1) high-density lipoprotein cholesterol (HDL-C), (2) systolic blood pressure, (3) serum insulin, and (4) fibrinogen. Analysis.-Analyses presented are by intention to treat. P values for primary endpoints are adjusted for multiple comparisons; 95% confidence intervals around estimated effects were calculated without this adjustment. Results.-Mean changes in HDL-C segregated treatment regimens into three statistically distinct groups: (1) placebo (decrease of 0.03 mmol/L [1.2 mg/dL]); (2) MPA regimens (increases of 0.03 to 0.04 mmol/L [1.2 to 1.6 mg/dl]); and (3) CEE with cyclic MP (increase of 0.11 mmol/L [4.1 mg/dL]) and CEE alone (increase of 0.14 mmol/L [5.6 mg/dL]). Active treatments decreased mean low-density lipoprotein cholesterol (0.37 to 0.46 mmol/L [14.5 to 17.7 mg/dL]) and increased mean triglyceride (0.13 to 0.15 mmol/L [11.4 to 13.7 mg/dL]) compared with placebo. Placebo was associated with a significantly greater increase in mean fibrinogen than any active treatment (0.10 g/L compared with -0.02 to 0.06 g/L); differences among active treatments were not significant. Systolic blood pressure increased and postchallenge insulin levels decreased during the trial, but neither varied significantly by treatment assignment. Compared with other active treatments, unopposed estrogen was associated with a significantly increased risk of adenomatous or atypical hyperplasia (34% vs 1%) and of hysterectomy (6% vs 1%). No other adverse effect differed by treatment assignment or hysterectomy status. Conclusions.-Estrogen alone or in combination with a progestin improves lipoproteins and lowers fibrinogen levels without detectable effects on postchallenge insulin or blood pressure. Unopposed estrogen is the optimal regimen for elevation of HDL-C, but the high rate of endometrial hyperplasia restricts use to women without a uterus. In women with a uterus, CEE with cyclic MP has the most favorable effect on HDL-C and no excess risk of endometrial hyperplasia.	JOHNS HOPKINS UNIV,BALTIMORE,MD; STANFORD UNIV,STANFORD,CA; UNIV CALIF LOS ANGELES,LOS ANGELES,CA; UNIV CALIF SAN DIEGO,SAN DIEGO,CA; IOWA STATE UNIV SCI & TECHNOL,AMES,IA; UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX; BOWMAN GRAY SCH MED,WINSTON SALEM,NC; NICHHD,BETHESDA,MD; NIAMSD,BETHESDA,MD; NIDDKD,BETHESDA,MD; NIA,BETHESDA,MD; US PHS,CTR SUPPLY SERV,CTR DRUG DISTRIBUT,PERRY POINT,MD; NW LIPID RES CTR,LIPID LAB,SEATTLE,WA; WISHARD MEM HOSP,GLUCOSE INSULIN LAB,INDIANAPOLIS,IN; UNIV VERMONT,HEMOSTASIS LAB,BURLINGTON,VT; NCI,PATHOL LAB,BETHESDA,MD; MASSACHUSETTS GEN HOSP,BOSTON,MA; JEWISH HOSP ST LOUIS,ST LOUIS,MO; GEORGE WASHINGTON UNIV,WASHINGTON,DC; NHLBI,BETHESDA,MD 20892	Johns Hopkins University; Stanford University; University of California System; University of California Los Angeles; University of California System; University of California San Diego; Iowa State University; University of Texas System; University of Texas Health San Antonio; Wake Forest University; Wake Forest Baptist Medical Center; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); United States Public Health Service; University of Vermont; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Harvard University; Massachusetts General Hospital; Barnes-Jewish Hospital; George Washington University; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			zacur, howard/W-2170-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL040185, U01HL040154, U01HL040195] Funding Source: NIH RePORTER; NHLBI NIH HHS [U01-HL40195, U01-HL40154, U01-HL40185] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bachorik P S, 1986, Methods Enzymol, V129, P78; BARRETTCONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1861, DOI 10.1001/jama.265.14.1861; BARRETTCONNOR E, 1990, ARTERIOSCLEROSIS, V10, P531, DOI 10.1161/01.ATV.10.4.531; BARRETTCONNOR E, 1990, MENOPAUSE, P199; BASS KM, 1993, ARCH INTERN MED, V153, P2209, DOI 10.1001/archinte.153.19.2209; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; BUSH TL, 1990, MENOPAUSE BIOL CLIN, P211; CAGNACCI A, 1992, J CLIN ENDOCR METAB, V74, P1396, DOI 10.1210/jc.74.6.1396; CASTELLI WP, 1988, AM J OBSTET GYNECOL, V158, P1553, DOI 10.1016/0002-9378(88)90189-5; CLAUSS A., 1957, ACTA HAEMATOL, V17, P237; DECLEYN K, 1989, MATURITAS, V11, P235, DOI 10.1016/0378-5122(89)90216-8; EDWARDS AL, 1985, EXPT DESIGN PSYCHOL; FALKEBORN M, 1992, BRIT J OBSTET GYNAEC, V99, P821, DOI 10.1111/j.1471-0528.1992.tb14414.x; GANGAR KF, 1993, BAILLIERE CLIN ENDOC, V7, P47, DOI 10.1016/S0950-351X(05)80270-8; GILLIGAN DM, 1994, CIRCULATION, V90, P786, DOI 10.1161/01.CIR.90.2.786; GLUECK CJ, 1994, J LAB CLIN MED, V123, P59; GODSLAND IF, 1993, METABOLISM, V42, P846, DOI 10.1016/0026-0495(93)90058-V; GOLDBOURT U, 1979, AM J EPIDEMIOL, V109, P296, DOI 10.1093/oxfordjournals.aje.a112683; GORDON DJ, 1989, CIRCULATION, V79, P8, DOI 10.1161/01.CIR.79.1.8; GRADY D, 1992, ANN INTERN MED, V117, P1016, DOI 10.7326/0003-4819-117-12-1016; GRUCHOW HW, 1988, AM HEART J, V115, P954, DOI 10.1016/0002-8703(88)90063-4; HAINLINE A, 1982, MANUAL LABORATORY OP; HASSAGER C, 1987, CIRCULATION, V76, P753, DOI 10.1161/01.CIR.76.4.753; HENDERSON BE, 1988, AM J OBSTET GYNECOL, V159, P312, DOI 10.1016/S0002-9378(88)80074-7; HUNT K, 1987, BRIT J OBSTET GYNAEC, V94, P620, DOI 10.1111/j.1471-0528.1987.tb03166.x; JACOBS DR, 1990, AM J EPIDEMIOL, V131, P32, DOI 10.1093/oxfordjournals.aje.a115483; JENSEN J, 1987, AM J OBSTET GYNECOL, V156, P66, DOI 10.1016/0002-9378(87)90204-3; KANNEL WB, 1987, JAMA-J AM MED ASSOC, V258, P1183, DOI 10.1001/jama.258.9.1183; LAAKSO M, 1993, AM J EPIDEMIOL, V137, P959, DOI 10.1093/oxfordjournals.aje.a116768; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LIP GYH, 1994, J HUM HYPERTENS, V8, P491; LOBO RA, 1991, J CLIN ENDOCR METAB, V73, P925, DOI 10.1210/jcem-73-5-925; LOBO RA, 1994, OBSTET GYNECOL, V84, P987; MASHCHAK CA, 1982, AM J OBSTET GYNECOL, V144, P511, DOI 10.1016/0002-9378(82)90218-6; MASHCHAK CA, 1985, J REPROD MED, V30, P805; Meilahn E N, 1992, Ann Epidemiol, V2, P445; MILLER VT, 1990, ENDOCRIN METAB CLIN, V19, P381, DOI 10.1016/S0889-8529(18)30331-1; MOORJANI S, 1991, J CLIN ENDOCR METAB, V73, P373, DOI 10.1210/jcem-73-2-373; MORGAN CR, 1963, DIABETES, V12, P115, DOI 10.2337/diab.12.2.115; NABULSI AA, 1993, NEW ENGL J MED, V328, P1069, DOI 10.1056/NEJM199304153281501; NEWNHAM HH, 1993, BAILLIERE CLIN ENDOC, V7, P61, DOI 10.1016/S0950-351X(05)80271-X; PSATY BM, 1994, ARCH INTERN MED, V154, P1333, DOI 10.1001/archinte.154.12.1333; RAVNIKAR VA, 1993, LANCET, V342, P133; RIEDEL M, 1993, CLIN INVESTIGATOR, V71, P406; RIJPKEMA AHM, 1990, MATURITAS, V12, P259, DOI 10.1016/0378-5122(90)90007-S; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Sacks Frank M., 1994, Current Opinion in Lipidology, V5, P236, DOI 10.1097/00041433-199405030-00012; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Stevenson J C, 1994, Int J Fertil Menopausal Stud, V39 Suppl 1, P50; TIKKANEN MJ, 1986, MATURITAS, V8, P7, DOI 10.1016/0378-5122(86)90003-4; TIKKANEN MJ, 1993, CARDIOVASCULAR RISK, V3, P138; Trinder P, 1969, ANN CLIN BIOCH INT J, V6, P24; WALSH BW, 1993, J CLIN INVEST, V91, P2126, DOI 10.1172/JCI116437; WALSH BW, 1991, NEW ENGL J MED, V325, P1196, DOI 10.1056/NEJM199110243251702; Warnick G R, 1986, Methods Enzymol, V129, P101; 1992, SAS P229 SAS I INC T; 1978, J CHRON DIS, V31, P651; IN PRESS CONTROL CLI	58	2065	2093	0	49	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 18	1995	273	3					199	208		10.1001/jama.1995.03520270033028	http://dx.doi.org/10.1001/jama.1995.03520270033028			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	QB234	7807658				2023-01-03	WOS:A1995QB23400023
J	DEKLERK, ESMD; BLOMMERS, J; KUIK, DJ; BEZEMER, PD; FEENSTRA, L				DEKLERK, ESMD; BLOMMERS, J; KUIK, DJ; BEZEMER, PD; FEENSTRA, L			EFFECT OF HOMEOPATHIC MEDICINES ON DAILY BURDEN OF SYMPTOMS IN CHILDREN WITH RECURRENT UPPER RESPIRATORY-TRACT INFECTIONS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To investigate the intrinsic effects of individually prescribed homoeopathic medicines. Design-Randomised double blind placebo controlled study. Setting-Paediatric outpatient department of university hospital. Patients-175 children with frequently-recurring upper respiratory tract infections. Of the 170 children evaluable, 86 were randomised to homoeopathic medicines (47 boys, 39 girls; median age at start 4.2 years; median number of episodes in past year 4) and 84 to placebo (43 boys, 41 girls; median age at start 3.6 years; median number of episodes in past year 4). Main outcome measures-Mean score for daily symptoms, number of antibiotic courses, and number of adenoidectomies and tonsillectomies over one year of follow up. Results-The mean daily symptom score was 2.61 in the placebo group-and 2.21 in the treatment group (difference 0.41; 95% confidence interval -0.02 to 0.83). In both groups the use of antibiotics was greatly reduced compared:with that in the year before entering the trial (from 73 to 33 in the treatment group and from 69 to 43 in the placebo group). The proportion of children in the treatment group having adenoidectomies was lower in the treatment group (16%, 8/50) than in the placebo group (21%, 9/42). The proportion having tonsillectomies was the same in both groups (5%). Conclusion-Individually prescribed homoeopathic-medicines seem to add little to careful counselling of children with recurrent upper respiratory tract-infection in reducing the daily burden of symptoms, use of antibiotics, and need for adenoidectomy and tonsillectomy.	UNIV HOSP ST RAPHAEL,B-3000 LOUVAIN,BELGIUM		DEKLERK, ESMD (corresponding author), VRIJE UNIV AMSTERDAM,FAC GENEESKUNDE,VAKGRP EPIDEMIOL & BIOSTAT,1081 BT AMSTERDAM,NETHERLANDS.							BOYD H, 1983, WORLD HEALTH FORUM, V4, P102; CAMPBELL ACH, 1977, BRIT HOMOEOPATHIC J, V66, P20; COURT SDM, 1973, POSTGRAD MED J, V49, P771, DOI 10.1136/pgmj.49.577.771; DEKLERK ESM, 1993, EFFECTS HOMOEOPATHIC; DEKLERK ESM, 1986, SIMILIA SIMILIBUS CU, V16, P78; Pocock SJ., 2013, CLIN TRIALS PRACTICA; SCHWARTZ D, 1980, CLIN TRIALS; WILLIAMS RL, 1993, JAMA-J AM MED ASSOC, V270, P1314	8	40	42	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1994	309	6965					1329	1332						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PT625	7866080				2023-01-03	WOS:A1994PT62500019
J	HO, MTP; MASSEY, JB; POWNALL, HJ; ANDERSON, RE; HOLLYFIELD, JG				HO, MTP; MASSEY, JB; POWNALL, HJ; ANDERSON, RE; HOLLYFIELD, JG			MECHANISM OF VITAMIN-A MOVEMENT BETWEEN ROD OUTER SEGMENTS, INTERPHOTORECEPTOR RETINOID-BINDING PROTEIN, AND LIPOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article									BAYLOR COLL MED,DEPT MED,HOUSTON,TX 77030	Baylor College of Medicine	HO, MTP (corresponding author), BAYLOR COLL MED,CULLEN EYE INST,PROGRAM NEUROSCI,HOUSTON,TX 77030, USA.			Pownall, Henry/0000-0001-8412-506X				ADLER AJ, 1982, BIOCHEM BIOPH RES CO, V108, P1601, DOI 10.1016/S0006-291X(82)80091-0; ADLER AJ, 1985, INVEST OPHTH VIS SCI, V26, P273; BAKER JM, 1979, BIOCHIM BIOPHYS ACTA, V551, P260; BANGHAM AD, 1964, BIOCHEM J, V90, P133, DOI 10.1042/bj0900133; BAZAN NG, 1985, J BIOL CHEM, V260, P3677; BERNSTEIN PS, 1987, P NATL ACAD SCI USA, V84, P1849, DOI 10.1073/pnas.84.7.1849; BOYER TD, 1980, J BIOL CHEM, V255, P627; BRIDGES CDB, 1976, EXP EYE RES, V22, P435, DOI 10.1016/0014-4835(76)90182-2; BRIDGES CDB, 1986, PINEAL RETINAL RELAT, P383; CHARLTON SC, 1976, J BIOL CHEM, V251, P7952; DOODY MC, 1980, BIOCHEMISTRY-US, V19, P108, DOI 10.1021/bi00542a017; DOWLING JE, 1960, NATURE, V188, P114, DOI 10.1038/188114a0; FEX G, 1987, BIOCHIM BIOPHYS ACTA, V901, P255, DOI 10.1016/0005-2736(87)90122-2; FONG SL, 1984, J BIOL CHEM, V259, P6534; FUTTERMAN S, 1972, J BIOL CHEM, V247, P5168; HOGAN MJ, 1971, HISTOLOGY HUMAN EYE, P403; HUANG CH, 1969, BIOCHEMISTRY-US, V8, P344, DOI 10.1021/bi00829a048; KRINSKY NI, 1958, J BIOL CHEM, V232, P881; LAI YL, 1982, NATURE, V298, P848, DOI 10.1038/298848a0; LEE RH, 1982, METHOD ENZYMOL, V81, P496; LIOU GI, 1982, VISION RES, V22, P1457, DOI 10.1016/0042-6989(82)90210-3; MASSEY JB, 1984, BIOCHIM BIOPHYS ACTA, V793, P387, DOI 10.1016/0005-2760(84)90253-4; NICHOLS JW, 1983, J BIOL CHEM, V258, P5368; OTTONELLO S, 1987, J BIOL CHEM, V262, P3975; POWNALL HJ, 1983, J AM CHEM SOC, V105, P2440, DOI 10.1021/ja00346a055; RANDO RR, 1982, BIOCHEM BIOPH RES CO, V104, P430, DOI 10.1016/0006-291X(82)90655-6; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SAARI JC, 1984, VISION RES, V24, P1595, DOI 10.1016/0042-6989(84)90317-1; SAARI JC, 1985, J BIOL CHEM, V260, P195; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STRUCK DK, 1981, BIOCHEMISTRY-US, V20, P4093, DOI 10.1021/bi00517a023; WHITMER DI, 1987, BIOCHEM J, V244, P41, DOI 10.1042/bj2440041; WHITMER DI, 1984, J BIOL CHEM, V259, P1969	34	109	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1989	264	2					928	935						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	R8200	2910871				2023-01-03	WOS:A1989R820000038
J	SHETTY, MR				SHETTY, MR			WHITE LINES IN THE FINGERNAILS INDUCED BY COMBINATION CHEMOTHERAPY	BRITISH MEDICAL JOURNAL			English	Note											SHETTY, MR (corresponding author), NW COMMUNITY HOSP,ARLINGTON HTS,IL 60005, USA.							JAMES WD, 1983, ARCH DERMATOL, V119, P334, DOI 10.1001/archderm.119.4.334	1	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 24	1988	297	6664					1635	1635		10.1136/bmj.297.6664.1635-a	http://dx.doi.org/10.1136/bmj.297.6664.1635-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R6153	3147769	Bronze, Green Published			2023-01-03	WOS:A1988R615300009
J	LATINI, R				LATINI, R			MULTICENTER, CROSS-SECTIONAL STUDY OF VENTRICULAR ARRHYTHMIAS IN CHRONICALLY HEMODIALYZED PATIENTS	LANCET			English	Article											LATINI, R (corresponding author), MARIO NEGRI INST PHARMACOL RES, VIA ERITREA 62, I-20157 MILAN, ITALY.		Latini, Roberto/AAB-1410-2020	Latini, Roberto/0000-0002-3729-4650				ARONOW WS, 1987, AM J CARDIOL, V60, P730, DOI 10.1016/0002-9149(87)90395-X; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; BIGGER JT, 1987, CIRCULATION, V75, P28; BLUMBERG A, 1983, NEPHRON, V33, P91, DOI 10.1159/000182919; BRADLEY JR, 1987, LANCET, V1, P295; BRYNGER H, 1980, P EDTA, V17, P36; BURTON PR, 1987, LANCET, V1, P1115; COMTY CM, 1983, REPLACEMENT RENAL FU, P595; DEGOULET P, 1982, NEPHRON, V31, P103, DOI 10.1159/000182627; DEMELLO VR, 1981, SOUTHERN MED J, V74, P178, DOI 10.1097/00007611-198102000-00013; GOKAL R, 1987, LANCET, V2, P1105; KOSTIS JB, 1987, J AM COLL CARDIOL, V10, P231, DOI 10.1016/S0735-1097(87)80001-3; KYRIAKIDIS M, 1984, NEPHRON, V38, P26, DOI 10.1159/000183273; LEVY D, 1985, CIRCULATION, V72, P46; MACDONALD IL, 1981, CLIN NEPHROL, V15, P321; MAHER ER, 1987, LANCET, V1, P452; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCLENACHAN JM, 1987, NEW ENGL J MED, V317, P787, DOI 10.1056/NEJM198709243171302; MESSERLI FH, 1984, AM J MED, V77, P18, DOI 10.1016/0002-9343(84)90430-3; MIETTINEN O, 1976, AM J EPIDEMIOL, V103, P226, DOI 10.1093/oxfordjournals.aje.a112220; MION C, 1985, P EUR DIAL TRANS, V21, P490; MORRISON G, 1980, KIDNEY INT, V17, P811, DOI 10.1038/ki.1980.93; MOSS AJ, 1979, CIRCULATION, V60, P998, DOI 10.1161/01.CIR.60.5.998; NIWA A, 1985, JPN HEART J, V26, P403; QUEREDA C, 1986, NEPHRON, V42, P181, DOI 10.1159/000183661; RAMIREZ G, 1984, NEPHRON, V36, P212, DOI 10.1159/000183156; RUBERMAN W, 1981, CIRCULATION, V64, P297, DOI 10.1161/01.CIR.64.2.297; TURIEL M, 1986, NEW TRENDS ARRHYTHMI, V11, P43; WEBER H, 1984, NEPHRON, V37, P180, DOI 10.1159/000183240; Wizemann V, 1986, Contrib Nephrol, V52, P42; WIZEMANN V, 1985, NEPHRON, V39, P356, DOI 10.1159/000183405; 1985, SAS USERS GUIDE STAT; 1986, SPSSX USERS GUIDE; 1985, CENSIMENTO DEI SERVI	34	66	66	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG 6	1988	2	8606					305	309						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P5449	2899721				2023-01-03	WOS:A1988P544900004
J	CARMICHAEL, AJ; MCHUGH, MM; MARTIN, AM; FARROW, M				CARMICHAEL, AJ; MCHUGH, MM; MARTIN, AM; FARROW, M			SEROLOGICAL MARKERS OF RENAL ITCH IN PATIENTS RECEIVING LONG-TERM HEMODIALYSIS	BRITISH MEDICAL JOURNAL			English	Note									ROYAL INFIRM,DEPT MED,SUNDERLAND SR2 7JE,ENGLAND; SUNDERLAND POLYTECH,DEPT MATH & COMP STUDIES,SUNDERLAND SR2 3SD,ENGLAND	Sunderland Royal Hospital; University of Sunderland								GRAF H, 1979, BRIT MED J, V2, P1478, DOI 10.1136/bmj.2.6203.1478-a; MASSRY SG, 1968, NEW ENGL J MED, V279, P697, DOI 10.1056/NEJM196809262791308; MATSUMOTO M, 1985, CLIN NEPHROL, V23, P285; NIELSEN T, 1980, DAN MED BULL, V27, P269; YOUNG AW, 1973, NEW YORK STATE J MED, V73, P2670	5	47	48	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 4	1988	296	6636					1575	1575		10.1136/bmj.296.6636.1575	http://dx.doi.org/10.1136/bmj.296.6636.1575			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N7292	3135016	Bronze, Green Published			2023-01-03	WOS:A1988N729200013
J	WEINBERGER, MH; COHEN, SJ; MILLER, JZ; LUFT, FC; GRIM, CE; FINEBERG, NS				WEINBERGER, MH; COHEN, SJ; MILLER, JZ; LUFT, FC; GRIM, CE; FINEBERG, NS			DIETARY-SODIUM RESTRICTION AS ADJUNCTIVE TREATMENT OF HYPERTENSION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MARTIN LUTHER KING JR GEN HOSP, LOS ANGELES, CA 90059 USA; CHARLES R DREW POSTGRAD MED CTR, LOS ANGELES, CA USA	Charles R. Drew University of Medicine & Science	WEINBERGER, MH (corresponding author), INDIANA UNIV, SCH MED,DEPT MED,HYPERTENS RES CTR,541 CLIN DR, ROOM 409, INDIANAPOLIS, IN 46223 USA.			Luft, Friedrich/0000-0002-8635-1199	NHLBI NIH HHS [HL 30561] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R18HL030561, R01HL030561] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1981, LANCET, V2, P539; BEARD TC, 1982, LANCET, V2, P455; DUSTAN HR, 1974, ARCH INTERN MED, V133, P1007, DOI 10.1001/archinte.133.6.1007; FLEISS JL, 1973, STATISTICAL METHODS, P20; FUJITA T, 1980, AM J MED, V69, P334, DOI 10.1016/0002-9343(80)90002-9; GROBBEE DE, 1986, BRIT MED J, V293, P27, DOI 10.1136/bmj.293.6538.27; KAPLAN NM, 1985, ANN INTERN MED, V102, P359, DOI 10.7326/0003-4819-102-3-359; KEMPNER W, 1948, AM J MED, V4, P545, DOI 10.1016/0002-9343(48)90441-0; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; KULLER LH, 1986, CIRCULATION, V73, P114, DOI 10.1161/01.CIR.73.1.114; LANG CL, 1985, J AM DIET ASSOC, V85, P477; LANGFORD HG, 1985, JAMA-J AM MED ASSOC, V253, P657, DOI 10.1001/jama.253.5.657; LASSER NL, 1984, AM J MED, V76, P52, DOI 10.1016/0002-9343(84)90957-4; MACGREGOR GA, 1985, HYPERTENSION, V7, P628, DOI 10.1161/01.HYP.7.4.628; MACGREGOR GA, 1982, LANCET, V1, P351, DOI 10.1016/S0140-6736(82)91389-7; MORGAN T, 1978, LANCET, V1, P227; PARIJS J, 1973, AM HEART J, V85, P22, DOI 10.1016/0002-8703(73)90522-X; STAMLER R, 1987, JAMA-J AM MED ASSOC, V257, P1484, DOI 10.1001/jama.257.11.1484; SULLIVAN JM, 1987, HYPERTENSION, V9, P398, DOI 10.1161/01.HYP.9.4.398; WALLENSTEIN S, 1980, CIRC RES, V47, P1, DOI 10.1161/01.RES.47.1.1; WASSERTHEILSMOLLER S, 1986, J HYPERTENS, V4, pS343; WEINBERGER MH, 1986, AM J MED, V80, P64, DOI 10.1016/0002-9343(86)90162-2; WEINBERGER MH, 1986, HYPERTENSION, V8, P127, DOI 10.1161/01.HYP.8.6_Pt_2.II127; WEINBERGER MH, 1985, ARCH INTERN MED, V145, P1102, DOI 10.1001/archinte.145.6.1102	25	55	56	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 6	1988	259	17					2561	2565		10.1001/jama.259.17.2561	http://dx.doi.org/10.1001/jama.259.17.2561			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N1994	3357230				2023-01-03	WOS:A1988N199400028
J	CURFMAN, GD				CURFMAN, GD			SHORTER HOSPITAL STAY FOR MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		ABRAHAM AS, 1975, NEW ENGL J MED, V292, P719, DOI 10.1056/NEJM197504032921403; AHLMARK G, 1979, ACTA MED SCAND, V206, P87; GIBSON RS, 1983, CIRCULATION, V68, P321, DOI 10.1161/01.CIR.68.2.321; HAMMERMAN H, 1983, J AM COLL CARDIOL, V2, P979, DOI 10.1016/S0735-1097(83)80249-6; HARPUR JE, 1971, LANCET, V2, P1331; HILL JD, 1978, LANCET, V1, P837; HUTTER AM, 1973, NEW ENGL J MED, V288, P1141, DOI 10.1056/NEJM197305312882201; LEVINE SA, 1952, JAMA-J AM MED ASSOC, V148, P1365, DOI 10.1001/jama.1952.02930160001001; Mallory GK, 1939, AM HEART J, V18, P647; MCNEER JF, 1978, NEW ENGL J MED, V298, P229, DOI 10.1056/NEJM197802022980501; PRYOR DB, 1983, ANN INTERN MED, V99, P528, DOI 10.7326/0003-4819-99-4-528; TOPOL EJ, 1988, NEW ENGL J MED, V318, P1083, DOI 10.1056/NEJM198804283181702; WHITE PD, 1972, MY LIFE MED, P180	13	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	APR 28	1988	318	17					1123	1125		10.1056/NEJM198804283181708	http://dx.doi.org/10.1056/NEJM198804283181708			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N0896	3281017				2023-01-03	WOS:A1988N089600008
J	RUBENSTEIN, DG; TREISTER, NW; KAPOOR, AS; MAHRER, PR				RUBENSTEIN, DG; TREISTER, NW; KAPOOR, AS; MAHRER, PR			TRANSFER OF ACUTELY ILL CARDIAC PATIENTS FOR DEFINITIVE CARE - DEMONSTRATED SAFETY IN 755 CASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note									KAISER PERMANENTE HOSP,DIV CARDIOL,CARDIAC CATHETERIZAT LAB,1526 N EDGEMONT ST,LOS ANGELES,CA 90027	Kaiser Permanente								ABRAMS HL, 1975, CIRCULATION, V52, P11; ADAMS DF, 1973, CIRCULATION, V48, P609, DOI 10.1161/01.CIR.48.3.609; AGNEW TM, 1983, NEW ZEAL MED J, V96, P465; BUDGE JS, 1987, ANN INTERN MED, V106, P414; CHAMBERLAIN DA, 1983, POSTGRAD MED J, V59, P89; CHEITLIN MD, 1985, JAMA, V253, P2555; GORE JM, 1983, ANN EMERG MED, V12, P675, DOI 10.1016/S0196-0644(83)80414-4; HANSING CE, 1979, JAMA-J AM MED ASSOC, V242, P735, DOI 10.1001/jama.242.8.735; HANSING CE, 1979, JAMA-J AM MED ASSOC, V242, P731, DOI 10.1001/jama.242.8.731; JUDKINS MP, 1976, CIRCULATION, V53, pA1; KENNEDY RH, 1982, NEW ENGL J MED, V307, P986, DOI 10.1056/NEJM198210143071605; LEWIS RP, 1979, JAMA-J AM MED ASSOC, V241, P1902, DOI 10.1001/jama.241.18.1902; SELZER A, 1971, CALIF MED, V115, P1; SILVERMAN KJ, 1984, NEW ENGL J MED, V310, P1712, DOI 10.1056/NEJM198406283102606; TWEED WA, 1980, CAN MED ASS J, V122, P809; WENNERBLOM B, 1982, EUR HEART J, V3, P504, DOI 10.1093/oxfordjournals.eurheartj.a061345; WILLIAMS DO, 1982, CIRCULATION, V66, P693; 1976, CIRCULATION, V53, pA1	18	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1988	259	11					1695	1698		10.1001/jama.259.11.1695	http://dx.doi.org/10.1001/jama.259.11.1695			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M3903	2963919				2023-01-03	WOS:A1988M390300032
J	COHEN, EP				COHEN, EP			DIRECT-TO-THE-PUBLIC ADVERTISEMENT OF PRESCRIPTION DRUGS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											COHEN, EP (corresponding author), MED COLL WISCONSIN,MILWAUKEE,WI 53226, USA.							BADER M, 1986, NEW ENGL J MED, V314, P523; BENHAM L, 1972, J LAW ECON, V15, P337, DOI 10.1086/466740; BOLINN GW, 1982, NEW ENGL J MED, V307, P1413, DOI 10.1056/NEJM198212023072301; BOSY L, 1986, AM MED NEWS     0425, P26; BOSY L, 1986, AM MED NEWS     1107, P23; BUDIANSKY S, 1982, NATURE, V298, P784, DOI 10.1038/298784c0; COLLINS A, 1987, AM MED NEWS     1016, P7; COLLINS A, 1987, AM MED NEWS     1002, P4; DRAPER R, 1986, NEW YORK REV BOOKS, V33, P14; HAYES AH, 1983, FEB M PHARM ADV COUN; KERR HD, 1986, NEW ENGL J MED, V314, P523; KRUPKA LR, 1985, SOC SCI MED, V20, P191, DOI 10.1016/0277-9536(85)90231-X; MACKOWIAK JI, 1985, SOC SCI MED, V20, P1191, DOI 10.1016/0277-9536(85)90197-2; MASSON A, 1985, NEW ENGL J MED, V313, P513, DOI 10.1056/NEJM198508223130811; MCMAHON FG, 1986, NEW ENGL J MED, V314, P524; MELLIN G W, 1962, N Engl J Med, V267, P1184, DOI 10.1056/NEJM196212062672305; MOLOTSKY I, 1984, NY TIMES        1115, pB12; MORRIS LA, 1984, DRUG ADVERTISING CON; OBRIEN M, 1986, NEW ENGL J MED, V314, P523; PIERPAOLI PG, 1986, AM J HOSP PHARM, V43, P1763, DOI 10.1093/ajhp/43.7.1763; ROSENBERG IH, 1982, NEW ENGL J MED, V307, P1444, DOI 10.1056/NEJM198212023072309; WEGNER F, 1983, ARGUMENTS PRESCRIPTI; YUDKIN JS, 1978, LANCET, V1, P810; 1984, AM COLL PHYSICIANS O, V4, P9; 1987, NY TIMES        0916, pB32; 1984, AM COLL PHYSICIANS O, V4, P1; 1987, CHICAGO TRIBUNE 0917, P39; 1985, DEC P HOUS DEL WASH	28	32	32	0	8	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 11	1988	318	6					373	376		10.1056/NEJM198802113180608	http://dx.doi.org/10.1056/NEJM198802113180608			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	L9761	3123930				2023-01-03	WOS:A1988L976100007
J	ANNAS, GJ				ANNAS, GJ			WOMEN AND CHILDREN FIRST	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material														Annas, George/0000-0001-5836-7831				KIPLING R, 1940, COMPLETE VERSE DEFIN, P432; KRAUTHAMMER C, 1995, WASHINGTON POST 0203, pA19; MAIER T, 1995, NEWSDAY         0622, P6; NORDHEIMER J, 1995, NY TIMES        0606, pB1; PARISI VM, 1995, NEW ENGL J MED, V333, P1635, DOI 10.1056/NEJM199512143332412; ROVNER J, 1995, LANCET, V346, P171, DOI 10.1016/S0140-6736(95)91219-3; SIMPSON AWB, 1984, CANNIBALISM COMMON L, P97; WERTZ RW, 1977, LYING IN HIST CHILDB; 1995, HOSPITAL LENGTH STAY; 1995, AM MED NEWS     0807, P13; 1995, MMWR-MORBID MORTAL W, V44, P335	11	44	45	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 14	1995	333	24					1647	1651		10.1056/NEJM199512143332420	http://dx.doi.org/10.1056/NEJM199512143332420			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TK065	7477216				2023-01-03	WOS:A1995TK06500032
J	CANDELISE, L; ARITZU, E; CICCONE, A; RICCI, S; WARDLAW, J; TOGNONI, G; RONCAGLIONI, MC; NEGRI, E; COLOMBO, F; BOCCARDI, E; DEGRANDI, C; SCIALFA, G; ARGENTINO, C; BERTELE, V; MAGGIONI, AP; PERRONE, P; BARNETT, HJM; BOGOUSSLAVSKY, J; DELFAVERO, A; LOI, U; PETO, R; WARLOW, C; CANZI, S; COMPARETTI, S; CLERICI, F; PALUMBO, A; SGARONI, G; POLONARA, S; REGINELLI, R; CERAVOLO, MG; PROVINCIALI, L; DELGOBBO, M; SCARPINO, O; BOTTACCHI, E; DALESSANDRO, G; DIGIOVANNI, M; BLANC, S; ROVEYAZ, L; RALLI, L; VANNI, D; REFI, C; FEDERICO, F; CONTE, C; INCHINGOLO, V; INSABATO, R; SALSA, F; LORIZIO, A; ROTTOLI, MR; BRUNI, L; DEFANTI, CA; FERA, L; CAMERLINGO, M; CASTO, L; CENSORI, B; MAMOLI, A; PORAZZI, D; GRAMPA, G; LASPINA, I; GIGLIA, L; AVENIA, V; GUELI, S; LOLLI, V; MIELE, V; SANTANGELO, M; COPPOLA, G; TRIANNI, G; MARRA, M; GRECO, E; TONTI, D; PRETOLANI, E; STELLIO, M; ARNABOLDI, M; CIOLA, R; DANIELI, G; REZZONICO, M; GUIDOTTI, M; PELLEGRINI, G; RAUDINO, F; DELFAVERO, C; FRATTINI, T; RICCARDI, T; LEVIMINZI, C; LOCATELLI, F; PASSERI, F; LOMBARDO, G; COCCO, F; PRATESI, M; SANTINI, S; CARDOPATRI, F; TAFANI, O; LANDINI, GC; PIERAGNOLI, E; BELLESI, R; BAGNOLI, L; GHETTI, A; MARRAZZA, OB; MENEGAZZO, P; SPOLVERI, S; CAPPELLETTI, C; CANDELIERE, G; COSTANTINO, G; DACUNO, F; LOMUZIO, T; RIZZITELLI, FP; BOVIO, G; GRILLI, GP; ZOCCHI, M; MAZZANTI, I; PISAPIA, G; NUZZI, R; RUSSO, G; LAMA, G; BALDASSARRI, G; BETTINI, R; CANI, E; CERIOLI, E; DEGIORGI, M; GARAGNANI, A; PASQUALI, S; CHIOMA, V; FINI, C; MARZARA, G; BALOTTA, A; BERTUZZI, D; MASINA, M; MATACENA, C; MICHELINI, M; PIRAZZOLI, G; SACCHET, C; MAROTTA, P; CALVI, L; SCACCABAROZZI, C; MENOZZI, C; SASANELLI, F; BASCELLI, C; PONTRELLI, V; SCHIERONI, F; BELVEDERE, D; DECAPITANI, E; DICOSTANZO, M; RASCAROLI, M; CITTERIO, O; MILANI, R; CAPIALBI, R; ARENA, G; MUSOLINO, R; DIPERRI, R; BONAVENTI, C; FINZI, F; MESSINA, A; ROMANAZZI, V; STERZI, R; BOTTINI, G; SANTILLI, I; BRUCATO, A; DEJULI, E; PALMIERI, G; RAGAINI, S; THIELLA, G; ALLI, C; CAROSELLA, L; RIZZATO, G; CANDELISE, L; ARITZU, E; BIANCHI, M; CICCONE, A; MOTTO, C; PINARDI, G; SCARLATO, G; BETTINELLI, A; PORRO, F; RANDAZZO, A; MARINI, U; LATTUADA, P; PIETRA, A; FRANCESCHI, M; VOLOUTE, MA; MALFERRARI, G; BONDI, M; GARUTI, W; MELINI, L; COLOMBO, A; ALBORINI, G; PANZETTI, P; SCARPA, M; SORGATO, P; CRISI, G; BONASERA, N; BASSO, F; NATALI, E; MONACO, P; GASPARRO, AM; TRIOLO, F; LECHI, A; COLONNA, F; DASCOLA, I; GIORGI, C; SCODITTI, U; BASSI, P; MENOZZI, R; PIAZZA, P; DEGLIANTONI, G; DESIMONI, M; GIANNINI, A; MICILI, G; BOSONE, D; CAVALLINI, A; MARTELLI, A; BARZIZZA, F; POLI, M; RICCI, S; BIAGINI, S; CAPOCCHI, G; CELANI, MG; PICCHIARELLI, A; RIGHETTI, E; ZAMPOLINI, M; CAPUTO, N; BARTOLINI, S; SANTONI, M; SITA, D; TAGLIOLI, M; VOLPI, G; ROSSI, F; ALOY, F; CASTELLANO, AE; MINOTTA, F; GATTA, A; VINATTIERI, A; CANTINI, A; REBUCCI, GG; BISSI, G; DEBLASI, F; PASCARELLI, E; TURIAMO, F; GUIDETTI, D; BARATTI, M; FERRARINI, G; GHIDONI, E; GRECO, G; MARCELLO, N; MOTTI, L; SOLIME, F; TERENZIANI, S; ZUCCO, R; TROISO, A; VENEZIANI, M; IORI, I; CURATOLA, L; BOLLETTINI, G; CARBONI, T; GOBBATO, R; INFRICCIOLO, P; SABATINI, D; SFRAPPINI, M; FANCELLU, A; CASU, G; DELEDDA, MG; SPANU, MA; PIRISI, A; MARRAS, FA; ROSATI, G; BRAMBILLA, A; ERLI, GC; FELICE, B; GRANDI, R; MIRABILE, D; ZADRA, M; CAVESTRI, R; GORI, D; LONGHINI, E; MIELE, N; DIVIZIA, G; GRASSELLI, S; PEZZELLA, F; ZUCCARI, F; SALLUSTO, L; LINCESSO, F; SCARPATI, C; IANNONE, G; BARTOCCI, A; COSTANTINI, F; DESANTIS, L; LANCIA, G; MOSCHINI, E; PACI, A; SENSIDONI, A; TRENTA, A; BARTOLINI, N; OTTAVIANO, P; BISCOTTINI, B; ALUNNI, G; BARTOLINI, I; BELLADONNA, D; BOCCALI, A; CRUCIANI, M; IBBA, R; LUCCIOLI, R; MARCECA, A; PACINI, M; PALLONE, M; GIRARDI, P; ORRICO, D; LANZA, E; BALLINI, A; GRANDI, FC; MUSCO, G; STEIDL, L; SANTORO, G; VEMCO, A; DUDINE, P; MILONE, FF; MUNARI, L; PERRETI, A; PORTA, M; LONGONI, C; FERANI, R; WATT, M; SANDERCOCK, P; FENNETRY, A; BANNISTER, P; CLARKE, CE; BAMFORD, J; VENABLES, G; CORREIA, M				CANDELISE, L; ARITZU, E; CICCONE, A; RICCI, S; WARDLAW, J; TOGNONI, G; RONCAGLIONI, MC; NEGRI, E; COLOMBO, F; BOCCARDI, E; DEGRANDI, C; SCIALFA, G; ARGENTINO, C; BERTELE, V; MAGGIONI, AP; PERRONE, P; BARNETT, HJM; BOGOUSSLAVSKY, J; DELFAVERO, A; LOI, U; PETO, R; WARLOW, C; CANZI, S; COMPARETTI, S; CLERICI, F; PALUMBO, A; SGARONI, G; POLONARA, S; REGINELLI, R; CERAVOLO, MG; PROVINCIALI, L; DELGOBBO, M; SCARPINO, O; BOTTACCHI, E; DALESSANDRO, G; DIGIOVANNI, M; BLANC, S; ROVEYAZ, L; RALLI, L; VANNI, D; REFI, C; FEDERICO, F; CONTE, C; INCHINGOLO, V; INSABATO, R; SALSA, F; LORIZIO, A; ROTTOLI, MR; BRUNI, L; DEFANTI, CA; FERA, L; CAMERLINGO, M; CASTO, L; CENSORI, B; MAMOLI, A; PORAZZI, D; GRAMPA, G; LASPINA, I; GIGLIA, L; AVENIA, V; GUELI, S; LOLLI, V; MIELE, V; SANTANGELO, M; COPPOLA, G; TRIANNI, G; MARRA, M; GRECO, E; TONTI, D; PRETOLANI, E; STELLIO, M; ARNABOLDI, M; CIOLA, R; DANIELI, G; REZZONICO, M; GUIDOTTI, M; PELLEGRINI, G; RAUDINO, F; DELFAVERO, C; FRATTINI, T; RICCARDI, T; LEVIMINZI, C; LOCATELLI, F; PASSERI, F; LOMBARDO, G; COCCO, F; PRATESI, M; SANTINI, S; CARDOPATRI, F; TAFANI, O; LANDINI, GC; PIERAGNOLI, E; BELLESI, R; BAGNOLI, L; GHETTI, A; MARRAZZA, OB; MENEGAZZO, P; SPOLVERI, S; CAPPELLETTI, C; CANDELIERE, G; COSTANTINO, G; DACUNO, F; LOMUZIO, T; RIZZITELLI, FP; BOVIO, G; GRILLI, GP; ZOCCHI, M; MAZZANTI, I; PISAPIA, G; NUZZI, R; RUSSO, G; LAMA, G; BALDASSARRI, G; BETTINI, R; CANI, E; CERIOLI, E; DEGIORGI, M; GARAGNANI, A; PASQUALI, S; CHIOMA, V; FINI, C; MARZARA, G; BALOTTA, A; BERTUZZI, D; MASINA, M; MATACENA, C; MICHELINI, M; PIRAZZOLI, G; SACCHET, C; MAROTTA, P; CALVI, L; SCACCABAROZZI, C; MENOZZI, C; SASANELLI, F; BASCELLI, C; PONTRELLI, V; SCHIERONI, F; BELVEDERE, D; DECAPITANI, E; DICOSTANZO, M; RASCAROLI, M; CITTERIO, O; MILANI, R; CAPIALBI, R; ARENA, G; MUSOLINO, R; DIPERRI, R; BONAVENTI, C; FINZI, F; MESSINA, A; ROMANAZZI, V; STERZI, R; BOTTINI, G; SANTILLI, I; BRUCATO, A; DEJULI, E; PALMIERI, G; RAGAINI, S; THIELLA, G; ALLI, C; CAROSELLA, L; RIZZATO, G; CANDELISE, L; ARITZU, E; BIANCHI, M; CICCONE, A; MOTTO, C; PINARDI, G; SCARLATO, G; BETTINELLI, A; PORRO, F; RANDAZZO, A; MARINI, U; LATTUADA, P; PIETRA, A; FRANCESCHI, M; VOLOUTE, MA; MALFERRARI, G; BONDI, M; GARUTI, W; MELINI, L; COLOMBO, A; ALBORINI, G; PANZETTI, P; SCARPA, M; SORGATO, P; CRISI, G; BONASERA, N; BASSO, F; NATALI, E; MONACO, P; GASPARRO, AM; TRIOLO, F; LECHI, A; COLONNA, F; DASCOLA, I; GIORGI, C; SCODITTI, U; BASSI, P; MENOZZI, R; PIAZZA, P; DEGLIANTONI, G; DESIMONI, M; GIANNINI, A; MICILI, G; BOSONE, D; CAVALLINI, A; MARTELLI, A; BARZIZZA, F; POLI, M; RICCI, S; BIAGINI, S; CAPOCCHI, G; CELANI, MG; PICCHIARELLI, A; RIGHETTI, E; ZAMPOLINI, M; CAPUTO, N; BARTOLINI, S; SANTONI, M; SITA, D; TAGLIOLI, M; VOLPI, G; ROSSI, F; ALOY, F; CASTELLANO, AE; MINOTTA, F; GATTA, A; VINATTIERI, A; CANTINI, A; REBUCCI, GG; BISSI, G; DEBLASI, F; PASCARELLI, E; TURIAMO, F; GUIDETTI, D; BARATTI, M; FERRARINI, G; GHIDONI, E; GRECO, G; MARCELLO, N; MOTTI, L; SOLIME, F; TERENZIANI, S; ZUCCO, R; TROISO, A; VENEZIANI, M; IORI, I; CURATOLA, L; BOLLETTINI, G; CARBONI, T; GOBBATO, R; INFRICCIOLO, P; SABATINI, D; SFRAPPINI, M; FANCELLU, A; CASU, G; DELEDDA, MG; SPANU, MA; PIRISI, A; MARRAS, FA; ROSATI, G; BRAMBILLA, A; ERLI, GC; FELICE, B; GRANDI, R; MIRABILE, D; ZADRA, M; CAVESTRI, R; GORI, D; LONGHINI, E; MIELE, N; DIVIZIA, G; GRASSELLI, S; PEZZELLA, F; ZUCCARI, F; SALLUSTO, L; LINCESSO, F; SCARPATI, C; IANNONE, G; BARTOCCI, A; COSTANTINI, F; DESANTIS, L; LANCIA, G; MOSCHINI, E; PACI, A; SENSIDONI, A; TRENTA, A; BARTOLINI, N; OTTAVIANO, P; BISCOTTINI, B; ALUNNI, G; BARTOLINI, I; BELLADONNA, D; BOCCALI, A; CRUCIANI, M; IBBA, R; LUCCIOLI, R; MARCECA, A; PACINI, M; PALLONE, M; GIRARDI, P; ORRICO, D; LANZA, E; BALLINI, A; GRANDI, FC; MUSCO, G; STEIDL, L; SANTORO, G; VEMCO, A; DUDINE, P; MILONE, FF; MUNARI, L; PERRETI, A; PORTA, M; LONGONI, C; FERANI, R; WATT, M; SANDERCOCK, P; FENNETRY, A; BANNISTER, P; CLARKE, CE; BAMFORD, J; VENABLES, G; CORREIA, M			RANDOMIZED CONTROLLED TRIAL OF STREPTOKINASE, ASPIRIN, AND COMBINATION OF BOTH IN TREATMENT OF ACUTE ISCHEMIC STROKE	LANCET			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; THROMBOLYTIC THERAPY; REPERFUSION	In ischaemic stroke, thrombolytic drugs speed the recanalisation of intracerebral arteries. The effects of aspirin are not known. A trial was conducted to determine whether, separately or together, streptokinase and aspirin have clinical benefits in acute ischaemic stroke similar to those in acute myocardial infarction. 622 patients with acute ischaemic stroke within 6 hours of symptom onset were randomised with a 2x2 factorial design to (i) a 1-hour intravenous infusion of 1 . 5 MU streptokinase, (ii) 300 mg/day buffered aspirin for 10 days, (iii) both active treatments, or (iv) neither. Early results raised a question whether the trial should be continued. Streptokinase (alone or with aspirin) was associated with an excess of 10-day case fatality (odds ratio 2 . 7; 95% confidence interval 1 . 7-4 . 3; 2p<0.00001). Of the four groups randomised, only patients allocated to streptokinase plus aspirin had a significantly higher risk of early death than those given neither streptokinase nor aspirin (odds ratio 3 . 5; 95% CI 1 . 9-6 . 5; 2p<0.00001). Streptokinase (alone or with aspirin) and aspirin (alone or with streptokinase) reduced, albeit not significantly, the incidence of combined six-month case fatality and severe disability: odds ratio for streptokinase 0 . 9 (95% CI 0 . 7-1 . 3) and odds ratio for aspirin 0 . 9 (95% CI 0 . 6-1 . 3). The risk of early death with thrombolytic treatments should be weighed against the potential benefit of a marginal reduction of severe disability after the first six months.	IST RIC FARMACOL MARIO NEGRI, MILAN, ITALY; INST NEUROL SCI, GLASGOW, LANARK, SCOTLAND; NEUROL CLIN, PERUGIA, ITALY; OSPED NIGUARDA CA GRANDA, MILAN, ITALY; UNIV ROMA LA SAPIENZA, ROME, ITALY; IST RIC FARMACOL MARIO NEGRI, CONSORZIO MARIO NEGRI SUD, I-66030 SANTA MARIA IMBARO, ITALY; OSPED LEGNANO, LEGNANO, ITALY; JOHN P ROBARTS RES INST, LONDON, ON N6A 5K8, CANADA; CHU VAUDOIS, CH-1011 LAUSANNE, SWITZERLAND; POLICLIN, PERUGIA, ITALY; CORTE APPELLO, PALAZZO GIUSTIZIA, MILAN, ITALY; RADCLIFFE INFIRM, CLIN TRIAL SERV UNIT, OXFORD OX2 6HE, ENGLAND; WESTERN GEN HOSP, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND; OSPED TORRETTE, NEUROL CLIN, ANCONA, ITALY; IST MALATTIE SISTEMA NERVOSO, ANCONA, ITALY; OSPED INRCA, DIV NEUROL, ANCONA, ITALY; OSPED REG, DIV NEUROL, AOSTA, ITALY; OSPED REG, DIV RADIOL, AOSTA, ITALY; OSPED REG, DIV GERIATR, AOSTA, ITALY; OSPED POLICLIN, NEUROL CLIN 1, BARI, ITALY; OSPED USL 5, DIV NEUROL, BASSANO DEL GRAPPA, ITALY; OSPED USL 23, DIV MED, AREZZO, ITALY; OSPED USL 23, DIV RADIOL, AREZZO, ITALY; OSPED RIUNITI BERGAMO, DIV NEUROL 1, BERGAMO, ITALY; OSPED RIUNITI BERGAMO, DIV NEUROL 2A, BERGAMO, ITALY; OSPED GEN PROV, DIV NEUROL, BUSTO ARSIZIO, ITALY; OSPED S ELIA, DIV NEUROL, CALTANISSETTA, ITALY; OSPED CIVILE F CARRANO, DIV NEUROL, CASARANO, ITALY; OSPED B RAMAZZINI, USL 14, DIV NEUROL, CARPI, ITALY; OSPED GEN PROVINCIALE M BUFALINI, USL 39, DIV MED, CESENA, ITALY; OSPED GEN PROVINCIALE M BUFALINI, USL 39, DIV NEUROFISIOPATOL, CESENA, ITALY; OSPED S ANNA COMO, DIV NEUROL, COMO, ITALY; OSPED VALDUCE, DIV NEUROL, COMO, ITALY; OSPED VALDUCE, DIV RADIOL, COMO, ITALY; OSPED MAGGIORE CREMA, DIV NEUROL, CREMA, ITALY; OSPED S GIUSEPPE, DIV MED, EMPOLI, ITALY; OSPED SM ANNUNZIATA, FLORENCE, ITALY; OSPED S GIOVANNI DI DIO, DIV MED INTERNA, FLORENCE, ITALY; OSPED RIUNITI FOGGIA, DIV NEUROL, FOGGIA, ITALY; OSPED MISERICORDIA, USL 28, DIV NEUROL, GROSSETO, ITALY; OSPED S MARCO, DIV MED REP DONNE, GROTTAGLIE, ITALY; OSPED NUOVO, DIV GEN MED, IMOLA, ITALY; OSPED NUOVO, DIV GERIATR, IMOLA, ITALY; OSPED USL 16, DIV NEUROL, Lecce, ITALY; OSPED PREDABISSI, USL 57, DIV NEUROL, MELEGNANO, ITALY; OSPED S LEOPOLDO MANDIC, USL 14, DIV NEUROL, MERATE, ITALY; OSPED S LEOPOLDO MANDIC, USL 14, SERV RADIODIAGNOST, MERATE, ITALY; POLICLIN UNIV MESSINI, NEUROL CLIN 1, MESSINI, ITALY; OSPED FATEBENEFRATELLI OFTALMICO, DIV NEUROCHIRURG, MILAN, ITALY; OSPED MAGGIORE NIGUARDA CA GRANDA, DIV NEUROL, MILAN, ITALY; OSPED MAGGIORE NIGUARDA CA GRANDA, DIV MED GEN BRERA 2A, MILAN, ITALY; OSPED MAGGIORE NIGUARDA CA GRANDA, DIV MED GEN RIZZI 5A, MILAN, ITALY; OSPED MAGGIORE POLICLIN, CLIN NEUROL PADIGLIONE PONTI, MILAN, ITALY; OSPED MAGGIORE POLICLIN, DIV NEURORADIOL, MILAN, ITALY; OSPED S CARLO BORROMEO, DIV MED, MILAN, ITALY; OSPED S CARLO BORROMEO, DIV NEUROL, MILAN, ITALY; OSPED SAN RAFFAELE, DIV NEUROL, MILAN, ITALY; OSPED CIVILE, DIV MED GEN 1, MODENA, ITALY; OSPED POLICLIN, NEUROL CLIN, MODENA, ITALY; OSPED POLICLIN, SERV NEURORADIOL, MODENA, ITALY; OSPED CIVILE, DIV NEUROL, PALERMO, ITALY; VILLA SOFIA USL 61, DIV NEUROL, PALERMO, ITALY; OSPED RIUNITI PARMA, IST NEUROL, USL 8, PARMA, ITALY; OSPED RIUNITI PARMA, CATTEDRA NEURORADIOL, PARMA, ITALY; FDN IST NEUROL C MONDINO, DIV 3, PAVIA, ITALY; POLICLIN SAN MATTEO, PRESIDIO BELGIOIOSO, I-27100 PAVIA, ITALY; OSPED C MIRA, CASORATE PRIMO, ITALY; OSPED USL 3, NEUROL CLIN, PERUGIA, ITALY; OSPED USL 3, DIV NEURORADIOL, PERUGIA, ITALY; PRESIDIO OSPED RIUNITI, USL 8, DIV NEUROL, PISTOIA, ITALY; IST SCI SANATRIX, DIV NEUROL, POZZILLI, ITALY; IST SCI SANATRIX, REPARTO ANESTESIOL & TERAPIA INTENS, POZZILLI, ITALY; OSPED USL 9, DIV NEUROL, PRATO, ITALY; OSPED S MARIA DELLE CROCI, DIV NEUROL, RAVENNA, ITALY; PRESIDIO OSPED RIUNITI, USL 31, DIV NEUROCHIRURG & MED, Reggio Di Calabria, ITALY; ARCISPEDALE S MARIA NUOVA, DIV NEUROL, REGGIO EMILIA, ITALY; ARCISPEDALE S MARIA NUOVA, DIV RADIOL, REGGIO EMILIA, ITALY; ARCISPEDALE S MARIA NUOVA, DIV RADIOL, REGGIO EMILIA, ITALY; OSPED USL 22, DIV NEUROL, San Benedetto Tronto, ITALY; OSPED USL 22, DIV GERIATR 312, San Benedetto Tronto, ITALY; OSPED USL 1, DIV MED 3, SASSARI, ITALY; UNIV SASSARI, NEUROL CLIN, I-07100 SASSARI, ITALY; PRESIDIO OSPED BOLOGNINI, USL 30, DIV NEUROL, SERIATE, ITALY; PRESIDIO OSPED, USL 65, DIV MED CAMPARI, SESTO SAN GIOVANNI, ITALY; OSPED CIVILE S MATTEO INFERMI, DIV NEUROFISIOPATOL MED GEN GERIATR, SPOLETO, ITALY; OSPED CIVILE, DIV NEUROL, TARANTO, ITALY; OSPED CIVILE, DIV RADIOL, TARANTO, ITALY; OSPED SANTA MARIA, DIV NEUROL, TERNI, ITALY; OSPED SANTA MARIA, DIV NEURORADIOL, TERNI, ITALY; OSPED CIVILE, DIV MED, TODI, ITALY; OSPED S CHIARA, DIV NEUROL, Trento, ITALY; OSPED GEN PROV, USL 32, DIV MED 2A, TREVIGLIO, ITALY; OSPED MAGGIORE TRIESTE, DIV NEUROL, TRIESTE, ITALY; OSPED MULTIZONALE, USL 3, DIV GEN MED, VARESE, ITALY; OSPED S BORTOLO, DIV NEUROL, VICENZA, ITALY; POLICLIN S MARCO, DIV NEUROL, ZINGONIA, ITALY; POLICLIN S MARCO, SERV TERAPIA INTENS, ZINGONIA, ITALY; INST NEUROL SCI, DEPT NEUROL, BELFAST, ANTRIM, NORTH IRELAND; UNIV EDINBURGH, WESTERN GEN HOSP, DEPT CLIN SCI, EDINBURGH, MIDLOTHIAN, SCOTLAND; INST NEUROL SCI, DEPT NEURORADIOL, GLASGOW, LANARK, SCOTLAND; SO GEN HOSP, MED UNIT A, GLASGOW G51 4TF, LANARK, SCOTLAND; BARNES HOSP, ROBERT BARNES MED UNIT, MANCHESTER, LANCS, ENGLAND; HULL ROYAL INFIRM, DEPT NEUROL, Kingston Upon Hull HU3 2JZ, N HUMBERSIDE, ENGLAND; ST JAMES UNIV HOSP, DEPT NEUROL, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; ROYAL HALLAMSHIRE HOSP, DEPT NEUROL, SHEFFIELD S10 2JF, S YORKSHIRE, ENGLAND; HOSP GERAL SANTO ANTONIO, SERV NEUROL, OPORTO, PORTUGAL	Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Glasgow; IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca' Granda; Sapienza University Rome; Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Western University (University of Western Ontario); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Radcliffe Infirmary; University of Oxford; University of Edinburgh; IRCCS INRCA; Azienda USL della Valle d'Aosta; Azienda USL della Valle d'Aosta; Azienda USL della Valle d'Aosta; Ospedali Riuniti di Bergamo; Ospedali Riuniti di Bergamo; Ospedale Sant'Anna di Como; Azienda USL di Imola; Azienda USL di Imola; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda Ospedale Maggiore Policlinico; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS Fondazione Casimiro Mondino; IRCCS Fondazione San Matteo; IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova; IRCCS Arcispedale S. Maria Nuova; University of Sassari; ULSS 8 Berica; Ospedale San Bortolo di Vicenza; University of Edinburgh; University of Glasgow; University of Glasgow; University of Hull; Saint James's University Hospital; University of Sheffield	CANDELISE, L (corresponding author), UNIV MILAN, IST CLIN NEUROL, VIA F SFORZA 35, I-20122 MILAN, ITALY.		Bamford, John/ABE-6218-2021; musco, giovanna/I-7122-2012; brucato, antonio/U-6879-2019; Bertele, Vittorio/AAA-6461-2020; sandercock, peter/GQI-3167-2022; Bosone, Daniele/AAB-8569-2020; roncaglioni, maria carla/AAB-1875-2020; De Simoni, Maria Grazia/I-6021-2012; Ciccone, Alfonso/AAB-8068-2022; Negri, Eva Vanna Lorenza/AAC-5698-2019; Hernandez, María/GYU-3543-2022; boccardi, edoardo/AAC-2904-2019; Censori, Bruno/ABB-9273-2020; Wardlaw, Joanna M/Y-3456-2019; Masina, Marco/J-9585-2019; Ballini, Andrea/R-5821-2016; cruciani, mario/A-3181-2012; celani, maria grazia/AAF-4143-2020; Musco, Giovanna/Q-2756-2019; Reginelli, Alfonso/AAL-4730-2020	musco, giovanna/0000-0002-0469-2994; brucato, antonio/0000-0002-7566-5600; Bertele, Vittorio/0000-0002-0032-7033; sandercock, peter/0000-0001-8484-0135; roncaglioni, maria carla/0000-0002-2029-7847; De Simoni, Maria Grazia/0000-0001-6695-5297; Ciccone, Alfonso/0000-0002-4590-3575; Negri, Eva Vanna Lorenza/0000-0001-9712-8526; Censori, Bruno/0000-0001-7235-5909; Wardlaw, Joanna M/0000-0002-9812-6642; Masina, Marco/0000-0002-5784-7099; 				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; BELL BA, 1985, J NEUROSURG, V62, P31, DOI 10.3171/jns.1985.62.1.0031; BROTT T, 1991, CEREBROVAS BRAIN MET, V3, P91; BROTT TG, 1992, STROKE, V23, P632, DOI 10.1161/01.STR.23.5.632; CANDELISE L, 1994, CEREBROVASC DIS, V4, P341, DOI 10.1159/000108505; CLARK WM, 1991, STROKE, V22, P872, DOI 10.1161/01.STR.22.7.872; COLLER BS, 1990, NEW ENGL J MED, V322, P33, DOI 10.1056/NEJM199001043220107; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DELZOPPO GJ, 1993, THROMBOLYTIC THERAPY, V2, P86; DONNAN GA, 1995, LANCET, V345, P578; GOMEZ CR, 1994, STROKE, V25, P1920, DOI 10.1161/01.STR.25.10.1920; HOMMEL M, 1995, LANCET, V345, P57, DOI 10.1016/S0140-6736(95)91179-0; LINCOFF AM, 1993, CIRCULATION, V87, P1792; LYDEN PD, 1993, CEREBROVAS BRAIN MET, V5, P1; RINGELSTEIN EB, 1992, NEUROLOGY, V42, P289, DOI 10.1212/WNL.42.2.289; SOLOMON NA, 1994, STROKE, V25, P1721, DOI 10.1161/01.STR.25.9.1721; VANDEWERF F, 1990, LANCET, V336, P71; WARDLAW JM, 1992, STROKE, V23, P1826, DOI 10.1161/01.STR.23.12.1826; 1993, STROKE, V24, P1618	20	492	500	0	25	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	DEC 9	1995	346	8989					1509	1514						6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	TJ291	7491044				2023-01-03	WOS:A1995TJ29100008
J	NIGHTINGALE, SL				NIGHTINGALE, SL			PHARMACEUTICAL PROMOTION HEARINGS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											NIGHTINGALE, SL (corresponding author), US FDA,OFF HLTH AFFAIRS,PARKLAWN BLDG,5600 FISHERS LN,ROCKVILLE,MD 20857, USA.							1995, FED REG         0814, V60, P41891; 1995, FED REG         0816, V60, P42581	2	0	0	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	1995	274	14					1109	1109						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	RY056	7563473				2023-01-03	WOS:A1995RY05600006
J	KALE, R				KALE, R			SOUTH-AFRICA HEALTH - TRADITIONAL HEALERS IN SOUTH-AFRICA - A PARALLEL HEALTH-CARE SYSTEM	BRITISH MEDICAL JOURNAL			English	Article							MEDICINES											FREEMAN M, 1992, SOC SCI MED, V34, P1183, DOI 10.1016/0277-9536(92)90311-D; GRAHAM R, 1993, WHITE WOMAN WITCH DO, V229, P234; KARIM SSA, 1992, BRINDGING GAP PROJEC; MCVANN A, 1992, S AFR MED J, V81, P139; SEGAL I, 1994, BARAGWANATH HOSPITAL, P17; VANRENSBURG HCJ, 1982, PROFILE DISEASE HLTH, P180; VEALE DJH, 1992, J ETHNOPHARMACOL, V36, P185, DOI 10.1016/0378-8741(92)90043-Q; WOOD R, 1990, S AFR MED J, V77, P640	8	116	119	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 6	1995	310	6988					1182	1185		10.1136/bmj.310.6988.1182	http://dx.doi.org/10.1136/bmj.310.6988.1182			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	QX566	7767156	Green Published			2023-01-03	WOS:A1995QX56600030
J	ALLENMERSH, TG; EARLAM, S; FORDY, C; ABRAMS, K; HOUGHTON, J				ALLENMERSH, TG; EARLAM, S; FORDY, C; ABRAMS, K; HOUGHTON, J			QUALITY-OF-LIFE AND SURVIVAL WITH CONTINUOUS HEPATIC-ARTERY FLOXURIDINE INFUSION FOR COLORECTAL LIVER METASTASES	LANCET			English	Article							PROSPECTIVE RANDOMIZED TRIAL; CANCER-PATIENTS; OF-LIFE; CHEMOTHERAPY; 5-FLUOROURACIL; COMPLICATIONS; LEUCOVORIN; CARCINOMA	Very few patients with liver metastases from colorectal cancer can be cured. We have investigated whether a treatment to slow the growth of liver metastases, hepatic-artery infusion of floxuridine, improves palliation in this setting. In a randomised study of 100 patients, we compared quality of life and survival in patients who received hepatic-artery infusion of floxuridine and in those who received conventional symptom palliation. 95% of control patient survival time was spent with normal quality-of-life scores, which suggests that the aim of treatment should be to prolong normal-quality survival rather than merely to sustain quality of life. There was a significant prolongation (p=0.03) in overall survival in floxuridine-treated patients compared with controls (median 405 vs 226 days). There were similar significant prolongations in normal-quality (ie, normal symptom scores) survival for physical symptoms (p=0.04), anxiety (p=0.04), and depression (p=0.04). This survival benefit was associated with significant reductions in metastasis size on computed tomography (p=0.001) and in serum carcinoembryonic antigen concentration (p=0.006) in floxuridine-treated patients. There was no evidence of treatment-related hepatotoxicity as assessed by serum aspartate aminotransferase and bilirubin measurements. This is the first demonstration that survival can be prolonged with normal quality of life in patients with colorectal liver metastases. We conclude that hepatic-artery floxuridine infusion can be recommended for suitable patients.	CHARING CROSS & WESTMINSTER MED SCH,LONDON,ENGLAND; RAYNE INST,CANC RES CAMPAIGN,CTR CLIN TRIALS,LONDON,ENGLAND	Imperial College London; University of London; King's College London			Abrams, Keith/AAA-2557-2020	Abrams, Keith/0000-0002-7557-1567				ARBUCK SG, 1989, CANCER, V63, P1036, DOI 10.1002/1097-0142(19890315)63:6+<1036::AID-CNCR2820631309>3.0.CO;2-K; AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457; BYRNE M, 1992, BRIT MED J, V304, P1523, DOI 10.1136/bmj.304.6841.1523; CHANG AE, 1987, ANN SURG, V206, P685, DOI 10.1097/00000658-198712000-00001; DEHAES JCJM, 1986, EUR J SURG ONCOL, V12, P337; DWORKIN MJ, 1991, CANCER TREAT REV, V18, P213, DOI 10.1016/0305-7372(91)90013-P; FELDSTEIN ML, 1991, CANCER, V67, P851, DOI 10.1002/1097-0142(19910201)67:3+<851::AID-CNCR2820671417>3.0.CO;2-G; GREENWAY B, 1988, BRIT J SURG, V75, P511; HOHN DC, 1986, CANCER, V57, P465, DOI 10.1002/1097-0142(19860201)57:3<465::AID-CNCR2820570311>3.0.CO;2-S; HYRNIUK WM, 1987, SEMIN ONCOL, V12, P3; JAFFE BM, 1968, SURG GYNECOL OBSTETR, V127, P1; KEMENY N, 1992, CANCER, V69, P327, DOI 10.1002/1097-0142(19920115)69:2<327::AID-CNCR2820690209>3.0.CO;2-U; KEMENY N, 1983, AM J MED, V74, P786, DOI 10.1016/0002-9343(83)91066-5; KEMENY N, 1993, CANCER, V71, P9, DOI 10.1002/1097-0142(19930101)71:1<9::AID-CNCR2820710104>3.0.CO;2-Y; KEMENY N, 1986, J CLIN ONCOL S, V5, P349; MAGUIRE P, 1989, BRIT J CANCER, V60, P437, DOI 10.1038/bjc.1989.301; MARTIN JK, 1990, ARCH SURG-CHICAGO, V125, P1022; MOONEY B, 1980, GUT, V21, pA903; MUELLER BU, 1992, J CLIN ONCOL, V10, P1943, DOI 10.1200/JCO.1992.10.12.1943; OCONNELL MJ, 1989, CANCER, V63, P1026, DOI 10.1002/1097-0142(19890315)63:6+<1026::AID-CNCR2820631307>3.0.CO;2-R; ONEILL WM, 1993, PRESCRIBERS J, V33, P250; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; ROUGIER P, 1992, J CLIN ONCOL, V10, P1112, DOI 10.1200/JCO.1992.10.7.1112; STEELE G, 1989, ANN SURG, V210, P127, DOI 10.1097/00000658-198908000-00001; TRAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; WOOD CB, 1980, RECENT ADV SURG, V10, P259; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Zwinderman A H, 1992, Qual Life Res, V1, P219, DOI 10.1007/BF00635621; 1992, J CLIN ONCOL, V10, P904; 1992, J CLIN ONCOL, V10, P896	30	439	443	1	7	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	NOV 5	1994	344	8932					1255	1260		10.1016/S0140-6736(94)90750-1	http://dx.doi.org/10.1016/S0140-6736(94)90750-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	PP701	7526096				2023-01-03	WOS:A1994PP70100008
J	MARINI, JJ; CULVER, BH				MARINI, JJ; CULVER, BH			SYSTEMIC GAS EMBOLISM COMPLICATING MECHANICAL VENTILATION IN THE ADULT RESPIRATORY-DISTRESS SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article									UNIV MINNESOTA, DEPT MED, ST PAUL, MN 55101 USA; UNIV WASHINGTON, DEPT MED, SEATTLE, WA 98144 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Washington; University of Washington Seattle					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019153, T32HL007123] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-07123, HL-19153] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBELDA SM, 1983, AM REV RESPIR DIS, V127, P360; ALBIN MS, 1983, ANESTHESIOLOGY, V58, P113, DOI 10.1097/00000542-198302000-00001; BLANCO CE, 1979, ACTA PAEDIATR SCAND, V68, P925; BRAVERMAN IM, 1981, SKIN SIGNS SYSTEMIC, P439; BROWN ZA, 1977, AM J DIS CHILD, V131, P984, DOI 10.1001/archpedi.1977.02120220050008; BUTLER BD, 1985, MED INSTRUM, V19, P59; CHOPRA DR, 1976, CLIN PEDIATR, V15, P178, DOI 10.1177/000992287601500208; DETRANO R, 1985, CLEVELAND CLIN Q, V52, P229, DOI 10.3949/ccjm.52.2.229; DURANT TM, 1949, AM HEART J, V38, P481, DOI 10.1016/0002-8703(49)90001-0; ERICKSON AD, 1979, ANN INTERN MED, V90, P937, DOI 10.7326/0003-4819-90-6-937; FRAKER TD, 1979, CIRCULATION, V59, P379, DOI 10.1161/01.CIR.59.2.379; FRIES CC, 1957, ANN SURG, V145, P461, DOI 10.1097/00000658-195704000-00002; GOLDFARB D, 1963, J THORAC CARDIOV SUR, V46, P368, DOI 10.1016/S0022-5223(19)33669-4; GREGORY GA, 1970, NEW ENGL J MED, V282, P1141, DOI 10.1056/NEJM197005142822007; GROSFELD JL, 1971, J PEDIATR SURG, V6, P339, DOI 10.1016/0022-3468(71)90476-3; GULLACE G, 1982, BRIT HEART J, V47, P445; HEALEY JE, 1969, SYNOPSIS CLIN ANATOM, P94; HWANG TL, 1983, ANN NEUROL, V13, P214, DOI 10.1002/ana.410130222; KOGUTT MS, 1978, AM J ROENTGENOL, V131, P425, DOI 10.2214/ajr.131.3.425; LEITCH DR, 1986, AVIAT SPACE ENVIR MD, V57, P931; Little V M, 1985, J Neurosurg Nurs, V17, P164; Macklin MT, 1944, MEDICINE, V23, P281, DOI 10.1097/00005792-194412000-00001; MAROON JC, 1974, ANESTH ANALG, V53, P399; MARTIN RW, 1983, ANESTHESIOLOGY, V58, P117, DOI 10.1097/00000542-198302000-00003; MURPHY BP, 1985, ANN SURG, V201, P242, DOI 10.1097/00000658-198502000-00019; PETERSEN GW, 1983, CRIT CARE MED, V11, P67, DOI 10.1097/00003246-198302000-00002; ROHLFING BM, 1976, RADIOLOGY, V121, P25, DOI 10.1148/121.1.25; SCHLAEPFER K, 1922, J HOPKINS MED J, V33, P321; SHENNIB HF, 1988, CHEST, V93, P1301, DOI 10.1378/chest.93.6.1301; SPAMPINATO N, 1981, ANN THORAC SURG, V32, P602, DOI 10.1016/S0003-4975(10)61805-X; THOMAS AN, 1973, J THORAC CARDIOV SUR, V66, P533; VALDESCRUZ LM, 1984, J AM COLL CARDIOL, V3, P978, DOI 10.1016/S0735-1097(84)80356-3; WESTCOTT JL, 1974, RADIOLOGY, V111, P367, DOI 10.1148/111.2.367; WOODRING JH, 1985, CRIT CARE MED, V13, P786, DOI 10.1097/00003246-198510000-00003	34	74	74	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAY 1	1989	110	9					699	703		10.7326/0003-4819-110-9-699	http://dx.doi.org/10.7326/0003-4819-110-9-699			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	U4463	2930107				2023-01-03	WOS:A1989U446300006
J	HIBBARD, BM				HIBBARD, BM			IRON AND FOLATE SUPPLEMENTS DURING PREGNANCY - SUPPLEMENTATION IS VALUABLE ONLY IN SELECTED PATIENTS	BRITISH MEDICAL JOURNAL			English	Article											HIBBARD, BM (corresponding author), UNIV WALES COLL MED,CARDIFF CF4 4XN,S GLAM,WALES.							BENTLEY DP, 1985, CLIN HAEMATOL, V14, P613; BONNAR J, 1969, LANCET, V1, P457; DAWSON EB, 1975, J REPROD MED S, V32, P478; FENTON V, 1977, BRIT J HAEMATOL, V37, P145, DOI 10.1111/j.1365-2141.1977.tb08819.x; GOODLIN RC, 1982, J REPROD MED, V27, P639; HEMMINKI E, 1978, BRIT J OBSTET GYNAEC, V85, P404, DOI 10.1111/j.1471-0528.1978.tb14905.x; HIBBARD BM, 1972, J OBSTET GYN BR COMM, V79, P584; HIBBARD BM, 1988, PRINCIPLES OBSTETRIC, P243; SVANBERG B, 1975, ACTA OBSTET GYNECO S, V48, P7; TAYLOR DJ, 1976, BRIT J OBSTET GYNAEC, V83, P760, DOI 10.1111/j.1471-0528.1976.tb00740.x	10	30	30	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 19	1988	297	6659					1324	&		10.1136/bmj.297.6659.1324	http://dx.doi.org/10.1136/bmj.297.6659.1324			0	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	R0450	3144378	Green Published, Bronze			2023-01-03	WOS:A1988R045000033
J	WEAVER, WD; HILL, D; FAHRENBRUCH, CE; COPASS, MK; MARTIN, JS; COBB, LA; HALLSTROM, AP				WEAVER, WD; HILL, D; FAHRENBRUCH, CE; COPASS, MK; MARTIN, JS; COBB, LA; HALLSTROM, AP			USE OF THE AUTOMATIC EXTERNAL DEFIBRILLATOR IN THE MANAGEMENT OF OUT-OF-HOSPITAL CARDIAC-ARREST	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									UNIV WASHINGTON,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	WEAVER, WD (corresponding author), UNIV WASHINGTON,HARBORVIEW MED CTR,DIV CARDIOL,325 9TH AVE,SEATTLE,WA 98104, USA.							CUMMINS RO, 1984, LANCET, V2, P318; EISENBERG MS, 1984, JAMA-J AM MED ASSOC, V251, P1723, DOI 10.1001/jama.251.13.1723; ROZKOVEC A, 1983, CLIN CARDIOL, V6, P527, DOI 10.1002/clc.4960061103; STULTS KR, 1986, CIRCULATION, V73, P701, DOI 10.1161/01.CIR.73.4.701; STULTS KR, 1984, NEW ENGL J MED, V310, P219, DOI 10.1056/NEJM198401263100403; WEAVER WD, 1986, AM J CARDIOL, V57, P1017, DOI 10.1016/0002-9149(86)90667-3; WEAVER WD, 1984, CIRCULATION, V69, P943, DOI 10.1161/01.CIR.69.5.943; WEAVER WD, 1985, ANN INTERN MED, V102, P53, DOI 10.7326/0003-4819-102-1-53; WEAVER WD, 1986, J AM COLL CARDIOL, V7, P752, DOI 10.1016/S0735-1097(86)80332-1; WEAVER WD, 1987, J AM COLL CARDIOL, V10, P1259, DOI 10.1016/S0735-1097(87)80128-6	10	273	283	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 15	1988	319	11					661	666		10.1056/NEJM198809153191101	http://dx.doi.org/10.1056/NEJM198809153191101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	Q0375	3412383				2023-01-03	WOS:A1988Q037500001
J	ROSENTHAL, A; RYAN, LM; MCCARTY, DJ				ROSENTHAL, A; RYAN, LM; MCCARTY, DJ			ARTHRITIS ASSOCIATED WITH CALCIUM-OXALATE CRYSTALS IN AN ANEPHRIC PATIENT TREATED WITH PERITONEAL-DIALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note											ROSENTHAL, A (corresponding author), MED COLL WISCONSIN, DEPT MED, 8700 W WISCONSIN AVE, BOX 118, MILWAUKEE, WI 53226 USA.				NIAMS NIH HHS [5 K04 AR01502-02, 1R01-AR38656-01] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K04AR001502, R01AR038656] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		DOHERTY M, 1986, CLIN RHEUM DIS, V12, P97; FAIRES JS, 1962, LANCET, V2, P682; FAYEMI AO, 1979, ARCH PATHOL LAB MED, V103, P58; HOFFMAN GS, 1982, ANN INTERN MED, V97, P36, DOI 10.7326/0003-4819-97-1-36; LOEB JN, 1972, ARTHRITIS RHEUM-US, V15, P189, DOI 10.1002/art.1780150209; PHELPS P, 1966, J EXP MED, V124, P115, DOI 10.1084/jem.124.1.115; REGINATO AJ, 1986, ARTHRITIS RHEUM, V29, P1387, DOI 10.1002/art.1780291112; SALYER WR, 1973, KIDNEY INT, V4, P61, DOI 10.1038/ki.1973.80; SCHUMACHER HR, 1987, J RHEUMATOL, V14, P361; SIMKIN PA, 1983, ARTHRITIS RHEUM, V26, P94, DOI 10.1002/art.1780260116; SIMKIN PA, 1977, ANN INTERN MED, V86, P230, DOI 10.7326/0003-4819-86-2-230; WIESSNER JH, 1986, J UROLOGY, V135, P835, DOI 10.1016/S0022-5347(17)45871-X; WORCESTER EM, 1986, J CLIN INVEST, V77, P1888, DOI 10.1172/JCI112516	13	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	SEP 2	1988	260	9					1280	1282		10.1001/jama.260.9.1280	http://dx.doi.org/10.1001/jama.260.9.1280			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	P7929	3404640				2023-01-03	WOS:A1988P792900031
J	GUSLANDI, M				GUSLANDI, M			COMBINED THERAPIES FOR UPPER GASTROINTESTINAL DISORDERS - ANY ADVANTAGE	LANCET			English	Article											GUSLANDI, M (corresponding author), UNIV MILAN,INST INTERNAL MED,VIA PACE 9,I-20122 MILAN,ITALY.							BANK S, 1985, GUT, V26, P603, DOI 10.1136/gut.26.6.603; BARDHAN KD, 1987, GUT, V28, P1505, DOI 10.1136/gut.28.11.1505; BODEMAR G, 1979, LANCET, V1, P444; BORKENT MV, 1988, GUT, V29, P385, DOI 10.1136/gut.29.3.385; DALMONTE PR, 1985, HEPATO-GASTROENTEROL, V32, P126; GUGLER R, 1981, EUR J CLIN PHARMACOL, V20, P225, DOI 10.1007/BF00544602; GUSLANDI M, 1980, CLIN THER, V3, P40; JAMALI F, 1985, CLIN PHARM THER, V63, P325; LIEBERMAN DA, 1986, ANN INTERN MED, V104, P21, DOI 10.7326/0003-4819-104-1-21; LONDONG W, 1981, GUT, V22, P542, DOI 10.1136/gut.22.7.542; MAGNANELLI M, 1984, INT J TISSUE REACT, V6, P189; MASCI E, 1985, DRUG EXP CLIN RES, V11, P687; MIHALY GW, 1982, BRIT MED J, V285, P998, DOI 10.1136/bmj.285.6347.998; MINOLI G, 1984, IRCS MED SCI-BIOCHEM, V12, P679; MORGAN A G, 1987, Alimentary Pharmacology and Therapeutics, V1, P633; MORGAN AG, 1985, GUT, V26, P1377, DOI 10.1136/gut.26.12.1377; POCH G, 1985, INT J CLIN PHARM TH, V23, P283; RUNE SJ, 1984, SCAND J GASTROENTERO, V19, P56, DOI 10.1080/00365521.1984.12005684; SALMON PR, 1987, DIGESTION, V37, P42, DOI 10.1159/000199557; TAKEMOTO T, 1987, Scandinavian Journal of Gastroenterology Supplement, V22, P49; TEMPLE JG, 1983, BRIT MED J, V286, P1863, DOI 10.1136/bmj.286.6381.1863; TONNESEN H, 1987, DIGESTION, V38, P69, DOI 10.1159/000199574; TULASSAY Z, 1987, AM J GASTROENTEROL, V82, P1217; VANDEVENTER GM, 1985, AM J MED, V79, P39, DOI 10.1016/0002-9343(85)90571-6; WIENBECK M, 1986, DIGESTION, V34, P144	25	11	11	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	JUN 18	1988	1	8599					1383	1385						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N8731	2898054				2023-01-03	WOS:A1988N873100014
J	METCALFE, MJ; SMITH, F; JENNINGS, K; PATERSON, N				METCALFE, MJ; SMITH, F; JENNINGS, K; PATERSON, N			DOES CARDIOVERSION OF ATRIAL-FIBRILLATION RESULT IN MYOCARDIAL DAMAGE	BRITISH MEDICAL JOURNAL			English	Note									UNIV ABERDEEN,DEPT CHEM PATHOL,ABERDEEN AB9 1FX,SCOTLAND	University of Aberdeen	METCALFE, MJ (corresponding author), ABERDEEN ROYAL INFIRM,DEPT CARDIOL,ABERDEEN AB9 2ZB,SCOTLAND.							COLEMAN RE, 1976, AM J CARDIOL, V37, P732, DOI 10.1016/0002-9149(76)90367-2; DOHERTY PW, 1979, AM J CARDIOL, V43, P225, DOI 10.1016/S0002-9149(79)80008-9; EHSANI A, 1976, AM J CARDIOL, V37, P12, DOI 10.1016/0002-9149(76)90492-6; GRIFFITHS PD, 1986, ANN CLIN BIOCHEM, V23, P238, DOI 10.1177/000456328602300303; SEIGEL A, 1981, JAMA-J AM MED ASSOC, V246, P2049	5	21	22	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 14	1988	296	6633					1364	1364		10.1136/bmj.296.6633.1364	http://dx.doi.org/10.1136/bmj.296.6633.1364			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N4544	3134987	Green Published, Bronze			2023-01-03	WOS:A1988N454400015
J	WESTGREN, M; SELBING, A; STANGENBERG, M				WESTGREN, M; SELBING, A; STANGENBERG, M			FETAL INTRACARDIAC TRANSFUSIONS IN PATIENTS WITH SEVERE RHESUS ISOIMMUNIZATION	BRITISH MEDICAL JOURNAL			English	Article									KING FAISAL SPECIALIST HOSP & RES CTR,DEPT OBSTET & GYNAECOL,RIYADH 11211,SAUDI ARABIA	King Faisal Specialist Hospital & Research Center								BANG J, 1982, BRIT MED J, V284, P373, DOI 10.1136/bmj.284.6313.373; BANG J, 1985, INTERVENTIONAL ULTRA, P122; BENACERRAF BR, 1987, AM J OBSTET GYNECOL, V156, P1218, DOI 10.1016/0002-9378(87)90148-7; BERKOWITZ RL, 1986, AM J OBSTET GYNECOL, V155, P574, DOI 10.1016/0002-9378(86)90282-6; DECRESPIGNY LC, 1985, OBSTET GYNECOL, V66, P529; GRANNUM PA, 1986, NEW ENGL J MED, V314, P1431, DOI 10.1056/NEJM198605293142207; NICOLAIDES KH, 1984, BRIT MED J, V288, P900, DOI 10.1136/bmj.288.6421.900; RODECK CH, 1981, LANCET, V1, P625	8	52	54	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAR 26	1988	296	6626					885	886		10.1136/bmj.296.6626.885	http://dx.doi.org/10.1136/bmj.296.6626.885			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M7851	3129060	Green Published			2023-01-03	WOS:A1988M785100007
J	LITTENBERG, B				LITTENBERG, B			AMINOPHYLLINE TREATMENT IN SEVERE, ACUTE ASTHMA - A META-ANALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									STANFORD UNIV,DIV GEN INTERNAL MED,STANFORD,CA 94305; VET ADM MED CTR,PALO ALTO,CA 94304	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	LITTENBERG, B (corresponding author), STANFORD UNIV,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,STANFORD,CA 94305, USA.			Littenberg, Benjamin/0000-0002-7647-1808				APPEL D, 1981, LUNG, V159, P243, DOI 10.1007/BF02713922; BESWICK K, 1975, PRACTITIONER, V214, P561; BRESNICK E, 1948, JAMA-J AM MED ASSOC, V136, P397, DOI 10.1001/jama.1948.72890230007008; BROWNER WS, 1987, JAMA-J AM MED ASSOC, V257, P2459, DOI 10.1001/jama.257.18.2459; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; ELLULMICALLEF R, 1982, EUR J RESPIR DIS, V63, P118; EVANS WV, 1980, BRIT J DIS CHEST, V74, P385, DOI 10.1016/0007-0971(80)90074-1; FANTA CH, 1982, AM J MED, V72, P416, DOI 10.1016/0002-9343(82)90498-3; FEMIPEARSE D, 1977, BRIT MED J, V1, P491, DOI 10.1136/bmj.1.6059.491; Glass G.V., 1981, META ANAL SOCIAL RES; HENDELES L, 1977, DRUG INTEL CLIN PHAR, V11, P12, DOI 10.1177/106002807701100101; HERMANN G, 1937, J LAB CLIN MED, V23, P135; HILLS M, 1979, BRIT J CLIN PHARMACO, V8, P7, DOI 10.1111/j.1365-2125.1979.tb05903.x; JACOBS MH, 1976, JAMA-J AM MED ASSOC, V235, P1983, DOI 10.1001/jama.235.18.1983; JOSEPHSON GW, 1979, JAMA-J AM MED ASSOC, V242, P639, DOI 10.1001/jama.242.7.639; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LIGHT RJ, 1984, SUMMING UP SCI REV R; LITTENBERG B, 1986, NEW ENGL J MED, V314, P150, DOI 10.1056/NEJM198601163140304; MESSER J, 1983, NEW ENGL J MED, V309, P21, DOI 10.1056/NEJM198307073090105; MITENKO PA, 1973, NEW ENGL J MED, V289, P600, DOI 10.1056/NEJM197309202891202; MOSES LE, 1986, THINK EXPLAIN STATIS, P54; PERSSON CGA, 1985, THORAX, V40, P881, DOI 10.1136/thx.40.12.881; PIERSON W, 1971, PEDIATRICS, V48, P642; ROSSING TH, 1981, AM REV RESPIR DIS, V123, P190; ROSSING TH, 1980, AM REV RESPIR DIS, V122, P365; SHARMA T N, 1984, Indian Journal of Chest Diseases and Allied Sciences, V26, P155; SIEGEL D, 1985, AM REV RESPIR DIS, V132, P283; STORR J, 1987, LANCET, V1, P880; TRIBE AE, 1976, MED J AUSTRALIA, V2, P749, DOI 10.5694/j.1326-5377.1976.tb128275.x; TUKEY JW, 1977, SCIENCE, V198, P679, DOI 10.1126/science.333584; WILLIAMS SJ, 1975, BRIT MED J, V4, P685, DOI 10.1136/bmj.4.5998.685	31	149	151	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 18	1988	259	11					1678	1684		10.1001/jama.259.11.1678	http://dx.doi.org/10.1001/jama.259.11.1678			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M3903	3278146				2023-01-03	WOS:A1988M390300029
J	TOMLINSON, T; BRODY, H				TOMLINSON, T; BRODY, H			ETHICS AND COMMUNICATION IN DO-NOT-RESUSCITATE ORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material											TOMLINSON, T (corresponding author), MICHIGAN STATE UNIV,E LANSING,MI 48824, USA.		Brody, Howard/GQA-6310-2022					ANNAS GJ, 1982, HASTINGS CENT REP, V12, P30, DOI 10.2307/3560662; BEDELL SE, 1986, JAMA-J AM MED ASSOC, V256, P233, DOI 10.1001/jama.256.2.233; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BLACKHALL LJ, 1987, NEW ENGL J MED, V317, P1281, DOI 10.1056/NEJM198711123172009; BRETT AS, 1986, NEW ENGL J MED, V315, P1347, DOI 10.1056/NEJM198611203152109; CHARLSON ME, 1986, JAMA-J AM MED ASSOC, V255, P1316, DOI 10.1001/jama.255.10.1316; DAILA F, 1986, CRIT CARE MED, V14, P1066; LIPTON HL, 1986, JAMA-J AM MED ASSOC, V256, P1164, DOI 10.1001/jama.256.9.1164; MILES SH, 1982, ANN INTERN MED, V96, P660, DOI 10.7326/0003-4819-96-5-660; UHLMANN RF, 1984, CRIT CARE MED, V12, P879, DOI 10.1097/00003246-198410000-00009; YOUNGNER SJ, 1987, HASTINGS CENT REP, V17, P24, DOI 10.2307/3562438; YOUNGNER SJ, 1985, JAMA-J AM MED ASSOC, V253, P54; 1983, 0402884 PRES COMM ST; 1982, 03835158673 PRES COM, V1, P43	14	213	213	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 7	1988	318	1					43	46		10.1056/NEJM198801073180109	http://dx.doi.org/10.1056/NEJM198801073180109			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	L5234	3336383				2023-01-03	WOS:A1988L523400009
J	PALCA, J; ANDERSON, A				PALCA, J; ANDERSON, A			FIRM MEDICAL FOUNDATION	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1988	333	6175					734	734						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	N9254	3386718				2023-01-03	WOS:A1988N925400078
J	BRAHAMS, D				BRAHAMS, D			ILLEGIBLE PRESCRIPTIONS	LANCET			English	Editorial Material																			0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1988	1	8593					1061	1061						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	N2401	2896907				2023-01-03	WOS:A1988N240100053
J	PALCA, J; ANDERSON, A				PALCA, J; ANDERSON, A			ALBERTA HOPES TO KEEP THE WHEELS OF RESEARCH WELL OILED	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1988	333	6175					734	734						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	N9254	3386718				2023-01-03	WOS:A1988N925400076
J	BRAHAMS, D				BRAHAMS, D			DISPENSING FORGED PRESCRIPTIONS	LANCET			English	Editorial Material																			0	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1988	1	8589					837	838						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	M8674	2895360				2023-01-03	WOS:A1988M867400051
J	BRAHAMS, D				BRAHAMS, D			PERTUSSIS-VACCINE - COURT FINDS NO JUSTIFICATION FOR ASSOCIATION WITH PERMANENT BRAIN-DAMAGE	LANCET			English	Editorial Material																		BRAHAMS D, 1985, LANCET, V2, P1137	1	5	5	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	APR 9	1988	1	8589					837	837						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	M8674	2895360				2023-01-03	WOS:A1988M867400050
J	PALCA, J; ANDERSON, A				PALCA, J; ANDERSON, A			LOOKING TO THE EAST FOR HERBAL REMEDIES	NATURE			English	Editorial Material																			0	0	0	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUN 23	1988	333	6175					734	734						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	N9254	3386718				2023-01-03	WOS:A1988N925400077
J	BRAHAMS, D				BRAHAMS, D			SUICIDE VERDICT REQUIRES DEATH WITHIN A YEAR AND A DAY	LANCET			English	Editorial Material																			0	2	2	0	0	LANCET LTD	LONDON	42 BEDFORD SQUARE, LONDON, ENGLAND WC1B 3SL	0140-6736			LANCET	Lancet	MAY 7	1988	1	8593					1061	1061						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	N2401	2896907				2023-01-03	WOS:A1988N240100052
